"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,S,US D0541944 S,063-444-227-158-949,2007-05-01,2007,US 26202106 F,2006-06-26,US 26202106 F,2006-06-26,Foot sole massager,,KARL STAR IND CO LTD,CHANG DAVID,KARL-STAR INDUSTRIAL CO. LTD (2006-05-04),https://lens.org/063-444-227-158-949,Design Right,no,0,7,1,1,0,,,2803;;D24/213,0,0,,,,EXPIRED
2,US,A1,US 2020/0075084 A1,121-324-222-743-300,2020-03-05,2020,US 201916565913 A,2019-09-10,US 201916565913 A;;US 201816117230 A,2018-08-30,LOW POWER DELAY BUFFER BETWEEN EQUALIZER AND HIGH SENSITIVITY SLICER,"An apparatus includes a continuous-time linear equalizer circuit, a buffer and at least one slicer. The continuous-time linear equalizer circuit may be configured to generate a first intermediate signal by equalizing an input signal relative to a reference voltage. The input signal may be single-ended. The first intermediate signal may be differential. The buffer may be configured to generate a second intermediate signal by delaying the first intermediate signal. The second intermediate signal may be differential. The slicer may be configured to generate an output signal by slicing the second intermediate signal. The output signal may be single-ended.",INTEGRATED DEVICE TECH,CHANG DAVID,,https://lens.org/121-324-222-743-300,Patent Application,yes,1,0,3,3,0,G11C11/4093;;G11C11/4093;;G11C5/04;;G11C7/02;;G11C7/1057;;G11C7/1069;;G11C7/1084;;G11C7/1096;;G11C11/4076;;G11C11/4076,G11C11/4093;;G11C11/4076,,0,0,,,,ACTIVE
3,CA,A1,CA 2600195 A1,158-459-786-977-656,2006-09-28,2006,CA 2600195 A,2006-03-22,US 66438105 P;;US 38627106 A;;US 2006/0010582 W,2005-03-22,COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS,,AMGEN INC,CHANG DAVID,,https://lens.org/158-459-786-977-656,Patent Application,no,0,0,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K31/444;;A61K39/395;;A61P35/00,,0,0,,,,INACTIVE
4,US,A,US 5299925 A,154-008-480-366-598,1994-04-05,1994,US 79574491 A,1991-11-21,US 79574491 A,1991-11-21,Bicycle rear-wheel hub assembly,"A bicycle rear-wheel hub includes an inner casing disposed in the hub at one side, an outer casing disposed on the inner casing, an axle inserted through the hub and a set of flywheels disposed on the outer casing. The hub includes an inner thread and a wheel shoulder at one end, and a rubber ring set inside the wheel shoulder in front of the inner thread. The inner casing has an outer thread at one end for engaging with the inner thread of the hub. The inner casing also has a tool hole at the opposite end for inserting a tool. The outer casing has a number of elongated grooves around the outer wall surface for fastening the set of flywheels. The flywheels each has a number of inner projections formed in a center hole for engaging with the elongated grooves of the outer casing.",TAIWAN BICYCLE IND DEV CO LTD,CHANG DAVID,TAIWAN BICYCLE INDUSTRIAL DEVELOPMENT CO. LTD (1991-11-11);;INDUSTRIAL DEVELOPMENT BUREAU (1996-02-17),https://lens.org/154-008-480-366-598,Granted Patent,yes,8,18,1,1,0,B62M9/10;;B62M9/10;;Y10S474/903;;Y10S474/903,B62M9/10,474/160;;474/164;;474/903,0,0,,,,EXPIRED
5,US,A1,US 2011/0056464 A1,197-408-038-105-152,2011-03-10,2011,US 94401110 A,2010-11-11,US 94401110 A;;US 28724808 A,2008-10-07,COOLING FEATURE FOR FUEL INJECTOR AND FUEL SYSTEM USING SAME,"A thermal load control assembly for a fuel injector includes a rail inlet port, a cooling inlet port and a fuel drain port. A leakage path channels leaked fuel originating from the rail inlet port to the fuel drain port. A cooling path channels fuel originating from the cooling inlet port to the fuel drain port. A fuel system using a thermal load control assembly includes a single fuel tank that supplies fuel to the rail inlet port and the cooling inlet port of a plurality of fuel injectors and collect fuel from the fuel drain port of the plurality of fuel injectors.",CATERPILLAR INC,CHANG DAVID,,https://lens.org/197-408-038-105-152,Patent Application,yes,5,5,8,8,0,F02M47/027;;F02M47/027;;F02M53/04;;F02M53/04;;F02M53/043;;F02M53/043;;F02M2700/077;;F02M2700/077,F02M69/46,123/456,0,0,,,,DISCONTINUED
6,KR,B1,KR 870001587 B1,026-070-549-042-695,1987-09-10,1987,KR 840008041 A,1984-12-15,KR 840008041 A,1984-12-15,SPORTING SHOES,"This invention relates to sporting shoes. In a pair of sporting shoes composed of the upper part and the outsole which is composed of the outer outsole and intermediate outsole with the whole length of the shoe, the intermediate outsole has a slot going across the bottom of a heel and the slot includes the internal space to be able to insert the plug into the slot from both sides of a shoe. And because this plug has enough size to fill the slot, it offers an suitable buffer and glues to the intermediate outsole not to be removable from the outsole in running.",HI TEC INTERNATIONAL LTD,CHANG DAVID,,https://lens.org/026-070-549-042-695,Granted Patent,no,0,0,2,2,0,A43B13/42;;A43B13/14,A43B5/00,,0,0,,,,EXPIRED
7,WO,A3,WO 2010/042359 A3,069-914-028-655-581,2010-07-08,2010,US 2009/0058954 W,2009-09-30,US 28724808 A,2008-10-07,COOLING FEATURE FOR FUEL INJECTOR AND FUEL SYSTEM USING SAME,"A thermal load control assembly for a fuel injector (100) includes a rail inlet port (14), a cooling inlet port (16) and a fuel drain port (18). A leakage path channels leaked fuel originating from the rail inlet port (14) to the fuel drain port (18). A cooling path channels fuel originating from the cooling inlet port (16) to the fuel drain port (18). A fuel system (500) using a thermal load control assembly includes a single fuel tank (90) that supplies fuel to the rail inlet port (14) and the cooling inlet port (16) of a plurality of fuel injectors (200) and collect fuel from the fuel drain port (18) of the plurality of fuel injectors (200).",CATERPILLAR INC;;CHANG DAVID,CHANG DAVID,,https://lens.org/069-914-028-655-581,Search Report,yes,5,0,8,8,0,F02M47/027;;F02M47/027;;F02M53/04;;F02M53/04;;F02M53/043;;F02M53/043;;F02M2700/077;;F02M2700/077,F02M53/04;;F02M51/06;;F02M61/04;;F02M61/16,,0,0,,,,PENDING
8,CA,A1,CA 2558998 A1,080-080-397-708-765,2007-03-09,2007,CA 2558998 A,2006-09-08,CN 200520118496 U,2005-09-09,BARBECUING DEVICE,"A device for barbequing food, said device including: a cabinet (1) for stori ng a power source; a burner (3) connectable to said power source for cooking said food, and a means for steam cleaning (5) said device.",CHANG DAVID,CHANG DAVID,,https://lens.org/080-080-397-708-765,Patent Application,no,0,0,9,9,0,A47J37/0713;;A47J37/0745;;A47J37/0786;;A47J37/0713;;A47J37/0786;;A47J37/0745,A47J37/07,,0,0,,,,DISCONTINUED
9,CA,A,CA 807331 A,109-352-916-168-623,1969-02-25,1969,CA 807331D A,,CA 807331T A,,TWO-PROBE FLUX SENSITIVE MAGNETIC HEAD,,IBM,CHANG DAVID,,https://lens.org/109-352-916-168-623,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
10,PT,E,PT 1762164 E,000-906-192-984-893,2008-12-22,2008,PT 06018449 T,2006-09-04,CN 200520118496 U,2005-09-09,BARBECUING DEVICE,"A device for barbequing food, said device including: a cabinet (1) for storing a power source; a burner (3) connectable to said power source for cooking said food, and a means for steam cleaning (5) said device.",CHANG DAVID,CHANG DAVID,,https://lens.org/000-906-192-984-893,Granted Patent,no,0,0,9,9,0,A47J37/0713;;A47J37/0745;;A47J37/0786;;A47J37/0713;;A47J37/0786;;A47J37/0745,A47J37/07,,0,0,,,,ACTIVE
11,US,S,US D0385727 S,023-990-273-142-427,1997-11-04,1997,US 5987096 F,1996-09-17,US 5987096 F,1996-09-17,Table,,CHANG DAVID,CHANG DAVID,,https://lens.org/023-990-273-142-427,Design Right,yes,4,8,1,1,0,,,D 6480;;0603,0,0,,,,EXPIRED
12,US,B2,US 6619475 B2,034-962-294-129-177,2003-09-16,2003,US 10468702 A,2002-03-21,US 10468702 A;;US 60380300 A,2000-06-26,Golf bag with honeycomb cell structure,"
    A golf bag having a club-separating staggered honeycomb-like cell structure and a method for manufacturing is disclosed. The golf bag includes a plurality of individual hollow fabric-lined plastic or soft fabric tubes coupled to a top opening or collar, and confined or anchored by a bottom or base. The full-length tubing separates and protects the shafts of the golf clubs and prevent them from becoming entangled. The collar comprises a plurality of openings arranged in a honeycomb cell configuration. The cell openings are elongated to maximize the separation between club heads and also allow easy access for club retrieval and replacement. The base as configured keeps the lower end of the tubes in line with cell openings at the other end of the golf bag. The method of manufacturing consists of shaping, positioning and attaching a plurality of tubing to the collar and the base to form the honeycomb cell structure. 
",CHANG DAVID,CHANG DAVID,,https://lens.org/034-962-294-129-177,Granted Patent,yes,18,7,2,2,0,A63B55/00;;A63B55/53;;A63B57/0032;;A63B57/203;;A63B55/40;;A63B55/40;;A63B55/53;;A63B57/203;;A63B57/0032,A63B55/00;;A63B55/04;;A63B55/57;;A63B57/00,206/315.6;;206/315.3;;211/70.2,0,0,,,,EXPIRED
13,US,S,US D0362136 S,129-549-566-707-408,1995-09-12,1995,US 905093 F,1993-06-04,US 905093 F,1993-06-04,Table,,CHANG DAVID,CHANG DAVID,,https://lens.org/129-549-566-707-408,Design Right,yes,7,2,1,1,0,,,D 6474,1,0,,,"Shoner Wohnen Mag. Jan. 1989, p. 72-""Roll-IT""-D6/474.",EXPIRED
14,DE,A1,DE 1424405 A1,144-471-972-803-610,1968-10-31,1968,DE 1424405 A,1961-03-18,US 1593560 A;;US 1605860 A;;US 41645364 A,1960-03-18,Magnetkopf zur statischen Abfuehlung von magnetisch aufgezeichneten Daten,,IBM,CHANG DAVID,,https://lens.org/144-471-972-803-610,Patent Application,no,0,0,10,10,0,G11B5/265;;G11B5/265;;G11B5/335;;G11B5/335;;G11B23/0007;;G11B23/0007;;H03K3/02;;H03K3/02,G11B5/265;;G11B5/335;;G11B23/00;;H03K3/02,,0,0,,,,DISCONTINUED
15,MX,A,MX 2007011545 A,166-183-853-575-477,2008-03-11,2008,MX 2007011545 A,2006-03-22,US 66438105 P;;US 38627106 A;;US 2006/0010582 W,2005-03-22,COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS.,"This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.",AMGEN INC,CHANG DAVID,,https://lens.org/166-183-853-575-477,Patent Application,no,0,0,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K31/444;;A61K39/395;;A61P35/00,,0,0,,,,ACTIVE
16,US,A1,US 2003/0055319 A1,025-976-978-768-595,2003-03-20,2003,US 95309301 A,2001-09-14,US 95309301 A,2001-09-14,Surgical retractor,"
   A surgical retractor comprises a pair of arms having a common pivotal connection and a pair of retractor blades, each blade detachably connected to an arm by a rotating knee joint which allows the retractor blade to rotate about an axis parallel to the arm and also about an axis perpendicular to the arm. A detent locking mechanism allows any selected pair of a plurality of pairs of retractor blades to be detachably attached to the arms. The knee joint comprises an open sleeve for easy sanitizing. The arms are opened and closed using handles having a locking ratchet mechanism and pawl allowing the arms to be locked in any open position. 
",CHANG DAVID,CHANG DAVID,,https://lens.org/025-976-978-768-595,Patent Application,yes,0,61,2,2,0,A61B17/0206;;A61B2017/00473;;A61B2017/2837;;A61B2090/0813;;A61B17/0206;;A61B2017/2837;;A61B2017/00473;;A61B2090/0813,A61B17/00;;A61B17/02;;A61B17/28;;A61B19/00,60021,0,0,,,,EXPIRED
17,US,B2,US 9271561 B2,034-940-828-446-402,2016-03-01,2016,US 201414175683 A,2014-02-07,US 201414175683 A;;US 201361762376 P,2013-02-08,Apparatus for improving the interchangeability of portable electronic devices amongst various supports and related methods,"Disclosed are apparatus and related methods of interchangeably securing (a) portable electronic devices or (b) portable electronic devices that are housed within protective cases to one more supports. In one embodiment, the apparatus may be a holster with a coupling means for removably securing the holster to a support (e.g., a clip, armband, or vehicle mount) that features cooperating coupling means. In another embodiment, the apparatus may be a protective case with a coupling means for removably securing the holster to a support that features cooperating coupling means.",CHANG DAVID,CHANG DAVID,,https://lens.org/034-940-828-446-402,Granted Patent,yes,36,3,2,2,0,A45F5/021;;A45F5/021;;A45F2005/025;;A45F2005/025;;A45F2200/0508;;A45F2200/0508;;A45F2200/0516;;A45F2200/0516;;A45F2200/0525;;A45F2200/0525,A45F5/02,,0,0,,,,INACTIVE
18,AU,B2,AU 2006/226897 B2,051-106-765-598-290,2009-05-07,2009,AU 2006/226897 A,2006-03-22,US 66438105 P;;US 38627106 A;;US 2006/0010582 W,2005-03-22,Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors,,AMGEN INC,CHANG DAVID,,https://lens.org/051-106-765-598-290,Granted Patent,no,1,0,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K31/444;;A61K39/395;;A61P35/00,,2,2,005-993-015-380-052;;081-940-125-686-439,10.1016/s0959-8049(02)00013-8;;12008203;;pmc2364099;;11506500;;10.1054/bjoc.2001.1936,"Jung, Y. D. et al, European Journal of Cancer (2001) vol 38, no 8 pp 1133 - 1140.;;Shaheen, R. M et al, British Journal of Cancer (2001) Vol 85 No 4 pp 584 - 589",INACTIVE
19,CN,A,CN 102177332 A,088-553-966-211-838,2011-09-07,2011,CN 200980139657 A,2009-09-30,US 2009/0058954 W;;US 28724808 A,2008-10-07,Cooling feature for fuel injector and fuel system using same,"A thermal load control assembly for a fuel injector (100) includes a rail inlet port (14), a cooling inlet port (16) and a fuel drain port (18). A leakage path channels leaked fuel originating from the rail inlet port (14) to the fuel drain port (18). A cooling path channels fuel originating from the cooling inlet port (16) to the fuel drain port (18). A fuel system (500) using a thermal load control assembly includes a single fuel tank (90) that supplies fuel to the rail inlet port (14) and the cooling inlet port (16) of a plurality of fuel injectors (200) and collect fuel from the fuel drain port (18) of the plurality of fuel injectors (200).",CATERPILLAR INC,DAVID CHANG,,https://lens.org/088-553-966-211-838,Patent Application,no,0,5,8,8,0,F02M47/027;;F02M47/027;;F02M53/04;;F02M53/04;;F02M53/043;;F02M53/043;;F02M2700/077;;F02M2700/077,F02M53/04;;F02M51/06;;F02M61/04;;F02M61/16,,0,0,,,,INACTIVE
20,US,A,US 6015360 A,118-579-791-029-752,2000-01-18,2000,US 9837798 A,1998-06-17,US 9837798 A,1998-06-17,Automatic gearshifting device of multi-stage fly wheel of bicycle,"An automatic gearshifting device of a bicycle multi-stage fly wheel is composed of a main body, a rotary shaft, an urging member, a plurality of weights located in a receiving cell of the main body, and a drive chain guiding mechanism. The rotary shaft is fastened pivotally with the main body. The urging member is slidably mounted on the rotary shaft such that the urging member is capable of being actuated by the centrifugal force of the weights in motion to slide in the direction of the longitudinal axis of the rotary shaft so as to enable the drive chain guiding mechanism to shift the drive chain from one tooth to another tooth of the bicycle multi-stage fly wheel gear cluster.",FALCON IND CO LTD,CHANG DAVID,FALCON INDUSTRIAL CO. LTD (1998-06-08),https://lens.org/118-579-791-029-752,Granted Patent,yes,9,25,1,1,0,B62M25/00;;B62M25/00;;B62M9/123;;B62M9/123,B62M9/123;;B62M25/00,474/80;;474/78;;474/82,0,0,,,,EXPIRED
21,US,S,US D0682815 S,010-634-996-872-762,2013-05-21,2013,US 201129390939 F,2011-04-29,US 201129390939 F,2011-04-29,Case,,CHANG DAVID,CHANG DAVID,SEIDIO INC (2013-05-21),https://lens.org/010-634-996-872-762,Design Right,no,0,18,1,1,0,,,1403;;D14/250,0,0,,,,ACTIVE
22,US,B1,US 6188201 B1,011-056-314-478-501,2001-02-13,2001,US 40160899 A,1999-09-22,TW 88212094 U;;JP 2000211198 A;;CN 00137452 A,1999-07-19,Device for converting direct current input into multiple voltage outputs,"A power converting device is adapted for use with a battery pack. The power converting device includes a housing formed with a battery receiving space that is adapted for receiving the battery pack therein, a battery connector mounted on the housing inside the receiving space and adapted to be connected electrically with the battery pack when the battery pack is disposed inside the battery receiving space, at least two output connectors mounted on the housing and accessible from an exterior of the housing, and a power converting circuit mounted inside the housing and connected electrically to the battery connector and the output connectors. The power converting circuit is adapted to be connected electrically to the battery pack via the battery connector, and is adapted to convert electrical power of the battery pack into at least two voltage outputs that can be tapped at the output connectors, respectively.",PACIFIC TECHNOLOGY CO LTD,CHANG DAVID,PACIFIC TECHNOLOGY CO. LTD (1999-09-08);;MOBILETECH INC (2000-12-08),https://lens.org/011-056-314-478-501,Granted Patent,yes,2,5,5,5,0,G06F1/26;;H01M6/06;;H01M10/425;;H01M10/46;;H01M10/48;;H02J7/0042;;H02J7/0068;;H01M10/4207;;H01M16/00;;H01M2200/00;;H01M2220/30;;H02J1/082;;Y02E60/10;;H01M50/296;;H01M50/251;;G06F1/26;;H01M10/425;;H02J7/0042;;H02J7/0068;;H01M6/06;;H01M10/46;;H01M10/48;;H02J7/00;;G06F1/30;;H01M2220/30;;H01M10/4207;;H01M2200/00;;H01M16/00;;H02J1/082;;H01M50/296;;H01M50/251,B08B7/00;;G06F1/26;;G06F1/30;;G06F19/00;;H01L21/304;;H01M6/06;;H01M10/42;;H01M10/44;;H01M10/46;;H01M10/48;;H01M50/251;;H01M50/296;;H02J1/00;;H02J7/00,320/137,0,0,,,,EXPIRED
23,US,B2,US 7849836 B2,027-489-573-811-203,2010-12-14,2010,US 28724808 A,2008-10-07,US 28724808 A,2008-10-07,Cooling feature for fuel injector and fuel system using same,"A thermal load control assembly for a fuel injector includes a rail inlet port, a cooling inlet port and a fuel drain port. A leakage path channels leaked fuel originating from the rail inlet port to the fuel drain port. A cooling path channels fuel originating from the cooling inlet port to the fuel drain port. A fuel system using a thermal load control assembly includes a single fuel tank that supplies fuel to the rail inlet port and the cooling inlet port of a plurality of fuel injectors and collect fuel from the fuel drain port of the plurality of fuel injectors.",CATERPILLAR INC,CHANG DAVID,CATERPILLAR INC (2008-08-28),https://lens.org/027-489-573-811-203,Granted Patent,yes,36,14,8,8,0,F02M47/027;;F02M47/027;;F02M53/04;;F02M53/04;;F02M53/043;;F02M53/043;;F02M2700/077;;F02M2700/077,F02M53/04,123/456;;239/132;;239/132.1;;239/132.3;;239/132.5,0,0,,,,ACTIVE
24,US,A,US 4891632 A,049-108-583-904-303,1990-01-02,1990,US 14629388 A,1988-01-20,US 14629388 A,1988-01-20,Computer graphic drawing apparatus with coarse and fine controls,"An improved computer graphic drawing apparatus having a housing unit adapted for being held in hand during graphic drawing operations, a coarse adjusting device movably disposed in the housing unit, and an IC arrangement disposed in the housing unit and electrically connected to the coarse adjusting device for being coupled with a host computer. The improvement resides in a few adjusting device movably disposed in the housing unit and includes: a tracking member movably installed on one side of the housing unit; a first and a second rotary member separately installed in the housing unit and rotatably engaged with the tracking member for being rotated on X and Y coordinate axes; and a first and a second encoding device respectively provided in the housing unit and electrically connected to the IC arrangement in conjunction with both rotary members so as to effect signal conversion and transmission in accomplishing fine adjustment operations.",KING PHOENIX CO LTD,CHANG DAVID,KING PHOENIX CO. LTD. A CORP. OF TAIWAN (1988-01-08),https://lens.org/049-108-583-904-303,Granted Patent,yes,10,57,1,1,0,G06F3/038;;G06F3/038;;G06F3/0312;;G06F3/0312;;G06F3/03543;;G06F3/03543;;G06F2203/0333;;G06F2203/0333,G06F3/038,340/710;;340/706;;340/709;;178/18;;X273148B,0,0,,,,EXPIRED
25,US,A1,US 2014/0073377 A1,089-765-800-934-711,2014-03-13,2014,US 201314025636 A,2013-09-12,US 201314025636 A;;US 201261700143 P,2012-09-12,PROTECTIVE CASE FOR PORTABLE ELECTRONIC DEVICES,"The present application is directed to a protective case for housing an electronic device including a front cover member defined by an outer surface and an inner surface and a back cover member having an outer surface and an inner surface defining a first thickness of the back cover member, the inner surface including one or more raised surface areas defining a second thickness of the back cover member along a predetermined pattern.",CHANG DAVID,CHANG DAVID,,https://lens.org/089-765-800-934-711,Patent Application,yes,2,8,1,1,0,A45C2011/002;;H04B1/3888;;H04B1/3888;;B65D81/022;;A45C2011/002,B65D81/02;;H04B1/38,455/575.8;;206/37,0,0,,,,DISCONTINUED
26,US,A,US 3239823 A,136-760-066-122-603,1966-03-08,1966,US 19526762 A,1962-05-16,US 19526762 A,1962-05-16,Twin gap flux responsive head,,IBM,DAVID CHANG,,https://lens.org/136-760-066-122-603,Granted Patent,no,5,13,1,1,0,G11B5/335;;G11B5/335,G11B5/335,,0,0,,,,EXPIRED
27,WO,A2,WO 2006/102504 A2,147-814-106-618-663,2006-09-28,2006,US 2006/0010582 W,2006-03-22,US 66438105 P;;US 38627106 A,2005-03-22,COMBINATIONS FOR THE TREATMENT OF CANCER,"This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.",AMGEN INC,CHANG DAVID,,https://lens.org/147-814-106-618-663,Patent Application,yes,0,5,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K31/444;;A61K39/395;;A61P35/00,,1,1,018-372-145-491-105,15157501;;10.1016/0962-8924(96)84935-x,"G. BREIER ET AL., TRENDS IN CELL BIOLOGY, vol. 6, 1996, pages 454 - 456",PENDING
28,DE,D1,DE 602006003966 D1,159-143-583-488-970,2009-01-15,2009,DE 602006003966 T,2006-09-04,CN 200520118496 U,2005-09-09,Grill-Gerät,"A device for barbequing food, said device including: a cabinet (1) for storing a power source; a burner (3) connectable to said power source for cooking said food, and a means for steam cleaning (5) said device.",CHANG DAVID,CHANG DAVID,,https://lens.org/159-143-583-488-970,Granted Patent,no,0,0,9,9,0,A47J37/0713;;A47J37/0745;;A47J37/0786;;A47J37/0713;;A47J37/0786;;A47J37/0745,A47J37/07,,0,0,,,,INACTIVE
29,US,S,US D0450389 S,002-098-970-494-592,2001-11-13,2001,US 13849301 F,2001-03-14,US 13849301 F,2001-03-14,UV light,,CHANG DAVID,CHANG DAVID,,https://lens.org/002-098-970-494-592,Design Right,yes,7,2,1,1,0,,,D24/210;;2803,0,0,,,,EXPIRED
30,US,A1,US 2010/0074909 A1,015-915-518-126-16X,2010-03-25,2010,US 59210309 A,2009-11-19,US 59210309 A;;US 38627106 A;;US 66438105 P,2005-03-22,Combinations for the treatment of cancer,"This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.",AMGEN INC,CHANG DAVID,,https://lens.org/015-915-518-126-16X,Patent Application,yes,4,2,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61P35/00;;A61K39/395,424/174.1,4,2,014-714-615-027-617;;019-537-469-767-795,12865797;;10.1097/01.tp.0000071362.99021.d9;;10.1016/j.critrevonc.2007.04.011;;17624800,"ClinicalTrials .gov (Jan 18, 2005) 5 pages.;;Pfeiffer (News Center pg 52 September 10, 2004);;Kirk et al. (Transplantation. 2003 Jul 15;76(1):120-9);;Magdelaine-Beuzelin Critical Reviews in Oncology/Hematology 64 (2007) 210-225",DISCONTINUED
31,US,A,US 3399393 A,038-031-662-162-772,1968-08-27,1968,US 41645364 A,1964-12-07,US 41645364 A;;US 1593560 A;;US 1605860 A,1960-03-18,Two-probe three-gap flux sensitive magnetic head,,IBM,DAVID CHANG,,https://lens.org/038-031-662-162-772,Granted Patent,no,2,4,10,10,0,G11B5/265;;G11B5/265;;G11B5/335;;G11B5/335;;G11B23/0007;;G11B23/0007;;H03K3/02;;H03K3/02,G11B5/265;;G11B5/335;;G11B23/00;;H03K3/02,340/174.1,0,0,,,,EXPIRED
32,US,A1,US 2020/0185013 A1,134-994-609-629-785,2020-06-11,2020,US 201816214480 A,2018-12-10,US 201816214480 A,2018-12-10,SERIES CONTINUOUS TIME LINEAR EQUALIZERS,An apparatus includes a first continuous time linear equalizer circuit and a second continuous time linear equalizer circuit. The first continuous time linear equalizer circuit may be configured to generate an intermediate signal by filtering an input signal using a first passive bandpass filter having an inductor. The second continuous time linear equalizer circuit may be configured to generate an output signal by filtering the intermediate signal.,INTEGRATED DEVICE TECH,CHANG DAVID,INTEGRATED DEVICE TECHNOLOGY INC (2018-12-07),https://lens.org/134-994-609-629-785,Patent Application,yes,8,4,2,2,0,G11C5/04;;G11C7/1048;;G11C5/063;;G11C7/1048;;G11C7/1072;;G11C7/1084;;G11C7/225,G11C7/10,,0,0,,,,ACTIVE
33,AT,T1,AT E520402 T1,162-571-535-979-926,2011-09-15,2011,AT 06739398 T,2006-03-22,US 66438105 P;;US 2006/0010582 W,2005-03-22,ANTI-EGFR-ANTIKÖRPER UND VEGFR-INHIBITOREN UMFASSENDE KOMBINATIONEN FÜR DIE BEHANDLUNG VON KREBS,,AMGEN INC,CHANG DAVID,,https://lens.org/162-571-535-979-926,Granted Patent,no,0,0,2,15,0,,,,0,0,,,,INACTIVE
34,DE,T5,DE 112009002378 T5,162-149-350-144-478,2012-01-19,2012,DE 112009002378 T,2009-09-30,US 28724808 A;;US 2009/0058954 W,2008-10-07,"Kühlprinzip für Treibstoffinjektor und Treibstoffsystem, das denselben verwendet","Ein Treibstoffinjektor (100), welcher folgendes aufweist: einen Injektorkörper (10), der einen Düsenauslass (62) definiert, einen „common rail”-Einlassanschluss (14), einen Kühleinlassanschluss (16) und einen Treibstoffauslassanschluss (18); einen Leckagepfad, der den „common rail”-Einlassanschluss (14) mit dem Treibstoffauslassanschluss (18) strömungsmitteltechnisch verbindet; und einen Kühlpfad, der den Kühleinlassanschluss (16) mit dem Treibstoffauslassanschluss (18) strömungsmitteltechnisch verbindet.",CATERPILLAR INC,CHANG DAVID,,https://lens.org/162-149-350-144-478,Patent Application,no,1,2,8,8,0,F02M47/027;;F02M47/027;;F02M53/04;;F02M53/04;;F02M53/043;;F02M53/043;;F02M2700/077;;F02M2700/077,F02M53/04;;F02M51/06;;F02M61/04;;F02M61/16,,0,0,,,,DISCONTINUED
35,US,B2,US 10665293 B2,032-112-789-419-084,2020-05-26,2020,US 201916565913 A,2019-09-10,US 201916565913 A;;US 201816117230 A,2018-08-30,Low power delay buffer between equalizer and high sensitivity slicer,"An apparatus includes a continuous-time linear equalizer circuit, a buffer and at least one slicer. The continuous-time linear equalizer circuit may be configured to generate a first intermediate signal by equalizing an input signal relative to a reference voltage. The input signal may be single-ended. The first intermediate signal may be differential. The buffer may be configured to generate a second intermediate signal by delaying the first intermediate signal. The second intermediate signal may be differential. The slicer may be configured to generate an output signal by slicing the second intermediate signal. The output signal may be single-ended.",INTEGRATED DEVICE TECH,CHANG DAVID,,https://lens.org/032-112-789-419-084,Granted Patent,yes,3,0,3,3,0,G11C11/4093;;G11C11/4093;;G11C5/04;;G11C7/02;;G11C7/1057;;G11C7/1069;;G11C7/1084;;G11C7/1096;;G11C11/4076;;G11C11/4076,G11C11/40;;G11C11/4076;;G11C11/4093,,0,0,,,,ACTIVE
36,EP,B1,EP 1762164 B1,106-652-075-932-273,2008-12-03,2008,EP 06018449 A,2006-09-04,CN 200520118496 U,2005-09-09,Barbecuing device,"A device for barbequing food, said device including: a cabinet (1) for storing a power source; a burner (3) connectable to said power source for cooking said food, and a means for steam cleaning (5) said device.",CHANG DAVID,CHANG DAVID,,https://lens.org/106-652-075-932-273,Granted Patent,yes,2,0,9,9,0,A47J37/0713;;A47J37/0745;;A47J37/0786;;A47J37/0713;;A47J37/0786;;A47J37/0745,A47J37/07,,0,0,,,,ACTIVE
37,WO,A3,WO 2006/102504 A3,151-359-612-728-120,2006-12-07,2006,US 2006/0010582 W,2006-03-22,US 66438105 P;;US 38627106 A,2005-03-22,COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS,"This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.",AMGEN INC,CHANG DAVID,,https://lens.org/151-359-612-728-120,Search Report,yes,1,0,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K39/395;;A61K31/444;;A61P35/00,,8,7,018-286-727-509-407;;012-135-753-166-122;;005-993-015-380-052;;081-940-125-686-439;;037-980-954-321-315;;003-828-498-404-757;;038-240-454-996-722,16951187;;10.1158/0008-5472.can-05-4665;;10.1038/sj.onc.1208625;;15806152;;10.1016/s0959-8049(02)00013-8;;12008203;;pmc2364099;;11506500;;10.1054/bjoc.2001.1936;;10.1002/jcp.20666;;16688779;;10.1158/1078-0432.ccr-05-1682;;16609035;;15289342;;10.1158/0008-5472.can-04-0562,"POLVERINO ANTHONY ET AL: ""AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts."", CANCER RESEARCH. 1 SEP 2006, vol. 66, no. 17, 1 September 2006 (2006-09-01), pages 8715 - 8721, XP002399536, ISSN: 0008-5472;;LUWOR RODNEY B ET AL: ""The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression"", ONCOGENE, vol. 24, no. 27, June 2005 (2005-06-01), Published online 04.04.2005, pages 4433 - 4441, XP002399537, ISSN: 0950-9232;;JUNG Y D ET AL: ""Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model"", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, no. 8, May 2002 (2002-05-01), pages 1133 - 1140, XP004352362, ISSN: 0959-8049;;SHAHEEN R M ET AL: ""INHIBITED GROWTH OF COLON CANCER CARCINOMATOSIS BY ANTIBODIES TO VASCULAR ENDOTHELIAL AND EPIDERMAL GROWTH FACTOR RECEPTORS"", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 85, no. 4, 17 August 2001 (2001-08-17), pages 584 - 589, XP008052140, ISSN: 0007-0920;;HERBST, RS ET AL., 40TH ASCO ANNUAL MEETING, NEW ORLEANS, LA (USA), 5 June 2004 (2004-06-05) - 8 June 2004 (2004-06-08), XP002399538;;MORELLI MARIA PIA ET AL: ""Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases"", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 208, no. 2, August 2006 (2006-08-01), pages 344 - 353, XP002399539, ISSN: 0021-9541;;TONRA JAMES R ET AL: ""Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 APR 2006, vol. 12, no. 7 Pt 1, 1 April 2006 (2006-04-01), pages 2197 - 2207, XP002399540, ISSN: 1078-0432;;HUANG SHYHMIN ET AL: ""Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor."", CANCER RESEARCH. 1 AUG 2004, vol. 64, no. 15, 1 August 2004 (2004-08-01), pages 5355 - 5362, XP002399541, ISSN: 0008-5472",PENDING
38,US,A1,US 2007/0056577 A1,137-388-206-864-819,2007-03-15,2007,US 51784106 A,2006-09-07,CN 200520118496 U,2005-09-09,Barbecuing device,"A device for barbequing food, said device including: a cabinet for storing a power source; a burner connectable to said power source for cooking said food, and a means for steam cleaning said device.",CHANG DAVID,CHANG DAVID,,https://lens.org/137-388-206-864-819,Patent Application,yes,7,40,9,9,0,A47J37/0713;;A47J37/0745;;A47J37/0786;;A47J37/0713;;A47J37/0786;;A47J37/0745,A47J37/00,12602500R,0,0,,,,DISCONTINUED
39,US,S,US D0471030 S,145-020-199-929-462,2003-03-04,2003,US 15369002 F,2002-01-14,US 15369002 F,2002-01-14,Sectional desk,,CHANG DAVID,CHANG DAVID,PRODUCT DEPOT INTERNATIONAL CORP (2001-11-28),https://lens.org/145-020-199-929-462,Design Right,no,0,12,1,1,0,,,D 6423;;D6/426;;D6/480,0,0,,,,EXPIRED
40,DE,A1,DE 1474391 A1,182-677-101-507-551,1969-08-21,1969,DE 1474391 A,1965-12-06,US 1593560 A;;US 1605860 A;;US 41645364 A,1960-03-18,Magnetkopf zur Abfuehlung von magnetischen Markierungen,,IBM,CHANG DAVID,,https://lens.org/182-677-101-507-551,Patent Application,no,0,0,10,10,0,G11B5/265;;G11B5/265;;G11B5/335;;G11B5/335;;G11B23/0007;;G11B23/0007;;H03K3/02;;H03K3/02,G11B5/265;;G11B5/335;;G11B23/00;;H03K3/02,,0,0,,,,DISCONTINUED
41,US,A1,US 2003/0200680 A1,078-845-377-421-177,2003-10-30,2003,US 13479002 A,2002-04-29,US 13479002 A,2002-04-29,Shoe with a counter portion,"
   A shoe has a sole, an upper and a counter portion. The upper is securely connected to the sole and has a rear end defined with an opening. The counter portion is detachably connected to the rear end of the upper to close the opening in the upper. A fastener and a connecting device are respectively mounted on two opposite sides of the upper and the counter portion to connect the counter portion to the rear end of the upper. Accordingly, a wearer's foot in the shoe can be vented. Also, for a pair of tied shoes with the counter portions can be put on or taken off without tying or untying the laces. The use of the shoe is versatile and convenient. 
",CHANG DAVID,CHANG DAVID,,https://lens.org/078-845-377-421-177,Patent Application,yes,7,35,1,1,0,A43B3/101;;A43B3/24;;A43B3/248;;A43B7/06;;A43B11/00;;A43B23/088;;A43B3/248;;A43B3/101;;A43B11/00;;A43B3/24;;A43B7/06;;A43B23/088,A43B3/10;;A43B3/24;;A43B7/06;;A43B11/00;;A43B23/02,36/69;;X0361;;36/105,0,0,,,,DISCONTINUED
42,US,B1,US 10475506 B1,103-273-116-071-133,2019-11-12,2019,US 201816117230 A,2018-08-30,US 201816117230 A,2018-08-30,Low power delay buffer between equalizer and high sensitivity slicer,"An apparatus includes a continuous-time linear equalizer circuit, a buffer and at least one slicer. The continuous-time linear equalizer circuit may be configured to generate a first intermediate signal by equalizing an input signal relative to a reference voltage. The input signal may be single-ended. The first intermediate signal may be differential. The buffer may be configured to generate a second intermediate signal by delaying the first intermediate signal. The second intermediate signal may be differential. The slicer may be configured to generate an output signal by slicing the second intermediate signal. The output signal may be single-ended.",INTEGRATED DEVICE TECH,CHANG DAVID,INTEGRATED DEVICE TECHNOLOGY INC (2018-08-29),https://lens.org/103-273-116-071-133,Granted Patent,yes,2,0,3,3,0,G11C11/4093;;G11C11/4093;;G11C5/04;;G11C7/02;;G11C7/1057;;G11C7/1069;;G11C7/1084;;G11C7/1096;;G11C11/4076;;G11C11/4076,G11C11/40;;G11C11/4076;;G11C11/4093,,0,0,,,,ACTIVE
43,US,B1,US 10658016 B1,136-001-406-018-574,2020-05-19,2020,US 201816214480 A,2018-12-10,US 201816214480 A,2018-12-10,Series continuous time linear equalizers,An apparatus includes a first continuous time linear equalizer circuit and a second continuous time linear equalizer circuit. The first continuous time linear equalizer circuit may be configured to generate an intermediate signal by filtering an input signal using a first passive bandpass filter having an inductor. The second continuous time linear equalizer circuit may be configured to generate an output signal by filtering the intermediate signal.,INTEGRATED DEVICE TECH,CHANG DAVID,INTEGRATED DEVICE TECHNOLOGY INC (2018-12-07),https://lens.org/136-001-406-018-574,Granted Patent,yes,8,4,2,2,0,G11C5/04;;G11C7/1048;;G11C5/063;;G11C7/1048;;G11C7/1072;;G11C7/1084;;G11C7/225,G11C7/10,,0,0,,,,ACTIVE
44,EP,A1,EP 1762164 A1,138-288-014-332-699,2007-03-14,2007,EP 06018449 A,2006-09-04,CN 200520118496 U,2005-09-09,Barbecuing device,"A device for barbequing food, said device including: a cabinet (1) for storing a power source; a burner (3) connectable to said power source for cooking said food, and a means for steam cleaning (5) said device.
",CHANG DAVID,CHANG DAVID,,https://lens.org/138-288-014-332-699,Patent Application,yes,2,4,9,9,0,A47J37/0713;;A47J37/0745;;A47J37/0786;;A47J37/0713;;A47J37/0786;;A47J37/0745,A47J37/07,,0,0,,,,ACTIVE
45,EP,A2,EP 1915151 A2,184-283-686-493-298,2008-04-30,2008,EP 06739398 A,2006-03-22,US 2006/0010582 W;;US 66438105 P;;US 38627106 A,2005-03-22,COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS,,AMGEN INC,CHANG DAVID,,https://lens.org/184-283-686-493-298,Patent Application,yes,0,0,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K31/444;;A61K39/395;;A61P35/00,,0,0,,,,ACTIVE
46,US,S,US D0632386 S,194-559-469-924-087,2011-02-08,2011,US 36288010 F,2010-06-01,US 36288010 F,2010-06-01,Oral supplement,,HERBALIFE INTERNAT OF AMERICA,CHANG DAVID,HERBALIFE INTERNATIONAL OF AMERICA (2010-05-25),https://lens.org/194-559-469-924-087,Design Right,no,0,7,2,2,0,,,2801;;D24/101,0,0,,,,ACTIVE
47,CN,A,CN 102105185 A,005-070-331-350-503,2011-06-22,2011,CN 200880128852 A,2008-08-05,US 2008/0009450 W;;US 7268308 A,2008-05-16,Method and apparatus for vascular access,"The present invention relates to methods and apparatus that facilitate arterial and/or venous access using a securable/anchored structure such as a diaphragm on an outer/adventitial surface of a vessel, as well as to related structures and features. Further methods and apparatus may involve using a semi-permeable sheath with a filter segment to prevent potential embolization. Advantages of some implementations herein relating to eliminating the chamber of a vascular access device may be achieved by making the vessel itself the chamber and incorporating the device as part of the vessel, for example, without reliance of an indwelling catheter sheath to remotely gain access. Some innovations herein relate to facilitating access including methods and devices for automating the access process and preventing embolization.",DAVID CHANG,DAVID CHANG,,https://lens.org/005-070-331-350-503,Patent Application,no,6,1,3,3,0,A61B17/320016;;A61B2017/00778;;A61M1/3653;;A61M1/3661;;A61M1/3655;;A61M1/3661;;A61B17/320016,A61M5/178,,0,0,,,,DISCONTINUED
48,US,S,US D0532931 S,020-176-294-897-76X,2006-11-28,2006,US 22131605 F,2005-01-13,US 22131605 F,2005-01-13,UV gel light,,CHANG DAVID,CHANG DAVID,,https://lens.org/020-176-294-897-76X,Design Right,no,0,14,1,1,0,,,2803;;D28/54.1;;D24/210,0,0,,,,EXPIRED
49,US,B2,US 9209850 B2,025-239-522-771-921,2015-12-08,2015,US 201314084574 A,2013-11-19,US 201314084574 A;;US 201361762372 P,2013-02-08,Protective case for controlling sound waves,The present application is directed to a protective case for an electronic device including a first member and a second member operationally configured to house an electronic device therein; wherein the first member is operationally configured to direct sound waves to an inner surface of the second member; and wherein the second member is operationally configured to dictate travel of sound waves within the protective case.,CHANG DAVID,CHANG DAVID,,https://lens.org/025-239-522-771-921,Granted Patent,yes,8,4,2,2,0,H04B1/3816;;H04M1/035;;H04M1/185;;H04R1/345;;H04R2499/11;;H04B1/3888;;G10K11/002;;H04B1/3888;;G10K11/002;;H04B1/3816;;H04M1/035;;H04M1/185;;H04R1/345;;H04R2499/11,H04M1/00;;G10K11/00;;H04B1/3816;;H04B1/3888;;H04M1/03;;H04M1/18,,0,0,,,,INACTIVE
50,US,A1,US 2014/0228081 A1,064-474-764-391-897,2014-08-14,2014,US 201314084574 A,2013-11-19,US 201314084574 A;;US 201361762372 P,2013-02-08,PROTECTIVE CASE FOR CONTROLLING SOUND WAVES,The present application is directed to a protective case for an electronic device including a first member and a second member operationally configured to house an electronic device therein; wherein the first member is operationally configured to direct sound waves to an inner surface of the second member; and wherein the second member is operationally configured to dictate travel of sound waves within the protective case.,CHANG DAVID,CHANG DAVID,,https://lens.org/064-474-764-391-897,Patent Application,yes,8,14,2,2,0,H04B1/3816;;H04M1/035;;H04M1/185;;H04R1/345;;H04R2499/11;;H04B1/3888;;G10K11/002;;H04B1/3888;;G10K11/002;;H04B1/3816;;H04M1/035;;H04M1/185;;H04R1/345;;H04R2499/11,H04B1/38;;G10K11/00,455/575.8;;181/202,0,0,,,,INACTIVE
51,US,B2,US 9456673 B2,085-705-755-112-435,2016-10-04,2016,US 201314084561 A,2013-11-19,US 201314084561 A;;US 201361826770 P,2013-05-23,Fluid sealable protective case for portable electronic devices,"The present application is directed to a protective case for a portable electronic device, including a back cover and a front cover for housing a portable electronic device therein, wherein the back cover and the front cover include one or more mating surfaces operationally configured to fluidly seal the perimeter of the protective case.",CHANG DAVID,CHANG DAVID,,https://lens.org/085-705-755-112-435,Granted Patent,yes,19,2,2,2,0,A45C11/00;;A45C11/00;;A45C11/22;;A45C11/22;;A45C13/008;;A45C13/008;;A45C2011/002;;A45C2011/002,B65D85/00;;A45C11/00;;A45C11/22;;A45C13/00,,0,0,,,,INACTIVE
52,US,S,US D0615752 S,130-831-623-361-39X,2010-05-18,2010,US 34207909 F,2009-08-18,US 34207909 F,2009-08-18,Clip locking mechanism,,CHANG DAVID,CHANG DAVID,,https://lens.org/130-831-623-361-39X,Design Right,no,0,0,1,1,0,,,0301;;D 3218,0,0,,,,ACTIVE
53,ES,T3,ES 2367872 T3,139-600-440-832-661,2011-11-10,2011,ES 06739398 T,2006-03-22,US 66438105 P,2005-03-22,COMBINACIONES PARA EL TRATAMIENTO DE CANCER QUE COMPRENDEN UN ANTICUERPO ANTI-EGFR E INHIBIDORES DE VEGFR.,"Uso de un anticuerpo anti-EGFR completamente humano en combinación con un inhibidor de VEGFR, en donde el anticuerpo anti-EGFR completamente humano es panitumumab y el inhibidor de VEGFR es N-(2,3-dihidro-3,3-dimetil-1H-indol-6-il)-2-[(4-piridinilmetil)amino]-3-piridincarboxamida, para la fabricación de un medicamento para el control o tratamiento de cáncer de pulmón no microcítico, carcinoma de colon y carcinoma epidermoide en un sujeto.",AMGEN INC,CHANG DAVID,,https://lens.org/139-600-440-832-661,Granted Patent,no,0,0,2,15,0,,A61K31/444;;A61K39/395;;A61P35/00,,0,0,,,,ACTIVE
54,CA,C,CA 2600195 C,175-868-677-100-517,2012-10-16,2012,CA 2600195 A,2006-03-22,US 66438105 P;;US 38627106 A;;US 2006/0010582 W,2005-03-22,COMBINATIONS FOR THE TREATMENT OF CANCER,"This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.",AMGEN INC,CHANG DAVID,,https://lens.org/175-868-677-100-517,Granted Patent,no,0,0,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K39/395;;A61K31/4045;;A61K31/455;;A61K31/502;;A61P35/00,,0,0,,,,INACTIVE
55,US,A1,US 2007/0299372 A1,181-445-579-491-190,2007-12-27,2007,US 47426806 A,2006-06-26,US 47426806 A;;GB 0613020 A,2006-06-26,Foot sole massager,"A foot sole massager comprised of a casing, a power unit in the casing, and a mobile part; the mobile part being driven by the power unit; the mobile part being comprised of multiple pieces and located at where in corresponding to toes of a user when stepping into the foot sole massager; the mobile part operating in a specific or a preset sequence to work out toes of the user to stimulate and enhance the circulation system of the user for the user to stay fit.",CHANG DAVID,CHANG DAVID,,https://lens.org/181-445-579-491-190,Patent Application,yes,3,30,3,3,0,A61H7/004;;A61H1/0266;;A61H1/0266;;A61H2001/027;;A61H2001/027;;A61H2201/1284;;A61H2201/1284;;A61H2205/12;;A61H2205/12,A61H1/02,601/28;;601/27,0,0,,,,DISCONTINUED
56,EP,B1,EP 1915151 B1,191-337-012-702-887,2011-08-17,2011,EP 06739398 A,2006-03-22,US 2006/0010582 W;;US 66438105 P;;US 38627106 A,2005-03-22,COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS,,AMGEN INC,CHANG DAVID,,https://lens.org/191-337-012-702-887,Granted Patent,yes,1,0,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K31/444;;A61K39/395;;A61P35/00,,8,0,,,"POLVERINO ANTHONY ET AL: ""AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts."" CANCER RESEARCH. 1 SEP 2006, vol. 66, no. 17, 1 September 2006 (2006-09-01), pages 8715-8721, XP002399536 ISSN: 0008-5472;;LUWOR RODNEY B ET AL: ""The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression"" ONCOGENE, vol. 24, no. 27, June 2005 (2005-06), pages 4433-4441, XP002399537 Published online 04.04.2005 ISSN: 0950-9232;;JUNG Y D ET AL: ""Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model"" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, no. 8, May 2002 (2002-05), pages 1133-1140, XP004352362 ISSN: 0959-8049;;SHAHEEN R M ET AL: ""INHIBITED GROWTH OF COLON CANCER CARCINOMATOSIS BY ANTIBODIES TO VASCULAR ENDOTHELIAL AND EPIDERMAL GROWTH FACTOR RECEPTORS"" BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 85, no. 4, 17 August 2001 (2001-08-17), pages 584-589, XP008052140 ISSN: 0007-0920;;HERBST, RS ET AL.: 40TH ASCO ANNUAL MEETING, NEW ORLEANS, LA (USA), 5 June 2004 (2004-06-05), - 8 June 2004 (2004-06-08) XP002399538 & HERBST ROY S ET AL: ""Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer."" JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 10 APR 2005, vol. 23, no. 11, 10 April 2005 (2005-04-10), pages 2544-2555, XP002399538 ISSN: 0732-183X;;MORELLI MARIA PIA ET AL: ""Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases"" JOURNAL OF CELLULAR PHYSIOLOGY, vol. 208, no. 2, August 2006 (2006-08), pages 344-353, XP002399539 ISSN: 0021-9541;;TONRA JAMES R ET AL: ""Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy."" CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 APR 2006, vol. 12, no. 7 Pt 1, 1 April 2006 (2006-04-01), pages 2197-2207, XP002399540 ISSN: 1078-0432;;HUANG SHYHMIN ET AL: ""Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor."" CANCER RESEARCH. 1 AUG 2004, vol. 64, no. 15, 1 August 2004 (2004-08-01), pages 5355-5362, XP002399541 ISSN: 0008-5472",ACTIVE
57,AU,A1,AU 2006/225286 A1,015-602-889-727-83X,2008-01-17,2008,AU 2006/225286 A,2006-10-06,CN 200620118792 U,2006-06-23,Barbecuing device,,CHANG DAVID,CHANG DAVID,,https://lens.org/015-602-889-727-83X,Patent Application,no,0,1,2,2,0,,A47J37/07;;B08B3/02,,0,0,,,,DISCONTINUED
58,US,B1,US 6191498 B1,038-980-313-838-433,2001-02-20,2001,US 40160799 A,1999-09-22,TW 88212094 U;;JP 2000211198 A;;CN 00137452 A,1999-07-19,Power-supplying device for generating different voltage outputs,"A power-supplying device is adapted to generate different voltage outputs, and includes an input power providing unit for providing an input power signal, a selector unit operable so as to generate a voltage select signal corresponding to a selected one of the voltage outputs, a processor unit connected to the selector unit so as to receive the voltage select signal therefrom and so as to generate a converter control signal corresponding to the voltage select signal, and an adjustable dc-to-dc converter connected to the input power providing unit and the processor unit so as to receive the input power signal and the converter control signal respectively therefrom. The converter is controlled by the converter control signal so as to process the input power signal in order to generate the selected one of the voltage outputs.",PACIFIC TECHNOLOGY CO LTD,CHANG DAVID,PACIFIC TECHNOLOGY CO. LTD (1999-09-08);;MOBILETECH INC (2000-12-08),https://lens.org/038-980-313-838-433,Granted Patent,yes,7,32,5,5,0,G06F1/26;;H01M6/06;;H01M10/425;;H01M10/46;;H01M10/48;;H02J7/0042;;H02J7/0068;;H01M10/4207;;H01M16/00;;H01M2200/00;;H01M2220/30;;H02J1/082;;Y02E60/10;;H01M50/296;;H01M50/251;;G06F1/26;;H01M10/425;;H02J7/0042;;H02J7/0068;;H01M6/06;;H01M10/46;;H01M10/48;;H02J7/00;;G06F1/30;;H01M2220/30;;H01M10/4207;;H01M2200/00;;H01M16/00;;H02J1/082;;H01M50/296;;H01M50/251,B08B7/00;;G06F1/26;;G06F1/30;;G06F19/00;;H01L21/304;;H01M6/06;;H01M10/42;;H01M10/44;;H01M10/46;;H01M10/48;;H01M50/251;;H01M50/296;;H02J1/00;;H02J7/00,307/11;;307/80,0,0,,,,EXPIRED
59,US,A1,US 2014/0346078 A1,056-389-166-452-577,2014-11-27,2014,US 201314084561 A,2013-11-19,US 201314084561 A;;US 201361826770 P,2013-05-23,FLUID SEALABLE PROTECTIVE CASE FOR PORTABLE ELECTRONIC DEVICES,"The present application is directed to a protective case for a portable electronic device, including a back cover and a front cover for housing a portable electronic device therein, wherein the back cover and the front cover include one or more mating surfaces operationally configured to fluidly seal the perimeter of the protective case.",CHANG DAVID,CHANG DAVID,,https://lens.org/056-389-166-452-577,Patent Application,yes,9,13,2,2,0,A45C11/00;;A45C11/00;;A45C11/22;;A45C11/22;;A45C13/008;;A45C13/008;;A45C2011/002;;A45C2011/002,A45C13/00,206/521,0,0,,,,INACTIVE
60,EP,A1,EP 0890829 A1,071-165-022-013-293,1999-01-13,1999,EP 97111485 A,1997-07-07,EP 97111485 A,1997-07-07,Hygienic protecting means for electronic thermometer,"A hygienic protecting device for an electronic thermometer includes: a disposable wrapping film wrapped on a front housing portion of an infrared thermometer, a fastening cup member made as truncated cone shape and disposed about the disposable film on the front housing portion of the thermometer having a probe mounted within the front housing portion for fastening the disposable film on the front housing portion for preventing contamination when inserting the front housing portion and the probe into a person's ear canal, and a dust-proof thin film wrapped on the probe for shielding the probe for preventing contamination in the probe with a fastening ring fastening the dust-proof thin film on the probe and a circular contacting ring disposed about the dust-proof thin film and retained between the dust-proof thin film on the probe and an inside wall in the front housing portion for forming an air space annularly defined between the probe and the front housing portion for minimizing the thermal transfer between the housing portion and the probe for preventing the influence by ambient temperature for ensuring a reliable temperature measurement in the ear canal of the person to be measured for a reliable and precise measurement of a body temperature.",UEBE GMBH,CHANG DAVID,"CHANG, JANG CHEN (1999-09-08)",https://lens.org/071-165-022-013-293,Patent Application,yes,4,6,1,1,0,G01J5/02;;G01J5/021;;G01J5/04;;G01J5/049;;G01J5/06,G01J5/02;;G01K1/08,,0,0,,,,DISCONTINUED
61,US,A,US 4989108 A,120-834-419-495-519,1991-01-29,1991,US 41666389 A,1989-10-03,US 41666389 A,1989-10-03,Electro-mechanical latch,"An electro-mechanical latch includes a solenoid having an armature movable from a normally biased first position to a second position in response to an electrical current applied to the solenoid, and means for holding the armature in the second position to allow subsequent removal of the current from the solenoid. When the armature is in its first position, it is adapted to latch a device in a parked position. The armature is non-interactive with said device in its second position. The electro-mechanical latch of the present invention further includes means for releasing the holding of the armature in response to the device returning to its parked position whereby the armature returns to its normally biased first position to latch the device. An important advantage of the present invention is that the current need be applied to the solenoid only for moving the armature to release the device. The current may then be removed since the armature will be held in a position which is non-interactive with the device.",MICROPOLIS CORP,CHANG DAVID,MICROPOLIS (1989-09-19);;DISCOVISION ASSOCIATES (1999-08-27);;MICROPOLIS (S) LIMITED (1997-06-25);;RESEARCH INVESTMENT NETWORK INC (2000-06-30),https://lens.org/120-834-419-495-519,Granted Patent,yes,6,35,1,1,0,E05B47/0002;;E05B47/023;;E05B2047/0074;;G11B19/20;;G11B19/20;;E05B47/023;;E05B2047/0074;;E05B47/0002,E05B47/00;;E05B47/02;;G11B19/20,360/105,0,0,,,,EXPIRED
62,US,S,US D0386932 S,199-026-221-535-475,1997-12-02,1997,US 6024496 F,1996-09-25,US 6024496 F,1996-09-25,CD frame,,CHANG DAVID,CHANG DAVID,,https://lens.org/199-026-221-535-475,Design Right,yes,12,2,1,1,0,,,D 6630;;0604,0,0,,,,EXPIRED
63,GB,A,GB 2439718 A,010-045-981-254-077,2008-01-09,2008,GB 0613020 A,2006-07-03,GB 0613020 A;;US 47426806 A,2006-06-26,Toe massager,"A foot sole massager 1 comprised of a casing, a power unit in the casing, and a mobile part 12; the mobile part 12 being driven by the power unit 11; the mobile part 12 being comprised of multiple pieces and located at where in corresponding to toes of a user when stepping into the foot sole massager 1; the mobile part 12 operating in a specific or a preset sequence to work out toes of the user to stimulate and enhance the circulation system of the user for the user to stay fit.",KARL STAR IND CO LTD,CHANG DAVID,,https://lens.org/010-045-981-254-077,Patent Application,no,6,0,3,3,0,A61H7/004;;A61H1/0266;;A61H1/0266;;A61H2001/027;;A61H2001/027;;A61H2201/1284;;A61H2201/1284;;A61H2205/12;;A61H2205/12,A61H7/00,A5R REQ           REQ,0,0,,,,DISCONTINUED
64,EP,A1,EP 2257322 A1,016-187-605-849-570,2010-12-08,2010,EP 08795077 A,2008-08-05,US 2008/0009450 W;;US 7268308 A,2008-05-16,METHOD AND APPARATUS FOR VASCULAR ACCESS,,CHANG DAVID,CHANG DAVID,,https://lens.org/016-187-605-849-570,Patent Application,yes,0,0,3,3,0,A61B17/320016;;A61B2017/00778;;A61M1/3653;;A61M1/3661;;A61M1/3655;;A61M1/3661;;A61B17/320016,A61M5/178,,0,0,,,,DISCONTINUED
65,US,B2,US 6663562 B2,098-298-447-953-642,2003-12-16,2003,US 95309301 A,2001-09-14,US 95309301 A,2001-09-14,Surgical retractor,"
    A surgical retractor comprises a pair of arms having a common pivotal connection and a pair of retractor blades, each blade detachably connected to an arm by a rotating knee joint which allows the retractor blade to rotate about an axis parallel to the arm and also about an axis perpendicular to the arm. A detent locking mechanism allows any selected pair of a plurality of pairs of retractor blades to be detachably attached to the arms. The knee joint comprises an open sleeve for easy sanitizing. The arms are opened and closed using handles having a locking ratchet mechanism and pawl allowing the arms to be locked in any open position. 
",CHANG DAVID,CHANG DAVID,,https://lens.org/098-298-447-953-642,Granted Patent,yes,10,60,2,2,0,A61B17/0206;;A61B2017/00473;;A61B2017/2837;;A61B2090/0813;;A61B17/0206;;A61B2017/2837;;A61B2017/00473;;A61B2090/0813,A61B17/00;;A61B17/02;;A61B17/28;;A61B19/00,600/219;;600/213,0,0,,,,EXPIRED
66,WO,A2,WO 2010/042359 A2,025-096-362-412-288,2010-04-15,2010,US 2009/0058954 W,2009-09-30,US 28724808 A,2008-10-07,COOLING FEATURE FOR FUEL INJECTOR AND FUEL SYSTEM USING SAME,"A thermal load control assembly for a fuel injector (100) includes a rail inlet port (14), a cooling inlet port (16) and a fuel drain port (18). A leakage path channels leaked fuel originating from the rail inlet port (14) to the fuel drain port (18). A cooling path channels fuel originating from the cooling inlet port (16) to the fuel drain port (18). A fuel system (500) using a thermal load control assembly includes a single fuel tank (90) that supplies fuel to the rail inlet port (14) and the cooling inlet port (16) of a plurality of fuel injectors (200) and collect fuel from the fuel drain port (18) of the plurality of fuel injectors (200).",CATERPILLAR INC;;CHANG DAVID,CHANG DAVID,,https://lens.org/025-096-362-412-288,Patent Application,yes,0,0,8,8,0,F02M47/027;;F02M47/027;;F02M53/04;;F02M53/04;;F02M53/043;;F02M53/043;;F02M2700/077;;F02M2700/077,F02M53/04;;F02M51/06;;F02M61/04;;F02M61/16,,0,0,,,,PENDING
67,US,A1,US 2002/0170839 A1,165-164-382-244-072,2002-11-21,2002,US 10468702 A,2002-03-21,US 10468702 A;;US 60380300 A,2000-06-26,Golf bag with honeycomb cell structure,"
   A golf bag having a club-separating staggered honeycomb-like cell structure and a method for manufacturing is disclosed. The golf bag includes a plurality of individual hollow fabric-lined plastic or soft fabric tubes coupled to a top opening or collar, and confined or anchored by a bottom or base. The full-length tubing separates and protects the shafts of the golf clubs and prevent them from becoming entangled. The collar comprises a plurality of openings arranged in a honeycomb cell configuration. The cell openings are elongated to maximize the separation between club heads and also allow easy access for club retrieval and replacement. The base as configured keeps the lower end of the tubes in line with cell openings at the other end of the golf bag. The method of manufacturing consists of shaping, positioning and attaching a plurality of tubing to the collar and the base to form the honeycomb cell structure. 
",CHANG DAVID,CHANG DAVID,,https://lens.org/165-164-382-244-072,Patent Application,yes,0,6,2,2,0,A63B55/00;;A63B55/53;;A63B57/0032;;A63B57/203;;A63B55/40;;A63B55/40;;A63B55/53;;A63B57/203;;A63B57/0032,A63B55/00;;A63B55/04;;A63B55/57;;A63B57/00,206/315.6;;211/70.2,0,0,,,,EXPIRED
68,US,A,US 4763608 A,013-512-067-587-880,1988-08-16,1988,US 3051287 A,1987-03-27,US 3051287 A,1987-03-27,Pig holder,"A pig holder which comprises a U-shaped support for holding pigs of different sizes together with a rubber band and buckles respectively located on each side of the U-shaped member. The U-shaped member extends above a base and is supported in a manner which permits free access to the body of the pig, allows adjusting the height of the U-shaped support and permits rotation of the U-shaped support about the base.",CHANG DAVID,CHANG DAVID,,https://lens.org/013-512-067-587-880,Granted Patent,yes,5,1,1,1,0,A61D3/00;;A61D3/00,A61D3/00,119/98,0,0,,,,EXPIRED
69,US,A1,US 2010/0084489 A1,010-018-085-095-916,2010-04-08,2010,US 28724808 A,2008-10-07,US 28724808 A,2008-10-07,Cooling Feature for fuel injector and fuel system using same,"A thermal load control assembly for a fuel injector includes a rail inlet port, a cooling inlet port and a fuel drain port. A leakage path channels leaked fuel originating from the rail inlet port to the fuel drain port. A cooling path channels fuel originating from the cooling inlet port to the fuel drain port. A fuel system using a thermal load control assembly includes a single fuel tank that supplies fuel to the rail inlet port and the cooling inlet port of a plurality of fuel injectors and collect fuel from the fuel drain port of the plurality of fuel injectors.",CATERPILLAR INC,CHANG DAVID,CATERPILLAR INC (2008-08-28),https://lens.org/010-018-085-095-916,Patent Application,yes,34,22,8,8,0,F02M47/027;;F02M47/027;;F02M53/04;;F02M53/04;;F02M53/043;;F02M53/043;;F02M2700/077;;F02M2700/077,B05B1/24,239/132;;123/456;;239/124,0,0,,,,ACTIVE
70,US,S,US D0710839 S,071-309-032-772-381,2014-08-12,2014,US 201329453333 F,2013-04-26,US 201329453333 F,2013-04-26,Protective cover,,CHANG DAVID,CHANG DAVID,,https://lens.org/071-309-032-772-381,Design Right,no,0,25,1,1,0,,,1403;;D14/250,0,0,,,,ACTIVE
71,HK,A2,HK 1093855 A2,101-276-682-523-115,2007-03-16,2007,HK 06111172 A,2006-10-11,HK 06111172 A,2006-10-11,Foot sole massager,,KARL STAR IND CO LTD,CHANG DAVID,,https://lens.org/101-276-682-523-115,Limited Patent,no,0,0,1,1,0,,A61H/,,0,0,,,,INACTIVE
72,CN,B,CN 102177332 B,029-989-478-154-86X,2014-09-10,2014,CN 200980139657 A,2009-09-30,US 2009/0058954 W;;US 28724808 A,2008-10-07,Cooling feature for fuel injector and fuel system using same,,CATERPILLAR INC,CHANG DAVID,,https://lens.org/029-989-478-154-86X,Granted Patent,no,0,0,8,8,0,F02M47/027;;F02M47/027;;F02M53/04;;F02M53/04;;F02M53/043;;F02M53/043;;F02M2700/077;;F02M2700/077,F02M53/04;;F02M51/06;;F02M61/04;;F02M61/16,,0,0,,,,INACTIVE
73,WO,A1,WO 2022/156097 A1,035-891-861-726-367,2022-07-28,2022,CN 2021093537 W,2021-05-13,CN 202110080782 A,2021-01-20,FACE-MASK-BASED FILTER LAYER STRUCTURE,"The present invention relates to the technical field of respiratory protection devices, and particularly provides a face-mask-based filter layer structure. Two sides of a filter layer are provided with continuous and mutually crossed rack-shaped ventilation grooves, and each of the ventilation grooves comprises a first ventilation groove, a second ventilation groove, a third ventilation groove or a fourth ventilation groove; each of the ventilation grooves comprises a first ventilation groove wall and a second ventilation groove wall which are connected to each other, the first ventilation groove walls and the second ventilation groove walls being formed by folding the filter layers; and each of the ventilation grooves is formed by one or more of the first ventilation groove, the second ventilation groove, the third ventilation groove and the fourth ventilation groove. The filter layer structure can effectively reduce the exhalation resistance under the condition that the filter effect remains unchanged, such that the filter layer structure is more comfortable to wear and use for long periods of time.",FARSTAR WUXI MEDICAL EQUIPMENT CO LTD,CHANG DAVID,,https://lens.org/035-891-861-726-367,Patent Application,yes,7,0,2,2,0,A41D13/1107;;A41D27/28;;A41D31/14,A41D27/28;;A41D13/11;;A41D31/14,,0,0,,,,PENDING
74,AU,A1,AU 2006/226897 A1,085-605-191-993-207,2006-09-28,2006,AU 2006/226897 A,2006-03-22,US 66438105 P;;US 38627106 A;;US 2006/0010582 W,2005-03-22,Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors,,AMGEN INC,CHANG DAVID,,https://lens.org/085-605-191-993-207,Patent Application,no,0,0,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K31/444;;A61K39/395;;A61P35/00,,0,0,,,,INACTIVE
75,US,S,US D0463922 S,085-572-343-202-964,2002-10-08,2002,US 15378202 F,2002-01-14,US 15378202 F,2002-01-14,Sectional shelf,,CHANG DAVID,CHANG DAVID,PRODUCT DEPOT INTERNATIONAL CORP (2001-11-28),https://lens.org/085-572-343-202-964,Design Right,no,0,0,1,1,0,,,D 6426,0,0,,,,EXPIRED
76,US,S,US D0710345 S,139-206-602-243-638,2014-08-05,2014,US 201329453334 F,2013-04-26,US 201329453334 F,2013-04-26,Protective cover,,CHANG DAVID,CHANG DAVID,,https://lens.org/139-206-602-243-638,Design Right,no,0,8,1,1,0,,,1403;;D14/250,0,0,,,,ACTIVE
77,US,B1,US 10360970 B1,136-551-339-907-748,2019-07-23,2019,US 201815924668 A,2018-03-19,US 201815924668 A,2018-03-19,Standing and resonant wave clocking in DDR RCD and data buffer,An apparatus includes a plurality of termination points and a clock mesh network. The termination points may be configured to send/receive timing signals. Each of the termination points may comprise an inductor. The clock mesh network may be configured to provide a path to transmit the timing signals from a clock source to a plurality of components and implement a condition using the inductors. The inductors for each of the termination points may be implemented to meet the condition. Values for the inductors may be determined based on characteristics of the clock mesh network. The condition may prevent power loss.,INTEGRATED DEVICE TECH,CHANG DAVID,INTEGRATED DEVICE TECHNOLOGY INC (2018-03-16),https://lens.org/136-551-339-907-748,Granted Patent,yes,1,2,1,1,0,G06F1/10;;G11C5/04;;G11C7/1057;;G11C7/1084;;G11C7/222;;G11C11/4093;;G11C11/4076;;G11C29/023;;G11C29/028;;G11C29/50012;;G11C11/4076;;H03H7/32;;G11C11/4093;;G06F1/10,G11C11/40;;G11C11/4076;;G11C11/4093;;H03H7/32,,0,0,,,,ACTIVE
78,ES,T3,ES 2318635 T3,165-486-620-697-491,2009-05-01,2009,ES 06018449 T,2006-09-04,CN 200520118496 U,2005-09-09,APARATO PARA ASAR A LA PARRILLA.,"A device for barbequing food, said device including: a cabinet (1) for storing a power source; a burner (3) connectable to said power source for cooking said food, and a means for steam cleaning (5) said device.",CHANG DAVID,CHANG DAVID,,https://lens.org/165-486-620-697-491,Granted Patent,no,0,0,9,9,0,A47J37/0713;;A47J37/0745;;A47J37/0786;;A47J37/0713;;A47J37/0786;;A47J37/0745,A47J37/07,,0,0,,,,ACTIVE
79,US,A1,US 2006/0216288 A1,143-322-918-383-234,2006-09-28,2006,US 38627106 A,2006-03-21,US 38627106 A;;US 66438105 P,2005-03-22,Combinations for the treatment of cancer,"This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.",AMGEN INC,CHANG DAVID,AMGEN INC (2006-03-21),https://lens.org/143-322-918-383-234,Patent Application,yes,25,29,13,15,0,A61K31/444;;A61K39/395;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61P11/06;;A61P15/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61K45/06;;A61K39/395;;A61K31/444;;A61K39/39558;;A61K2039/505,A61K31/44;;A61K39/395;;A61K31/4439;;A61K31/4545;;A61K31/55,424/143.1;;514/352;;514/210.2;;514/318;;514/340;;514/217.04,0,0,,,,DISCONTINUED
80,US,S,US D0464213 S,176-128-904-607-856,2002-10-15,2002,US 15434302 F,2002-01-28,US 15434302 F,2002-01-28,Computer table,,CHANG DAVID,CHANG DAVID,PRODUCT DEPOT INTERNATIONAL CORP (2001-12-31),https://lens.org/176-128-904-607-856,Design Right,no,0,2,1,1,0,,,D 6426,0,0,,,,EXPIRED
81,AT,T1,AT E415848 T1,189-637-011-810-280,2008-12-15,2008,AT 06018449 T,2006-09-04,CN 200520118496 U,2005-09-09,GRILL-GERÄT,"A device for barbequing food, said device including: a cabinet (1) for storing a power source; a burner (3) connectable to said power source for cooking said food, and a means for steam cleaning (5) said device.",CHANG DAVID,CHANG DAVID,,https://lens.org/189-637-011-810-280,Granted Patent,no,0,0,9,9,0,A47J37/0713;;A47J37/0745;;A47J37/0786;;A47J37/0713;;A47J37/0786;;A47J37/0745,,,0,0,,,,INACTIVE
82,WO,A1,WO 2009/108164 A1,186-734-937-803-362,2009-09-03,2009,US 2008/0009450 W,2008-08-05,US 7268308 A,2008-05-16,METHOD AND APPARATUS FOR VASCULAR ACCESS,"The present invention relates to methods and apparatus that facilitate arterial and/or venous access using a securable/anchored structure such as a diaphragm on an outer/adventitial surface of a vessel, as well as to related structures and features. Further methods and apparatus may involve using a semi-permeable sheath with a filter segment to prevent potential embolization. Advantages of some implementations herein relating to eliminating the chamber of a vascular access device may be achieved by making the vessel itself the chamber and incorporating the device as part of the vessel, for example, without reliance of an indwelling catheter sheath to remotely gain access. Some innovations herein relate to facilitating access including methods and devices for automating the access process and preventing embolization.",CHANG DAVID,CHANG DAVID,,https://lens.org/186-734-937-803-362,Patent Application,yes,20,1,3,3,0,A61B17/320016;;A61B2017/00778;;A61M1/3653;;A61M1/3661;;A61M1/3655;;A61M1/3661;;A61B17/320016,A61M5/178,,0,0,,,,PENDING
83,US,A1,US 2014/0305985 A1,195-154-235-296-787,2014-10-16,2014,US 201414175683 A,2014-02-07,US 201414175683 A;;US 201361762376 P,2013-02-08,Apparatus for improving the interchangeability of portable electronic devices amongst various supports and related methods,"Disclosed are apparatus and related methods of interchangeably securing (a) portable electronic devices or (b) portable electronic devices that are housed within protective cases to one more supports. In one embodiment, the apparatus may be a holster with a coupling means for removably securing the holster to a support (e.g., a clip, armband, or vehicle mount) that features cooperating coupling means. In another embodiment, the apparatus may be a protective case with a coupling means for removably securing the holster to a support that features cooperating coupling means.",CHANG DAVID,CHANG DAVID,,https://lens.org/195-154-235-296-787,Patent Application,yes,36,18,2,2,0,A45F5/021;;A45F5/021;;A45F2005/025;;A45F2005/025;;A45F2200/0508;;A45F2200/0508;;A45F2200/0516;;A45F2200/0516;;A45F2200/0525;;A45F2200/0525,A45F5/02,224/676,0,0,,,,INACTIVE
84,CN,A,CN 101005351 A,173-024-225-117-702,2007-07-25,2007,CN 200710004267 A,2007-01-19,US 33620506 A,2006-01-20,System and method for information processing,"A system and method that allows an administrator to set a new password at a wireless access point, such as a traditional WAP or a wireless router. The wireless access point creates a message that includes the new password. The message is encrypted using the old password that was previously set for the wireless network. The encrypted message is wirelessly transmitted from the wireless access point to the active client devices (those clients currently accessing the wireless network). The clients decrypt the message using the old password that was previously provided to the clients. The clients retrieve the new password from the message. The clients construct a new message that is encrypted using the new password. The new message is wirelessly transmitted from the clients to the wireless access device and serves as an acknowledgement.",IBM,VISHWANATH CHANG DAVID Y CHANG,,https://lens.org/173-024-225-117-702,Patent Application,no,0,23,7,7,0,H04L63/0428;;H04L63/0846;;H04W12/06;;H04W12/033;;H04L63/0846;;H04L63/0428;;H04W12/06;;H04W12/033,H04L9/00;;G06F21/44;;H04L29/06,,0,0,,,,INACTIVE
85,US,A,US 4123595 A,004-930-736-285-608,1978-10-31,1978,US 83554377 A,1977-09-22,US 83554377 A,1977-09-22,Metallic coated article,"A metallic article is provided with improved resistance to high temperature environmental conditions, particularly hot corrosion resistance, through the interdiffusion with the article substrate of a complex graded coating including an inner portion which includes Al, Cr and at least one of the elements Fe, Co and Ni and an outer portion including at least one element selected from Hf, Pt, Rh and Pd.",GEN ELECTRIC,CHANG DAVID R,,https://lens.org/004-930-736-285-608,Granted Patent,yes,7,71,11,11,0,C23C28/021;;C23C28/023;;C23C28/028;;F01D5/288;;F01D25/007;;Y10T428/12458;;Y10T428/12875;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;Y10T428/12458;;Y10T428/12875;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;F01D25/007;;C23C28/028;;C23C28/021;;F01D5/288;;C23C28/023,C23C10/28;;C23C10/52;;C23C10/26;;C23C10/54;;C23C10/56;;C23C28/02;;F01D5/28;;F01D25/00,428/667,0,0,,,,EXPIRED
86,CA,A1,CA 2957924 A1,006-362-923-126-688,2018-01-21,2018,CA 2957924 A,2017-02-14,TW 105122979 A,2016-07-21,SHOE WITH FLEXIBLE UPPER,"A shoe includes an outsole, a main body containing a flexible upper, and at least one elastic lace. The flexible upper is formed of a four-way stretch fabric. In use, the flexible upper can be deformed in response to the shape differences of users' feet, and the elastic lace can limit the deformation of the flexible upper to allow the shoe to be firmly worn by a user. With the shoe of the present invention, the unfit problem of conventional shoes due to the insufficient elasticity of the mesh fabrics making the uppers of the shoes can be solved.",CHANG GARY DAVID,CHANG GARY DAVID,,https://lens.org/006-362-923-126-688,Patent Application,no,0,0,5,5,0,A43B23/027;;A43B23/027;;A43B13/04;;A43B13/22;;A43B23/0205;;A43B23/0205;;A43B23/0265;;A43B23/0265;;A43C1/02;;A43C1/02,A43B23/02;;A43B1/00;;A43B1/10,,0,0,,,,ACTIVE
87,US,S,US D0681624 S,064-723-509-016-47X,2013-05-07,2013,US 201229431866 F,2012-09-11,US 201229431866 F,2012-09-11,Protective cover,,CHANG DAVID S,CHANG DAVID S,SEIDIO INC (2013-05-07),https://lens.org/064-723-509-016-47X,Design Right,no,0,5,1,1,0,,,1403;;D14/250,0,0,,,,ACTIVE
88,MX,A,MX 9500424 A,072-420-314-323-949,1997-10-31,1997,MX 9500424 A,1995-01-11,US 17490593 A,1993-12-29,THICKENED ALKALI HYPOCHLORITE COMPOSITIONS.,"According to the invention, a thickened alkali metal hypochlorite composition exhibiting a high level of stability has been discovered. An alkali metal C10 - C14 straight chain alkyl benzene sulfonate used in conjunction with a molar ratio of tertiary amine oxide to the sulfonate ranging from about 5:1 to about 11:1 has been discovered to increase the viscosity of alkali metal hypochlorite bleaches.",RECKITT & COLMAN INC,CHANG DAVID L,,https://lens.org/072-420-314-323-949,Patent Application,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,PENDING
89,EP,A1,EP 1696806 A1,089-013-679-561-367,2006-09-06,2006,EP 04811840 A,2004-11-22,US 2004/0039187 W;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,APPARATUS FOR TREATING A CAROTID ARTERY,,VNUS MED TECH INC,CHANG DAVID W,"SILK ROAD MEDICAL, INC. (2011-04-27)",https://lens.org/089-013-679-561-367,Patent Application,yes,0,0,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,,0,0,,,,ACTIVE
90,DE,D1,DE 69409445 D1,093-294-776-439-935,1998-05-14,1998,DE 69409445 T,1994-07-15,US 9750693 A,1993-07-27,Prozessüberwachung in einem Mehrfachverarbeitungsanbieter,,IBM,CHANG DAVID YU,,https://lens.org/093-294-776-439-935,Granted Patent,no,0,0,7,7,0,G06F11/0715;;G06F11/0715;;G06F11/3006;;G06F11/3006;;G06F11/302;;G06F11/302;;G06F11/3055;;G06F11/3055;;G06F11/3089;;G06F11/3089;;G06F11/328;;G06F11/328,G06F11/30;;G06F11/32;;G06F13/00,,0,0,,,,EXPIRED
91,US,A,US 3611405 A,099-144-771-776-427,1971-10-05,1971,US 3611405D A,1969-11-05,US 87417069 A,1969-11-05,FUNCTIONAL CHECKING OF AN OPTICAL CHANNEL,,IBM,CHANG DAVID C,,https://lens.org/099-144-771-776-427,Granted Patent,no,0,5,7,7,0,G02F1/29;;G02F1/29,G02B26/10;;G02F1/01;;G02F1/29;;G11B7/00;;G11B7/004;;G11C13/04,346/1,0,0,,,,EXPIRED
92,US,A1,US 2010/0191170 A1,106-246-480-903-35X,2010-07-29,2010,US 75303910 A,2010-04-01,US 75303910 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,METHOD AND APPARATUS FOR TREATING A CAROTID ARTERY,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",CHANG DAVID W,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15);;CHANG DAVID W (2005-11-02);;VNUS MEDICAL TECHNOLOGIES INC (2004-12-09),https://lens.org/106-246-480-903-35X,Patent Application,yes,101,22,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M1/00;;A61B17/12;;A61B17/22;;A61M1/36;;A61M25/10,604/9,2,2,023-546-745-949-35X;;028-839-258-555-020,10.1161/01.cir.97.1.121;;9443447;;11241119;;10.1067/mva.2001.112278,"Bettman, M. et al, ""Carotid Stenting and Angioplasty..."", etc. Circulation, 1998; 97:121-123.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" J Vasc Surg 2001 ; 33:504-9.",ACTIVE
93,US,A1,US 2021/0222609 A1,109-283-543-267-664,2021-07-22,2021,US 202016749642 A,2020-01-22,US 202016749642 A,2020-01-22,IGNITOR FOR NATURAL GAS ENGINE,"In one aspect, an engine ignition apparatus for a natural gas engine may include a housing including a drive piston, a floating piston, a controllable hydraulic fluid chamber located between the drive piston and the floating piston, and an ignition chamber acted on by the floating piston, the ignition chamber having an outlet formed by a plurality of orifices, the outlet being in direct communication with a combustion chamber of the engine. In another aspect, an engine ignition apparatus for a natural gas engine may include, among other features, a controllable valve connected to a hydraulic fluid chamber, and configured to open and release a hydraulic fluid from the hydraulic fluid chamber, and to close. In still another aspect, a method for controlling an engine ignition apparatus for an engine includes, among other features, controlling a volume of a hydraulic fluid chamber of an ignition apparatus.",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2020-01-22),https://lens.org/109-283-543-267-664,Patent Application,yes,0,1,4,4,0,F02M26/01;;F02D15/04;;F02D41/0085;;F02D19/02;;F02D41/0027;;F02B19/14;;F02B19/06;;F02B2043/103;;F02B1/12;;Y02T10/12;;Y02T10/30;;F02B1/12;;F02M26/01;;F02D37/02;;F02B3/06;;F02B2075/125;;F02B2275/14;;F02D13/0215;;F02D2041/001;;F02D2041/389,F02M26/01;;F02B1/12,,0,0,,,,ACTIVE
94,US,B2,US 7998104 B2,115-115-682-132-553,2011-08-16,2011,US 99630104 A,2004-11-22,US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15);;CHANG DAVID W (2005-11-02);;VNUS MEDICAL TECHNOLOGIES INC (2004-12-09),https://lens.org/115-115-682-132-553,Granted Patent,yes,106,94,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M29/00;;A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,604/9;;604/8;;604/96.01;;604/317,29,24,020-746-684-497-43X;;009-555-772-505-698;;024-321-843-309-136;;002-478-877-804-626;;107-686-988-816-391;;040-075-091-947-635;;022-030-526-030-972;;033-078-657-817-419;;028-839-258-555-020;;001-001-379-646-544;;056-537-645-364-701;;016-207-092-214-742;;022-030-526-030-972;;040-075-091-947-635;;018-373-571-777-960;;034-095-739-046-671;;053-599-451-169-494;;061-407-975-772-244;;071-968-223-548-381;;016-207-092-214-742;;002-908-369-553-055;;017-528-531-432-121;;095-706-461-958-467;;093-172-129-212-966,10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;9293823;;10.1016/s0002-9610(97)90065-9;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;15239376;;10.1016/s1051-0443(07)61746-1;;11932374;;11241119;;10.1067/mva.2001.112278;;15111851;;10.1016/j.jvs.2004.01.045;;15253268;;10.1007/s10016-004-0018-5;;15218468;;10.1016/j.jvs.2004.03.034;;15239376;;10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;10.1016/j.jvs.2004.06.026;;15337876;;pmc8334090;;2145730;;10731266;;10.1007/s002709900294;;9853153;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1179/016164104225013978;;15142330;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084,"Bergeron et al. (1999). ""Percutaneous stenting of the internal carotid artery: the European Cast I Study"" J. Endovasc. Surg. 6:15-159.;;Bergeron P. et al. (1996) ""Recurrent Carotid Disease: Will Stents be an alternative to surgery?"" J Endovasc Surg; 3: 76-79.;;Criado et al. (1997) ""Evolving indications for and early results of carotid artery stenting"" Am. J. Surg.; 174:111-114.;;Diethrich et al., (1996). ""Percutaneous techniques for endoluminal carotid interventions"" J. Endovasc. Surg. 3:182-202.;;Henry et al. (1999) ""Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System"" J. Endovasc. Surg. 6:321-331.;;Adami, M.D., et al., (2002) ""Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results"" J Endovasc Ther 9:147-154.;;Bates, M.D., et al. (2004) ""Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques"" The West Virginal Medical Journal, vol. 99:60-63.;;Michael S. Stecker t al., ""Stent Placement in Common Carotid and Internal Carotid Artery Stenoses with Use of an Open Transcervical Approach in a Patient with Previous Endarterectomy""; J. Vasc Interv Radiol 2002; 13:413-417.;;Takao Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" (J Vasc Surg 2001; 33:504-9).;;David W. Chang, M.D., et al, ""A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention"" (J Vasc Surg 2004; 39:994-1002.);;Enrique Criado, M.D, et al. ""Transcervical Carotid Artery Angioplasty and Stenting with Carotid Flow Reversal: Surgical Technique"" Ann Vasc Surg 2004; 18: 257-261.;;Enrique Criado, M.D., et al. ""Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient"" Journal of Vascular Surgery, vol. 40, No. 1, 2004.;;MomaPresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig-Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Mark C. Bates, M.D., et al. ""Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques"" The West Virginal Medical Journal, Mar./Apr., vol. 99, 2004:99.;;David W. Chang, M.D., ""Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention"" 30th Global: Vascular and Endovascular Issues, Techniques and Horizons.;;Carlo A. Adami, M.D., et al., ""Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results"" J Endovasc Ther 2002; 9:147-154.;;Mark C. Bates M.D., et al. ""Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model"" Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Enrique Criado, M.D., et al. ""Transcervical carotid stenting with internal carotid artery flow reversal: Feasability and preliminary results"" (J Vasc Surg 2004; 40: 476-83).;;J. Theron, et al. ""New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection"" AJNR 11:869-874, Sep./Oct. 1990 0195-6108/90/1106-0869 @ American Society of Neurology.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device-INVATEC.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.;;Reekers, J. A. (1998). ""A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures."" Cardiovasc Intervent Radiol 21(5): 431-3.;;Chang, M.D., ""Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention"" 30th Global: Vascular and Endovascular Issues, Techniques and Horizons. XXVII 6.1-XXVII 6.2.;;Criado, M.D., et al. (2004) ""Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient"" Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) ""First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting"" Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). ""Direct percutaneous carotid artery stenting with distal protection: technical case report."" Neurol Res 26(3): 338-41.;;Ouriel, K., R. K. Greenberg, et al. (2001). ""Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion."" J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). ""Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices"" J. Vasc. Surg. 32:1127-1136.",ACTIVE
95,US,B2,US 8002728 B2,150-224-080-814-161,2011-08-23,2011,US 17628208 A,2008-07-18,US 17628208 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/150-224-080-814-161,Granted Patent,yes,103,26,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M37/00;;A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,604/6.15;;604/5.01;;604/6.16,26,22,040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;001-001-379-646-544;;024-321-843-309-136;;056-537-645-364-701;;016-207-092-214-742;;034-095-739-046-671;;002-478-877-804-626;;107-686-988-816-391;;028-839-258-555-020;;095-706-461-958-467;;093-172-129-212-966;;070-361-200-679-138;;033-078-657-817-419;;053-599-451-169-494;;016-207-092-214-742;;002-908-369-553-055;;017-528-531-432-121;;061-407-975-772-244,10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;15253268;;10.1007/s10016-004-0018-5;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.jvs.2004.06.026;;15337876;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11241119;;10.1067/mva.2001.112278;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1016/j.jvs.2005.01.003;;15838474;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1179/016164104225013978;;15142330;;10731266,"Adami, M.D., et al., ""Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results"" J Endovasc Ther 2002; 9:147-154.;;Bates M.D., et al. ""Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model"" Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. ""Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques"" The West Virginal Medical Journal, Mar./Apr. 2004, vol. 99.;;Bergeron et al. (1999). ""Percutaneous stenting of the internal carotid artery: the European CAST I Study"" J. Endovasc. Surg. 6:15-159.;;Bergeron P. et al. (1996) ""Recurrent Carotid Disease: Will Stents be an alternative to surgery?"" J Endovasc Surg; 3: 76-79.;;Chang, M.D., ""Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention"" 30th Global: Vascular and Endovascular Issues, Techniques and Horizons.;;Chang, M.D., et al, ""A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention"" (J Vasc Surg 2004; 39:994-1002.).;;Criado et al. (1997) ""Evolving indications for and early results of carotid artery stenting"" Am. J. Surg.; 174:111-114.;;Criado, M.D, et al. ""Transcervical Carotid Artery Angioplasty and Stenting with Carotid Flow Reversal: Surgical Technique"" Ann Vasc Surg 2004; 18: 257-261.;;Criado, M.D., et al. ""Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient"" Journal of Vascular Surgery, vol. 40, No. 1.;;Criado, M.D., et al. ""Transcervical carotid stenting with internal carotid artery flow reversal: Feasability and preliminary results"" (J Vasc Surg 2004; 40: 476-83).;;Diethrich et al., (1996). ""Percutaneous techniques for endoluminal carotid interventions"" J. Endovasc. Surg. 3:182-202.;;Henry et al. (1999) ""Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System"" J. Endovasc. Surg. 6:321-331.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device-INVATEC.;;MomaPresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig-Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). ""Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion."" J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). ""Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices"" J. Vasc. Surg. 32:1127-1136.;;Parodi, J. C., L. M. Ferreira, et al. (2005). ""Cerebral protection during carotid stenting using flow reversal."" J Vasc Surg 41(3): 416-22.;;Stecker et al., ""Stent Placement in Common Carotid and Internal Carotid Artery Stenoses with Use of an Open Transcervical Approach in a Patient with Previous Endarterectomy""; J. Vasc Intery Radiol 2002; 13:413-417.;;Theron, et al. ""New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection"" AJNR 11:869-874, Sep./Oct. 1990 0195-6108/90/1106-0869 @ American Society of Neurology.;;Criado, M.D., et al. (2004) ""Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient"" Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) ""First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting"" Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). ""Direct percutaneous carotid artery stenting with distal protection: technical case report."" Neurol Res 26(3): 338-41.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.",ACTIVE
96,US,B2,US 10828460 B2,146-002-809-646-695,2020-11-10,2020,US 201916411543 A,2019-05-14,US 201916411543 A;;US 201715613921 A;;US 201615082257 A;;US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 66414205 P;;US 62942004 P,2004-11-18,Endoluminal delivery of anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/146-002-809-646-695,Granted Patent,yes,70,1,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M19/00;;A61B6/00;;A61B18/14;;A61M5/00;;A61M25/00;;A61M25/04;;A61M25/10,,1,1,107-686-988-816-391,10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133,Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.,ACTIVE
97,US,A,US 3976436 A,156-028-374-107-171,1976-08-24,1976,US 54976975 A,1975-02-13,US 54976975 A,1975-02-13,Metal of improved environmental resistance,"An alloy based on Fe, Co or Ni, and including Al, is provided with improved environmental resistance through the inclusion in the composition of the combination of 0.1-10 weight percent Hf and 0.5-20 wt. % of an element selected from Pt, Rh and Pd. The combination is particularly useful in providing an article coated with such alloy.",GEN ELECTRIC,CHANG DAVID R,,https://lens.org/156-028-374-107-171,Granted Patent,yes,2,33,11,12,0,C22C19/00;;C22C19/052;;C22C19/053;;C22C38/00;;Y10T428/12931;;Y10T428/12931;;C22C38/00;;C22C19/052;;C22C19/053;;C22C19/00,C22C19/00;;C22C19/05;;C22C19/07;;C22C27/06;;C22C30/00;;C22C38/00;;C23C4/08;;C23C10/58,29/196.6,0,0,,,,EXPIRED
98,US,A,US 3492502 A,176-991-034-823-332,1970-01-27,1970,US 3492502D A,1967-07-14,US 65357167 A,1967-07-14,BI-DIRECTIONAL CAPACITIVE LOAD DRIVER,,IBM,CHANG DAVID C,,https://lens.org/176-991-034-823-332,Granted Patent,no,2,3,12,12,0,H03K17/60;;H03K17/601;;H03K17/601;;H03K17/60,H02M3/28;;H02M9/04;;G05F1/46;;H03K17/60,307/246,0,0,,,,EXPIRED
99,DK,A,DK 471189 A,039-764-714-312-109,1990-03-27,1990,DK 471189 A,1989-09-25,US 24914388 A,1988-09-26,DYNAMISK INFRAROEDT MAAL,,HUGHES AIRCRAFT CO,CHANG DAVID B,,https://lens.org/039-764-714-312-109,Patent Application,no,0,0,8,9,0,F41J2/02;;F41J2/02;;G02F2/02;;G02F2/02,F41J2/02;;G02F2/02,,0,0,,,,EXPIRED
100,US,A1,US 2015/0025616 A1,046-538-460-622-307,2015-01-22,2015,US 201414508354 A,2014-10-07,US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method And Apparatus For Treating A Carotid Artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",CHANG DAVID W;;SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/046-538-460-622-307,Patent Application,yes,2,53,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/22;;A61B17/12;;A61F2/82;;A61M1/00;;A61M1/36;;A61M25/10;;A61M27/00,623/1.11;;606/191;;604/8;;604/508;;606/194,0,0,,,,ACTIVE
101,US,A1,US 2004/0221868 A1,058-475-257-175-812,2004-11-11,2004,US 43068003 A,2003-05-06,US 43068003 A,2003-05-06,Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals,"
   Preparations for the sustained release of a nutraceutical are described that include a solid matrix coated with a methylcellulose-containing coating. The solid matrix contains a polyphenol and the nutraceutical. Methods of controllably releasing a nutraceutical are also described that include administering to a patient a preparation containing a solid matrix coated with methylcellulose-containing coating. The solid matrix includes a polyphenol and a therapeutically effective amount of the nutraceutical. 
",CHANG DAVID S.,CHANG DAVID S,ACCESS BUSINESS GROUP INTERNATIONAL LLC (2003-08-13),https://lens.org/058-475-257-175-812,Patent Application,yes,27,8,2,2,0,A61K9/2068;;A61K9/2068;;A61K9/2866;;A61K9/2866,A01N65/00;;A61C15/00;;A61K9/20;;A61K9/28,132/321,0,0,,,,EXPIRED
102,EP,A4,EP 0151637 A4,069-411-374-288-417,1986-01-07,1986,EP 84903231 A,1984-08-14,US 52332583 A,1983-08-15,INTRAWAVEGUIDE FIBER OPTIC BEAMSPLITTER/COUPLER.,,CHANG DAVID B,CHANG DAVID B,,https://lens.org/069-411-374-288-417,Search Report,no,1,0,9,10,0,G02B6/2817;;Y10S359/90;;G02B6/2817;;Y10S359/90,G02B6/287;;G02B6/28,,5,2,136-416-957-909-028;;053-678-372-470-399,10.1109/jqe.1982.1071658;;10.1063/1.1654036,"PATENTS ABSTRACTS OF JAPAN, vol. 2, no. 153, 22nd December 1978, page 9764 E 78; & JP - A - 53 120 452 (NIPPON DENKI K.K.) 20-10-1978;;PATENTS ABSTRACTS OF JAPAN, vol. 7, no. 113 (P-197)[1258], 18th May 1983; & JP - A - 58 034 408 (NIHON ITA GLASS K.K.) 28-02-1983;;IEEE JOURNAL OF QUANTUM ELECTRONICS, vol. QE-18, no. 7, July 1982, pages 1072-1077, IEEE, New York, US; S.L. CHEN et al.: ""Integrated optical beam splitters formed in glass channel waveguides having variable weighting as determined by mask dimensions"";;APPLIED PHYSICS LETTERS, vol. 20, no. 12, 15th June 1972, pages 506-508; Y. OHMACHI et al.: ""Laser-induced refractive-index change in As-S-Ge glasses"";;See also references of WO 8500898A1",DISCONTINUED
103,US,A,US 5549842 A,066-681-845-204-736,1996-08-27,1996,US 45147795 A,1995-05-26,US 45147795 A;;US 17490593 A,1993-12-29,Thickened alkali metal hypochlorite composition,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C.sub.10 -C.sub.16 alkali metal sarcosinate, and (f) C.sub.10 -C.sub.14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,RECKITT BENCKISER LLC (2010-12-31),https://lens.org/066-681-845-204-736,Granted Patent,yes,31,33,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,510/191;;252/187.24;;252/187.25;;252/187.26;;252/186.36;;510/238;;510/373;;510/490;;510/503,1,0,,,"Abstract Only: EP 79 697, Nov. 7, 1981 GB033642.",EXPIRED
104,US,A,US 4769780 A,070-301-218-467-18X,1988-09-06,1988,US 82840886 A,1986-02-10,US 82840886 A,1986-02-10,High speed multiplier,"A high speed multiplier includes a logic circuit for performing multiplication a multiplicand stored in a first resister and a multiplier stored in a second register, which includes means connected to the second register for selectively gating a selected portion of a multiplier stored in the second register to a recoding means; shift gate means connected to outputs of the first register and controlled by outputs of the recoding means to gate selected groups of multiples of the multiplicand to an adder means for adding a group of multiples of the multiplicand under the control of the control signals; means for accumulating successive intermediate products generated by the adder means; spill adder means, connected to the means for accumulating, for generating a low order portion of a final result of the multiply; storage means for storing the low order portion of the final result; means for generating a high order portion of the final result from outputs of the means for accumulating; and means for storing the high order portion of the final result, wherein the multiplier operates at a rate double the system clock frequency on a 10 bit wide data path on each such double frequency cycle.",IBM,CHANG DAVID C,INTERNATIONAL BUSINESS MACHINES CORPORATION A CORP OF NEW YORK (1986-02-10),https://lens.org/070-301-218-467-18X,Granted Patent,yes,6,21,1,1,0,G06F7/5338;;G06F2207/3844;;G06F7/5338;;G06F2207/3844,G06F7/52,364/760,1,0,,,"Larson, High Speed Multiply Using Four Input Carry Save Adder IBM Tech. Disclosure Bulletin vol. 16 No. 7 pp. 2053 2054.",EXPIRED
105,US,A,US 4123594 A,125-919-797-085-554,1978-10-31,1978,US 83554277 A,1977-09-22,US 83554277 A,1977-09-22,Metallic coated article of improved environmental resistance,"A metallic article is provided with improved resistance to high temperature environmental conditions, particularly hot corrosion resistance, through the interdiffusion with the article substrate of a complex graded coating including an inner portion which includes Cr and at least one of the elements Fe, Co and Ni and an outer portion including Al and at least one element selected from Hf, Pt, Rh and Pd.",GEN ELECTRIC,CHANG DAVID R,,https://lens.org/125-919-797-085-554,Granted Patent,yes,7,82,11,11,0,C23C28/021;;C23C28/023;;C23C28/028;;F01D25/007;;Y10T428/12806;;Y10T428/12931;;Y10T428/12743;;Y10T428/12757;;Y10T428/12875;;Y10T428/12458;;Y10T428/1275;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;Y10T428/12743;;Y10T428/12757;;Y10T428/12875;;Y10T428/12458;;Y10T428/1275;;Y10T428/12854;;F01D25/007;;C23C28/028;;C23C28/023;;C23C28/021,C23C10/52;;C23C10/54;;C23C10/56;;C23C10/28;;C23C28/02;;F01D25/00,428/651,0,0,,,,EXPIRED
106,US,A,US 5094758 A,149-602-277-074-769,1992-03-10,1992,US 65976691 A,1991-02-25,US 65976691 A,1991-02-25,Desalinization system and method,"A system and method are disclosed for desalinating sea water. The system includes an energy source such as a laser 13, and a container 19 (partly or wholly transparent) for holding the sea water, the sea water having sodium and chlorine ions and a solvent (H.sub.2 O) with a predetermined dielectric value. The system applies a predetermined amount of energy, in the form of a laser beam 35 through the transparent container 19, to the seawater substantially at a resonance frequency of the solvent, for reducing the dielectric value of the solvent and vibrating the ions, permitting them to combine and precipitate out of the seawatewr, thereby desalinating the seawater. To increase the effect of the beam 35, the system includes a pair of mirors 15,17 for reflecting the beam back and forth through the sea water. The method employed by the system provides for holding the sea water in a container and applying energy to the sea water, at a resonance frequency of the solvent, sufficient to reduce the dielectric value of the solvent and vibrate the ions.",HUGHES AIRCRAFT CO,CHANG DAVID B,HUGHES AIRCRAFT COMPANY A CORP. OF DE (1991-02-22);;HE HOLDINGS INC. A DELAWARE CORP (1997-12-17);;RAYTHEON COMPANY (1997-12-17),https://lens.org/149-602-277-074-769,Granted Patent,yes,7,4,1,2,0,B01D43/00;;B01J19/121;;C02F1/30;;C02F1/36;;Y10S210/918;;C02F1/36;;B01J19/121;;C02F1/30;;B01D43/00;;Y10S210/918,B01D43/00;;B01J19/12;;C02F1/30;;C02F1/36,210/748;;210/702;;210/918;;210/542;;423/499;;423/659;;422/186;;X250432R;;204/157.41;;204/157.48,0,0,,,,EXPIRED
107,CA,C,CA 2957924 C,172-317-379-229-056,2019-01-08,2019,CA 2957924 A,2017-02-14,TW 105122979 A,2016-07-21,SHOE WITH FLEXIBLE UPPER,"A shoe includes an outsole, a main body containing a flexible upper, and at least one elastic lace. The flexible upper is formed of a four-way stretch fabric. In use, the flexible upper can be deformed in response to the shape differences of users' feet, and the elastic lace can limit the deformation of the flexible upper to allow the shoe to be firmly worn by a user. With the shoe of the present invention, the unfit problem of conventional shoes due to the insufficient elasticity of the mesh fabrics making the uppers of the shoes can be solved.",CHANG GARY DAVID,CHANG GARY DAVID,,https://lens.org/172-317-379-229-056,Granted Patent,no,0,0,5,5,0,A43B23/0265;;A43B23/0205;;A43B23/027;;A43C1/02;;A43B23/0265;;A43B13/04;;A43B13/22;;A43B23/0205;;A43B23/027;;A43C1/02,A43B23/02;;A43B1/00;;A43B1/10,,0,0,,,,ACTIVE
108,EP,B1,EP 0636985 B1,184-303-325-456-710,1998-04-08,1998,EP 94305231 A,1994-07-15,US 9750693 A,1993-07-27,Process monitoring in a multiprocessing server,,IBM,CHANG DAVID YU,,https://lens.org/184-303-325-456-710,Granted Patent,yes,0,0,7,7,0,G06F11/0715;;G06F11/0715;;G06F11/3006;;G06F11/3006;;G06F11/302;;G06F11/302;;G06F11/3055;;G06F11/3055;;G06F11/3089;;G06F11/3089;;G06F11/328;;G06F11/328,G06F11/30;;G06F11/32;;G06F13/00,,4,0,,,"IBM TECHNICAL DISCLOSURE BULLETIN., vol.36, no.6B, June 1993, NEW YORK US pages 269 - 270 'Remote Database Status';;IBM TECHNICAL DISCLOSURE BULLETIN., vol.31, no.8, January 1989, NEW YORK US pages 195 - 198 'Method for Managing Client/Server Relationships in the AIX Operating System';;IBM TECHNICAL DISCLOSURE BULLETIN., vol.28, no.9, February 1986, NEW YORK US pages 3848 - 3855 'Multi-thread Host Server for PC Support';;AT&T 'UNIX System 5 (User's Reference Manual)' 1987 , PRENTICE HALL , ENGLEWOOD CLIFFS, US PS(1) Command * page 210 - page 213 *",EXPIRED
109,CN,B,CN 102086827 B,014-955-731-966-328,2015-04-08,2015,CN 201010579861 A,2010-12-02,US 63005509 A,2009-12-03,Fluid injector with thermal load control,,CATERPILLAR INC,CHANG DAVID Y,,https://lens.org/014-955-731-966-328,Granted Patent,no,0,0,5,5,0,F02M53/043;;F02M63/0225;;F02M63/0225;;F02M53/043,F02M51/06;;F02M53/04;;F02M61/04,,0,0,,,,INACTIVE
110,US,A,US 4575180 A,022-168-422-274-296,1986-03-11,1986,US 52332583 A,1983-08-15,US 52332583 A,1983-08-15,Intrawaveguide fiber optic beamsplitter/coupler,An intrawaveguide fiber optic beamsplitter/coupler and method is enclosed and claimed in which an oriented slot is formed in an intact optical fiber whereby the internal slot functions to divide and direct light along desired paths.,CHANG DAVID B,CHANG DAVID B,,https://lens.org/022-168-422-274-296,Granted Patent,yes,16,24,9,10,0,G02B6/2817;;Y10S359/90;;G02B6/2817;;Y10S359/90,G02B6/28;;G02B6/287,350/96.15;;156/643;;350/96.16;;350/320,8,8,128-246-055-468-770;;034-456-122-266-384;;075-342-168-312-181;;007-422-751-165-653;;009-531-759-487-599;;007-776-191-231-496;;136-416-957-909-028;;053-678-372-470-399,10.1049/el:19820661;;10.1049/el:19830012;;10.1364/ao.20.002420;;20332970;;10.1109/jsac.1983.1145958;;10.1364/ao.20.003128;;20333111;;10.1049/el:19820383;;10.1109/jqe.1982.1071658;;10.1063/1.1654036,"Kawachi et al, Fabrication of Single Polarisation Single Mode Fibre Coupler, Electronics Letters, Oct. 28, 1982, vol. 18, No. 22, pp. 962 964.;;Villarruel et al, Polarisation Preserving Single Mode Fibre Coupler, Electronics Letters, Jan. 6, 1983, vol. 19, No. 1, pp. 17 and 18.;;Parriaux et al, Distributed Coupling on Polished Single Mode Optical Fibers, Applied Optics, vol. 20, No. 14, Jul. 15, 1981, pp. 2420 2423.;;Personick, Review of Fundamentals of Optical Fiber Systems, IEEE Journal on Selected Areas in Communications, vol. SAC 1, No. 3, Apr., 1983, pp. 373 380.;;Winzer et al, Single Mode and Multimode All Fiber Directional Couplers for WDM, Applied Optics, vol. 20, No. 18, Sep. 15, 1981, pp. 3128 3135.;;Sch ner et al, Novel Method for Making Single Mode Optical Fibre Directional Couplers, Electronics Letters, Jun. 24, 1982, vol. 18, No. 13, pp. 566 568.;;Chen et al. IEEE Journal of Quantum Electronics vol. QE 18, No. 7, Jul. 1982, pp. 1072 1077.;;Ohmachi et al. Applied Physics Letters, vol. 20, No. 12, Jun. 15, 1972, pp. 506 508.",EXPIRED
111,BR,A,BR 9408443 A,040-519-866-064-585,1997-08-05,1997,BR 9408443 A,1994-11-21,US 17490593 A;;US 9413519 W,1993-12-29,Composição aquosa de hipoclorito limpador de banheiro aditivo de lavanderia e limpador de vaso sanitário,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,,https://lens.org/040-519-866-064-585,Patent Application,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
112,MX,A,MX PA01009723 A,066-119-260-387-997,2002-07-02,2002,MX PA01009723 A,2000-03-23,US 12633599 P;;US 0007707 W,1999-03-26,FIBER OPTIC ILLUMINATOR ADAPTOR ASSEMBLY FOR MULTIPLE LIGHT GUIDE CONNECTORS.,"An adaptor assembly (10) for coupling light guide connectors (70) of varying configurations to a structure housing a source of focused light includes an internal adaptor having an internal optic guide element (12), a coupling structure (20), a housing (40), and a connector locking mechanism. The coupling structure (20) can be inserted into and releasably retained within the structure housing the focused light. A light guide connector (70) is inserted into a light guide receiving channel formed in the housing and is releasably retained therein by the connector locking mechanism. An internal optic guide element (12) extends through the coupling structure (20) to transmit focused light from the source of focused light to the light guide connector inserted into the connector-receiving channel.",COGENT LIGHT TECH,CHANG DAVID D,,https://lens.org/066-119-260-387-997,Patent Application,no,0,0,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,PENDING
113,US,B2,US 11849954 B2,066-588-314-651-047,2023-12-26,2023,US 202016939396 A,2020-07-27,US 202016939396 A;;US 201916581034 A;;US 201916256229 A;;US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,Method and apparatus for treating an arterial lesion,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/066-588-314-651-047,Granted Patent,yes,179,0,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M16/00;;A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/01;;A61M25/09;;A61M25/10;;A61M27/00;;A61M39/00,,49,0,,,"U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769.;;U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, US 2016-0242764.;;U.S. Appl. No. 15/141,060, filed Apr. 28, 2016, US 2016-0317288.;;U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, US 2017-0209260.;;U.S. Appl. No. 15/641,966, filed Jul. 5, 2017, US 2017-0296798.;;U.S. Appl. No. 15/901,502, filed Feb. 21, 2018, US 2018-0235789.;;U.S. Appl. No. 16/056,208, filed Aug. 6, 2018, US 2019-0175885.;;U.S. Appl. No. 16/148,849, filed Oct. 1, 2018, US 2019-0269538.;;U.S. Appl. No. 16/171,784, filed Oct. 26, 2018, US 2019-0125512.;;U.S. Appl. No. 16/177,716, filed Nov. 1, 2018, US 2019-0150916.;;U.S. Appl. No. 16/250,825, filed Jan. 17, 2019, US 2019-0350568.;;U.S. Appl. No. 16/281,311, filed Feb. 21, 2019, US 2019-0388654.;;U.S. Appl. No. 16/297,348, filed Mar. 8, 2019, US 2020-0038576.;;U.S. Appl. No. 16/299,524, filed Mar. 12, 2019, US 2019-0366070.;;U.S. Appl. No. 16/353,492, filed Mar. 14, 2019, US 2020-0009406.;;U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, US 2019-0231962.;;U.S. Appl. No. 16/411,543, filed May 14, 2019, US 2020-0108221.;;U.S. Appl. No. 16/513,030, filed Jul. 16, 2019, US 2020-0170637.;;U.S. Appl. No. 16/530,783, filed Aug. 2, 2019, US 2020-0054871.;;U.S. Appl. No. 16/544,083, filed Aug. 19, 2019, US 2020-0171277.;;U.S. Appl. No. 16/547,042, filed Aug. 21, 2019, US 2020-0113587.;;U.S. Appl. No. 16/880,594, filed May 21, 2020, US 2020-0282127.;;U.S. Appl. No. 16/894,474, filed Jun. 5, 2020, US 2020-0297912.;;Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther 9:147-154.;;Bates M.D., et al. “Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model” Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) “Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques” The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). “Percutaneous stenting of the internal carotid artery: the European CAST | Study” J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79.;;Bettmann, M. et al, “Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association”. Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012.;;Chang, D.W., et al., “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., “Carotid Angioplasty And Stenting Using Transcervical Occlusion And Protective Shunting Via A Mini Incision In The Neck: A New Technique For Difficult Femoral Access Or Filter Placement May Be The Better Carotid Artery Intervention” 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2.;;Criado et al. (1997).“Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114.;;Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-68.;;Criado, M.D., et al. (2004) “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient” Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device—Invatec.;;Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.;;Momapresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002. 37 pages.;;Ohki, M.D., et al., “Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis” (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41.;;Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3.;;Stecker et al., (2002). “Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy” J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection” . AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology.",ACTIVE
114,EP,A2,EP 0652519 A2,105-747-850-867-616,1995-05-10,1995,EP 94308109 A,1994-11-03,US 14732193 A,1993-11-04,Monitoring of data stream connections in a computer network.,Provided are systems and methods for monitoring data stream connections in a parallel server network composed of multiple workstations. A user defined application task for the network is decomposed/ subdivided into multiple work units/subtasks individually distributed for relatively concurrent execution in selected workstations. The monitor detects and provides to the user data stream connection status information (29) about the complete system as the application is being executed. The monitor process is executed as a daemon on the coordinate workstation accessed by the user. Node registration requests from the subordinate workstations to the coordinate workstation provide the coordinate workstation daemon process with information regarding the status of data streams in subordinate workstations.,IBM,CHANG DAVID YU,,https://lens.org/105-747-850-867-616,Patent Application,yes,0,4,1,1,0,G06F11/3006;;G06F11/3055;;G06F11/328;;G06F11/3404;;H04L43/00,G06F11/30;;G06F11/32;;G06F11/34;;H04L12/26,,0,0,,,,DISCONTINUED
115,HK,A1,HK 1044046 A1,115-634-116-983-219,2002-10-04,2002,HK 02105596 A,2002-07-30,US 12633599 P;;US 0007707 W,1999-03-26,FIBER OPTIC ILLUMINATOR ADAPTOR ASSEMBLY FOR MULTIPLE LIGHT GUIDE CONNECTORS,,COGENT LIGHT TECH,DAVID D CHANG,,https://lens.org/115-634-116-983-219,Patent Application,no,0,0,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B/;;G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,PENDING
116,EP,B1,EP 0737242 B1,152-321-603-396-286,2001-08-01,2001,EP 95904119 A,1994-11-21,US 9413519 W;;US 17490593 A,1993-12-29,THICKENED ALKALY METAL HYPOCHLORITE COMPOSITIONS,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT BENCKISER INC,CHANG DAVID L,RECKITT BENCKISER INC. (2001-03-21),https://lens.org/152-321-603-396-286,Granted Patent,yes,5,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,1,0,,,"DATABASE WPI Section Ch, Week 9431 Derwent Publications Ltd., London, GB; Class D25, AN 94-253131 & JP,A,06 184 594 ( KAO CORP) , 5 July 1994",EXPIRED
117,CN,A,CN 107152539 A,180-146-653-637-033,2017-09-12,2017,CN 201710118589 A,2017-03-01,US 201662304308 P,2016-03-06,Valve Control Device,"The invention relates to a valve control device. The valve control device includes a housing provided with a control shaft, a motor for driving the control shaft to rotate, a control circuit board connected to the motor, and a sensor for detecting a rotational position of the control shaft. The sensor is connected to the control circuit board, which controls the motor to drive the control shaft to rotate in response to a position signal returned by the sensor. The valve control device may further include a position pointer, an indicating light, or a buzzer to facilitate observation of the opening and closing position of the valve.",CHANG DAVID ANTHONY,CHANG DAVID ANTHONY,,https://lens.org/180-146-653-637-033,Patent Application,no,5,0,4,4,0,F16K5/0442;;F16K31/041;;F16K37/0083;;F16K31/042;;F16K31/043;;F16K37/0041;;F16K31/042;;F16K31/043;;F16K31/046;;F16K37/0041,F16K5/04;;F16K31/04;;F16K37/00,,0,0,,,,DISCONTINUED
118,WO,A2,WO 2006/055826 A2,030-286-083-647-832,2006-05-26,2006,US 2005/0041931 W,2005-11-18,US 62942004 P;;US 66414205 P,2004-11-18,ENDOLUMINAL DELIVERY OF ANESTHESIA,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",CHANG DAVID W,CHANG DAVID W,,https://lens.org/030-286-083-647-832,Patent Application,yes,0,14,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M29/00,,0,0,,,,PENDING
119,CA,A1,CA 2366653 A1,029-145-930-210-611,2000-10-19,2000,CA 2366653 A,2000-03-23,US 12633599 P;;US 0007707 W,1999-03-26,FIBER OPTIC ILLUMINATOR ADAPTOR ASSEMBLY FOR MULTIPLE LIGHT GUIDE CONNECTORS,"An adaptor assembly (10) for coupling light guide connectors (70) of varying configurations to a structure housing a source of focused light includes an internal adaptor having an internal optic guide element (12), a coupling structure (20), a housing (40), and a connector locking mechanism. The coupling structure (20) can be inserted into and releasably retained within the structure housing the focused light. A light guide connector (70) is inserted into a light guide receiving channel formed in the housing and is releasably retained therein by the connector locking mechanism. An internal optic guide element (12) extends through the coupling structure (20) to transmit focused light from the source of focused light to the light guide connector inserted into the connector-receiving channel.",COGENT LIGHT TECH,CHANG DAVID D,,https://lens.org/029-145-930-210-611,Patent Application,no,0,0,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,DISCONTINUED
120,WO,A1,WO 1985/000898 A1,033-188-707-818-485,1985-02-28,1985,US 8401275 W,1984-08-14,US 52332583 A,1983-08-15,INTRAWAVEGUIDE FIBER OPTIC BEAMSPLITTER/COUPLER,"An intrawaveguide fiber optic beamsplitter/coupler and method in which an oriented slot (10) is formed in an intact optical fiber (12) whereby the internal slot (10) functions to divide and direct light along desired paths (16, 18).",CHANG DAVID B,CHANG DAVID B,,https://lens.org/033-188-707-818-485,Patent Application,yes,8,4,9,10,0,G02B6/2817;;Y10S359/90;;G02B6/2817;;Y10S359/90,G02B6/28;;G02B6/287,G2J JGEC          JGEC,1,0,,,See also references of EP 0151637A4,PENDING
121,US,B2,US 8414516 B2,038-774-443-730-095,2013-04-09,2013,US 75303910 A,2010-04-01,US 75303910 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",CHANG DAVID W;;SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15);;CHANG DAVID W (2005-11-02);;VNUS MEDICAL TECHNOLOGIES INC (2004-12-09),https://lens.org/038-774-443-730-095,Granted Patent,yes,101,82,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M5/00;;A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,604/8;;604/103.01,28,22,023-546-745-949-35X;;028-839-258-555-020;;040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;001-001-379-646-544;;024-321-843-309-136;;056-537-645-364-701;;034-095-739-046-671;;016-207-092-214-742;;002-908-369-553-055;;002-478-877-804-626;;107-686-988-816-391;;095-706-461-958-467;;093-172-129-212-966;;017-528-531-432-121;;033-078-657-817-419;;053-599-451-169-494;;061-407-975-772-244;;071-968-223-548-381,10.1161/01.cir.97.1.121;;9443447;;11241119;;10.1067/mva.2001.112278;;10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;15253268;;10.1007/s10016-004-0018-5;;10.1016/j.jvs.2004.06.026;;15337876;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1179/016164104225013978;;15142330;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730;;10731266;;10.1007/s002709900294;;9853153,"Bettman, M. et al, ""Carotid Stenting and Angioplasty . . . "", etc. Circulation, 1998; 97:121-123.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" J Vasc Surg 2001 ; 33:504-9.;;Adami, M.D., et al., (2002) ""Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results"" J Endovasc Ther 9:147-154.;;Bates M.D., et al. ""Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model"" Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) ""Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques"" The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). ""Percutaneous stenting of the internal carotid artery: the European CAST I Study"" J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) ""Recurrent Carotid Disease: Will Stents be an alternative to surgery?"" J Endovasc Surg; 3: 76-79.;;Chang, D.W., et al, ""A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention"" (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., ""Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May be the Better Carotid Artery Intervention"" 30th Global: Vascular and Endovascular Issues, Techniques and Horizons. XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) ""Evolving indications for and early results of carotid artery stenting"" Am. J. Surg.; 174:111-114.;;Criado et al. (2004). ""Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique"" J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). ""Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results"" J. Vasc. Surg. 40:476-483.;;Criado, M.D., et al. (2004) ""Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient"" Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) ""First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting"" Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). ""Percutaneous techniques for endoluminal carotid interventions"" J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;Henry et al. (1999) ""Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System"" J. Endovasc. Surg. 6:321-331.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device-INVATEC.;;MomaPresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig-Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). ""Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion."" J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). ""Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices"" J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). ""Direct percutaneous carotid artery stenting with distal protection: technical case report."" Neurol Res 26(3): 338-41.;;Stecker et al., (2002). ""Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy"" J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. ""New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection"" AJNR 11:869-874, Sep./Oct. 1990 0195-6108/90/1106-0869 @ American Society of Neurology.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.;;Bettman, M. et al, ""Carotid Stenting and Angioplasty . . . "", etc. Circulation, 1998, 97:121-123.;;Reekers J. A. (1998). ""A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures."" Cardiovasc Intervent Radiol 21(5): 431-3.",ACTIVE
122,EP,A1,EP 0737242 A1,070-466-461-410-277,1996-10-16,1996,EP 95904119 A,1994-11-21,US 9413519 W;;US 17490593 A,1993-12-29,THICKENED ALKALY METAL HYPOCHLORITE COMPOSITIONS,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,RECKITT BENCKISER INC. (2001-03-21),https://lens.org/070-466-461-410-277,Patent Application,yes,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
123,US,A,US 5752966 A,074-188-761-540-602,1998-05-19,1998,US 81474097 A,1997-03-07,US 81474097 A,1997-03-07,Exovascular anastomotic device,"An anastomotic device includes a flexible member, formable into a loop and a plurality of tissue penetrating anchoring elements slidably mounted on the flexible member. The tissue penetrating anchoring elements extend generally towards a center of the loop formed by the flexible member. The device is adapted for anastomosing vessel segments or a vessel and a graft. In a further embodiment, an exovascular anastomotic device is suitable for end-to-side anastomoses and it includes an anastomotic ring and a harness assembly.",CHANG; DAVID W.,CHANG DAVID W,,https://lens.org/074-188-761-540-602,Granted Patent,yes,20,105,2,2,0,A61B17/11;;A61B2017/1135;;A61B17/11;;A61B2017/1135,A61B17/11,606/151;;606/153,0,0,,,,EXPIRED
124,US,A1,US 2005/0132987 A1,088-715-917-489-664,2005-06-23,2005,US 92649604 A,2004-08-26,US 92649604 A;;US 74300003 A,2003-12-23,Internal combustion engine valve seating velocity control,"The present disclosure provides an engine having a gas exchange valve and an actuator for the gas exchange valve, and also a method of reducing valve seating impact velocity. The actuator includes a body having a fluid inlet and a fluid outlet. A plunger is reciprocable in the body and has a travel distance between an advanced position and a retracted position, the plunger and body defining a chamber. A flow restriction orifice is disposed in at least one of the plunger and the body, and the chamber is in unrestricted fluid communication with the outlet over a first portion of the travel distance and in restricted fluid communication with the outlet by way of the orifice over at least a second portion of the travel distance.",CHANG DAVID Y.,CHANG DAVID Y,CATERPILLAR INC (2004-08-24),https://lens.org/088-715-917-489-664,Patent Application,yes,9,18,2,5,0,F01L1/146;;F01L1/181;;F01L13/0015;;F01L2001/054;;F01L2305/00;;F01L9/10;;F01L1/181;;F01L2001/054;;F01L1/146;;F01L13/0015;;F01L2305/00;;F01L9/10,F01L9/10;;F01L1/34,123/90.12;;123/90.16,0,0,,,,EXPIRED
125,US,B2,US 9295817 B2,089-944-694-435-129,2016-03-29,2016,US 201213674792 A,2012-11-12,US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 62942004 P;;US 66414205 P,2004-11-18,Endoluminal delivery of anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",CHANG DAVID W;;SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/089-944-694-435-129,Granted Patent,yes,62,65,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M31/00;;A61M25/00;;A61M25/04;;A61M25/10,,1,1,107-686-988-816-391,10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133,"Henry et al. (1999) ""Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System"" J. Endovasc. Surg. 6:321-331.",ACTIVE
126,ZA,B,ZA 9410406 B,111-691-348-211-694,1996-06-29,1996,ZA 9410406 A,1994-12-29,US 17490593 A,1993-12-29,Thickened alkali metal hypochlorite compositions,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,,https://lens.org/111-691-348-211-694,Granted Patent,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
127,BR,A,BR 0009342 A,109-934-013-765-953,2002-09-03,2002,BR 0009342 A,2000-03-23,US 12633599 P;;US 0007707 W,1999-03-26,Montagem de adaptador de iluminador de fibra óptica para conectores de guia de luz múltiplos,"""MONTAGEM DE ADAPTADOR DE ILUMINADOR DE FIBRA óPTICA PARA CONECTORES DE GUIA DE LUZ MúLTIPLOS"". Uma montagem de adaptador (10) , para acoplamento de conectores de guia de luz (70) de configurações variáveis em uma estrutura que aloja uma fonte de luz focalizada, inclui um adaptador interno tendo um elemento de guia óptico interno (12), uma estrutura de acoplamento (20), um alojamento (40) e um mecanismo de trava de conector. A estrutura de acoplamento (20) pode ser inserida e retida, desprendidamente, dentro da estrutura que aloja a luz focalizada. Um conector de guia de luz (70) é inserido em um canal receptor de guia de luz no alojamento e é retido, desprendidamente, nele pelo mecanismo de trava de conector. Um elemento de guia óptico interno (12) se estende pela estrutura de acoplamento (20) , para transmitir a luz focalizada da fonte de luz focalizada para o conector de guia de luz inserido no canal receptor de conector.",COGENT LIGHT TECH,CHANG DAVID D,,https://lens.org/109-934-013-765-953,Patent Application,no,0,0,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,DISCONTINUED
128,US,A1,US 2009/0018455 A1,136-975-691-356-18X,2009-01-15,2009,US 17628208 A,2008-07-18,US 17628208 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,METHOD AND APPARATUS FOR TREATING A CAROTID ARTERY,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/136-975-691-356-18X,Patent Application,yes,99,103,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B5/026;;A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,600/504;;604/9,0,0,,,,ACTIVE
129,AT,T1,AT E203764 T1,042-320-657-498-576,2001-08-15,2001,AT 95904119 T,1994-11-21,US 17490593 A;;US 9413519 W,1993-12-29,VERDICKTE ALKALIMETALLHYPOCHLORITZUBEREITUNGEN,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT BENCKISER INC,CHANG DAVID L,,https://lens.org/042-320-657-498-576,Granted Patent,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,DISCONTINUED
130,EP,A1,EP 2260776 A1,049-967-090-655-631,2010-12-15,2010,EP 10009848 A,2004-11-22,EP 04811840 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Apparatus for treating the carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (312) (with or without blocking of blood flow through the external carotid artery (320)), shunting blood from the internal carotid artery (342) and treating the lesion in the carotid artery.
",VNUS MED TECH INC,CHANG DAVID W,"SILK ROAD MEDICAL, INC. (2011-08-31)",https://lens.org/049-967-090-655-631,Patent Application,yes,2,13,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,,0,0,,,,DISCONTINUED
131,US,A1,US 2004/0065283 A1,057-268-550-535-188,2004-04-08,2004,US 26379902 A,2002-10-04,US 26379902 A,2002-10-04,Engine valve actuator,"
   An engine valve actuator for an internal combustion engine is provided. The engine valve actuator includes a housing having an opening and a first fluid passageway leading to the opening. An adjustment member is disposed in the housing and includes a protrusion that extends into the opening of the housing. A piston is disposed in the opening of the housing and has a bore adapted to receive the protrusion, a chamber, and a second fluid passageway that connects the bore with the chamber. The piston is adapted to move in a first direction relative to the housing in response to an introduction of pressurized fluid into the first fluid passageway. The piston moves in the first direction until the protrusion substantially withdraws from the bore. A push rod is operatively engaged with the piston such that movement of the piston in the first direction causes a corresponding movement of the push rod to thereby engage and open the engine valve. 
",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2002-10-01),https://lens.org/057-268-550-535-188,Patent Application,yes,31,5,4,4,0,F01L1/26;;F01L13/065;;F01L9/10;;F01L1/26;;F01L13/065;;F01L9/10,F01L1/26;;F01L9/10;;F01L13/06,123/90.12;;123/90.15;;123/90.16,0,0,,,,EXPIRED
132,CN,A,CN 1905841 A,061-441-439-114-781,2007-01-31,2007,CN 200480040717 A,2004-11-22,US 52406903 P,2003-11-21,Method and apparatus for treating a carotid artery,,CHANG DAVID W,CHANG DAVID W,"SILK ROAD MEDICINE CO.,LTD. (2010-01-15)",https://lens.org/061-441-439-114-781,Patent Application,no,0,10,2,30,0,,A61B17/12;;A61F2/958,,0,0,,,,ACTIVE
133,US,B2,US 8343089 B2,064-411-096-482-620,2013-01-01,2013,US 75302710 A,2010-04-01,US 75302710 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC;;CHANG DAVID W,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15);;CHANG DAVID W (2005-11-02);;VNUS MEDICAL TECHNOLOGIES INC (2004-12-09),https://lens.org/064-411-096-482-620,Granted Patent,yes,102,65,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M5/00;;A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,604/9;;604/523,27,22,023-546-745-949-35X;;028-839-258-555-020;;040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;001-001-379-646-544;;024-321-843-309-136;;056-537-645-364-701;;034-095-739-046-671;;016-207-092-214-742;;002-908-369-553-055;;002-478-877-804-626;;107-686-988-816-391;;095-706-461-958-467;;093-172-129-212-966;;017-528-531-432-121;;033-078-657-817-419;;053-599-451-169-494;;061-407-975-772-244;;071-968-223-548-381,10.1161/01.cir.97.1.121;;9443447;;11241119;;10.1067/mva.2001.112278;;10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;15253268;;10.1007/s10016-004-0018-5;;10.1016/j.jvs.2004.06.026;;15337876;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1179/016164104225013978;;15142330;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730;;10731266;;10.1007/s002709900294;;9853153,"Bettman, M. et al, ""Carotid Stenting and Angioplasty . . . "", etc. Circulation, 1998; 97:121-123.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" J Vasc Surg 2001; 33:504-9.;;Adami, M.D., et al., (2002) ""Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results"" J Endovasc Ther 9:147-154.;;Bates M.D., et al. ""Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model"" Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) ""Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques"" The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). ""Percutaneous stenting of the internal carotid artery: the European CAST I Study"" J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) ""Recurrent Carotid Disease: Will Stents be an alternative to surgery?"" J Endovasc Surg; 3: 76-79.;;Chang, D.W., et al, ""A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention"" (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., ""Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention"" 30th Global: Vascular and Endovaseular Issues, Techniques and Horizons. XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) ""Evolving indications for and early results of carotid artery stenting"" Am. J. Surg.; 174:111-114.;;Criado et al. (2004). ""Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique"" J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). ""Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results"" J. Vasc. Surg. 40:476-483.;;Criado, M.D., et al. (2004) ""Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient"" Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) ""First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting"" Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). ""Percutaneous techniques for endolurninal carotid interventions"" J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;Henry et al. (1999) ""Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System"" J. Endovasc. Surg. 6:321-331.;;Mo.Ma Brochure; Proximal Flow Blockage Cerebral Protection Device-INVATEC.;;MomaPresn (AET) 2002 Biamino, G; Mo.Ma as a distal protective device, University of Leipzig-Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). ""Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion."" J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). ""Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices"" J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). ""Direct percutaneous carotid artery stenting with distal protection: technical case report."" Neurol Res 26(3): 338-41.;;Stecker et al., (2002). ""Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy"" J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. ""New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection"" AJNR 11:869-874, Sep./Oct. 1990 0195-6108/90/1106-0869 @ American Society of Neurology.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.;;Reekers, J. A. (1998). ""A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures."" Cardiovasc Intervent Radiol 21(5): 431-3.",ACTIVE
134,EP,B1,EP 0361661 B1,057-045-750-208-917,1993-08-04,1993,EP 89308224 A,1989-08-14,US 24914388 A,1988-09-26,DYNAMIC INFRARED TARGET,,HUGHES AIRCRAFT COMPANY,"CHANG, DAVID B.",,https://lens.org/057-045-750-208-917,Granted Patent,yes,6,0,8,9,0,F41J2/02;;F41J2/02;;G02F2/02;;G02F2/02,F41J2/02;;G02F2/02,,0,0,,,,EXPIRED
135,DE,B1,DE 1763611 B1,137-129-184-644-519,1970-06-18,1970,DE 1763611 A,1968-07-03,US 65357167 A,1967-07-14,Schaltungsanordnung zur Speisung einer kapazitiven Last mit einer in der Polaritaet umkehrbaren Hochspannung,,IBM,CHING CHANG DAVID,,https://lens.org/137-129-184-644-519,Patent Application,no,1,0,12,12,0,H03K17/60;;H03K17/601;;H03K17/601;;H03K17/60,G05F1/46;;H02M3/28;;H02M9/04;;H03K17/60,,0,0,,,,EXPIRED
136,DK,D0,DK 471189 D0,141-439-688-276-420,1989-09-25,1989,DK 471189 A,1989-09-25,US 24914388 A,1988-09-26,DYNAMISK INFRAROEDT MAAL,,HUGHES AIRCRAFT CO,CHANG DAVID B,,https://lens.org/141-439-688-276-420,Patent Application,no,0,0,8,9,0,F41J2/02;;F41J2/02;;G02F2/02;;G02F2/02,F41J2/02;;G02F2/02,,0,0,,,,EXPIRED
137,US,B2,US 10188399 B2,166-014-949-562-104,2019-01-29,2019,US 201615168786 A,2016-05-31,US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/166-014-949-562-104,Granted Patent,yes,151,4,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M16/00;;A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/01;;A61M25/09;;A61M25/10;;A61M27/00;;A61M39/00,,46,22,040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;023-546-745-949-35X;;001-001-379-646-544;;024-321-843-309-136;;056-537-645-364-701;;034-095-739-046-671;;061-407-975-772-244;;016-207-092-214-742;;002-908-369-553-055;;002-478-877-804-626;;107-686-988-816-391;;028-839-258-555-020;;095-706-461-958-467;;093-172-129-212-966;;017-528-531-432-121;;071-968-223-548-381;;033-078-657-817-419;;053-599-451-169-494,10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;10.1161/01.cir.97.1.121;;9443447;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;15253268;;10.1007/s10016-004-0018-5;;10.1016/j.jvs.2004.06.026;;15337876;;10731266;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11241119;;10.1067/mva.2001.112278;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1179/016164104225013978;;15142330;;10.1007/s002709900294;;9853153;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730,"U.S. Appl. No. 12/645,179, filed Dec. 22, 2009, US 2010-0217276.;;U.S. Appl. No. 12/686,202, filed Jan. 12, 2010, US 2010-0204684.;;U.S. Appl. No. 12/966,948, filed Dec. 13, 2010, US 2011-0087147.;;U.S. Appl. No. 13/816,670, filed Feb. 12, 2013, US 2013-0197621.;;U.S. Appl. No. 13/961,746, filed Aug. 7, 2013, US 2014-0046346.;;U.S. Appl. No. 14/042,520, filed Sep. 30, 2013, US 2014-0031925.;;U.S. Appl. No. 14/078,149, filed Nov. 12, 2013, US 2014-0135661.;;U.S. Appl. No. 14/221,917, filed Mar. 21, 2014, US 2014-0296868.;;U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769.;;U.S. Appl. No. 14/475,346, filed Sep. 2, 2014, US 2014-0371653.;;U.S. Appl. No. 14/476,651, filed Sep. 3, 2014, US 2015-0080942.;;U.S. Appl. No. 14/508,354, filed Oct. 7, 2014, US 2015-0025616.;;U.S. Appl. No. 14/622,310, filed Feb. 13, 2015, US 2015-0150562.;;U.S. Appl. No. 14/710,400, filed May 12, 2015, US 2015-0327843.;;U.S. Appl. No. 14/935,252, filed Nov. 6, 2015, US 2016-0128688.;;U.S. Appl. No. 15/044,493, filed Feb. 16, 2016, US 2016-0158044.;;U.S. Appl. No. 15/050,039, filed Feb. 22, 2016, US 2016-0166804.;;PCT/US2015/030375, filed May 12, 2015, WO 2015/175537.;;PCT/US2015/042180, filed Jul. 27, 2015, WO 2016/018781.;;PCT/US2015/047717, filed Aug. 31, 2015, WO 2016/036660.;;Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther 9:147-154.;;Bates M.D., et al. “Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model” Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) “Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques” The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). “Percutaneous stenting of the internal carotid artery: the European CAST I Study” J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79.;;Bettmann, M. et al, “Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association”. Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012.;;Chang, D.W., et al, “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., “Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention” 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114.;;Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.;;Criado, M.D., et al. (2004) “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient.” Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device—INVATEC.;;Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.;;Momapresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Ohki, M.D., et al., “Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis” (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41.;;Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3.;;Stecker et al., (2002). “Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy” J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection” . AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology.",ACTIVE
138,US,B2,US 6957634 B2,194-999-749-565-444,2005-10-25,2005,US 26379902 A,2002-10-04,US 26379902 A,2002-10-04,Engine valve actuator,"An engine valve actuator for an internal combustion engine is provided. The engine valve actuator includes a housing having an opening and a first fluid passageway leading to the opening. An adjustment member is disposed in the housing and includes a protrusion that extends into the opening of the housing. A piston is disposed in the opening of the housing and has a bore adapted to receive the protrusion, a chamber, and a second fluid passageway that connects the bore with the chamber. The piston is adapted to move in a first direction relative to the housing in response to an introduction of pressurized fluid into the first fluid passageway. The piston moves in the first direction until the protrusion substantially withdraws from the bore. A push rod is operatively engaged with the piston such that movement of the piston in the first direction causes a corresponding movement of the push rod to thereby engage and open the engine valve.",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2002-10-01),https://lens.org/194-999-749-565-444,Granted Patent,yes,42,7,4,4,0,F01L1/26;;F01L13/065;;F01L9/10;;F01L1/26;;F01L13/065;;F01L9/10,F01L1/26;;F01L9/10;;F01L13/06,123/90.12;;123/90.45;;123/90.46;;123/90.52,7,1,043-080-006-736-450,10.4271/980180,"Edwards et al., ""The Potential of a Combined Miller Cycle and Internal EGR Engine for Future Heavy Duty Truck Applications,"" The Engineering Society for Advancing Mobility Land Sea Air and Space International, International Congress and Exposition, Feb. 23-26, 1998, pp. 1-19.;;Obert, ""Internal Combustion Engines and Air Pollution,"" Based on Internal Combustion Engines, Third Edition, 1973, pp. 612-614.;;Challen et al., ""Diesel Engine Reference Book, Section Edition,"" SAE International, 1999, pp. 75, 81, 84, 146, and 263-305.;;Yorihiro Fukuzawa et al., ""Development of High Efficiency Miller Cycle Gas Engine"", Mitsubishi Heavy Industries, Ltd., Technical Review, vol. 38, No. 3, Oct. 2001, pp. 146-150.;;Request for Inter Partes Reexamination Transmittal Form for U.S. Pat. No. 6,688,280, and Attachment to Request for Inter Parties Reexamination Transmittal Form, Sep. 17, 2004.;;Request for Inter Partes Reexamination Transmittal Form for U.S. Pat. No. 6,651,618, and Attachment to Request for Inter Parties Reexamination Transmittal Form, Aug. 27, 2004.;;http://www.mazda.com.au/corpora/209.html, Oct. 16, 2001, pp. 1-6.",EXPIRED
139,EP,A4,EP 1188081 A4,009-952-992-460-638,2002-10-16,2002,EP 00919563 A,2000-03-23,US 0007707 W;;US 12633599 P,1999-03-26,FIBER OPTIC ILLUMINATOR ADAPTOR ASSEMBLY FOR MULTIPLE LIGHT GUIDE CONNECTORS,,COGENT LIGHT TECH,CHANG DAVID D,,https://lens.org/009-952-992-460-638,Search Report,no,6,0,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,DISCONTINUED
140,US,S,US D0706254 S,037-268-514-065-064,2014-06-03,2014,US 201229436013 F,2012-10-31,US 201229436013 F,2012-10-31,Protective case kickstand,,CHANG DAVID S,CHANG DAVID S,,https://lens.org/037-268-514-065-064,Design Right,no,0,131,1,1,0,,,1403;;D14/250;;D14/217,0,0,,,,ACTIVE
141,US,B2,US 9662118 B2,045-750-868-084-081,2017-05-30,2017,US 201414508354 A,2014-10-07,US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",CHANG DAVID W;;SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/045-750-868-084-081,Granted Patent,yes,151,68,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/00;;A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/01;;A61M25/09;;A61M25/10;;A61M27/00,,26,22,040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;023-546-745-949-35X;;001-001-379-646-544;;024-321-843-309-136;;056-537-645-364-701;;034-095-739-046-671;;061-407-975-772-244;;016-207-092-214-742;;002-908-369-553-055;;002-478-877-804-626;;107-686-988-816-391;;028-839-258-555-020;;095-706-461-958-467;;093-172-129-212-966;;017-528-531-432-121;;071-968-223-548-381;;033-078-657-817-419;;053-599-451-169-494,10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;10.1161/01.cir.97.1.121;;9443447;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;15253268;;10.1007/s10016-004-0018-5;;10.1016/j.jvs.2004.06.026;;15337876;;10731266;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11241119;;10.1067/mva.2001.112278;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1179/016164104225013978;;15142330;;10.1007/s002709900294;;9853153;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730,"Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther 9:147-154.;;Bates M.D., et al. “Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model” Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) “Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques” The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). “Percutaneous stenting of the internal carotid artery: the European Cast I Study” J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79.;;Bettmann, M. et al, “Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association”. Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012.;;Chang, D.W., et al, “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., “Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention” 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114.;;Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-68.;;Criado, M.D., et al. (2004) “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient” Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. AI-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device—INVATEC.;;MOMAPRESN (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Ohki, M.D., et al., “Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis” (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41.;;Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3.;;Stecker et al., (2002). “Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy” J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection” . AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology.",ACTIVE
142,US,B2,US 9669183 B2,047-595-305-380-421,2017-06-06,2017,US 201615082257 A,2016-03-28,US 201615082257 A;;US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 66414205 P;;US 62942004 P,2004-11-18,Endoluminal delivery of anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/047-595-305-380-421,Granted Patent,yes,64,65,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M31/00;;A61B6/00;;A61B18/14;;A61M5/00;;A61M19/00;;A61M25/00;;A61M25/04;;A61M25/10,,1,1,107-686-988-816-391,10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133,Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.,ACTIVE
143,US,A,US 4796131 A,061-844-946-652-265,1989-01-03,1989,US 10736987 A,1987-10-09,US 10736987 A,1987-10-09,Head positioner preloaded stop,"A Winchester or hard disk drive, with a head positioner rotor is provided with a bidirectional preloaded stop. The head positioner rotor is provided with a plate having two spaced stop surfaces, both of which engage a single stop, which may be in the form of a U-shaped spring, which is partially compressed, and which has two pivoted, high strength plastic members against which the stop surfaces of the head positioner rotor impinge. The plate may also be provided with a notch into which the armature of an electromagnet fits so that the head positioner rotor is locked in the position with the heads adjacent the drive spindle, when the drive is turned off. When the rotor is energized, and the disks get up to speed, the electromagnetic is energized, and the head positioner rotor is freed to move to a selected track for reading or writing digital information.",MICROPOLIS CORP,CHANG DAVID D,MICROPOLIS CORPORATION CHATSWORTH CALIFORNIA A CORP. OF DE (1987-10-01);;DISCOVISION ASSOCIATES (1999-08-27);;MICROPOLIS (S) LIMITED (1997-06-25);;RESEARCH INVESTMENT NETWORK INC (2000-06-30),https://lens.org/061-844-946-652-265,Granted Patent,yes,6,13,2,2,0,G11B5/54;;G11B5/54,G11B5/54;;G11B21/02,360/106,1,0,,,"Pertec, Mini Wini, May 1980.",EXPIRED
144,US,A1,US 2016/0279379 A1,066-504-192-832-85X,2016-09-29,2016,US 201615082257 A,2016-03-28,US 201615082257 A;;US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 66414205 P;;US 62942004 P,2004-11-18,Endoluminal Delivery Of Anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/066-504-192-832-85X,Patent Application,yes,2,34,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M19/00;;A61B6/00;;A61B18/14;;A61M5/00;;A61M25/04,,0,0,,,,ACTIVE
145,SG,A1,SG 48756 A1,150-157-733-226-838,1998-05-18,1998,SG 1996001286 A,1994-11-21,US 17490593 A,1993-12-29,Thickened alkali metal hypochlorite compositions,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,,https://lens.org/150-157-733-226-838,Patent Application,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,PENDING
146,US,B1,US 6769385 B1,174-104-750-257-11X,2004-08-03,2004,US 38550303 A,2003-03-12,US 38550303 A,2003-03-12,System for controlling engine valve seating velocity,"
    A velocity control system for an engine valve is provided. The system includes a valve having a housing defining an opening, a chamber adapted to receive a fluid, a first fluid passageway connecting the opening with the chamber, a second fluid passageway connecting the opening with the chamber, and a third fluid passageway connecting the opening with the chamber. A piston is slidably disposed in the chamber and is moveable from a first position to a second position. The movement of the piston from the first position to the second position forces fluid from the chamber at a first flow rate during movement of the piston through a first travel distance and at a second flow rate during movement of the piston through a second travel distance. The first flow rate is greater than the second flow rate. A check valve is adapted to prevent fluid from flowing from the chamber through the first fluid passageway when the piston is moving from the first position to the second position. 
",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2003-03-04),https://lens.org/174-104-750-257-11X,Granted Patent,yes,8,10,1,1,0,F01L1/16;;F01L1/34;;F01L1/46;;F02B75/20;;F02B2275/34;;F01L9/10;;F01L1/16;;F02B75/20;;F01L1/46;;F01L1/34;;F02B2275/34;;F01L9/10,F01L1/34;;F01L1/46;;F01L9/10;;F02B75/20,123/90.16;;123/90.12;;123/90.49;;123/90.55;;123/90.57,0,0,,,,EXPIRED
147,US,A,US 4371657 A,192-383-186-163-290,1983-02-01,1983,US 24057381 A,1981-03-04,US 24057381 A,1981-03-04,Crater resistant acrylic enamel,"A crater resistant enamel coating composition used for the exterior of trucks and automobiles in which the binder is a blend of (A) an acrylic polymer having hydroxy groups and contains about 0.1-10% by weight of a polymerized perfluoro carbon constituent of the formula ##STR1## where R is H or CH.sub.3, R.sup.1 is alkyl, R.sup.2 is perfluoro alkyl and n is 0 or 1 and (B) an aminoplast crosslinking agent such as an alkylated melamine formaldehyde resin. After the composition is applied and baked by conventional techniques, a finish is formed that has an excellent appearance.",DU PONT,CHANG DAVID C,E.I. DU PONT DE NEMOURS AD COMPANY A CORP. OF DE (1981-02-24),https://lens.org/192-383-186-163-290,Granted Patent,yes,12,23,2,3,0,C09D133/066;;C09D133/066;;C08L61/20;;C08L61/20;;C08L61/32;;C08L61/32;;C09D161/32;;C09D161/32;;Y10T428/31678;;Y10T428/31678,C08L61/20;;C08L61/32;;C09D133/06;;C09D161/32,C3M MF            MF;;C3M MFNB          MFNB;;C3M M116          MF;;C3M M171          MF,0,0,,,,EXPIRED
148,US,A1,US 2017/0254434 A1,011-954-480-557-699,2017-09-07,2017,US 201715450041 A,2017-03-06,US 201715450041 A;;US 201662304308 P,2016-03-06,Valve Control Device,"A valve control device includes a housing provided with a control shaft, a motor for driving the control shaft to rotate, a control circuit board connected to the motor, and a sensor for detecting a rotational position of the control shaft. The sensor is connected to the control circuit board, which controls the motor to drive the control shaft to rotate in response to a position signal returned by the sensor. The valve control device may further include a position pointer, an indicating light, or a buzzer to facilitate observation of the opening and closing position of the valve.",CHANG DAVID ANTHONY,CHANG DAVID ANTHONY,,https://lens.org/011-954-480-557-699,Patent Application,yes,13,2,4,4,0,F16K5/0442;;F16K31/041;;F16K37/0083;;F16K31/042;;F16K31/043;;F16K37/0041;;F16K31/042;;F16K31/043;;F16K31/046;;F16K37/0041,F16K31/04;;F16K37/00,,0,0,,,,INACTIVE
149,AU,B2,AU 683523 B2,021-630-659-144-001,1997-11-13,1997,AU 1995/012930 A,1994-11-21,US 17490593 A;;US 9413519 W,1993-12-29,Thickened alkaly metal hypochlorite compositions,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,RECKITT BENCKISER INC. (2002-08-22),https://lens.org/021-630-659-144-001,Granted Patent,no,2,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
150,US,B2,US 9526504 B2,019-104-654-997-580,2016-12-27,2016,US 201514622310 A,2015-02-13,US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/019-104-654-997-580,Granted Patent,yes,99,63,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M16/00;;A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/36;;A61M25/01;;A61M25/09;;A61M25/10;;A61M27/00;;A61M39/00,,26,22,040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;023-546-745-949-35X;;001-001-379-646-544;;024-321-843-309-136;;056-537-645-364-701;;034-095-739-046-671;;061-407-975-772-244;;016-207-092-214-742;;002-908-369-553-055;;002-478-877-804-626;;107-686-988-816-391;;028-839-258-555-020;;095-706-461-958-467;;093-172-129-212-966;;017-528-531-432-121;;071-968-223-548-381;;033-078-657-817-419;;053-599-451-169-494,10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;10.1161/01.cir.97.1.121;;9443447;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;15253268;;10.1007/s10016-004-0018-5;;10.1016/j.jvs.2004.06.026;;15337876;;10731266;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11241119;;10.1067/mva.2001.112278;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1179/016164104225013978;;15142330;;10.1007/s002709900294;;9853153;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730,"Adami, M.D., et al., (2002) ""Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results"" J Endovasc Ther 9:147-154.;;Bates M.D., et al. ""Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model"" Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) ""Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques"" The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). ""Percutaneous stenting of the internal carotid artery: the European Cast I Study"" J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) ""Recurrent Carotid Disease: Will Stents be an alternative to surgery?"" J Endovasc Surg; 3: 76-79.;;Bettmann, M. et al, ""Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association"". Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012.;;Chang, D.W., et al, ""A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention"" (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., ""Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention"" 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) ""Evolving indications for and early results of carotid artery stenting"" Am. J. Surg.; 174:111-114.;;Criado et al. (2004). ""Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique"" J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). ""Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results"" J. Vasc. Surg. 40:476-483.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.;;Criado, M.D., et al. (2004) ""Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient"" Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) ""First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting"" Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). ""Percutaneous techniques for endoluminal carotid interventions"" J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device-INVATEC.;;Henry et al. (1999) ""Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System"" J. Endovasc. Surg. 6:321-331.;;Momapresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig-Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis."" (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). ""Hemodynamic conditions at the carotid blfurcation during protective common carotid occlusion,"" J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). ""Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices"" J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). ""Direct percutaneous carotid artery stenting with distal protection: technical case report."" Neurol Res 26(3): 338-41.;;Reekers, J. A. (1998). ""A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures."" Cardiovasc Intervent Radiol 21(5): 431-3.;;Stecker et al., (2002). ""Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy"" J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. ""New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection"" . AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology.",ACTIVE
151,US,A1,US 2019/0254680 A1,106-952-651-866-660,2019-08-22,2019,US 201916256229 A,2019-01-24,US 201916256229 A;;US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,Method and Apparatus for Treating a Carotid Artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/106-952-651-866-660,Patent Application,yes,0,16,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/09;;A61M25/10;;A61M27/00,,0,0,,,,ACTIVE
152,US,B2,US 11326507 B2,104-273-488-422-957,2022-05-10,2022,US 202117365781 A,2021-07-01,US 202117365781 A;;US 202016749642 A,2020-01-22,Ignitor for natural gas engine,"In one aspect, an engine ignition apparatus for a natural gas engine may include a housing including a drive piston, a floating piston, a controllable hydraulic fluid chamber located between the drive piston and the floating piston, and an ignition chamber acted on by the floating piston, the ignition chamber having an outlet formed by a plurality of orifices, the outlet being in direct communication with a combustion chamber of the engine. In another aspect, an engine ignition apparatus for a natural gas engine may include, among other features, a controllable valve connected to a hydraulic fluid chamber, and configured to open and release a hydraulic fluid from the hydraulic fluid chamber, and to close. In still another aspect, a method for controlling an engine ignition apparatus for an engine includes, among other features, controlling a volume of a hydraulic fluid chamber of an ignition apparatus.",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2020-01-22),https://lens.org/104-273-488-422-957,Granted Patent,yes,11,0,4,4,0,F02M26/01;;F02D15/04;;F02D41/0085;;F02D19/02;;F02D41/0027;;F02B19/14;;F02B19/06;;F02B2043/103;;F02B1/12;;Y02T10/12;;Y02T10/30;;F02B1/12;;F02M26/01;;F02D37/02;;F02B3/06;;F02B2075/125;;F02B2275/14;;F02D13/0215;;F02D2041/001;;F02D2041/389,B60T7/12;;F02B1/12;;F02B3/06;;F02B75/12;;F02D13/02;;F02D37/02;;F02D41/00;;F02D41/38;;F02M26/01,,0,0,,,,ACTIVE
153,DK,B1,DK 170002 B1,148-332-845-925-362,1995-04-24,1995,DK 471189 A,1989-09-25,US 24914388 A,1988-09-26,Dynamisk infrarødt billedsystem og infrarødt mål til brug i dette system,,HUGHES AIRCRAFT CO,CHANG DAVID B,,https://lens.org/148-332-845-925-362,Granted Patent,no,0,0,8,9,0,F41J2/02;;F41J2/02;;G02F2/02;;G02F2/02,F41J2/02;;G02F2/02,,0,0,,,,EXPIRED
154,US,A1,US 2011/0132293 A1,151-744-528-630-869,2011-06-09,2011,US 63005509 A,2009-12-03,US 63005509 A,2009-12-03,FLUID INJECTOR WITH THERMAL LOAD CONTROL,"A common rail single fluid injection system includes fuel injectors and control valve assemblies with an internal cooling fluid circuit to improve overall life and performance of the injector. This is accomplished by supplying cooling fluid to the injector and allowing the same to come in direct contact with one of the hottest locations within the fuel injector; the high-pressure leak split spot. By providing cooling fluid directly to this location and then allowing the cooling fluid to drain out of the injector, the present disclosure effectively and efficiently manages thermal loads within the injector.",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2009-12-02),https://lens.org/151-744-528-630-869,Patent Application,yes,15,0,5,5,0,F02M53/043;;F02M63/0225;;F02M63/0225;;F02M53/043,F02M51/00;;F01P1/06,123/41.31;;123/472,0,0,,,,ACTIVE
155,EP,B1,EP 0031403 B1,134-860-446-851-897,1983-11-02,1983,EP 80105792 A,1980-09-25,US 10781179 A,1979-12-28,DATA PROCESSING APPARATUS INCLUDING A TIME OF DAY CLOCK,,INTERNATIONAL BUSINESS MACHINES CORPORATION,"CHANG, DAVID C.",,https://lens.org/134-860-446-851-897,Granted Patent,yes,0,0,8,8,0,G04G3/022;;G04G99/006;;G06F9/4825;;G06F9/4825;;G04G99/006;;G04G3/022,G04G3/02;;G04G99/00;;G06F1/14;;G06F9/48,,0,0,,,,EXPIRED
156,EP,A1,EP 1188081 A1,179-506-063-634-028,2002-03-20,2002,EP 00919563 A,2000-03-23,US 0007707 W;;US 12633599 P,1999-03-26,FIBER OPTIC ILLUMINATOR ADAPTOR ASSEMBLY FOR MULTIPLE LIGHT GUIDE CONNECTORS,,COGENT LIGHT TECH,CHANG DAVID D,,https://lens.org/179-506-063-634-028,Patent Application,yes,0,0,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,DISCONTINUED
157,US,A,US 5223763 A,009-662-469-750-774,1993-06-29,1993,US 66197791 A,1991-02-28,US 66197791 A,1991-02-28,Wind power generator and velocimeter,"An apparatus and method are disclosed for producing electrical power from wind flow. The apparatus includes a conduit (13) with a variably sloped wall (59) for channeling the wind flow along a predetermined path (23), a baffle (25) positioned in the path of the flow for forming vortices (27-33) in the flow, and a plurality of piezoelectric transducers (35-45) positioned in sequence, each positioned a predetermined distance from the other, in the path of the flow for producing electrical output signals in response to pressure applied by the vortices upon the transducers. The individual output signals are combined to produce an aggregate power output. The system also includes a frequency counter (61) responsive to the output signal of at least one transducer for determining wind velocity. The method employed by the system includes the steps of channeling the wind flow along a predetermined path, forming vortices in the flow by positioning a baffle in the path of the flow and by varying the slope of the wall (and hence, the flow) so that the Reynold's Number representative of the flow is in the range from 40 to 300, conducive to formation of vortices, and positioning the transducers in the path of the vortices for producing electrical power in response to pressure from the vortices upon the transducers.",HUGHES AIRCRAFT CO,CHANG DAVID B,HUGHES AIRCRAFT COMPANY A DE CORP (1991-02-22);;HE HOLDINGS INC. A DELAWARE CORP (1997-12-17);;RAYTHEON COMPANY (1997-12-17),https://lens.org/009-662-469-750-774,Granted Patent,yes,14,84,1,1,0,H02N2/185;;H02N2/185,H01L41/113,310/339;;73/861.22,0,0,,,,EXPIRED
158,DE,A1,DE 10356160 A1,026-100-313-913-102,2004-07-08,2004,DE 10356160 A,2003-12-02,US 32248302 A,2002-12-19,Motorventilbetätigungsvorrichtung,"Eine Motorventilbetätigungsvorrichtung für einen Verbrennungsmotor wird vorgesehen. Die Motorventilbetätigungsvorrichtung weist ein Gehäuse mit einer Öffnung auf. Ein Einstellglied ist in dem Gehäuse angeordnet und definiert eine Kammer. Ein Kolben ist in der Öffnung des Gehäuses angeordnet und hat einen Vorsprung, der geeignet ist, um in der Kammer des Einstellgliedes aufgenommen zu werden. Der Kolben hat eine erste Position, wo der Vorsprung des Kolbens in der Kammer angeordnet ist und ein Teil des Kolbens einen entsprechenden Teil des Einstellgliedes berührt, und eine zweite Position, wo der Teil des Kolbens von dem entsprechenden Teil des Einstellgliedes getrennt ist. Ein Strömungsmitteldurchlassweg ist geeignet, um unter Druck gesetztes Strömungsmittel zu der Öffnung zu liefern. Das unter Druck gesetzte Strömungsmittel wirkt auf den Kolben, um den Kolben zu der zweiten Position zu bewegen, um dadurch zu gestatten, dass unter Druck gesetztes Strömungsmittel in die Kammer eintritt, um zu verhindern, dass der Kolben in die erste Position zurückkehrt. Eine Druckstange ist betriebsmäßig mit dem Kolben in Eingriff und ist geeignet, um mit dem Motorventil in Eingriff zu kommen und dieses zu öffnen.",CATERPILLAR INC,CHANG DAVID Y,,https://lens.org/026-100-313-913-102,Patent Application,no,0,0,2,2,0,F01L1/24;;F01L9/10;;F01L1/24;;F01L9/10,F01L9/10;;F01L1/24,,0,0,,,,DISCONTINUED
159,US,A,US 5117676 A,063-166-830-255-009,1992-06-02,1992,US 65967091 A,1991-02-25,US 65967091 A,1991-02-25,Leak detector for natural gas pipelines,"A simple acoustic detection system is described for measuring leaks from long gas pipelines. Microphones are strung along (and attached to) the pipeline exterior. The outputs of the microphones are spectrally analyzed. A peak at a frequency f.congruent.V.sub.s /(2d) and its harmonics indicates a leak in the vicinity of the recording microphone, where V.sub.s is the velocity of sound in the gas and d is the thickness of the pipe wall.",HUGHES AIRCRAFT CO,CHANG DAVID B,HE HOLDINGS INC (1995-12-08);;RAYTHEON COMPANY (1997-12-17);;HUGHES AIRCRAFT COMPANY LOS ANGELES CA A CORP OF DE (1991-02-22),https://lens.org/063-166-830-255-009,Granted Patent,yes,5,108,1,1,0,G01M3/243;;G01M3/243,G01M3/24,73 405 A;;73/592,0,0,,,,EXPIRED
160,DE,T2,DE 68908060 T2,109-893-618-357-225,1994-03-03,1994,DE 68908060 T,1989-08-14,US 24914388 A,1988-09-26,Aktives Wärmeziel.,,HUGHES AIRCRAFT CO,CHANG DAVID B,"RAYTHEON CO. (N.D.GES.D. STAATES DELAWARE), LEXING (1999-08-26)",https://lens.org/109-893-618-357-225,Granted Patent,no,0,0,8,9,0,F41J2/02;;F41J2/02;;G02F2/02;;G02F2/02,F41J2/02;;G02F2/02,,0,0,,,,EXPIRED
161,KR,A,KR 20030044699 A,128-444-535-477-147,2003-06-09,2003,KR 20010075544 A,2001-11-30,KR 20010075544 A,2001-11-30,DIGITAL INFRARED THERMAL IMAGING SYSTEM,"PURPOSE: A digital infrared thermal imaging system is provided to achieve improved accuracy and allow for ease of operation and convenience of maintenance. CONSTITUTION: A digital infrared thermal imaging system comprises an infrared detector(1) for creating digital data corresponding to the intensity level of the infrared radiation from the flat surface of a test object; a control circuit(2) coupled to the infrared detector, and which receives the digital data from the infrared detector and generates image frame data reflecting the intensity level of the infrared radiation from the flat surface of the test object by processing the digital data; and a display unit(3) coupled to the control circuit, and which generates a visible output corresponding to the image frame data.",TELESIS TECH INC,CHANG DAVID O,,https://lens.org/128-444-535-477-147,Patent Application,no,4,1,1,1,0,A61B5/015;;G01J5/00,A61B5/00,,0,0,,,,DISCONTINUED
162,CN,A,CN 1145635 A,146-519-750-308-887,1997-03-19,1997,CN 94194760 A,1994-11-21,US 17490593 A,1993-12-29,Thickened alkaly metal hypochlorite compositions,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,RECKITT BENCKISER INC. (2002-11-29),https://lens.org/146-519-750-308-887,Patent Application,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
163,US,A,US 4894623 A,152-920-641-634-956,1990-01-16,1990,US 22399088 A,1988-07-25,US 22399088 A,1988-07-25,Compact tunable RF generator using a current carrying diffraction grating,A compact tunable generator of radio frequency (RF) electromagnetic energy is disclosed. A thin conducting film is applied to a diffraction grating formed from a nonconducting substrate. A voltage source is applied to the film so that a current flows in the convoluted plane of the film in a direction perpendicular to the grooves of the grating. The frequency of the RF energy radiated by this system is determined both by the grating spacing and the applied voltage. The power levels are adequate for testing sensitive receiver systems over a wide range of frequencies.,HUGHES AIRCRAFT CO,CHANG DAVID B,HUGHES AIRCRAFT COMPANY LOS ANGELES CALIFORNIA A DE CORP (1988-07-20),https://lens.org/152-920-641-634-956,Granted Patent,yes,1,2,1,1,0,H01Q13/20;;H01Q13/20,H01Q13/20,331/96;;X331107DP,0,0,,,,EXPIRED
164,DE,D1,DE 68908060 D1,167-756-229-337-266,1993-09-09,1993,DE 68908060 T,1989-08-14,US 24914388 A,1988-09-26,AKTIVES WAERMEZIEL.,,HUGHES AIRCRAFT CO,CHANG DAVID B,"RAYTHEON CO. (N.D.GES.D. STAATES DELAWARE), LEXING (1999-08-26)",https://lens.org/167-756-229-337-266,Granted Patent,no,0,0,8,9,0,F41J2/02;;F41J2/02;;G02F2/02;;G02F2/02,F41J2/02;;G02F2/02,,0,0,,,,EXPIRED
165,US,A1,US 2020/0108221 A1,170-758-587-734-541,2020-04-09,2020,US 201916411543 A,2019-05-14,US 201916411543 A;;US 201715613921 A;;US 201615082257 A;;US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 66414205 P;;US 62942004 P,2004-11-18,ENDOLUMINAL DELIVERY OF ANESTHESIA,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/170-758-587-734-541,Patent Application,yes,4,12,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M19/00;;A61B6/00;;A61B18/14;;A61M5/00;;A61M25/00;;A61M25/04;;A61M25/10,,0,0,,,,ACTIVE
166,WO,A1,WO 2005/051206 A1,199-816-027-457-06X,2005-06-09,2005,US 2004/0039187 W,2004-11-22,US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,METHOD AND APPARATUS FOR TREATING A CAROTID ARTERY,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",VNUS MED TECH INC;;CHANG DAVID W,CHANG DAVID W,,https://lens.org/199-816-027-457-06X,Patent Application,yes,4,54,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,,0,0,,,,PENDING
167,US,A1,US 2018/0020774 A1,197-574-559-194-692,2018-01-25,2018,US 201715431816 A,2017-02-14,TW 105122979 A,2016-07-21,Shoe with Flexible Upper,"A shoe includes an outsole, a main body containing a flexible upper, and at least one elastic lace. The flexible upper is formed of a four-way stretch fabric. In use, the flexible upper can be deformed in response to the shape differences of users' feet, and the elastic lace can limit the deformation of the flexible upper to allow the shoe to be firmly worn by a user. With the shoe of the present invention, the unfit problem of conventional shoes due to the insufficient elasticity of the mesh fabrics making the uppers of the shoes can be solved.",CHANG GARY DAVID,CHANG GARY DAVID,,https://lens.org/197-574-559-194-692,Patent Application,yes,112,3,5,5,0,A43B23/027;;A43B23/027;;A43B13/04;;A43B13/22;;A43B23/0205;;A43B23/0205;;A43B23/0265;;A43B23/0265;;A43C1/02;;A43C1/02,A43B23/02;;A43B13/04;;A43B13/22;;A43C1/02,,0,0,,,,DISCONTINUED
168,US,A1,US 2020/0015826 A1,007-255-254-802-935,2020-01-16,2020,US 201916581034 A,2019-09-24,US 201916581034 A;;US 201916256229 A;;US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,METHOD AND APPARATUS FOR TREATING AN ARTERIAL LESION,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/007-255-254-802-935,Patent Application,yes,0,17,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/09;;A61M25/10;;A61M27/00,,0,0,,,,ACTIVE
169,US,B2,US 10779835 B2,008-125-212-927-909,2020-09-22,2020,US 201916256229 A,2019-01-24,US 201916256229 A;;US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/008-125-212-927-909,Granted Patent,yes,176,4,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M16/00;;A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M16/01;;A61M25/01;;A61M25/09;;A61M25/10;;A61M27/00;;A61M39/00,,51,22,040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;023-546-745-949-35X;;001-001-379-646-544;;024-321-843-309-136;;056-537-645-364-701;;034-095-739-046-671;;061-407-975-772-244;;016-207-092-214-742;;002-908-369-553-055;;002-478-877-804-626;;107-686-988-816-391;;028-839-258-555-020;;095-706-461-958-467;;093-172-129-212-966;;017-528-531-432-121;;071-968-223-548-381;;033-078-657-817-419;;053-599-451-169-494,10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;10.1161/01.cir.97.1.121;;9443447;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;15253268;;10.1007/s10016-004-0018-5;;10.1016/j.jvs.2004.06.026;;15337876;;10731266;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11241119;;10.1067/mva.2001.112278;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1179/016164104225013978;;15142330;;10.1007/s002709900294;;9853153;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730,"Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther 9:147-154.;;Bates M.D., et al. “Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model” Catheterization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) “Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques” The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). “Percutaneous stenting of the internal carotid artery: the European Cast I Study” J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79.;;Bettmann, M. et al, “Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association”. Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012.;;Chang, D.W., et al, “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., “Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention” 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114.;;Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.;;Criado, M.D., et al. (2004) “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient” Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadelphia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device—INVATEC.;;Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.;;MomaPresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002. 37 pages.;;Ohki, M.D., et al., “Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis” (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41.;;Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3.;;Stecker et al., (2002). “Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy”. J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection”. AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology.;;U.S. Appl. No. 14/078,149, filed Nov. 12, 2013, US 2014-0135661.;;U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769.;;U.S. Appl. No. 14/935,252, filed Nov. 6, 2015, US 2016-0128688.;;U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, US 2016-0242764.;;U.S. Appl. No. 15/141,060, filed Apr. 28, 2016, US 2016-0317288.;;U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, US 2017-0209260.;;U.S. Appl. No. 15/489,055, filed Apr. 17, 2017, US 2017-0312491.;;U.S. Appl. No. 15/613,921, filed Jun. 5, 2017, US 2017-0368296.;;U.S. Appl. No. 15/628,190, filed Jun. 20, 2017, US 2018-0008294.;;U.S. Appl. No. 15/641,966, filed Jul. 5, 2017, US 2017-0296798.;;U.S. Appl. No. 15,728,747, filed Oct. 10, 2017, US 2018-0154063.;;U.S. Appl. No. 15/728,915, filed Oct. 10, 2017, US 2018-0185614.;;U.S. Appl. No. 15/901502, filed Feb. 21, 2018, US 2018-0235789.;;U.S. Appl. No. 16/008,703, filed Jun. 14, 2018, US 2018-0289884.;;U.S. Appl. No. 16/210,533, filed Dec. 5, 2018, US 2019-0105439.;;Int'l App. No. PCT/US18/18943, filed Feb. 21, 2018, WO 2018/156574.;;Int'l App. No. PCT/US18/40264, filed Jun. 29, 2018, WO 2019/010077.;;U.S. Appl. No. 15/339,638, filed Jan. 5, 2017, US 2017-0209260.;;U.S. Appl. No. 16/056,208, filed Aug. 6, 2018, US 2019-0175885.;;U.S. Appl. No. 16/148,849, filed Oct. 1, 2018, US 2019-0269538.;;U.S. Appl. No. 16/171,784, filed Oct. 26, 2018, US 2019-0125512.;;U.S. Appl. No. 16/177,716, filed Nov. 1, 2018, US 2019-0150916.;;U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, US 2019-0231962.;;U.S. Appl. No. 16/410,485, filed May 13, 2019, US 2019-0262530.;;Int'l App. No. PCT/US18/57789, filed Oct. 26, 2018, WO 2019/089385.",ACTIVE
170,US,A1,US 2006/0106338 A1,063-683-970-359-34X,2006-05-18,2006,US 28222205 A,2005-11-18,US 28222205 A;;US 62942004 P;;US 66414205 P,2004-11-18,Endoluminal delivery of anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",CHANG DAVID W,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/063-683-970-359-34X,Patent Application,yes,47,73,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M29/00,604/104;;604/101.03,0,0,,,,ACTIVE
171,IN,B,IN 190595 B,104-771-875-856-415,2003-08-09,2003,IN 1596DE1994 A,1994-12-09,IN 1596DE1994 A,1994-12-09,An aqueous thickened alkali metal hypochlorite composition,,RECKITT BENCKISER INC,CHANG DAVID LUNGPAO,,https://lens.org/104-771-875-856-415,Granted Patent,no,0,0,1,1,0,,C01B11/10,,0,0,,,,EXPIRED
172,EP,A1,EP 0361661 A1,111-989-211-561-679,1990-04-04,1990,EP 89308224 A,1989-08-14,US 24914388 A,1988-09-26,Dynamic infrared target.,"An inexpensive broadband dynamic IR target with a fast response time, good spatial resolution, and adequate dynamic range is disclosed. The IR target is made by coating a thin photo-conductive film (20) on a transparent insulator (22). The emissivity of the film-substrate block is changed by irradiating the block with a visible image of the desired IR image. The image temperature varies from the block temperature T by an amount related to the photo-conductivity produced change in the emissivity.  ",HUGHES AIRCRAFT CO,CHANG DAVID B,,https://lens.org/111-989-211-561-679,Patent Application,yes,6,4,8,9,0,F41J2/02;;F41J2/02;;G02F2/02;;G02F2/02,F41J2/02;;G02F2/02,,0,0,,,,EXPIRED
173,US,B2,US 10328232 B2,134-038-146-994-013,2019-06-25,2019,US 201715613921 A,2017-06-05,US 201715613921 A;;US 201615082257 A;;US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 66414205 P;;US 62942004 P,2004-11-18,Endoluminal delivery of anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/134-038-146-994-013,Granted Patent,yes,65,3,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M19/00;;A61B6/00;;A61B18/14;;A61M5/00;;A61M25/00;;A61M25/04;;A61M25/06;;A61M25/10,,1,1,107-686-988-816-391,10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133,Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.,ACTIVE
174,ES,T3,ES 2390273 T3,138-694-754-342-458,2012-11-08,2012,ES 04811840 T,2004-11-22,US 52406903 P;;US 56984304 P;;US 58706704 P;;US 2004/0039187 W,2003-11-21,Aparato para el tratamiento de una arteria carótida,"Un aparato para el uso en la angioplastia de carótida, comprendiendo dicho aparato:un catéter (224, 324) que tiene un extremo distal y un extremo proximal opuesto a dicho extremo distal; y unprimer y segundo miembros oclusivos (225, 252, 325, 352), al menos dicho primer miembro oclusivo (252, 352)situado en dicho catéter, configurados dicho primer y segundo miembros oclusivos para invertir la direcciónnatural del flujo sanguíneo en la arteria carótida interna de un paciente cuando dicho primer miembro oclusivoocluye la arteria carótida común (212, 312) y dicho segundo miembro oclusivo (225, 325) ocluye la arteriacarótida externa (220, 320);en el que dicho catéter tiene una primera parte del eje que se extiende de forma proximal desde dicho primermiembro oclusivo (252, 352), teniendo dicha primera parte del eje una sección transversal máximadimensionada para insertarse dentro de la arteria carótida común (212, 312), teniendo dicha primera parte deleje una longitud de entre aproximadamente 2 centímetros y aproximadamente 25 centímetros de forma que seaadecuada para el acceso transcervical a la arteria carótida común; yen el que dicho catéter tiene un puerto de entrada de sangre (374) situado distal respecto a dicho primermiembro oclusivo (252, 352);caracterizado por que:el aparato comprende adicionalmente un depósito de recogida de sangre (598) para la conexión a dichocatéter (224, 324) para recoger de forma pasiva la sangre desde dicho puerto de entrada de sangre (374); y eldepósito de recogida (598) incluye un puerto de entrada de sangre (592) con una primera válvula (591) que,cuando está abierta, permite que la sangre fluya de forma pasiva dentro del depósito de recogida (598)durante la inversión de la dirección natural del flujo sanguíneo en la arteria carótida interna de un paciente, unpuerto de salida de sangre (593) con una segunda válvula (590) que, cuando está abierta, permite que lasangre fluya fuera del depósito de recogida, un puerto de salida de aire (596) para purgar el aire fuera deldepósito de recogida mientras la sangre se recoge en el depósito de recogida en uso, y un émbolo (594) parausarlo para expulsar la sangre recogida fuera del depósito de recogida a través del puerto de salida de sangre(593) y devolverla a la vasculatura del paciente tras la restauración de la dirección natural del flujo sanguíneode la arteria carótida interna del paciente.",VNUS MED TECH INC;;SILK ROAD MEDICAL INC,CHANG DAVID W,,https://lens.org/138-694-754-342-458,Granted Patent,no,0,0,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,,0,0,,,,ACTIVE
175,TW,B,TW I607714 B,168-799-740-779-252,2017-12-11,2017,TW 105122979 A,2016-07-21,TW 105122979 A,2016-07-21,TW I607714 B,,CHANG GARY DAVID,CHANG GARY DAVID,,https://lens.org/168-799-740-779-252,Granted Patent,no,1,0,5,5,0,A43B23/027;;A43B23/027;;A43B13/04;;A43B13/22;;A43B23/0205;;A43B23/0205;;A43B23/0265;;A43B23/0265;;A43C1/02;;A43C1/02,,,0,0,,,,ACTIVE
176,US,A1,US 2013/0172852 A1,183-928-476-220-020,2013-07-04,2013,US 201213674792 A,2012-11-12,US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 62942004 P;;US 66414205 P,2004-11-18,ENDOLUMINAL DELIVERY OF ANESTHESIA,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",CHANG DAVID W;;SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/183-928-476-220-020,Patent Application,yes,4,39,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M25/10,604/508;;604/512,0,0,,,,ACTIVE
177,CN,C,CN 100530027 C,194-028-552-539-996,2009-08-19,2009,CN 200480007324 A,2004-03-10,US 40133403 A,2003-03-27,System and method for integrated security roles,,IBM,YU CHANG DAVID,,https://lens.org/194-028-552-539-996,Granted Patent,no,0,0,9,9,0,G06F21/6236;;G06F21/6236;;H04L63/102;;H04L63/102,G06F1/00;;G06F21/00;;H04L29/06,,0,0,,,,ACTIVE
178,US,B1,US 6708656 B1,194-576-001-481-916,2004-03-23,2004,US 32248302 A,2002-12-19,US 32248302 A,2002-12-19,Engine valve actuator,"
    An engine valve actuator for an internal combustion engine is provided. The engine valve actuator includes a housing having an opening. An adjustment member is disposed in the housing and defines a chamber. A piston is disposed in the opening of the housing and has a protrusion adapted to be received in the chamber of the adjustment member. The piston has a first position where the protrusion of the piston is disposed in the chamber and a portion of the piston contacts a corresponding portion of the adjustment member and a second position where the portion of the piston is separated from the corresponding portion of the adjustment member. A fluid passageway is adapted to provide pressurized fluid to the opening. The pressurized fluid acts on the piston to move the piston towards the second position to thereby allow pressurized fluid to enter the chamber to prevent the piston from returning to the first position. A push rod is operatively engaged with the piston and is adapted to engage and open the engine valve. 
",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2002-12-16),https://lens.org/194-576-001-481-916,Granted Patent,yes,11,9,2,2,0,F01L1/24;;F01L9/10;;F01L1/24;;F01L9/10,F01L9/10;;F01L1/24,123/90.12;;92/13.6;;92/13.8,0,0,,,,EXPIRED
179,US,B2,US 7879011 B2,002-554-940-517-243,2011-02-01,2011,US 28222205 A,2005-11-18,US 28222205 A;;US 62942004 P;;US 66414205 P,2004-11-18,Endoluminal delivery of anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/002-554-940-517-243,Granted Patent,yes,49,38,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M1/00;;A61M5/178;;A61M29/00,604/164.13;;604/523;;604/35,1,0,,,"International Search Report mailed Aug. 17, 2006, for PCT Application No. PCT/US05/41931 filed Nov. 18, 2005, 4 pages.",ACTIVE
180,US,B2,US 10722239 B2,038-875-369-968-638,2020-07-28,2020,US 201916581034 A,2019-09-24,US 201916581034 A;;US 201916256229 A;;US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,Method and apparatus for treating an arterial lesion,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/038-875-369-968-638,Granted Patent,yes,176,4,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M16/00;;A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/01;;A61M25/09;;A61M25/10;;A61M27/00;;A61M39/00,,43,22,040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;023-546-745-949-35X;;001-001-379-646-544;;024-321-843-309-136;;056-537-645-364-701;;034-095-739-046-671;;061-407-975-772-244;;016-207-092-214-742;;002-908-369-553-055;;002-478-877-804-626;;107-686-988-816-391;;028-839-258-555-020;;095-706-461-958-467;;093-172-129-212-966;;017-528-531-432-121;;071-968-223-548-381;;033-078-657-817-419;;053-599-451-169-494,10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;10.1161/01.cir.97.1.121;;9443447;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;15253268;;10.1007/s10016-004-0018-5;;10.1016/j.jvs.2004.06.026;;15337876;;10731266;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11241119;;10.1067/mva.2001.112278;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1179/016164104225013978;;15142330;;10.1007/s002709900294;;9853153;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730,"U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769.;;U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, US 2016-0242764.;;U.S. Appl. No. 15/141,060, filed Apr. 28, 2016, US 2016-0317288.;;U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, US 2017-0209260.;;U.S. Appl. No. 15/641,966, filed Jul. 5, 2017, US 2017-0296798.;;U.S. Appl. No. 15/728,747, filed Oct. 10, 2017, US 2018-0154063.;;U.S. Appl. No. 15/901,502, filed Feb. 21, 2018, US 2018-0235789.;;U.S. Appl. No. 16/008,703, filed Jun. 14, 2018, US 2018-0289884.;;U.S. Appl. No. 16/056,208, filed Aug. 6, 2018, US 2019-0175885.;;U.S. Appl. No. 16/148,849, filed Oct. 1, 2018, US 2019-0269538.;;U.S. Appl. No. 16/171,784, filed Oct. 26, 2018, US 2019-0125512.;;U.S. Appl. No. 16/177,716, filed Nov. 1, 2018, US 2019-0150916.;;U.S. Appl. No. 16/256,229, filed Jan. 24, 2019, US 2019-0254680.;;U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, US 2019-0231962.;;U.S. Appl. No. 16/410,485, filed May 13, 2019, US 2019-0262530.;;PCT/US18/40264, Jun. 29, 2018, WO 2019/010077.;;PCT/US18/57789, Oct. 26, 2018, WO 2019/089385.;;Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther 9:147-154.;;Bates M.D., et al. “Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model” Catheterization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) “Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques” The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). “Percutaneous stenting of the internal carotid artery: the European CAST I Study” J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79.;;Bettmann, M. et al, “Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association”. Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012.;;Chang, D.W., et al, “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., “Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting Via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention” 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114.;;Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.;;Criado, M.D., et al. (2004) “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient” Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadelphia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device—INVATEC.;;Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.;;MomaPresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002. 37 pages.;;Ohki, M.D., et al., “Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis” (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41.;;Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3.;;Stecker et al., (2002). “Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy”. J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection”. AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology.",ACTIVE
181,KR,Y1,KR 950001929 Y1,026-594-538-673-827,1995-03-23,1995,KR 920015874 U,1992-08-24,KR 920015874 U,1992-08-24,CUPPING CUP VLAVE IN CUPPING VESSEL,,CHANG DAVID K,CHANG DAVID K,,https://lens.org/026-594-538-673-827,Unknown,no,0,0,2,2,0,A61M1/08;;A61M2205/07;;A61M2205/3331,A61M1/08,,0,0,,,,DISCONTINUED
182,CH,A,CH 493145 A,038-111-814-113-698,1970-06-30,1970,CH 1038368 A,1968-07-11,US 65357167 A,1967-07-14,Treiberschaltung für eine mit bipolarer Hochspannung zu beaufschlagende kapazitive Last,,IBM,DAVID CHING CHANG,,https://lens.org/038-111-814-113-698,Granted Patent,no,0,0,12,12,0,H03K17/60;;H03K17/601;;H03K17/601;;H03K17/60,G05F1/46;;H02M3/28;;H02M9/04;;H03K17/60,,0,0,,,,EXPIRED
183,US,B2,US 8870805 B2,046-648-728-073-597,2014-10-28,2014,US 96697410 A,2010-12-13,US 96697410 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",CHANG DAVID W;;SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/046-648-728-073-597,Granted Patent,yes,99,66,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M5/00;;A61B17/12;;A61B17/22;;A61B17/3207;;A61M1/00;;A61M1/36;;A61M25/10,604/8;;623/1.11;;604/4.01,26,22,040-075-091-947-635;;018-373-571-777-960;;022-030-526-030-972;;020-746-684-497-43X;;009-555-772-505-698;;023-546-745-949-35X;;001-001-379-646-544;;024-321-843-309-136;;061-407-975-772-244;;056-537-645-364-701;;034-095-739-046-671;;016-207-092-214-742;;002-908-369-553-055;;002-478-877-804-626;;107-686-988-816-391;;028-839-258-555-020;;095-706-461-958-467;;093-172-129-212-966;;017-528-531-432-121;;071-968-223-548-381;;033-078-657-817-419;;053-599-451-169-494,10.1177/152660280200900202;;12010092;;10.1583/1545-1550(2002)009<0147:uotpae>2.0.co;2;;14517938;;10.1002/ccd.10632;;15239376;;10.1583/1074-6218(1999)006<0155:psotic>2.0.co;2;;10473333;;10.1177/152660289900600207;;10.1177/152660289600300115;;8798129;;10.1583/1074-6218(1996)003<0076:rcdwsb>2.0.co;2;;10.1161/01.cir.97.1.121;;9443447;;15111851;;10.1016/j.jvs.2004.01.045;;9293823;;10.1016/s0002-9610(97)90065-9;;10731266;;15253268;;10.1007/s10016-004-0018-5;;10.1016/j.jvs.2004.06.026;;15337876;;15218468;;10.1016/j.jvs.2004.03.034;;10.1016/j.ejvs.2004.08.012;;15531198;;10.1177/152660289600300210;;8798137;;10.1583/1074-6218(1996)003<0182:ptfeci>2.0.co;2;;10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133;;11241119;;10.1067/mva.2001.112278;;11668307;;10.1067/mva.2001.119041;;10.1067/mva.2000.109209;;11107084;;10.1179/016164104225013978;;15142330;;10.1007/s002709900294;;9853153;;10.1016/s1051-0443(07)61746-1;;11932374;;pmc8334090;;2145730,"Adami, M.D., et al., (2002) ""Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results"" J Endovasc Ther 9:147-154.;;Bates M.D., et al. ""Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model"" Catherization and Cardiovascular Intervention 60:270-275 (2003).;;Bates, M.D., et al. (2004) ""Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques"" The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron et al. (1999). ""Percutaneous stenting of the internal carotid artery: the European Cast I Study"" J. Endovasc. Surg. 6:155-159.;;Bergeron P. et al. (1996) ""Recurrent Carotid Disease: Will Stents be an alternative to surgery?"" J Endovasc Surg; 3: 76-79.;;Bettman, M. et al, ""Carotid Stenting and Angioplasty . . . "" etc. Circulation, 1998, 97:121-123.;;Chang, D.W., et al, ""A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention"" (J Vasc Surg 2004; 39:994-1002.).;;Chang, M.D., ""Carotid Angioplasty and Stenting Using Transcervical Occlusion and Protective Shunting via a Mini Incision in the Neck: A New Technique for Difficult Femoral Access or Filter Placement May Be the Better Carotid Artery Intervention"" 30th Global: Vascular and Endovascular Issues, Techniques and Horizons. XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) ""Evolving indications for and early results of carotid artery stenting"" Am. J. Surg.; 174:111-114.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-68.;;Criado et al. (2004). ""Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique"" J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). ""Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results"" J. Vasc. Surg. 40:476-483.;;Criado, M.D., et al. (2004) ""Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient"" Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) ""First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting"" Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diederich et al., (1996). ""Percutaneous techniques for endoluminal carotid interventions"" J. Endovasc. Surg. 3:182-202.;;Diederich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;Henry et al. (1999) ""Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System"" J. Endovasc. Surg. 6:321-331.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device-INVATEO.;;MOMAPRESN (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig-Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" (J Vasc Surg 2001; 33:504-9).;;Ouriei, K., R. K. Greenberg, et al. (2001). ""Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion."" J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). ""Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices"" J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). ""Direct percutaneous carotid artery stenting with distal protection: technical case report."" Neurol Res 26(3): 338-41.;;Reekers, J. A. (1998). ""A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures."" Cardiovasc Intervent Radiol 21(5): 431-3.;;Stecker et al., (2002). ""Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy"" J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. ""New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection"" AJNR 11:869-874, Sep./Oct. 1990 0195-6108/90/1106-0869 @ American Society of Neurology.",ACTIVE
184,CA,A,CA 1153472 A,043-356-329-314-257,1983-09-06,1983,CA 363546 A,1980-10-29,US 10781179 A,1979-12-28,TIME OF DAY CLOCK CONTROL,"TIME OF DAY CLOCK CONTROL A time of day clock for a computer is run off a clock for the computer processor by selecting the processor clock cycle T such that a binary multiple N of the time of day unit cycle D contains an integral number K of processor cycles T or ND = KT in accordance with the equation: D = ( R + ? ) T, where R is the integer nearest the actual D/T ratio, and X represents the number of time of day cycles D of longer or shorter duration than R processor cycles needed to establish the fractional relationship between the two cycles over the period ND. P09-79-001",IBM,CHANG DAVID C,,https://lens.org/043-356-329-314-257,Granted Patent,no,0,0,8,8,0,G04G3/022;;G04G99/006;;G06F9/4825;;G06F9/4825;;G04G99/006;;G04G3/022,G04G3/02;;G04G99/00;;G06F1/14;;G06F9/48,354-231,0,0,,,,EXPIRED
185,EP,A3,EP 0031403 A3,057-289-223-875-25X,1981-07-15,1981,EP 80105792 A,1980-09-25,US 10781179 A,1979-12-28,DATA PROCESSING APPARATUS INCLUDING A TIME OF DAY CLOCK,"The time of day clock in data processing apparatus is run off the clock for the apparatus via control logic (16, 18) responsive to both clocks by selecting the processor clock cycle T such that a binary multiple N of the time of day unit cycle D contains an integral number K of processor cycles T or ND = KT in accordance with the equation:
  where R is the integer nearest the actual D/T ratio, N and represents the number of D cycles containing R processor cycles T while X represents the number of D cycles of longer or shorter duration than R processor cycles needed to establish the actuel proportional relationship between the two cycles over the period ND.",INTERNATIONAL BUSINESS MACHINES CORPORATION,"CHANG, DAVID C.",,https://lens.org/057-289-223-875-25X,Search Report,yes,1,0,8,8,0,G04G3/022;;G04G99/006;;G06F9/4825;;G06F9/4825;;G04G99/006;;G04G3/022,G04G3/02;;G04G99/00;;G06F1/14;;G06F9/48,,2,0,,,"IBM TECHNICAL DISCLOSURE BULLETIN, Vol. 13, No. 8, January 1971 New York (US) HASLAM: ""Timer for data processing systems"" pages 2429-2430;;IBM TECHNICAL DISCLOSURE BULLETIN, Vol. 17, No. 7, December 1974 New York (US) DUKE: ""Regulation of time of day clock"" pages 2043-2045.",EXPIRED
186,NZ,A,NZ 277629 A,108-834-287-906-384,1997-07-27,1997,NZ 27762994 A,1994-11-21,US 17490593 A,1993-12-29,"ALKALI METAL HYPOCHLORITE COMPOSITIONS WITH ENHANCED VISCOSITY CONTAINING TERTIARY AMINE, ALKALI METAL SARCOSINATE AND ALKYL BENZYL SULPHONATE; CLEANING COMPOSITIONS","Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,,https://lens.org/108-834-287-906-384,Patent Application,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,PENDING
187,US,B1,US 6409391 B1,177-474-069-396-60X,2002-06-25,2002,US 53230000 A,2000-03-22,US 53230000 A;;US 12633599 P,1999-03-26,Fiber optic illumination adaptor assembly for multiple light guide connectors,"
    An adaptor assembly for coupling light guide connectors of varying configurations to a structure housing a source of focused light includes an internal adaptor having an internal optic guide element, a coupling structure, a housing, and a connector locking mechanism. The coupling structure can be inserted into and releasably retained within the structure housing the focused light. A light guide connector is inserted into a light guide receiving channel formed in the housing and is releasably retained therein by the connector locking mechanism. An internal optic guide element extends through the coupling structure to transmit focused light from the source of focused light to the light guide connector inserted into the connector-receiving channel. The housing includes heat dissipating elements to facilitate dissipation of heat generated at the interface between the optic guide element and the light guide of the connector. The adaptor assembly also includes a external adaptor having a body portion and an elongated insertion member. The elongated insertion member can be inserted into the connector-receiving channel of the internal adaptor, and the external adaptor can be releasably coupled to the internal adaptor by a releasable connecting mechanism. A short type of optical connector can be inserted into a connector-receiving cavity formed in the body portion of the external adaptor and releasably retained therein by a connector locking mechanism. Focused light from the light source is transmitted through the adaptor assembly by the first mentioned internal optic guide element of the internal adaptor and a second internal optic guide element disposed within the elongated insertion portion of the external adaptor. 
",COGENT LIGHT TECH,CHANG DAVID D,WAVIEN INC (2000-03-17),https://lens.org/177-474-069-396-60X,Granted Patent,yes,10,60,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,385/53;;385/55;;385/56;;385/60;;385/76;;385/77;;385/115;;385/139;;385/78,0,0,,,,EXPIRED
188,US,A,US 4355071 A,183-651-074-213-603,1982-10-19,1982,US 14626180 A,1980-05-05,US 14626180 A;;US 6025579 A;;US 90241678 A,1978-05-03,Clear coat/color coat finish containing ultraviolet light stabilizer,The weatherability and durability of clear coat/color coat finishes can be significantly increased by incorporating one or more ultraviolet light stabilizers into the color coat.,DU PONT,CHANG DAVID C,,https://lens.org/183-651-074-213-603,Granted Patent,yes,11,55,1,12,0,B05D7/532;;B05D2202/00;;Y10T428/263;;Y10T428/31522;;Y10T428/31565;;Y10T428/31688;;Y10T428/31786;;Y10T428/31594;;Y10T428/31591;;Y10T428/31576;;Y10T428/31515;;Y10T428/31703;;Y10T428/31681;;Y10T428/31699;;Y10T428/263;;Y10T428/31522;;Y10T428/31565;;Y10T428/31688;;Y10T428/31786;;Y10T428/31594;;Y10T428/31591;;Y10T428/31576;;Y10T428/31515;;Y10T428/31703;;Y10T428/31681;;Y10T428/31699;;B05D7/532;;B05D2202/00,B05D5/00;;B05D7/00;;B05D7/16,428/334,0,0,,,,EXPIRED
189,CA,A,CA 1198540 A,184-096-763-654-97X,1985-12-24,1985,CA 397407 A,1982-03-02,US 24057381 A,1981-03-04,CRATER RESISTANT ACRYLIC ENAMEL,"TITLE Crater Resistant Acrylic Enamel A crater resistant enamel coating composition used for the exterior of trucks and automobiles in which the binder is a blend of (A) an acrylic polymer having hydroxy groups and contains about 0.1-10% by weight of a polymerized perfluoro carbon constituent of the formula where R is H < IMG > of CH3, R1 is alkyl, R2 is perfluoro alkyl and n is O or 1 and (B) an aminoplast crosslinking agent such as an alkylated melamine formaldehyde resin. After the composition is applied and baked by conventional techniques, a finish is formed that has an excellent appearance.",DU PONT,CHANG DAVID C,,https://lens.org/184-096-763-654-97X,Granted Patent,no,0,0,2,3,0,C09D133/066;;C09D133/066;;C08L61/20;;C08L61/20;;C08L61/32;;C08L61/32;;C09D161/32;;C09D161/32;;Y10T428/31678;;Y10T428/31678,C08L61/20;;C08L61/32;;C09D133/06;;C09D161/32,400-5471,0,0,,,,EXPIRED
190,WO,A1,WO 2000/062109 A1,198-585-697-102-936,2000-10-19,2000,US 0007707 W,2000-03-23,US 12633599 P,1999-03-26,FIBER OPTIC ILLUMINATOR ADAPTOR ASSEMBLY FOR MULTIPLE LIGHT GUIDE CONNECTORS,"An adaptor assembly (10) for coupling light guide connectors (70) of varying configurations to a structure housing a source of focused light includes an internal adaptor having an internal optic guide element (12), a coupling structure (20), a housing (40), and a connector locking mechanism. The coupling structure (20) can be inserted into and releasably retained within the structure housing the focused light. A light guide connector (70) is inserted into a light guide receiving channel formed in the housing and is releasably retained therein by the connector locking mechanism. An internal optic guide element (12) extends through the coupling structure (20) to transmit focused light from the source of focused light to the light guide connector inserted into the connector-receiving channel.",COGENT LIGHT TECH;;CHANG DAVID D,CHANG DAVID D,,https://lens.org/198-585-697-102-936,Patent Application,yes,4,4,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,G2J JGEAX1        JGEAX1;;G2J JG2           JGEAX1,0,0,,,,PENDING
191,US,A1,US 2005/0132986 A1,002-752-066-916-500,2005-06-23,2005,US 74300003 A,2003-12-23,US 74300003 A,2003-12-23,ENGINE VALVE ACTUATION SYSTEM,"An engine valve actuation system includes an engine valve moveable between first and second positions, a valve actuation assembly connected to move the engine valve between the first and second positions, a fluid actuator configured to selectively modify a timing of the engine valve in moving from the second to the first position, a source of fluid, and a pair of passages in the cylinder that allow fluid to flow from the chamber to the fluid source. The fluid actuator includes a cylinder and a piston at least partly defining a chamber. The piston is slidably movable in the cylinder between a first position and a second position, and blocks at least a portion of one of the passages at an intermediate position between the second position and the first position to reduce fluid flow from the chamber when the piston moves from the second position toward the first position.",CHANG DAVID Y.,CHANG DAVID Y,CATERPILLAR INC (2004-02-16),https://lens.org/002-752-066-916-500,Patent Application,yes,24,8,3,5,0,F01L9/10;;F01L9/10,F01L9/10;;F01L1/34,123/90.12,0,0,,,,EXPIRED
192,US,B1,US 11066977 B1,000-624-302-692-061,2021-07-20,2021,US 202016749642 A,2020-01-22,US 202016749642 A,2020-01-22,Ignitor for natural gas engine,"In one aspect, an engine ignition apparatus for a natural gas engine may include a housing including a drive piston, a floating piston, a controllable hydraulic fluid chamber located between the drive piston and the floating piston, and an ignition chamber acted on by the floating piston, the ignition chamber having an outlet formed by a plurality of orifices, the outlet being in direct communication with a combustion chamber of the engine. In another aspect, an engine ignition apparatus for a natural gas engine may include, among other features, a controllable valve connected to a hydraulic fluid chamber, and configured to open and release a hydraulic fluid from the hydraulic fluid chamber, and to close. In still another aspect, a method for controlling an engine ignition apparatus for an engine includes, among other features, controlling a volume of a hydraulic fluid chamber of an ignition apparatus.",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2020-01-22),https://lens.org/000-624-302-692-061,Granted Patent,yes,7,4,4,4,0,F02M26/01;;F02D15/04;;F02D41/0085;;F02D19/02;;F02D41/0027;;F02B19/14;;F02B19/06;;F02B2043/103;;F02B1/12;;Y02T10/12;;Y02T10/30;;F02B1/12;;F02M26/01;;F02D37/02;;F02B3/06;;F02B2075/125;;F02B2275/14;;F02D13/0215;;F02D2041/001;;F02D2041/389,F02B19/00;;F02B1/12;;F02B3/06;;F02B75/12;;F02D13/02;;F02D37/02;;F02D41/00;;F02D41/38;;F02M26/01,,0,0,,,,ACTIVE
193,DE,A1,DE 10342457 A1,023-077-424-928-057,2004-04-15,2004,DE 10342457 A,2003-09-15,US 26379902 A,2002-10-04,Motorventilbetätiger,"Ein Motorventilbetätiger (12) für einen internen Verbrennungsmotor (10) ist vorgesehen. Der Motorventilbetätiger (12) umfasst ein Gehäuse (30), welches eine Öffnung (34) und einen ersten Strömungsmitteldurchlass (32) hat, welcher zu der Öffnung (34) führt. Ein Einstellglied (36) ist im Gehäuse (30) untergebracht und schließt einen Vorsprung (37) ein, welcher sich in die Öffnung (34) des Gehäuses (30) erstreckt. Ein Kolben (38) ist in der Öffnung (34) des Gehäuses (30) untergebracht und hat eine Bohrung (44), welche geeignet ist, um den Vorsprung (37) aufzunehmen, eine Kammer (50) und einen zweiten Strömungsmitteldurchlass (40), welcher die Bohrung (44) mit der Kammer (50) verbindet. Der Kolben (38) ist eingestellt, um sich als Reaktion auf ein Einführen von Druckstörmungsmittel in den ersten Strömungsmitteldurchlass (32) in einer ersten Richtung relativ zum Gehäuse (30) zu bewegen. Der Kolben (38) bewegt sich in der ersten Richtung, bis sich der Vorsprung (37) im Wesentlichen aus der Bohrung (44) zurückzieht. Eine Schubstange (54) steht betriebsmäßig mit dem Kolben (38) in Eingriff, so dass die Bewegung des Kolbens (38) in der ersten Richtung eine entsprechende Bewegung der Schubstange (54) hervorruft, um dabei mit dem Motorventil (24) in Eingriff zu kommen und es zu öffnen.",CATERPILLAR INC,CHANG DAVID Y,,https://lens.org/023-077-424-928-057,Patent Application,no,0,0,4,4,0,F01L1/26;;F01L13/065;;F01L9/10;;F01L1/26;;F01L13/065;;F01L9/10,F01L1/26;;F01L9/10;;F01L13/06,,0,0,,,,DISCONTINUED
194,EP,A1,EP 0636985 A1,034-581-492-454-086,1995-02-01,1995,EP 94305231 A,1994-07-15,US 9750693 A,1993-07-27,Process monitoring in a multiprocessing server.,"A system and method for determining and displaying the status of client application programs executing on a multiprocessing server. Server process control blocks (5) and synchronization object descriptors (10) are created in the shared memory (11) of the server (3). Application program interfaces APIs (8) are linked to the control blocks and descriptors during the execution of the various multiprocessing application programs (7). A status utility (13) related to the service process monitor (12) selectively accesses information from the control blocks (5) and descriptors (10) to determine the status of the individual multiple processes executing on the server workstation (3). In a preferred form, the status information is conveyed to and displayed on a video display (4) associated with the service process monitor. In contrast to operating system monitors which disclose the status of all processes as a whole, the present server process monitor particularizes the information to the specific client process. Thereby, the information is of a granularity to identify processes which are hung up on semaphores, message queues, or the like. The information is at the level used by a system administrator or software developer.",IBM,CHANG DAVID YU,,https://lens.org/034-581-492-454-086,Patent Application,yes,0,7,7,7,0,G06F11/0715;;G06F11/0715;;G06F11/3006;;G06F11/3006;;G06F11/302;;G06F11/302;;G06F11/3055;;G06F11/3055;;G06F11/3089;;G06F11/3089;;G06F11/328;;G06F11/328,G06F11/30;;G06F11/32;;G06F13/00,,4,0,,,"""Remote Database Status"", IBM TECHNICAL DISCLOSURE BULLETIN., vol. 36, no. 6B, June 1993 (1993-06-01), NEW YORK US, pages 269 - 270;;""Method for Managing Client/Server Relationships in the AIX Operating System"", IBM TECHNICAL DISCLOSURE BULLETIN., vol. 31, no. 8, January 1989 (1989-01-01), NEW YORK US, pages 195 - 198;;""Multi-thread Host Server for PC Support"", IBM TECHNICAL DISCLOSURE BULLETIN., vol. 28, no. 9, February 1986 (1986-02-01), NEW YORK US, pages 3848 - 3855;;AT&T: ""UNIX System 5 (User's Reference Manual)"", 1987, PRENTICE HALL, ENGLEWOOD CLIFFS, US",EXPIRED
195,CN,A,CN 102086827 A,050-857-800-233-854,2011-06-08,2011,CN 201010579861 A,2010-12-02,US 63005509 A,2009-12-03,Fluid injector with thermal load control,"The present invention discloses a fluid injector with thermal load control. A common rail single fluid injection system includes fuel injectors and control valve assemblies with an internal cooling fluid circuit to improve overall life and performance of the injector. This is accomplished by supplying cooling fluid to the injector and allowing the same to come in direct contact with one of the hottest locations, the high-pressure leak split spot within the fuel injector. By providing cooling fluid directly to this location and then allowing the cooling fluid to drain out of the injector, the present disclosure effectively and efficiently manages thermal loads within the injector.",CATERPILLAR INC,CHANG DAVID Y,,https://lens.org/050-857-800-233-854,Patent Application,no,4,1,5,5,0,F02M53/043;;F02M63/0225;;F02M63/0225;;F02M53/043,F02M51/06;;F02M53/04;;F02M61/04,,0,0,,,,INACTIVE
196,US,B2,US 7115283 B2,056-176-246-549-767,2006-10-03,2006,US 43068003 A,2003-05-06,US 43068003 A,2003-05-06,Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals,Preparations for the sustained release of a nutraceutical are described that include a solid matrix coated with a methylcellulose-containing coating. The solid matrix contains a polyphenol and the nutraceutical. Methods of controllably releasing a nutraceutical are also described that include administering to a patient a preparation containing a solid matrix coated with methylcellulose-containing coating. The solid matrix includes a polyphenol and a therapeutically effective amount of the nutraceutical.,ACCESS BUSINESS GROUP INT LLC,CHANG DAVID S,ACCESS BUSINESS GROUP INTERNATIONAL LLC (2003-08-13),https://lens.org/056-176-246-549-767,Granted Patent,yes,27,3,2,2,0,A61K9/2068;;A61K9/2068;;A61K9/2866;;A61K9/2866,A01N65/00;;A61C15/00;;A61K9/20;;A61K9/28,424/725,1,1,129-865-943-870-986,12575156,"PubMed Abstract No. 12575156: Li, Y.; Huang, C.; Cen, Y.; Xu, S.; and Xu, S. ""Preparation of Tea Polyphenols Sustained-Release Microcapsule""; Zhong Yao Cai, 2000, 23(5), 281-4.",EXPIRED
197,US,A1,US 2002/0163746 A1,078-077-425-709-88X,2002-11-07,2002,US 84950701 A,2001-05-04,US 84950701 A,2001-05-04,Server accelerator switch,"
   A system with one or more server accelerator (SA) switches provides accelerated or faster response to a network user. The SA switches may send data directly to a user, i.e., an initiating computer, without further intervention or post-processing of retrieved data by an origin server, thereby reducing the load on an origin server. The requirements from an origin server are thereby reduced, thus, also enabling an origin server to handle more user requests. 
",CHANG DAVID Y.,CHANG DAVID Y,ACUTE COMMUNICATIONS CORPORATION (2001-06-20),https://lens.org/078-077-425-709-88X,Patent Application,yes,0,5,1,1,0,H04L69/329;;H04L9/40;;H04L69/329;;H04L9/40,H04L29/06;;H04L29/08,360/1,0,0,,,,DISCONTINUED
198,US,A,US 4396680 A,081-254-304-795-972,1983-08-02,1983,US 32256781 A,1981-11-18,US 32256781 A;;US 24057381 A,1981-03-04,Substrate coated with crater resistant acrylic enamel,"A substrate of either metal or plastic which is coated with a crater resistant enamel coating composition is used for the exterior of trucks and automobiles; the binder of the coating composition is a blend of (A) an acrylic polymer having hydroxy groups and contains about 0.1-10% by weight of a polymerized perfluoro carbon constituent of the formula ##STR1## where R is H or CH.sub.3, R.sup.1 is alkyl, R.sup.2 is perfluoro alkyl and n is 0 or 1 and (B) an aminoplast crosslinking agent such as an alkylated melamine formaldehyde resin; The composition is applied and baked by conventional techniques, to form a finish on the substrate that has an excellent appearance.",DU PONT,CHANG DAVID C,ZIMMER ORTHOPAEDIC SURGICAL PRODUCTS INC (2002-06-28);;E.I. DU PONT DE NEMOURS AND COMPANY A CORP. OF DE (1981-11-10),https://lens.org/081-254-304-795-972,Granted Patent,yes,10,58,1,3,0,C09D133/066;;C09D133/066;;C08L61/20;;C08L61/20;;C08L61/32;;C08L61/32;;C09D161/32;;C09D161/32;;Y10T428/3154;;Y10T428/3154;;Y10T428/31544;;Y10T428/31544;;Y10T428/3162;;Y10T428/3162;;Y10T428/31634;;Y10T428/31634;;Y10T428/31649;;Y10T428/31649;;Y10T428/31688;;Y10T428/31688;;Y10T428/31696;;Y10T428/31696;;Y10T428/31699;;Y10T428/31699;;Y10T428/31877;;Y10T428/31877;;Y10T428/31906;;Y10T428/31906;;Y10T428/31924;;Y10T428/31924;;Y10T428/31928;;Y10T428/31928;;Y10T428/31935;;Y10T428/31935,C08L61/20;;C08L61/32;;C09D133/06;;C09D161/32,428/421;;428/422;;428/463;;428/460;;428/462;;428/506;;428/520;;428/522;;428/519;;524/512;;428/431;;428/436;;428/442;;428/514,0,0,,,,EXPIRED
199,US,A,US 5177970 A,082-589-210-733-43X,1993-01-12,1993,US 65966991 A,1991-02-25,US 65966991 A,1991-02-25,Refrigerator of air conditioner based on a fluid of electric dipoles,"A refrigeration apparatus wherein the working fluid is a suspension of electric dipoles. The apparatus conducts the fluid from the region to be cooled to a heat exchanger, and employs different fluid conduit geometries. The fluid conduits present the fluid to the region to be cooled in a cold unaligned state, whereupon the fluid absorbs energy from the region and is heated. The dipoles in this warmed fluid are then aligned in another region by the conduit geometry, and the fluid becomes hot as a result of this alignment. The heated fluid with the aligned fluid is then cooled in the heat exchanger, and the cooler aligned dipole fluid becomes even cooler when the fluid flows to a region where the dipoles can no longer maintain their alignment and the process then repeats. The alignment and unalignment of the dipoles in the fluid is controlled by the geometry of the fluid container. In the aligned region, the conduits are cylindrical or planer; in the unaligned region, the conduits are spherical. No compression of the fluid is required.",HUGHES AIRCRAFT CO,CHANG DAVID B,HUGHES AIRCRAFT COMPANY LOS ANGELES CA A CORP. OF DE (1991-02-22),https://lens.org/082-589-210-733-43X,Granted Patent,yes,1,18,1,1,0,F25B21/00;;F25B21/00;;F25B2321/0021;;F25B2321/0021;;Y02B30/00;;Y02B30/00,F25B21/00,62/3.1;;62/467;;165/96,0,0,,,,EXPIRED
200,US,A1,US 2021/0205571 A1,082-781-435-348-241,2021-07-08,2021,US 202017074299 A,2020-10-19,US 202017074299 A;;US 201916411543 A;;US 201715613921 A;;US 201615082257 A;;US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 66414205 P;;US 62942004 P,2004-11-18,ENDOLUMINAL DELIVERY OF ANESTHESIA,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/082-781-435-348-241,Patent Application,yes,2,1,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M19/00;;A61B6/00;;A61B18/14;;A61M5/00;;A61M25/00;;A61M25/04;;A61M25/10,,0,0,,,,PENDING
201,CA,A,CA 1144434 A,094-983-399-767-57X,1983-04-12,1983,CA 333570 A,1979-08-10,US 6025579 A,1979-07-26,CLEAR COAT/COLOR COAT FINISH CONTAINING AN ULTRAVIOLET LIGHT STABILIZER,"A substrate that has a finish of a clear coat toplayer in firm adherence to a color coat layer that is in adherence with the substrate; wherein the clear coat consists essentially of a transparent film forming binder; the color coat consists essentially of a film forming binder and pigments; the color coat contains an ultraviolet light stabilizer and optionally, both the clear coat and the color coat contain an antioxidant and an ultraviolet light stabilizer; this finish has an excellent appearance and has excellent weatherability and durability and is particularly useful as a finish for automobiles and trucks.",DU PONT,CHANG DAVID C,,https://lens.org/094-983-399-767-57X,Granted Patent,no,0,0,10,12,0,B05D7/532;;B05D2202/00,B05D5/00;;B05D7/00;;B05D7/16,117-132,0,0,,,,EXPIRED
202,US,A1,US 2020/0330637 A1,156-102-350-402-638,2020-10-22,2020,US 201916386334 A,2019-04-17,US 201916386334 A,2019-04-17,DIFFUSER FOR ESSENTIAL OILS,"A diffuser includes a housing with at least one inlet and at least one vent outlet, and a microblower carried by the housing. The microblower has an inlet side to receive air from the at least one inlet, and an outlet port. A bottle adapted to carry essential oil is included and has a neck opening. A tube directs air from the microblower outlet port into the neck opening to generate oil-laden air. A fan draws ambient air in from the at least one inlet and exhausts ambient air and oil-laden air through the at least one vent outlet.",GREENAIR INC,CHANG DAVID T,GREENAIR INC (2019-04-15),https://lens.org/156-102-350-402-638,Patent Application,yes,0,4,2,2,0,A61L9/122;;A61L2209/14;;A61L2209/133;;A61L9/22;;A61L2209/11;;A61L2209/13;;A61L9/122;;A61L9/14;;A61L2209/132;;A61L2209/12;;A61L9/013;;B01F23/213,A61L9/12;;A61L9/013;;A61L9/14,,0,0,,,,ACTIVE
203,AU,A,AU 2000/040225 A,166-744-699-977-159,2000-11-14,2000,AU 2000/040225 A,2000-03-23,US 12633599 P;;US 0007707 W,1999-03-26,Fiber optic illuminator adaptor assembly for multiple light guide connectors,,COGENT LIGHT TECH,CHANG DAVID D,,https://lens.org/166-744-699-977-159,Patent Application,no,0,0,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,DISCONTINUED
204,CA,A1,CA 2179409 A1,005-114-193-350-581,1995-07-06,1995,CA 2179409 A,1994-11-21,US 17490593 A;;US 9413519 W,1993-12-29,Thickened Alkali Metal Hypochlorite Compositions,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT & COLMAN INC,CHANG DAVID L,,https://lens.org/005-114-193-350-581,Patent Application,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
205,US,A1,US 2008/0243080 A1,004-094-206-206-094,2008-10-02,2008,US 7268308 A,2008-05-16,US 7268308 A;;US 92089207 P;;US 92015307 P,2007-03-27,Method and apparatus for vascular access,"A method and apparatus is described that facilitates appropriate placement of a closure device and allows ease of placement with repeated access without bleeding. A suitable biocompatible polymer diaphragm such as silicone or nipple is place on the adventitia of the vessel through a small cutdown incision. The puncture surface is a diaphragm that functions as a self-sealing valve. For embodiments designed for small catheter access such as 4 to 9 Fr, this may be a polymer that elastically seals around the puncture once the catheter is removed. Especially for larger access catheters, such as 10 French to 24 French, a preformed aperture or slit may be cut into the material, allowing controlled and atraumatic penetration of the device and artery. The sealing element may also be fixed to the outside wall of the vessel with holdfasts through a method that facilitates percutaneous delivery through the use of a guiding wire. A method and apparatus is also described that minimizes the potential migration of emboli generated upstream from the access site, an anchoring cannula and method for facilitating localizing of the access device.",CHANG DAVID W,CHANG DAVID W,,https://lens.org/004-094-206-206-094,Patent Application,yes,13,21,1,1,0,A61B17/3423;;A61M25/01;;A61M25/01;;A61B17/3423,A61B17/08;;A61M5/178;;A61M29/00,604/164.01;;606/213;;606/200,0,0,,,,DISCONTINUED
206,US,A,US 5636376 A,016-571-743-537-037,1997-06-03,1997,US 45793095 A,1995-06-01,US 45793095 A;;US 9750693 A,1993-07-27,System and method for selectively and contemporaneously monitoring processes in a multiprocessing server,"A system, method and program product for determining and displaying the status of client application programs executing on a multiprocessing server. Server process control blocks and synchronization object descriptors are created in the shared memory of the server. Application program interfaces APIs are linked to the control blocks and descriptors during the execution of the various multiprocessing application programs. A status utility related to the service process monitor selectively accesses information from the control blocks and descriptors to determine the status of the individual multiple processes executing on the server workstation. In a preferred form, the status information is conveyed to and displayed on a video display associated with the service process monitor. In contrast to operating system monitors which disclose the status of all processes as a whole, the present server process monitor particularizes the information to the specific client process. Thereby, the information is of a granularity to identify processes which are hung up on semaphores, message queues, or the like. The information is at the level used by a system administrator or software developer.",IBM,CHANG DAVID Y,,https://lens.org/016-571-743-537-037,Granted Patent,yes,6,60,7,7,0,G06F11/0715;;G06F11/0715;;G06F11/3006;;G06F11/3006;;G06F11/302;;G06F11/302;;G06F11/3055;;G06F11/3055;;G06F11/3089;;G06F11/3089;;G06F11/328;;G06F11/328,G06F11/30;;G06F11/32;;G06F13/00,395/704;;395/200.03;;395/674;;364/131,8,1,000-665-727-005-774,10.1002/spe.4380040309,"AT&T Unix System 5 (User s Reference Manual), 1987, Prentice Hall Englewood Cliffs, US.;;IBM Technical Disclosure Bulletin, vol. 28, No. 9, Feb. 86, Multi Thread Host Server For PC Support , pp. 3848 3855.;;IBM Technical Disclosure Bulletin, vol. 31, No. 8, Jan. 89, Method for Managing Client/Server Relationships in the AIX Operating System , pp. 195 198.;;IBM Technical Disclosure Bulletin, vol. 36, No. 6B, Jun. 93, Remote Database Status , pp. 269 270.;;IBM Technical Disclosure Bulletin, vol. 34, No. 4A, Sep. 91, Real Time Database Performance Monitor Application Workstation , pp. 49 50.;;IBM Technical Disclosure Bulletin, vol. 34, No. 4A, Sep. 91, Internal Performance Measurement Counters , pp. 51 52.;;Telemat. Inform., 1991, UK, A Hierarchial Distributed Control Model for Coordinating Intelligent Systems , vol. 8, No. 4, pp. 385 402, (Abstract).;;Software Pract. and Exper., Jul Sep. 1974, GB, Use of a Software Monitor in the Validation of an Analytic Computer System Model , vol. 4, No. 3, pp. 255 263, (Abstract).",EXPIRED
207,US,A,US 4349890 A,035-751-703-473-320,1982-09-14,1982,US 10781179 A,1979-12-28,US 10781179 A,1979-12-28,Time of day clock control,"A time of day clock for a computer is run off a clock for the computer processor by selecting the processor clock cycle T such that a binary multiple N of the time of day unit cycle D contains an integral number K of processor cycles T or ND=KT in accordance with the equation: D=(R.+-.X/N)T, where R is the integer nearest the actual D/T ratio, while X represents the number of D cycles of longer or shorter duration than R processor cycles needed to establish the actual proportional relationship between the two cycles over the period ND.",IBM,CHANG DAVID C,,https://lens.org/035-751-703-473-320,Granted Patent,yes,2,12,8,8,0,G04G3/022;;G04G99/006;;G06F9/4825;;G06F9/4825;;G04G99/006;;G04G3/022,G04G3/02;;G04G99/00;;G06F1/14;;G06F9/48,364/900,1,0,,,"Regulation of Time of Day Clock, Duke, IBM TDB, vol. 17, No. 7, Dec. 1974, pp. 2043-2045.",EXPIRED
208,TW,A,TW 201803480 A,050-355-269-799-596,2018-02-01,2018,TW 105122979 A,2016-07-21,TW 105122979 A,2016-07-21,Shoe with flexible vamp wherein the flexible vamp is formed of a four-way stretch fabric capable of being stretched and deformed in response to the shape change of a foot,"Provided is a shoe with flexible vamp, which includes a sole, a shoe body, and at least one first flexible shoelace. In use of the shoe, because the flexible vamp is formed of a four-way stretch fabric, the flexible vamp can be stretched and deformed in response to the shape change of a foot, so as to allow the shoe to be firmly worn by the foot. As a result, it is able to solve the problem of unfit shoe shape encountered when the user wears the shoe in the prior implementation due to the insufficient flexibility of the mesh fabric. Moreover, the sole is provided with a treading surface, an assembling surface arranged on the other surface of the sole that is opposite to the treading surface, and at least one first channel arranged on the assembling surface to pass through the two opposite sides of the assembling surface. The shoe body is connected to the sole through the assembling surface, and includes an insole and a flexible vamp. The insole has a shape corresponding to that of the assembling surface. The flexible vamp is formed of a four-way stretch fabric and fixed to a peripheral edge of the insole. The shoe body is provided with a receiving space defined by the insole and the flexible vamp, and a shoe opening defined and looped by the flexible vamp and communicated with the receiving space to allow one foot of a user to be accommodated in the receiving space. The flexible vamp is provided with a deformable length to conform to the foot. The at least one first flexible shoelace is routed through the first channel to loop around the shoe body so as to allow the first flexible shoelace to limit the deformation extent of the deformable length for the flexible vamp.",CHANG GARY DAVID,CHANG GARY-DAVID,,https://lens.org/050-355-269-799-596,Patent of Addition,no,0,0,5,5,0,A43B23/027;;A43B23/027;;A43B13/04;;A43B13/22;;A43B23/0205;;A43B23/0205;;A43B23/0265;;A43B23/0265;;A43C1/02;;A43C1/02,A43C11/00,,0,0,,,,ACTIVE
209,US,A1,US 2020/0330721 A1,096-823-633-376-017,2020-10-22,2020,US 201916386341 A,2019-04-17,US 201916386341 A,2019-04-17,ADJUSTABLE DIFFUSER FOR MULTIPLE ESSENTIAL OILS,"A diffuser for multiple essential oils includes a housing that has at least one inlet and at least one outlet. At least two microblowers are carried by the housing to receive air though the at least one inlet. At least two bottles, each adapted to carry an essential oil, are associated with a corresponding one of the microblowers to generate a corresponding flow of oil-laden air. A controller selectively adjusts operation of each microblower to control the corresponding flows of oil-laden air to obtain a desired combination of oil-laden air exhausted through the at least one outlet.",GREENAIR INC,CHANG DAVID T,GREENAIR INC (2019-04-16),https://lens.org/096-823-633-376-017,Patent Application,yes,0,2,1,1,0,A61L9/013;;A61M21/02;;A61L9/122;;A61L9/14;;A61L2209/11;;A61L2209/13;;A61L2209/14;;A61M2021/0016;;A61M2205/3553;;A61M2205/75;;B05B7/2472,A61M21/02,,0,0,,,,DISCONTINUED
210,EP,A1,EP 0151637 A1,108-488-533-415-689,1985-08-21,1985,EP 84903231 A,1984-08-14,US 52332583 A,1983-08-15,INTRAWAVEGUIDE FIBER OPTIC BEAMSPLITTER/COUPLER.,"Diviseur de faisceaux/coupleur de fibres optiques dans un guide d'ondes, où une fente orientée (10) est formée dans une fibre optique intacte (12), cette fente interne (10) permettant de diviser et de diriger la lumière le long des cheminements désirés.",CHANG DAVID B,CHANG DAVID B,,https://lens.org/108-488-533-415-689,Patent Application,yes,0,0,9,10,0,G02B6/2817;;Y10S359/90;;G02B6/2817;;Y10S359/90,G02B6/287;;G02B6/28,,0,0,,,,DISCONTINUED
211,US,A,US 5160634 A,111-734-169-757-517,1992-11-03,1992,US 80089991 A,1991-11-22,US 80089991 A;;US 65976691 A,1991-02-25,Desalinization system,"A system and method are disclosed for desalinating sea water. The system includes an energy source such as a laser 13, and a container 19 (partly or wholly transparent) for holding the sea water, the sea water having sodium and chlorine ions and a solvent (H.sub.2 O) with a predetermined dielectric value. The system applies a predetermined amount of energy, in the form of a laser beam 35 through the transparent container 19, to the seawater substantially at a resonance frequency of the solvent, for reducing the dielectric value of the solvent and vibrating the ions, permitting them to combine and precipitate out of the seawater, thereby desalinating the seawater. To increase the effect of the beam 35, the system includes a pair of mirrors 15,17 for reflecting the beam back and forth through the sea water. The method employed by the system provides for holding the sea water in a container and applying energy to the sea water, at a resonance frequency of the solvent, sufficient to reduce the dielectric value of the solvent and vibrate the ions.",HUGHES AIRCRAFT CO,CHANG DAVID B,HUGHES AIRCRAFT COMPANY A CORP. OF DE (1991-02-22);;HE HOLDINGS INC (1997-12-16);;RAYTHEON COMPANY (1997-12-17),https://lens.org/111-734-169-757-517,Granted Patent,yes,7,1,1,2,0,B01D43/00;;B01D43/00;;B01J19/121;;B01J19/121;;C02F1/36;;C02F1/36;;C02F1/30;;C02F1/30;;Y10S210/918;;Y10S210/918,B01D43/00;;B01J19/12;;C02F1/30;;C02F1/36,210/748;;210/702;;210/542;;210/918;;422/186;;X250432R;;204/157.41;;204/157.48,0,0,,,,EXPIRED
212,AU,A,AU 1995/012930 A,123-524-954-750-812,1995-07-17,1995,AU 1995/012930 A,1994-11-21,US 17490593 A;;US 9413519 W,1993-12-29,Thickened alkaly metal hypochlorite compositions,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT BENCKISER INC,CHANG DAVID L,RECKITT BENCKISER INC. (2002-08-22),https://lens.org/123-524-954-750-812,Patent Application,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
213,US,A1,US 2005/0284431 A1,144-773-639-796-617,2005-12-29,2005,US 14628105 A,2005-06-07,US 14628105 A;;US 74300003 A,2003-12-23,Engine valve actuation system,"An engine valve actuation system includes an engine valve moveable between first and second positions, a valve actuation assembly connected to move the engine valve between the first and second positions, a fluid actuator configured to selectively modify a timing of the engine valve in moving from the second to the first position, a source of fluid, and a pair of passages in the cylinder that allow fluid to flow from the chamber to the fluid source. The fluid actuator includes a cylinder and a piston at least partly defining a chamber. The piston is slidably movable in the cylinder between a first position and a second position, and blocks at least a portion of one of the passages at an intermediate position between the second position and the first position to reduce fluid flow from the chamber when the piston moves from the second position toward the first position.",CATERPILLAR INC,CHANG DAVID Y,,https://lens.org/144-773-639-796-617,Patent Application,yes,7,0,3,5,0,F01L9/10;;F01L9/10,F01L9/10;;F01L1/34,123/90.13,0,0,,,,DISCONTINUED
214,US,A1,US 2021/0324783 A1,178-008-916-292-35X,2021-10-21,2021,US 202117365781 A,2021-07-01,US 202117365781 A;;US 202016749642 A,2020-01-22,IGNITOR FOR NATURAL GAS ENGINE,"In one aspect, an engine ignition apparatus for a natural gas engine may include a housing including a drive piston, a floating piston, a controllable hydraulic fluid chamber located between the drive piston and the floating piston, and an ignition chamber acted on by the floating piston, the ignition chamber having an outlet formed by a plurality of orifices, the outlet being in direct communication with a combustion chamber of the engine. In another aspect, an engine ignition apparatus for a natural gas engine may include, among other features, a controllable valve connected to a hydraulic fluid chamber, and configured to open and release a hydraulic fluid from the hydraulic fluid chamber, and to close. In still another aspect, a method for controlling an engine ignition apparatus for an engine includes, among other features, controlling a volume of a hydraulic fluid chamber of an ignition apparatus.",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2020-01-22),https://lens.org/178-008-916-292-35X,Patent Application,yes,0,0,4,4,0,F02M26/01;;F02D15/04;;F02D41/0085;;F02D19/02;;F02D41/0027;;F02B19/14;;F02B19/06;;F02B2043/103;;F02B1/12;;Y02T10/12;;Y02T10/30;;F02B1/12;;F02M26/01;;F02D37/02;;F02B3/06;;F02B2075/125;;F02B2275/14;;F02D13/0215;;F02D2041/001;;F02D2041/389,F02B1/12;;F02M26/01,,0,0,,,,ACTIVE
215,EP,A4,EP 1827555 A4,196-240-145-773-479,2010-03-10,2010,EP 05851855 A,2005-11-18,US 2005/0041931 W;;US 62942004 P;;US 66414205 P,2004-11-18,ENDOLUMINAL DELIVERY OF ANESTHESIA,,CHANG DAVID W,CHANG DAVID W,,https://lens.org/196-240-145-773-479,Search Report,no,7,0,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M29/00;;A61B17/00;;A61M19/00;;A61M25/04,,0,0,,,,DISCONTINUED
216,US,B2,US 10967092 B2,189-793-614-250-037,2021-04-06,2021,US 201916386334 A,2019-04-17,US 201916386334 A,2019-04-17,Diffuser for essential oils,"A diffuser includes a housing with at least one inlet and at least one vent outlet, and a microblower carried by the housing. The microblower has an inlet side to receive air from the at least one inlet, and an outlet port. A bottle adapted to carry essential oil is included and has a neck opening. A tube directs air from the microblower outlet port into the neck opening to generate oil-laden air. A fan draws ambient air in from the at least one inlet and exhausts ambient air and oil-laden air through the at least one vent outlet.",GREENAIR INC,CHANG DAVID T,GREENAIR INC (2019-04-15),https://lens.org/189-793-614-250-037,Granted Patent,yes,4,2,2,2,0,A61L9/122;;A61L2209/14;;A61L2209/133;;A61L9/22;;A61L2209/11;;A61L2209/13;;A61L9/122;;A61L9/14;;A61L2209/132;;A61L2209/12;;A61L9/013;;B01F23/213,A61L9/14;;A61L9/013;;A61L9/12;;B01F3/04,,1,0,,,"www.audiowell.com ; Aromatherapy has this way!; release time: Aug. 4, 2018.",ACTIVE
217,US,A1,US 2015/0150562 A1,192-809-376-258-317,2015-06-04,2015,US 201514622310 A,2015-02-13,US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and Apparatus for Treating a Carotid Artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/192-809-376-258-317,Patent Application,yes,0,28,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/22;;A61B17/12;;A61B17/34;;A61M1/00;;A61M1/36;;A61M25/09;;A61M25/10,,0,0,,,,ACTIVE
218,CA,C,CA 2179409 C,046-968-680-257-268,2000-04-18,2000,CA 2179409 A,1994-11-21,US 17490593 A;;US 9413519 W,1993-12-29,THICKENED ALKALI METAL HYPOCHLORITE COMPOSITIONS,"According to the invention, a thickened alkali metal hypochlorite composition exhibiting a high level of stability has been discovered. An alkali metal C10-C14 straight chain alkyl benzene sulfonate used in conjunction with a molar ratio of tertiary amine oxide to the sulfonate ranging from about 5:1 to about 11:1 has been discovered to increase the viscosity of alkali metal hypochlorite bleaches.",,CHANG DAVID L,,https://lens.org/046-968-680-257-268,Granted Patent,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
219,US,A1,US 2017/0368296 A1,056-460-711-151-569,2017-12-28,2017,US 201715613921 A,2017-06-05,US 201715613921 A;;US 201615082257 A;;US 201213674792 A;;US 201113017905 A;;US 28222205 A;;US 66414205 P;;US 62942004 P,2004-11-18,Endoluminal Delivery Of Anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/056-460-711-151-569,Patent Application,yes,0,84,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M19/00;;A61B6/00;;A61B18/14;;A61M5/00;;A61M25/00;;A61M25/04;;A61M25/10,,0,0,,,,ACTIVE
220,US,S,US D0401971 S,087-150-356-958-077,1998-12-01,1998,US 6057096 F,1996-10-01,US 6057096 F,1996-10-01,Brush stand,,CHANG DAVID S,CHANG DAVID S,,https://lens.org/087-150-356-958-077,Design Right,yes,6,15,1,1,0,,,D19/85;;1906,0,0,,,,EXPIRED
221,US,A,US 5165242 A,097-019-120-452-407,1992-11-24,1992,US 65966891 A,1991-02-25,US 65966891 A,1991-02-25,Refrigerator or air conditioner based on a magnetic fluid,"A refrigeration apparatus employing a working fluid of magnetic dipoles. The apparatus exploits a phase change in the working fluid from unaligned magnetic dipoles to aligned magnetic dipoles, so that no compression of the fluid is required. In a first embodiment, alignment is achieved by judicious application of RF fields tuned to the resonance frequency of the dipoles. In a second embodiment, alignment and randomization of orientation is achieved by operating always below the Curie temperature, and using geometry of the fluid conduit to permit or disallow the formation of a self aligning magnetic field. In both embodiments, the aligned portion of the fluid flow corresponds to the compressor-radiator-expansion valve poriton of the conventional cycle, and the unaligned portion corresponds to the vapor portion of the conventional cycle.",HUGHES AIRCRAFT CO,CHANG DAVID B,HUGHES AIRCRAFT COMPANY LOS ANGELES CA A CORP OF DE (1991-02-22),https://lens.org/097-019-120-452-407,Granted Patent,yes,1,21,1,1,0,F25B21/00;;F25B21/00;;F25B2321/0021;;F25B2321/0021;;Y02B30/00;;Y02B30/00,F25B21/00,62/31;;62/467;;165/96,0,0,,,,EXPIRED
222,US,B2,US 11918226 B2,121-345-247-483-00X,2024-03-05,2024,US 17308199,2021-05-05,,,Method and apparatus for treating an arterial lesion,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.","Silk Road Medical, Inc.",David W. Chang,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/121-345-247-483-00X,Granted Patent,yes,191,0,1,1,0,A61B17/12109;;A61B17/12036;;A61B17/12045;;A61B17/12136;;A61B17/22;;A61B17/320758;;A61B17/3415;;A61F2/82;;A61M1/34;;A61M1/36;;A61M1/3613;;A61M1/3655;;A61M1/67;;A61M25/09;;A61M25/1011;;A61M25/104;;A61M27/002;;A61B2017/12127;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M2025/0177;;A61M2025/1052;;A61M2205/3331;;A61M2205/3334;;A61M2205/7545,A61M16/00;;A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/09;;A61M25/10;;A61M27/00;;A61M25/01;;A61M39/00,,70,0,,,"Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther. 9:147-154.;;Bates M.D., et al.(2003). “Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model” Catherization and Cardiovascular Intervention 60:270-275.;;Bates, M.D., et al. (2004) “Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques” The West Virginal Medical Journal, vol. 99:60-63.;;Bergeron, P., et al. (1999, First Published May 1, 1999 Research Article). “Percutaneous Stenting of the Internal Carotid Artery: The European CAST I Study.” Journal of Endovascular Therapy. 6(2), 155-159. https://doi.org/10.1177/152660289900600207.;;Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79.;;Bettmann, M. et al., “Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association”. Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012.;;Chang, D.W., et al., “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002).;;Chang, M.D., “Carotid Angioplasty And Stenting Using Transcervical Occlusion And Protective Shunting Via A Mini Incision In The Neck: A New Technique For Difficult Femoral Access Or Filter Placement May Be The Better Carotid Artery Intervention” 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2.;;Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114.;;Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261.;;Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483.;;Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8.;;Criado, M.D., et al. (2004) “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient” Journal of Vascular Surgery, 40(1):92-7.;;Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633.;;Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202.;;Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.;;Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.;;MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device—INVATEC.;;Momapresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002.;;Ohki, M.D., et al., “Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis” (J Vasc Surg 2001; 33:504-9).;;Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80.;;Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136.;;Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41.;;Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3.;;Stecker et al., (2002). “Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy” J. Vasc. Interv. Radiol. 13:413-417.;;Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection.” AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology.;;U.S. Appl. No. 16/171,784, filed Oct. 26, 2018, US 2019-0125512.;;U.S. Appl. No. 16/281,311, filed Feb. 21, 2019, US 2019-0388654.;;U.S. Appl. No. 16/297,348, filed Mar. 8, 2019, US 2020-0038576.;;U.S. Appl. No. 16/299,524, filed Mar. 12, 2019, US 2019-0366070.;;U.S. Appl. No. 16/353,492, filed Mar. 14, 2019, US 2020-0009406.;;U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, US 2019-0231962.;;U.S. Appl. No. 16/513,030, filed Jul. 16, 2019, US 2020-0170637.;;U.S. Appl. No. 16/544,083, filed Aug. 19, 2019, US 2020-0171277.;;U.S. Appl. No. 16/880,594, filed May 21, 2020, US 2020-0282127.;;U.S. Appl. No. 17/092,635, filed Nov. 9, 2020, US 2021-0228847.;;U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769.;;U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, US 2016-0242764.;;U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, US 2017-0209260.;;U.S. Appl. No. 16/530,783, filed Aug. 2, 2019, US 2020-0054871.;;U.S. Appl. No. 16/894,474, filed Jun. 5, 2020, US 2020-0297912.;;U.S. Appl. No. 16/906,457, filed Jun. 19, 2020, US 2020-0397472.;;U.S. Appl. No. 16/939,396, filed Jul. 27, 2020, US 2020-0397446.;;U.S. Appl. No. 16/951,767, filed Nov. 18, 2020, US 2021-0145453.;;U.S. Appl. No. 16/999,634, filed Aug. 21, 2020, US 2020-0375728.;;U.S. Appl. No. 16/999,640, filed Aug. 21, 2020, US 2020-0375729.;;U.S. Appl. No. 17/000,004, filed Aug. 21, 2020, US 2020-0390438.;;U.S. Appl. No. 17/074,299, filed Oct. 19, 2020, US 2021-0205571.;;U.S. Appl. No. 17/108,711, filed Dec. 1, 2020, US 2021-0212679.;;U.S. Appl. No. 17/149,450, filed Jan. 14, 2021, US 2021-0298929.;;U.S. Appl. No. 17/179,746, filed Feb. 19, 2021, US 2021-0244522.;;U.S. Appl. No. 17/193,962, filed Mar. 5, 2021, US 2021-0290257.;;U.S. Appl. No. 17/206,665, filed Mar. 19, 2021, US 2021-0307945.;;U.S. Appl. No. 17/220,718, filed Apr. 1, 2021, US 2021-0290213.;;U.S. Appl. No. 17/237,911, filed Apr. 22, 2021, US 2021-0236790.;;U.S. Appl. No. 17/307,359, filed May 4, 2021, US 2021-0322738.;;U.S. Appl. No. 17/345,502, filed Jun. 11, 2021, US 2021-0299343.;;U.S. Appl. No. 17/345,544, filed Jun. 11, 2021, US 2021-0299425.;;U.S. Appl. No. 17/398,969, filed Aug. 10, 2021, US 2022-0047267.;;U.S. Appl. No. 17/406,822, filed Aug. 19, 2021, US 2022-0040502.;;U.S. Appl. No. 17/470,213, filed Sep. 9, 2021, US 2022-0202552.;;U.S. Appl. No. 17/555,127, filed Dec. 17, 2021, US 2022-0193321.;;U.S. Appl. No. 17/684,745, filed Mar. 2, 2022, US 2023-0045964.;;U.S. Appl. No. 17/749,423, filed May 20, 2022, US 2023-0001161.;;U.S. Appl. No. 17/749,454, filed May 20, 2022, US 2023-0097442.;;U.S. Appl. No. 17/773,200, filed Apr. 29, 2022, US 2022-0401111.;;U.S. Appl. No. 17/773,206, filed Apr. 29, 2022, US 2022-0378565.;;U.S. Appl. No. 17/899,279, filed Aug. 30, 2022, US 2023-0067426.;;U.S. Appl. No. 17/951,727, filed Sep. 23, 2022, US 2023-0101242.;;U.S. Appl. No. 18/071,323, filed Nov. 29, 2022, US 2023-0165696.",UNKNOWN
223,US,B2,US 7178491 B2,128-495-776-549-877,2007-02-20,2007,US 45461603 A,2003-06-05,US 45461603 A,2003-06-05,Control system and method for engine valve actuator,A system and method for controlling a variable valve actuation system for an engine is provided. An engine valve is moved between a first position where the engine valve blocks a flow of fluid and a second position where the engine valve allows a flow of fluid. Fluid is provided to a chamber of a valve actuator adapted to operatively engage the engine valve. A parameter indicative of a viscosity of the fluid provided to the chamber of the valve actuator is sensed. Fluid is trapped within the chamber of the valve actuator to prevent the engine valve from moving to the first position. A response time of the valve actuator is determined based on the viscosity of the fluid provided to the chamber of the valve actuator. The response time indicates the time required to release the fluid from the chamber of the valve actuator to allow the engine valve to move to the first position.,CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2003-05-22),https://lens.org/128-495-776-549-877,Granted Patent,yes,43,15,2,2,0,F01L1/00;;F01L1/026;;F01L1/267;;F01L13/0015;;F01L2800/00;;F02D13/0226;;F02D13/0269;;Y02T10/12;;F01L9/10;;F02D13/0226;;F01L1/00;;F01L1/267;;F01L2800/00;;F02D13/0269;;F01L13/0015;;F01L1/026;;Y02T10/12;;F01L9/10,F01L1/00;;F01L1/26;;F01L9/10;;F01L13/00;;F02D13/02,123/90.13;;123/90.15;;123/90.16;;123/90.12;;123/320,7,1,043-080-006-736-450,10.4271/980180,"Edwards et al., ""The Potential of a Combined Miller Cycle and Internal EGR Engine for Future Heavy Duty Truck Applications,"" The Engineering Society for Advancing Mobility Land Sea Air and Space International, International Congress and Exposition, Feb. 23-26, 1998, pp. 1-19.;;Obert, ""Internal Combustion Engines and Air Pollution,"" Based on Internal Combustion Engines, Third Edition, 1973, pp. 612-614.;;Challen et al., ""Diesel Engine Reference Book, Section Edition,"" SAE International, 1999, pp. 75, 81, 84, 146, and 263-305.;;Yorihiro Fukuzawa et al., ""Development of High Efficiency Miller Cycle Gas Engine"", Mitsubishi Heavy Industries, Ltd., Technical Review, vol. 38, No. 3, Oct. 2001, pp. 146-150.;;Request for Inter Partes Reexamination Transmittal Form for U.S. Appl. No. 6,688,280, and Attachment to Request for Inter Parties Reexamination Transmittal Form, Sep. 17, 2004.;;Request for Inter Partes Reexamination Transmittal Form for U.S. Appl. No. 6,651,618, and Attachment to Request for Inter Parties Reexamination Transmittal Form, Aug. 27, 2004.;;http://www.mazda.com.au/corpora/209.html, Oct. 16, 2001, p. 1-6.",INACTIVE
224,US,A,US 5675798 A,167-928-052-999-608,1997-10-07,1997,US 64992096 A,1996-05-16,US 64992096 A;;US 46970495 A;;US 9750693 A,1993-07-27,System and method for selectively and contemporaneously monitoring processes in a multiprocessing server,"A system, method and program product for determining and displaying the status of client application programs executing on a multiprocessing server. Server process control blocks and synchronization object descriptors are created in the shared memory of the server. Application program interfaces APIs are linked to the control blocks and descriptors during the execution of the various multiprocessing application programs. A status utility related to the service process monitor selectively accesses information from the control blocks and descriptors to determine the status of the individual multiple processes executing on the server workstation. In a preferred form, the status information is conveyed to and displayed on a video display associated with the service process monitor. In contrast to operating system monitors which disclose the status of all processes as a whole, the present server process monitor particularizes the information to the specific client process. Thereby, the information is of a granularity to identify processes which are hung up on semaphores, message queues, or the like. The information is at the level used by a system administrator or software developer.",IBM,CHANG DAVID YU,,https://lens.org/167-928-052-999-608,Granted Patent,yes,9,78,7,7,0,G06F11/0715;;G06F11/0715;;G06F11/3006;;G06F11/3006;;G06F11/302;;G06F11/302;;G06F11/3055;;G06F11/3055;;G06F11/3089;;G06F11/3089;;G06F11/328;;G06F11/328,G06F11/30;;G06F11/32;;G06F13/00,395/680;;395/200.03;;395/200.08;;395/326,8,1,000-665-727-005-774,10.1002/spe.4380040309,"AT&T UNIX System 5 (User s Reference Manual), 1987, Prentice Hall Englewood Cliffs, US.;;IBM Technical Disclosure Bulletin, vol. 28, No. 9, Feb. 86, Multi Thread Host Server For PC Support , pp. 3848 3855.;;IBM Technical Disclosure Bulletin, vol. 31, No. 8, Jan. 89, Method for Managing Client/Server Relationships in the AIX Operating System , pp. 195 198.;;IBM Technical Disclosure Bulletin, vol. 36, No. 6B, Jun. 93, Remote Database Status , pp. 269 270.;;Telemat. Inform., 1991, UK, A Hierarchical Distributed Control Model, for Coordinating Intelligent Systems , vol. 8, No. 4, pp. 385 402 (Abstract).;;Software Pract. & Exper., Jul. Sep. 1974, GB, Use of a Software Monitor in the Validation of an Analytic Computer System Model , vol. 4, No. 3, pp. 255 263. (Abstract).;;IBM TDB, Real Time Database Performance Monitor Application Workstation , vol. 34, No. 4A, Sep. 1991, pp. 49 50.;;IBM TDB, Internal Performance Measurement Counters , vol. 34, No. 4A, Sep. 1991, pp. 51 52.",EXPIRED
225,US,A,US 4208465 A,177-580-719-345-468,1980-06-17,1980,US 90241678 A,1978-05-03,US 90241678 A,1978-05-03,Clear coat/color coat finish containing an antioxidant and an ultraviolet light stabilizer,A substrate that has a finish of a clear coat toplayer in firm adherence to a color coat layer that is in adherence with the substrate; wherein the clear coat consists essentially of a transparent film forming binder; the color coat consists essentially of a film forming binder and pigments; both the clear coat and the color coat contain an antioxidant and an ultraviolet light stabilizer; This finish has an excellent appearance and has excellent weatherability and durability and is particularly useful as a finish for automobiles and trucks.,DU PONT,CHANG DAVID C,,https://lens.org/177-580-719-345-468,Granted Patent,yes,8,46,1,12,0,B05D7/532;;B05D7/532;;B05D2202/00;;B05D2202/00;;Y10T428/31522;;Y10T428/31522;;Y10T428/31529;;Y10T428/31529;;Y10T428/31681;;Y10T428/31681;;Y10T428/31699;;Y10T428/31699,B05D5/00;;B05D7/00;;B05D7/16,B2E EQ            EQ,0,0,,,,EXPIRED
226,ES,T3,ES 2160152 T3,192-352-105-990-269,2001-11-01,2001,ES 95904119 T,1994-11-21,US 17490593 A,1993-12-29,COMPOSICIONES ESPESADAS DE HIPOCLORITO DE METAL ALCALINO.,"Thickened aqueous hypochlorite compositions comprises (a) an alkali metal hypochlorite, (b) a tertiary amine oxide with one alkyl group having from 10 to 16 carbon atoms and the two other alkyl groups having from 1 to 3 carbon atoms, (c) an alkali metal salt, (d) a pH stabilizer to bring the pH to a level of 11 or higher, (e) a C10-C16 alkali metal sarcosinate, and (f) C10-C14 straight chain alkyl benzene sulfonate. The molar ratio of (b):(f) is from about 5:1 to about 11:1 and is adjusted so that the viscosity of the composition is between 231 and 402 cps. The compositions are useful for general cleaning purposes, particularly bathrooms and toilet bowls, and also as a laundry additive.",RECKITT BENCKISER INC,CHANG DAVID L,,https://lens.org/192-352-105-990-269,Granted Patent,no,0,0,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,0,0,,,,EXPIRED
227,US,A1,US 2011/0125131 A1,026-688-677-040-39X,2011-05-26,2011,US 201113017905 A,2011-01-31,US 201113017905 A;;US 28222205 A;;US 62942004 P;;US 66414205 P,2004-11-18,ENDOLUMINAL DELIVERY OF ANESTHESIA,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/026-688-677-040-39X,Patent Application,yes,55,20,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M19/00,604/508,0,0,,,,ACTIVE
228,US,A,US 4929841 A,029-789-088-766-602,1990-05-29,1990,US 24914388 A,1988-09-26,US 24914388 A,1988-09-26,Dynamic infrared target,"An inexpensive broadband dynamic IR target with a fast response time, good spatial resolution, and adequate dynamic range is disclosed. The IR target is made by coating a thin photo-conductive film on a transparent insulator. The emissivity of the film-substrate block is changed by irradiating the block with a visible image of the desired IR image. The image temperature varies from the block temperature T by an amount related to the photo-conductivity produced change in the emissivity.",HUGHES AIRCRAFT CO,CHANG DAVID B,HUGHES AIRCRAFT COMPANY A DE CORP (1988-09-20),https://lens.org/029-789-088-766-602,Granted Patent,yes,5,4,8,9,0,F41J2/02;;F41J2/02;;G02F2/02;;G02F2/02,F41J2/02;;G02F2/02,250504R;;250/493.1,0,0,,,,EXPIRED
229,EP,A2,EP 1827555 A2,043-519-290-540-380,2007-09-05,2007,EP 05851855 A,2005-11-18,US 2005/0041931 W;;US 62942004 P;;US 66414205 P,2004-11-18,ENDOLUMINAL DELIVERY OF ANESTHESIA,,CHANG DAVID W,CHANG DAVID W,,https://lens.org/043-519-290-540-380,Patent Application,yes,0,0,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M29/00;;A61B17/00;;A61M19/00;;A61M25/04,,0,0,,,,DISCONTINUED
230,WO,A3,WO 2006/055826 A3,066-194-481-266-099,2006-11-09,2006,US 2005/0041931 W,2005-11-18,US 62942004 P;;US 66414205 P,2004-11-18,ENDOLUMINAL DELIVERY OF ANESTHESIA,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",CHANG DAVID W,CHANG DAVID W,,https://lens.org/066-194-481-266-099,Search Report,yes,1,0,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M31/00,,0,0,,,,PENDING
231,CN,A,CN 1344377 A,080-826-863-255-782,2002-04-10,2002,CN 00805416 A,2000-03-23,US 12633599 P,1999-03-26,Fiber optical illuminator adaptor assembly for multiple light guide connectors,,COGENT LIGHT TECH INC,CHANG DAVID D,,https://lens.org/080-826-863-255-782,Patent Application,no,0,2,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,DISCONTINUED
232,US,B2,US 10385986 B2,085-434-019-458-014,2019-08-20,2019,US 201715450041 A,2017-03-06,US 201715450041 A;;US 201662304308 P,2016-03-06,Valve control device,"A valve control device includes a housing provided with a control shaft, a motor for driving the control shaft to rotate, a control circuit board connected to the motor, and a sensor for detecting a rotational position of the control shaft. The sensor is connected to the control circuit board, which controls the motor to drive the control shaft to rotate in response to a position signal returned by the sensor. The valve control device may further include a position pointer, an indicating light, or a buzzer to facilitate observation of the opening and closing position of the valve.",CHANG DAVID ANTHONY,CHANG DAVID ANTHONY,,https://lens.org/085-434-019-458-014,Granted Patent,yes,13,0,4,4,0,F16K5/0442;;F16K31/041;;F16K37/0083;;F16K31/042;;F16K31/043;;F16K37/0041;;F16K31/042;;F16K31/043;;F16K31/046;;F16K37/0041,F16K31/04;;F16K37/00,,0,0,,,,INACTIVE
233,US,A1,US 2020/0397446 A1,100-121-499-696-170,2020-12-24,2020,US 202016939396 A,2020-07-27,US 202016939396 A;;US 201916581034 A;;US 201916256229 A;;US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,METHOD AND APPARATUS FOR TREATING AN ARTERIAL LESION,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/100-121-499-696-170,Patent Application,yes,0,7,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/09;;A61M25/10;;A61M27/00,,0,0,,,,ACTIVE
234,DE,D1,DE 3065472 D1,182-737-379-548-27X,1983-12-08,1983,DE 3065472 T,1980-09-25,US 10781179 A,1979-12-28,DATA PROCESSING APPARATUS INCLUDING A TIME OF DAY CLOCK,,IBM,CHANG DAVID C,,https://lens.org/182-737-379-548-27X,Granted Patent,no,0,0,8,8,0,G04G3/022;;G04G99/006;;G06F9/4825;;G06F9/4825;;G04G99/006;;G04G3/022,G04G3/02;;G04G99/00;;G06F1/14;;G06F9/48,,0,0,,,,EXPIRED
235,US,A1,US 2016/0271315 A1,193-509-920-684-611,2016-09-22,2016,US 201615168786 A,2016-05-31,US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,Method and Apparatus for Treating a Carotid Artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/193-509-920-684-611,Patent Application,yes,0,95,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61M1/36;;A61B17/12;;A61B17/22;;A61M1/00;;A61M1/34;;A61M25/10,,0,0,,,,ACTIVE
236,WO,A1,WO 2008/027701 A1,194-166-230-279-808,2008-03-06,2008,US 2007/0075414 W,2007-08-07,US 83660006 P;;US 88146107 A,2006-08-08,AN INTEGRATED QUARTZ OSCILLATOR ON AN ACTIVE ELECTRONIC SUBSTRATE,"An oscillator having a quartz resonator, and a base wafer containing active electronics, wherein the quartz resonator is bonded directly to the base wafer and subsequently hermetically capped.",HRL LAB LLC;;KUBENA RANDALL L;;CHANG DAVID T,CHANG DAVID T,,https://lens.org/194-166-230-279-808,Patent Application,yes,3,0,3,5,0,B81B2201/0271;;B81B2201/0271;;B81B2207/012;;B81B2207/012;;B81C1/00253;;B81C1/00253;;H04R17/10;;H04R17/10;;H04R31/00;;H04R31/00;;Y10T29/42;;Y10T29/42,H04R31/00,,0,0,,,,PENDING
237,US,B1,US 6286025 B1,197-528-215-584-50X,2001-09-04,2001,US 35266294 A,1994-12-09,US 35266294 A,1994-12-09,Method and system of process identification by user defined process variables,"A method and system is provided for attaching user defined information to a process object in a data processing system. The method comprises creating a process control block corresponding to an invoked process. The control block has system defined process variables that are assigned values by the operating system. The method further comprises defining a user defined process variable in the process control block, and assigning a value to the user defined process variable.",IBM,CHANG DAVID YU,INTERNATIONAL BUSINESS MACHINES CORPORATION (1994-12-08),https://lens.org/197-528-215-584-50X,Granted Patent,yes,3,37,1,1,0,G06F9/4843;;G06F9/4843;;G06F11/006;;G06F11/006;;G06F11/302;;G06F11/302;;G06F11/3055;;G06F11/3055,G06F9/48;;G06F11/00;;G06F11/30,709/100,2,0,,,"(no author) ""Borland Turbo Debugger Ver. 2.5 User's Guide"", Borland International, Inc. pp. 106-117, 1991.;;Stevens, W., Richard, ""Advanced Programming in the UNIX Environment"", Addison-Wesley, pp. 85-90, 130, 172, 173, 188, 189, 190, 192, 210, 238-240, 1992.*",EXPIRED
238,US,A1,US 2005/0274337 A1,019-434-140-080-785,2005-12-15,2005,US 14120105 A,2005-06-01,US 14120105 A;;US 26379902 A,2002-10-04,Engine valve actuator,"An engine valve actuator for an internal combustion engine is provided. The engine valve actuator includes a housing having an opening and a first fluid passageway leading to the opening. An adjustment member is disposed in the housing and includes a protrusion that extends into the opening of the housing. A piston is disposed in the opening of the housing and has a bore adapted to receive the protrusion, a chamber, and a second fluid passageway that connects the bore with the chamber. The piston is adapted to move in a first direction relative to the housing in response to an introduction of pressurized fluid into the first fluid passageway. The piston moves in the first direction until the protrusion substantially withdraws from the bore. A push rod is operatively engaged with the piston such that movement of the piston in the first direction causes a corresponding movement of the push rod to thereby engage and open the engine valve.",CATERPILLAR INC,CHANG DAVID Y,,https://lens.org/019-434-140-080-785,Patent Application,yes,3,17,4,4,0,F01L1/26;;F01L13/065;;F01L9/10;;F01L1/26;;F01L13/065;;F01L9/10,F01L1/26;;F01L9/10;;F01L13/06,123/90.12;;123/90.14,0,0,,,,DISCONTINUED
239,CA,A,CA 896943 A,051-304-002-646-060,1972-04-04,1972,CA 896943D A,,CA 896943T A,,ELECTRO-OPTIC LIGHT BEAM CONTROL FOR DISPLAYING AND PRINTING,,IBM,CHANG DAVID C,,https://lens.org/051-304-002-646-060,Granted Patent,no,0,0,1,1,0,,B41B21/04;;B41B21/16;;B41B21/26;;B41B27/28;;G02F1/31;;G06K15/12,,0,0,,,,EXPIRED
240,US,A,US 3532033 A,052-505-933-694-199,1970-10-06,1970,US 3532033D A,1968-06-18,US 73790668 A,1968-06-18,ELECTRO-OPTIC LIGHT BEAM CONTROL FOR DISPLAYING AND PRINTING,,IBM,CHANG DAVID C,,https://lens.org/052-505-933-694-199,Granted Patent,no,0,5,4,4,0,B41B21/04;;B41B21/04;;B41B21/16;;B41B21/16;;B41B27/28;;B41B27/28;;G02F1/31;;G02F1/31;;G06K15/12;;G06K15/12,B41B21/04;;B41B21/16;;B41B27/28;;G02F1/31;;G06K15/12,95/4.5,0,0,,,,EXPIRED
241,EP,A2,EP 0031403 A2,061-561-606-735-048,1981-07-08,1981,EP 80105792 A,1980-09-25,US 10781179 A,1979-12-28,Data processing apparatus including a time of day clock.,"The time of day clock in data processing apparatus is run off the clock for the apparatus via control logic (16, 18) responsive to both clocks by selecting the processor clock cycle T such that a binary multiple N of the time of day unit cycle D contains an integral number K of processor cycles T or ND = KT in accordance with the equation:
  where R is the integer nearest the actual D/T ratio, N and represents the number of D cycles containing R processor cycles T while X represents the number of D cycles of longer or shorter duration than R processor cycles needed to establish the actuel proportional relationship between the two cycles over the period ND.",IBM,CHANG DAVID C,,https://lens.org/061-561-606-735-048,Patent Application,yes,0,0,8,8,0,G04G3/022;;G04G99/006;;G06F9/4825;;G06F9/4825;;G04G99/006;;G04G3/022,G04G3/02;;G04G99/00;;G06F1/14;;G06F9/48,,0,0,,,,EXPIRED
242,CA,A,CA 818031 A,079-450-306-326-316,1969-07-15,1969,CA 818031D A,,CA 818031T A,,BI-DIRECTIONAL CAPACITIVE LOAD DRIVER,,IBM,CHANG DAVID C,,https://lens.org/079-450-306-326-316,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
243,KR,Y1,KR 950005777 Y1,092-360-918-142-245,1995-07-21,1995,KR 920016047 U,1992-08-26,KR 920016047 U,1992-08-26,VENTILATED SHOES,,DAVID KI CHANG,DAVID KI CHANG,,https://lens.org/092-360-918-142-245,Unknown,no,0,0,2,2,0,A43B21/285;;A43B7/081;;A43B7/082;;A43B7/087,A43B7/06;;A43B21/24,,0,0,,,,EXPIRED
244,DE,A1,DE 102010053388 A1,104-672-138-887-672,2011-06-09,2011,DE 102010053388 A,2010-12-03,US 63005509 A,2009-12-03,Fluidinjektor mit Regulierung einer thermischen Last,,CATERPILLAR INC,CHANG DAVID Y,,https://lens.org/104-672-138-887-672,Patent Application,no,1,0,5,5,0,F02M53/043;;F02M63/0225;;F02M63/0225;;F02M53/043,F02M53/04,,0,0,,,,DISCONTINUED
245,US,B2,US 8201754 B2,114-698-580-030-979,2012-06-19,2012,US 63005509 A,2009-12-03,US 63005509 A,2009-12-03,Fluid injector with thermal load control,"A common rail single fluid injection system includes fuel injectors and control valve assemblies with an internal cooling fluid circuit to improve overall life and performance of the injector. This is accomplished by supplying cooling fluid to the injector and allowing the same to come in direct contact with one of the hottest locations within the fuel injector; the high-pressure leak split spot. By providing cooling fluid directly to this location and then allowing the cooling fluid to drain out of the injector, the present disclosure effectively and efficiently manages thermal loads within the injector.",CHANG DAVID Y;;CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2009-12-02),https://lens.org/114-698-580-030-979,Granted Patent,yes,18,2,5,5,0,F02M53/043;;F02M63/0225;;F02M63/0225;;F02M53/043,B05B1/24;;B05B15/00,239/132;;239/132.3,0,0,,,,ACTIVE
246,WO,A1,WO 1995/018209 A1,119-288-188-271-540,1995-07-06,1995,US 9413519 W,1994-11-21,US 17490593 A,1993-12-29,THICKENED ALKALY METAL HYPOCHLORITE COMPOSITIONS,"According to the invention, a thickened alkali metal hypochlorite composition exhibiting a high level of stability has been discovered. An alkali metal C10-C14 straight chain alkyl benzene sulfonate used in conjunction with a molar ratio of tertiary amine oxide to the sulfonate ranging from about 5:1 to about 11:1 has been discovered to increase the viscosity of alkali metal hypochlorite bleaches.",EASTMAN KODAK CO;;CHANG DAVID L,CHANG DAVID L,,https://lens.org/119-288-188-271-540,Patent Application,yes,5,9,21,21,0,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/3956;;C11D17/003;;C11D1/83;;C11D3/3956;;C11D1/22;;C11D17/003;;C11D1/10;;C11D1/12;;C11D1/75,C11D1/10;;C11D1/12;;C11D1/22;;C11D1/75;;C11D1/83;;C11D3/395;;C11D7/54;;C11D17/00,,1,0,,,"DATABASE WPI Section Ch Week 3194, Derwent World Patents Index; Class D25, AN 94-253131",PATENTED
247,US,A1,US 2005/0154344 A1,132-022-090-967-593,2005-07-14,2005,US 99630104 A,2004-11-22,US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,Method and apparatus for treating a carotid artery,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",CHANG DAVID W.,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15);;CHANG DAVID W (2005-11-02);;VNUS MEDICAL TECHNOLOGIES INC (2004-12-09),https://lens.org/132-022-090-967-593,Patent Application,yes,98,142,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,604/6.09;;604/8,0,0,,,,ACTIVE
248,US,A1,US 2021/0251634 A1,135-389-968-303-462,2021-08-19,2021,US 202117308199 A,2021-05-05,US 202117308199 A;;US 202016939396 A;;US 201916581034 A;;US 201916256229 A;;US 201615168786 A;;US 201514622310 A;;US 201414508354 A;;US 96697410 A;;US 99630104 A;;US 58706704 P;;US 56984304 P;;US 52406903 P,2003-11-21,METHOD AND APPARATUS FOR TREATING AN ARTERIAL LESION,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/135-389-968-303-462,Patent Application,yes,0,2,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61B17/3207;;A61B17/34;;A61F2/82;;A61M1/00;;A61M1/34;;A61M1/36;;A61M25/09;;A61M25/10;;A61M27/00,,0,0,,,,ACTIVE
249,GB,B,GB 2155200 B,153-432-737-071-725,1987-04-08,1987,GB 8507899 A,1984-08-14,US 52332583 A;;US 8401275 W,1983-08-15,INTRAWAVEGUIDE FIBER OPTIC BEAMSPLITTER/COUPLER,,CHANG DAVID B,CHANG DAVID B,,https://lens.org/153-432-737-071-725,Granted Patent,no,0,0,9,10,0,G02B6/2817;;Y10S359/90;;G02B6/2817;;Y10S359/90,G02B6/287;;G02B6/28,G2JGEC,0,0,,,,EXPIRED
250,US,A1,US 2010/0191169 A1,142-283-054-724-576,2010-07-29,2010,US 75302710 A,2010-04-01,US 75302710 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,METHOD AND APPARATUS FOR TREATING A CAROTID ARTERY,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",CHANG DAVID W,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15);;CHANG DAVID W (2005-11-02);;VNUS MEDICAL TECHNOLOGIES INC (2004-12-09),https://lens.org/142-283-054-724-576,Patent Application,yes,101,13,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61M1/00;;A61B17/22;;A61F2/82;;A61M1/36;;A61M25/10,604/9;;623/1.11,2,2,023-546-745-949-35X;;028-839-258-555-020,10.1161/01.cir.97.1.121;;9443447;;11241119;;10.1067/mva.2001.112278,"Bettman, M. et al, ""Carotid Stenting and Angioplasty..."", etc. Circulation, 1998; 97:121-123.;;Ohki, M.D., et al., ""Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis"" J Vasc Surg 2001; 33:504-9.",ACTIVE
251,GB,A,GB 2155200 A,002-418-013-399-999,1985-09-18,1985,GB 8507899 A,1984-08-14,US 52332583 A;;US 8401275 W,1983-08-15,INTRAWAVEGUIDE FIBER OPTIC BEAMSPLITTER/COUPLER,,CHANG DAVID B,CHANG DAVID B,,https://lens.org/002-418-013-399-999,Patent Application,no,7,2,9,10,0,G02B6/2817;;Y10S359/90;;G02B6/2817;;Y10S359/90,G02B6/287;;G02B6/28,G2J JGDB          JGDB;;G2J JGEC          JGEC;;G2J JGECS         JGECS,1,0,,,JP A 56-161504,EXPIRED
252,CA,A,CA 942888 A,037-233-497-608-935,1974-02-26,1974,CA 97065 A,1970-10-30,US 87417069 A,1969-11-05,FUNCTIONAL CHECKING OF AN OPTICAL CHANNEL,,IBM,CHANG DAVID C,,https://lens.org/037-233-497-608-935,Granted Patent,no,0,0,7,7,0,G02F1/29;;G02F1/29,G02B26/10;;G02F1/01;;G02F1/29;;G11B7/00;;G11B7/004;;G11C13/04,352-64,0,0,,,,EXPIRED
253,US,A1,US 2011/0082408 A1,034-820-228-716-898,2011-04-07,2011,US 96697410 A,2010-12-13,US 96697410 A;;US 99630104 A;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,METHOD AND APPARATUS FOR TREATING A CAROTID ARTERY,"One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery.",CHANG DAVID W,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/034-820-228-716-898,Patent Application,yes,99,22,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61M5/00;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,604/9,0,0,,,,ACTIVE
254,US,A1,US 2004/0244742 A1,040-584-332-159-468,2004-12-09,2004,US 45461603 A,2003-06-05,US 45461603 A,2003-06-05,CONTROL SYSTEM AND METHOD FOR ENGINE VALVE ACTUATOR,"
   A system and method for controlling a variable valve actuation system for an engine is provided. An engine valve is moved between a first position where the engine valve blocks a flow of fluid and a second position where the engine valve allows a flow of fluid. Fluid is provided to a chamber of a valve actuator adapted to operatively engage the engine valve. A parameter indicative of a viscosity of the fluid provided to the chamber of the valve actuator is sensed. Fluid is trapped within the chamber of the valve actuator to prevent the engine valve from moving to the first position. A response time of the valve actuator is determined based on the viscosity of the fluid provided to the chamber of the valve actuator. The response time indicates the time required to release the fluid from the chamber of the valve actuator to allow the engine valve to move to the first position. 
",CATERPILLAR INC,CHANG DAVID Y,CATERPILLAR INC (2003-05-22),https://lens.org/040-584-332-159-468,Patent Application,yes,99,15,2,2,0,F01L1/00;;F01L1/026;;F01L1/267;;F01L13/0015;;F01L2800/00;;F02D13/0226;;F02D13/0269;;Y02T10/12;;F01L9/10;;F02D13/0226;;F01L1/00;;F01L1/267;;F01L2800/00;;F02D13/0269;;F01L13/0015;;F01L1/026;;Y02T10/12;;F01L9/10,F01L1/00;;F01L1/26;;F01L9/10;;F01L13/00;;F02D13/02,123/90.13;;123/90.16;;123/90.15,0,0,,,,EXPIRED
255,US,B2,US 8308709 B2,054-927-898-059-271,2012-11-13,2012,US 201113017905 A,2011-01-31,US 201113017905 A;;US 28222205 A;;US 62942004 P;;US 66414205 P,2004-11-18,Endoluminal delivery of anesthesia,"Described herein are methods and devices for selectively applying fluids (particularly anesthetics) to a target tissue from within a blood vessel while minimizing the amount of fluid applied to non-target tissue. The injection catheters described herein may include an elongate body, a directional injector, and one or more holdfasts for securing the catheter before extending the injector. The methods of selectively applying anesthetic to a target structure generally include the steps of inserting an injection catheter into a body vessel, positioning the injection catheter within the body vessel near the target structure, anchoring the injection catheter before extending a directional injector from the injection catheter, and applying anesthetic from the injection catheter to the target structure.",CHANG DAVID W;;SILK ROAD MEDICAL INC,CHANG DAVID W,SILK ROAD MEDICAL INC (2008-04-15),https://lens.org/054-927-898-059-271,Granted Patent,yes,57,36,17,17,0,A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/0084;;A61M25/04;;A61M25/1011;;A61M2025/009;;A61M25/10;;A61B6/487;;A61B18/1492;;A61M5/007;;A61M19/00;;A61M2210/12,A61M31/00,604/509;;604/512,1,1,107-686-988-816-391,10.1583/1074-6218(1999)006<0321:cswcpf>2.0.co;2;;10893133,"Henry et al. (1999) ""Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System"" J. Endovasc. Surg. 6:321-331.",ACTIVE
256,DE,A1,DE 1930124 A1,062-293-620-107-871,1970-02-26,1970,DE 1930124 A,1969-06-13,US 73790668 A,1968-06-18,Elektrooptische Anordnung,,IBM,CHING CHANG DAVID,,https://lens.org/062-293-620-107-871,Patent Application,no,0,0,4,4,0,B41B21/04;;B41B21/04;;B41B21/16;;B41B21/16;;B41B27/28;;B41B27/28;;G02F1/31;;G02F1/31;;G06K15/12;;G06K15/12,B41B21/04;;B41B21/16;;B41B27/28;;G02F1/31;;G06K15/12,,0,0,,,,DISCONTINUED
257,US,A,US 4018569 A,086-100-669-483-779,1977-04-19,1977,US 65904576 A,1976-02-18,US 65904576 A;;US 54976975 A,1975-02-13,Metal of improved environmental resistance,"An alloy based on Fe, Co or Ni, and including Al, is provided with improved environmental resistance through the inclusion in the composition of the combination of 0.1-10 weight percent Hf and 0.5-20 wt. % of an element selected from Pt, Rh and Pd. The combination is particularly useful in providing an article coated with such alloy.",GEN ELECTRIC,CHANG DAVID R,,https://lens.org/086-100-669-483-779,Granted Patent,yes,2,27,1,12,0,C22C19/052;;C22C19/052;;C22C19/00;;C22C19/00;;C22C19/053;;C22C19/053;;C22C38/00;;C22C38/00;;Y10T428/12931;;Y10T428/12931,C22C19/00;;C22C19/05;;C22C38/00,C7A AA23X         S           2;;C7A AA23Y         S           2;;C7A AA230         S           2;;C7A AA249         S           1;;C7A AA249         S           3;;C7A AA25Y         S           1;;C7A AA25Y         S           2;;C7A AA25Y         S           3;;C7A AA250         S           1;;C7A AA250         S           2;;C7A AA250         S           3;;C7A AA253         S           1;;C7A AA253         S           2;;C7A AA253         S           3;;C7A AA255         S           1;;C7A AA255         S           2;;C7A AA255         S           3;;C7A AA257         S           1;;C7A AA257         S           2;;C7A AA257         S           3;;C7A AA259         S           1;;C7A AA259         S           2;;C7A AA259         S           3;;C7A AA260         S           1;;C7A AA260         S           2;;C7A AA260         S           3;;C7A AA279         S           3;;C7A AA28X         S           1;;C7A AA28Y         S           1;;C7A AA280         S           1;;C7A AA299         S           2;;C7A AA299         S           3;;C7A AA329         S           1;;C7A AA329         S           2;;C7A AA329         S           3;;C7A AA339         S           1;;C7A AA339         S           2;;C7A AA339         S           3;;C7A AA349         S           1;;C7A AA349         S           2;;C7A AA349         S           3;;C7A AA35X         S           3;;C7A AA35Y         S           3;;C7A AA350         S           3;;C7A AA369         S           1;;C7A AA369         S           2;;C7A AA389         S           1;;C7A AA389         S           2;;C7A AA389         S           3;;C7A AA409         S           1;;C7A AA409         S           2;;C7A AA409         S           3;;C7A AA439         S           1;;C7A AA439         S           2;;C7A AA439         S           3;;C7A AA459         S           1;;C7A AA459         S           2;;C7A AA459         S           3;;C7A AA48X         S           1;;C7A AA48X         S           2;;C7A AA48X         S           3;;C7A AA48Y         S           1;;C7A AA48Y         S           2;;C7A AA48Y         S           3;;C7A AA481         S           1;;C7A AA481         S           2;;C7A AA481         S           3;;C7A AA483         S           1;;C7A AA483         S           2;;C7A AA483         S           3;;C7A AA529         S           1;;C7A AA529         S           2;;C7A AA529         S           3;;C7A AA549         S           1;;C7A AA549         S           2;;C7A AA549         S           3;;C7A AA579         S           1;;C7A AA579         S           2;;C7A AA579         S           3;;C7A AA599         S           1;;C7A AA599         S           2;;C7A AA599         S           3;;C7A AA609         S           1;;C7A AA609         S           2;;C7A AA609         S           3;;C7A AA629         S           1;;C7A AA629         S           2;;C7A AA629         S           3;;C7A AA67X         S           1;;C7A AA67X         S           2,0,0,,,,EXPIRED
258,US,A,US 5165084 A,113-716-507-174-829,1992-11-17,1992,US 65976191 A,1991-02-25,US 65976191 A,1991-02-25,System and method for measuring changes in sea level,"A system for determining changes in sea level based on the measurement of distance between capacitive elements. The system includes an electrically conductive sphere 17, 117 mounted on an electrically non-conductive buoy 13, 113, positioned a predetermined distance above sea level with the sphere and the sea (earth) acting as capacitive elements separated by the predetermined distance. The system also includes an ion source 25 for imparting charge to the sphere 17, a clock 23, an electrometer 21 for detecting (measuring) the voltage on the sphere at selected clock times. In an alternative embodiment, the ion source and electrometer are replaced with a swept frequency voltage generator 121, an inductor 127, and an ammeter 125. The inductor 127 and the sphere 117 form an LC component. In response to voltages of various frequencies applied to the sphere 117 by the generator 121, the ammeter 125 at each clock time, detects (measures) the current at the resonant frequency of the LC component. The measured voltages (or currents) are then averaged over time to compensate for wave motion (bobbing) of the buoy and dimensional changes in the buoy due to thermal (solar) effects. From each averaged voltage (or current) capacitance and sea level are calculated, and the change in sea level noted.",HUGHES AIRCRAFT CO,CHANG DAVID B,HUGHES AIRCRAFT COMPANY A DE CORP (1991-02-22),https://lens.org/113-716-507-174-829,Granted Patent,yes,5,1,1,1,0,G01F23/263;;G01F23/263;;G01C13/008;;G01C13/008,G01C13/00;;G01F23/26,361/284;;X 73304C,0,0,,,,EXPIRED
259,EP,B1,EP 1696806 B1,162-869-655-720-005,2012-08-29,2012,EP 04811840 A,2004-11-22,US 2004/0039187 W;;US 52406903 P;;US 56984304 P;;US 58706704 P,2003-11-21,APPARATUS FOR TREATING A CAROTID ARTERY,,SILK ROAD MEDICAL INC,CHANG DAVID W,"SILK ROAD MEDICAL, INC. (2011-04-27)",https://lens.org/162-869-655-720-005,Granted Patent,yes,4,0,28,30,0,A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61B17/12136;;A61B17/320758;;A61M1/67;;A61B17/22;;A61B2017/22001;;A61B2017/22055;;A61B2017/22065;;A61B2017/22067;;A61B2017/22069;;A61B2017/320716;;A61M1/3633;;A61M25/1011;;A61M2025/1052;;A61M2205/7545;;A61M1/3613;;A61B17/12045;;A61M1/36;;A61M2205/3331;;A61M1/67;;A61B17/12136;;A61B17/320758;;A61B2017/12127;;A61B17/12109;;A61F2/82;;A61M25/104;;A61M27/002;;A61B17/12036;;A61B17/3415;;A61M25/09;;A61M2025/0177;;A61M1/34;;A61M1/3655;;A61M2205/3334,A61B17/12;;A61B17/22;;A61M1/00;;A61M1/36;;A61M25/10,,0,0,,,,ACTIVE
260,TW,B,TW 504595 B,153-616-777-047-339,2002-10-01,2002,TW 89105489 A,2000-03-24,US 12633599 P,1999-03-26,Fiber optic illuminator adaptor assembly for multiple light guide connectors,"An adaptor assembly for coupling light guide connectors of varying configurations to a structure housing a source of focused light includes an internal adaptor having an internal optic guide element, a coupling structure, a housing, and a connector locking mechanism. The coupling structure can be inserted into and releasably retained within the structure housing the focused light. A light guide connector is inserted into a light guide receiving channel formed in the housing and is releasably retained therein by the connector locking mechanism. An internal optic guide element extends through the coupling structure to transmit focused light from the source of focused light to the light guide connector inserted into the connector-receiving channel. The housing includes heat dissipating elements to facilitate dissipation of heat generated at the interface between the optic guide element and the light guide of the connector. The adaptor assembly also includes an external adapter having a body portion and an elongated insertion member. The elongated insertion member can be inserted into the connector-receiving channel of the internal adaptor, and the external adaptor can be releasably coupled to the internal adaptor by a releasable connecting mechanism. A short type of optical connector can be inserted into a connector-receiving cavity formed in the body portion of the external adaptor and releasably retained therein by a connector locking mechanism. Focused light from the light source is transmitted through the adapter assembly by the first mentioned internal optic guide element of the internal adaptor and a second internal optic guide element disposed within the elongated insertion portion of the external adaptor.",COGENT LIGHT TECH,CHANG DAVID D,,https://lens.org/153-616-777-047-339,Granted Patent,no,0,1,13,13,0,G02B6/3821;;G02B6/3825;;G02B6/3893;;G02B6/421;;G02B6/4292;;G02B6/4296;;G02B6/00;;G02B6/3893;;G02B6/421;;G02B6/3825;;G02B6/3821;;G02B6/4296;;G02B6/4292,G02B6/00;;G02B6/38;;G02B6/42,,0,0,,,,EXPIRED
261,TW,U,TW 592044 U,027-359-399-671-181,2004-06-11,2004,TW 91217423 U,2002-10-30,US 21111002 A,2002-08-02,"An improved backless, strapless bra",,BRAGEL INTERNAT INC,CHEN DAVID;;CHANG JASPER;;CHANG ALICE,,https://lens.org/027-359-399-671-181,Limited Patent,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
262,US,S,US D0664373 S,198-807-572-761-605,2012-07-31,2012,US 201129405372 F,2011-11-01,US 201129405372 F,2011-11-01,Bed frame,,PAMUDJI ALBERT;;CHANG DAVID;;CHANG JOHNSON;;WILLIAMS IMP COMPANY INC;;MAINLINE WORLD FURNITURE INC,PAMUDJI ALBERT;;CHANG DAVID;;CHANG JOHNSON,WILLIAMS IMPORT COMPANY INC (2012-02-10);;MAINLINE WORLD FURNITURE INC (2012-02-10),https://lens.org/198-807-572-761-605,Design Right,no,0,7,2,2,0,,,0602;;D 6393,0,0,,,,ACTIVE
263,US,A1,US 2007/0041596 A1,163-216-522-297-184,2007-02-22,2007,US 19916405 A,2005-08-09,US 19916405 A,2005-08-09,Condenser microphone,"A condenser microphone includes: a casing including a peripheral wall that has a top end and a bottom end defining a bottom opening, and a flange that is bent inwardly from the top end of the peripheral wall; a substrate having an inner surface that is attached to the bottom end, that covers the bottom opening, and that cooperates with the peripheral wall and the flange to define an accommodating space thereamong; a diaphragm-and-ring assembly disposed in the accommodating space; a spacer disposed in the accommodating space between the diaphragm-and-ring assembly and the inner surface of the substrate; and a backplate.",PAN DAVID;;CHANG WILLIAM;;CHANG JACK,PAN DAVID;;CHANG WILLIAM;;CHANG JACK,HIT INCORPORATED (2005-07-26),https://lens.org/163-216-522-297-184,Patent Application,yes,5,1,1,1,0,H04R19/04;;H04R19/04,H04R25/00,381/174,0,0,,,,DISCONTINUED
264,US,A,US 6089004 A,060-495-711-964-02X,2000-07-18,2000,US 14316998 A,1998-08-28,US 14316998 A,1998-08-28,Swiveled-eye hinged-foot safety stirrup,"A stirrup has a pair of arms, an eye on the arms for receiving a strap, and a foot on the arms for supporting the foot of a rider. The eye and the foot of the stirrup are rotatable relative to the arms. The arms define a plane and the upper surface of the foot of the stirrup is perpendicular to this plane in one terminal position of the foot of the stirrup. The foot of the stirrup can only rotate backwards from this position. The eye has an opening for a strap, and the eye is freely rotatable relative to the arms through an angle of 90 degrees to and from a position in which the opening is coplanar with the arms.",EASTWEST INTERNATIONAL TAIWAN,HSI-CHANG CHANG;;ROBART DAVID A,EASTWEST INTERNATIONAL (TAIWAN) ENTERPRISES (1998-08-22),https://lens.org/060-495-711-964-02X,Granted Patent,yes,4,3,1,1,0,B68C3/025;;B68C3/025;;B68C2003/0008;;B68C2003/0008;;B68C2003/0041;;B68C2003/0041,B68C3/00;;B68C3/02,54/49,0,0,,,,EXPIRED
265,US,S,US D0664375 S,116-420-944-185-477,2012-07-31,2012,US 201129405374 F,2011-11-01,US 201129405374 F,2011-11-01,Dresser,,PAMUDJI ALBERT;;CHANG DAVID;;CHANG JOHNSON;;WILLIAMS IMP COMPANY INC;;MAINLINE WORLD FURNITURE INC,PAMUDJI ALBERT;;CHANG DAVID;;CHANG JOHNSON,WILLIAMS IMPORT COMPANY INC (2012-02-10);;MAINLINE WORLD FURNITURE INC (2012-02-10),https://lens.org/116-420-944-185-477,Design Right,no,0,4,1,1,0,,,0604;;D 6441,0,0,,,,ACTIVE
266,TW,B,TW 575407 B,150-043-309-007-681,2004-02-11,2004,TW 91118608 A,2002-08-16,US 15925102 A,2002-05-31,Attachable breast form enhancement system and using method thereof,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNAT INC,CHEN DAVID;;CHANG JASPER;;CHANG ALICE,,https://lens.org/150-043-309-007-681,Granted Patent,no,0,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/00;;A41C3/12;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
267,US,B1,US 6360717 B1,142-434-132-696-060,2002-03-26,2002,US 63863400 A,2000-08-14,US 63863400 A,2000-08-14,Fuel injection system and a method for operating,"
    The present invention provides a fuel injection system and method of operating the fuel injection system. The fuel injection system includes at least one hydraulically actuated fuel injector fluidly connected with a source of high pressure actuation fluid. A viscosity sensor determines the viscosity of the hydraulically actuated fuel injector. A controller in communication with the fuel injector and the viscosity sensor is configured to determine the rate of change of the viscosity of the high pressure hydraulic actuation fluid. The supply of high pressure actuated fluid to the fuel injector is based, at least in part, on the rate of change of the determined viscosity of the high pressure actuation fluid. 
",CATERPILLAR INC,CHANG DAVID Y;;MACK DAVID C,CATERPILLAR INC (2000-08-10),https://lens.org/142-434-132-696-060,Granted Patent,yes,16,12,2,2,0,F02D41/3809;;F02M57/025;;F02D41/3809;;F02M57/025,F02D41/38;;F02M57/02,123/381;;123/494,0,0,,,,EXPIRED
268,DE,A1,DE 10136330 A1,160-877-858-159-761,2002-03-14,2002,DE 10136330 A,2001-07-26,US 63863400 A,2000-08-14,Fuel injection system operating method based on rate of change of viscosity of high pressure actuating flow medium,"The method involves determining the viscosity of a high pressure actuating flow medium, and determining the rate of change of the viscosity. The delivery of flow medium to the fuel injection device is then controlled, based at least partially on the rate of change of the desired viscosity of the medium. An Independent claim is included for a fuel injection system.",CATERPILLAR INC,CHANG DAVID Y;;MACK DAVID C,,https://lens.org/160-877-858-159-761,Patent Application,no,0,0,2,2,0,F02D41/3809;;F02M57/025;;F02D41/3809;;F02M57/025,F02D41/38;;F02M57/02,,0,0,,,,DISCONTINUED
269,US,B2,US 8574276 B2,009-367-147-693-525,2013-11-05,2013,US 1448208 A,2008-01-15,US 1448208 A;;US 88088707 P;;US 88081307 P;;US 88088307 P;;US 88081207 P;;US 2008/0000499 W,2007-01-17,Fiber optic brush for light delivery,"A phototherapy apparatus is disclosed including: a body member; a plurality of elongated light transmitting elements, each of the elements extending between a proximal end enclosed within the body member and a distal end located outside of and distal to the body member; where the tips of the proximal ends of the light transmitting elements are located in close proximity to each other; and an optical connector configured to detachably receive an end of a lightguide and to couple light delivered by the lightguide from a source into the light transmitting elements at the proximal ends. The light coupled into each of the light transmitting elements is transmitted along the element and emitted from the distal end.",GOURGOULIATOS ZAFIRIOS;;CHANG DAVID;;LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,LERNER MEDICAL DEVICES INC (2008-01-14),https://lens.org/009-367-147-693-525,Granted Patent,yes,35,2,4,18,0,A61N5/0616;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N2005/0661;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N5/0616;;A61N2005/0661,A61N5/06,607/88;;607/94;;607/89,4,1,020-232-052-306-844,15186234;;10.1111/j.1365-4632.2004.01993.x,"Taneja, A. et al., ""Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study"", International Journal of Dermatology, vol. 43, pp. 462-467, 2004.;;PCT International Search Report (PCT/US08/00495); Date of mailing Jun. 18, 2008; 1 page.;;PCT International Search Report (PCT/US08/00499); Date of mailing Jul. 7, 2008; 1 page.;;PCT International Search Report (PCT/US08/00545); Date of mailing Jul. 11, 2008; 1 page.",INACTIVE
270,FI,C,FI 91542 C,042-653-015-878-919,1994-07-11,1994,FI 873418 A,1987-08-06,US 80675585 A;;US 8602554 W,1985-12-09,Hybridoomia ihmisen monitehoisia granulosyyttipesäkkeitä stimuloivia tekijöitä vastaan,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/042-653-015-878-919,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
271,US,B1,US 6262933 B1,076-907-864-275-291,2001-07-17,2001,US 49418600 A,2000-01-28,US 49418600 A;;US 11782799 P,1999-01-29,High speed programmable address decoder,"A high-performance address decoder circuit provides higher speed read and write access for an embedded memory of a programmable logic integrated circuit. The address decoder is programmable to allow addressing of the memory in different data widths and depths. The circuitry can be used as column address decoder or row address decoder, or both. In a dual-port memory implementation of the memory, there can be two instances of each of the decoders, one for writing and one for reading.",ALTERA CORP,CHANG WANLI;;JEFFERSON DAVID,ALTERA CORPORATION (2000-04-28),https://lens.org/076-907-864-275-291,Granted Patent,yes,47,14,2,2,0,G11C8/10;;G11C8/10,G11C8/10,365/230.06;;365/230.03;;326/40;;326/105,32,12,075-347-089-846-516;;095-770-817-893-091;;084-919-347-343-506;;131-365-349-629-373;;080-800-033-458-075;;019-403-927-145-587;;025-274-696-871-168;;017-787-634-850-103;;043-274-752-375-920;;019-277-823-761-911;;019-258-191-895-546;;023-739-976-007-926,10.1109/cicc.1990.124842;;10.1109/4.126539;;10.1109/cmpcon.1993.289700;;10.1109/t-c.1969.222754;;10.1109/tc.1970.5008902;;10.1109/tc.1977.1674879;;10.1109/tc.1979.1675426;;10.1109/tc.1984.1676396;;10.1109/fpga.1993.279481;;10.1109/fpga.1993.279480;;10.1109/jssc.1989.572595;;10.1109/54.500200,"Masumoto, Rodney T., ""Configurable On-Chip RAM Incorporated into High Speed Logic Array,"" IEEE Custom Integrated Circuits Conference, Jun. 1985, CH2157-6/85/0000-0240, pp. 240-243.;;Landry, Steve, ""Application-Specific ICs, Relying on RAM, Implement Almost Any Logic Function,"" Electronic Design, Oct. 31, 1985, pp. 123-130.;;Bursky, Dave, ""Shrink Systems with One-Chip Decoder, EPROM, and RAM,"" Electronic Design, Jul. 28, 1988, pp. 91-94.;;Kawana, Keiichi et al., ""An Efficient Logic Block Interconnect Architecture for User-Reprogrammable Gate Array,"" IEEE 1990 Custom Integrated Circuits Conf., May 1990, CH2860-5/90/0000-0164, pp. 31.3.1 to 31.3.4.;;Shubat, Alexander et al., ""A Family of User-Programmable Peripherals with a Functional Unit Architecture,"" IEEE Jor. of Solid-State Circuits, vol. 27, No. 4, Apr. 1992, 0018-9200/92$03.00, pp. 515-529.;;""AT&T's Orthogonal ORCA Targets the FPGA Future,"" 8029 Electronic Engineering, 64, No. 786, Jun. 1992, pp. 9-10.;;Bursky, Dave, ""FPGA Advances Cut Delays, Add Flexibility,"" 2328 Electronic Design, 40, No. 20, Oct. 1, 1992, pp. 35-43.;;Smith, Daniel, ""Intel's FLEXlogic FPGA Architecture,"" IEEE 1063-6390/93, 1993 pp. 378-384.;;Bursky, Dave, ""Denser, Faster FPGAs Vie for Gate-Array Applications,"" 2328 Electronic Design, 41, No. 11, May 27, 1993, pp. 55-75.;;Ngai, Kai-Kit Tony, ""An SRAM-Programmable Field-Reconfigurable Memory,"" Presentation at University of Toronto, Canada, Jun. 1993, pp. 1-14.;;Kautz, ""Cellular Logic in Memory Arrays,"" IEEE Trans. on Computers, vol. C-18, No. 8, Aug. 1969, pp. 719-727.;;Stone, ""A Logic in Memory Computer,"" IEEE Trans. on Computers, Jan. 1970, pp. 73-78.;;Manning, ""An Approach to Highly Integrated Computer Maintained Cellular Arrays,"" IEEE Trans. on Computers, vol. C-26, No. 6, Jun. 1977,pp. 536-552.;;Patil et al., ""A Programmable Logic Approach for VLSI,"" IEEE Trans. on Computers, vol. C-28, No. 9, Sep. 1979, pp. 594-601.;;Seitz, ""Concurrent VLSI Architectures,"" IEEE Trans. on Computers, vol. C-33, No. 12, Dec. 1984, pp. 1247-1265.;;Hsieh et al., ""Third Generation Architecture Boosts Speed and Density of Field Programmable Gate Arrays,"" Proc. of IEEE CICC Conf., May 1990, pp. 31.2.1 to 31.2.7.;;Bursky, ""Combination RAM/PLD Opens New Applications Options,"" Electronic Design, May 23, 1991, pp. 138-140.;;Ling et al., ""WASMII: A Data Driven Computer on a Virtual Hardware,"" Proc. of IEEE Field Prog. Custom Computing Machines Conf., Napa, California, Apr. 1993, pp. 33-42.;;Casselman, ""Virtual Computing and The Virtual Computer,"" IEEE, Jul. 1993, p. 43.;;Quenot et al., ""A Reconfigurable Compute Engine for Real-Time Vision Automata Prototyping,"" Proc. of IEEE FCCM Conf., Napa, California, Feb. 1994, pp. 91-100.;;Plus Logic ""FPSL5110 Intelligent Data Buffer"" Product Brief, Plus Logic, Inc., San Jose, California, Oct. 1990, pp. 1-6.;;Larsson, T, ""Programmable Logic Circuits: The Luxury Alternatives are Coming Soon,"" Elteknik-med-Aktuell Electronik, No. 4, Feb. 15-Mar. 9, 1988, pp. 37-38, (with English abstract).;;Intel Preliminary Datasheet, ""iFX780: 10ns FLEXlogic FPGA with SRAM Option,"" Nov. 1993, pp. 2-24 to 2-46.;;Quinnell, Richard A., ""FPGA Family Offers Speed, Density, On-Chip RAM, and Wide-Decode Logic,"" EDN Dec. 6, 1990, pp. 62-63.;;Satoh, Hisayasu et al., ""A 209K-Transistor ECL Gate Array with RAM,"" IEEE Jor. of Solid-State Circuits, vol. 24, No. 5, Oct. 1989, pp. 1275-1279.;;Ngai, Kai-Kit Tony, ""An SRAM-Programmable Field-Reconfigurable Memory,"" Manuscript Thesis, The University of Toronto Library, Aug. 18, 1994, pp. 1-68.;;Reddy, S. et al., ""A High Density Embedded Array Programmable Logic Architecture,"" Proc. of the IEEE 1996 Custom Integrated Circuits Conf. (CICC), San Diego, California, May 5-8, 1996 pp. 251-254.;;Brown, S. et al., ""FPGA and CPLD Architectures: A Tutorial,"" IEEE Design & Test of Computers, vol. 13, No. 2, Jun. 1, 1996, pp. 42-57.;;Altera 1996 Data Book, ""FLEX 10K Embedded Programmable Logic Family,"" Jun. 1996, pp. 29-90.;;Nelson, Rick, ""Embedded Memory Enhances Programmable Logic for Complex, Compact Designs,"" EDN Electrical Design News, vol. 41, No. 23, Nov. 7, 1996, pp. 91-106.;;Altera 1999 Device Data Book, ""APEX 20K Programmable Logic Device Family,"" May 1999, pp. 23-88.;;Xilinx Corporation Data Sheet, ""Virtex(TM)2.5V Field Programmable Gate Arrays,"" Jan. 28, 2000, pp. 1-72.",EXPIRED
272,DE,T2,DE 69619372 T2,102-009-613-012-91X,2002-07-11,2002,DE 69619372 T,1996-06-05,US 46536795 A;;US 9609041 W,1995-06-05,FEHLERERKENNUNGS- UND FEHLERKORREKTURVERFAHREN,,FUJITSU LTD,SAXENA NIRMAL;;CHANG DAVID,,https://lens.org/102-009-613-012-91X,Granted Patent,no,0,2,8,8,0,G06F11/1008;;H03M13/15;;G06F11/1008;;H03M13/15,G06F11/10;;G06F12/16;;H03M13/01;;H03M13/15,,0,0,,,,EXPIRED
273,WO,A3,WO 2008/088795 A3,098-703-142-536-182,2008-09-25,2008,US 2008/0000499 W,2008-01-15,US 88088307 P;;US 88081207 P;;US 88081307 P;;US 88088707 P;;US 2008/0000499 W,2007-01-17,FIBER OPTIC BRUSH FOR LIGHT DELIVERY,"A phototherapy apparatus is disclosed including: a body member; a plurality of elongated light transmitting elements, each of the elements extending between a proximal end enclosed within the body member and a distal end located outside of and distal to the body member; where the tips of the proximal ends of the light transmitting elements are located in close proximity to each other; and an optical connector configured to detachably receive an end of a lightguide and to couple light delivered by the lightguide from a source into the light transmitting elements at the proximal ends. The light coupled into each of the light transmitting elements is transmitted along the element and emitted from the distal end.",LERNER MEDICAL DEVICES INC;;GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/098-703-142-536-182,Search Report,yes,7,0,4,18,0,A61N5/0616;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N2005/0661;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N5/0616;;A61N2005/0661,A61N5/06,,0,0,,,,PENDING
274,US,B2,US 9264046 B2,119-572-492-999-286,2016-02-16,2016,US 201514626445 A,2015-02-19,US 201514626445 A;;US 201313849115 A;;US 201361757947 P,2013-01-29,Resonant inductor coupling clock distribution,The present disclosure provides for a clock distribution network for distributing clocking signals within a synchronous sequential logic circuit. The clock distribution network distributes the one or more clock signals by inductively and/or capacitively coupling a clocking signal from a primary distribution node to various secondary distribution nodes within the synchronous sequential logic circuit. The various secondary distribution nodes resonate at respective resonant frequencies to generate other clocking signals for use within the synchronous sequential logic circuit in response to receiving the clocking signal.,BROADCOM CORP,CHANG DAVID;;HUKKOO AJAT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2013-03-21),https://lens.org/119-572-492-999-286,Granted Patent,yes,8,0,8,16,0,G06F1/10;;G06F1/10;;H03K19/096;;H03K19/096;;H01F38/14;;H02J50/05;;H02J50/10,H03K19/096;;G06F1/00;;G06F1/10;;G06F1/26;;G06F1/32;;G06F5/16;;H01F38/14;;H02J5/00,,0,0,,,,INACTIVE
275,EP,A1,EP 0029593 A1,125-190-369-048-905,1981-06-03,1981,EP 80107267 A,1980-11-21,US 9628979 A;;US 14626280 A,1979-11-21,"A coating composition based on acrylic polymer blends, articles coated therewith, and process for preparing said coated articles.","A liquid coating composition is disclosed consisting essentially of an acrylic polymer blend, an inert organic solvent, an ultraviolet light stabilizer, and an antioxidant. The weatherability and durability of finishes prepared therefrom are significantly increased.",DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/125-190-369-048-905,Patent Application,yes,4,2,5,6,0,C09D133/12;;C08L33/10,C08L33/10;;C09D133/12,,1,0,,,"CHEMICAL ABSTRACTS, Vol. 83, 1975 page 55, Abstract No. 180327g Columbus, Ohio (US) & JP-A-50 58141 (SANKYO CO. LTD.) (May 20, 1975) * The whole Abstract *",DISCONTINUED
276,US,A1,US 2010/0117383 A1,128-501-733-284-862,2010-05-13,2010,US 37729207 A,2007-08-16,AU 2006/904478 A;;AU 2006/906441 A;;AU 2007/001164 W,2006-08-17,DOOR STRIKE,"A door strike including: a latch retainer for retaining a door latch; a lock actuator which operates when power is applied; a mode selector rotatable between at least two positions; in a first position of the mode selector the strike adopts a power to open mode, in the second position of the mode selector the strike adopts a power to lock mode.",SHANGHAI ONE TOP CORP,MACKLE TREVOR;;CHANG DAVID,SHANGHAI ONE TOP CORPORATION (2009-12-09),https://lens.org/128-501-733-284-862,Patent Application,yes,2,4,9,9,0,E05B47/0047;;E05B47/0047;;E05B63/0065;;E05B63/0065;;E05B2047/0073;;E05B2047/0073;;E05B2047/0076;;E05B2047/0076;;Y10T292/699;;Y10T292/699,E05B15/02;;E05B47/00,292/341.16,0,0,,,,DISCONTINUED
277,KR,A,KR 20140006990 A,141-807-360-417-45X,2014-01-16,2014,KR 20137031492 A,2011-05-27,CN 2011000905 W,2011-05-27,LIQUID SOAPS WITH TRICLOCARBAN,,COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/141-807-360-417-45X,Patent Application,no,0,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/02;;C11D9/30;;C11D9/50,,0,0,,,,DISCONTINUED
278,EP,A1,EP 2714882 A1,158-925-431-703-811,2014-04-09,2014,EP 11866929 A,2011-05-27,CN 2011000905 W,2011-05-27,LIQUID SOAPS WITH TRICLOCARBAN,,COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/158-925-431-703-811,Patent Application,yes,0,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/00;;C11D9/02;;C11D9/30;;C11D9/50,,0,0,,,,DISCONTINUED
279,EP,A1,EP 2054570 A1,181-334-940-022-095,2009-05-06,2009,EP 07784803 A,2007-08-16,AU 2007/001164 W;;AU 2006/904478 A;;AU 2006/906441 A,2006-08-17,A DOOR STRIKE,,FIRE & SECURITY HARDWARE PTY L,MACKLE TREVOR;;CHANG DAVID,"DIERCKX, AMELIE (2014-10-22);;SHANGHAI ONE TOP CORPORATION (2014-10-22);;LEQUY, MICHEL (2014-10-22)",https://lens.org/181-334-940-022-095,Patent Application,yes,0,0,9,9,0,E05B47/0047;;E05B47/0047;;E05B63/0065;;E05B63/0065;;E05B2047/0073;;E05B2047/0073;;E05B2047/0076;;E05B2047/0076;;Y10T292/699;;Y10T292/699,E05B47/00;;E05B15/02,,0,0,,,,ACTIVE
280,DK,B1,DK 173517 B1,196-434-799-030-012,2001-01-22,2001,DK 412887 A,1987-08-07,US 80675585 A;;US 8602554 W,1985-12-09,"Murint afledt hybridomacellelinie for human, pluripotent granulocytkolonistimulerende faktor (hpG-CSF), monoklonalt antisto","Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/196-434-799-030-012,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
281,DE,D1,DE 69619372 D1,010-097-721-576-058,2002-03-28,2002,DE 69619372 T,1996-06-05,US 46536795 A;;US 9609041 W,1995-06-05,FEHLERERKENNUNGS- UND FEHLERKORREKTURVERFAHREN,,FUJITSU LTD,SAXENA NIRMAL;;CHANG DAVID,,https://lens.org/010-097-721-576-058,Granted Patent,no,0,0,8,8,0,G06F11/1008;;H03M13/15;;G06F11/1008;;H03M13/15,G06F11/10;;G06F12/16;;H03M13/01;;H03M13/15,,0,0,,,,EXPIRED
282,WO,A1,WO 2008/088813 A1,038-192-817-301-309,2008-07-24,2008,US 2008/0000544 W,2008-01-15,US 88088307 P;;US 88081207 P;;US 88081307 P;;US 88088707 P;;US 2008/0000544 W,2007-01-17,FIBER OPTIC PHOTOTHERAPY DEVICE,"A phototherapy apparatus for the treatment of skin disease is disclosed including: an at least partially hollow body element; a plurality of light emitting elements enclosed within the body element; and a plurality of elongated light transmitting elements, each of the light transmitting elements having a proximal end detachably affixed to the body element in proximity to one or more of the light emitting elements, and extending to an end distal the body element. For each of the elongated light transmitting elements, at least a portion of light incident from the light emitting elements onto the proximal end is directed through the light transmitting element and emitted from the distal end.",LERNER MEDICAL DEVICES INC;;GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/038-192-817-301-309,Patent Application,yes,3,1,6,18,0,A61N5/0617;;A61N5/0617;;A61N5/0616;;A61N5/0616;;A61N5/067;;A61N5/067;;A61N2005/063;;A61N2005/063;;A61N2005/0644;;A61N2005/0644;;A61N2005/0652;;A61N2005/0652;;A61N2005/0661;;A61N2005/0661,A61B18/18,,1,1,020-232-052-306-844,15186234;;10.1111/j.1365-4632.2004.01993.x,"TANEJA A. ET AL.: ""Broad-Band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study"", INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 43, 2004, pages 462 - 467, XP008110032",PENDING
283,US,A,US 3429494 A,052-880-990-301-819,1969-02-25,1969,US 3429494D A,1967-05-22,US 64032067 A,1967-05-22,ELECTRICAL MOTOR-TACHOMETER MOUNTING,,AMPEX,CHANG DAVID TEH-LIANG,,https://lens.org/052-880-990-301-819,Granted Patent,no,1,4,1,1,0,H02K7/20;;H02K7/20,H02K7/20,226/188,0,0,,,,EXPIRED
284,CA,A1,CA 3065979 A1,049-211-377-121-856,2021-06-23,2021,CA 3065979 A,2019-12-23,CA 3065979 A,2019-12-23,URINARY METABOLOMIC BIOMARKERS FOR DETECTING COLORECTAL CANCER AND POLYPS,"ABSTRACT The invention relates to methods and compositions for detecting colorectal cancer and colorectal polyps by measurement of metabolites in bodily fluids such as urine, including diacetylspermine and kynurenine. CA 3065979 2019-12-23",METABOLOMIC TECH INC,DENG LU;;CHANG DAVID,,https://lens.org/049-211-377-121-856,Patent Application,no,0,0,2,2,0,G01N33/57419;;G01N33/57488,G01N33/48;;G01N33/483;;G01N33/53,,0,0,,,,ACTIVE
285,CA,C,CA 1309791 C,073-414-067-021-26X,1992-11-03,1992,CA 553472 A,1987-12-03,CA 553472 A;;US 90619586 A,1986-09-11,PROCESS FOR IMPROVING THE APPEARANCE OF A MULTILAYER FINISH,"An improved process for applying a multilayer finish on a primer coated substrate by using a guide coating composition that is applied over the primer of the substrate and then a water borne base coating composition containing metallic pigments and a clear coating composition are applied: before the base coating composition is applied, the guide coating composition is dried at ambient temperatures or at elevated temperatures but not fully cured or crosslinked; the guide coating contains a polymeric latex in an aqueous carrier, preferably an acrylic latex, and optionally, a crosslinking agent and metallic flake pigments; the process improves the appearance, particularly head-on-brightness of water borne basecoat/clear coat finishes in which the base coat contains metallic flake pigments.",DU PONT,CHANG DAVID C K,,https://lens.org/073-414-067-021-26X,Granted Patent,no,0,0,1,3,0,,B05D1/36;;B05D7/00;;B32B27/00,D34005475    M;;1170152    S,0,0,,,,EXPIRED
286,WO,A3,WO 2009/056260 A3,079-584-713-392-285,2010-02-18,2010,EP 2008009027 W,2008-10-24,US 133007 P,2007-11-01,REMOTE DATA COLLECTING SYSTEMS AND METHODS,"The present invention provides a remote data collecting system comprising a measuring device comprising at least two scales in communication with a terminal center. The terminal center is in communication with a control center. The control center can be linked to a computer with software to collect, distribute, analyze, and display data collected from the measuring device. The remote data collecting system is particularly useful for uncontrolled environment (e.g., in-home) product testing such as testing the palatability of pet foods.",NESTEC SA;;CHANG DAVID;;CHANGPU MA,CHANG DAVID;;CHANGPU MA,,https://lens.org/079-584-713-392-285,Search Report,yes,5,0,8,8,0,A01K5/00;;A01K5/00;;A01K5/0114;;A01K5/0114;;A01K29/00;;A01K29/00;;A23K50/40;;A23K50/40;;G01G19/4146;;G01G19/4146;;G01G23/3735;;G01G23/3735;;G01G23/3742;;G01G23/3742;;G16H20/60;;G16H20/60;;G16H40/67;;G16H40/67,G01G19/414;;A01K5/02;;G06F19/00,,1,0,,,"""WAEGE-ELEKTRONIK GEHT INS NETZ"", WDM : WAGEN DOSIEREN + MISCHEN, VERLAG COATING THOMAS & CO., ST. GALLEN, CH, vol. 32, no. 1, 1 February 2001 (2001-02-01), pages 25, XP000992086, ISSN: 1435-2176",PENDING
287,EP,A1,EP 2120762 A1,094-716-175-820-910,2009-11-25,2009,EP 08705601 A,2008-01-15,US 2008/0000544 W;;US 88088307 P;;US 88081207 P;;US 88081307 P;;US 88088707 P,2007-01-17,FIBER OPTIC PHOTOTHERAPY DEVICE,,LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/094-716-175-820-910,Patent Application,yes,0,0,6,18,0,A61N5/0617;;A61N5/0617;;A61N5/0616;;A61N5/0616;;A61N5/067;;A61N5/067;;A61N2005/063;;A61N2005/063;;A61N2005/0644;;A61N2005/0644;;A61N2005/0652;;A61N2005/0652;;A61N2005/0661;;A61N2005/0661,A61B18/18,,1,0,,,See references of WO 2008088813A1,DISCONTINUED
288,WO,A1,WO 2000/045825 A1,084-860-818-546-200,2000-08-10,2000,US 0002628 W,2000-02-02,US 11824499 P;;US 49567500 A,1999-02-02,DELIVERY SYSTEM AND METHODS FOR GENE THERAPY,"According to the present invention, there is provided a gene therapy material which includes a nucleic acid material and a carbohydrate wherein the carbohydrate preferably is a modified pectin. Also in accordance with the present invention, there is provided a gene therapy material including a nucleic acid material, a carbohydrate material associated with the nucleic acid material, and a protective coating disposed about the carbohydrate material. Also in accordance with the present invention, there is provided a method for treating a tumor of the type which has carbohydrate binding sites expressed on the surface thereof by providing a therapeutic material, incorporating the therapeutic material into a body of a modified pectin material so as to produce a therapeutic composition, and administering the therapeutic composition to a patient.",SAFESCIENCE INC,PLATT DAVID;;CHANG YAN,,https://lens.org/084-860-818-546-200,Patent Application,yes,2,2,5,8,0,A61K38/45;;A61K48/00;;A61K48/00;;A61K38/45,A61K38/45;;A61K48/00,,5,5,007-803-052-092-597;;071-564-907-744-809;;141-407-109-723-614;;049-767-401-211-231;;089-342-269-812-378,10.1093/jnci/87.5.348;;7853416;;9741926;;10.1016/s0168-3659(97)00252-6;;9699667;;9195221;;10.1089/hum.1997.8.8-985;;9017421;;10.1089/hum.1997.8.2-177,"PIENTA ET AL.: ""Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin"", J. NATL. CANCER INST.,, vol. 87, no. 5, 1 March 1995 (1995-03-01), pages 348 - 353, XP002927382;;LEONG ET AL.: ""DNA-polycation nanospheres as non-viral gene delivery vehicles"", J. CONTROL. RELEASE,, vol. 53, no. 1-3, 30 April 1998 (1998-04-30), pages 183 - 193, XP004121269;;TANAKA ET AL.: ""Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA"", CANCER RES.,, vol. 58, no. 15, 1 August 1998 (1998-08-01), pages 3362 - 3369, XP000857409;;CRYSTAL ET AL.: ""Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine"", HUM. GENE THER.,, vol. 8, 20 May 1997 (1997-05-20), pages 985 - 1001, XP002927381;;XU ET AL.: ""Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity"", HUM. GENE THER.,, vol. 8, no. 2, 20 January 1997 (1997-01-20), pages 177 - 185, XP002070390",PENDING
289,TW,A,TW 200619403 A,098-006-077-851-069,2006-06-16,2006,TW 93137649 A,2004-12-06,TW 93137649 A,2004-12-06,Method for fabricating inner chamber of PVD,"A method for fabricating inner chamber of PVD (physical vapor deposition). A non-conductive chamber substrate is provided having an inner surface for absorbing unwanted species. A plasma spraying step is executed on the inner surface of the substrate. Powder offered from the plasma spraying contains element powder, such as silicon or aluminum. The carrier plasma offered from the plasma spraying includes oxygen plasma. In the process of the plasma spraying, the element powder is oxidized to form a rough ceramic layer coated on the inner surface of the substrate.",DURATEK INC,TU DAVID;;CHANG CHARLIE,,https://lens.org/098-006-077-851-069,Patent of Addition,no,0,0,1,1,0,,,,0,0,,,,PENDING
290,US,A1,US 2013/0073758 A1,093-778-848-692-464,2013-03-21,2013,US 201213609032 A,2012-09-10,US 201213609032 A;;US 97469907 A,2007-10-15,DYNAMIC PORT POWER ALLOCATION APPARATUS AND METHODS,"Methods and apparatus for dynamically adjusting the amount of power (or current) distributed to one or more connected devices via electrical interfaces. In one embodiment, the apparatus comprises a first module adapted to detect current drawn by a first set of ports, and a second module adapted to adjust the current provided to a second set of ports based on the detected current. The second module is also optionally adapted to distribute unreserved current among the devices according to an allocation protocol. In the exemplary context of a plurality of interconnected serial bus devices, the invention enables a device to draw more current than that required to be reserved for that device (such as to comply with a specification such as USB), yet without increasing the total amount of power which must be dedicated to the serial ports as a whole. Power supply efficiency may also be advantageously optimized.",CHANG RAY;;FERGUSON DAVID,CHANG RAY;;FERGUSON DAVID,,https://lens.org/093-778-848-692-464,Patent Application,yes,3,17,5,5,0,G06F1/266;;G06F1/266;;H02J7/00,G06F13/42,710/106,0,0,,,,ACTIVE
291,US,B2,US 11078827 B2,114-653-609-188-720,2021-08-03,2021,US 201816157793 A,2018-10-11,US 201816157793 A,2018-10-11,Pre-chamber ignition system having igniter with gas orifice structured for pre-expanding outgoing combustion gases,"An ignition system for a gaseous fuel engine includes an igniter and an actuator structured to apply an actuating force to a piston within the igniter, to autoignite an ignition charge of fuel and air within the igniter. A housing of the igniter includes a gas orifice having a flow area that is increased between a combustion pre-chamber in the igniter and a main combustion chamber in the engine, to limit velocity of outgoing combustion gases to below a threshold velocity for engine mis-fire.",CATERPILLAR INC,CHANG DAVID YU ZHANG,CATERPILLAR INC (2018-10-10),https://lens.org/114-653-609-188-720,Granted Patent,yes,20,1,2,2,0,F02B19/108;;F02B19/18;;F02B19/06;;F02B19/108;;F02B19/14;;Y02T10/12,F02B19/18;;F02B19/06;;F02B19/10;;F02B19/14,,0,0,,,,ACTIVE
292,US,A,US 3698655 A,132-097-292-179-823,1972-10-17,1972,US 3698655D A,1970-12-21,US 9984270 A,1970-12-21,PACKING GUIDE FOR FLEXIBLE MATERIALS,,DAVID T L CHANG,CHANG DAVID T L,,https://lens.org/132-097-292-179-823,Granted Patent,no,0,5,1,1,0,G11B15/43;;G11B15/58;;G11B15/60;;G11B15/43;;G11B15/60;;G11B15/58,G11B15/43;;G11B15/58;;G11B15/60,242/76;;242/75.2,0,0,,,,EXPIRED
293,US,A1,US 2010/0299074 A1,135-893-633-397-383,2010-11-25,2010,US 73438808 A,2008-10-24,US 73438808 A;;US 133007 P;;EP 2008009027 W,2007-11-01,REMOTE DATA COLLECTING SYSTEMS AND METHODS,"The present invention provides a remote data collecting system comprising a measuring device comprising at least two scales in communication with a terminal center. The terminal center is in communication with a control center. The control center can be linked to a computer with software to collect, distribute, analyze, and display data collected from the measuring device. The remote data collecting system is particularly useful for uncontrolled environment (e.g., in-home) product testing such as testing the palatability of pet foods.",CHANG DAVID;;MA CHANGPU,CHANG DAVID;;MA CHANGPU,NESTEC S.A (2010-05-17),https://lens.org/135-893-633-397-383,Patent Application,yes,19,27,8,8,0,A01K5/00;;A01K5/00;;A01K5/0114;;A01K5/0114;;A01K29/00;;A01K29/00;;A23K50/40;;A23K50/40;;G01G19/4146;;G01G19/4146;;G01G23/3735;;G01G23/3735;;G01G23/3742;;G01G23/3742;;G16H20/60;;G16H20/60;;G16H40/67;;G16H40/67,G01G19/414;;G06F19/00,702/19;;702/173;;702/188,0,0,,,,DISCONTINUED
294,CA,A1,CA 2660708 A1,143-836-499-923-627,2008-02-21,2008,CA 2660708 A,2007-08-16,AU 2006/904478 A;;AU 2006/906441 A;;AU 2007/001164 W,2006-08-17,A DOOR STRIKE,"A door strike including: a latch retainer for retaining a door latch; a l ock actuator which operates when power is applied; a mode selector rotatable between at least two positions; in a first position of the mode selector th e strike adopts a power to open mode, in the second position of the mode sel ector the strike adopts a power to lock mode.",SHANGHAI ONE TOP CORP,MACKLE TREVOR;;CHANG DAVID,,https://lens.org/143-836-499-923-627,Patent Application,no,0,0,9,9,0,E05B47/0047;;E05B47/0047;;E05B63/0065;;E05B63/0065;;E05B2047/0073;;E05B2047/0073;;E05B2047/0076;;E05B2047/0076;;Y10T292/699;;Y10T292/699,E05B47/00;;E05B15/02,,0,0,,,,DISCONTINUED
295,ES,T3,ES 2590763 T3,176-649-630-939-987,2016-11-23,2016,ES 08845599 T,2008-10-24,US 133007 P;;EP 2008009027 W,2007-11-01,Sistema y método de recopilación remota de datos,"Un sistema de recopilación remota de datos, que comprende: un dispositivo de medición (4) que comprende al menos dos balanzas (10, 12) en comunicación con un centro de terminal (14), comprendiendo las balanzas (10, 12) un receptáculo para contener un producto; un centro de control (16) en comunicación con el centro de terminal (14), teniendo el centro de control (16) la capacidad de recopilar y distribuir datos relacionados con producto retirado del receptáculo de cada balanza y un ordenador (18) con un software para organizar, analizar y visualizar los datos, en el que cada una de las al menos dos balanzas (10, 12) se comunica con el centro de control (16) únicamente mediante el centro de terminal (14) y el ordenador (18) con el software para organizar, analizar y visualizar los datos se comunica con el centro de terminal (14) únicamente mediante el centro de control (16).",NESTEC SA,CHANG DAVID;;MA CHANGPU,,https://lens.org/176-649-630-939-987,Granted Patent,no,0,0,8,8,0,A01K5/00;;A01K5/00;;A01K5/0114;;A01K5/0114;;A01K29/00;;A01K29/00;;A23K50/40;;A23K50/40;;G01G19/4146;;G01G19/4146;;G01G23/3735;;G01G23/3735;;G01G23/3742;;G01G23/3742;;G16H20/60;;G16H20/60;;G16H40/67;;G16H40/67,G01G23/37;;A01K5/00;;A01K5/01;;A01K29/00;;G01G19/414;;G06F19/00,,0,0,,,,ACTIVE
296,MX,A,MX PA06001495 A,176-059-990-600-602,2006-05-15,2006,MX PA06001495 A,2004-08-06,US 49292203 P;;US 2004/0025561 W,2003-08-06,RICE FLOUR COMPOSITIONS.,"Rice flour compositions having a Peak Viscosity of from about 4 RVU to about 130 RVU. In one embodiment, the rice flour compositions have a Final Viscosity of from about 4 RVU to about 220 RVU. Preferably, the compositions have a WAI of from about 2.6 to about 9. In a preferred embodiment, the Peak Viscosity of the rice flour compositions is <= about 55(WAI) 145. The compositions can be used to produce food products such as fabricated sheeted snacks, extruded products, sauces, coatings for fried foods, dog foods, dog biscuits, baby foods and breads. The preferred doughs formed from the inventive rice flour composition are sheetable and elastic, and fabricated snacks made from the doughs have the desired taste and texture characteristics. A dry blend for a preferred fabricated snack comprises from about 2 % to about 100 %, preferably from about 3 % to about 33 %, most preferably from about 4 % to about 17 %, of the rice flour composition.",PROCTER & GAMBLE,CHANG DAVID SHANG-JIE,,https://lens.org/176-059-990-600-602,Patent Application,no,0,0,16,16,0,A21D2/362;;A21D2/362;;A23K50/40;;A23K50/40;;A23L7/117;;A23L7/117;;A23L7/13;;A23L7/13;;A23L7/198;;A23L7/198;;A23L19/19;;A23L19/19,A23L1/0522;;A21D2/36;;A21D10/00;;A23K1/18;;A23L1/164;;A23L7/10;;A23L19/18;;C08B30/00,,0,0,,,,ACTIVE
297,US,B1,US 6500807 B1,178-969-658-929-946,2002-12-31,2002,US 49567500 A,2000-02-01,US 49567500 A;;US 11824499 P,1999-02-02,Modified pectin and nucleic acid composition,"
    According to the present invention, there is provided a gene therapy material which includes a nucleic acid material and a carbohydrate wherein the carbohydrate preferably is a modified pectin. Also in accordance with the present invention, there is provided a gene therapy material including a nucleic acid material, a carbohydrate material associated with the nucleic acid material, and a protective coating disposed about the carbohydrate material. 
",SAFESCIENCE INC,PLATT DAVID;;CHANG YAN,TANG CAPITAL PARTNERS LP (2009-07-07);;PROSPECT THERAPEUTICS INC (2007-01-30);;SAFESCIENCE INC (2000-02-01),https://lens.org/178-969-658-929-946,Granted Patent,yes,31,37,5,8,0,A61K38/45;;A61K48/00;;A61K48/00;;A61K38/45,A61K38/45;;A61K48/00,514/44;;514/54;;536/23.1,15,13,019-810-335-711-889;;009-416-320-508-847;;030-772-469-172-263;;003-177-179-268-907;;038-200-406-461-559;;071-564-907-744-809;;049-767-401-211-231;;089-342-269-812-378;;007-803-052-092-597;;141-407-109-723-614;;029-845-091-384-932;;018-402-683-313-167;;018-402-683-313-167,9579858;;9305836;;10.1038/38410;;9330203;;10.1111/j.2042-7158.1997.tb06856.x;;9034229;;10.1023/a:1012019820603;;8865314;;10.1023/a:1016016404404;;9741926;;10.1016/s0168-3659(97)00252-6;;9195221;;10.1089/hum.1997.8.8-985;;9017421;;10.1089/hum.1997.8.2-177;;10.1093/jnci/87.5.348;;7853416;;9699667;;10.1074/jbc.273.7.4065;;9461599;;10.1038/7385;;10202926;;10.1038/7385;;10202926,"Anderson, ""Human gene therapy"", Nature, 392(Supp.):25-30, Apr. 1998.*;;Verma and Somia, ""Gene therapy-promises, problems and prospects"", Nature, 389:239-242, Sep. 1997.*;;www.harcourt.com/dictionary, Academic Press Online Dictionary of Science and Technology, accessed by PTO Jun. 5, 2000.*;;Wakerly et. al.; Studies on Amidated Pectins as Potential Carriers in Colonic Drug Delivery, 1997, J. Pharm. Pharmacol 49: 622-625.*;;Adkin et. al.; The use of scintigraphy to provide ""proof of conceptaaaa"" for novel polysaccharide preparations designed for colonic drug delivery, 1997, Pharm Res.: 103-107 Abstract.*;;Wakerly et. al.; Pectin/ethylcellulose film coating formulations for colonic drug delivery, 1996, Pharm Res.: 1210-2 Abstract.*;;US 5,849,884, 12/1998, Woiszwillo et al. (withdrawn);;Leong et al. ""DNA-polycation nonospheres as non-viral gene delivery vehicles"" Journal of Controlled Release 53 (1998) 183-193.;;Crystal et al. ""Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector Containing the E. coli Cytosine Deaminase Gene to Metastatic Colon Carcinoma of the Liver in Association with the Oral Administration of the Pro-Drug 5-Fluorocytosine"" Human Gene Therapy 8:985-10001 (May 20, 1997).;;Xu et al. ""Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors In Vivo Through a Bystander Mechanism Without Evidence of Toxicity"" Human Gene Therapy 8:177-185 (Jan. 20, 1997).;;Pienta et al. ""Inhibition of Spontaneous Metastasis in a Rat Prostate Cancer Model by Oral Administration of Modified Citrus Pectin"" Journal of the National Cancer Institute, vol. 87, No. 5, pp. 348-353 (Mar. 1, 1995).;;Tanaka et al. ""Viral Vector-targeted Antiangiogenic Gene Therapy Utilizing an Angiostatin Complementary DNA"" Cancer Research 58, 3362-3369 (Aug. 1, 1998).;;Zrihan-Licht et al. ""Csk Homologous Kinase, a Novel Signaling Molecule, Directly Associates with the Activated ErbB-2 Receptor in Breast Cancer Cells and Inhibits Their Proliferation"" The Journal of Biological Chemistry, vol. 273, No. 7, pp. 4065-4072 (Feb. 13, 1998).;;Roy et al. (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy.;;Nature Medicine, vol. 5, No. 4, pp. 387-391.",EXPIRED
298,EP,A4,EP 1261354 A4,002-236-820-362-765,2004-09-15,2004,EP 00904645 A,2000-02-02,US 0002628 W;;US 49567500 A,2000-02-01,DELIVERY SYSTEM AND METHODS FOR GENE THERAPY,,SAFESCIENCE INC,PLATT DAVID;;CHANG YAN,"PROSPECT THERAPEUTICS, INC. (2007-11-28);;GLYCOGENESYS, INC. (2007-11-21)",https://lens.org/002-236-820-362-765,Search Report,no,1,0,2,8,0,,A61K31/715;;A61K48/00;;C12N15/63,,2,0,,,"PLATT DAVID ET AL: ""Effect of a modified natural complex carbohydrates in cancer"", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 219, no. 1-2, 2000, & 219TH MEETING OF THE AMERICAN CHEMICAL SOCIETY.; SAN FRANCISCO, CALIFORNIA, USA; MARCH 26-30, 2000, pages CARB 62, XP009033721, ISSN: 0065-7727;;See also references of WO 0045825A1",DISCONTINUED
299,US,B2,US 10437279 B2,012-604-590-485-522,2019-10-08,2019,US 201816194657 A,2018-11-19,US 201816194657 A;;US 201816106119 A;;US 201715729802 A,2017-10-11,Open loop solution in data buffer and RCD,"An apparatus includes a clock tree circuit, a first phase interpolator circuit and a second phase interpolator circuit. The clock tree circuit may be configured to generate a first clock delayed from a system clock by a constant time. The first phase interpolator circuit may be in a calibration loop and configured to generate a second clock with a programmable phase delay relative to the first clock. The programmable phase delay may be controlled by a control value. The calibration loop may be configured to determine the control value that results in a given delay between the system clock and the second clock. The second phase interpolator circuit may be in a normal signal path and configured to generate a third clock with the given delay relative to the first clock using the control value such that the third clock is offset from the system clock by the given delay.",INTEGRATED DEVICE TECH,CHANG DAVID;;SHI XUDONG,,https://lens.org/012-604-590-485-522,Granted Patent,yes,14,3,2,5,0,G11C29/1201;;G11C29/12015;;G11C2029/0403;;H03K5/05;;G11C29/023;;G11C29/028;;G11C11/4076;;G11C5/04;;G11C7/222;;G11C29/50012;;G06F1/10;;G11C2207/2254;;G11C7/222;;H03K5/05;;H03L7/08;;G11C29/023;;G11C29/028;;G11C5/04;;G11C29/00;;G11C11/4096;;G11C11/4076;;G11C7/1066;;G11C7/106;;G11C7/1039;;G06F1/08;;G11C29/12015;;G11C29/50012;;G11C29/1201;;G11C2029/0403,G06F1/10;;G06F1/08;;G11C5/04;;G11C7/10;;G11C7/22;;G11C11/4076;;G11C11/4096;;G11C29/00;;G11C29/02;;H03K5/05;;H03L7/08,,0,0,,,,ACTIVE
300,EP,A1,EP 0029594 A1,058-045-820-545-107,1981-06-03,1981,EP 80107268 A,1980-11-21,US 9628579 A;;US 14626980 A,1979-11-21,"A liquid acrylic coating composition, articles coated therewith and process for preparing said coated articles.","A liquid coating composition is disclosed comprising 10-60% by weight of film-forming polymer and solvent for said polymer wherein said polymer consists essentially of
 (a) 50-80% by weight of an acrylic polymer which consists essentially of
 styrene, methyl methacrylate, an alkyl (meth)acrylate, a hydroxyalkyl (meth)acrylate, and an a,B-unsaturated monocarboxylicacid; (b) 5-50 % by weight, based on the weight of the polymer, of cellulose acetate butyrate; (c) 5-50% by weight, based on the weight of the polymer, of a melamine formaldehyde resin; and (d) at least one ultraviolet light stabilizer. The weatherability and durability of finishes prepared therefrom are significantly increased.",DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/058-045-820-545-107,Patent Application,yes,4,11,3,4,0,C09D133/066;;C08L1/14;;C08L61/20,C08L1/14;;C08L61/20;;C09D133/06,,0,0,,,,DISCONTINUED
301,US,A1,US 2019/0187744 A1,066-607-507-189-46X,2019-06-20,2019,US 201816194657 A,2018-11-19,US 201816194657 A;;US 201816106119 A;;US 201715729802 A,2017-10-11,OPEN LOOP SOLUTION IN DATA BUFFER AND RCD,"An apparatus includes a clock tree circuit, a first phase interpolator circuit and a second phase interpolator circuit. The clock tree circuit may be configured to generate a first clock delayed from a system clock by a constant time. The first phase interpolator circuit may be in a calibration loop and configured to generate a second clock with a programmable phase delay relative to the first clock. The programmable phase delay may be controlled by a control value. The calibration loop may be configured to determine the control value that results in a given delay between the system clock and the second clock. The second phase interpolator circuit may be in a normal signal path and configured to generate a third clock with the given delay relative to the first clock using the control value such that the third clock is offset from the system clock by the given delay.",INTEGRATED DEVICE TECH,CHANG DAVID;;SHI XUDONG,,https://lens.org/066-607-507-189-46X,Patent Application,yes,0,11,2,5,0,G11C29/1201;;G11C29/12015;;G11C2029/0403;;H03K5/05;;G11C29/023;;G11C29/028;;G11C11/4076;;G11C5/04;;G11C7/222;;G11C29/50012;;G06F1/10;;G11C2207/2254;;G11C7/222;;H03K5/05;;H03L7/08;;G11C29/023;;G11C29/028;;G11C5/04;;G11C29/00;;G11C11/4096;;G11C11/4076;;G11C7/1066;;G11C7/106;;G11C7/1039;;G06F1/08;;G11C29/12015;;G11C29/50012;;G11C29/1201;;G11C2029/0403,G06F1/10;;G06F1/08;;G11C5/04;;G11C7/10;;G11C7/22;;G11C11/4076;;G11C11/4096;;G11C29/00;;G11C29/02;;H03K5/05;;H03L7/08,,0,0,,,,ACTIVE
302,CA,A1,CA 2053755 A1,084-371-334-308-786,1992-04-23,1992,CA 2053755 A,1991-10-18,US 60607790 A,1990-10-22,STABLE AQUEOUS ALUMINUM FLAKE DISPERSION,"19 FP-0170 TITLE STABLE AQUEOUS ALUMINUM FLAKE DISPERSION A stable waterborne high solids metallic flake pigment dispersion containing an aqueous carrier, film forming binder and metallic flake pigment and having a solids content of about 40-90% by weight; wherein the film forming polymer is a phosphated acrylic polymer neutralized with ammonia or a primary, secondary or tertiary amine and contains metallic flake pigments in a pigment to binder weight ratio of about 30/100-1000/100 and is non-reactive with the binder and the dispersion has a pH of about 7-9. 19",DU PONT,CHANG DAVID C K,,https://lens.org/084-371-334-308-786,Patent Application,no,0,0,3,3,0,C09D133/062;;C09D133/062;;C08L61/20;;C08L61/20;;C09D5/38;;C09D5/38;;C09D17/006;;C09D17/006;;C09D143/02;;C09D143/02,C08L61/20;;C09D5/38;;C09D17/00;;C09D133/06;;C09D143/02,,0,0,,,,DISCONTINUED
303,DE,A1,DE 1800668 A1,106-895-109-467-477,1969-06-19,1969,DE 1800668 A,1968-10-02,US 67222467 A,1967-10-02,Bandtransportvorrichtung,,AMPEX,T L CHANG DAVID,,https://lens.org/106-895-109-467-477,Patent Application,no,0,0,5,5,0,G11B15/58,G11B15/58,,0,0,,,,DISCONTINUED
304,US,A1,US 2013/0190310 A1,125-785-356-494-749,2013-07-25,2013,US 201113812735 A,2011-07-26,US 201113812735 A;;US 36769610 P;;US 2011/0045331 W,2010-07-26,MIG6 AND THERAPEUTIC EFFICACY,"We identify markers capable of guiding the decision to incorporate epidermal growth factor receptor (EGFR) inhibitors, in particular EGFR tyrosine kinase inhibitors (TKIs), into chemotherapeutic regimens. Mitogen-inducible gene 6 (Mig6), a negative regulator of EGFR, is selectively upregulated during the development of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, resulting in decreased EGFR phosphorylation. The ratio of Mig6/EGFR expression highly correlates with erlotinib sensitivity. A low Mig6/EGFR ratio correlates with a high response rate to gefitinib and a marked increase in progression-free survival for patients. The ratio of Mig6 to EGFR is a major predictor of biologic and clinical responses to EGFR inhibitors.",SIDRANSKY DAVID;;CHANG XIAOFEI;;UNIV JOHNS HOPKINS,SIDRANSKY DAVID;;CHANG XIAOFEI,THE JOHNS HOPKINS UNIVERSITY (2013-02-05),https://lens.org/125-785-356-494-749,Patent Application,yes,0,5,5,5,0,C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;G01N2333/91205;;G01N2800/44;;C12Q1/6886;;G01N2333/91205;;G01N2800/44;;C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;C12Q1/6886;;C12Q1/485,C12Q1/68;;C12Q1/48,514/234.5;;435/7.23;;435/6.12;;506/9;;514/266.4,7,7,063-209-100-790-947;;038-299-859-340-285;;038-601-812-322-578;;001-213-111-120-386;;131-959-048-672-341;;052-006-255-744-372;;021-323-521-292-044,19892746;;10.1093/annonc/mdp477;;19556865;;10.4161/cbt.8.14.9195;;10.1158/0008-5472.can-07-5200;;18413752;;pmc2867293;;20421427;;10.1083/jcb.201002032;;10.1056/nejmoa050736;;16014883;;10.4161/cc.6.5.3928;;17351343;;10.1093/jnci/dji112;;15870435,"Wirth et al., ""Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck"" 21 Annals of Oncology 342-347 (November 5, 2009);;Cho et al., ""Cancer research on non-small cell lung cancer in smokers and non-smokers"" 8(14) Cancer Biology & Therapy 1309-1312 (July 15, 2009);;Jimeno et al. ""Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer"" 68 Cancer Research 2841-2849 (2008);;Frosi et al., ""A two-tiered mechanims of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation"" 189(3) Journal of Cell Biology 557-571 (April 26, 2010);;Tsao et al., ""Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome"" 353(2) New England Journal of Medicine 133-144 (2005);;Zhang et al., ""Mig-6, Signal Transduction, Stress Response and Cancer"" 6(5) Cell Cycle 507-513 (2007);;Cappuzzo et al., ""Epidermal Growth Factor Receptor Gene and Protein and Gefinitib Sensitivity in Non-Small-Cell Lung Cancer"" 97(9) Journal of the National Cancer Institute 643-655 (2005)",DISCONTINUED
305,AU,A4,AU 2017/100805 A4,154-606-386-853-066,2017-08-17,2017,AU 2017/100805 A,2017-06-20,AU 2017/100805 A,2017-06-20,SELF-ADHESIVE FLOORING AND METHOD FOR MANUFACTURING SAME,"The present invention relates generally to flooring, and particularly to self-adhesive flooring, and to a method of manufacturing same. The flooring may be multilayered. In preferred embodiments, the self-adhesive flooring may have vibration absorption, sound absorption, and flame resistive properties. The self-adhesive flooring product includes a lower adhesive layer for adhering said flooring product to a floor; a resilient intermediate layer; a decorative layer; and an upper wear resistant layer. Figure 1 20- 5 Figure 2 9183217_1 (GHMatters) P105509.AU 19/06/17",MILLENNIUM IND PTY LTD,CHANG DAVID;;HERDMAN JEFF,,https://lens.org/154-606-386-853-066,Limited Patent,no,0,2,1,1,0,,E04F15/00,,0,0,,,,ACTIVE
306,NO,D0,NO 873334 D0,158-812-577-797-442,1987-08-10,1987,NO 873334 A,1987-08-10,US 80675585 A;;US 8602554 W,1985-12-09,HYBRIDOMER MOT HUMAN FLERPOTENT GRANULOCYTTKOLONI-STIMULERENDE FAKTOR.,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/158-812-577-797-442,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;G01N33/53;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
307,US,A1,US 2019/0107862 A1,176-845-998-849-435,2019-04-11,2019,US 201816106119 A,2018-08-21,US 201816106119 A;;US 201715729802 A,2017-10-11,OPEN LOOP SOLUTION IN DATA BUFFER AND RCD,An apparatus comprising an open loop circuit and a delay circuit. The open loop circuit may be configured to generate an in-phase clock signal by performing a phase alignment in response to (i) a clean version of a system clock and (ii) a delayed version of a strobe signal. The delay circuit may be configured to (i) generate the delayed version of the strobe signal in response to (a) the strobe signal received from a memory interface and (b) a delay amount received from a calibration circuit and (ii) adjust a delay of transferring a data signal through the apparatus in response to (a) the delay amount and (b) the in-phase clock signal. The data signal may be received from the memory interface. The delay of transferring the data signal may be implemented to keep a latency of a data transfer within a pre-defined range.,INTEGRATED DEVICE TECH,CHANG DAVID;;SHI XUDONG,,https://lens.org/176-845-998-849-435,Patent Application,yes,10,2,3,5,0,G06F1/10;;G06F1/10;;G06F1/08;;G06F1/08;;G11C5/04;;G11C5/04;;G11C7/1039;;G11C7/1039;;G11C7/106;;G11C7/106;;G11C7/1066;;G11C7/1066;;G11C7/222;;G11C7/222;;G11C11/4076;;G11C11/4076;;G11C11/4096;;G11C11/4096;;G11C29/00;;G11C29/00;;G11C29/023;;G11C29/023;;G11C29/028;;G11C29/028;;G11C2207/2254;;G11C2207/2254;;H03K5/05;;H03L7/07;;H03L7/07;;H03L7/08;;H03L7/0812;;H03L7/0812;;H03L7/0814;;H03L7/0814,G06F1/10;;G06F1/08;;G11C7/22;;H03K5/05;;H03L7/08,,0,0,,,,ACTIVE
308,US,A,US 3898693 A,184-682-350-422-910,1975-08-05,1975,US 50053374 A,1974-08-26,US 50053374 A,1974-08-26,Video recorder/reproducer transport using vacuum columns and servos,"An improved tape transport for use in the magnetic tape recording and reproducing of high frequency signals, such as video signals. The transport is adapted to include a helical scanner head assembly for recording and reproducing signals on the tape in a helical scan format. Vacuum chambers are included for handling the tape passing to and from the scanner head assembly. A vacuum chamber is positioned intermediate the tape take-up source and the capstan, and another vacuum chamber is positioned intermediate the scanner head assembly and the tape supply source. The scanner head assembly supports a separate record head and a separate playback head spaced apart relative to one another such that record and playback may be realized simultaneously.",VIDEO MEMORY CORP,CHANG DAVID T L,,https://lens.org/184-682-350-422-910,Granted Patent,no,5,13,1,1,0,G11B15/58;;G11B15/58;;G11B27/024;;G11B27/024;;H04N17/06;;H04N17/06,G11B15/58;;G11B27/024;;H04N17/06,360/73,0,0,,,,EXPIRED
309,DK,A,DK 412887 A,026-770-655-202-645,1987-08-07,1987,DK 412887 A,1987-08-07,US 80675585 A;;US 8602554 W,1985-12-09,"HYBRIDOMAER FOR HUMAN, PLURIPOTENT GRANULOCYTKOLONISTIMULERENDE FAKTOR","Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/026-770-655-202-645,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;G01N33/53;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
310,CN,C,CN 1035628 C,045-571-669-364-95X,1997-08-13,1997,CN 86107666 A,1986-12-08,US 80675585 A,1985-12-09,Method for producing monoclonal antibodies,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/045-571-669-364-95X,Granted Patent,no,3,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,G01N33/53;;A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
311,FR,A1,FR 2313454 A1,048-051-452-142-619,1976-12-31,1976,FR 7603713 A,1976-02-11,US 54976975 A,1975-02-13,"ALLIAGE A BASE DE FER, COBALT OU NICKEL",,GEN ELECTRIC,CHANG DAVID RONG-HWAN,,https://lens.org/048-051-452-142-619,Patent Application,no,0,3,11,12,0,C22C19/00;;C22C19/052;;C22C19/053;;C22C38/00;;Y10T428/12931;;Y10T428/12931;;C22C38/00;;C22C19/052;;C22C19/053;;C22C19/00,C22C19/00;;C22C19/05;;C22C19/07;;C22C27/06;;C22C30/00;;C22C38/00;;C23C4/08;;C23C10/58,,1,0,,,NEANT,EXPIRED
312,US,B2,US 11840720 B2,071-410-950-663-72X,2023-12-12,2023,US 201916725914 A,2019-12-23,US 201916725914 A,2019-12-23,Urinary metabolomic biomarkers for detecting colorectal cancer and polyps,"The invention relates to methods and compositions for detecting colorectal cancer and colorectal polyps by measurement of metabolites in bodily fluids such as urine, including diacetylspermine and kynurenine.",METABOLOMIC TECH INC,DENG LU;;CHANG DAVID,METABOLOMIC TECHNOLOGIES INC (2020-01-03),https://lens.org/071-410-950-663-72X,Granted Patent,yes,28,0,2,2,0,A61K31/00;;G01N33/57419;;G01N2800/52;;G01N33/57484;;G01N33/57488;;G01N33/58;;G01N33/6848;;C40B30/06;;C12Q1/6886;;C12Q2600/158;;C12Q2600/106;;A61K45/06;;G01N2800/7028;;G01N2800/50;;G01N2800/52;;G01N33/493;;G01N33/492;;G01N33/57419,G01N33/48;;A61K45/06;;C12Q1/6886;;G01N33/49;;G01N33/493;;G01N33/574,,138,106,029-279-104-820-016;;097-094-497-333-459;;001-374-734-900-167;;070-421-226-367-070;;029-073-666-325-881;;050-120-822-488-894;;031-517-800-981-940;;034-717-441-977-784;;022-362-417-973-614;;046-672-509-944-68X;;055-986-711-505-195;;016-569-902-573-666;;007-065-897-074-567;;002-099-238-459-15X;;010-588-921-702-000;;110-034-213-498-943;;008-937-900-799-043;;030-501-331-557-748;;029-110-964-150-661;;032-214-371-723-609;;027-738-113-890-080;;053-255-739-432-643;;015-676-636-943-894;;015-187-232-145-856;;014-716-974-074-625;;002-495-107-738-102;;011-766-856-355-633;;038-336-189-027-854;;016-267-009-475-496;;049-018-690-573-977;;091-985-737-103-785;;000-872-372-352-428;;078-223-204-612-761;;002-229-419-921-860;;055-988-975-153-831;;153-191-562-976-762;;027-637-887-931-488;;010-025-852-300-120;;016-472-723-070-368;;056-588-596-374-523;;005-096-364-474-137;;095-830-931-802-140;;040-731-081-947-503;;039-021-494-709-819;;095-731-224-559-600;;004-952-096-197-462;;021-655-881-960-30X;;027-393-680-748-581;;105-509-119-660-233;;031-355-620-974-242;;013-233-282-641-69X;;163-251-542-247-372;;052-419-693-840-036;;014-716-974-074-625;;048-051-268-505-678;;000-456-642-612-355;;075-666-280-606-471;;046-462-020-008-268;;134-730-917-254-285;;008-453-634-162-718;;016-651-224-395-209;;061-061-225-812-467;;011-766-856-355-633;;006-441-845-457-427;;005-096-364-474-137;;020-279-602-532-01X;;057-978-487-523-120;;078-063-130-078-390;;118-655-753-756-280;;016-220-957-325-73X;;059-060-146-969-662;;121-668-791-420-850;;047-093-440-493-146;;074-259-572-165-669;;131-340-692-443-495;;039-268-188-061-246;;016-267-009-475-496;;120-838-807-189-116;;005-485-898-680-575;;053-120-989-224-152;;024-059-086-242-999;;022-494-093-278-037;;040-936-750-551-813;;110-086-542-505-088;;006-695-842-861-985;;070-999-942-783-391;;014-131-025-746-115;;116-286-571-338-244;;053-362-082-174-021;;112-225-064-481-578;;016-860-822-335-469;;054-642-356-907-943;;110-063-128-612-919;;041-437-217-202-236;;005-592-032-132-731;;054-642-356-907-943;;067-478-925-120-842;;004-165-870-281-880;;007-262-891-864-704;;123-837-297-412-30X;;003-239-376-085-297;;107-020-137-758-09X;;079-674-136-660-823;;068-631-740-952-807;;031-356-267-225-391;;026-037-887-231-742,7768972;;10.1007/bf01209602;;30208276;;10.1021/acs.analchem.8b02372;;10.1053/j.gastro.2018.07.017;;pmc6240353;;30031768;;30300613;;10.1053/j.gastro.2018.10.010;;pmc5449420;;28611516;;10.3748/wjg.v23.i20.3632;;10.1136/gutjnl-2014-309086;;26041752;;24645800;;10.1056/nejmoa1311194;;22356323;;10.1056/nejmoa1108895;;10.1136/gutjnl-2011-301583;;22387523;;10.3389/fphar.2013.00175;;24454288;;pmc3887272;;10.9778/cmajo.20140073;;26389092;;pmc4565170;;10.1038/s41395-018-0023-x;;pmc6476786;;29487413;;10.1016/j.gtc.2013.05.003;;23931864;;30326005;;pmc6583619;;10.1001/jamainternmed.2018.4637;;10.2174/1745017901814010063;;29643929;;pmc5872199;;pmc6154741;;10.2147/ppa.s172143;;30271126;;10.1016/j.ctarc.2016.12.004;;10.1007/s40291-017-0259-y;;28155091;;10.1155/2013/893913;;11992300;;10.7326/0003-4819-136-9-200205070-00007;;30248228;;10.1111/codi.14431;;10.1016/j.aca.2018.06.081;;pmc6162048;;30193624;;pmc5877617;;10.3390/ijms19030756;;29518931;;10.21873/anticanres.12634;;29848716;;pmc3940838;;10.1038/ctg.2014.2;;24646506;;pmc5618317;;10.3390/metabo7030032;;28640228;;27909808;;10.1007/s00384-016-2729-9;;10.4172/2153-0769.1000151;;10.1155/2013/303982;;pmc3838851;;24307992;;22696204;;10.1007/s00384-012-1518-3;;29762782;;10.1093/nar/gky310;;pmc6030889;;10.7150/jca.16244;;pmc5118662;;27877214;;27694567;;10.1093/ije/dyw221;;29915533;;10.3389/fnhum.2018.00226;;pmc5994544;;29311683;;10.1038/s41598-017-18317-7;;pmc5758601;;21693065;;pmc3133555;;10.1186/1471-2105-12-253;;10.18637/jss.v033.i01;;pmc2929880;;20808728;;16096348;;10.1093/bioinformatics/bti623;;13240580;;pmc1826044;;10.5301/jbm.2008.4964;;15646840;;10.1177/172460080401900411;;15837752;;10.1158/1078-0432.ccr-04-2275;;10.1016/j.dld.2004.10.006;;15888284;;26505680;;10.1038/bjc.2015.349;;pmc4815893;;17426784;;10.5507/bp.2006.033;;10.18632/oncotarget.16727;;28389626;;pmc5471069;;10.1002/ijc.24191;;19142968;;10.1158/1055-9965.epi-10-0712;;21098649;;25105552;;10.1021/pr500443c;;10.3390/cancers10080246;;30060469;;pmc6116151;;10.1002/cem.775;;10.1002/cem.695;;10.1007/978-1-4757-2440-0;;17699303;;10.2215/cjn.02560706;;pmc3940838;;10.1038/ctg.2014.2;;24646506;;10.2217/fon.10.107;;20919825;;10.1039/c004994h;;20617254;;10.1002/cbic.200500151;;16206229;;14754875;;10.1093/carcin/bgh079;;pmc4535307;;10.1016/j.ebiom.2015.05.022;;26288805;;8472349;;0008472349;;10.1093/clinchem/39.4.561;;27980503;;pmc5126183;;10.1007/s11306-016-1137-z;;27998490;;10.1016/j.aca.2016.11.055;;27909808;;10.1007/s00384-016-2729-9;;31421118;;10.1016/j.cca.2019.08.011;;15837752;;10.1158/1078-0432.ccr-04-2275;;10.1038/sj.bjc.6600336;;12087451;;pmc2375406;;10.1007/s00432-013-1405-5;;23443255;;pmc5475285;;28642837;;10.1007/s40495-017-0088-z;;10.1002/9781118537282;;19710155;;10.3945/jn.109.108001;;11007345;;10.1007/s004200000160;;10.1055/s-2003-36410;;12510223;;10.1371/journal.pone.0073076;;24023812;;pmc3762851;;10.1021/pr8006232;;19063642;;17502626;;10.1200/jco.2006.09.7550;;pmc2569965;;18799019;;10.1186/1476-4598-7-72;;10.1155/2013/303982;;pmc3838851;;24307992;;10.1002/cem.1007;;10.1002/cem.1009;;6452080;;10.3748/wjg.v16.i27.3402;;20632442;;pmc2904886;;18490203;;10.1016/j.jchromb.2008.04.034;;10.1016/j.cca.2008.12.009;;19135043;;12817423;;10.1309/uyn7-0n9w-2dvn-9art;;10.1309/uyn70n9w2dvn9art;;10.1016/j.cgh.2006.07.015;;16996805;;18384785;;10.1053/j.gastro.2008.02.002;;10.1007/s10620-008-0665-4;;19117128;;10.1002/cncr.2820360944;;1203876;;20691711;;10.1016/j.mrfmmm.2010.07.008;;10.1146/annurev.pathol.4.110807.092317;;19400693;;10.1016/j.gtc.2007.08.007;;17996799;;20121166;;10.1021/pr901081y;;pmc4865713;;27190585;;10.4251/wjgo.v8.i5.459;;10.1021/pr9006427;;19817432;;pmc1382412;;7883225;;10.1136/gut.36.2.251;;20121166;;10.1021/pr901081y;;10.1097/00000478-200301000-00008;;12502929;;10.1002/cem.724;;10.1002/cem.860;;31151939;;10.1158/1055-9965.epi-18-1291;;pmc6677589;;32968743;;10.1039/d0mo00087f;;10.1016/j.envint.2017.07.019;;pmc5569895;;28759762;;10.3389/fcell.2021.593510;;33598460;;pmc7882692;;pmc7759636;;10.3389/fmolb.2020.559688;;33363202;;34395249;;pmc8362851;;10.3389/fonc.2021.680910;;10.1371/journal.pone.0149823;;pmc4767415;;26914934,"Sugimoto et al., J Cancer Res Clin Oncol., 1995, 121:317-319.;;Deng et al., American J of Gastroenterology, 2018, 113: p. S153.;;Zhang et al., Anal. Chem., 2018, 90:11941-11948.;;Levin TR, Corley DA, Jensen CD, Schottinger JE, Quinn VP, Zauber AG, et al. Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology 2018 doi 10.1053/j.gastro.2018.07.017.;;Dube C. Organized screening is better than opportunistic screening at decreasing the burden of colorectal cancer in the United States. Gastroenterology 2018;155(5):1302-4 doi 10.1053/j.gastro.2018.10.010.;;Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: An update. World J Gastroenterol 2017;23(20):3632-42 doi 10.3748/wjg.v23.120.3632.;;Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015;64(10):1637-49 doi 10.1136/gutjnl-2014-309086.;;Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. New England Journal of Medicine 2014;370(14):1287-97 doi 10.1056/NEJMoa1311194.;;Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366(8):697-706 doi 10.1056/NEJMoa1108895.;;Van Roon AH, Goede SL, van Ballegooijen M, van Vuuren AJ, Looman CW, Biermann K, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013;62(3):409-15 doi 10.1136/gutjnl-2011-301583.;;Zubero MB, Arana-Arri E, Pijoan JI, Portillo I, Idigoras I, Lopez-Urrutia A, et al. Population-based colorectal cancer screening: comparison of two fecal occult blood test. Frontiers in pharmacology 2014;4:175 doi 10.3389/fphar.2013.00175.;;Singh H, Bernstein CN, Samadder JN, Ahmed R. Screening rates for colorectal cancer in Canada: a cross-sectional study. CMAJ open 2015;3(2):E149-57 doi 10.9778/cmajo.20140073.;;Singal AG, Corley DA, Kamineni A, Garcia M, Zheng Y, Doria-Rose PV, et al. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. Am J Gastroenterol 2018;113(5):746-54 doi 10.1038/s41395-018-0023-x.;;Church J. Complications of Colonoscopy. Gastroenterology Clinics of North America 2013;42(3):639-57 doi 10.1016/j.gtc.2013.05.003.;;Dougherty MK, Brenner AT, Crockett SD, Gupta S, Wheeler SB, Coker-Schwimmer M, et al. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. JAMA internal medicine 2018 doi 10.1001/jamainternmed.2018.4637.;;Cossu G, Saba L, Minerba L, Mascalchi M. Colorectal Cancer Screening: The Role of Psychological, Social and Background Factors in Decision-making Process. Clinical practice and epidemiology in mental health : CP & EMH 2018;14:63-9 doi 10.2174/1745017901814010063.;;Osborne JM, Flight I, Wilson CJ, Chen G, Ratcliffe J, Young GP. The impact of sample type and procedural attributes on relative acceptability of different colorectal cancer screening regimens. Patient preference and adherence 2018;12:1825-36 doi 10.2147/ppa.S172143.;;Liles EG, Coronado GD, Perrin N, Harte AH, Nungesser R, Quigley N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications 2017;10:27-31 doi https://doi.org/10.1016/j.ctarc.2016.12.004.;;Lamb YN, Dhillon S. Epi proColon((R)) 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. Molecular diagnosis & therapy 2017;21(2):225-32 doi 10.1007/s40291-017-0259-y.;;Anabtawi A, Mathew LM. Improving compliance with screening of diabetic patients for microalbuminuria in primary care practice. ISRN endocrinology 2013;2013:893913 doi 10.1155/2013/893913.;;Oboler SK, Prochazka AV, Gonzales R, Xu S, Anderson RJ. Public expectations and attitudes for annual physical examinations and testing. Annals of internal medicine 2002;136(9):652-9.;;Widlak MM, Neal M, Daulton E, Thomas CL, Tomkins C, Singh B, et al. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2018 doi 10.1111/codi.14431.;;Guo C, Xie C, Chen Q, Cao X, Guo M, Zheng S, et al. A novel malic acid-enhanced method for the analysis of 5-methyl-2′-deoxycytidine, 5-hydroxymethyl-2′-deoxycytidine, 5-methylcytidine and 5-hydroxymethylcytidine in human urine using hydrophilic interaction liquid chromatography-tandem mass spectrometry. Analytica chimica acta 2018;1034:110-8 doi 10.1016/j.aca.2018.06.081.;;Nakajima T, Katsumata K, Kuwabara H, Soya R, Enomoto M, Ishizaki T, et al. Urinary Polyamine Biomarker Panels with Machine-Learning Differentiated Colorectal Cancers, Benign Disease, and Healthy Controls. International journal of molecular sciences 2018;19(3) doi 10.3390/ijms19030756.;;Venalainen MK, Roine AN, Hakkinen MR, Vepsalainen JJ, Kumpulainen PS, Kiviniemi MS, et al. Altered Polyamine Profiles in Colorectal Cancer. Anticancer research 2018;38(6):3601-7 doi 10.21873/anticanres.12634.;;Wang H, Tso V, Wong C, Sadowski D, Fedorak RN. Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps. Clin Transl Gastroenterol 2014;5:e54 doi 10.1038/ctg.2014.2.;;Deng L, Chang D, Foshaug RR, Eisner R, Tso VK, Wishart DS, et al. Development and Validation of a High-Throughput Mass Spectrometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps. Metabolites 2017;7(3):32 doi 10.3390/metabo7030032.;;Deng L, Fang H, Tso VK, Sun Y, Foshaug RR, Krahn SC, et al. Clinical validation of a novel urine-based metabolomic test for the detection of colonic polyps on Chinese population. Int J Colorectal Dis 2017;32(5):741-3 doi 10.1007/s00384-016-2729-9.;;Tso V ER, Macleod S, Ismond KP, Foshaug RR, Wang H, Joseph R, Chang D, Taylor N and Fedorak RN. Consistency of Metabolite Determination from NMR Spectra over Time and Between Operators. Metabolomics 2015;5(3):151 doi 10.4172/2153-0769.1000151.;;Eisner R, Greiner R, Tso V, Wang H, Fedorak RN. A machine-learned predictor of colonic polyps based on urinary metabolomics. Biomed Res Int 2013;2013:303982 doi 10.1155/2013/303982.;;Wong CK, Fedorak RN, Prosser CI, Stewart ME, van Zanten SV, Sadowski DC. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis 2012;27(12):1657-64 doi 10.1007/s00384-012-1518-3.;;R Core Team. 2018 R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing <https://www.R-project.org>.;;Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Research 2018;46(W1):W486-W94 doi 10.1093/nar/gky310.;;Altobelli E, Angeletti PM, Latella G. Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis. Journal of Cancer 2016;7(14):1984-2004 doi 10.7150/jca.16244.;;Qiu G, Zheng Y, Wang H, Sun J, Ma H, Xiao Y, et al. Plasma metabolomics identified novel metabolites associated with risk of type 2 diabetes in two prospective cohorts of Chinese adults. International Journal of Epidemiology 2016;45(5):1507-16 doi 10.1093/ije/dyw221.;;Stoessel D, Stellmann J-P, Willing A, Behrens B, Rosenkranz SC, Hodecker SC, et al. Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring. Frontiers in human neuroscience 2018;12:226—doi 10.3389/fnhum.2018.00226.;;Delplancke TDJ, de Seymour JV, Tong C, Sulek K, Xia Y, Zhang H, et al. Analysis of sequential hair segments reflects changes in the metabolome across the trimesters of pregnancy. Scientific reports 2018;8(1):36—doi 10.1038/s41598-017-18317-7.;;Lê Cao K-A, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics 2011;12(1):253 doi 10.1186/1471-2105-12-253.;;Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. Journal of Statistical Software 2010;33(1):1-22 doi 10.18637/jss.v033.101.;;Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005;21(20):3940-1 doi 10.1093/bioinformatics/bti623.;;Spacek M. Kynurenine in disease, with particular reference to cancer. Canadian Medical Association journal 1955;73(3):198-201.;;Enjoji M, Nakamuta M, Arimura E, Morizono S, Kuniyoshi M, Fukushima M, et al. Clinical significance of urinary N1, N12-diacetylspermine levels in patients with hepatocellular carcinoma. The International journal of biological markers 2004;19(4):322-7.;;Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, et al. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):2986-90 doi 10.1158/1078-0432. Ccr-04-2275.;;Yamaguchi K, Nakamura M, Shirahane K, Konomi H, Torata N, Hamasaki N, et al. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2005;37(3):190-4 doi 10.1016/j.dld.2004.10.006.;;Takahashi Y, Sakaguchi K, Horio H, Hiramatsu K, Moriya S, Takahashi K, et al. Urinary N1, N12-diacetylspermine is a non-invasive marker for the diagnosis and prognosis of non-small-cell lung cancer. Br J Cancer 2015;113(10):1493-501 doi 10.1038/bjc.2015.349.;;Stejskal D, Humenanska V, Hanulova Z, Fiala R, Vrtal R, Solichova P, et al. Evaluation of urine N1,N12-Diacetylspermine as potential tumor marker for urinary bladder cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006;150(2):235-7.;;Zhang F, Zhang Y, Zhao W, Deng K, Wang Z, Yang C, et al. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review. Oncotarget 2017;8(21):35460-72 doi 10.18632/oncotarget.16727.;;Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. International journal of cancer 2009;124(10):2406-15 doi 10.1002/ijc.24191.;;Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiology Biomarkers & Prevention 2011;20(1):140-7 doi 10.1158/1055-9965.Epi-10-0712.;;Ni Y, Xie G, Jia W. Metabonomics of Human Colorectal Cancer: New Approaches for Early Diagnosis and Biomarker Discovery. Journal of Proteome Research 2014;13(9):3857-70 doi 10.1021/pr500443c.;;Erben V, Bhardwaj M, Schrotz-King P, Brenner H. Metabolomics biomarkers for detection of colorectal neoplasms: a systematic review. Cancers 2018;10(246):1-24 doi 10.3390/cancers10080246.;;Trygg, J., et al., “O2-PLS, a two-block (X-Y) latent variable regression (LVR) method with an integral OSC filter,” Journal of Chemometrics, 2003, vol. 17, pp. 53-64.;;Trygg, J., et al., “Orthogonal projections to latent structures (O-PLS),” Journal of Chemometrics, 2002, vol. 16, pp. 119-128.;;“Vapnik, V.N. (1995) The Nature of Statistical Leaming Theory. New York, NY: Springer.”.;;Waikar and Bonventre, “Can We Rely on Blood Urea Nitrogen as a Biomarker to Determine When to Initiate Dialysis?”, Clin. J. Am. Soc. Neprol., 2006, v. 1, pp. 903-906.;;Wang, et al., “Development and Validation of a Highly Sensitive Urine-Based Test to Identify Patients with Colonic Adenomatous Polyps” Clinical and Translational Gastroenterology (2014) vol. 5, e54, pp. 1-8.;;Wang, H., et al., “Metabolomics and detection of colorectal cancer in humans: a systematic review,” Future Oncology, 2010, vol. 6(9), pp. 1395-1406.;;Wang, H., et al., “The Role ofNMR Urine Metabolomics as a New Method for Screening Colorectal Cancer—A Preliminary Analysis,” Canadian Journal Gastroenterology, 2009, vol. 23(Supplement A):144, Canadian Digestive Diseases Week: Feb. 27-Mar. 2, 2009 in Banff, Alberta.;;Wang, W., et al., “Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry,” Mal. BioSyst., 2010, vol. 6, pp. 1947-1955.;;Want et al., “The Expanding Role of Mass Spectrometry in Metabolite Profiling and Characterization” ChemBioChem (2005) vol. 6, pp. 1941-195.;;Wenzel, “Ascorbic acid suppresses drug-induced apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions”, Carcinogenesis (2004) vol. 25, No. 5, pp. 703-712.;;WIPO Application No. PCT/CA2011/050315, International Preliminary Report on Patentability, dated Nov. 27, 2012.;;WIPO Application No. PCT/CA2011/050315, International Search Report, dated Aug. 22, 2011.;;WIPO Application No. PCT/CA2011/050315, Written Opinion of the International Searching Authority, dated Aug. 22, 2011.;;Wishart, D.S., “Is Cancer a Genetic Disease or a Metabolic Disease?” EBioMedicine (2015) vol. 2, pp. 478-479.;;Zweig, M.H., et al., “Receiver-Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine,” Clin. Chem., 1993, vol. 39(4), pp. 561-577.;;Rotter M, Brandmaier S, Prehn C, Adam J, Rabstein S, Gawrych K, et al. Stability of targeted metabolite profiles of urine samples under different storage conditions. Metabolomics 2017;13(1):4 doi 10.1007/s11306-016-1137-z.;;Laparre J, Kaabia Z, Mooney M, Buckley T, Sherry M, Le Bizec B, et al. Impact of storage conditions on the urinary metabolomics fingerprint. Analytica chimica acta 2017;951:99-107 doi 10.1016/j.aca.2016.11.055.;;Deng, L et al., “Clinical Validation of a Novel Urine-Based Metabolomic Test for the Detection of Colonic Polyps on Chinese Population” Int. J. Colorectal Disease (2017) vol. 32, pp. 741-743.;;Office Action dated Mar. 23, 2021 in connection with Canadian Application No. 3,065,979.;;Iwasaki et al., “Current status of urinary diagnostic biomarkers for colorectal cancer”, Clinica Chimica Acta., vol. 498, pp. 76-83, Aug. 14, 2019.;;Hiramatsu et al., “N1, N12-Diacetylspermine as a Sensitive and Specific Novel Marker for Early-and Late-Stage Colorectal and Breast Cancers”, Clin. Cancer Res., 11(8), pp. 2986-2990, Apr. 15, 2005.;;Huang et al., “Serum tryptophan decrease correlates with immune activiation”, British J. of Cancer, 86, pp. 1691-1692, 2002.;;Kuwata et al., “Increase of N-diacetylspermine in tissues from colorectal cancer and its liver metastasis1, N 12-diacetylspermine in tissues from colorectal cancer and its liver metastasis”, J. of Cancer Res. & Clin. Oncology, 139 (6), pp. 925-932, Jun. 2013.;;Rattray et al., “Environmental influences in the etiology of colorectal cancer: the premise of metabolomics”, Curr. Pharmacl, Rep., 3(3) pp. 114-125, Jun. 2017.;;International Search Report dated Oct. 11, 2018 in connection with PCT/CA2018/050421.;;Dec. 8, 2021 Office Action issued in connection with Canadian Application No. 3,065,979 (No References Cited).;;Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Oct. 19, 2018, 2018. Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer <https://gco.iarc.fr/tomorrow>. Oct. 19, 2018 The Wayback Machine≤https://web.archive.org/web/20181004142957/http://gco.iarc.fr/today/home.;;Cifuentes A. Foodomics: Advanced Mass Spectrometry in Modern Food Science and Nutrition. Wiley; 2013.;;“Trigonelline in Coffee”, Apr. 23, 2015: https://www.coffeechemistry.com/chemistry/alkaloids/trigonelline-incoffee?print= 1 &tmpl=component.;;Allred, et al., “Trigonelline Is a Novel Phytoestrogen in Coffee Beans1 ,2” the Journal of Nutrition Biochemical, Molecular and Genetic Mechanisms (2009) No. 139, pp. 1833-1838.;;Berode et al., “Urinary methanol and formic acid as indicators of occupation exposure to methyl formate”, Int. Arch. Occuup. Environ. Health, 2000, v. 73, pp. 410-414.;;Bond, “Colon Polyps and Cancer,” Endoscopy; 35 (1):27-35, (2003).;;Bouatra, S. et al., “The Human Urine Metabolome” Plos One (2013) vol. 8, Issue 9, e73076, p. 1-28.;;Chan et al. “Metabolic Profiling of Human Colorectal Cancer Using High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance (HR-MAS NMR) Spectroscopy and Gas Chromatography Mass Spectrometry (GC/MS)”, J. Proteom. Res., 2009, v.8, pp. 352-361.;;Claudino, W.M. et al., “Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications” Journal of Clinical Oncology (2007) vol. 25, pp. 2840-2846.;;Communication issued by the Australia Patent Office in Australian Application No. 2011256064 dated Feb. 26, 2016.;;Communication issued by the Australia Patent Office in Australian Application No. 2011256064 dated Jan. 29, 2015.;;Communication issued by the Australia Patent Office in Australian Application No. 2011256064 dated May 20, 2016.;;Communication issued by the Canada Patent Office in Canada Application No. 2799757 dated May 16, 2017.;;Communication issued by the Canada Patent Office in Canada Application No. 2799757 dated May 4, 2016.;;Communication issued by the Canada Patent Office in Canada Application No. 2799757 dated Nov. 30, 2017.;;Communication issued by the Canada Patent Office in Canada Application No. 2799757 dated Oct. 25, 2016.;;Communication issued by the European Patent Office in European Application No. 11782836.8 dated Apr. 29, 2015.;;Communication issued by the European Patent Office in European Application No. 11782836.8 dated Feb. 8, 2016.;;Communication issued by the European Patent Office in European Application No. 11782836.8 dated Jun. 17, 2014.;;Communication issued by the European Patent Office in European Application No. 11782836.8 dated Oct. 29, 2013.;;Communication issued by the European Patent Office in European Application No. 11782836.8 dated Oct. 6, 2016.;;Communication issued by the Japan Patent Office in Japanese Application No. 2013-510462 dated Jan. 13, 2015.;;Communication issued by the Japan Patent Office in Japanese Application No. 2013-510462 dated Sep. 15, 2015.;;Denkert, C., et al., “Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover,” Molecular Cancer, 2008, vol. 7, No. 1, pp. 1-15.;;Eisner, R. “A Machine-Learned Predictor of Colonic Polyps Based on Urinary Metabolomics” BioMed Research International, Hindawi Publishing Corporation (2013) Article ID 303982, pp. 1-11, 11 pages total.;;EPO Application No. EP 11782836.8 (Published as EP2572193), Supplementary European Search Report and European Search Opinion, dated Nov. 20, 2013.;;Eriksson, L., et al., “Multi- and Megavariate Data Analysis: Part II, Method Extensions and Advanced Applications,” Umetrics Academy, 2005, Chapter 23.;;Eriksson, L., et al., “Separating Y-predictive and Y-orthogonal variation in multi-block spectral data,” Journal of Chemometrics, 2006, vol. 20, pp. 352-361.;;Gabrielsson, J., et al., “The OPLS methodology for analysis of multi-block batch process data,” Journal of Chemometrics, 2006, vol. 20, pp. 362-369.;;Griner, P.F., et al., “Selection and interpretation of diagnostic tests and procedures,” Principles and applications, Ann. Intern. Med., 1981, vol. 94(4 Pt 2), pp. 557-592.;;Gurudu, S.R., et al., “Sessile serrated adenomas: Demographic, endoscopic and pathological characteristics,” World Journal of Gastroenterology, 2010, vol. 16(27), pp. 3402-3405.;;Guy et al., “Global Metabolic Profiling Analysis on Human Urine by UPLC-TOFMS: Issue and Method Validation in Nutritional Metabolomics” Journal of Chromatography B (2008) vol. 871, pp. 253-260.;;Hsu, W-Y., et al., “Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry,” Clinica ChimicaActa, 2009, vol. 402, pp. 31-37.;;Jass, J.R., “Hyperplastic-like Polyps as Precursors of Microsatellite-Unstable Colorectal Cancer,” American Journal of Clinical Pathology, 2003, vol. 119, pp. 773-775.;;Joanna Karpasea-Jones, “Your Cup of Coffee Could Protect You from Colon Cancer”: http://www.empowher.com/colorectal-cancer/content/your-cup-coffee-could-protect-you-colon-cancer; source: Texas Agrilife Communications Press Release, Kathleen Philips, Nov. 12, 2009.;;Johnson, J.C. et al., “Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia” Clinical Gastroenterology and Hepatology (2006) vol. 4, pp. 1358-1365.;;Levin et al., “Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology,” Gastroenterology, 134: 1570-1595, (2008).;;Ma, Y.-L., et al., “Ultra-High Performance Liquid Chromatography-Mass Spectrometry for the Metabolomic Analysis of Urine in Colorectal Cancer,” Dig. Dis. Sci., 2009, vol. 54, pp. 2655-2662.;;Muto et al., “The Evolution of Cancer of the Colon and Rectum,” Cancer, 36:2251-2270, (1975).;;Nambiar, P.R. et al., “An ‘omics’ based survey of human colon cancer” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis (2010) vol. 693, pp. 3-18.;;Noffsinger, A.E., “Serrated Polyps and Colorectal Cancer: New Pathway to Malignancy,” Annual Review of Pathology-Mechanisms of Disease, 2009, vol. 4, pp. 343-364.;;O'Brien, M.J., “Hyperplastic and Serrated Polyps of the Colorectum,” Gastroenterology Clinics of North America, 2007, vol. 36, pp. 947-968.;;Qiu, Y., et al., “Urinary Metabonomic Study of Colorectal Cancer,” Journal of Proteome Research, 2010, vol. 9, pp. 1627-1634.;;Sarosiek, I. et al., “Urinary Metabolites as Noninvasive Biomarkers of Gastrointestinal Diseases: A Clinical Review” World Journal of Gastrointestinal Oncology (2016) vol. 8, Issue 5, pp. 459-465.;;Slupsky, C.M., et al., “Pneumococcal Pneumonia: Potential for Diagnosis through a Urinary Metabolic Profile,” Journal of Proteome Research, 2009, vol. 8, No. 12, pp. 5550-5558.;;Spigelman, A.D. et al., “Caffeine Phenotyping of Cytochrome P4501A2, N-Acetyltransferase, and Xanthine Oxidase in Patients with Familial Adenomatous Polyposis” Gut (1995) vol. 36, pp. 251-254.;;Supporting Information for Qiu, Y. et al., “Urinary Metabonomic Study on Colorectal Cancer” Journal of Proteome Research (2010) vol. 9, pp. 1627-1637, 9 pages total.;;The Human Metabolome Database (HMDB), Metabocard for Ascorbic acid (HMDBOOO44). [Retrieved from the Internet Dec. 15, 2016: <http://www.hmdb.ca/metabolites/hmdb00044>].;;The Human Metabolome Database (HMDB) Metabocard for Trigonelline (HMDBOO875). [Retrieved from the Internet Dec. 15, 2016: <http://www.hmdb.ca/metabolites/HMDB00875>].;;Torlakovic, E., et al, “Morphologic Reappraisal of Serrated Colorectal Polyps,” American Journal of Surgical Pathology, 2003, vol. 27(1), pp. 65-81.;;Trygg, J., “O2-PLS for qualitative and quantitative analysis in multivariate calibration,” Journal of Chemometrics, 2002, vol. 16, pp. 283-293.;;Trygg, J., “Prediction and spectral profile estimation in multivariate calibration,” Journal of Chemometrics, 2004, vol. 18, pp. 166-172.;;Deng L. et al., “Urinary Metabolomics to Identify a Unique Biomarker Panel for Detecting Colorectal Cancer: a Multicenter Study” Cancer Epidemiol Biomarkers Prey, 28(8) Aug. 2019, pp. 1283-1291.;;Eriksson et al., 2013 Multi-and Megavariate Data Analysis, Basic Principles and Applications (vol. 1), Umetrics Academy, pp. 455-456.;;Aguilan et al., 2020, Molecular Omics, Guide for protein fold change and p-valve calculation for non-experts in proteonomics, 16(6):573-582.;;Fischer et al., Low-level maternal exposure to nicotine associates with significant metabolic pertubations in second-trimester amniotic fluid, Environ Int. 2017, 107:227-234 and supplement 7.;;Du et al., Serum Metabolomics Study of Papillary Thyroid Carcinoma Based on HPLC-Q-TOF-MS/MS, Frontiers in Cell and Developmental Biology, 2021, vol. 9, Article 593510.;;Margarin et al., Fetal Metabolomic Alterations Following Porcine Reproductive and Respiratory Syndrome Virus Infection, Frontiers in Molecular Biosciences, 2020, vol. 7, Article 559688.;;Juang et al., The Clinical Experiences of Urine Metabolomics of Genitourinary Urothelial Cancer in a Tertiary Hospital in Taiwan, Frontiers in Oncology, 2021, vol. 11, Article 680910.;;Gooding et al., LC-MS-based metabolomics analysis to identify meprin-β-associated changes in kidney tissue from mice with STZ-induced type 1 diabetes and diabetic kidney injury, Am J Physiol Renal Physiol, 2019, 317:F1034-F1046.;;Chiu et al., Metabolomics Reveals Dynamic Metabolic Changes Associated with Age in Early Childhood, PLOS ONE, 2016, 1-14; DOI:10.1371/journal.pone.0149823.",ACTIVE
313,EP,A1,EP 4154296 A1,061-387-493-862-831,2023-03-29,2023,EP 21729005 A,2021-05-21,US 202063029226 P;;IB 2021054403 W,2020-05-22,SIMPLIFICATION OF METHOD OR SYSTEM USING SCOUT MRM,,DH TECHNOLOGIES DEV PTE LTD,COX DAVID;;LIU CHANG,,https://lens.org/061-387-493-862-831,Patent Application,yes,0,0,5,5,0,H01J49/0031;;H01J49/004;;H01J49/0454;;H01J49/0404;;H01J49/0081;;H01J49/0404;;H01J49/0454;;H01J49/164,H01J49/00;;H01J49/04,,0,0,,,,PENDING
314,CA,A1,CA 2398197 A1,058-118-593-574-438,2000-08-10,2000,CA 2398197 A,2000-02-02,US 11824499 P;;US 49567500 A;;US 0002628 W,1999-02-02,DELIVERY SYSTEM AND METHODS FOR GENE THERAPY,"According to the present invention, there is provided a gene therapy materia l which includes a nucleic acid material and a carbohydrate wherein the carbohydrate preferably is a modified pectin. Also in accordance with the present invention, there is provided a gene therapy material including a nucleic acid material, a carbohydrate material associated with the nucleic acid material, and a protective coating disposed about the carbohydrate material. Also in accordance with the present invention, there is provided a method for treating a tumor of the type which has carbohydrate binding sites expressed on the surface thereof by providing a therapeutic material, incorporating the therapeutic material into a body of a modified pectin material so as to produce a therapeutic composition, and administering the therapeutic composition to a patient.",SAFESCIENCE INC,CHANG YAN;;PLATT DAVID,,https://lens.org/058-118-593-574-438,Patent Application,no,0,0,5,8,0,A61K38/45;;A61K48/00;;A61K48/00;;A61K38/45,A61K38/45;;A61K48/00,,0,0,,,,DISCONTINUED
315,AU,A1,AU 2011/369300 A1,064-909-319-260-629,2013-05-02,2013,AU 2011/369300 A,2011-05-27,CN 2011000905 W,2011-05-27,Liquid soaps with triclocarban,"An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount that is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.",COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/064-909-319-260-629,Patent Application,no,0,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/00;;C11D9/02;;C11D9/30;;C11D9/50,,0,0,,,,INACTIVE
316,EP,A1,EP 0553691 A1,070-773-343-320-975,1993-08-04,1993,EP 93100746 A,1993-01-19,US 82394292 A,1992-01-22,Passive shield for CVD wafer processing which prevents frontside edge and backside deposition.,"An apparatus for CVD processing is described wherein a wafer (10) mounted on a vertically movable workpiece support means (40) beneath a gas outlet or showerhead is raised into contact with a shield ring (100) which normally rests on a ring support in a chamber of the apparatus. The shield ring (100) engages the frontside edge of the wafer (10), lifting the shield ring (100) off its support, when the support means (40) and the wafer (10) are raised to a deposition position in the chamber. The shield ring (100) by engaging the frontside edge of the wafer (10), shields the edge of the top surface of the wafer, as well as the end edge and the backside of the wafer, during the deposition. Matching tapered edges, respectively on the support means (40) and the shield ring (100) permit alignment of the shield ring (100) with respect to the support means (40) and alignment of the wafer (10) to the support means (40) and the shield ring (100). Alignment means are also disclosed to circularly align the shield ring (100) to its support in the chamber. Multi-unit shield rings (102, 104, 105) permit the use of wider shield rings and prevent cracking of the shield ring due to thermal stresses caused by temperature differences near and away from the wafer (10) during processing. These shield rings (102, 104, 105) may also have tapered edges (106, 108) to ensure alignment of the rings with respect to each other.",APPLIED MATERIALS INC,CHENG DAVID;;CHANG MEI,,https://lens.org/070-773-343-320-975,Patent Application,yes,4,20,7,7,0,C23C16/04;;C23C16/042;;C23C16/45521;;C23C16/4585;;H01L21/283;;C23C16/45521;;C23C16/04;;C23C16/4585;;C23C16/042,C23C14/50;;C23C16/00;;C23C16/04;;C23C16/44;;C23C16/455;;C23C16/458;;H01L21/205;;H01L21/302;;H01L21/3065,,0,0,,,,DISCONTINUED
317,CN,A,CN 115668439 A,078-391-793-366-804,2023-01-31,2023,CN 202180037079 A,2021-05-21,US 202063029226 P;;IB 2021054403 W,2020-05-22,Simplification of methods or systems using reconnaissance MRM,"Each sample of a series of samples is ejected at an ejection time and according to a sample sequence. Each ejected sample in the series is ionized, thereby producing an ion beam. A list of different sets of MRM transitions is received. Each set in the list corresponds to a different sample. A group of one or more different sets is selected from the list. Initially, each set selected for the set corresponds to a different sample of the first sample or the first several samples of the series. The mass spectrometer is instructed to perform each transition in each set of the group on the ion beam until a transition in a set of the group is detected, after which one or more subsequent sets to be monitored are selected from the list using the set of detected transitions and the sample order.",DH TECHNOLOGIES DEV PTE LTD,COX DAVID;;LIU CHANG,,https://lens.org/078-391-793-366-804,Patent Application,no,0,0,5,5,0,H01J49/0031;;H01J49/004;;H01J49/0454;;H01J49/0404;;H01J49/0081;;H01J49/0404;;H01J49/0454;;H01J49/164,H01J49/00;;H01J49/04,,0,0,,,,PENDING
318,CO,A2,CO 6801775 A2,095-681-800-948-637,2013-11-29,2013,CO 13268125 A,2013-11-14,CO 13268125 A,2013-11-14,Jabones líquidos con triclocarbán,,COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/095-681-800-948-637,Patent Application,no,0,0,1,1,0,,C11D17/08,,0,0,,,,DISCONTINUED
319,AU,B2,AU 764289 B2,104-237-344-355-11X,2003-08-14,2003,AU 2001/065534 A,2001-08-29,TW 89216064 U,2000-09-18,Shoe with a pivotal counter portion,,CHANG DAVID,CHANG DAVID;;LAIO YUI,,https://lens.org/104-237-344-355-11X,Granted Patent,no,3,1,8,8,0,A43B3/242;;A43B3/242;;A43B3/24;;A43B3/24;;A43B11/00;;A43B11/00;;A43B23/088;;A43B23/088;;A43C11/00;;A43C11/00;;A43C11/008;;A43C11/008;;A43C11/08;;A43C11/08,A43B3/24;;A43B23/02;;A43C11/00;;A43C11/08,,0,0,,,,EXPIRED
320,US,A1,US 2016/0373399 A1,142-126-455-590-872,2016-12-22,2016,US 201615257171 A,2016-09-06,US 201615257171 A;;US 201514966574 A;;US 201414339536 A;;US 201113185485 A,2011-07-18,METHOD AND APPARATUS FOR SOCIAL NETWORK COMMUNICATION OVER A MEDIA NETWORK,"A system that transmits a request to initiate a communication session with a member device of a social network may include, for example, activating a speech capture element, maintaining activation of the speech capture element in accordance with a pattern of prior speech messages, detecting a speech message at the activated speech capture element, and transmitting the detected speech message, or a derivative thereof, to the member device of the social network. Other embodiments are disclosed.",AT & T IP I LP,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I L.P (2011-07-15),https://lens.org/142-126-455-590-872,Patent Application,yes,12,1,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,G10L15/22;;H04L12/58;;G10L25/87,,0,0,,,,INACTIVE
321,WO,A1,WO 1987/003689 A1,137-336-260-698-933,1987-06-18,1987,US 8602554 W,1986-11-26,US 80675585 A,1985-12-09,HYBRIDOMA'S TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/137-336-260-698-933,Patent Application,yes,2,7,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;G01N33/53;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,C3H HF5A          HF5A;;C3H H810          HF5A;;C6F FHA2          FHA2;;C6F F10X          FHA2,1,1,162-289-052-834-539,6605995,"THE JOURNAL OF IMMUNOLOGY, Volume 131, No. 6, issued December 1983, (San Diego, California), LOPEZ et al., ""Activation of Granulocyte Cytotoxic Function by Purified Mouse Colony-Stimulating Factor"", pp. 2983-2988.",PATENTED
322,PT,A,PT 83892 A,006-310-800-651-373,1987-01-01,1987,PT 8389286 A,1986-12-09,US 80675585 A,1985-12-09,HYBRIDOMA CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR BACKGROUND OF THE INVENTION,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/006-310-800-651-373,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;G01N33/53;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
323,WO,A1,WO 2023/012724 A1,000-166-734-143-263,2023-02-09,2023,IB 2022057271 W,2022-08-04,US 202163230336 P,2021-08-06,CHROMATOGRAPHIC-LIKE SEPARATION USING SAMPLE DROPLET EJECTION,"Disclosed are methods for separating target and non-target analytes in a sample. The methods can utilize an acoustic droplet ejector (ADE) and an open port interface (OPI) to achieve liquid chromatography (LC)-like separation for an analytical instrument such as, for example, a mass spectrometer.",DH TECHNOLOGIES DEV PTE LTD,COX DAVID;;LIU CHANG,,https://lens.org/000-166-734-143-263,Patent Application,yes,6,0,1,1,0,H01J49/0454;;G01N30/724;;G01N30/06;;G01N30/72,G01N30/06;;G01N30/72,,2,2,004-962-956-173-874;;035-173-945-292-352,10.1016/j.trac.2005.07.007;;10.1002/rcm.1020;;12720286,"MANISALI I ET AL: ""Electrospray ionization source geometry for mass spectrometry: past, present, and future"", TRAC TRENDS IN ANALYTICAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 25, no. 3, 1 March 2006 (2006-03-01), pages 243 - 256, XP027892004, ISSN: 0165-9936, [retrieved on 20060301];;JAMES W. HAGERJ. C. YVES LE BLANC: ""Product ion scanning using a Q-q-Qiinear ion trap (Q TRAP@) mass spectrometer"", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 17, 2003, pages 1056 - 1064",PENDING
324,WO,A1,WO 2008/088792 A1,026-308-767-731-496,2008-07-24,2008,US 2008/0000495 W,2008-01-15,US 88081207 P;;US 88081307 P;;US 88088307 P;;US 88088707 P;;US 2008/0000495 W,2007-01-17,LIGHT SOURCE AND FIBER OPTIC BRUSH FOR LIGHT DELIVERY,"A phototherapy apparatus is disclosed including, a handpiece including a body member and a grip; a plurality of elongated light transmitting elements, each of the elements extending between a proximal end enclosed within the body member and a distal end located outside of and distal to the body member; an ultraviolet light source; a light collection element; and one or more optical coupling elements. The one or more optical coupling elements are configured to direct at least a portion of the collected light to the proximal ends of the light transmitting elements to couple at least portion of the collected light into the light transmitting elements. The light coupled into each of the light transmitting elements is transmitted along the element and emitted from the distal end.",LERNER MEDICAL DEVICES INC;;GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/026-308-767-731-496,Patent Application,yes,6,15,4,18,0,A61N5/0616;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N2005/0654;;A61N2005/0661;;A61N5/0617;;A61N2005/0661;;A61N2005/0644;;A61N2005/063;;A61N2005/0654;;A61N5/0616,A61B5/06,,0,0,,,,PENDING
325,US,A1,US 2014/0057824 A1,034-066-760-562-619,2014-02-27,2014,US 201114114294 A,2011-05-27,CN 2011000905 W,2011-05-27,Liquid Soaps with Triclocarban,"An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount Othat is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.",SHI MANYING;;CHANG DAVID;;COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,COLGATE-PALMOLIVE COMPANY (2011-05-27),https://lens.org/034-066-760-562-619,Patent Application,yes,0,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D9/32;;C11D9/30,510/383,0,0,,,,ACTIVE
326,AU,B2,AU 2007/284079 B2,058-665-201-070-568,2012-04-12,2012,AU 2007/284079 A,2007-08-16,AU 2006/904478 A;;AU 2006/906441 A;;AU 2007/001164 W;;AU 2007/284079 A,2006-08-17,A door strike,"A door strike including: a latch retainer for retaining a door latch; a lock actuator which operates when power is applied; a mode selector rotatable between at least two positions; in a first position of the mode selector the strike adopts a power to open mode, in the second position of the mode selector the strike adopts a power to lock mode.",ALLEGION AUSTRALIA PTY LTD,CHANG DAVID;;MACKLE TREVOR,ALLEGION (AUSTRALIA) PTY LTD (2020-05-14);;FIRE & SECURITY HARDWARE PTY LTD (2009-04-02),https://lens.org/058-665-201-070-568,Granted Patent,no,9,0,9,9,0,E05B47/0047;;E05B63/0065;;E05B2047/0073;;E05B2047/0076;;Y10T292/699;;Y10T292/699;;E05B47/0047;;E05B2047/0076;;E05B2047/0073;;E05B63/0065,E05B47/00;;E05B15/02,,0,0,,,,ACTIVE
327,FR,A1,FR 2404055 A1,063-274-097-981-005,1979-04-20,1979,FR 7818671 A,1978-06-22,US 83554377 A,1977-09-22,PIECE METALLIQUE COMPORTANT UN REVETEMENT AMELIOREE CONTRE LA CORROSION ET L'OXYDATION A CHAUD,"<P>Pièce en superalliage comportant un revêtement progressif. Elle comprend un substrat en un superalliage un revêtement progressif constitué par : 1. Une partie intérieure du revêtement adjacent au substrat et ayant diffusé avec lui et comprenant essentiellement de l'Al, du Cr et au moins un élément choisi dans le groupe constitué par Fe, Co et Ni le reste étant constitué par les éléments qui ont diffusé depuis le substrat et la partie extérieure du revêtement, et 2. une partie extérieure du revêtement adjacent à la partie intérieure du revêtement et ayant diffusé avec elle, et comprenant de 5 à 50 % en poids d'éléments choisis dans le groupe constitué par Hf, Pt, Rh et Pd, le reste étant constitué par les éléments ayant diffusé depuis la partie intérieure du revêtement. </P><P>Application aux pièces de moteurs à turbine à gaz.</P>",GEN ELECTRIC,CHANG DAVID RONG HWAN,,https://lens.org/063-274-097-981-005,Patent Application,no,4,0,11,11,0,C23C28/021;;C23C28/023;;C23C28/028;;F01D5/288;;F01D25/007;;Y10T428/12458;;Y10T428/12875;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;Y10T428/12458;;Y10T428/12875;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;F01D25/007;;C23C28/028;;C23C28/021;;F01D5/288;;C23C28/023,C23C10/28;;C23C10/52;;C23C10/54;;C23C10/56;;C23C28/02;;F01D5/28;;F01D25/00;;C23C10/26,,0,0,,,,EXPIRED
328,US,A1,US 2020/0116074 A1,068-193-691-962-197,2020-04-16,2020,US 201816157793 A,2018-10-11,US 201816157793 A,2018-10-11,PRE-CHAMBER IGNITION SYSTEM HAVING IGNITER WITH GAS ORIFICE STRUCTURED FOR PRE-EXPANDING OUTGOING COMBUSTION GASES,"An ignition system for a gaseous fuel engine includes an igniter and an actuator structured to apply an actuating force to a piston within the igniter, to autoignite an ignition charge of fuel and air within the igniter. A housing of the igniter includes a gas orifice having a flow area that is increased between a combustion pre-chamber in the igniter and a main combustion chamber in the engine, to limit velocity of outgoing combustion gases to below a threshold velocity for engine mis-fire.",CATERPILLAR INC,CHANG DAVID YU ZHANG,CATERPILLAR INC (2018-10-10),https://lens.org/068-193-691-962-197,Patent Application,yes,0,2,2,2,0,F02B19/108;;F02B19/18;;F02B19/06;;F02B19/108;;F02B19/14;;Y02T10/12,F02B19/10,,0,0,,,,ACTIVE
329,US,A,US 4918838 A,160-225-265-264-028,1990-04-24,1990,US 22845888 A,1988-08-05,GB 8818349 A,1988-08-02,Shoe sole having compressible shock absorbers,"This is a sole with compressible shock absorbers which not only provides an improved shock absorbing function but also provides more comfort for the wearer. The shock absorbers consist of a polygonal replaceable air bellows placed in a polygonal recess on the forefoot section of the shoe and a cylindrical replaceable air cylinder placed in a circular recess on the heel section of the shoe. The air cylinder and air bellows are made of an integrally resilient air-tight material such that, during exercise, the shock absorbers absorb and then return the energy in a controlled upward direction, by way of the bellows-type body and the friction caused between the inside wall of the recess and the bellows itself. Moreover, since the shock absorbers can be placed easily by hand, the wearer can adjust the shoes in line with his weight and type of sport performed. The uses of the shoe are therefore maximized because the air cylinder and air bellows will continue to function even after the outer sole has experienced considerable wear and tear.",FAR EAST ATHLETICS LTD,CHANG DAVID J H,FAR EAST ATHLETICS LTD. 7F-12 25 PO AI ROAD TAIPEI TAIWAN R.O.C (1988-05-20);;HI-TEC SPORTS PLC A PUBLIC LIMITED COMPANY OF GREAT BRITAIN (1990-07-24),https://lens.org/160-225-265-264-028,Granted Patent,yes,5,174,3,3,0,A43B1/0018;;A43B13/20;;A43B21/28;;A43B13/188;;A43B13/203;;A43B1/0018;;A43B13/20;;A43B21/28,A43B13/20;;A43B21/28,36/28;;36/29,0,0,,,,EXPIRED
330,US,A1,US 2015/0162914 A1,173-037-915-715-614,2015-06-11,2015,US 201514626445 A,2015-02-19,US 201514626445 A;;US 201313849115 A;;US 201361757947 P,2013-01-29,Resonant Inductor Coupling Clock Distribution,The present disclosure provides for a clock distribution network for distributing clocking signals within a synchronous sequential logic circuit. The clock distribution network distributes the one or more clock signals by inductively and/or capacitively coupling a clocking signal from a primary distribution node to various secondary distribution nodes within the synchronous sequential logic circuit. The various secondary distribution nodes resonate at respective resonant frequencies to generate other clocking signals for use within the synchronous sequential logic circuit in response to receiving the clocking signal.,BROADCOM CORP,CHANG DAVID;;HUKKOO AJAT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2013-03-21),https://lens.org/173-037-915-715-614,Patent Application,yes,0,0,8,16,0,G06F1/10;;G06F1/10;;H03K19/096;;H03K19/096;;H01F38/14;;H02J50/05;;H02J50/10,H03K19/096;;H01F38/14;;H02J5/00,,0,0,,,,INACTIVE
331,TW,A,TW 202045634 A,176-587-397-093-418,2020-12-16,2020,TW 108118910 A,2019-05-31,TW 108118910 A,2019-05-31,Ink compositions,"An ink composition is provided. The ink composition includes acrylic resin having 10-50 parts by weight, a block copolymer having formula (I) and 1-5 parts by weight, epoxy resin having 0-20 parts by weight, and white toner having 5-50 parts by weight, based on 100 parts by weight of the ink composition.",GELIE CO LTD,HO CHANG-DAR DAVID,,https://lens.org/176-587-397-093-418,Patent of Addition,no,0,0,1,1,0,,C09D11/10;;C09D5/33;;C09D7/40;;C09D11/037;;C09D133/04;;C09D153/00;;C09D163/00;;H01L33/46,,0,0,,,,PENDING
332,WO,A2,WO 2008/088795 A2,194-783-289-550-459,2008-07-24,2008,US 2008/0000499 W,2008-01-15,US 88088307 P;;US 88081207 P;;US 88081307 P;;US 88088707 P;;US 2008/0000499 W,2007-01-17,FIBER OPTIC BRUSH FOR LIGHT DELIVERY,"A phototherapy apparatus is disclosed including: a body member; a plurality of elongated light transmitting elements, each of the elements extending between a proximal end enclosed within the body member and a distal end located outside of and distal to the body member; where the tips of the proximal ends of the light transmitting elements are located in close proximity to each other; and an optical connector configured to detachably receive an end of a lightguide and to couple light delivered by the lightguide from a source into the light transmitting elements at the proximal ends. The light coupled into each of the light transmitting elements is transmitted along the element and emitted from the distal end.",LERNER MEDICAL DEVICES INC;;GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/194-783-289-550-459,Patent Application,yes,0,11,4,18,0,A61N5/0616;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N2005/0661;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N5/0616;;A61N2005/0661,A61B18/18,,0,0,,,,PENDING
333,ZA,B,ZA 201307931 B,018-025-530-751-253,2019-07-31,2019,ZA 201307931 A,2013-10-23,CN 2011000905 W,2011-05-27,LIQUID SOAPS WITH TRICLOCARBAN,,COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/018-025-530-751-253,Granted Patent,no,0,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,,,0,0,,,,ACTIVE
334,TW,S,TW D170696 S,024-770-688-463-566,2015-09-21,2015,TW 103306964 F,2014-11-27,US 201429495041 F,2014-06-26,DIETARY SUPPLEMENT,【物品用途】;本設計物品，係提供營養補充保健用之膳食補充錠。;【設計說明】;本設計之特點在於膳食補充錠整體呈扁圓形錠狀，該補充錠視覺正面具有向下凹陷之葉片造型。該造型葉片沿著葉柄處向外並朝上順勢擴展，連續彎延形成一掌狀深裂葉狀(配合參考前視圖)。本案利用造形柔美的葉片妝點，構成整體外觀具特異視覺效果之膳食補充錠，其整體造型簡約利落中又富涵變化巧思，實為一獨到之設計。;後視圖為普通消費者於選購或使用時不會注意之視面，故省略之。,通路實業集團國際公司;;ACCESS BUSINESS GROUP INT LLC,CHANG DAVID;;HEISLER DANIEL,,https://lens.org/024-770-688-463-566,Design Right,no,0,0,2,2,0,,,28-01,0,0,,,,ACTIVE
335,WO,A1,WO 2021/234646 A1,056-352-302-774-871,2021-11-25,2021,IB 2021054403 W,2021-05-21,US 202063029226 P,2020-05-22,SIMPLIFICATION OF METHOD OR SYSTEM USING SCOUT MRM,"Each sample of a series of samples is ejected at an ejection time and according to a sample order. Each ejected sample of the series is ionized, producing ion beam. A list of different sets of MRM transitions is received. Each set of the list corresponds to a different sample. A group of one or more different sets is selected from the list. Initially, each set selected for the group corresponds to a different sample of one or more first samples of the series. A mass spectrometer is instructed to execute each transition of each set of the group on the ion beam until a transition of a set of the group is detected, upon which, one or more next sets are selected from the list to be monitored using the set of the detected transition and the sample order.",DH TECHNOLOGIES DEV PTE LTD,COX DAVID;;LIU CHANG,,https://lens.org/056-352-302-774-871,Patent Application,yes,6,0,5,5,0,H01J49/0031;;H01J49/004;;H01J49/0454;;H01J49/0404;;H01J49/0081;;H01J49/0404;;H01J49/0454;;H01J49/164,H01J49/00;;H01J49/04,,2,2,030-074-239-250-950;;035-173-945-292-352,10.1177/2211068215619124;;26721821;;10.1002/rcm.1020;;12720286,"SINCLAIR ET AL., JOURNAL OF LABORATORY AUTOMATION, vol. 21, no. 1, 2016, pages 19 - 26;;JAMES W. HAGERJ. C. YVES LE BLANC: ""Product ion scanning using a Q-q-Q linear ion trap (Q TRAP) mass spectrometer"", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 17, 2003, pages 1056 - 1064, XP055199582, DOI: 10.1002/rcm.1020",PENDING
336,US,S,US D0847536 S,070-349-585-055-075,2019-05-07,2019,US 201629582578 F,2016-10-28,US 201629582578 F,2016-10-28,Mat,,VARIDESK LLC,PATTON DAVID;;CHANG COCO,VARIDESK LLC (2016-11-02),https://lens.org/070-349-585-055-075,Design Right,no,120,14,1,1,0,,,0611;;D 6582,8,0,,,"Matheson, “How Anti-Fatigue Mats Reduce Fatigue,” which was published on the Internet and believed to have been available since at least Jun. 17, 2013, and was retrieved from the Internet on Dec. 21, 2016; URL:<https://web.archive.org/web/20130617040513/http://www.mathesongas.com/industrialgas/pdfs/safety/matting.pdf>, 13 pages.;;36 Beads foot massage pad ball massage pad foot massage device, accessed Jun. 15, 2016, http://www.aliexpress.com/item/36-beads-foot-massage-pad-ball-massage-pad-foot-mat-foot-massage-device-massage-carpet-mat/32650133815.html., pp. 1/18-6/18.;;Bathroom Advice on pressure pad Multi-function Mats Point massage cushion The foot pad Non-slip mat, accessed Jun. 15, 2016, http://www.aliexpress.com/item/Bathroom-Advice-on-pressure-mad-Multi-function-Mats-Point-massage-cushion-The-foot-pad-Non-slip/1147009316.html., pp. 1/20-20/20.;;Ergodriven, “Infinite Positions on Topo: The Not-Flat Standing Desk Anti-Fatigue Mat,” https://www.youtube.com/watch?v=R8OACVDwwoE, allegedly published on Jan. 15, 2015 (last accessed Nov. 10, 2016), pp. 1-2.;;International Search Report and Written Opinion issued in International Application No. PCT/US2017/058747, dated Jan. 16, 2018.;;The Original ¾″ Gorilla Grip Anti-Fatique Comfort Mat. Amazon.com. Aug. 15, 2016. <https://www.amazon.com/dp/B01H6AEHC8?psc=1>. Accessed Aug. 11, 2017.;;Dffice Action dated Jan. 11, 2018 in Design U.S. Appl. No. 29/582,580. [Provided in IFW].;;Notice of Allowance issued in U.S. Appl. No. 29/582,580, dated May 17, 2018 [Available in IFW].",ACTIVE
337,EP,A1,EP 0033725 A1,111-659-051-204-733,1981-08-19,1981,EP 79901288 A,1981-02-09,US 7900540 W,1979-07-26,CLEAR COAT/COLOR COAT FINISH CONTAINING AN ULTRAVIOLET LIGHT STABILIZER.,"Un substrat est revetu d'une couche de finition consistant en un revetement transparent qui adhere fermement a une couche de revetement colore qui elle-meme adhere au substrat. Le revetement transparent consiste essentiellement en un liant formant un film transparent; le revetement colore consiste essentiellement en un liant formant un film ainsi qu'en pigments; le revetement colore contient un element stabilisateur vis-a-vis des ultra-violets et, eventuellement le revetement transparent ainsi que le revetement colore contiennent un antioxidant ainsi qu'un element stabilisateur vis-a-vis des ultra-violets. Cette couche de finition presente un apparence, une resistance aux intemperies et une duree de vie excellentes et s'avere particulierement utile en tant que couche de finition pour les automobiles et les camions.",DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/111-659-051-204-733,Patent Application,yes,0,0,2,2,0,B05D7/532;;B05D2201/00;;B05D2202/00,B05D7/02;;B05D7/16;;B05D7/26,,1,0,,,See references of WO 8100233A1,DISCONTINUED
338,US,A1,US 2015/0021995 A1,126-464-999-390-096,2015-01-22,2015,US 201414271213 A,2014-05-06,US 201414271213 A;;US 201213609032 A;;US 97469907 A,2007-10-15,DYNAMIC PORT POWER ALLOCATION APPARATUS AND METHODS,"Methods and apparatus for dynamically adjusting the amount of power (or current) distributed to one or more connected devices via electrical interfaces. In one embodiment, the apparatus comprises a first module adapted to detect current drawn by a first set of ports, and a second module adapted to adjust the current provided to a second set of ports based on the detected current. The second module is also optionally adapted to distribute unreserved current among the devices according to an allocation protocol. In the exemplary context of a plurality of interconnected serial bus devices, the invention enables a device to draw more current than that required to be reserved for that device (such as to comply with a specification such as USB), yet without increasing the total amount of power which must be dedicated to the serial ports as a whole. Power supply efficiency may also be advantageously optimized.",APPLE INC,CHANG RAY;;FERGUSON DAVID,,https://lens.org/126-464-999-390-096,Patent Application,yes,4,10,5,5,0,G06F1/266;;G06F1/266;;H02J7/00,H02J7/00,307/31;;320/162,0,0,,,,DISCONTINUED
339,US,A1,US 2002/0095823 A1,129-448-460-251-956,2002-07-25,2002,US 89938801 A,2001-07-05,TW 89216064 U,2000-09-18,Shoe with a pivotal counter portion,"
   A shoe has a sole, an upper and a counter portion. The upper is securely connected to the sole and has a rear end defined with an opening. The counter portion is pivotally connected to a rear end of the sole to close the opening in the upper. A fastener is mounted on the upper and the pivotal counter portion to connect the pivotal counter portion to the rear end of the upper. Accordingly, a wearer's foot in the shoe can be vented. Also, for a pair of tied shoes with the pivotal counter portions can be put on or taken off without tying or untying the laces. The use of the shoe becomes more versatile and more convenient. 
",LAIO YUI;;CHANG DAVID,LAIO YUI;;CHANG DAVID,CHANG DAVID (2001-06-29),https://lens.org/129-448-460-251-956,Patent Application,yes,0,45,8,8,0,A43B3/242;;A43B3/242;;A43B3/24;;A43B3/24;;A43B11/00;;A43B11/00;;A43B23/088;;A43B23/088;;A43C11/00;;A43C11/00;;A43C11/008;;A43C11/008;;A43C11/08;;A43C11/08,A43B3/24;;A43B23/02;;A43C11/00;;A43C11/08,36/138;;36/105,0,0,,,,EXPIRED
340,BR,A2,BR 112013027986 A2,131-127-957-765-738,2019-09-24,2019,BR 112013027986 A,2011-05-27,CN 2011000905 W,2011-05-27,sabões líquidos com triclocarban,,COLGATE PALMOLIVE CO,DAVID CHANG;;MANYING SHI,,https://lens.org/131-127-957-765-738,Patent Application,no,0,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D9/30;;C11D9/00;;C11D9/02;;C11D9/50;;C11D17/08,,0,0,,,,DISCONTINUED
341,EP,A1,EP 2104450 A1,137-252-373-469-709,2009-09-30,2009,EP 08724515 A,2008-01-15,US 2008/0000495 W;;US 88081207 P;;US 88081307 P;;US 88088307 P;;US 88088707 P,2007-01-17,LIGHT SOURCE AND FIBER OPTIC BRUSH FOR LIGHT DELIVERY,,LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/137-252-373-469-709,Patent Application,yes,0,0,4,18,0,A61N5/0616;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N2005/0654;;A61N2005/0661;;A61N5/0617;;A61N2005/0661;;A61N2005/0644;;A61N2005/063;;A61N2005/0654;;A61N5/0616,A61B5/06,,0,0,,,,DISCONTINUED
342,US,B2,US 9172383 B2,184-774-180-264-312,2015-10-27,2015,US 201314027079 A,2013-09-13,US 201314027079 A;;US 201361757947 P;;US 201361804595 P;;US 201313849115 A,2013-01-29,Induction-coupled clock distribution for an integrated circuit,"An integrated circuit package including an induction-coupled clock distribution system is disclosed. An exemplary embodiment of the disclosure includes a transmission module coupled to a main clock line, a clock reception module coupled to the transmission module, the clock reception module including a clock output line, and an electronic circuit coupled to the clock output line of the clock reception module, the electronic circuit including at least one clocked element and configured to operate synchronously with a clocking signal received through the clock output line of the clock reception module. The transmission module may be disposed on the supporting case of the IC package, and the electronic circuit and the clock reception module may be disposed on the semiconductor die of the IC package.",BROADCOM CORP,CHANG DAVID;;HUKKOO AJAT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2013-12-11),https://lens.org/184-774-180-264-312,Granted Patent,yes,9,1,4,16,0,G06F1/10;;G06F1/10;;H03L7/06,H01L23/02;;G06F1/10;;H03L7/06,,0,0,,,,ACTIVE
343,EP,A1,EP 0029595 A1,003-743-687-552-596,1981-06-03,1981,EP 80107269 A,1980-11-21,US 9628279 A;;US 14626380 A,1979-11-21,"An improved high solids coating composition of a low molecular weight glycidyl acrylic polymer and an alkylated melamine cross-linking agent, and a substrate coated therewith.","The improved high solids coating composition contains at least 50% by weight of a binder of film-forming constituents in which the constituents are of
 (A) an acrylic polymer that has a number average molecular weight of about 500-10,000, and is of
 glycidyl methacrylate, an alkyl methacrylate, and optionally an alkyl acrylate, a hydroxyalkyl methacrylate, a hydroxyalkyl acrylate or styrene; (B) an alkylated melamine formaldehyde cross-linking agent; the improvement used with this composition is the addition of select ultraviolet light stabilizers and optionally, antioxidants. The composition is particularly useful for clear coat/color coat exterior finishes for automobiles, trucks and airplanes.",DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/003-743-687-552-596,Patent Application,yes,3,18,5,6,0,C09D133/068;;C08L61/20;;C09D133/14,C08L61/20;;C09D133/06;;C09D133/14,,1,0,,,"CHEMICAL ABSTRACTS, Vol. 81, No. 24, December 16, 1974, page 133, Ref. 154 716x Columbus, Ohio (US) & JP - A - 74 55 737 (DAINIPPON PRINTING CO. LTD.) (May 30, 1974) * The whole Abstract *",DISCONTINUED
344,US,A1,US 2021/0404422 A1,020-458-233-031-239,2021-12-30,2021,US 202016912300 A,2020-06-25,US 202016912300 A,2020-06-25,GASEOUS FUEL MIXER ASSEMBLY FOR ENGINE AND ENGINE SYSTEM OPERATING METHOD,"A gaseous fuel mixer assembly for an engine includes a mixer housing forming gas delivery openings, and positioned to extend across a flow path formed by an intake conduit for the engine. A spool valve is within a central bore in the mixer housing and includes gas distribution openings selectively connectable to the gas delivery openings by moving the spool valve within the mixer housing using a piezoelectric actuator coupled with the spool valve by way of a pivot arm. Sealing lands of the spool valve are in an alternating arrangement with the gas distribution openings, such that at the closed position the sealing lands block the gas distribution openings from the gas delivery openings, and at the open position the respective openings are fluidly connected.",CATERPILLAR INC,CHANG DAVID YU ZHANG,,https://lens.org/020-458-233-031-239,Patent Application,yes,0,0,2,2,0,F02M21/0209;;F02M21/0254;;F02M21/0278;;F02M21/04;;F02M21/0215;;F02M21/042;;B01F23/10;;B01F25/31331;;B01F35/718051;;Y02T10/30;;F02M21/04;;F02M35/10262;;F02M21/0254;;F02M21/0209;;F02M21/0278;;B01F23/191;;B01F25/1051;;B01F25/3142,F02M21/04;;F02M21/02;;F02M35/10,,0,0,,,,ACTIVE
345,EP,A1,EP 0029598 A1,047-672-650-113-814,1981-06-03,1981,EP 80107272 A,1980-11-21,US 9628379 A;;US 14626580 A,1979-11-21,"An improved high solids coating composition of a low molecular weight acrylic polymer and a polyisocyanate cross-linking agent, and a substrate coated therewith.","An improved high solids coating composition that contains at least 50% by weight of a binder of film-forming constituents in which the constituents are of
 (A) an acrylic polymer that has a number average molecular weight of about 500-10,000, a hydroxyl content of at least 2% by weight and contains about 2-10% by weight of a chain transfer agent, and consists essentially of
 an alkyl methacrylate, a hydroxyalkyl acrylate, ora hydroxyalkyl methacrylate; and optionally, an alkyl acrylate or styrene and (B) an organic polyisocyanate cross-linking agent; the improvement used with this composition is the addition of select ultraviolet light stabilizers and optionally, antioxidants. The composition is particularly useful for clear coat/color coat exterior finishes for automobiles, trucks and airplanes.",DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/047-672-650-113-814,Patent Application,yes,3,31,5,6,0,C09D133/066;;C08G18/6229;;C08G18/6254;;C08K5/005;;C09D175/04,C08G18/62;;C08L75/04;;C09D133/06;;C09D175/04,,0,0,,,,DISCONTINUED
346,CN,C,CN 1070611 C,054-239-980-850-864,2001-09-05,2001,CN 92114700 A,1992-12-12,US 80675585 A,1985-12-09,Hybridoma cell lines and thier monoclonal antibodies to human pluripotent granulocyte colony stimulating factor,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",HIRIN AMGEN INC,CHANG DAVID;;ATTROCK BRUCE,,https://lens.org/054-239-980-850-864,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,G01N33/53;;A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
347,EP,A3,EP 0392134 A3,068-757-032-678-37X,1991-06-26,1991,EP 90100711 A,1990-01-15,US 33760789 A,1989-04-13,PROCESS AND APPARATUS FOR TREATMENT OF BACKSIDE OF SEMICONDUCTOR WAFER,"A process and an apparatus are disclosed for the treatment of the backside or back surface of a semiconductor wafer such as a silicon wafer. By spacing the back side of a semiconductor wafer a predetermined distance from a cathode in a vacuum chamber and controlling the rf power and the pressure, a confined plasma may be used both to clean the back side of the wafer to remove impurities, including moisture and other occluded gases; as well as to deposit a layer of oxide on the back surface of the wafer to inhibit subsequent deposition of poorly adherent materials on the back side of the wafer which might otherwise flake off during processing of the front side of the wafer to form integrated circuits thereon.  ",APPLIED MATERIALS INC.,"CHANG, MEI;;CHENG, DAVID",,https://lens.org/068-757-032-678-37X,Search Report,yes,2,0,6,6,0,C23C8/36;;C23C14/022;;C23C16/0245;;H01L21/02046;;H01L21/02238;;H01L21/02252;;H01L21/67069;;H01L21/6875;;Y10S438/906;;Y10S438/928;;H01L21/08;;H01L21/31612;;H01L21/67069;;C23C14/022;;C23C8/36;;H01L21/02238;;H01L21/02046;;H01L21/6875;;H01L21/02252;;C23C16/0245;;Y10S438/928;;Y10S438/906,C23C8/36;;C23C14/02;;C23C16/02;;H01L21/00;;H01L21/306;;H01L21/316;;H01L21/687,,1,0,,,"EXTENDED ABSTRACTS, vol. 84, no. 1, 6th - 11th May 1984, pages 143-144, abstract no. 97, Pennington, New York, US; K.Y. TSAO et al.: ""Reproducible LPCVD tungsten via plasma pretreatment""",DISCONTINUED
348,CN,A,CN 101842673 A,063-193-837-072-065,2010-09-22,2010,CN 200880114420 A,2008-10-24,EP 2008009027 W;;US 133007 P,2007-11-01,Remote data collecting systems and methods,"The present invention provides a remote data collecting system comprising a measuring device comprising at least two scales in communication with a terminal center. The terminal center is in communication with a control center. The control center can be linked to a computer with software to collect, distribute, analyze, and display data collected from the measuring device. The remote data collecting system is particularly useful for uncontrolled environment (e.g., in-home) product testing such as testing the palatability of pet foods.",NESTEC SA,DAVID CHANG;;MA CHANGPU,,https://lens.org/063-193-837-072-065,Patent Application,no,0,9,8,8,0,A01K5/00;;A01K5/00;;A01K5/0114;;A01K5/0114;;A01K29/00;;A01K29/00;;A23K50/40;;A23K50/40;;G01G19/4146;;G01G19/4146;;G01G23/3735;;G01G23/3735;;G01G23/3742;;G01G23/3742;;G16H20/60;;G16H20/60;;G16H40/67;;G16H40/67,G01G19/414;;A01K5/02;;G06F19/00,,0,0,,,,DISCONTINUED
349,US,A1,US 2013/0317574 A1,110-579-468-713-588,2013-11-28,2013,US 201313958354 A,2013-08-02,US 201313958354 A;;US 1444208 A;;US 88088307 P;;US 88081207 P;;US 88081307 P;;US 88088707 P,2007-01-17,Phototherapy Handpiece,"A phototherapy device is disclosed including: a handpiece; and a beamshaping element housed in the handpiece. The beamshaping element is adapted to receive a beam of light from an ultraviolet light source, modify the shape of the beam, and direct the modified beam to provide illumination of a region of a treatment surface, the region, having a tilable cross section at the treatment surface with an irregularly shaped boundary. In some embodiments, the irregularly shaped boundary is composed of three or more segments, each segment being sinusoid-like. In some embodiments, the beamshaping element includes a screen disposed between the light source and the treatment surface, the screen including a light transmissive with an irregularly shaped boundary, and where the irregularly shaped boundary of the illuminated area corresponds to the irregularly shaped boundary of the light transmissive region.",LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/110-579-468-713-588,Patent Application,yes,5,5,4,18,0,A61N5/0616;;A61N2005/0644;;A61N2005/0661;;A61B2090/036;;A61B2090/065;;A61N5/0616;;A61N2005/0644;;A61N2005/0661;;A61B2090/036;;A61B2090/065;;A61N5/0624,A61N5/06,607/89;;607/94,0,0,,,,DISCONTINUED
350,CA,C,CA 2062302 C,150-463-593-539-466,2003-07-29,2003,CA 2062302 A,1992-03-04,CA 2062302 A;;US 55708490 A,1990-07-25,WATERBORNE BASECOAT/HIGH SOLIDS CLEAR FINISH FOR AUTOMOTIVE SUBSTRATES HAVING AN IMPROVED APPEARANCE,"An improved process for forming a multilayer finish on a substrate by applying a layer of a waterborne basecoating composition to the substrate; at least partially drying the coating, applying a layer of a solvent based high solids clear coating to the basecoating and curing the coatings; the improvement that is used therewith is as follows: A. a waterborne basecoating composition that has a film forming binder of an acrylic polymer neutralized with ammonia, a primary amine or a secondary amine without the presence of a tertiary amine a water dispersible or water dilutable alkylated melamine formaldehyde resin and the composition contains pigments in a pigment to binder weight ratio of about 0.5/100 to 200/100; B. a high solids solvent based clear coating composition having a film forming binder of an acrylic polymer, a polyester or a polyesterurethane and an alkylated melamine formaldehyde crosslinking agent and about 0.1-5% by weight, based an the weight of the binder, of a strong acid catalyst; wherein the basecoating composition and the and the clear coating composition are cured at about 100-180.degree.C to form a glossy wrinkle free finish having an automotive quality appearance.",DU PONT,CHANG DAVID C K,,https://lens.org/150-463-593-539-466,Granted Patent,no,0,0,3,3,0,B05D7/534;;B05D2451/00;;B05D2502/00;;B05D2504/00;;B05D2508/00;;C08L61/32;;C09D133/066;;Y10T428/264;;Y10T428/2982;;Y10T428/31909;;Y10T428/31928;;Y10T428/31935;;Y10T428/31692;;Y10T428/31862;;Y10T428/264;;Y10T428/2982;;Y10T428/31909;;Y10T428/31928;;Y10T428/31935;;Y10T428/31692;;Y10T428/31862;;B05D7/534;;B05D2504/00;;B05D2508/00;;B05D2451/00;;C09D133/066;;B05D2502/00;;C08L61/32,B05D7/00;;C08L61/32;;C09D133/06,,0,0,,,,EXPIRED
351,EP,B1,EP 0227367 B1,160-647-902-225-09X,1992-03-11,1992,EP 86309541 A,1986-12-08,US 80675585 A,1985-12-09,HYBRIDOMA CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.","KIRIN-AMGEN, INC.","CHANG, DAVID;;ALTROCK, BRUCE",,https://lens.org/160-647-902-225-09X,Granted Patent,yes,1,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
352,PT,B,PT 83892 B,152-994-073-008-296,1989-06-30,1989,PT 8389286 A,1986-12-09,US 80675585 A,1985-12-09,LINHAS DE CELULAS DE HIBRIDOMA E OS SEUS ANTICORPOS MONOCLONAIS CONTRA O FACTOR HUMANO ESTIMULANTE DAS COLONIAS PLURIPOTENCIAIS DE GRANULOCITOS,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/152-994-073-008-296,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
353,EP,B1,EP 2205948 B1,175-589-607-543-572,2016-07-27,2016,EP 08845599 A,2008-10-24,EP 2008009027 W;;US 133007 P,2007-11-01,REMOTE DATA COLLECTING SYSTEM AND METHOD,,NESTEC SA,CHANG DAVID;;MA CHANGPU,"SOCIETE DES PRODUITS NESTLE S.A. (2019-12-05);;SOCIETE DES PRODUITS NESTLE S.A., CH (2020-02-03);;SOCIETE DES PRODUITS NESTLE S.A.; CH (2019-06-20)",https://lens.org/175-589-607-543-572,Granted Patent,yes,5,0,8,8,0,A01K5/00;;A01K5/00;;A01K5/0114;;A01K5/0114;;A01K29/00;;A01K29/00;;A23K50/40;;A23K50/40;;G01G19/4146;;G01G19/4146;;G01G23/3735;;G01G23/3735;;G01G23/3742;;G01G23/3742;;G16H20/60;;G16H20/60;;G16H40/67;;G16H40/67,G01G23/37;;A01K5/00;;A01K5/01;;A01K29/00;;G01G19/414;;G06F19/00,,1,0,,,"""WAEGE-ELEKTRONIK GEHT INS NETZ"" WDM : WAGEN DOSIEREN + MISCHEN, VERLAG COATING THOMAS & CO., ST. GALLEN, CH, vol. 32, no. 1, 1 February 2001 (2001-02-01), page 25, XP000992086 ISSN: 1435-2176",ACTIVE
354,US,A,US 4962049 A,188-748-541-424-753,1990-10-09,1990,US 33760789 A,1989-04-13,US 33760789 A,1989-04-13,Process for the plasma treatment of the backside of a semiconductor wafer,"A process is disclosed for the treatment of the backside or back surface of a semiconductor wafer such as a silicon wafer. By spacing the back side of a semiconductor wafer a predetermined distance from a cathode in a vacuum chamber and controlling the rf power and the pressure, a confined plasma may be used both to clean the back side of the wafer to remove impurities, including moisture and other occluded gases; as well as to deposit a layer of oxide on the back surface of the wafer to inhibit subsequent deposition of poorly adherent materials on the back side of the wafer which might otherwise flake off during processing of the front side of the wafer to form integrated circuits thereon.",APPLIED MATERIALS INC,CHANG MEI;;CHENG DAVID,APPLIED MATERIALS INC. A DE. CORP (1989-04-24),https://lens.org/188-748-541-424-753,Granted Patent,yes,7,55,6,6,0,C23C8/36;;C23C14/022;;C23C16/0245;;H01L21/02046;;H01L21/02238;;H01L21/02252;;H01L21/67069;;H01L21/6875;;Y10S438/906;;Y10S438/928;;H01L21/08;;H01L21/31612;;H01L21/67069;;C23C14/022;;C23C8/36;;H01L21/02238;;H01L21/02046;;H01L21/6875;;H01L21/02252;;C23C16/0245;;Y10S438/928;;Y10S438/906,C23C8/36;;C23C14/02;;C23C16/02;;H01L21/00;;H01L21/306;;H01L21/316;;H01L21/687,437/13;;437/238;;437/235;;437/241;;437/242;;437/10;;437/239,0,0,,,,EXPIRED
355,US,A1,US 2016/0099906 A1,010-825-142-648-013,2016-04-07,2016,US 201514966574 A,2015-12-11,US 201514966574 A;;US 201414339536 A;;US 201113185485 A,2011-07-18,METHOD AND APPARATUS FOR SOCIAL NETWORK COMMUNICATION OVER A MEDIA NETWORK,"A system that transmits a request to initiate a communication session with a member device of a social network may include, for example, activating a speech capture element, maintaining activation of the speech capture element in accordance with a pattern of prior speech messages, detecting a speech message at the activated speech capture element, and transmitting the detected speech message, or a derivative thereof, to the member device of the social network. Other embodiments are disclosed.",AT & T IP I LP,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I LP (2011-07-15);;MICROSOFT TECHNOLOGY LICENSING LLC (2023-09-20),https://lens.org/010-825-142-648-013,Patent Application,yes,0,1,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,G10L15/26;;H04L12/58;;H04L29/08,,0,0,,,,ACTIVE
356,US,A1,US 2014/0210527 A1,031-429-214-911-675,2014-07-31,2014,US 201314027079 A,2013-09-13,US 201314027079 A;;US 201361757947 P;;US 201361804595 P;;US 201313849115 A,2013-01-29,INDUCTION-COUPLED CLOCK DISTRIBUTION FOR AN INTEGRATED CIRCUIT,"An integrated circuit package including an induction-coupled clock distribution system is disclosed. An exemplary embodiment of the disclosure includes a transmission module coupled to a main clock line, a clock reception module coupled to the transmission module, the clock reception module including a clock output line, and an electronic circuit coupled to the clock output line of the clock reception module, the electronic circuit including at least one clocked element and configured to operate synchronously with a clocking signal received through the clock output line of the clock reception module. The transmission module may be disposed on the supporting case of the IC package, and the electronic circuit and the clock reception module may be disposed on the semiconductor die of the IC package.",BROADCOM CORP,CHANG DAVID;;HUKKOO AJAT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2013-12-11),https://lens.org/031-429-214-911-675,Patent Application,yes,1,1,4,16,0,G06F1/10;;G06F1/10;;H03L7/06,H03L7/06,327/156;;327/141,0,0,,,,ACTIVE
357,US,S,US D0827333 S,045-792-506-622-837,2018-09-04,2018,US 201629582580 F,2016-10-28,US 201629582580 F,2016-10-28,Mat,,VARIDESK LLC,PATTON DAVID;;CHANG COCO,VARIDESK LLC (2016-11-02),https://lens.org/045-792-506-622-837,Design Right,no,0,7,1,1,0,,,0611;;D 6582,0,0,,,,ACTIVE
358,EP,A2,EP 2598890 A2,063-189-683-963-954,2013-06-05,2013,EP 11815062 A,2011-07-26,US 36769610 P;;US 2011/0045331 W,2010-07-26,MIG6 AND THERAPEUTIC EFFICACY,,UNIV JOHNS HOPKINS,SIDRANSKY DAVID;;CHANG XIAOFEI,,https://lens.org/063-189-683-963-954,Patent Application,yes,0,0,5,5,0,C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;G01N2333/91205;;G01N2800/44;;C12Q1/6886;;G01N2333/91205;;G01N2800/44;;C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;C12Q1/6886;;C12Q1/485,G01N33/68;;C12Q1/68;;G01N33/574,,0,0,,,,DISCONTINUED
359,FR,A1,FR 2404054 A1,057-832-708-303-171,1979-04-20,1979,FR 7818670 A,1978-06-22,US 83554277 A,1977-09-22,PIECE METALLIQUE POURVUE D'UN REVETEMENT DE PROTECTION CONTRE LA CORROSION ET L'OXYDATION A CHAUD,"<P>Pièce comportant un revêtement présentant une meilleure résistance à la corrosion et à l'oxydation à chaud. </P><P>Elle comprend un substrat en un superalliage à base d'un élément choisi dans le groupe constitué par Fe, Co et Ni et un revêtement progressif constitué par : 1 une partie intérieure du revêtement adjacente au substrat et ayant diffusé avec lui et comprenant essentiellement du Cr et au moins un élément choisi dans le groupe constitué par Fe, Co et Ni, le reste étant constitué par les éléments qui ont diffusé depuis le substrat et la partie extérieure du revêtement, et 2 une partie extérieure du revêtement adjacente à la partie intérieure du revêtement et ayant diffusé avec elle, et comprenant essentiellement de l'Al et au moins un élément choisi dans le groupe constitué par Hf, Pt, Rh et Pd, le reste étant constitué par les éléments ayant diffusé depuis la partie intérieure du revêtement. </P><P>Application aux moteurs à turbine à gaz.</P>",GEN ELECTRIC,CHANG DAVID RONG HWANG,,https://lens.org/057-832-708-303-171,Patent Application,no,4,0,11,11,0,C23C28/021;;C23C28/023;;C23C28/028;;F01D25/007;;Y10T428/12806;;Y10T428/12931;;Y10T428/12743;;Y10T428/12757;;Y10T428/12875;;Y10T428/12458;;Y10T428/1275;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;Y10T428/12743;;Y10T428/12757;;Y10T428/12875;;Y10T428/12458;;Y10T428/1275;;Y10T428/12854;;F01D25/007;;C23C28/028;;C23C28/023;;C23C28/021,C23C10/52;;C23C10/54;;C23C10/56;;C23C28/02;;F01D25/00;;C23C10/28,,0,0,,,,EXPIRED
360,CA,A1,CA 2062302 A1,111-815-889-993-133,1993-09-05,1993,CA 2062302 A,1992-03-04,CA 2062302 A;;US 55708490 A,1990-07-25,WATERBORNE BASECOAT/HIGH SOLIDS CLEAR FINISH FOR AUTOMOTIVE SUBSTRATES HAVING AN IMPROVED APPEARANCE,"FA-0334 TITLE WATERBORNE BASECOAT/HIGH SOLIDS Clear FINISH FOR AUTOMOTIVE SUBSTRATES HAVING AN IMPROVED APPEARANCE An improved process for forming a multilayer finish on a SUBSTRATE by applying a layer of a waterborne basecoating composition to the substrate, at least partially drying the coating, applying a layer of a solvent based high solids clear coating to the basecoating and curing the coatings; the improvement that is used therewith is as follows: A. a waterborne basecoating composition that has a film forming binder of an acrylic polymer neutralized with ammonia, a primary amine or a secondary amine without the presence of a tertiary amine a water dispersible or water dilatable alkylated melamine formaldehyde resin and the composition contains pigments in a pigment to binder weight ratio of about 0.5/100 to 200/100; B. a high solids solvent BASED clear coating composition having a film forming binder of an acrylic polymer, a polyester or a polyesterurethane and an alkylated melamine formaldehyde crosslinking agent and about 0.1 5% by weight, based on the weight of the binder, of a strong acid catalyst: wherein the basecoating composition and the and the clear coating composition are cured at about 100-180.degree.C to form a glossy wrinkle free finish having an automotive quality appearance.",DU PONT,CHANG DAVID C K,,https://lens.org/111-815-889-993-133,Patent Application,no,0,0,3,3,0,B05D7/534;;B05D2451/00;;B05D2502/00;;B05D2504/00;;B05D2508/00;;C08L61/32;;C09D133/066;;Y10T428/264;;Y10T428/2982;;Y10T428/31909;;Y10T428/31928;;Y10T428/31935;;Y10T428/31692;;Y10T428/31862;;Y10T428/264;;Y10T428/2982;;Y10T428/31909;;Y10T428/31928;;Y10T428/31935;;Y10T428/31692;;Y10T428/31862;;B05D7/534;;B05D2504/00;;B05D2508/00;;B05D2451/00;;C09D133/066;;B05D2502/00;;C08L61/32,B05D7/00;;C08L61/32;;C09D133/06,,0,0,,,,EXPIRED
361,US,B2,US 9000805 B2,117-850-110-210-361,2015-04-07,2015,US 201313849115 A,2013-03-22,US 201313849115 A;;US 201361757947 P,2013-01-29,Resonant inductor coupling clock distribution,The present disclosure provides for a clock distribution network for distributing clocking signals within a synchronous sequential logic circuit. The clock distribution network distributes the one or more clock signals by inductively and/or capacitively coupling a clocking signal from a primary distribution node to various secondary distribution nodes within the synchronous sequential logic circuit. The various secondary distribution nodes resonate at respective resonant frequencies to generate other clocking signals for use within the synchronous sequential logic circuit in response to receiving the clocking signal.,BROADCOM CORP,CHANG DAVID;;HUKKOO AJAT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2013-03-21),https://lens.org/117-850-110-210-361,Granted Patent,yes,6,5,8,16,0,G06F1/10;;G06F1/10;;H03K19/096;;H03K19/096;;H01F38/14;;H02J50/05;;H02J50/10,H03K19/096;;G06F1/00;;G06F1/26;;G06F1/32;;G06F5/16,326/93;;326/46;;326/38,0,0,,,,INACTIVE
362,EP,A4,EP 2598890 A4,116-480-728-523-27X,2013-12-25,2013,EP 11815062 A,2011-07-26,US 36769610 P;;US 2011/0045331 W,2010-07-26,MIG6 AND THERAPEUTIC EFFICACY,,UNIV JOHNS HOPKINS,SIDRANSKY DAVID;;CHANG XIAOFEI,,https://lens.org/116-480-728-523-27X,Search Report,no,0,0,5,5,0,C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;G01N2333/91205;;G01N2800/44;;C12Q1/6886;;G01N2333/91205;;G01N2800/44;;C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;C12Q1/6886;;C12Q1/485,G01N33/68;;C12Q1/68;;G01N33/574,,3,3,077-093-658-342-568;;047-425-274-146-912;;029-025-061-750-088,10.1158/1538-7445.am10-2703;;10.1053/j.semtcvs.2008.09.005;;19038731;;19674104;;10.1111/j.1742-4658.2009.07220.x,"X. CHANG ET AL: ""Abstract 2703: Loss of dependence on EGFR signaling by upregulation of Mig6 confers drug resistance to erlotinib"", CANCER RESEARCH, vol. 70, no. 8 Supplement, 15 April 2010 (2010-04-15), pages 2703 - 2703, XP055085966, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM10-2703;;SEEMA HARICHAND-HERDT ET AL: ""Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer: Focus on Inhibition of Epidermal Growth Factor Receptor"", SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, vol. 20, no. 3, 1 September 2008 (2008-09-01), pages 217 - 223, XP055033916, ISSN: 1043-0679, DOI: 10.1053/j.semtcvs.2008.09.005;;TAKESHI NAGASHIMA ET AL: ""Mutation of epidermal growth factor receptor is associated with MIG6 expression"", FEBS JOURNAL, vol. 276, no. 18, 10 September 2009 (2009-09-10), pages 5239 - 5251, XP055085988, ISSN: 1742-464X, DOI: 10.1111/j.1742-4658.2009.07220.x",DISCONTINUED
363,US,A1,US 2016/0109899 A1,125-339-158-073-986,2016-04-21,2016,US 201514879905 A,2015-10-09,US 201514879905 A;;US 201314027079 A;;US 201361757947 P;;US 201361804595 P;;US 201313849115 A,2013-01-29,Induction-Coupled Clock Distribution for an Integrated Circuit,"An integrated circuit package including an induction-coupled clock distribution system is disclosed. An exemplary embodiment of the disclosure includes a transmission module coupled to a main clock line, a clock reception module coupled to the transmission module, the clock reception module including a clock output line, and an electronic circuit coupled to the clock output line of the clock reception module, the electronic circuit including at least one clocked element and configured to operate synchronously with a clocking signal received through the clock output line of the clock reception module. The transmission module may be disposed on the supporting case of the IC package, and the electronic circuit and the clock reception module may be disposed on the semiconductor die of the IC package.",BROADCOM CORP,CHANG DAVID;;HUKKOO AJAT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2013-12-11),https://lens.org/125-339-158-073-986,Patent Application,yes,1,0,4,16,0,G06F1/10;;G06F1/10;;H03L7/06,G06F1/10,,0,0,,,,ACTIVE
364,KR,B1,KR 970000637 B1,146-724-066-741-652,1997-01-16,1997,KR 870700690 A,1987-08-10,US 80675585 A;;US 8602554 W,1985-12-09,HYBRIDOMA CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/146-724-066-741-652,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;G01N33/53;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
365,WO,A2,WO 2009/056260 A2,168-537-684-764-362,2009-05-07,2009,EP 2008009027 W,2008-10-24,US 133007 P,2007-11-01,REMOTE DATA COLLECTING SYSTEMS AND METHODS,"The present invention provides a remote data collecting system comprising a measuring device comprising at least two scales in communication with a terminal center. The terminal center is in communication with a control center. The control center can be linked to a computer with software to collect, distribute, analyze, and display data collected from the measuring device. The remote data collecting system is particularly useful for uncontrolled environment (e.g., in-home) product testing such as testing the palatability of pet foods.",NESTEC SA;;CHANG DAVID;;CHANGPU MA,CHANG DAVID;;CHANGPU MA,,https://lens.org/168-537-684-764-362,Patent Application,yes,0,6,8,8,0,A01K5/00;;A01K5/00;;A01K5/0114;;A01K5/0114;;A01K29/00;;A01K29/00;;A23K50/40;;A23K50/40;;G01G19/4146;;G01G19/4146;;G01G23/3735;;G01G23/3735;;G01G23/3742;;G01G23/3742;;G16H20/60;;G16H20/60;;G16H40/67;;G16H40/67,G06F19/00,,0,0,,,,PENDING
366,TW,A,TW 200607321 A,178-384-580-461-373,2006-02-16,2006,TW 93123880 A,2004-08-10,TW 93123880 A,2004-08-10,Mobile phone with automatically emergent calling function and method thereof,"A mobile phone with the automatically emergent calling function that comprises a wireless communicating module, an emergent key, an emergent phone directory and a central processing module. First, setting the priority of dialing the numbers of the emergent phone directory and the function of the emergent key before entering the emergent calling process. Next, it can finish the emergent process by pressing the emergent key twice continuously. Then, it will dial the phone number and send the helping message automatically. Therefore, the emergent calling is faster and the reliability is better.",INVENTEC APPLIANCES CORP,HO DAVID;;CHANG CHENG,,https://lens.org/178-384-580-461-373,Patent of Addition,no,0,1,2,2,0,,,,0,0,,,,INACTIVE
367,US,A1,US 2008/0172112 A1,183-086-585-731-729,2008-07-17,2008,US 1445008 A,2008-01-15,US 1445008 A;;US 88081207 P;;US 88088307 P;;US 88081307 P;;US 88088707 P;;US 2008/0000495 W,2007-01-17,LIGHT SOURCE AND FIBER OPTIC BRUSH FOR LIGHT DELIVERY,"A phototherapy apparatus is disclosed including: a handpiece including a body member and a grip; a plurality of elongated light transmitting elements, each of the elements extending between a proximal end enclosed within the body member and a distal end located outside of and distal to the body member; an ultraviolet light source; a light collection element; and one or more optical coupling elements. The proximal ends of the light transmitting elements are located in close proximity to each other The light collection element is configured to collect at least a portion of the light emitted from the light source. The one or more optical coupling elements are configured to direct at least a portion of the collected light to the proximal ends of the light transmitting elements to couple at least portion of the collected light into the light transmitting elements The light coupled into each of the light transmitting elements is transmitted along the element and emitted from the distal end.",LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,ADVANCED DISTRIBUTED SENSOR SYSTEMS INC (2009-01-29);;LERNER MEDICAL DEVICES INC (2008-01-14),https://lens.org/183-086-585-731-729,Patent Application,yes,22,30,4,18,0,A61N5/0616;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N2005/0654;;A61N2005/0661;;A61N5/0617;;A61N2005/0661;;A61N2005/0644;;A61N2005/063;;A61N2005/0654;;A61N5/0616,A61N5/067,607/89;;607/94;;607/88,0,0,,,,INACTIVE
368,MX,A,MX 2013013759 A,015-224-995-004-816,2014-01-08,2014,MX 2013013759 A,2011-05-27,CN 2011000905 W,2011-05-27,LIQUID SOAPS WITH TRICLOCARBAN.,"An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount that is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.",COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/015-224-995-004-816,Patent Application,no,0,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/00;;C11D9/02;;C11D9/30;;C11D9/50,,0,0,,,,DISCONTINUED
369,EP,A2,EP 2205948 A2,013-313-087-167-697,2010-07-14,2010,EP 08845599 A,2008-10-24,EP 2008009027 W;;US 133007 P,2007-11-01,REMOTE DATA COLLECTING SYSTEM AND METHOD,,NESTEC SA,CHANG DAVID;;MA CHANGPU,"SOCIETE DES PRODUITS NESTLE S.A. (2019-12-05);;SOCIETE DES PRODUITS NESTLE S.A., CH (2020-02-03);;SOCIETE DES PRODUITS NESTLE S.A.; CH (2019-06-20)",https://lens.org/013-313-087-167-697,Patent Application,yes,0,0,8,8,0,A01K5/00;;A01K5/00;;A01K5/0114;;A01K5/0114;;A01K29/00;;A01K29/00;;A23K50/40;;A23K50/40;;G01G19/4146;;G01G19/4146;;G01G23/3735;;G01G23/3735;;G01G23/3742;;G01G23/3742;;G16H20/60;;G16H20/60;;G16H40/67;;G16H40/67,G01G23/37;;A01K5/00;;A01K5/01;;A01K29/00;;G01G19/414;;G06F19/00,,1,0,,,See references of WO 2009056260A3,ACTIVE
370,US,A,US 5104922 A,012-361-605-882-026,1992-04-14,1992,US 60607790 A,1990-10-22,US 60607790 A,1990-10-22,Stable aqueous aluminum flake dispersion,"A stable waterborne high solids metallic flake pigment dispersion containing an aqueous carrier, film forming binder and metallic flake pigment and having a solids content of about 40-90% by weight; wherein the film forming polymer is a phosphated acrylic polymer neutralized with ammonia or a primary, secondary or tertiary amine and contains metallic flake pigments in a pigment to binder weight ratio of about 30/100-1000/100 and is non-reactive with the binder and the dispersion has a pH of about 7-9.",DU PONT,CHANG DAVID C K,E. I. DU PONT DE NEMOURS AND COMPANY (1990-10-18),https://lens.org/012-361-605-882-026,Granted Patent,yes,1,38,3,3,0,C09D133/062;;C09D133/062;;C08L61/20;;C08L61/20;;C09D5/38;;C09D5/38;;C09D17/006;;C09D17/006;;C09D143/02;;C09D143/02,C08L61/20;;C09D5/38;;C09D17/00;;C09D133/06;;C09D143/02,524/441;;524/440;;524/512;;524/558;;525/330.4;;525/329.8,0,0,,,,EXPIRED
371,AU,A1,AU 2007/284079 A1,029-204-324-653-946,2008-02-21,2008,AU 2007/284079 A,2007-08-16,AU 2006/904478 A;;AU 2006/906441 A;;AU 2007/001164 W;;AU 2007/284079 A,2006-08-17,A door strike,,SHANGHAI ONE TOP CORP,CHANG DAVID;;MACKLE TREVOR,ALLEGION (AUSTRALIA) PTY LTD (2020-05-14);;FIRE & SECURITY HARDWARE PTY LTD (2009-04-02),https://lens.org/029-204-324-653-946,Patent Application,no,0,0,9,9,0,E05B47/0047;;E05B47/0047;;E05B63/0065;;E05B63/0065;;E05B2047/0073;;E05B2047/0073;;E05B2047/0076;;E05B2047/0076;;Y10T292/699;;Y10T292/699,E05B47/00;;E05B15/02,,0,0,,,,ACTIVE
372,US,B2,US 7318398 B2,032-343-542-589-91X,2008-01-15,2008,US 64111503 A,2003-08-15,US 64111503 A,2003-08-15,Engine valve actuation system,"An engine valve actuation system includes an engine valve moveable between a first position that blocks a flow of fluid and a second position that allows a flow of fluid. The system also includes a valve actuation assembly connected to move the engine valve between the first position and the second position and a fluid actuator configured to selectively modify a timing of the engine valve in moving from the second position to the first position. The fluid actuator includes a first piston. The system further includes an accumulator including a second piston, wherein the second piston is slidably movable in the first piston.",CATERPILLAR INC,CHANG DAVID YU-ZHANG,CATERPILLAR INC (2003-08-14),https://lens.org/032-343-542-589-91X,Granted Patent,yes,62,2,2,2,0,F01L9/10;;F01L9/10,F01L9/10,123/90.12;;123/90.15;;123/90.16,7,1,043-080-006-736-450,10.4271/980180,"Edwards et al., ""The Potential of a Combined Miller Cycle and Internal EGR Engine for Future Heavy Duty Truck Applications,"" The Engineering Society for Advancing Mobility Land Sea Air and Space International, International Congress and Exposition, Feb. 23-26, 1998, pp. 1-19.;;Obert, ""Internal Combustion Engines and Air Pollution,"" Based on Internal Combustion Engines, Third Edition, 1973, pp. 612-614.;;Challen et al., ""Diesel Engine Reference Book, Section Edition,"" SAE International, 1999, pp. 75, 81, 84, 146, and 263-305.;;Yorihiro Fukuzawa et al., ""Development of High Efficiency Miller Cycle Gas Engine"", Mitsubishi Heavy Industries, Ltd., Technical Review, vol. 38, No. 3, Oct. 2001, pp. 146-150.;;Request for Inter Partes Reexamination Transmittal Form for US Patent 6,688,280, and Attachment to Request for Inter Parties Reexamination Transmittal Form, Sep. 17, 2004.;;Request for Inter Partes Reexamination Transmittal Form for US Patent 6,651,618, and Attachment to Request for Inter Parties Reexamination Transmittal Form, Aug. 27, 2004.;;http://www.mazda.com.au/corpora/209.html, Oct. 16, 2001, p. 1-6.",EXPIRED
373,KR,A,KR 20030022608 A,051-130-691-566-99X,2003-03-17,2003,KR 20010055946 A,2001-09-11,KR 20010055946 A,2001-09-11,SHOE WITH A PIVOTAL COUNTER PORTION,"PURPOSE: A shoe with a rotatable counter portion is provided to freely change the style of the shoe by virtue of the rotatable counter portion, which is rotatably and separably coupled to an outer shell of the shoe as well as completely separable from the shoe bottom sole. CONSTITUTION: The shoe(10) consists of a bottom sole(12) and an outer shell(11) firmly fixed to the bottom sole. The bottom sole is formed at the rear end thereof with an opening portion(111). A rotatable counter portion(20) is selectively connected to the opening portion of the shoe. Fasteners(30) are symmetrically mounted to the upper ends of both the opening portion and counter portion. The counter portion is rotatably connected to the rear end of the bottom sole through a rotatable connecter(25). The bottom sole has a recess(13) formed at the upper surface of the bottom sole near the rear end of the bottom sole. In the recess is firmly mounted a rotatable ratch(40).",CHANG DAVID,CHANG DAVID;;LAIO YUI,,https://lens.org/051-130-691-566-99X,Patent Application,no,4,0,1,1,0,A43B3/244;;A43B1/0045;;A43B11/00;;A43B23/0295,A43B3/24,,0,0,,,,DISCONTINUED
374,US,S,US D0744635 S,076-375-176-123-513,2015-12-01,2015,US 201429495041 F,2014-06-26,US 201429495041 F,2014-06-26,Dietary supplement,,ACCESS BUSINESS GROUP INT LLC,CHANG DAVID;;HEISLER DANIEL,ACCESS BUSINESS GROUP INTERNATIONAL LLC (2014-06-24),https://lens.org/076-375-176-123-513,Design Right,no,0,4,2,2,0,,,2401;;D24/102,0,0,,,,ACTIVE
375,ZA,B,ZA 869042 B,093-900-012-377-954,1987-08-26,1987,ZA 869042 A,1986-12-01,US 80675585 A,1985-12-09,HYBRIDOMA CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/093-900-012-377-954,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
376,US,B2,US 9501089 B2,096-412-613-140-094,2016-11-22,2016,US 201514879905 A,2015-10-09,US 201514879905 A;;US 201314027079 A;;US 201361757947 P;;US 201361804595 P;;US 201313849115 A,2013-01-29,Induction-coupled clock distribution for an integrated circuit,"An integrated circuit package including an induction-coupled clock distribution system is disclosed. An exemplary embodiment of the disclosure includes a transmission module coupled to a main clock line, a clock reception module coupled to the transmission module, the clock reception module including a clock output line, and an electronic circuit coupled to the clock output line of the clock reception module, the electronic circuit including at least one clocked element and configured to operate synchronously with a clocking signal received through the clock output line of the clock reception module. The transmission module may be disposed on the supporting case of the IC package, and the electronic circuit and the clock reception module may be disposed on the semiconductor die of the IC package.",BROADCOM CORP,CHANG DAVID;;HUKKOO AJAT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2013-12-11),https://lens.org/096-412-613-140-094,Granted Patent,yes,10,0,4,16,0,G06F1/10;;G06F1/10;;H03L7/06,H01L23/02;;G06F1/10;;H03L7/06,,0,0,,,,ACTIVE
377,US,A,US 4214259 A,105-761-751-915-142,1980-07-22,1980,US 89441978 A,1978-04-07,US 89441978 A,1978-04-07,Color video tape recorder/reproducer with chrome corrector,"An EIAJ-2, video tape recorder and reproducer machine having broadcast quality response characteristics achieved through the use of a wide band direct type FM modulator for encoding a video signal for recording onto a video tape, a pair of record/playback heads carried by a rotating drum which is partially wrapped by a length of the video tape which is transported past the drum such that the heads scan the tape in helical fashion, the speed of the drum being such that each head records upon a respective track of the video tape a segment of the modulated video signal which correspond to 1/3 of a field of the video signal, an FM demodulator for decoding the frequency modulated video signal which is recovered during playback, circuits for synchronizing the speed of the drum with the synchronization pulses of the video signal and for controlling the speed with which the tape is transported pass the drum and circuitry for minimizing distortion of the video signal caused when the segmented portions of the video signal are spliced together.",RECORTEC INC,CHANG DAVID T L,,https://lens.org/105-761-751-915-142,Granted Patent,yes,6,5,1,1,0,G11B5/588;;G11B15/1808;;H04N5/78263;;H04N5/931;;H04N9/79;;G11B5/588;;G11B15/1808;;H04N9/79;;H04N5/931;;H04N5/78263,G11B5/588;;G11B15/18;;H04N5/7826;;H04N5/931;;H04N9/79,358/8,2,0,,,"Video Tape Recorders by H. Kybott; .COPYRGT.1974 by Howard W. Sams and Co., Inc., pp. 265, 301-305, 343-345.;;Television Broadcasting by H. E. Ennes; .COPYRGT.1973 by Howard W. Sams, Inc., pp. 97-101.",EXPIRED
378,US,B1,US 6459303 B1,105-332-263-316-946,2002-10-01,2002,US 82949901 A,2001-04-09,US 82949901 A;;US 49418600 A;;US 11782799 P,1999-01-29,High speed programmable address decoder,"
    A high-performance address decoder circuit provides higher speed read and write access for an embedded memory of a programmable logic integrated circuit. The address decoder is programmable to allow addressing of the memory in different data widths and depths. The circuitry can be used as column address decoder or row address decoder, or both. In a dual-port memory implementation of the memory, there can be two instances of each of the decoders, one for writing and one for reading. 
",ALTERA CORP,CHANG WANLI;;JEFFERSON DAVID,,https://lens.org/105-332-263-316-946,Granted Patent,yes,44,2,2,2,0,G11C8/10;;G11C8/10,G11C8/10,326/105;;326/40;;326/106;;326/113;;365/230.06,32,12,075-347-089-846-516;;095-770-817-893-091;;084-919-347-343-506;;131-365-349-629-373;;080-800-033-458-075;;019-403-927-145-587;;025-274-696-871-168;;017-787-634-850-103;;043-274-752-375-920;;019-277-823-761-911;;019-258-191-895-546;;023-739-976-007-926,10.1109/cicc.1990.124842;;10.1109/4.126539;;10.1109/cmpcon.1993.289700;;10.1109/t-c.1969.222754;;10.1109/tc.1970.5008902;;10.1109/tc.1977.1674879;;10.1109/tc.1979.1675426;;10.1109/tc.1984.1676396;;10.1109/fpga.1993.279481;;10.1109/fpga.1993.279480;;10.1109/jssc.1989.572595;;10.1109/54.500200,"Masumoto, Rodney T., ""Configuration On-Chip RAM Incorporated into High Speed Logic Array,"" IEEE Custom Integrated Circuits Conference, Jun. 1985, CH2157-6/85/0000-0240, pp. 240-243.;;Landry, Steve, ""Application -Specific ICs, Relying on RAM, Implement Almost any Logic Function,"" Electronic Design, Oct. 31, 1985, pp. 123-130.;;Bursky, Dave, ""Shrink System with One-Chip Decoder, EPROM, and RAM,"" Electronic Design, Jul. 28, 1988, pp. 91-94.;;Kawana, Keiichi et al., ""An Efficient Logic Block Interconnect Architecture for User-Reprogrammable Gate Array,"" IEEE 1990 Custom Integrated Circuits Conf., May 1990, CH2860-5/90/0000-0164, pp. 31.3.1 to 31.3.4.;;Shubat, Alexander et al., ""A Family of User-programmable Peripherals with a Functional Unit Architecture,"" IEEE Jor. of Solid-State Circuits, vol. 27, No. 4, Apr. 1992, 0018-9200/92$03.00, pp. 515-529.;;""AT&T's Orthogonal ORCA Target the FPGA Future,"" 8029 Electronic Engineering, 64, No. 786, Jun. 1992, pp. 9-10.;;Bursky, Dave, ""FPGA Advances Cut Delays, Add Flexibility,"" 2328 Electronic Design, 40, No. 20, Oct. 1, 1992, pp. 35-43.;;Smith, Daniel, ""Intel's FLEXlogic FPGA Architecture,"" IEEE 1063-6390/93, 1993 pp. 378-384.;;Bursky, Dave, ""Denser, Faster FPGAs Vie for Gate-Array Applications,"" 2328 Electronic Design, 41, No. 11, May 27, 1993, pp. 55-75.;;Ngai, Kai-Kit Tony, ""An SRAM-Programmable Field-Reconfigurable Memory,"" Presentation at University of Toronto, Canada, Jun. 1993, pp. 1-14.;;Kautz, ""Cellular Logic in Memory Arrays,"" IEEE Trans. on Computers, vol. C-18, No. 8, Aug. 1969, pp. 719-727.;;Stone, ""A Logic in Memory Computer,"" IEEE Trans. on Computers, Jan. 1970, pp. 73-78.;;Manning, ""An Approach to Highly Integrated Computer Maintained Cellular Arrays,"" IEEE Trans. on Computers, vol. C-26, No. 6, Jun. 1977, pp. 536-552.;;Patil et al., ""A Programmable Logic Approach for VLSI,"" IEEE Trans. on Computers, vol. C-28, No. 9, Sep. 1979, pp. 594-601.;;Seitz, ""Concurrent VLSI Architectures,"" IEEE Trans. on Computers, vol. C-33, No. 12, Dec. 1984, pp. 1247-1265.;;Hsieh et al., ""Third Generation Architecture Boosts Speed and Density of Field Programmable Gate Arrays,"" Proc. of IEEE CICC Conf. May 1990, pp. 31.2.1 to 31.2.7.;;Bursky, ""Combination RAM/PLD Opens New Application Options,"" Electronic Design, May 23, 1991, pp. 138-140.;;Ling et al., ""WASMII: Data Driven Computer on a Virtual Hardware,"" Proc. of IEEE Field Prog. Custom Computing Machines Conf., Napa, California, Apr. 1993, pp. 33-42.;;Casselman, ""Virtual Computing and The Virtual Computer,"" IEEE, Jul. 1993, p. 43.;;Quenot et al., ""A Reconfigurable Compute Engine for Real-Time Vision Automata Prototyping, "" Proc. of IEEE FCCM Conf., Napa, California, Feb. 1994, pp. 91-100.;;Plus Logic ""FPSL5110 Intelligent Data Buffer"" Product Brief, Plus Logic, Inc., San Jose, California, Oct. 1990, pp. 1-6.;;Larsson, T, ""Programmable Logic Circuits: The Luxury Alternatives are Coming Soon,"" Elteknik-med-Aktuell Electronik, No. 4, Feb. 25-Mar. 9, 1988, pp. 37-8, (with English abstract).;;Intel Preliminary Datasheet, ""iFX780: 10ns FLEXlogic FPGA with SRAM Option,"" Nov. 1993, pp. 2-24 to 2-46.;;Quinnell, Richard A., ""FPGA Family Offers Speed, Density, On-Chip RAM, and Wide-Decode Logic,""EDN Dec. 6, 1990, pp. 62-63.;;Satoh, Hisayasu et al., ""A 209K-Transistor ECL Gate Array with RAM,"" IEEE Jor. of Solid-State Circuit, vol. 24, No. 5, Oct. 1989, pp. 1275-1279.;;Ngai, Kai-Kit Tony, ""An SRAM-Programmable Field-Reconfigurable Memory,"" Manuscript Thesis, The University of Toronto Library, Aug. 18, 1994, pp. 1-68.;;Reddy, S. et al., ""A High Density Embedded Array Programmable Logic Architecture,"" Proc. of the IEEE 1996 Custom Integrated Circuits conf. (CICC), San Diego, California, May 5-8, 1996, pp. 251-254.;;Brown, S. et al., ""FPGA and CPLD Architectures: A Tutorial,"" IEEE Design & Test of computers, vol. 13, No. 2, Jun. 1, 1996, pp. 42-57.;;Altera 1996 Data Book, ""FLEX 10K Embedded Programmable Logic Family,"" Jun. 1996, pp. 29-90.;;Nelson, Rick, ""Embedded Memory Enhances Programmable Logic for Complex, Compact Designs,"" EDN Electrical Design News, vol. 41, No. 23, Nov. 7, 1996, pp. 91-106.;;Altera 1999 Device Data Book, ""APEX 20K Programmable Logic Device Family,"" May 1999, pp. 23-88.;;Xilinx Corporation Data Sheet, ""Virtex(TM) 2.5 V Field Programmable Gate Arrays,"" Jan. 28, 2000, pp. 1-72.",EXPIRED
379,FI,B,FI 91542 B,116-885-253-557-286,1994-03-31,1994,FI 873418 A,1987-08-06,US 80675585 A;;US 8602554 W,1985-12-09,Hybridoomia ihmisen monitehoisia granulosyyttipesäkkeitä stimuloivia tekijöitä vastaan,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/116-885-253-557-286,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
380,US,A,US 5552286 A,126-826-587-662-249,1996-09-03,1996,US 38294295 A,1995-01-31,US 38294295 A;;US 24305594 A;;US 44511889 A;;US 20138688 A;;US 80675585 A,1985-12-09,Hybridoma cell lines and their monoclonal antibodies to human pluripotent granulocyte colony stimulating factor,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/126-826-587-662-249,Granted Patent,yes,9,2,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,435/7.2;;435/240.27;;435/172.2;;435/70.21;;436/537;;436/548;;530/388.23;;530/388.7;;530/388.1,32,27,134-977-805-309-039;;022-841-812-928-969;;080-193-694-942-137;;038-926-270-750-716;;061-023-136-775-302;;016-885-379-849-406;;029-973-855-031-077;;007-993-648-187-212;;069-891-491-100-992;;052-538-595-191-839;;034-880-156-226-340;;004-237-140-184-659;;016-374-765-417-789;;025-302-143-740-227;;052-909-054-214-911;;018-072-874-262-244;;016-971-392-505-000;;064-093-046-389-048;;071-503-477-584-593;;028-149-998-594-57X;;003-434-545-711-302;;032-214-325-101-614;;011-448-671-728-436;;006-604-788-531-742;;024-896-039-888-752;;009-764-183-234-413;;162-289-052-834-539,3876234;;10.1002/ijc.2910260517;;6972358;;300377;;10.1016/s0021-9258(18)71855-3;;6973347;;10.1182/blood.v58.3.630.630;;308816;;10.1021/bi00608a026;;6967053;;10.1002/ijc.2910250210;;2990035;;10.1126/science.2990035;;10.1002/jcp.1041160211;;6602806;;10.1016/0145-2126(85)90131-6;;3874326;;6802860;;6976968;;10.1002/jcp.1041090115;;10.1016/s0076-6879(85)16046-5;;3003519;;10.1016/s0021-9258(18)32158-6;;6190815;;10.1073/pnas.81.12.3765;;6610179;;pmc345300;;6978344;;10.1002/jcp.1041100108;;10.1093/jnci/69.6.1235;;6982994;;6601024;;10.1247/csf.9.67;;6609780;;10.1182/blood.v60.1.238.238;;6979358;;6606642;;10.1002/jcb.240210403;;pmc554546;;10.1002/j.1460-2075.1985.tb03973.x;;3902470;;7421601;;10.1016/s0076-6879(80)70041-1;;313822;;10.1182/blood.v54.3.614.614;;10.1182/blood.v54.3.614.bloodjournal543614;;10.1038/314625a0;;2986009;;3489940;;pmc386775;;10.1073/pnas.83.20.7633;;10.1073/pnas.82.5.1526;;pmc397296;;3871951;;6605995,"Begley, et al., Exp. Hematol., 13, 956 962 (1985).;;Burgess, et al., Int. J. Cancer, 26, 647 (1980).;;Burgess, et al., J. Biol. Chem., 252, 1998 2003 (1977).;;Das, et al., Blood, 58, 630 641 (1981).;;Fojo, et al., Biochemistry, 17, 3109 3116 (1978).;;Metcalf, Int. J. Cancer, 25, 225 (1980).;;Metcalf, Science, 229, 16 22 (1985).;;Metcalf, et al., J. Cell. Physiol., 116, 198 206 (1983).;;Metcalf, et al., Leukemia Research, 9, No. 5, pp. 521 527 (1985).;;Moore, J. Cell Physiol. Supp. 1, 53 64 (1982).;;Mortstyn, et al., J. Cell Physiol., 109, 133 142 (1981).;;Nicola, Methods in Enzymology, 116, 600 619 (1985).;;Nicola, et al., Genes and Cancer, pp. 591 610 (1984).;;Nicola, et al., J. Biol. Chem., 258, 9017 (1983).;;Nicola, et al., PNAS (USA), 81, 3765 3769 (1984).;;Okabe, et al., J. Cell. Physiol., 110, 43 49 (1982).;;Okabe, et al., JNCI, 69, 1235 1243 (1982).;;Platzer, et al., Haematology and Blood Transfusion in Modern Trends in Human Leukemia VI, 29, 418, 422 (1985).;;Ruppert, et al., Exp. Hematol., 11, 154 161 (1983).;;Tsuneoka, et al., Cell Structure and Function, 9, 67 81 (1984).;;Waheed, et al., Blood, 60, 238 244 (1982).;;Welte, et al., J. Cell. Biochem., Supp. 9A, 116 (1985).;;Welte, et al., Leukemia: Recent Advances in Biology and Treatment, UCLA Symposia on Molecular and Cellular Biology, Gale, et al., eds., New Series, 28, 339 347 (1985).;;Wang, F. F. et al., J. Cell. Biochem, 21:263 275, 1983.;;De Lamarter, J. F. et al, Embo, 4(10):2575 2581, 1985.;;Souza, L., Blood, 66(5):102, Aug. 21, 1985, abstract.;;Maurer, P. H. et al, Methods in Enzymology, vol. 70:49 70, 1980.;;Nicola, et al., Blood, 54, 614 627 (1979).;;Nicola, et al., Nature, 314, 625 628 (1985).;;Tsuchiya, et al., Proc. Natl. Acad. Sci. (USA), 83, 7633 7637 (1986).;;Welte, et al., Proc. Natl. Acad. Sci. (USA), 82, 1526 1530 (1985).;;Lopez, et al., J. Immunol., vol. 131, No. 6, (1983), pp. 2983 2988.",EXPIRED
381,US,B2,US 11236705 B2,126-666-519-688-690,2022-02-01,2022,US 202016912300 A,2020-06-25,US 202016912300 A,2020-06-25,Gaseous fuel mixer assembly for engine and engine system operating method,"A gaseous fuel mixer assembly for an engine includes a mixer housing forming gas delivery openings, and positioned to extend across a flow path formed by an intake conduit for the engine. A spool valve is within a central bore in the mixer housing and includes gas distribution openings selectively connectable to the gas delivery openings by moving the spool valve within the mixer housing using a piezoelectric actuator coupled with the spool valve by way of a pivot arm. Sealing lands of the spool valve are in an alternating arrangement with the gas distribution openings, such that at the closed position the sealing lands block the gas distribution openings from the gas delivery openings, and at the open position the respective openings are fluidly connected.",CATERPILLAR INC,CHANG DAVID YU ZHANG,CATERPILLAR INC (2020-06-23),https://lens.org/126-666-519-688-690,Granted Patent,yes,10,0,2,2,0,F02M21/0209;;F02M21/0254;;F02M21/0278;;F02M21/04;;F02M21/0215;;F02M21/042;;B01F23/10;;B01F25/31331;;B01F35/718051;;Y02T10/30;;F02M21/04;;F02M35/10262;;F02M21/0254;;F02M21/0209;;F02M21/0278;;B01F23/191;;B01F25/1051;;B01F25/3142,F02M21/04;;F02M21/02;;F02M35/10,,0,0,,,,ACTIVE
382,US,A1,US 2008/0172113 A1,179-121-202-969-067,2008-07-17,2008,US 1444208 A,2008-01-15,US 1444208 A;;US 88081307 P;;US 88081207 P;;US 88088707 P;;US 88088307 P;;US 2008/0000544 W,2007-01-17,FIBER OPTIC PHOTOTHERAPY DEVICE,"A phototherapy apparatus for the treatment of skin disease is disclosed including: an at least partially hollow body element; a plurality of light emitting elements enclosed within the body element; and a plurality of elongated light transmitting elements, each of the light transmitting elements having a proximal end detachably affixed to the body element in proximity to one or more of the light emitting elements, and extending to an end distal the body element. For each of the elongated light transmitting elements, at least a portion of light incident from the light emitting elements onto the proximal end is directed through the light transmitting element and emitted from the distal end.",LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,DARIVOFF PHILIP M (2023-08-18);;LERNER MEDICAL DEVICES INC (2008-01-14);;LERNER ETHAN A (2023-08-18),https://lens.org/179-121-202-969-067,Patent Application,yes,40,37,6,18,0,A61N5/0617;;A61N5/0617;;A61N5/0616;;A61N5/0616;;A61N5/067;;A61N5/067;;A61N2005/063;;A61N2005/063;;A61N2005/0644;;A61N2005/0644;;A61N2005/0652;;A61N2005/0652;;A61N2005/0661;;A61N2005/0661,A61B18/18,607/90,0,0,,,,ACTIVE
383,EP,A1,EP 1287755 A1,152-370-334-137-69X,2003-03-05,2003,EP 01120925 A,2001-08-31,EP 01120925 A,2001-08-31,Shoe with a pivotal counter portion,"A shoe has a sole (10), an upper (11) and a counter portion (20). The upper (11) is securely connected to the sole (10) and has a rear end defined with an opening (111). The counter portion (20) is pivotally connected to a rear end of the sole (10) to close the opening (111) in the upper (11). A fastener (30) is mounted on the upper (11) and the pivotal counter portion (20) to connect the pivotal counter portion (20) to the rear end of the upper (11). Accordingly, a wearer's foot in the shoe can be vented. Also, for a pair of tied shoes with the pivotal counter portions can be put on or taken off without tying or untying the laces. The use of the shoe becomes more versatile and more convenient.",CHANG DAVID,CHANG DAVID;;LAIO YUI,,https://lens.org/152-370-334-137-69X,Patent Application,yes,3,1,1,1,0,A43B3/242;;A43B3/101;;A43B3/102;;A43B3/24;;A43B11/00,A43B3/10;;A43B3/24;;A43B11/00,,0,0,,,,DISCONTINUED
384,MX,A,MX PA01010295 A,013-980-904-642-128,2002-05-06,2002,MX PA01010295 A,2000-04-13,US 12915499 P;;US 0009879 W,1999-04-14,ELECTRICALLY CONDUCTIVE COATINGS APPLIED BY INTERNALLY CHARGED ELECTROSTATIC SPRAYERS.,"The present invention provides compositions comprising a graphite, binder precursor and low polarity solvent that upon hardening form layers of an electrically conductive material. The compositions of the present invention are sprayable by an internally charged electrostatic sprayer.",DU PONT,CHANG DAVID C K,,https://lens.org/013-980-904-642-128,Patent Application,no,0,0,14,17,0,B05D1/04;;B05D1/04;;C09D5/24;;C08L61/28;;C09D5/002;;C09D5/24;;C09D7/20;;C09D7/61,B05D1/04;;B05D5/12;;B05D7/14;;B05D7/24;;C08J7/04;;C09D5/00;;C09D5/24;;C09D7/12;;C09D201/00;;C09J9/02;;H01B1/24;;H01B13/00,,0,0,,,,EXPIRED
385,US,A1,US 2008/0172114 A1,036-635-908-598-520,2008-07-17,2008,US 1446208 A,2008-01-15,US 1446208 A;;US 88088707 P;;US 88088307 P;;US 88081207 P;;US 88081307 P,2007-01-17,PHOTOTHERAPY HANDPIECE,"A phototherapy device is disclosed including: a handpiece; and a beamshaping element housed in the handpiece. The beamshaping element is adapted to receive a beam of light from an ultraviolet light source, modify the shape of the beam, and direct the modified beam to provide illumination of a region of a treatment surface, the region, having a cross section at the treatment surface with an irregularly shaped boundary. In some embodiments, the irregularly shaped boundary is composed of one or more segments, each segment being sinusoid-like. In some embodiments, the beamshaping element includes a screen disposed between the light source and the treatment surface, the screen including a light transmissive region with an irregularly shaped boundary, and where the irregularly shaped boundary of the illuminated area corresponds to the irregularly shaped boundary of the light transmissive region.",LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,LERNER MEDICAL DEVICES INC (2008-01-14),https://lens.org/036-635-908-598-520,Patent Application,yes,35,6,4,18,0,A61N5/0616;;A61N2005/0644;;A61N2005/0661;;A61B2090/036;;A61B2090/065;;A61N5/0616;;A61N2005/0644;;A61N2005/0661;;A61B2090/036;;A61B2090/065;;A61N5/0624,A61N5/06,607/94,0,0,,,,DISCONTINUED
386,US,A1,US 2009/0100275 A1,030-142-340-708-972,2009-04-16,2009,US 97469907 A,2007-10-15,US 97469907 A,2007-10-15,Dynamic port power allocation apparatus and methods,"Methods and apparatus for dynamically adjusting the amount of power (or current) distributed to one or more connected devices via electrical interfaces. In one embodiment, the apparatus comprises a first module adapted to detect current drawn by a first set of ports, and a second module adapted to adjust the current provided to a second set of ports based on the detected current. The second module is also optionally adapted to distribute unreserved current among the devices according to an allocation protocol. In the exemplary context of a plurality of interconnected serial bus devices, the invention enables a device to draw more current than that required to be reserved for that device (such as to comply with a specification such as USB), yet without increasing the total amount of power which must be dedicated to the serial ports as a whole. Power supply efficiency may also be advantageously optimized.",CHANG RAY;;FERGUSON DAVID,CHANG RAY;;FERGUSON DAVID,APPLE INC (2007-11-05),https://lens.org/030-142-340-708-972,Patent Application,yes,18,201,5,5,0,G06F1/266;;G06F1/266;;H02J7/00,G06F1/26,713/300,0,0,,,,ACTIVE
387,US,A,US 4104685 A,051-560-802-868-115,1978-08-01,1978,US 75923877 A,1977-01-13,US 75923877 A,1977-01-13,Video recorder/reproducer transport having two movable tension guides for controlling tape tension,"A video recorder/reproducer tape transport including a supply reel, a take-up reel, a helical scanner head assembly for recording and reproducing signals on the tape in a helical scan format, a capstan, a first movable tension tape guide positioned within the tape path intermediate the scanner head assembly and one of said reels and being movable under tension between a first location and a second location, the first movable tension tape guide being constantly under tension urging it towards the first location in opposition to the tension on the tape, and a second movable tension tape guide positioned within the tape path intermediate the other of the reels and the capstan, and being movable under tension between a third and a fourth location, the second movable tension tape guide being constantly under tension urging it toward the third location in opposition to the tension on the tape.",RECORTEC INC,CHANG DAVID T L,,https://lens.org/051-560-802-868-115,Granted Patent,yes,5,24,1,1,0,G11B15/28;;G11B15/43;;G11B15/56;;G11B15/56;;G11B15/43;;G11B15/28,G11B15/28;;G11B15/43;;G11B15/56,360/84,0,0,,,,EXPIRED
388,WO,A1,WO 2008/019445 A1,046-348-490-591-452,2008-02-21,2008,AU 2007/001164 W,2007-08-16,AU 2006/904478 A;;AU 2006/906441 A,2006-08-17,A DOOR STRIKE,"A door strike including: a latch retainer for retaining a door latch; a lock actuator which operates when power is applied; a mode selector rotatable between at least two positions; in a first position of the mode selector the strike adopts a power to open mode, in the second position of the mode selector the strike adopts a power to lock mode.",SHANGHAI ONE TOP CORP;;FIRE & SECURITY HARDWARE PTY L;;MACKLE TREVOR;;CHANG DAVID,MACKLE TREVOR;;CHANG DAVID,,https://lens.org/046-348-490-591-452,Patent Application,yes,11,2,9,9,0,E05B47/0047;;E05B47/0047;;E05B63/0065;;E05B63/0065;;E05B2047/0073;;E05B2047/0073;;E05B2047/0076;;E05B2047/0076;;Y10T292/699;;Y10T292/699,E05B47/00;;E05B15/02,,2,0,,,"DATABASE WPI Week 200517, Derwent World Patents Index; Class Q47, AN 2005-155461, XP008102638;;See also references of EP 2054570A4",PENDING
389,US,A,US 4323930 A,042-302-138-204-231,1982-04-06,1982,US 19400880 A,1980-10-06,US 19400880 A,1980-10-06,Slow moving video tape reproduction,A U-Matic video tape recorder of the type which is modified so as to employ wide-band-direct circuitry for developing a modulated signal from a video signal and to divide each frame of the modulated signal into several segments for recordation upon respective tracks of a tape is further modified to include circuitry for transporting the tape at a reduced rate wherein each segment of the modulated signal is multiply reproduced and circuitry for combining one of each multiply reproduced segments of a signal developed by a demodulator of the reproduced modulated signal with a black-level video signal to develop a signal representing in slow motion the original video signal.,RECORTEC INC,CHANG DAVID T L,RECOTEC INC (1980-09-26),https://lens.org/042-302-138-204-231,Granted Patent,yes,8,7,1,1,0,H04N5/78266;;H04N5/783;;H04N5/93;;H04N5/78266;;H04N5/93;;H04N5/783,H04N5/7826;;H04N5/783;;H04N5/93,360/10,0,0,,,,EXPIRED
390,US,B2,US 9246868 B2,068-575-476-911-876,2016-01-26,2016,US 201414339536 A,2014-07-24,US 201414339536 A;;US 201113185485 A,2011-07-18,Method and apparatus for social network communication over a media network,"A system that incorporates teachings of the present disclosure may initiate a communication session with a member device of a social network and may activate a speech capture element based on a pattern of prior speech messages. A speech message may be detected at the speech capture element and, in turn, transmitted to the member device.",AT & T IP I LP,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I LP (2011-07-15);;MICROSOFT TECHNOLOGY LICENSING LLC (2023-09-20),https://lens.org/068-575-476-911-876,Granted Patent,yes,18,0,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,H04L12/58;;G06Q50/00;;G10L15/00;;G10L19/00;;H04L12/18;;H04M3/533,,0,0,,,,ACTIVE
391,WO,A1,WO 2021/021714 A1,067-779-849-612-800,2021-02-04,2021,US 2020/0043706 W,2020-07-27,US 201962879957 P,2019-07-29,METHOD OF CONTEXTUAL SPEECH DECODING FROM THE BRAIN,"Provided are methods of contextual decoding and/or speech decoding from the brain of a subject. The methods include decoding neural or optical signals from the cortical region of an individual, extracting context-related features and/or speech-related features from the neural or optical signals, and decoding the context-related features and/or speech-related features from the neural or optical signals. Contextual decoding and speech decoding systems and devices for practicing the subject methods are also provided.",UNIV CALIFORNIA,CHANG EDWARD;;MOSES DAVID,,https://lens.org/067-779-849-612-800,Patent Application,yes,5,3,5,5,0,A61B5/372;;G10L15/24;;A61B5/4064;;A61B5/024;;A61F4/00;;G06F3/015;;G10L13/02;;G10L15/142;;G10L15/22;;G10L15/24;;G10L25/18;;G10L25/24;;G10L25/63;;G10L2015/227,A61B5/0476;;A61B5/0402;;A61B5/0408,,0,0,,,,PENDING
392,US,A,US 5500605 A,079-235-560-263-339,1996-03-19,1996,US 12185093 A,1993-09-17,US 12185093 A,1993-09-17,Electrical test apparatus and method,"The invention is a method for testing an electronic device (10) of the type having on one side thereof an array of conductive projections, such as solder balls (15), arranged in a first configuration. An array of spring-loaded probes (25) is arranged in the first configuration. An insulative template (18) is formed comprising an array of apertures (19) arranged in the first configuration which is aligned with the spring-loaded conductive probes. The electronic device (10) is then forced against the template (18) such that each solder ball (15) projects into the aperture to contact a spring-loaded conductive probe (25). Electrical current is passed through at least part of the electronic device, at least some of the solder balls, and at least some of the conductive probes as is required for electrical testing of the electronic device.",AT & T CORP,CHANG DAVID D C,AT&T IPM CORP (1995-05-23);;AT&T CORP (1994-04-20);;AMERICAN TELEPHONE AND TELEGRAPH COMPANY (1993-09-13),https://lens.org/079-235-560-263-339,Granted Patent,yes,10,172,1,1,0,G01R1/0408;;G01R1/06711;;G01R1/06722;;G01R1/07314;;G01R1/06738;;G01R1/06711;;G01R1/07314;;G01R1/06722;;G01R1/0408;;G01R1/06738,G01R1/04;;G01R1/067;;G01R1/073,H2E EAHC          EAHC;;H2E EAHC          EAHCX;;H2E EAHCX         EAHCX;;H2E EAHP          EAHP,2,0,,,"BGAs Face Production Testing, by D. Hattas, Advanced Packaging, Summer 1993, pp. 44 46.;;Cost Effective Interconnections for High I/O MCM C to Card Assemblies, by T. Caulfield et al., Surface Mount Technology, Jul. 1993, pp. 18 20.",EXPIRED
393,EP,A2,EP 0227367 A2,078-188-661-807-280,1987-07-01,1987,EP 86309541 A,1986-12-08,US 80675585 A,1985-12-09,Hybridoma cell lines and their monoclonal antibodies to human pluripotent granulocyte colony stimulating factor.,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.  ",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/078-188-661-807-280,Patent Application,yes,0,2,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;G01N33/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
394,US,A,US 4731290 A,097-229-952-708-343,1988-03-15,1988,US 90619586 A,1986-09-11,US 90619586 A;;EP 87311191 A,1986-09-11,Process for improving the appearance of a multilayer finish,"An improved process for applying a multilayer finish on a primer coated substrate by using a guide coating composition that is applied over the primer of the substrate and then a water borne base coating composition containing metallic pigments and a clear coating composition are applied; before the base coating composition is applied, the guide coating composition is dried at ambient temperatures or at elevated temperatures but not fully cured or crosslinked; the guide coating contains a polymeric latex in an aqueous carrier, preferably an acrylic latex, and optionally, a crosslinking agent and metallic flake pigments; the process improves the appearance, particularly head-on-brightness of water borne basecoat/clear coat finishes in which the base coat contains metallic flake pigments.",DU PONT,CHANG DAVID C K,E.I. DU PONT DE NEMOURS AND COMPANY (1986-09-04),https://lens.org/097-229-952-708-343,Granted Patent,yes,12,47,1,3,0,B05D7/572;;B05D7/572;;B05D5/068;;B05D5/068;;Y10T428/264;;Y10T428/264;;Y10T428/31855;;Y10T428/31855,B05D5/06;;B05D7/00,B2E EQ            EQ          1;;B2E EQ            EQ          2;;B2E EQ            EQ          3;;B2E E1708         EQ          1;;B2E E1708         EQ          2;;B2E E1708         EQ          3;;B2E E409S         EQ          1;;B2E E415S         EQ          1;;B2E E436CU        EQ          2;;B2E E436CU        EQ          3;;B2E E436S         EQ          1;;B2E E443S         EQ          1;;B2E E443T         EQ          1;;B2E E443U         EQ          3;;B2E E444T         EQ          1;;B2E E444U         EQ          2;;B2E E444U         EQ          3;;B2E E448T         EQ          1;;B2E E448U         EQ          2;;B2E E448U         EQ          3;;B2E E450T         EQ          1;;B2E E450T         EQ          2;;B2E E450U         EQ          1;;B2E E489T         EQ          1;;B2E E489T         EQ          2;;B2E E489T         EQ          3;;B2E E489U         EQ          1;;B2E E489U         EQ          2;;B2E E506T         EQ          1;;B2E E506T         EQ          2;;B2E E506U         EQ          1;;B2E E506U         EQ          2;;B2E E508T         EQ          1;;B2E E508T         EQ          2;;B2E E508U         EQ          1;;B2E E508U         EQ          2;;B2E E509T         EQ          1;;B2E E509T         EQ          2;;B2E E509U         EQ          1;;B2E E509U         EQ          2;;B2E E610U         EQ          1;;B2E E610U         EQ          3;;B2E E621T         EQ          1;;U1S S1854,0,0,,,,EXPIRED
395,DE,A1,DE 2826910 A1,111-699-712-861-359,1979-04-05,1979,DE 2826910 A,1978-06-20,US 83554277 A,1977-09-22,UEBERZOGENER METALLGEGENSTAND,,GEN ELECTRIC,CHANG DAVID RONG-HWAN,,https://lens.org/111-699-712-861-359,Patent Application,no,0,1,11,11,0,C23C28/021;;C23C28/023;;C23C28/028;;F01D25/007;;Y10T428/12806;;Y10T428/12931;;Y10T428/12743;;Y10T428/12757;;Y10T428/12875;;Y10T428/12458;;Y10T428/1275;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;Y10T428/12743;;Y10T428/12757;;Y10T428/12875;;Y10T428/12458;;Y10T428/1275;;Y10T428/12854;;F01D25/007;;C23C28/028;;C23C28/023;;C23C28/021,C23C10/28;;C23C10/52;;C23C10/54;;C23C10/56;;C23C28/02;;F01D25/00,,1,0,,,NICHTS-ERMITTELT,EXPIRED
396,US,A,US 5100735 A,119-567-213-114-275,1992-03-31,1992,US 55708490 A,1990-07-25,US 55708490 A;;CA 2062302 A,1990-07-25,Waterborne basecoat/high solids clear finish for automotive substrates having an improved appearance,"An improved process for forming a multilayer finish on a substrate by applying a layer of a waterborne basecoating composition to the substrate, at least partially drying the coating, applying a layer of a solvent based high solids clear coating to the basecoating and curing the coatings; the improvement that is used therewith is as follows: A. a waterborne basecoating composition that has a film forming binder of an acrylic polymer neutralized with ammonia, a primary amine or a secondary amine without the presence of a tertiary amine a water dispersible or water dilutable alkylated melamine formaldehyde resin and the composition contains pigments in a pigment to binder weight ratio of about 0.5/100 to 200/100; B. a high solids solvent based clear coating composition having a film forming binder of an acrylic polymer, a polyester or a polyesterurethane and an alkylated melamine formaldehyde crosslinking agent and about 0.1-5% by weight, based on the weight of the binder, of a strong acid catalyst; wherein the basecoating composition and the clear coating composition are cured at about 100.degree.-180.degree. C. to form a glossy wrinkle free finish having an automotive quality appearance.",DU PONT,CHANG DAVID C K,E. I. DU PONT DE NEMOURS AND COMPANY (1990-07-20),https://lens.org/119-567-213-114-275,Granted Patent,yes,24,45,3,3,0,B05D7/534;;B05D2451/00;;B05D2502/00;;B05D2504/00;;B05D2508/00;;C08L61/32;;C09D133/066;;Y10T428/264;;Y10T428/2982;;Y10T428/31909;;Y10T428/31928;;Y10T428/31935;;Y10T428/31692;;Y10T428/31862;;Y10T428/264;;Y10T428/2982;;Y10T428/31909;;Y10T428/31928;;Y10T428/31935;;Y10T428/31692;;Y10T428/31862;;B05D7/534;;B05D2504/00;;B05D2508/00;;B05D2451/00;;C09D133/066;;B05D2502/00;;C08L61/32,B05D7/00;;C08L61/32;;C09D133/06,428/515;;428/335;;428/402;;428/461;;428/502;;428/520;;428/522;;427/407.1;;427/409,0,0,,,,EXPIRED
397,NZ,A,NZ 218336 A,129-035-344-630-531,1991-08-27,1991,NZ 21833686 A,1986-11-19,US 80675585 A,1985-12-09,MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR (HPG-CSF),"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/129-035-344-630-531,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;G01N33/53;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,DISCONTINUED
398,US,A1,US 2018/0192961 A1,174-271-189-806-264,2018-07-12,2018,US 201715715113 A,2017-09-25,US 201715715113 A;;US 2016/0024464 W;;US 201562139014 P,2015-03-27,APPLICATION OF THE EXTREMA DISTORTION METHOD TO OPTIMIZE CONTROL SIGNALS,"A system is described that observes a signal from a subject of interest, converts the signal to an electrical representation, uses the electrical representation to compute a synthetic control signal, and applies the synthetic control signal to control some aspect of operation of the subject. The procedure used to generate the synthetic control signal involves subjecting the electrical representation of the observed signal to random noise, allowing the extrema of the electrical representation to move, and obtaining a converged solution as the synthetic control signal.",UNIV MASSACHUSETTS MEDICAL SCHOOL,PAYDARFAR DAVID;;CHANG JOSHUA,,https://lens.org/174-271-189-806-264,Patent Application,yes,4,5,3,3,0,A61B5/7235;;A61B5/7235;;A61B5/24;;A61B5/24;;A61B5/4094;;A61B5/4094;;A61B5/7203;;A61M2021/0055,A61B5/00;;A61B5/04,,0,0,,,,ACTIVE
399,US,A1,US 2008/0172115 A1,182-287-409-721-729,2008-07-17,2008,US 1448208 A,2008-01-15,US 1448208 A;;US 88088707 P;;US 88081307 P;;US 88088307 P;;US 88081207 P;;US 2008/0000499 W,2007-01-17,FIBER OPTIC BRUSH FOR LIGHT DELIVERY,"A phototherapy apparatus is disclosed including: a body member; a plurality of elongated light transmitting elements, each of the elements extending between a proximal end enclosed within the body member and a distal end located outside of and distal to the body member; where the tips of the proximal ends of the light transmitting elements are located in close proximity to each other; and an optical connector configured to detachably receive an end of a lightguide and to couple light delivered by the lightguide from a source into the light transmitting elements at the proximal ends. The light coupled into each of the light transmitting elements is transmitted along the element and emitted from the distal end.",LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,LERNER MEDICAL DEVICES INC (2008-01-14),https://lens.org/182-287-409-721-729,Patent Application,yes,34,16,4,18,0,A61N5/0616;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N2005/0661;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N5/0616;;A61N2005/0661,A61N5/06,607/94,0,0,,,,INACTIVE
400,WO,A2,WO 2008/088814 A2,170-592-638-075-615,2008-07-24,2008,US 2008/0000545 W,2008-01-15,US 88081207 P;;US 88088307 P;;US 88081307 P;;US 88088707 P,2007-01-17,PHOTOTHERAPY HANDPIECE,"A phototherapy device is disclosed including: a handpiece; and a beamshaping element housed in the handpiece. The beamshaping element is adapted to receive a beam of light from an ultraviolet light source, modify the shape of the beam, and direct the modified beam to provide illumination of a region of a treatment surface, the region having a cross section at the treatment surface with an irregularly shaped boundary. In some embodiments, the irregularly shaped boundary is composed of one or more segments, each segment being sinusoid-like. In some embodiments, the beamshaping element includes a screen disposed between the light source and the treatment surface, the screen including a light transmissive region with an irregularly shaped boundary, and where the irregularly shaped boundary of the illuminated area corresponds to the irregularly shaped boundary of the light transmissive region.",LERNER MEDICAL DEVICES INC;;GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/170-592-638-075-615,Patent Application,yes,0,1,4,18,0,A61N5/0616;;A61N2005/0644;;A61N2005/0661;;A61B2090/036;;A61B2090/065;;A61N5/0616;;A61N2005/0644;;A61N2005/0661;;A61B2090/036;;A61B2090/065;;A61N5/0624,A61B18/18,,0,0,,,,PENDING
401,US,A1,US 2021/0189499 A1,182-820-286-184-267,2021-06-24,2021,US 201916725914 A,2019-12-23,US 201916725914 A,2019-12-23,URINARY METABOLOMIC BIOMARKERS FOR DETECTING COLORECTAL CANCER AND POLYPS,"The invention relates to methods and compositions for detecting colorectal cancer and colorectal polyps by measurement of metabolites in bodily fluids such as urine, including diacetylspermine and kynurenine.",METABOLOMIC TECH INC,DENG LU;;CHANG DAVID,METABOLOMIC TECHNOLOGIES INC (2020-01-03),https://lens.org/182-820-286-184-267,Patent Application,yes,0,3,2,2,0,A61K31/00;;G01N33/57419;;G01N2800/52;;G01N33/57484;;G01N33/57488;;G01N33/58;;G01N33/6848;;C40B30/06;;C12Q1/6886;;C12Q2600/158;;C12Q2600/106;;A61K45/06;;G01N2800/7028;;G01N2800/50;;G01N2800/52;;G01N33/493;;G01N33/492;;G01N33/57419,C12Q1/6886,,0,0,,,,ACTIVE
402,KR,B1,KR 100225703 B1,190-142-206-056-354,1999-10-15,1999,KR 930000769 A,1993-01-21,US 82394292 A,1992-01-22,PASSIVE SHIELD FOR CVD WAFER PROCESSING WHICH PROVIDES FRONTSIDE EDGE EXCLUSION AND PREVENTS BACKSIDE DEPOSITIONS,"본 발명은 CVD 프로세싱을 위한 진공증착 장치에 관한 것으로, 가스 출구 또는 샤우어헤드 하부의 수직으로 이동이 가능한 축열기 상에 장착된 웨이퍼는 상승되어, 통상 챔버내의 링 지지부 상에 놓이는 차폐링과 접촉하게 된다. 상기 차폐링은 웨이퍼의 전면에지와 결합하며, 상기 축열기 및 웨이퍼(10)가 챔버내의 증착위치로 상승될때 상기 차폐링을 그 지지부로 부터 상승시킨다. 상기 차폐링은 웨이퍼의 전면에지를 결합시키므로, 증착시키는 동안 웨이퍼의 단부 에지 및 후면은 물론이고, 웨이퍼의 상부 표면의 에지를 차폐시킨다. 상기 축열기 및 차폐링 상의 매칭하여 뾰족해진 에지는 축열기에 대해 차폐링의 정렬 및, 축열기 및 차폐링에 대해 웨이퍼의 정렬을 허용한다. 정렬수단은 상기 차폐링을 챔버내의 그 지지부에 회전하여 정렬하기 위해서 열린다, 다중-장치 차폐링은 더 넓은 링의 사용을 허용하며 처리중에 웨이퍼 주변의 온도차와 상기 웨이퍼로 부터 발생되는 열응력으로 인한 차폐링의 박리를 방지한다. 이러한 차폐링은 서로에 대해서 링의 정렬을 보장하기 위해서 에지를 뾰족하게 할 수 있다.",APPLIED MATERIALS INCOPORATED,CHENG DAVID;;CHANG MEI,,https://lens.org/190-142-206-056-354,Granted Patent,no,0,2,7,7,0,C23C16/04;;C23C16/042;;C23C16/45521;;C23C16/4585;;H01L21/283;;C23C16/45521;;C23C16/04;;C23C16/4585;;C23C16/042,C23C16/00;;C23C14/50;;C23C16/04;;C23C16/44;;C23C16/455;;C23C16/458;;H01L21/205;;H01L21/302;;H01L21/3065,,0,0,,,,EXPIRED
403,US,A1,US 2014/0337015 A1,184-399-476-466-632,2014-11-13,2014,US 201414339536 A,2014-07-24,US 201414339536 A;;US 201113185485 A,2011-07-18,METHOD AND APPARATUS FOR SOCIAL NETWORK COMMUNICATION OVER A MEDIA NETWORK,"A system that incorporates teachings of the present disclosure may initiate a communication session with a member device of a social network and may activate a speech capture element based on a pattern of prior speech messages. A speech message may be detected at the speech capture element and, in turn, transmitted to the member device.",AT & T IP I LP,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I LP (2011-07-15);;MICROSOFT TECHNOLOGY LICENSING LLC (2023-09-20),https://lens.org/184-399-476-466-632,Patent Application,yes,0,1,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,H04L12/58,704/201,0,0,,,,ACTIVE
404,CA,C,CA 3065979 C,063-941-733-774-805,2023-03-14,2023,CA 3065979 A,2019-12-23,CA 3065979 A,2019-12-23,URINARY METABOLOMIC BIOMARKERS FOR DETECTING COLORECTAL CANCER AND POLYPS,"ABSTRACT The invention relates to methods and compositions for detecting colorectal cancer and colorectal polyps by measurement of metabolites in bodily fluids such as urine, including diacetylspermine and kynurenine. CA 3065979 2019-12-23",METABOLOMIC TECH INC,DENG LU;;CHANG DAVID,,https://lens.org/063-941-733-774-805,Granted Patent,no,0,0,2,2,0,G01N33/57419;;G01N33/57488,G01N33/48;;G01N33/483;;G01N33/53,,0,0,,,,ACTIVE
405,EP,A1,EP 0029597 A1,073-941-213-599-268,1981-06-03,1981,EP 80107271 A,1980-11-21,US 9628679 A;;US 14626880 A,1979-11-21,"An aqueous thermosetting acrylic coating composition, articles coated therewith, and process for preparing said coated articles.","An aqueous coating composition is disclosed which comprises about 10-60% by weight of film-forming constituents which consist of
 (1) 60-90% by weight, based on the weight of the film-forming constituents, of an acrylic polymer consisting of polymerized monomers of methyl methacrylate, butyl acrylate, hydroxyethyl acrylate, and of acrylic acid or methacrylic acid; wherein 30-50% by weight of the acrylic polymer is dispersed and has a particle size of 0.01-0.10 microns and the remaining 50-70% is soluble and dissolved, and (2) 10-40% by weight, of hexakis(methoxymethyl)melamine; and
 the composition contains sufficient amine to provide a pH of about 7.1-7.5; and the composition contains about 1-20% by weight, of ultraviolet light stabilizer. The weatherability and durability of finishes prepared therefrom are significantly increased. I",DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/073-941-213-599-268,Patent Application,yes,4,6,5,6,0,C09D133/12;;C08L61/20,C08L61/20;;C09D133/12,,1,0,,,"CHEMICAL ABSTRACTS, Vol. 81, No. 24, 16th December 1974, page 133, No. 154716x Columbus, Ohio, U.S.A. & JP-A-49 55737 (DAINIPPON PRINTING CO., LTD.) 30-05-1974 * Abstract *",DISCONTINUED
406,CN,A,CN 103562371 A,088-703-413-594-286,2014-02-05,2014,CN 201180071204 A,2011-05-27,CN 2011000905 W,2011-05-27,Liquid soaps with triclocarban,"An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount that is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.",COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/088-703-413-594-286,Patent Application,no,5,1,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/00;;C11D9/02;;C11D9/30;;C11D9/50,,0,0,,,,DISCONTINUED
407,US,A,US 3501078 A,098-954-666-783-092,1970-03-17,1970,US 3501078D A,1967-10-02,US 67224867 A,1967-10-02,SINGLE-EDGE TROUGH TAPE GUIDE,,AMPEX,CHANG DAVID T L,,https://lens.org/098-954-666-783-092,Granted Patent,no,5,4,1,1,0,G11B15/58;;G11B15/60;;G11B15/58;;G11B15/60,G11B15/58;;G11B15/60,226/198,0,0,,,,EXPIRED
408,EP,A1,EP 0029592 A1,114-581-525-773-535,1981-06-03,1981,EP 80107266 A,1980-11-21,US 9628879 A;;US 14626480 A,1979-11-21,"A coating composition based on acrylic polymer blends, articles coated therewith, and process for preparing said coated articles.","A liquid coating composition is disclosed consisting essentially of an acrylic polymer blend, an inert organic solvent, and certain ultraviolet light stabilizers. The weatherability and durability of finishes prepared therefrom are significantly increased.",DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/114-581-525-773-535,Patent Application,yes,4,1,3,4,0,C09D133/10;;C08L33/10;;C08L2205/02,C08L33/10;;C09D133/10,,0,0,,,,DISCONTINUED
409,US,B2,US 8825493 B2,137-603-282-776-086,2014-09-02,2014,US 201113185485 A,2011-07-18,US 201113185485 A,2011-07-18,Method and apparatus for social network communication over a media network,"A system that transmits a request to initiate a communication session with a member device of a social network may include, for example, activating a speech capture element, maintaining activation of the speech capture element in accordance with a pattern of prior speech messages, detecting a speech message at the activated speech capture element, and transmitting the detected speech message, or a derivative thereof, to the member device of the social network.",CHANG HISAO;;MORNHINEWAY DAVID;;AT & T IP I LP,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I L.P (2011-07-15),https://lens.org/137-603-282-776-086,Granted Patent,yes,19,2,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,G10L21/00,704/275;;704/270;;704/9,0,0,,,,INACTIVE
410,EP,A4,EP 2054570 A4,146-564-599-727-634,2013-11-20,2013,EP 07784803 A,2007-08-16,AU 2007/001164 W;;AU 2006/904478 A;;AU 2006/906441 A,2006-08-17,A DOOR STRIKE,,SHANGHAI ONE TOP CORP;;DIERCKX AMELIE;;LEQUY MICHEL,MACKLE TREVOR;;CHANG DAVID,"DIERCKX, AMELIE (2014-10-22);;SHANGHAI ONE TOP CORPORATION (2014-10-22);;LEQUY, MICHEL (2014-10-22)",https://lens.org/146-564-599-727-634,Search Report,no,3,0,9,9,0,E05B47/0047;;E05B47/0047;;E05B63/0065;;E05B63/0065;;E05B2047/0073;;E05B2047/0073;;E05B2047/0076;;E05B2047/0076;;Y10T292/699;;Y10T292/699,E05B47/00;;E05B15/02,,1,0,,,See also references of WO 2008019445A1,ACTIVE
411,EP,A2,EP 0392134 A2,159-818-197-010-568,1990-10-17,1990,EP 90100711 A,1990-01-15,US 33760789 A,1989-04-13,Process for treatment of backside of semiconductor wafer.,"A process and an apparatus are disclosed for the treatment of the backside or back surface of a semiconductor wafer such as a silicon wafer. By spacing the back side of a semiconductor wafer a predetermined distance from a cathode in a vacuum chamber and controlling the rf power and the pressure, a confined plasma may be used both to clean the back side of the wafer to remove impurities, including moisture and other occluded gases; as well as to deposit a layer of oxide on the back surface of the wafer to inhibit subsequent deposition of poorly adherent materials on the back side of the wafer which might otherwise flake off during processing of the front side of the wafer to form integrated circuits thereon.  ",APPLIED MATERIALS INC,CHANG MEI;;CHENG DAVID,,https://lens.org/159-818-197-010-568,Patent Application,yes,0,3,6,6,0,C23C8/36;;C23C14/022;;C23C16/0245;;H01L21/02046;;H01L21/02238;;H01L21/02252;;H01L21/67069;;H01L21/6875;;Y10S438/906;;Y10S438/928;;H01L21/08;;H01L21/31612;;H01L21/67069;;C23C14/022;;C23C8/36;;H01L21/02238;;H01L21/02046;;H01L21/6875;;H01L21/02252;;C23C16/0245;;Y10S438/928;;Y10S438/906,C23C8/36;;C23C14/02;;C23C16/02;;H01L21/00;;H01L21/306;;H01L21/316;;H01L21/687,,0,0,,,,DISCONTINUED
412,US,B2,US 8206426 B2,163-730-040-484-886,2012-06-26,2012,US 1445008 A,2008-01-15,US 1445008 A;;US 88081207 P;;US 88088307 P;;US 88081307 P;;US 88088707 P;;US 2008/0000495 W,2007-01-17,Light source and fiber optic brush for light delivery,"A phototherapy apparatus is disclosed including: a handpiece including a body member and a grip; a plurality of elongated light transmitting elements, each of the elements extending between a proximal end enclosed within the body member and a distal end located outside of and distal to the body member; an ultraviolet light source; a light collection element; and one or more optical coupling elements. The proximal ends of the light transmitting elements are located in close proximity to each other The light collection element is configured to collect at least a portion of the light emitted from the light source. The one or more optical coupling elements are configured to direct at least a portion of the collected light to the proximal ends of the light transmitting elements to couple at least portion of the collected light into the light transmitting elements The light coupled into each of the light transmitting elements is transmitted along the element and emitted from the distal end.",GOURGOULIATOS ZAFIRIOS;;CHANG DAVID;;LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,ADVANCED DISTRIBUTED SENSOR SYSTEMS INC (2009-01-29);;LERNER MEDICAL DEVICES INC (2008-01-14),https://lens.org/163-730-040-484-886,Granted Patent,yes,22,1,4,18,0,A61N5/0616;;A61N5/0617;;A61N2005/063;;A61N2005/0644;;A61N2005/0654;;A61N2005/0661;;A61N5/0617;;A61N2005/0661;;A61N2005/0644;;A61N2005/063;;A61N2005/0654;;A61N5/0616,A61N5/06,607/94;;607/88;;607/89;;604/289;;604/290,4,1,020-232-052-306-844,15186234;;10.1111/j.1365-4632.2004.01993.x,"Taneja, A. et al., ""Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study"", International Journal of Dermatology, vol. 43, pp. 462-467, 2004.;;PCT International Search Report (PCT/US08/00495); Date of mailing Jun. 18, 2008; 1 page.;;PCT International Search Report (PCT/US08/00499); Date of mailing Jul. 7, 2008; 1 page.;;PCT International Search Report (PCT/US08/00545); Date of mailing Jul. 11, 2008; 1 page.",INACTIVE
413,WO,A1,WO 2016/160675 A1,180-296-409-038-200,2016-10-06,2016,US 2016/0024464 W,2016-03-28,US 201562139014 P,2015-03-27,THE APPLICATION OF THE EXTREMA DISTORTION METHOD TO OPTIMIZE CONTROL SIGNALS,"A system is described that observes a signal from a subject of interest, converts the signal to an electrical representation, uses the electrical representation to compute a synthetic control signal, and applies the synthetic control signal to control some aspect of operation of the subject. The procedure used to generate the synthetic control signal involves subjecting the electrical representation of the observed signal to random noise, allowing the extrema of the electrical representation to move, and obtaining a converged solution as the synthetic control signal.",UNIV MASSACHUSETTS MEDICAL SCHOOL,PAYDARFAR DAVID;;CHANG JOSHUA,,https://lens.org/180-296-409-038-200,Patent Application,yes,3,2,3,3,0,A61B5/7235;;A61B5/7235;;A61B5/24;;A61B5/24;;A61B5/4094;;A61B5/4094;;A61B5/7203;;A61M2021/0055,A61B5/00;;A61B5/0476;;G06K7/00;;G06K7/10;;G06K7/14,,2,0,,,"CHANG ET AL.: ""Flipping Biological Switches: Solving for Optimal Control: A Dissertation"", 30 March 2015 (2015-03-30), XP055317877, Retrieved from the Internet <URL:http://escholarship.umassmed.edu/Ggi/viewcontent.cgi?article=1765&context=gsbs-diss> [retrieved on 20160519];;SZELISKI: ""Computer Vision: Algorithms and Applications"", ELECTRONIC DRAFT, 2010, XP055317897, Retrieved from the Internet <URL:http://szeliski.org/Book/drafts/SzeliskiBook_20100903_draft.pdf> [retrieved on 20160519]",PENDING
414,CN,A,CN 1073208 A,180-434-259-282-242,1993-06-16,1993,CN 92114700 A,1992-12-12,US 80675585 A,1985-12-09,Hybridoma cell lines and their monoclonal antibodies to human pluripotent granulocyte colony stimulating factor,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/180-434-259-282-242,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,G01N33/53;;A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
415,EP,A1,EP 0320552 A1,177-282-903-200-108,1989-06-21,1989,EP 87311191 A,1987-12-18,EP 87311191 A,1987-12-18,A process for improving the appearance of a multilayer finish.,"An improved process for applying a multilayer finish on a primer coated substrate by using a guide coating composition that is applied over the primer of the substrate and then a water borne base coating composition containing metallic pigments and a clear coating composition are applied; before the base coating composition is applied, the guide coating composition is dried at ambient temperatures or at elevated temperatures but not fully cured or crosslinked; the guide coating contains a polymeric latex in an aqueous carrier, preferably an acrylic latex, and optionally, a crosslinking agent and metallic flake pigments; the process improves the appearance, particularly head-on-brightness of water borne basecoat/clear coat finishes in which the base coat contains metallic flake pigments.  ",DU PONT,CHANG DAVID CHI KUNG,,https://lens.org/177-282-903-200-108,Patent Application,yes,6,21,1,3,0,B05D7/572;;B05D5/068,B05D5/06;;B05D7/00,,0,0,,,,DISCONTINUED
416,US,B1,US 6625132 B1,182-708-586-672-959,2003-09-23,2003,US 19189498 A,1998-11-13,US 19189498 A;;US 6798297 P;;US 6532397 P,1997-11-13,Idle intersystem roaming determination and system reselection in a CDMA wireless communication system,"
    A wireless communication system and a mobile station employ at least one threshold to evaluate the quality of transmissions from a serving base station to determine when the mobile station enters a Dead Zone adjacent a border cell of the system. Such thresholds not only consider the ratio of carrier energy (Ec) to interference (Ec/Io) but also consider the energy of the carrier itself. When the relevant measured (or calculated) carrier energy Ec and/or carrier energy to interference ratio Ec/Io are passed, the mobile station performs system reselection, attempting to acquire a different system/carrier. The thresholds employed may be passed from the base station to the mobile station in the System Parameters message, for example. 
",NORTEL NETWORKS LTD,BOETTGER DAVID;;CHANG KIM,ERICSSON AB (2009-11-13);;NORTEL NETWORKS LIMITED (2000-08-30),https://lens.org/182-708-586-672-959,Granted Patent,yes,14,97,1,1,0,H04B1/7097;;H04B7/2628;;H04B2201/70702;;H04W36/30;;H04W88/06;;H04W36/30;;H04B2201/70702;;H04B7/2628;;H04W88/06;;H04B1/7097,H04B1/707;;H04B7/26;;H04W36/14;;H04W36/30;;H04W48/18;;H04W88/06,370/329;;370/335;;370/342;;370/332;;455/422;;455/513,0,0,,,,EXPIRED
417,WO,A3,WO 2008/088814 A3,009-792-397-305-932,2008-10-16,2008,US 2008/0000545 W,2008-01-15,US 88081207 P;;US 88088307 P;;US 88081307 P;;US 88088707 P,2007-01-17,PHOTOTHERAPY HANDPIECE,"A phototherapy device is disclosed including: a handpiece; and a beamshaping element housed in the handpiece. The beamshaping element is adapted to receive a beam of light from an ultraviolet light source, modify the shape of the beam, and direct the modified beam to provide illumination of a region of a treatment surface, the region having a cross section at the treatment surface with an irregularly shaped boundary. In some embodiments, the irregularly shaped boundary is composed of one or more segments, each segment being sinusoid-like. In some embodiments, the beamshaping element includes a screen disposed between the light source and the treatment surface, the screen including a light transmissive region with an irregularly shaped boundary, and where the irregularly shaped boundary of the illuminated area corresponds to the irregularly shaped boundary of the light transmissive region.",LERNER MEDICAL DEVICES INC;;GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,,https://lens.org/009-792-397-305-932,Search Report,yes,6,0,4,18,0,A61N5/0616;;A61N2005/0644;;A61N2005/0661;;A61B2090/036;;A61B2090/065;;A61N5/0616;;A61N2005/0644;;A61N2005/0661;;A61B2090/036;;A61B2090/065;;A61N5/0624,A61N5/06,,0,0,,,,PENDING
418,DE,A1,DE 2826909 A1,014-218-161-989-092,1979-04-05,1979,DE 2826909 A,1978-06-20,US 83554377 A,1977-09-22,UEBERZOGENER METALLGEGENSTAND,,GEN ELECTRIC,CHANG DAVID RONG-HWAN,,https://lens.org/014-218-161-989-092,Patent Application,no,0,2,11,11,0,C23C28/021;;C23C28/023;;C23C28/028;;F01D5/288;;F01D25/007;;Y10T428/12458;;Y10T428/12875;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;Y10T428/12458;;Y10T428/12875;;Y10T428/12854;;Y10T428/12806;;Y10T428/12931;;F01D25/007;;C23C28/028;;C23C28/021;;F01D5/288;;C23C28/023,C23C10/26;;C23C10/28;;C23C10/52;;C23C10/54;;C23C10/56;;C23C28/02;;F01D5/28;;F01D25/00,,1,0,,,NICHTS-ERMITTELT,EXPIRED
419,WO,A1,WO 2012/162854 A1,034-323-449-201-452,2012-12-06,2012,CN 2011000905 W,2011-05-27,CN 2011000905 W,2011-05-27,LIQUID SOAPS WITH TRICLOCARBAN,"An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount that is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.",COLGATE PALMOLIVE CO;;SHI MANYING;;CHANG DAVID,SHI MANYING;;CHANG DAVID,,https://lens.org/034-323-449-201-452,Patent Application,yes,3,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/00;;C11D9/02;;C11D9/30;;C11D9/50,,1,0,,,See also references of EP 2714882A4,PENDING
420,AU,A,AU 2000/026371 A,070-039-469-211-348,2000-08-25,2000,AU 2000/026371 A,2000-02-02,US 11824499 P;;US 49567500 A;;US 0002628 W,1999-02-02,Delivery system and methods for gene therapy,,SAFESCIENCE INC,PLATT DAVID;;CHANG YAN,,https://lens.org/070-039-469-211-348,Patent Application,no,0,0,5,8,0,A61K38/45;;A61K48/00;;A61K48/00;;A61K38/45,A61K38/45;;A61K48/00,,0,0,,,,DISCONTINUED
421,NO,L,NO 873334 L,109-091-654-464-007,1987-08-10,1987,NO 873334 A,1987-08-10,US 80675585 A;;US 8602554 W,1985-12-09,HYBRIDOMER MOT HUMAN FLERPOTENT GRANULOCYTTKOLONISTIMULERENDE FAKTOR.,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/109-091-654-464-007,Abstract,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;G01N33/53;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
422,EP,A4,EP 2714882 A4,135-063-818-429-107,2014-10-22,2014,EP 11866929 A,2011-05-27,CN 2011000905 W,2011-05-27,LIQUID SOAPS WITH TRICLOCARBAN,,COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/135-063-818-429-107,Search Report,no,3,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/00;;C11D9/02;;C11D9/30;;C11D9/50,,1,0,,,See also references of WO 2012162854A1,DISCONTINUED
423,EP,A1,EP 0489439 A1,129-439-519-115-365,1992-06-10,1992,EP 91120906 A,1991-12-05,US 62266490 A,1990-12-05,Vacuum deposition apparatus for CVD processing.,"An apparatus for CVD processing is described wherein a wafer (10) mounted on a vertically movable susceptor (40) beneath a gas outlet (20) or showerhead is raised into contact with a shield ring (50) which normally rests on a ring support (70) in the chamber (2). The shield ring (50) engages the frontside edge (11) of the wafer (10), lifting the shield ring (50) off its support (70), when the susceptor (40) and the wafer (10) are raised to a deposition position in the chamber (2). The shield ring (50), by engaging the frontside edge of the wafer (10), shields the edge of the top surface of the wafer (10) as well as the end edge and the backside of the wafer, during the deposition. Matching tapered edges (44, 54) respectively, on the susceptor (40) and the shield ring (50) permit alignment of the shield ring (50). Alignment means (52, 72) are also disclosed to circularly align the shield ring (50) to its support (70) in the chamber (2).",APPLIED MATERIALS INC,CHENG DAVID;;CHANG MEI,,https://lens.org/129-439-519-115-365,Patent Application,yes,4,23,5,5,0,C23C16/04;;C23C16/042;;C23C16/45521;;C23C16/4585;;C23C16/45521;;C23C16/4585;;C23C16/4412,C23C16/04;;C23C16/44;;C23C16/455;;H01L21/203;;C23C16/458;;H01L21/285,,0,0,,,,DISCONTINUED
424,US,B2,US 9461957 B2,166-132-456-205-202,2016-10-04,2016,US 201514966574 A,2015-12-11,US 201514966574 A;;US 201414339536 A;;US 201113185485 A,2011-07-18,Method and apparatus for social network communication over a media network,"A system that transmits a request to initiate a communication session with a member device of a social network may include, for example, activating a speech capture element, maintaining activation of the speech capture element in accordance with a pattern of prior speech messages, detecting a speech message at the activated speech capture element, and transmitting the detected speech message, or a derivative thereof, to the member device of the social network. Other embodiments are disclosed.",AT & T IP I LP;;AT & T IP I LP,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I LP (2011-07-15);;MICROSOFT TECHNOLOGY LICENSING LLC (2023-09-20),https://lens.org/166-132-456-205-202,Granted Patent,yes,18,4,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,H04L12/58;;G06Q50/00;;G10L15/00;;G10L15/26;;G10L19/00;;H04L12/18;;H04L29/08;;H04M3/533,,0,0,,,,ACTIVE
425,NZ,A,NZ 580059 A,176-369-311-625-415,2010-10-29,2010,NZ 58005907 A,2007-08-16,AU 2006/904478 A;;AU 2006/906441 A;;AU 2007/001164 W,2006-08-17,Door strike with selectable modes from power to open and power to close for striker,"A door strike including: a latch retainer for retaining a door latch; a lock actuator which operates when power is applied; a mode selector rotatable between at least two positions; in a first position of the mode selector the strike adopts a power to open mode, in the second position of the mode selector the strike adopts a power to lock mode.",SHANGHAI ONE TOP CORP,MACKLE TREVOR;;CHANG DAVID,,https://lens.org/176-369-311-625-415,Patent Application,no,0,0,9,9,0,E05B47/0047;;E05B47/0047;;E05B63/0065;;E05B63/0065;;E05B2047/0073;;E05B2047/0073;;E05B2047/0076;;E05B2047/0076;;Y10T292/699;;Y10T292/699,E05B47/00;;E05B15/02,,0,0,,,,PENDING
426,US,A1,US 2005/0034691 A1,192-809-797-323-973,2005-02-17,2005,US 64111503 A,2003-08-15,US 64111503 A,2003-08-15,Engine valve actuation system,"An engine valve actuation system includes an engine valve moveable between a first position that blocks a flow of fluid and a second position that allows a flow of fluid. The system also includes a valve actuation assembly connected to move the engine valve between the first position and the second position and a fluid actuator configured to selectively modify a timing of the engine valve in moving from the second position to the first position. The fluid actuator includes a first piston. The system further includes an accumulator including a second piston, wherein the second piston is slidably movable in the first piston.",CHANG DAVID YU-ZHANG,CHANG DAVID YU-ZHANG,CATERPILLAR INC (2003-08-14),https://lens.org/192-809-797-323-973,Patent Application,yes,33,18,2,2,0,F01L9/10;;F01L9/10,F01L9/10,123/90.12,0,0,,,,EXPIRED
427,US,A1,US 2013/0024187 A1,010-009-440-025-724,2013-01-24,2013,US 201113185485 A,2011-07-18,US 201113185485 A,2011-07-18,METHOD AND APPARATUS FOR SOCIAL NETWORK COMMUNICATION OVER A MEDIA NETWORK,"A system that incorporates teachings of the present disclosure may include, for example, transmitting a request to initiate a communication session with a member device of a social network, activating a speech capture element, maintaining activation of the speech capture element in accordance with a pattern of prior speech messages, detecting a speech message at the activated speech capture element, and transmitting the detected speech message, or a derivative thereof, to the member device of the social network. Other embodiments are disclosed.",AT & T IP I LP;;CHANG HISAO;;MORNHINEWAY DAVID,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I L.P (2011-07-15),https://lens.org/010-009-440-025-724,Patent Application,yes,14,16,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,G10L21/00,704/201;;X704E21019,0,0,,,,INACTIVE
428,US,A1,US 2014/0210518 A1,028-477-589-180-678,2014-07-31,2014,US 201313849115 A,2013-03-22,US 201313849115 A;;US 201361757947 P,2013-01-29,Resonant Inductor Coupling Clock Distribution,The present disclosure provides for a clock distribution network for distributing clocking signals within a synchronous sequential logic circuit. The clock distribution network distributes the one or more clock signals by inductively and/or capacitively coupling a clocking signal from a primary distribution node to various secondary distribution nodes within the synchronous sequential logic circuit. The various secondary distribution nodes resonate at respective resonant frequencies to generate other clocking signals for use within the synchronous sequential logic circuit in response to receiving the clocking signal.,BROADCOM CORP;;BROADCOM CORP,CHANG DAVID;;HUKKOO AJAT,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2013-03-21),https://lens.org/028-477-589-180-678,Patent Application,yes,6,6,8,16,0,G06F1/10;;G06F1/10;;H03K19/096;;H03K19/096;;H01F38/14;;H02J50/05;;H02J50/10,H03K19/096,326/93;;307/104,0,0,,,,INACTIVE
429,AU,B2,AU 601958 B2,063-218-418-632-572,1990-09-27,1990,AU 1986/066295 A,1986-11-26,US 80675585 A,1985-12-09,HYBRIDOMA'S TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/063-218-418-632-572,Granted Patent,no,3,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,G01N33/53;;A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
430,CA,C,CA 1296662 C,063-375-743-708-090,1992-03-03,1992,CA 524714 A,1986-12-05,US 80675585 A,1985-12-09,HYBRIDOMA CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"""HYBRIDOMA CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR"" Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/063-375-743-708-090,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,G01N33/53;;A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,D31950001112 M;;1670037    S,0,0,,,,EXPIRED
431,TW,B,TW I239752 B,079-305-241-579-898,2005-09-11,2005,TW 93119364 A,2004-06-30,TW 93119364 A,2004-06-30,Module of controlling chord light for an incoming phone and control method thereof,"A module of controlling chord light for an incoming phone is provided, mainly comprising a central processing module, a chord music module, and a keyboard backlight module. When the central processing module receives an incoming phone message, it transmits a message to the chord music module, and the central processing module controls the chord music module to make up music. At the same time, according to the synchronism message from the chord music, the central processing module controls the keyboard backlight module, and makes it to produce the synchronous effects of lighting. According to the chord music, the lighting function of the keyboard backlight module will become various effects of lighting, and will bring the users the enjoyment of vision.",INVENTEC APPLIANCES CORP,HO DAVID;;CHANG CHENG,,https://lens.org/079-305-241-579-898,Granted Patent,no,0,0,2,2,0,,H04M1/22,,0,0,,,,INACTIVE
432,EP,B1,EP 2054570 B1,067-571-109-711-579,2017-05-17,2017,EP 07784803 A,2007-08-16,AU 2007/001164 W;;AU 2006/904478 A;;AU 2006/906441 A,2006-08-17,A DOOR STRIKE,,SHANGHAI ONE TOP CORP;;DIERCKX AMÉLIE;;LEQUY MICHEL,MACKLE TREVOR;;CHANG DAVID,"DIERCKX, AMELIE (2014-10-22);;SHANGHAI ONE TOP CORPORATION (2014-10-22);;LEQUY, MICHEL (2014-10-22)",https://lens.org/067-571-109-711-579,Granted Patent,yes,12,0,9,9,0,E05B47/0047;;E05B47/0047;;E05B63/0065;;E05B63/0065;;E05B2047/0073;;E05B2047/0073;;E05B2047/0076;;E05B2047/0076;;Y10T292/699;;Y10T292/699,E05B47/00;;E05B15/02,,1,0,,,"DATABASE WPI Week 200517, Derwent Publications Ltd., London, GB; Class Q47, AN 2005-155461, XP008102638 & JP 2005 023659 A (HOSHINO KK) 27 January 2005",ACTIVE
433,TW,B,TW I225103 B,084-891-630-142-994,2004-12-11,2004,TW 89113731 A,2000-07-10,TW 89113731 A,2000-07-10,Sputtering target backplate,"A sputtering target backplate is used for mounting a sputtering target in a treatment chamber. One face of the backplate is a cooling face for contacting with a cooling liquid for heat dissipation, and the other face of the backplate is a support face for supporting the sputtering target, in which the support face of the backplate at least includes a buffer layer, in which the thermal expansion coefficient of the buffer layer is between the thermal expansion coefficients of the backplate and the sputtering target, thereby reducing the stress from the backplate on the sputtering target caused by thermal variations during the sputtering operation, and effectively preventing the cracking, warpage and delamination of the sputtering target.",DURATEK INC,TU DAVID;;CHANG CHARLIE,,https://lens.org/084-891-630-142-994,Granted Patent,no,0,2,1,1,0,,C23C14/34;;H01L21/203,,0,0,,,,EXPIRED
434,WO,A3,WO 2012/018609 A3,138-254-974-642-71X,2012-05-31,2012,US 2011/0045331 W,2011-07-26,US 36769610 P,2010-07-26,MIG6 AND THERAPEUTIC EFFICACY,"We identify markers capable of guiding the decision to incorporate epidermal growth factor receptor (EGFR) inhibitors, in particular EGFR tyrosine kinase inhibitors (TKIs), into chemotherapeutic regimens. Mitogen-inducible gene 6 (Mig6), a negative regulator of EGFR, is selectively upregulated during the development of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, resulting in decreased EGFR phosporylation. The ratio of Mig6/EGFR expression highly correlates with erlotinib sensitivity. A low Mig6/EGFR ratio correlates with a high response rate to gefitinib and a marked increase in progression-free survival for patients. The ratio of Mig6 to EGFR is a major predictor of biologic and clinical responses to EGFR inhibitors.",UNIV JOHNS HOPKINS;;SIDRANSKY DAVID;;CHANG XIAOFEI,SIDRANSKY DAVID;;CHANG XIAOFEI,,https://lens.org/138-254-974-642-71X,Search Report,yes,3,0,5,5,0,C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;G01N2333/91205;;G01N2800/44;;C12Q1/6886;;G01N2333/91205;;G01N2800/44;;C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;C12Q1/6886;;C12Q1/485,G01N33/68;;C12Q1/68;;G01N33/574,,4,4,005-451-061-816-412;;030-923-163-116-838;;000-214-474-904-014;;045-069-730-529-618,10.1016/j.canlet.2011.10.023;;22082529;;21333004;;10.1186/1752-0509-5-29;;pmc3224393;;10.1111/j.1432-0436.2007.00238.x;;17999740;;10.1038/nm1401;;16648858,"YOON, Y.-K. ET AL.: ""Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant canc er cells"", CANCER LETTERS, vol. 316, no. 1, March 2012 (2012-03-01), pages 77 - 84, XP028434072;;NARUO, Y. ET AL.: ""Epidermal growth factor receptor mutation in combination w ith expression of MIG6 alters gefitinib sensitivity"", BMC SYSTEMS BIOLOGY, vol. 18, no. 5, February 2011 (2011-02-01), pages 29 - 41;;SIBILIA, M. ET AL.: ""The epidermal growth factor receptor: from development t o tumorigenesis"", DIFFERENTIATION, vol. 75, no. 9, November 2007 (2007-11-01), pages 770 - 787, XP026770226;;FERBY, I. ET AL.: ""Mig6 is a negative regulator of EGF receptor-mediated ski n morphogenesis and tumor formation"", NATURE MEDICINE, vol. 12, no. 5, May 2006 (2006-05-01), pages 568 - 573, XP002423443",PENDING
435,WO,A1,WO 2014/209598 A1,141-367-510-372-730,2014-12-31,2014,US 2014/0041679 W,2014-06-10,US 201313931569 A,2013-06-28,METHODS AND SYSTEMS FOR SIGNAL COMMUNICATION IN GAMMA RAY DETECTORS,"Methods and systems for signal communication in gamma ray detectors are provided. One gamma ray detector includes a scintillator block having a plurality of scintillator crystals and a plurality of light sensors coupled to the scintillator crystals and having a plurality of microcells. Each of the plurality of light sensors have a local summing point in each of a plurality of signal summing regions, wherein the local summing points are connected to the plurality of microcells. The plurality of light sensors also each include a main summing point connected to the plurality of local summing points, wherein the main summing point is located a same distance from each of the local summing points.",GEN ELECTRIC,KIM CHANG;;MCDANIEL DAVID,,https://lens.org/141-367-510-372-730,Patent Application,yes,2,1,3,3,0,G01T1/1642;;G01T1/2914;;G01T1/20;;G01T1/16;;G01T1/1641;;G01T1/20183;;G01T1/20182;;G01T1/2985;;G01T1/2914;;G01T1/20;;G01T1/16;;G01T1/1641;;G01T1/1642;;G01T1/20183;;G01T1/20182,G01T1/24,,0,0,,,,PENDING
436,US,B2,US 6988471 B2,160-675-010-345-086,2006-01-24,2006,US 74300003 A,2003-12-23,US 74300003 A,2003-12-23,Engine valve actuation system,"An engine valve actuation system includes an engine valve moveable between first and second positions, a valve actuation assembly connected to move the engine valve between the first and second positions, a fluid actuator configured to selectively modify a timing of the engine valve in moving from the second to the first position, a source of fluid, and a pair of passages in the cylinder that allow fluid to flow from the chamber to the fluid source. The fluid actuator includes a cylinder and a piston at least partly defining a chamber. The piston is slidably movable in the cylinder between a first position and a second position, and blocks at least a portion of one of the passages at an intermediate position between the second position and the first position to reduce fluid flow from the chamber when the piston moves from the second position toward the first position.",CATERPILLAR INC,CHANG DAVID YU-ZHANG,CATERPILLAR INC (2004-02-16),https://lens.org/160-675-010-345-086,Granted Patent,yes,58,20,3,5,0,F01L9/10;;F01L9/10,F01L9/10;;F01L1/34,123/90.12;;123/90.15;;X123198 F;;91/407;;91/408,11,1,043-080-006-736-450,10.4271/980180,"Edwards et al., ""The Potential of a Combined Miller Cycle and Internal EGR Engine for Future Heavy Duty Truck Applications,"" The Engineering Society for Advancing Mobility Land Sea Air and Space International, International Congress and Exposition, Feb. 23-26, 1998, pp. 1-19.;;Obert, ""Internal Combustion Engines and Air Pollution,"" Based on Internal Combustion Engines, Third Edition, 1973, pp. 612-614.;;Challen et al., ""Diesel Engine Reference Book, Section Edition,"" SAE International, 1999, pp. 75, 81, 84, 146, and 263-305.;;Yorihiro Fukuzawa et al., ""Development of High Efficiency Miller Cycle Gas Engine"", Mitsubishi Heavy Industries, Ltd., Technical Review, vol. 38, No. 3, Oct. 2001, pp. 146-150.;;Request for Inter Partes Reexamination Transmittal Form for U.S. Pat. 6,688,280, and Attachment to Request for Inter Parties Reexamination Transmittal Form, Sep. 17, 2004.;;Request for Inter Partes Reexamination Transmittal Form for U.S. Pat. 6,651,618, and Attachment to Request for Inter Parties Reexamination Transmittal Form, Aug. 27, 2004.;;http://www.mazda.com.au/corpora/209.html, Oct. 16, 2001, p. 1-6.;;Specification for U.S. Appl. No. 10/309,312, Engine Valve Actuation System, filed Dec. 4, 2002.;;U.S. Patent and Trademark Office Action for U.S. Appl. No. 10/309,312, mailed Dec. 2, 2004.;;U.S. Patent and Trademark Office Action for U.S. Appl. No. 10/309,312, mailed Jul. 26, 2004.;;U.S. Patent and Trademark Office Action for U.S. Appl. No. 10/309,312, mailed Feb. 24, 2004.",INACTIVE
437,US,B1,US 11078826 B1,173-397-485-564-906,2021-08-03,2021,US 202017082401 A,2020-10-28,US 202017082401 A,2020-10-28,Gaseous fuel engine and sparkless operating strategy therefor,"Operating an internal combustion engine system includes advancing a prechamber piston in a fuel delivery igniter to push a main charge of fuel from a prechamber into a cylinder, and advancing the prechamber piston to compression-ignite a pilot charge within the prechamber. Combustion gases of the pilot charge are conveyed into the cylinder to ignite the main charge. Operation of the engine system provides sparkless gaseous fuel ignition.",CATERPILLAR INC,CHANG DAVID YU-ZHANG,CATERPILLAR INC (2020-10-27),https://lens.org/173-397-485-564-906,Granted Patent,yes,34,5,1,1,0,F02B19/108;;F02B19/12;;F02B19/06;;F02B19/108;;F02B19/14;;F02D19/024;;F02D41/0027;;F02D41/0027;;F02M21/0275;;F02P13/00;;Y02T10/12;;Y02T10/30,F02B19/00;;F02B19/10;;F02B19/12;;F02D41/00;;F02P13/00,,0,0,,,,ACTIVE
438,DE,D1,DE 3684264 D1,181-169-199-164-106,1992-04-16,1992,DE 3684264 T,1986-12-08,US 80675585 A,1985-12-09,HYBRIDOMAZELLEN UND DEREN MONOKLONALE ANTIKOERPER GEGEN DEN HUMANEN PLUROPOTENTEN GRANULOZYTEN-KOLONIE STIMULIERENDEN FAKTOR.,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/181-169-199-164-106,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;G01N33/53;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
439,FI,A0,FI 873418 A0,185-331-865-621-347,1987-08-06,1987,FI 873418 A,1987-08-06,US 80675585 A;;US 8602554 W,1985-12-09,Hybridoomia ihmisen monitehoisia granulosyyttipesäkkeitä stimuloivia tekijöitä vastaan,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/185-331-865-621-347,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;G01N33/53;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
440,US,S,US D0618264 S,198-097-698-592-161,2010-06-22,2010,US 31648309 F,2009-10-01,US 31648309 F,2009-10-01,Mini audio/video capturing device,,AIPTEK INT INC,CHANG ALLEN;;LIU DAVID,AIPTEK INTERNATIONAL INC (2009-09-04),https://lens.org/198-097-698-592-161,Design Right,no,0,5,1,1,0,,,1601;;D16/202;;D16/218,0,0,,,,ACTIVE
441,NO,B,NO 170031 B,004-936-835-203-951,1992-05-25,1992,NO 873334 A,1987-08-10,US 80675585 A;;US 8602554 W,1985-12-09,"MONOKLONALT ANTISTOFF, MURIN-AVLEDET HYBRIDOMCELLELINJE, SAMT ANVENDELSE AV ANTISTOFFET FOR ISOLERING ELLER KVANTITATIV PAAVISNING AV HUMAN FLERPOTENT GRANULOCYTTKOLONISTIMULERENDE FAKTOR (HPG-CSF)","Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/004-936-835-203-951,Unknown,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
442,US,B2,US 8523925 B2,028-774-161-246-745,2013-09-03,2013,US 1444208 A,2008-01-15,US 1444208 A;;US 88081307 P;;US 88081207 P;;US 88088707 P;;US 88088307 P;;US 2008/0000544 W,2007-01-17,Fiber optic phototherapy device,"A phototherapy apparatus for the treatment of skin disease is disclosed including: an at least partially hollow body element; a plurality of light emitting elements enclosed within the body element; and a plurality of elongated light transmitting elements, each of the light transmitting elements having a proximal end detachably affixed to the body element in proximity to one or more of the light emitting elements, and extending to an end distal the body element. For each of the elongated light transmitting elements, at least a portion of light incident from the light emitting elements onto the proximal end is directed through the light transmitting element and emitted from the distal end.",GOURGOULIATOS ZAFIRIOS;;CHANG DAVID;;LERNER MEDICAL DEVICES INC,GOURGOULIATOS ZAFIRIOS;;CHANG DAVID,DARIVOFF PHILIP M (2023-08-18);;LERNER MEDICAL DEVICES INC (2008-01-14);;LERNER ETHAN A (2023-08-18),https://lens.org/028-774-161-246-745,Granted Patent,yes,40,0,6,18,0,A61N5/0617;;A61N5/0617;;A61N5/0616;;A61N5/0616;;A61N5/067;;A61N5/067;;A61N2005/063;;A61N2005/063;;A61N2005/0644;;A61N2005/0644;;A61N2005/0652;;A61N2005/0652;;A61N2005/0661;;A61N2005/0661,A61B18/18,607/89;;607/88;;607/90,4,1,020-232-052-306-844,15186234;;10.1111/j.1365-4632.2004.01993.x,"Taneja, A. et al., ""Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study"", International Journal of Dermatology, vol. 43, pp. 462-467, 2004.;;PCT International Search Report (PCT/US08/00495); Date of mailing Jun. 18, 2008; 1 page.;;PCT International Search Report (PCT/US08/00499); Date of mailing Jul. 7, 2008; 1 page.;;PCT International Search Report (PCT/US08/00545); Date of mailing Jul. 11, 2008; 1 page.",ACTIVE
443,TW,A,TW 200707837 A,035-282-875-052-881,2007-02-16,2007,TW 94127439 A,2005-08-12,TW 94127439 A,2005-08-12,Antenna,"An antenna, which is for global positioning system, includes a spiral portion, and a connecting portion. In this case, the spiral portion has a plurality of spirals, which are series connection with each other. The connecting portion connects with the spiral portion.",DHARMA TECHNOLOGY CORP LTD,LIN RANDY;;CHANG DAVID,,https://lens.org/035-282-875-052-881,Patent of Addition,no,0,0,2,2,0,,H01Q1/10,,0,0,,,,INACTIVE
444,US,A1,US 2018/0270184 A1,067-784-441-520-01X,2018-09-20,2018,US 201815985080 A,2018-05-21,US 201815985080 A;;US 201615257171 A;;US 201514966574 A;;US 201414339536 A;;US 201113185485 A,2011-07-18,Method and Apparatus for Social Network Communication Over a Media Network,"A system that transmits a request to initiate a communication session with a member device of a social network may include, for example, activating a speech capture element, maintaining activation of the speech capture element in accordance with a pattern of prior speech messages, detecting a speech message at the activated speech capture element, and transmitting the detected speech message, or a derivative thereof, to the member device of the social network. Other embodiments are disclosed.",NUANCE COMMUNICATIONS INC,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I L. P (2011-07-15),https://lens.org/067-784-441-520-01X,Patent Application,yes,0,0,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,H04L12/58;;G06Q50/00;;G10L15/00;;G10L15/22;;G10L15/26;;G10L19/00;;G10L25/87;;H04L12/18;;H04L29/08;;H04M3/533,,0,0,,,,DISCONTINUED
445,US,B2,US 8778861 B2,081-411-925-572-292,2014-07-15,2014,US 201114114294 A,2011-05-27,CN 2011000905 W,2011-05-27,Liquid soaps with triclocarban,"An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount that is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.",SHI MANYING;;CHANG DAVID;;COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,COLGATE-PALMOLIVE COMPANY (2011-05-27),https://lens.org/081-411-925-572-292,Granted Patent,yes,9,2,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D1/94;;C11D3/48;;C11D10/04,510/131;;510/130;;510/490;;510/138;;510/149;;510/152;;510/155;;510/156;;510/159;;510/382;;510/388;;510/389;;510/426;;510/427;;510/430,19,0,,,"International Search Report and Written Opinion in International Application No. PCT/CN11/000905, mailed Mar. 8, 2012.;;Lifebuoy Antibacterial Deep Clean Body Wash, 2009, Mintel GNPD 1081040.;;Lifebuoy Bath Milk, 2009, Mintel GNPD 1127467.;;Lifebuoy Bath Milk, 2009, Mintel GNPD 1188864.;;Lifebuoy Cream Contra Bacterias Liquid Soap, 2010, Mintel GNPD 1374212.;;Lifebuoy Deep Clean Bodywash, 2008, Mintel GNPD 892457.;;Lifebuoy Deep Clean Bodywash, 2009, Mintel GNPD 1087464.;;Lifebuoy Deepclean Body Wash, 2007, Mintel GNPD 810173.;;Lifebuoy Deepclean Bodywash, 2008, Mintel GNPD 882156.;;Lifebuoy Extra Protection Bath Liquid, 2007 Mintel GNPD 712275.;;Lifebuoy Extra Protection Bath Liquid, 2008, Mintel GNPD 892847.;;Lifebuoy Family Body Wash, 2005, Mintel GNPB 386375.;;Lifebuoy Men Hydrating Body Wash, 2009, Mintel GNPD 1073295.;;Lifebuoy Milk Bath Softener, 2008, Mintel GNPD 892921.;;Lifebuoy Naturepure Body Wash, 2010, Mintel GNPD 1284084.;;Lifebuoy Naturepure Deep Clean Body Wash, 2009, Mintel GNPD 1230298.;;Lifebuoy Totalprotect Handwash, 2009, Mintel GNPD 1233988.;;Snake Brand Aroma Lavender Hygienic Body Wash, 2008, Mintel GNPD 887328.;;Tesco Propolis Anti-Bacterial Shower Cream, 2009, Mintel GNPD 1211339.",ACTIVE
446,GB,A,GB 2221378 A,138-242-425-730-241,1990-02-07,1990,GB 8818349 A,1988-08-02,GB 8818349 A,1988-08-02,SOLE WITH THE COMPRESSIBLE SHOCK ABSORBERS,,FAR EAST ATHLETICS LIMITED,CHANG DAVID J H,,https://lens.org/138-242-425-730-241,Patent Application,no,6,28,3,3,0,A43B1/0018;;A43B13/20;;A43B21/28;;A43B13/188;;A43B13/203;;A43B1/0018;;A43B13/20;;A43B21/28,A43B13/20;;A43B21/28,A3B B7A1          B7A1,0,0,,,,DISCONTINUED
447,AU,A,AU 2001/065534 A,151-797-904-812-121,2002-03-21,2002,AU 2001/065534 A,2001-08-29,TW 89216064 U,2000-09-18,Shoe with a pivotal counter portion,,CHANG DAVID,CHANG DAVID;;LAIO YUI,,https://lens.org/151-797-904-812-121,Patent Application,no,0,1,8,8,0,A43B3/242;;A43B3/242;;A43B3/24;;A43B3/24;;A43B11/00;;A43B11/00;;A43B23/088;;A43B23/088;;A43C11/00;;A43C11/00;;A43C11/008;;A43C11/008;;A43C11/08;;A43C11/08,A43B3/24;;A43B23/02;;A43C11/00;;A43C11/08,,0,0,,,,EXPIRED
448,AU,B2,AU 532344 B2,158-940-252-406-980,1983-09-29,1983,AU 1979/049896 A,1979-08-14,US 6025579 A,1979-07-26,CLEAR COAT/COLOUR COAT SUBSTRATES,,DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/158-940-252-406-980,Granted Patent,no,0,0,10,12,0,B05D7/532;;B05D2202/00,B05D5/00;;B05D7/00;;B05D7/16,,0,0,,,,EXPIRED
449,US,B2,US 10409320 B2,161-273-283-341-755,2019-09-10,2019,US 201816106119 A,2018-08-21,US 201816106119 A;;US 201715729802 A,2017-10-11,Open loop solution in data buffer and RCD,An apparatus comprising an open loop circuit and a delay circuit. The open loop circuit may be configured to generate an in-phase clock signal by performing a phase alignment in response to (i) a clean version of a system clock and (ii) a delayed version of a strobe signal. The delay circuit may be configured to (i) generate the delayed version of the strobe signal in response to (a) the strobe signal received from a memory interface and (b) a delay amount received from a calibration circuit and (ii) adjust a delay of transferring a data signal through the apparatus in response to (a) the delay amount and (b) the in-phase clock signal. The data signal may be received from the memory interface. The delay of transferring the data signal may be implemented to keep a latency of a data transfer within a pre-defined range.,INTEGRATED DEVICE TECH,CHANG DAVID;;SHI XUDONG,,https://lens.org/161-273-283-341-755,Granted Patent,yes,20,2,3,5,0,G06F1/10;;G06F1/10;;G06F1/08;;G06F1/08;;G11C5/04;;G11C5/04;;G11C7/1039;;G11C7/1039;;G11C7/106;;G11C7/106;;G11C7/1066;;G11C7/1066;;G11C7/222;;G11C7/222;;G11C11/4076;;G11C11/4076;;G11C11/4096;;G11C11/4096;;G11C29/00;;G11C29/00;;G11C29/023;;G11C29/023;;G11C29/028;;G11C29/028;;G11C2207/2254;;G11C2207/2254;;H03K5/05;;H03L7/07;;H03L7/07;;H03L7/08;;H03L7/0812;;H03L7/0812;;H03L7/0814;;H03L7/0814,G06F1/10;;G06F1/08;;G11C5/04;;G11C7/10;;G11C7/22;;G11C11/4076;;G11C11/4096;;G11C29/00;;G11C29/02;;H03K5/05;;H03L7/07;;H03L7/08;;H03L7/081,,0,0,,,,ACTIVE
450,US,A1,US 2019/0038379 A1,187-629-616-749-379,2019-02-07,2019,US 201816053174 A,2018-08-02,US 201816053174 A;;US 201762540609 P,2017-08-03,DENTAL RETRACTOR,"A dental retractor comprises an elongated body having a first axis, a second axis and a third axis, each being orthogonal to each other. The first axis extends longitudinally from a proximal end to a distal end. The first axis and the second axis define a first plane and a width of the elongated body. The first axis and the third axis define a second plane and a thickness of the elongated body. The elongated body includes a blade extending from the distal end and lying substantially in the first plane; and a wing extending from the blade and lying at an angle relative to the first plane.",TUFTS COLLEGE,ASGHAR SYED;;CHANG DAVID,,https://lens.org/187-629-616-749-379,Patent Application,yes,0,1,1,1,0,A61B17/02;;A61C3/00;;A61C5/80;;A61C3/00;;A61B1/247;;A61C5/80;;A61B17/02,A61B1/247;;A61C3/00;;A61C5/80,,0,0,,,,DISCONTINUED
451,MX,A,MX 9101685 A,182-808-232-596-360,1992-06-05,1992,MX 9101685 A,1991-10-21,US 60607790 A,1990-10-22,"DISPERSION ESTABLE DE BASE ACUOSA,DE PIGMENTOS LAMELARES METALICOS,CON ALTO CONTENIDO DE SOLIDOS",,DU PONT,CHANG DAVID C K,,https://lens.org/182-808-232-596-360,Patent Application,no,0,0,3,3,0,C09D133/062;;C09D133/062;;C08L61/20;;C08L61/20;;C09D5/38;;C09D5/38;;C09D17/006;;C09D17/006;;C09D143/02;;C09D143/02,C08L61/20;;C09D5/38;;C09D17/00;;C09D133/06;;C09D143/02,,0,0,,,,PENDING
452,US,B2,US 6594921 B2,006-082-051-729-652,2003-07-22,2003,US 89938801 A,2001-07-05,TW 89216064 U,2000-09-18,Shoe with a pivotal counter portion,"
    A shoe has a sole, an upper and a counter portion. The upper is securely connected to the sole and has a rear end defined with an opening. The counter portion is pivotally connected to a rear end of the sole to close the opening in the upper. A fastener is mounted on the upper and the pivotal counter portion to connect the pivotal counter portion to the rear end of the upper. Accordingly, a wearer's foot in the shoe can be vented. Also, for a pair of tied shoes with the pivotal counter portions can be put on or taken off without tying or untying the laces. The use of the shoe becomes more versatile and more convenient. 
",CHANG DAVID,LAIO YUI;;CHANG DAVID,CHANG DAVID (2001-06-29),https://lens.org/006-082-051-729-652,Granted Patent,yes,13,69,8,8,0,A43B3/242;;A43B3/242;;A43B3/24;;A43B3/24;;A43B11/00;;A43B11/00;;A43B23/088;;A43B23/088;;A43C11/00;;A43C11/00;;A43C11/008;;A43C11/008;;A43C11/08;;A43C11/08,A43B3/24;;A43B23/02;;A43C11/00;;A43C11/08,36/138;;36/105;;36/50.1,0,0,,,,EXPIRED
453,WO,A1,WO 1998/038922 A1,019-258-498-157-96X,1998-09-11,1998,US 9804387 W,1998-03-05,US 81474097 A,1997-03-07,EXOVASCULAR ANASTOMOTIC DEVICE,"An anastomotic device (100) includes a flexible member (102), formable into a loop and a plurality of tissue penetrating anchoring elements (110) slide mounted on the flexible member. The tissue penetrating anchoring elements (116) extend generally towards a center of the loop formed by the flexible member. The device is adapted for anastomosing vessel segments or a vessel and a graft. In a further embodiment, an exo-vascular anastomotic device is suitable for end to side anastomoses, and it includes an anastomotic ring and a harness assembly.",CHANG DAVID WEA LEE,CHANG DAVID WEA LEE,,https://lens.org/019-258-498-157-96X,Patent Application,yes,3,1,2,2,0,A61B17/11;;A61B2017/1135;;A61B17/11;;A61B2017/1135,A61B17/11,,0,0,,,,PENDING
454,US,B2,US 8719601 B2,021-346-952-302-007,2014-05-06,2014,US 201213609032 A,2012-09-10,US 201213609032 A;;US 97469907 A,2007-10-15,Dynamic remaining maximum power allocation to secondary port while staying within optimal efficiency range of power supply,"Methods and apparatus for dynamically adjusting the amount of power (or current) distributed to one or more connected devices via electrical interfaces. In one embodiment, the apparatus comprises a first module adapted to detect current drawn by a first set of ports, and a second module adapted to adjust the current provided to a second set of ports based on the detected current. The second module is also optionally adapted to distribute unreserved current among the devices according to an allocation protocol. In the exemplary context of a plurality of interconnected serial bus devices, the invention enables a device to draw more current than that required to be reserved for that device (such as to comply with a specification such as USB), yet without increasing the total amount of power which must be dedicated to the serial ports as a whole. Power supply efficiency may also be advantageously optimized.",CHANG RAY;;FERGUSON DAVID;;APPLE INC,CHANG RAY;;FERGUSON DAVID,,https://lens.org/021-346-952-302-007,Granted Patent,yes,21,4,5,5,0,G06F1/266;;G06F1/266;;H02J7/00,G06F1/26,713/300;;713/340,0,0,,,,ACTIVE
455,US,B2,US 7228826 B2,022-159-757-394-316,2007-06-12,2007,US 92649604 A,2004-08-26,US 92649604 A;;US 74300003 A,2003-12-23,Internal combustion engine valve seating velocity control,"The present disclosure provides an engine having a gas exchange valve and an actuator for the gas exchange valve, and also a method of reducing valve seating impact velocity. The actuator includes a body having a fluid inlet and a fluid outlet. A plunger is reciprocable in the body and has a travel distance between an advanced position and a retracted position, the plunger and body defining a chamber. A flow restriction orifice is disposed in at least one of the plunger and the body, and the chamber is in unrestricted fluid communication with the outlet over a first portion of the travel distance and in restricted fluid communication with the outlet by way of the orifice over at least a second portion of the travel distance.",CATERPILLAR INC,CHANG DAVID YU-ZHANG,CATERPILLAR INC (2004-08-24),https://lens.org/022-159-757-394-316,Granted Patent,yes,11,12,2,5,0,F01L1/146;;F01L1/181;;F01L13/0015;;F01L2001/054;;F01L2305/00;;F01L9/10;;F01L1/181;;F01L2001/054;;F01L1/146;;F01L13/0015;;F01L2305/00;;F01L9/10,F01L9/10;;F01L1/34,123/90.12;;123/90.13;;251/12,0,0,,,,INACTIVE
456,EP,A1,EP 1261354 A1,039-186-280-318-156,2002-12-04,2002,EP 00904645 A,2000-02-02,US 0002628 W;;US 49567500 A,2000-02-01,DELIVERY SYSTEM AND METHODS FOR GENE THERAPY,,SAFESCIENCE INC,PLATT DAVID;;CHANG YAN,"PROSPECT THERAPEUTICS, INC. (2007-11-28);;GLYCOGENESYS, INC. (2007-11-21)",https://lens.org/039-186-280-318-156,Patent Application,yes,0,0,2,8,0,,A61K31/715;;A61K48/00;;C12N15/63,,0,0,,,,DISCONTINUED
457,WO,A2,WO 2012/018609 A2,050-360-798-830-815,2012-02-09,2012,US 2011/0045331 W,2011-07-26,US 36769610 P,2010-07-26,MIG6 AND THERAPEUTIC EFFICACY,"We identify markers capable of guiding the decision to incorporate epidermal growth factor receptor (EGFR) inhibitors, in particular EGFR tyrosine kinase inhibitors (TKIs), into chemotherapeutic regimens. Mitogen-inducible gene 6 (Mig6), a negative regulator of EGFR, is selectively upregulated during the development of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, resulting in decreased EGFR phosporylation. The ratio of Mig6/EGFR expression highly correlates with erlotinib sensitivity. A low Mig6/EGFR ratio correlates with a high response rate to gefitinib and a marked increase in progression-free survival for patients. The ratio of Mig6 to EGFR is a major predictor of biologic and clinical responses to EGFR inhibitors.",UNIV JOHNS HOPKINS;;SIDRANSKY DAVID;;CHANG XIAOFEI,SIDRANSKY DAVID;;CHANG XIAOFEI,,https://lens.org/050-360-798-830-815,Patent Application,yes,0,3,5,5,0,C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;G01N2333/91205;;G01N2800/44;;C12Q1/6886;;G01N2333/91205;;G01N2800/44;;C07K16/18;;C12Q2600/106;;G01N33/57407;;G01N33/6872;;C12Q1/6886;;C12Q1/485,G01N33/68;;C12Q1/68;;G01N33/574,,0,0,,,,PENDING
458,NO,C,NO 170031 C,049-616-170-857-28X,1992-09-02,1992,NO 873334 A,1987-08-10,US 80675585 A;;US 8602554 W,1985-12-09,"MONOKLONALT ANTISTOFF, MURIN-AVLEDET HYBRIDOMCELLELINJE, SAMT ANVENDELSE AV ANTISTOFFET FOR ISOLERING ELLER KVANTITATIV PAAVISNING AV HUMAN FLERPOTENT GRANULOCYTTKOLONISTIMULERENDE FAKTOR (HPG-CSF)","Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/049-616-170-857-28X,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;G01N33/53;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
459,AU,A,AU 1986/066295 A,079-081-418-553-790,1987-06-30,1987,AU 1986/066295 A,1986-11-26,US 80675585 A,1985-12-09,HYBRIDOMA'S TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/079-081-418-553-790,Patent Application,no,0,1,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,G01N33/53;;A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
460,ES,T3,ES 2046173 T3,084-291-500-119-818,1994-02-01,1994,ES 86309541 T,1986-12-08,US 80675585 A,1985-12-09,LINEAS CELULARES DE HIBRIDOMA Y SUS ANTICUERPOS MONOCLONALES CON RESPECTO AL FACTOR ESTIMULADOR DE COLONIAS DE GRANULOCITOS PLURIPOTENTES HUMANOS.,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.","KIRIN-AMGEN, INC.","CHANG, DAVID;;ALTROCK, BRUCE",,https://lens.org/084-291-500-119-818,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;G01N33/53;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
461,EP,A1,EP 0029596 A1,131-653-160-349-497,1981-06-03,1981,EP 80107270 A,1980-11-21,US 9628179 A;;US 14626780 A,1979-11-21,"An improved high solids coating composition of a low molecular weight acrylic polymer and a nitrogen resin cross-linking agent, and a substrate coated therewith.","The improved high solids coating composition contains at least 50% by weight of a binder of film-forming constituents in which the constituents are of
 (A) an acrylic polymer that has a number average molecular weight of about 500-10,000 and preferably 500-4,500, a hydroxyl content of at least 2% by weight, a glass transition temperature of about -20°C to +20°C and contains about 2-10% by weight of a chain transfer agent, and is of
 an alkyl methacrylate, a hydroxyalkyl acrylate or a hydroxyalkyl methacrylate, and optionally, an alkyl acrylate or styrene and (B) an alkylated melamine formaldehyde cross-linking agent; the improvement used with this composition is the addition of select ultraviolet light stabilizers and optionally, antioxidants. The composition is particularly useful for clear cost/color coat exterior finishes for automobiles, trucks and airplanes.",DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/131-653-160-349-497,Patent Application,yes,3,3,5,6,0,C09D133/066;;C08L61/20,C08L61/20;;C09D133/06,,1,0,,,"CHEMICAL ABSTRACTS, Vol. 81, No. 24, December 16, 1974, page 133, Ref. 154716x Columbus, Ohio (US) & JP-A-74 55737 (DAINIPPON PRINTING CO. LTD.) (May 30, 1974) * The whole Abstract *",DISCONTINUED
462,MX,A,MX 153384 A,128-730-076-876-946,1986-10-07,1986,MX 18017679 A,1979-11-26,US 6025579 A,1979-07-26,PROCEDIMIENTO PARA FORMAR UN SUBSTRATO METALICO RECUBIERTO,,DU PONT,CHANG DAVID CHI-KUNG,,https://lens.org/128-730-076-876-946,Granted Patent,no,0,0,10,12,0,B05D7/532;;B05D2202/00,B05D5/00;;B05D7/00;;B05D7/16,79-3,0,0,,,,EXPIRED
463,TW,B,TW I277235 B,157-312-249-625-863,2007-03-21,2007,TW 94127439 A,2005-08-12,TW 94127439 A,2005-08-12,Antenna,"An antenna, which is for global positioning system, includes a spiral portion, and a connecting portion. In this case, the spiral portion has a plurality of spirals, which are series connection with each other. The connecting portion connects with the spiral portion.",DHARMA TECHNOLOGY CORP LTD,LIN RANDY;;CHANG DAVID,,https://lens.org/157-312-249-625-863,Granted Patent,no,0,2,2,2,0,,,,0,0,,,,INACTIVE
464,US,B2,US 9979690 B2,156-233-762-663-607,2018-05-22,2018,US 201615257171 A,2016-09-06,US 201615257171 A;;US 201514966574 A;;US 201414339536 A;;US 201113185485 A,2011-07-18,Method and apparatus for social network communication over a media network,"A system that transmits a request to initiate a communication session with a member device of a social network may include, for example, activating a speech capture element, maintaining activation of the speech capture element in accordance with a pattern of prior speech messages, detecting a speech message at the activated speech capture element, and transmitting the detected speech message, or a derivative thereof, to the member device of the social network. Other embodiments are disclosed.",NUANCE COMMUNICATIONS INC,CHANG HISAO;;MORNHINEWAY DAVID,NUANCE COMMUNICATIONS INC (2016-12-14);;AT&T INTELLECTUAL PROPERTY I L.P (2011-07-15),https://lens.org/156-233-762-663-607,Granted Patent,yes,26,0,9,9,0,G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04L12/1818;;H04L51/046;;H04M2201/60;;H04M2203/655;;H04L51/52;;G06Q50/01;;G10L15/00;;G10L19/00;;H04M3/53366;;H04M2201/60;;H04M2203/655;;H04L12/1818;;H04L51/046;;H04L51/52;;G10L15/26;;H04L67/141;;H04L67/306;;G10L15/22;;G10L25/87,H04L12/58;;G06Q50/00;;G10L15/00;;G10L15/22;;G10L15/26;;G10L19/00;;G10L25/87;;H04L12/18;;H04L29/08;;H04M3/533,,0,0,,,,INACTIVE
465,AU,B2,AU 2011/369300 B2,161-094-286-366-292,2014-10-02,2014,AU 2011/369300 A,2011-05-27,CN 2011000905 W,2011-05-27,Liquid soaps with triclocarban,"An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount that is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.",COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/161-094-286-366-292,Granted Patent,no,1,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/00;;C11D9/02;;C11D9/30;;C11D9/50,,0,0,,,,INACTIVE
466,US,B2,US 10506983 B2,166-913-862-203-642,2019-12-17,2019,US 201715715113 A,2017-09-25,US 201715715113 A;;US 2016/0024464 W;;US 201562139014 P,2015-03-27,Application of the extrema distortion method to optimize control signals,"A system is described that observes a signal from a subject of interest, converts the signal to an electrical representation, uses the electrical representation to compute a synthetic control signal, and applies the synthetic control signal to control some aspect of operation of the subject. The procedure used to generate the synthetic control signal involves subjecting the electrical representation of the observed signal to random noise, allowing the extrema of the electrical representation to move, and obtaining a converged solution as the synthetic control signal.",UNIV MASSACHUSETTS MEDICAL SCHOOL;;UNIV MASSACHUSETTS,PAYDARFAR DAVID;;CHANG JOSHUA,,https://lens.org/166-913-862-203-642,Granted Patent,yes,5,0,3,3,0,A61B5/7235;;A61B5/7235;;A61B5/24;;A61B5/24;;A61B5/4094;;A61B5/4094;;A61B5/7203;;A61M2021/0055,A61B5/00;;A61B5/04;;A61M21/00,,4,0,,,"International Search Report in parent IA No. PCT/US16/24464, dated Jul. 5, 2016.;;Written Opinion in parent IA No. PCT/US16/24464, dated Jul. 5, 2016.;;Szeliski, “Computer Vision: Algorithms and Applications”, Electronic draft, Sep. 3, 2010, Springer.;;Chang et ai, “Flipping Biological Switches: Solving for Optimal Control: A Dissertation”, University of Massachusetts Medical School, Mar. 30, 2015.",ACTIVE
467,TW,A,TW 200601786 A,180-687-608-532-234,2006-01-01,2006,TW 93119364 A,2004-06-30,TW 93119364 A,2004-06-30,Module of controlling chord light for an incoming phone and control method thereof,"A module of controlling chord light for an incoming phone is provided, mainly comprising a central processing module, a chord music module, and a keyboard backlight module. When the central processing module receives an incoming phone message, it transmits a message to the chord music module, and the central processing module controls the chord music module to make up music. At the same time, according to the synchronism message from the chord music, the central processing module controls the keyboard backlight module, and makes it to produce the synchronous effects of lighting. According to the chord music, the lighting function of the keyboard backlight module will become various effects of lighting, and will bring the users the enjoyment of vision.",INVENTEC APPLIANCES CORP,HO DAVID;;CHANG CHENG,,https://lens.org/180-687-608-532-234,Patent of Addition,no,0,1,2,2,0,,H04M1/22,,0,0,,,,INACTIVE
468,US,S,US D0334463 S,176-908-562-443-309,1993-04-06,1993,US 20979788 F,1988-06-22,US 20979788 F,1988-06-22,Shoe sole shock absorber,,HI TEC SPORTS LTD,CHANG DAVID J H,HI-TEC SPROTS PLC A PUBLIC LIMITED CO. OF GREAT BRITAIN (1990-07-24),https://lens.org/176-908-562-443-309,Design Right,yes,5,12,1,1,0,,,D 2314,0,0,,,,EXPIRED
469,CA,A1,CA 2834437 A1,198-587-141-505-333,2012-12-06,2012,CA 2834437 A,2011-05-27,CN 2011000905 W,2011-05-27,LIQUID SOAPS WITH TRICLOCARBAN,"An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount that is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.",COLGATE PALMOLIVE CO,SHI MANYING;;CHANG DAVID,,https://lens.org/198-587-141-505-333,Patent Application,no,0,0,14,14,0,C11D1/04;;C11D1/146;;C11D1/90;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/04;;C11D1/94;;C11D3/323;;C11D3/48;;C11D17/08;;C11D1/90;;C11D1/146;;C11D9/30;;C11D9/32,C11D17/08;;C11D9/00;;C11D9/02;;C11D9/30;;C11D9/50,,0,0,,,,DISCONTINUED
470,DK,D0,DK 412887 D0,015-877-215-724-168,1987-08-07,1987,DK 412887 A,1987-08-07,US 80675585 A;;US 8602554 W,1985-12-09,"HYBRIDOMAER FOR HUMAN, PLURIPOTENT GRANULOCYTKOLONISTIMULERENDE FAKTOR","Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/015-877-215-724-168,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;G01N33/53;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
471,US,B2,US 8266456 B2,031-207-365-701-241,2012-09-11,2012,US 97469907 A,2007-10-15,US 97469907 A,2007-10-15,Supplying remaining available current to port in excess of bus standard limit,"Methods and apparatus for dynamically adjusting the amount of power (or current) distributed to one or more connected devices via electrical interfaces. In one embodiment, the apparatus comprises a first module adapted to detect current drawn by a first set of ports, and a second module adapted to adjust the current provided to a second set of ports based on the detected current. The second module is also optionally adapted to distribute unreserved current among the devices according to an allocation protocol. In the exemplary context of a plurality of interconnected serial bus devices, the invention enables a device to draw more current than that required to be reserved for that device (such as to comply with a specification such as USB), yet without increasing the total amount of power which must be dedicated to the serial ports as a whole. Power supply efficiency may also be advantageously optimized.",CHANG RAY;;FERGUSON DAVID;;APPLE INC,CHANG RAY;;FERGUSON DAVID,APPLE INC (2007-11-05),https://lens.org/031-207-365-701-241,Granted Patent,yes,18,13,5,5,0,G06F1/266;;G06F1/266;;H02J7/00,G06F1/26,713/300;;710/105,0,0,,,,ACTIVE
472,US,B1,US 6658616 B1,028-170-466-565-053,2003-12-02,2003,US 44478199 A,1999-11-22,US 44478199 A,1999-11-22,Method for improving the efficiency of weighted random pattern tests through reverse weight simulation using effective pattern masks,"
    A method is defined which reduces the number of applied test patterns while maintaining identical fault coverage for a given set of weighted random patterns. Reduction is accomplished by simulating the weight sets in reverse order against a full (untested) fault list but allowing fault mark-off for initially effective patterns only (patterns which detected faults). This results in some patterns which initially detected only a few faults (due to their exposure to a small untested fault list) to detect a greater number of faults (due to their exposure to a full fault list), while other patterns which were initially effective become ineffective (detected no faults). Since the same faults are still detected there is no loss of coverage. Only those patterns which remain effective after exercising the reverse simulation are ultimately applied on the tester. 
",CADENCE DESIGN SYSTEMS INC,CHANG PAUL;;PRUDEN DAVID,INTERNATIONAL BUSINESS MACHINES CORPORATION (1999-11-18);;CADENCE DESIGN SYSTEMS INC (2002-12-19),https://lens.org/028-170-466-565-053,Granted Patent,yes,7,18,1,1,0,G01R31/318385;;G01R31/318385;;G01R31/31835;;G01R31/31835,G01R31/3183,714/728;;714/732;;714/739,5,3,009-286-224-619-384;;028-382-311-026-404;;117-261-433-701-792,10.1109/vtsa.1989.68602;;10.1109/test.1988.207809;;10.1147/rd.332.0149,"Waicukauski, et al. ""Testing VLSI Chips with Weighted Random Patterns"" Site Tech Library pp. 149-154.;;Waicukauski, et al. ""Fault Detection Effectiveness of Weighted Random Patterns"" 1988 IEEE-1988 International Test Conference. Paper 15.2 pp. 245-255.;;Waicukauski, et al. ""A Method for Generating Weighted Random Test Patterns"" IBM J. Res. Develop. vol. 33 No. 2 Mar. 2, 1989 pp. 149-160.;;Kapur, et al. ""Design of an Efficient Weighted Random Pattern Generation System"" 1994 IEEE-1994 International Test Conference. Paper 21.2 pp. 491-500.;;Chang, et al. ""A Highly Efficient Weight Generation Method for Handling Very Large Fan-In and XOR-Tree Designs"" 7<th >IEEE NATW, May 1998 pp. 34-41.",EXPIRED
473,US,B1,US 10082823 B1,030-669-720-635-892,2018-09-25,2018,US 201715729802 A,2017-10-11,US 201715729802 A,2017-10-11,Open loop solution in data buffer and RCD,An apparatus comprising an open loop circuit and a delay circuit. The open loop circuit may be configured to generate an in-phase clock signal by performing a phase alignment in response to (i) a clean version of a system clock and (ii) a delayed version of a strobe signal. The delay circuit may be configured to (i) generate the delayed version of the strobe signal in response to (a) the strobe signal received from a memory interface and (b) a delay amount received from a calibration circuit and (ii) adjust a delay of transferring a data signal through the apparatus in response to (a) the delay amount and (b) the in-phase clock signal. The data signal may be received from the memory interface. The delay of transferring the data signal may be implemented to keep a latency of a data transfer within a pre-defined range.,INTEGRATED DEVICE TECH,CHANG DAVID;;SHI XUDONG,INTEGRATED DEVICE TECHNOLOGY INC (2017-10-10),https://lens.org/030-669-720-635-892,Granted Patent,yes,10,11,3,5,0,G06F1/10;;G06F1/10;;G06F1/08;;G06F1/08;;G11C5/04;;G11C5/04;;G11C7/1039;;G11C7/1039;;G11C7/106;;G11C7/106;;G11C7/1066;;G11C7/1066;;G11C7/222;;G11C7/222;;G11C11/4076;;G11C11/4076;;G11C11/4096;;G11C11/4096;;G11C29/00;;G11C29/00;;G11C29/023;;G11C29/023;;G11C29/028;;G11C29/028;;G11C2207/2254;;G11C2207/2254;;H03K5/05;;H03L7/07;;H03L7/07;;H03L7/08;;H03L7/0812;;H03L7/0812;;H03L7/0814;;H03L7/0814,G06F1/10;;G06F1/08;;G11C7/22;;H03K5/05;;H03L7/08,,0,0,,,,ACTIVE
474,TW,A,TW 201216980 A,071-046-043-383-814,2012-05-01,2012,TW 100127825 A,2011-08-03,US 37021710 P,2010-08-03,Compositions and methods for treating hepatitis virus infection,"The present invention relates to a method for treating hepatitis virus infection comprising administering to a subject infected with a hepatitis virus an effective amount of a yolk or yolk antibody obtained from an egg of a fowl which has been immunized using Helicobacter pylori as an antigen. In particular, the method is effective in reducing virus titer and/or decreasing a level of glutamic oxaloacetic transaminase (GOT) or glutamic pyruvic transaminase (GPT) in the subject. Also provided is a composition for treating hepatitis virus infection which comprises the yolk or yolk antibody in combination with one or more supplemental ingredients such as Salviae Miltiorrhiza Radix, Oldennlandiae Hb., Zingiberis Radix, Ginseng Radix, Atractylodis Radix, Curcumae Radix, Angelicae Sinensis Radix, bee propolis, calcium lactate, soy proteins, probiotics, and grain bran.",ASIA HEPATO GENE CO,CHEN DAVID CHANG-PING,,https://lens.org/071-046-043-383-814,Patent of Addition,no,0,0,8,8,0,A61K35/57;;A61K36/232;;A61K36/258;;A61K36/284;;A61K36/537;;A61K36/748;;A61K36/9066;;A61K36/9068;;A61K39/40;;A61K2039/505;;C07K2317/11;;C07K2317/23;;C07K16/121;;A61P1/16;;A61P31/12;;A61P31/20;;A61K35/57;;A61K36/232;;A61K36/258;;A61K36/284;;A61K36/537;;A61K36/748;;A61K36/9066;;A61K36/9068;;A61K39/40;;A61K2039/505;;C07K2317/11;;C07K2317/23;;C07K16/121,A61K39/02;;A61K35/54;;A61K35/57;;A61K36/00;;A61K39/00;;A61P1/16;;A61P31/12,,0,0,,,,ACTIVE
475,EP,A3,EP 0227367 A3,066-596-725-034-211,1988-06-15,1988,EP 86309541 A,1986-12-08,US 80675585 A,1985-12-09,HYBRIDOMA CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.","KIRIN-AMGEN, INC.","CHANG, DAVID;;ALTROCK, BRUCE",,https://lens.org/066-596-725-034-211,Search Report,no,1,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;G01N33/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
476,AT,T1,AT E73491 T1,077-032-904-996-868,1992-03-15,1992,AT 86309541 T,1986-12-08,EP 86309541 A;;US 80675585 A,1985-12-09,HYBRIDOMAZELLEN UND DEREN MONOKLONALE ANTIKOERPER GEGEN DEN HUMANEN PLUROPOTENTEN GRANULOZYTEN- KOLONIE STIMULIERENDEN FAKTOR.,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/077-032-904-996-868,Granted Patent,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,G01N33/53;;A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,DISCONTINUED
477,FI,A,FI 873418 A,076-398-664-327-066,1987-08-06,1987,FI 873418 A,1987-08-06,US 80675585 A;;US 8602554 W,1985-12-09,Hybridoomia ihmisen monitehoisia granulosyyttipesäkkeitä stimuloivia tekijöitä vastaan,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.",KIRIN AMGEN INC,CHANG DAVID;;ALTROCK BRUCE,,https://lens.org/076-398-664-327-066,Patent Application,no,0,0,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,A61K39/00;;G01N33/53;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
478,DE,A1,DE 2605289 A1,106-329-962-802-264,1976-08-26,1976,DE 2605289 A,1976-02-11,US 54976975 A,1975-02-13,LEGIERUNG MIT VERBESSERTER BESTAENDIGKEIT GEGENUEBER DER UMGEBUNG,,GEN ELECTRIC,CHANG DAVID RONG-HWAN,,https://lens.org/106-329-962-802-264,Patent Application,no,0,3,11,12,0,C22C19/00;;C22C19/052;;C22C19/053;;C22C38/00;;Y10T428/12931;;Y10T428/12931;;C22C38/00;;C22C19/052;;C22C19/053;;C22C19/00,C22C19/00;;C22C19/05;;C22C19/07;;C22C27/06;;C22C30/00;;C22C38/00;;C23C4/08;;C23C10/58,,0,0,,,,EXPIRED
479,CN,A,CN 86107666 A,135-017-921-854-219,1987-09-30,1987,CN 86107666 A,1986-12-08,US 80675585 A,1985-12-09,HYBRIDOMA CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN PLURIPOTENT GRANULOCYTE COLONY STIMULATING FACTOR,"Murine-derived hybridoma tumor cell lines and monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of human pluripotent Granulocyte Colony Stimulating Factor and for quantitative detection of human pluripotent Granulocyte Colony Stimulating Factor in fluid samples.","KIRIN-AMGEN, INC.",DAVID CHANG;;BRUCE ALTROCK,,https://lens.org/135-017-921-854-219,Patent Application,no,0,5,37,37,0,C07K16/243;;G01N33/53;;C07K16/243,G01N33/53;;A61K39/00;;A61K39/395;;C07K1/20;;C07K1/22;;C07K14/005;;C07K14/195;;C07K14/52;;C07K14/53;;C07K14/535;;C07K16/00;;C07K16/24;;C12N5/00;;C12N5/10;;C12N5/12;;C12N5/18;;C12N15/00;;C12N15/02;;C12P21/00;;C12P21/08;;C12R1/91;;G01N33/00;;G01N33/577,,0,0,,,,EXPIRED
480,US,B1,US 6997148 B1,127-463-105-020-750,2006-02-14,2006,US 96690104 A,2004-10-15,US 96690104 A,2004-10-15,Engine valve actuator,"An engine valve actuator for an internal combustion engine is provided. The actuator includes a housing having an opening. An adjustment member is disposed in the housing and defines a fluid chamber having a chamber wall. A piston is also disposed in the opening. The piston defines a piston chamber and has a pressure surface, a protrusion extending from the pressure surface, and a groove disposed in the pressure surface surrounding the protrusion and in fluid communication with the piston chamber. A fluid passageway is adapted to controllably communicate pressurized fluid to the housing opening. A push rod is operatively engageable with the piston and is adapted to controllably actuate an engine valve of the engine.",CATERPILLAR INC,CHANG DAVID YU-ZHANG,CATERPILLAR INC (2004-10-13),https://lens.org/127-463-105-020-750,Granted Patent,yes,6,8,2,2,0,F01L13/065;;F16K31/1221;;F01L9/10;;F16K31/1221;;F01L13/065;;F01L9/10,F01L9/10,123/90.12;;123/90.15;;123/90.16;;123/90.63;;X123198 F;;251/101;;251/102;;92/13.6;;92/13.8,0,0,,,,INACTIVE
481,US,A,US 5851299 A,173-830-207-349-952,1998-12-22,1998,US 21820994 A,1994-03-25,US 21820994 A;;US 82394292 A;;US 62266490 A,1990-12-05,Passive shield for CVD wafer processing which provides frontside edge exclusion and prevents backside depositions,"An improved apparatus for CVD processing is described wherein a wafer mounted on a vertically movable susceptor beneath a gas outlet or showerhead is raised into contact with a shield ring which normally rests on a ring support in the chamber. The shield ring engages the frontside edge of the wafer, lifting the shield ring off its support, when the susceptor and the wafer are raised to a deposition position in the chamber. The shield ring, by engaging the frontside edge of the wafer, shields the edge of the top surface of the wafer, as well as the end edge and the backside of the wafer, during the deposition. Matching tapered edges, respectively, on the susceptor and the shield ring permit alignment of the shield ring with respect to the susceptor, and alignment of the wafer to the susceptor and the shield ring. Alignment means are also disclosed to circularly align the shield ring to its support in the chamber. Multi-unit shield rings permit the use of wider shield rings and prevent cracking of the shield ring due to thermal stresses caused by temperature differences near and away from the wafer during processing. These shield rings may also have tapered edges to ensure alignment of the rings with respect to each other.",APPLIED MATERIALS INC,CHENG DAVID;;CHANG MEI,,https://lens.org/173-830-207-349-952,Granted Patent,yes,24,279,7,7,0,C23C16/04;;C23C16/042;;C23C16/45521;;C23C16/4585;;H01L21/283;;C23C16/45521;;C23C16/04;;C23C16/4585;;C23C16/042,C23C16/00;;C23C16/04;;C23C16/44;;C23C16/455;;C23C14/50;;C23C16/458;;H01L21/205;;H01L21/302;;H01L21/3065,118/729;;118/728;;118/500;;118/719;;118/503;;156/345;;204/298.11,2,0,,,European Search Report EP 91120906.2;;European Search Report 93 10 0746,EXPIRED
482,AT,T1,AT E324808 T1,029-567-932-411-716,2006-06-15,2006,AT 03004678 T,2003-03-03,US 15925102 A,2002-05-31,VERBINDBARE BRUSTVERGRÖSSERUNGSVORRICHTUNG,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/029-567-932-411-716,Granted Patent,no,0,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/00;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
483,US,A1,US 2004/0224608 A1,018-226-100-938-043,2004-11-11,2004,US 80190104 A,2004-03-15,US 80190104 A;;US 15925102 A,2002-05-31,Attachable breast form enhancement system,"
   An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. 
",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/018-226-100-938-043,Patent Application,yes,27,2,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/00;;A41C3/06;;A41C3/12;;A41C3/10,450/81,0,0,,,,EXPIRED
484,EP,B1,EP 1366681 B1,045-329-539-912-211,2006-05-03,2006,EP 03004678 A,2003-03-03,US 15925102 A,2002-05-31,Attachable breast form enhancement system,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/045-329-539-912-211,Granted Patent,yes,5,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/14;;A41C3/00;;A41C3/02;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
485,WO,A1,WO 2004/012539 A1,063-623-209-661-632,2004-02-12,2004,US 0321665 W,2003-07-11,US 21111002 A,2002-08-02,"AN IMPROVED BACKLESS, STRAPLESS BRA","A backless, strapless bra (10) comprising a pair of bra cups (12) having an interior surface facing towards a user&apos;s skin that comprises a pressure sensitive adhesive layer (33) disposed thereon for adjoining the bra cups to the user&apos;s skin. The bra cups are permanently or removably adjoined by a connector (14) that is positioned between inner side portions of the bra cups. The connector can have a varierty of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra cup also includes a pull-up device (68) that attches to the top portion of the bra cups and allows the user to lift the bra cups and the user&apos;s breasts to provide additional breast push-up enhancement.",BRAGEL INTERNATIONAL INC;;CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/063-623-209-661-632,Patent Application,yes,7,2,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,PENDING
486,US,A1,US 2004/0224607 A1,121-228-794-325-454,2004-11-11,2004,US 80147904 A,2004-03-15,US 80147904 A;;US 21111002 A,2002-08-02,"Backless, strapless bra","
   An improved backless, strapless bra comprising a pair of bra cups having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector that is positioned between inner side portions of the bra cups. The connector can have a variety of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra can also be used with a pull-up device that attaches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement. 
",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/121-228-794-325-454,Patent Application,yes,8,8,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,450/81,0,0,,,,EXPIRED
487,US,B2,US 6780081 B2,156-112-212-146-92X,2004-08-24,2004,US 21111002 A,2002-08-02,US 21111002 A,2002-08-02,"Backless, strapless bra","
    An improved backless, strapless bra comprising a pair of bra cups having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector that is positioned between inner side portions of the bra cups. The connector can have a variety of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra can also be used with a pull-up device that attaches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement. 
",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,BRAGEL INTERNATIONAL INC (2002-08-28),https://lens.org/156-112-212-146-92X,Granted Patent,yes,33,50,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,450/81;;450/58;;450/54,3,0,,,"Dr. Leonard's-America's Leading Discount Healthcare Catalog, p. 15, Natural Looking Breast Enhancer Pads, Silicone Covered with Film, 1998.;;Abstract and Figures Only for French Patent No. 2505620 (Nov. 19, 1982).;;Figures Only for Italian Patent No. IT 0521811 (May 1955).",EXPIRED
488,DE,T2,DE 60304934 T2,171-137-658-652-290,2006-11-23,2006,DE 60304934 T,2003-03-03,US 15925102 A,2002-05-31,Verbindbare Brustvergrösserungsvorrichtung,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNAT INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/171-137-658-652-290,Granted Patent,no,0,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/14;;A41C3/00;;A41C3/02;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
489,AU,B2,AU 2003/249034 B2,025-735-649-088-743,2004-11-18,2004,AU 2003/249034 A,2003-07-11,US 21111002 A;;US 0321665 W,2002-08-02,"An improved backless, strapless bra",,BRAGEL INTERNATIONAL INC,CHANG ALICE;;CHANG JASPER;;CHEN DAVID E,,https://lens.org/025-735-649-088-743,Granted Patent,no,2,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
490,US,A1,US 2005/0250418 A1,192-207-563-413-329,2005-11-10,2005,US 17938305 A,2005-07-11,US 17938305 A;;US 80147904 A;;US 21111002 A,2002-08-02,"Backless, strapless bra","An improved backless, strapless bra comprising a pair of bra cups having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector that is positioned between inner side portions of the bra cups. The connector can have a variety of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra can also be used with a pull-up device that attaches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement.",CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/192-207-563-413-329,Patent Application,yes,34,2,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,450/81,0,0,,,,EXPIRED
491,DE,D1,DE 60234023 D1,017-120-112-840-498,2009-11-26,2009,DE 60234023 T,2002-12-30,US 21111002 A,2002-08-02,Rücken- und trägerloser Büstenhalter,,BRAGEL INTERNAT INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/017-120-112-840-498,Granted Patent,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
492,DE,D1,DE 60304934 D1,006-779-055-749-597,2006-06-08,2006,DE 60304934 T,2003-03-03,US 15925102 A,2002-05-31,Verbindbare Brustvergrösserungsvorrichtung,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/006-779-055-749-597,Granted Patent,no,0,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/14;;A41C3/00;;A41C3/02;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
493,EP,A1,EP 1386548 A1,111-572-083-376-538,2004-02-04,2004,EP 02029083 A,2002-12-30,US 21111002 A,2002-08-02,"A backless, strapless bra","An improved backless, strapless bra (10) comprising a pair of bra cups (12) having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer disposed thereon for adjoining the bra cups to the user's skin. The bra cups (12) are permanently or removably adjoined by a connector (14) that is positioned between inner side portions of the bra cups. The connector (14) can have a variety of configurations that enable the user to attach the bra cups (12). The connector (14) allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra can also be used with a pull-up device (68) that attaches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/111-572-083-376-538,Patent Application,yes,5,10,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
494,CA,C,CA 2459555 C,124-862-860-442-913,2005-07-05,2005,CA 2459555 A,2003-07-11,US 21111002 A;;US 0321665 W,2002-08-02,"AN IMPROVED BACKLESS, STRAPLESS BRA","A backless, strapless bra (10) comprising a pair of bra cups (12) having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer (33) disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector (14) that is positioned between inner side portions of the bra cups. The connector can have a varierty of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra cup also includes a pull-up device (68) that attches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement.",BRAGEL INTERNATIONAL INC,CHANG JASPER;;CHEN DAVID E;;CHANG ALICE,,https://lens.org/124-862-860-442-913,Granted Patent,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
495,ES,T1,ES 2222117 T1,142-203-539-709-961,2005-02-01,2005,ES 03004678 T,2003-03-03,US 15925102 A,2002-05-31,SISTEMA ADHERIBLE QUE MEJORA LA FORMA DEL PECHO.,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/142-203-539-709-961,Patent Application,no,0,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/00;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
496,AU,C1,AU 2003/249034 C1,197-868-407-727-289,2008-05-08,2008,AU 2003/249034 A,2003-07-11,US 21111002 A;;US 0321665 W,2002-08-02,"An improved backless, strapless bra",,BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/197-868-407-727-289,Amended Patent,no,2,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
497,HK,A2,HK 1088770 A2,133-462-617-200-766,2006-11-10,2006,HK 06107449 A,2006-06-30,US 17938305 A,2005-07-11,"Backless, strapless bra",,BRAGEL INTERNAT INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/133-462-617-200-766,Limited Patent,no,0,0,1,1,0,,A41C/,,0,0,,,,INACTIVE
498,ES,T1,ES 2222115 T1,163-112-161-710-909,2005-02-01,2005,ES 02029083 T,2002-12-30,US 21111002 A,2002-08-02,UN SUJETADOR MEJORADO SIN TIRANTES Y SIN PARTE POSTERIOR.,"Un sujetador mejorado sin parte posterior, sin tiras, que comprende: un par de copas de sujetador que tiene una superficie interior enfrentada a una piel de usuaria, en el que la superficie interior comprende una capa adhesiva sensible a la presión dispuesta sobre la misma para unir las copas del sujetador a la piel de la usuaria; y un conectador destinado a unir las copas de sujetador, en el que el conectador está posicionado entre porciones laterales interiores de cada una de las copas de sujetador.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/163-112-161-710-909,Patent Application,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
499,US,B2,US 7144296 B2,171-433-679-188-585,2006-12-05,2006,US 5321105 A,2005-02-07,US 5321105 A;;US 80190104 A;;US 15925102 A,2002-05-31,Attachable breast form enhancement system,"A backless, strapless breast form system to be worn in place of a traditional bra having a pair of breast forms. Each breast form includes a volume of silicone gel encased between thermoplastic film material, and a concave interior surface facing towards a user's breast having a pressure sensitive adhesive layer for securing the breast form to the user's breast. There is a connector adapted to adjoin the breast forms together, and the connector is positioned between inner sides of each of the breast forms.",CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/171-433-679-188-585,Granted Patent,yes,40,13,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/00;;A41C3/10;;A41C3/06;;A41C3/12;;A41C3/14,450/81;;450/54;;450/57;;450/38;;623/7,3,0,,,"Abstract and Figures Only for French Patent No. 2505620 (Nov. 19, 1982).;;Figures Only for Italian Patent No. IT 0521811 (May 1955).;;Dr. Leonard's-America's Leading Discount Healthcare Catalog, p. 15, Natural Looking Breast Enhancer Pads, Silicone Covered with Film, 1998.",EXPIRED
500,DE,T1,DE 19983904 T1,030-138-717-993-039,2002-11-21,2002,DE 19983904 T,1999-09-14,US 34241699 A;;US 9920952 W,1999-06-29,Verfahren zum Bearbeiten eines Films,,POUR PILLARS ENTPR CORP,LIN DAVID;;CHANG K;;CHANG CHI-PING,,https://lens.org/030-138-717-993-039,Patent Application,no,0,0,8,8,0,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B29C2793/0045;;B29K2705/00;;B29L2031/722;;B31F1/07;;B31F2201/0702;;B60P1/26;;B62D33/0273;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;B31F1/07;;B31F2201/0702;;B29K2705/00;;B29C2793/0045;;B29C51/08;;B60P1/26;;B29C51/14;;B26F1/24;;B62D33/0273;;B29C59/02;;B29L2031/722;;B29C59/04,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B31F1/07;;B60P1/26;;B62D33/027,,0,0,,,,DISCONTINUED
501,US,A1,US 2004/0023594 A1,027-475-129-877-700,2004-02-05,2004,US 21111002 A,2002-08-02,US 21111002 A,2002-08-02,"Backless, strapless bra","
   An improved backless, strapless bra comprising a pair of bra cups having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector that is positioned between inner side portions of the bra cups. The connector can have a variety of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra can also be used with a pull-up device that attaches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement. 
",CHEN DAVID E.;;CHANG JASPER;;CHANG ALICE,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,BRAGEL INTERNATIONAL INC (2002-08-28),https://lens.org/027-475-129-877-700,Patent Application,yes,6,5,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,450/81,0,0,,,,EXPIRED
502,HK,A1,HK 1062257 A1,083-224-777-711-789,2004-10-29,2004,HK 04105231 A,2004-07-16,US 21111002 A,2002-08-02,"A BACKLESS, STRAPLESS BRA",,BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/083-224-777-711-789,Patent Application,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C/;;A41C3/06;;A41C3/10,,0,0,,,,DISCONTINUED
503,WO,A8,WO 2004/012539 A8,142-560-240-137-458,2004-04-22,2004,US 0321665 W,2003-07-11,US 21111002 A,2002-08-02,"AN IMPROVED BACKLESS, STRAPLESS BRA","A backless, strapless bra (10) comprising a pair of bra cups (12) having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer (33) disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector (14) that is positioned between inner side portions of the bra cups. The connector can have a varierty of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra cup also includes a pull-up device (68) that attches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement.",BRAGEL INTERNATIONAL INC;;CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/142-560-240-137-458,Patent Application,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,PENDING
504,US,B2,US 6758720 B2,053-831-898-486-422,2004-07-06,2004,US 15925102 A,2002-05-31,US 15925102 A,2002-05-31,Attachable breast form enhancement system,"
    An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. 
",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,BRAGEL INTERNATIONAL INC (2003-01-30),https://lens.org/053-831-898-486-422,Granted Patent,yes,33,50,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/00;;A41C3/12;;A41C3/06;;A41C3/10,450/57;;450/54;;450/58;;2/267,3,0,,,"Dr. Leonard's-America's Leading Discount Healthcare Catalog, p. 15. Natural Looking Breast Enhancer Pads Silicon Covered With Film.*;;Figures Only for Italian Patent No. 0521811 (May 1955).;;Abstract and Figures Only for French Patent No. 2505620 (Nov. 19, 1982).",EXPIRED
505,US,A1,US 2005/0136796 A1,024-589-214-677-275,2005-06-23,2005,US 5321105 A,2005-02-07,US 5321105 A;;US 80190104 A;;US 15925102 A,2002-05-31,Attachable breast form enhancement system,"A backless, strapless breast form system to be worn in place of a traditional bra having a pair of breast forms. Each breast form includes a volume of silicone gel encased between thermoplastic film material, and a concave interior surface facing towards a user's breast having a pressure sensitive adhesive layer for securing the breast form to the user's breast. There is a connector adapted to adjoin the breast forms together, and the connector is positioned between inner sides of each of the breast forms.",CHEN DAVID E.;;CHANG JASPER;;CHANG ALICA,CHEN DAVID E;;CHANG JASPER;;CHANG ALICA,,https://lens.org/024-589-214-677-275,Patent Application,yes,34,2,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/00;;A41C3/12;;A41C3/06;;A41C3/10,450/54,0,0,,,,EXPIRED
506,ES,T4,ES 2222117 T4,048-779-190-219-568,2013-08-26,2013,ES 03004678 T,2003-03-03,US 15925102 A,2002-05-31,Sistema acoplable para realzar la forma del pecho,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/048-779-190-219-568,Granted Patent,no,0,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/14;;A41C3/00;;A41C3/02;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
507,EP,A2,EP 1366681 A2,155-542-840-538-119,2003-12-03,2003,EP 03004678 A,2003-03-03,US 15925102 A,2002-05-31,Attachable breast form enhancement system,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/155-542-840-538-119,Patent Application,yes,0,1,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/00;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
508,DE,T1,DE 02029083 T1,146-367-422-771-485,2005-05-04,2005,DE 02029083 T,2002-12-30,US 21111002 A,2002-08-02,Rücken- und trägerloser Büstenhalter,,BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/146-367-422-771-485,Patent Application,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,PENDING
509,US,B2,US 6852001 B2,033-329-030-280-906,2005-02-08,2005,US 80190104 A,2004-03-15,US 80190104 A;;US 15925102 A,2002-05-31,Attachable breast form enhancement system,"A backless, strapless breast form system to be worn in place of a traditional bra having a pair of breast forms. Each breast form includes a volume of silicone gel encased between thermoplastic film material, and a concave interior surface facing towards a user's breast having a pressure sensitive adhesive layer for securing the breast form to the user's breast. There is a connector having a first portion secured to an inner side surface of one breast form and a second portion secured to an inner side surface of the other breast form, where the first portion and the second portion are adapted to cooperatively engage, that adjoins the two breast forms together.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/033-329-030-280-906,Granted Patent,yes,34,28,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/00;;A41C3/12;;A41C3/06;;A41C3/10,450/57;;450/81,3,0,,,"Abstract and Figures Only for French Patent No. 2505620 (Nov. 19, 1982).;;Figures Only for Italian Patent No. IT 0521811 (May 1955).;;Dr. Leonard's-America's Leading Discount Healthcare Catalog, p. 15, Natural Looking Breast Enhancer Pads, Silicone Covered with Film, 1998.",EXPIRED
510,DE,T1,DE 03004678 T1,155-700-632-242-218,2005-01-13,2005,DE 03004678 T,2003-03-03,US 15925102 A,2002-05-31,Verbindbare Brustvergrösserungsvorrichtung,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/155-700-632-242-218,Patent Application,no,0,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/00;;A41C3/06;;A41C3/10,,0,0,,,,PENDING
511,ES,T3,ES 2222115 T3,190-947-843-147-003,2010-01-04,2010,ES 02029083 T,2002-12-30,US 21111002 A,2002-08-02,SUJETADOR SIN CINTAS EN LA ESPALDA Y SIN TIRANTES.,"Un sujetador mejorado sin parte posterior, sin tiras, que comprende: un par de copas de sujetador que tiene una superficie interior enfrentada a una piel de usuaria, en el que la superficie interior comprende una capa adhesiva sensible a la presión dispuesta sobre la misma para unir las copas del sujetador a la piel de la usuaria; y un conectador destinado a unir las copas de sujetador, en el que el conectador está posicionado entre porciones laterales interiores de cada una de las copas de sujetador.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/190-947-843-147-003,Granted Patent,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
512,EP,B1,EP 1386548 B1,060-815-888-120-180,2009-10-14,2009,EP 02029083 A,2002-12-30,US 21111002 A,2002-08-02,"A backless, strapless bra",,BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/060-815-888-120-180,Granted Patent,yes,6,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
513,BR,A,BR 0304522 A,076-930-834-638-966,2004-07-27,2004,BR 0304522 A,2003-07-11,US 21111002 A;;US 0321665 W,2002-08-02,Sutiã tipo frente-única e sem-alça aperfeiçoado,"""SUTIã TIPO FRENTE-úNICA E SEM-ALçA APERFEIçOADO"". Um sutiã tipo frente-única e sem-alça aperfeiçoado compreendendo um par de taças tendo uma superfície interna voltando-se para a pele da usuária que compreende uma camada de adesivo sensível a pressão disposta na mesma para unir as taças de sutiã na pele da usuária. As taças de sutiã são permanente e removivelmente unidas por um conector que é posicionado entre as porções do lado interno das taças de sutiã. O conector pode ter uma variedade de configurações que possibilitem a usuária fixar as taças de sutiã. O conector permite a usuária a criar uma quantidade desejada de clivagem de seios e aumento da impulsão dos seios. O sutiã pode também ser usado com um dispositivo de puxar para cima que fixa na porção do topo das taças de sutiã e permite a usuária a elevar as taças de sutiã e os seios da usuária a prover aumento de impulsão para cima do seio adicional.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/076-930-834-638-966,Patent Application,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,DISCONTINUED
514,EP,A3,EP 1366681 A3,084-805-741-218-409,2004-03-03,2004,EP 03004678 A,2003-03-03,US 15925102 A,2002-05-31,Attachable breast form enhancement system,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/084-805-741-218-409,Search Report,yes,5,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/00;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
515,AT,T1,AT E445340 T1,095-040-914-125-41X,2009-10-15,2009,AT 02029083 T,2002-12-30,US 21111002 A,2002-08-02,RÜCKEN- UND TRÄGERLOSER BÜSTENHALTER,,BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/095-040-914-125-41X,Granted Patent,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
516,ES,T3,ES 2222117 T3,026-980-727-910-022,2006-11-01,2006,ES 03004678 T,2003-03-03,US 15925102 A,2002-05-31,SISTEMA ADHERIBLE QUE REALZA LA FORMA DEL PECHO.,"An attachable breast form enhancement system comprising a pair of breast forms adjoined by a connector. The breast forms have an interior surface with a pressure sensitive adhesive layer that adjoins to the user's breasts. The pressure sensitive adhesive layer can be a permanently grown pressure sensitive adhesive that has an adhesion force to the breast forms that is greater than a cohesion force to the user's breasts. The connector adjoins the separated breast forms by attaching to the inner sides of the breast forms and pulling the user's breasts together. The connector can be either permanently or removably attached to the breast forms. Several different configurations of breast forms and connectors are available to achieve the benefits of the present breast form system. The improved breast form system allows a user to eliminate use of traditional bras by simply adhering the pair of breast forms to the user's breasts/skin, and then adjoining the breast forms with the connector. The breast form system provides for enhancement of breast size and shape, as well as provides for customization of breast cleavage and push-up enhancement. <IMAGE>",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG ALICE;;CHANG JASPER,,https://lens.org/026-980-727-910-022,Granted Patent,no,0,0,24,24,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/12;;A41C3/00;;A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
517,US,B2,US 7052359 B2,003-423-840-480-443,2006-05-30,2006,US 17938305 A,2005-07-11,US 17938305 A;;US 80147904 A;;US 21111002 A,2002-08-02,"Backless, strapless bra","An improved backless, strapless bra comprising a pair of bra cups having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector that is positioned between inner side portions of the bra cups. The connector can have a variety of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra can also be used with a pull-up device that attaches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement.",CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/003-423-840-480-443,Granted Patent,yes,40,28,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/00;;A41C3/06;;A41C3/10,450/54;;450/81;;450/58,3,0,,,"Abstract and Figures Only for French Patent No. 2505620 (Nov. 19, 1982).;;Figures Only for Italian Patent No. IT 0521811 (May 1955).;;Dr. Leonard's-America's Leading Discount Healthcare Catalog, p. 15, Natural Looking Breast Enhancer Pads, Silicone Covered with Film, 1998.",EXPIRED
518,US,B2,US 6916224 B2,160-966-256-751-017,2005-07-12,2005,US 80147904 A,2004-03-15,US 80147904 A;;US 21111002 A,2002-08-02,"Backless, strapless bra","An improved backless, strapless bra comprising a pair of bra cups having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector that is positioned between inner side portions of the bra cups. The connector can have a variety of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amount of breast cleavage and breast push-up enhancement. The bra can also be used with a pull-up device that attaches to the top portion of the bra cups and allows the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER;;CHANG ALICE,,https://lens.org/160-966-256-751-017,Granted Patent,yes,34,30,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,450/57;;450/81,3,0,,,"Abstract and Figures Only for French Patent No. 2505620 (Nov. 19, 1982).;;Figures Only for Italian Patent No. IT 0521811 (May 1955).;;Dr. Leonard's-America's Leading Discount Healthcare Catalog, p. 15, Natural Looking Breast Enhancer Pads, Siliconc Covered with Film, 1998.",EXPIRED
519,US,A1,US 2007/0231458 A1,086-477-424-588-425,2007-10-04,2007,US 63208605 A,2005-07-06,US 63208605 A;;US 58569704 P;;US 2005/0023895 W,2004-07-06,Spotting Device and Method for High Concentration Spot Deposition on Microarrays and Other Micorscale Devices,"Disclosed is a spotter device and methods for the formation of microassays, biochips, biosensors, and cell cultures. The spotter may be used to deposit highly concentrated spots of protein or other materials on a microarray a slide, wafer, or other substrate. The spotter uses microfluidic conduits and orifices to deposit proteins, other biomolecules, or chemicals on a spot on a substrate. Each orifice is part of a fluid pathways that includes an inlet and outlet conduit. When the spotter contacts a substrate a seal is formed between the orifices and the substrate.",UNIV UTAH RES FOUND,GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,UNIVERSITY OF UTAH RESEARCH FOUNDATION (2007-04-16);;UNIVERSITY OF UTAH (2007-03-01),https://lens.org/086-477-424-588-425,Patent Application,yes,21,37,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B05C5/00;;B05D1/36;;B05D5/00;;B23P17/00;;G01N1/28,427/2.11;;118/400;;29/592;;427/256;;427/258,0,0,,,,ACTIVE
520,US,A1,US 2020/0121769 A1,144-165-128-271-182,2020-04-23,2020,US 201916532258 A,2019-08-05,US 201916532258 A;;US 201614909954 A;;US 2014/0049652 W;;US 201461945339 P;;US 201461941032 P;;US 201361909977 P;;US 201361862027 P;;US 201361862026 P;;US 201361862024 P,2013-08-04,DIRECT APPLICATION SYSTEM AND METHOD FOR THE DELIVERY OF BIOACTIVE COMPOSITIONS AND FORMULATIONS,"The embodiments relate to improved skin quality, health and appearance using a new delivery method and certain bioactive compositions and formulations. The system incorporates microneedle delivery technology with unique compositions and formulations. Such development allows for the pursuit of personalized medicine, or treatment delivery that can expand to remote controlled environment, immediate compounding and ultimate personalization with a state of the art longitudinal data predictive analytics. Certain formulations described herein are unique, combinatory and synergistic. Secured by high-tech proprietary system, there are unlimited potentials using AQT technology including but not limited to 3-D printing of a biodegradable micro chips that can be delivered via injection, AQT or any other possible route.",AQUAVIT PHARMACEUTICALS INC,CHANG SOBIN;;GOLDBERG DAVID J;;SHAFER DAVID,,https://lens.org/144-165-128-271-182,Patent Application,yes,0,6,4,42,0,A61K39/08;;A61K9/0021;;A61M37/0015;;A61M2037/0023;;A61K9/08;;A61L27/20;;A61L27/54;;A61L2400/06;;A61M5/20;;A61M5/30;;A61M2205/3553;;A61M2205/505;;A61M2205/6054;;A61Q19/08;;A61K2800/91;;A61J1/065;;A61J2205/60;;A61J1/1418;;B65B3/003;;G16H20/13;;G16H20/17;;A61K8/19;;A61K8/23;;A61K8/27;;A61K8/355;;A61K8/361;;A61K8/498;;A61K8/553;;A61K8/65;;A61K8/66;;A61K8/675;;A61K8/678;;A61K8/735;;A61K8/98;;A61K9/0014;;A61K31/122;;A61K31/202;;A61K31/352;;A61K31/355;;A61K31/592;;A61K31/685;;A61K33/00;;A61K33/04;;A61K33/06;;A61K33/30;;A61K38/063;;A61K38/4893;;A61K2800/91;;A61M5/24;;A61M5/30;;A61M5/3298;;A61M2037/0023;;A61M2037/0061;;A61M2205/505;;A61M2205/6054;;A61Q7/00;;A61Q19/00;;A61Q19/08;;C12Y304/24069;;A61K39/08;;G16H20/13;;G16H20/17,A61K38/48;;A61K8/19;;A61K8/23;;A61K8/27;;A61K8/35;;A61K8/36;;A61K8/49;;A61K8/55;;A61K8/65;;A61K8/66;;A61K8/67;;A61K8/73;;A61K8/98;;A61K9/00;;A61K31/122;;A61K31/202;;A61K31/352;;A61K31/355;;A61K31/592;;A61K31/685;;A61K33/00;;A61K33/04;;A61K33/06;;A61K33/30;;A61K38/06;;A61Q7/00;;A61Q19/00,,0,0,,,,DISCONTINUED
521,TW,U,TW M525578 U,035-815-864-823-168,2016-07-11,2016,TW 105201771 U,2016-02-03,TW 105201771 U,2016-02-03,Clamping-holding holder of signal cable,,WANHO T MFG CO LTD,HSU DAVID WAN-CHANG;;ELLIOTT DAVID ROBERT,,https://lens.org/035-815-864-823-168,Limited Patent,no,0,1,1,1,0,,H02G3/32,,0,0,,,,ACTIVE
522,US,B2,US 10980865 B2,111-424-261-615-251,2021-04-20,2021,US 201414909954 A,2014-08-04,US 201414909954 A;;US 201361862024 P;;US 201361862026 P;;US 201361862027 P;;US 201361909977 P;;US 201461941032 P;;US 201461945339 P;;US 2014/0049652 W;;US 201414212415 A;;US 201361792624 P;;US 201361792970 P;;US 201361794558 P;;US 201361794274 P;;US 201361793946 P;;US 201361792246 P;;US 201361790912 P;;US 201361790469 P;;US 201261682056 P,2012-08-10,Direct application system and method for the delivery of bioactive compositions and formulations,"The embodiments relate to improved skin quality, health and appearance using a new delivery method and certain bioactive compositions and formulations. The system incorporates microneedle delivery technology with unique compositions and formulations. Such development allows for the pursuit of personalized medicine, or treatment delivery that can expand to remote controlled environment, immediate compounding and ultimate personalization with a state of the art longitudinal data predictive analytics. Certain formulations described herein are unique, combinatory and synergistic. Secured by high-tech proprietary system, there are unlimited potentials using AQT technology including but not limited to 3-D printing of a biodegradable micro chips that can be delivered via injection, AQT or any other possible route.",AQUAVIT PHARMACEUTICALS INC,CHANG SOBIN;;GOLDBERG DAVID J;;SHAFER DAVID,AQUAVIT PHARMACEUTICALS INC (2016-06-16),https://lens.org/111-424-261-615-251,Granted Patent,yes,107,1,2,42,0,A61K38/4893;;A61K38/4893;;A61K8/19;;A61K8/19;;A61K8/23;;A61K8/23;;A61K8/27;;A61K8/27;;A61K8/355;;A61K8/355;;A61K8/361;;A61K8/361;;A61K8/498;;A61K8/498;;A61K8/553;;A61K8/553;;A61K8/65;;A61K8/65;;A61K8/66;;A61K8/66;;A61K8/675;;A61K8/675;;A61K8/678;;A61K8/678;;A61K8/735;;A61K8/735;;A61K8/98;;A61K8/98;;A61K9/0014;;A61K9/0014;;A61K31/122;;A61K31/122;;A61K31/202;;A61K31/202;;A61K31/352;;A61K31/352;;A61K31/355;;A61K31/355;;A61K31/592;;A61K31/592;;A61K31/685;;A61K31/685;;A61K33/00;;A61K33/00;;A61K33/04;;A61K33/04;;A61K33/06;;A61K33/06;;A61K33/30;;A61K33/30;;A61K38/063;;A61K38/063;;A61K2800/91;;A61K2800/91;;A61M5/24;;A61M5/24;;A61M5/30;;A61M5/30;;A61M5/3298;;A61M5/3298;;A61M2037/0023;;A61M2037/0023;;A61M2037/0061;;A61M2037/0061;;A61M2205/505;;A61M2205/505;;A61M2205/6054;;A61M2205/6054;;A61Q7/00;;A61Q7/00;;A61Q19/00;;A61Q19/00;;A61Q19/08;;A61Q19/08;;C12Y304/24069;;C12Y304/24069,A61K38/48;;A61K8/19;;A61K8/23;;A61K8/27;;A61K8/35;;A61K8/36;;A61K8/49;;A61K8/55;;A61K8/65;;A61K8/66;;A61K8/67;;A61K8/73;;A61K8/98;;A61K9/00;;A61K31/122;;A61K31/202;;A61K31/352;;A61K31/355;;A61K31/592;;A61K31/685;;A61K33/00;;A61K33/04;;A61K33/06;;A61K33/30;;A61K38/06;;A61M5/24;;A61M5/30;;A61M5/32;;A61M37/00;;A61Q7/00;;A61Q19/00;;A61Q19/08,,34,13,034-892-166-717-598;;091-311-664-368-596;;194-964-076-661-158;;101-421-021-059-51X;;186-297-979-341-335;;150-537-599-857-560;;046-523-055-679-236;;019-912-127-486-143;;150-537-599-857-560;;034-892-166-717-598;;019-912-127-486-143;;046-523-055-679-236;;091-311-664-368-596,20855985;;10.1097/phm.0b013e3181f1c1c7;;10.1097/prs.0b013e318254b3f6;;22743885;;10.1201/9780203500231-12;;10.1201/9780203500231.ch8;;10.1201/9780203500231-15;;10.1016/j.jaad.2007.04.012;;17761356;;pmc3583886;;10.4161/derm.21923;;23467280;;16723701;;10.2353/ajpath.2006.051302;;pmc1606623;;10.1016/j.jaad.2007.04.012;;17761356;;20855985;;10.1097/phm.0b013e3181f1c1c7;;16723701;;10.2353/ajpath.2006.051302;;pmc1606623;;pmc3583886;;10.4161/derm.21923;;23467280;;10.1097/prs.0b013e318254b3f6;;22743885,"Borrione et al.: “Platelet-rich plasma in muscle healing”; Am J Phys Med Rehabil. 89(10):854-61. (2010).;;Fagien et al.: “Reconstituted injectable hyaluronic acid: expanded application in facial aesthetics and additional thoughts on the mechanism of action in cosmetic medicine”; Plastic and reconstructive surgery, 130: 208-217 (2012).;;International Search Report dated Feb. 10, 2015, regarding PCT/US2014/049652.;;International Search Report dated Nov. 4, 2013, regarding PCT/US2013/054421.;;Molnar, J.: “Nutrition and Wound Healing”; CRC Press, (2006), Chapter 7, “B vitamins and wound healing”; 23 pages.;;Molnar, J.: “Nutrition and Wound Healing”; CRC Press, (2006), Chapter 8, “Vitamin C and wound healing”; 30 pages.;;Molnar, J.: “Nutrition and Wound Healing”; CRC Press, (2006), Chapter 10, “Trace elements and wound healing”; 47 Pages.;;Olsen et al.: “A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men”; J Am Acad Dermatol, 57(5): 767-74 (2007).;;Papakonstantinou et al.: “Hyaluronic acid: A key molecule in skin aging”; Dermato-endocrinology, 4: 253-258 (2012).;;Varani et al.: “Decreased Collagen Production in Chronically Aged Skin”; Am J Pathol., 168(6): 1861-1868 (2006).;;Plaintiff's verified complaint, Aquavit Pharmaceuticals, Inc., V. U-B10 Med, Inc., Global Medi Jroducts, and Nyun Shi Eum aka Nyeon-Sik Eum, Case No. 1:19-CV-3351 (VEC), United States District Court Southern District of New York, (2019), pp. 1-60.;;Defendant U-Bio Med, Inc.'s answer to complaint, Aquavit Pharmaceuticals, Inc., V. U-Bio Med, Inc., Global Medi Products, and Nyun Shi Eum aka Nyeon-Sik Eum, Case No. 1:19-CV-3351 (VEC), United States District Court Southern District of New York, (2019), pp. 1-24.;;Sculptra Aesthetic (injectable poly-L-lactic Acid), 35 pages (2009), Sanofi-Aventis U.S. LLC., Bridgewater, New Jersey.;;Aquavit Pharmaceuticals, Inc., Aquavit Pharmaceuticals, Inc. Secures Preliminary Injunction and Restraining Order Against Counterfeiters on Patent and Trademark Infringement Case, (Apr. 29, 2019), 4 pages, Retrieved from: https://www.pmewswire.com/news-releases/aquavit-pharmaceuticals-inc-secures-preliminary-injunction-and-restraining-order-against-counterfeiters-on-patent-and-trademark-infringement-case-300840296.html.;;Olsen et al., A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men, Journal of the American Academy of Dermatology, (2017), 57(5):767-774, University of Minnesota, Minneapolis, Minnesota.;;Borrione et al., Platelet-Rich Plasma in Muscle Healing, Americal Journal of Physical medicine & Rehabilitation, (2010), 89(10):854-861, Wolters Kluwer, The Netherlands.;;Varani et al., Decreased Collagen Production in Chronologically Aged Skin, American Journal of Pathology, (2006), 168(6)1861-1868, American Society for Investigative Pathology, Rockville, Maryland.;;Sculptra Aesthetic (injectable poly-L-lactic Acid), Bradgewater, NJ. Sanofi-Aventis U.S. LLC. (2012), DJA X00033, Bridgewater, New Jersey.;;Papakonstantinou et al., Hyaluronic Acid, A Key Molecule in skin Aging, Dermato Endocrinology, (2012), 4(3):253-258, Landes bioscinence, Austin, Texas.;;Baumgartner, Chapter 10: Trace Elements and Wound Healing, Nutrition and Wound Healing, CRC Press, Edited by Joseph Molar, (2007) p. 173-216, Taylor & Francis Group, LLC, United Kingdom.;;Takana et al., Chapter 8: Vitamin C and Wound Healing, Nutrition and Wound Healing, edited by Joseph Molnar, CRC Press, (2007) p. 121-148, Taylor & Francis Group, LLC, United Kingdom.;;Liepa et al., Chapter 7: B Vitamins and Wound Healing, Nutrition and Wound Healing, edited by Joseph Molnar, CRC Press, (2007) p. 99-119, Taylor & Francis Group, LLC, United Kingdom.;;International Search Report from Int. Appl. No. PCT/US2013/054421, dated Nov. 4, 2013.;;International Search Report from Int. Appl. No. PCT/US2014/49652, dated Feb. 10, 2015.;;Fagien, Reconstituted injectable hyaluronic acid: expanded applications in facial aesthetics and additional thoughts on the mechanism of action in cosmetic medicine, Plast Reconstr Surg., (2012) 130:(1):208-217, Wolters Kluwer, The Netherlands.;;Office Action from U.S. Appl. No. 14/420,856, dated Jul. 16, 2018.;;Office Action from U.S. Appl. No. 14/420,856, dated Jun. 26, 2019.;;Office Action from U.S. Appl. No. 14/964,402, dated May 17, 2017.;;Office Action from U.S. Appl. No. 14/964,402, dated Dec. 26, 2017.;;European Official Communication from European Patent Appl. No. 12703657.2, dated Jan. 29, 2015.;;International Search Report from Int. Appl. No. PCT/US2012/022902, dated Apr. 24, 2012.;;Office Action from U.S. Appl. No. 13/982,213, dated Aug. 27, 2015.;;Office Action from U.S. Appl. No. 13/982,213, dated Dec. 30, 2015.;;Office Action from U.S. Appl. No. 13/982,213, dated Nov. 25, 2016.",ACTIVE
523,WO,A2,WO 2006/014460 A2,188-713-353-739-969,2006-02-09,2006,US 2005/0023895 W,2005-07-06,US 58569704 P,2004-07-06,SPOTTING DEVICE AND METHOD FOR HIGH CONCENTRATION SPOT DEPOSITION ON MICROARRAYS AND OTHER MICROSCALE DEVICES,"Disclosed is a spotter device and methods for the formation of microassays, biochips, biosensors, and cell cultures. The spotter may be used to deposit highly concentrated spots of protein or other materials on a microarray a slide, wafer, or other substrate. The spotter uses microfluidic conduits and orifices to deposit proteins, other biomolecules, or chemicals on a spot on a substrate. Each orifice is part of a fluid pathways that includes an inlet and outlet conduit. When the spotter contacts a substrate a seal is formed between the orifices and the substrate.",UNIV UTAH RES FOUND;;GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,,https://lens.org/188-713-353-739-969,Patent Application,yes,0,26,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B01L3/02;;G01D15/00,,1,0,,,See references of EP 1773498A4,PENDING
524,WO,A3,WO 2006/014460 A3,012-636-949-145-652,2006-06-29,2006,US 2005/0023895 W,2005-07-06,US 58569704 P,2004-07-06,SPOTTING DEVICE AND METHOD FOR HIGH CONCENTRATION SPOT DEPOSITION ON MICROARRAYS AND OTHER MICROSCALE DEVICES,"Disclosed is a spotter device and methods for the formation of microassays, biochips, biosensors, and cell cultures. The spotter may be used to deposit highly concentrated spots of protein or other materials on a microarray a slide, wafer, or other substrate. The spotter uses microfluidic conduits and orifices to deposit proteins, other biomolecules, or chemicals on a spot on a substrate. Each orifice is part of a fluid pathways that includes an inlet and outlet conduit. When the spotter contacts a substrate a seal is formed between the orifices and the substrate.",UNIV UTAH RES FOUND;;GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,,https://lens.org/012-636-949-145-652,Search Report,yes,5,0,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B01L3/02;;G01D15/00,,1,0,,,See also references of EP 1773498A4,PENDING
525,KR,A,KR 20070063498 A,056-758-081-553-986,2007-06-19,2007,KR 20077002867 A,2007-02-05,US 58569704 P,2004-07-06,SPOTTING DEVICE AND METHOD FOR HIGH CONCENTRATION SPOT DEPOSITION ON MICROARRAYS AND OTHER MICROSCALE DEVICES,"Disclosed is a spotter device and methods for the formation of microassays, biochips, biosensors, and cell cultures. The spotter may be used to deposit highly concentrated spots of protein or other materials on a microarray slide, wafer, or other substrate. It may also be used to perform various chemistry steps on the same spots. The spotter increases the surface density of substances at each spot by directing a flow of solution bearing the desired substance over the spot area until surface saturation is accomplished. The spotter uses microfluidic conduits and orifices to deposit proteins, other biomolecules, or chemicals on a spot on a separate substrate. Each orifice is part of a fluid pathways that includes an inlet conduit and an outlet conduit. When the spotter contacts a substrate a seal is formed between the orifices and the substrate. The same or different substances may be flowed across each orifice. Any number of orifices may be incorporated into a spotter. The spotter is particularly useful for depositing proteins in high concentrations on a substrate, since the spotter may be placed on a substrate for an extended period of time.",UNIV UTAH RES FOUND,GALE BRUCE;;CHANG YEN DAVID;;MYSZKA DAVID,,https://lens.org/056-758-081-553-986,Patent Application,no,0,1,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B01L3/02;;B01L3/00;;G01D15/00,,0,0,,,,DISCONTINUED
526,US,A1,US 2015/0319103 A1,008-001-962-194-842,2015-11-05,2015,US 201414268332 A,2014-05-02,US 201414268332 A,2014-05-02,User Access in a Multi-Tenant Cloud Environment,"Systems and methods for allowing one or more users to access a number of tenant systems in a multi-tenant cloud environment are disclosed. The method includes registering a user to the tenant systems based on an identity information received from the user. The same identity information is associated with each of the tenant systems. The method also includes creating an account corresponding to each of the tenant systems for the user. The method further includes allowing the user to access one or more of the tenant systems based on the identity information entered by the user. The user accesses the tenant systems by entering the same identity information. Further, the same identity information is used for identifying the user in each of the tenant systems.",ENSIM CORP,DAS SWARUP;;CHANG DAVID;;WIPPICH DAVID J,ENSIM CORPORATION (2014-04-16);;CLOUDBLUE LLC (2021-10-29);;INGRAM MICRO INC (2017-03-09),https://lens.org/008-001-962-194-842,Patent Application,yes,23,5,1,3,0,H04L12/6418;;H04L63/0815;;H04L47/808;;H04L67/10;;H04L63/0815;;H04L12/6418,H04L47/80,,0,0,,,,DISCONTINUED
527,US,B2,US 8210119 B2,112-852-771-869-937,2012-07-03,2012,US 63208605 A,2005-07-06,US 63208605 A;;US 58569704 P;;US 2005/0023895 W,2004-07-06,Spotting device and method for high concentration spot deposition on microarrays and other microscale devices,"Disclosed is a spotter device and methods for the formation of microassays, biochips, biosensors, and cell cultures. The spotter may be used to deposit highly concentrated spots of protein or other materials on a microarray a slide, wafer, or other substrate. The spotter uses microfluidic conduits and orifices to deposit proteins, other biomolecules, or chemicals on a spot on a substrate. Each orifice is part of a fluid pathways that includes an inlet and outlet conduit. When the spotter contacts a substrate a seal is formed between the orifices and the substrate.",GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID;;UNIV UTAH RES FOUND,GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,UNIVERSITY OF UTAH RESEARCH FOUNDATION (2007-04-16);;UNIVERSITY OF UTAH (2007-03-01),https://lens.org/112-852-771-869-937,Granted Patent,yes,27,9,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B05C1/06,118/256;;422/100;;347/185;;219/121.64;;118/200,1,0,,,"PCT Preliminary Report on Patentability and Written Opinion, PCT/US2005/023895, dated Jan. 9, 2007.",ACTIVE
528,EP,A2,EP 1773498 A2,170-727-794-495-967,2007-04-18,2007,EP 05764557 A,2005-07-06,US 2005/0023895 W;;US 58569704 P,2004-07-06,SPOTTING DEVICE AND METHOD FOR HIGH CONCENTRATION SPOT DEPOSITION ON MICROARRAYS AND OTHER MICROSCALE DEVICES,,UNIV UTAH RES FOUND,GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,,https://lens.org/170-727-794-495-967,Patent Application,yes,0,0,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B01J19/00;;B01L3/00;;C12M1/26;;G01N35/10,,0,0,,,,ACTIVE
529,US,A1,US 2023/0033858 A1,011-227-420-475-121,2023-02-02,2023,US 202217832416 A,2022-06-03,US 202217832416 A;;US 201916532258 A;;US 201614909954 A;;US 2014/0049652 W;;US 201461945339 P;;US 201461941032 P;;US 201361909977 P;;US 201361862027 P;;US 201361862026 P;;US 201361862024 P,2013-08-04,DIRECT APPLICATION SYSTEM AND METHOD FOR THE DELIVERY OF BIOACTIVE COMPOSITIONS AND FORMULATIONS,"The embodiments relate to improved skin quality, health and appearance using a new delivery method and certain bioactive compositions and formulations. The system incorporates microneedle delivery technology with unique compositions and formulations. Such development allows for the pursuit of personalized medicine, or treatment delivery that can expand to remote controlled environment, immediate compounding and ultimate personalization with a state of the art longitudinal data predictive analytics. Certain formulations described herein are unique, combinatory and synergistic. Secured by high-tech proprietary system, there are unlimited potentials using AQT technology including but not limited to 3-D printing of a biodegradable micro chips that can be delivered via injection, AQT or any other possible route.",AQUAVIT PHARMACEUTICALS INC,CHANG SOBIN;;GOLDBERG DAVID J;;SHAFER DAVID,,https://lens.org/011-227-420-475-121,Patent Application,yes,7,0,4,42,0,A61K39/08;;A61K9/0021;;A61M37/0015;;A61M2037/0023;;A61K9/08;;A61L27/20;;A61L27/54;;A61L2400/06;;A61M5/20;;A61M5/30;;A61M2205/3553;;A61M2205/505;;A61M2205/6054;;A61Q19/08;;A61K2800/91;;A61J1/065;;A61J2205/60;;A61J1/1418;;B65B3/003;;G16H20/13;;G16H20/17;;A61K8/19;;A61K8/23;;A61K8/27;;A61K8/355;;A61K8/361;;A61K8/498;;A61K8/553;;A61K8/65;;A61K8/66;;A61K8/675;;A61K8/678;;A61K8/735;;A61K8/98;;A61K9/0014;;A61K31/122;;A61K31/202;;A61K31/352;;A61K31/355;;A61K31/592;;A61K31/685;;A61K33/00;;A61K33/04;;A61K33/06;;A61K33/30;;A61K38/063;;A61K38/4893;;A61K2800/91;;A61M5/24;;A61M5/30;;A61M5/3298;;A61M2037/0023;;A61M2037/0061;;A61M2205/505;;A61M2205/6054;;A61Q7/00;;A61Q19/00;;A61Q19/08;;C12Y304/24069;;A61K39/08;;G16H20/13;;G16H20/17,A61K39/08;;A61K8/19;;A61K8/23;;A61K8/27;;A61K8/35;;A61K8/36;;A61K8/49;;A61K8/55;;A61K8/65;;A61K8/66;;A61K8/67;;A61K8/73;;A61K8/98;;A61K9/00;;A61K31/122;;A61K31/202;;A61K31/352;;A61K31/355;;A61K31/592;;A61K31/685;;A61K33/00;;A61K33/04;;A61K33/06;;A61K33/30;;A61K38/06;;A61K38/48;;A61Q7/00;;A61Q19/00;;G16H20/13;;G16H20/17,,0,0,,,,DISCONTINUED
530,US,B2,US 11223613 B2,076-147-762-572-050,2022-01-11,2022,US 201916291975 A,2019-03-04,US 201916291975 A;;US 201414268332 A,2014-05-02,Methods and systems for roles and membership management in a multi-tenant cloud environment,"Systems and methods for allowing one or more users to access a number of tenant systems in a multi-tenant cloud environment are disclosed. The method includes registering a user to the tenant systems based on an identity information received from the user. The same identity information is associated with each of the tenant systems. The method also includes creating an account corresponding to each of the tenant systems for the user. The method further includes allowing the user to access one or more of the tenant systems based on the identity information entered by the user. The user accesses the tenant systems by entering the same identity information. Further, the same identity information is used for identifying the user in each of the tenant systems.",INGRAM MICRO INC;;CLOUDBLUE LLC,DAS SWARUP;;CHANG DAVID HOU;;WIPPICH DAVID,ENSIM CORPORATION (2014-10-01);;CLOUDBLUE LLC (2021-10-29);;INGRAM MICRO INC (2017-03-09),https://lens.org/076-147-762-572-050,Granted Patent,yes,20,1,2,3,0,H04L12/6418;;H04L63/0815;;H04L63/0815;;H04L63/105;;G06F2009/45595;;G06F9/45558;;H04L63/108,G06F15/173;;G06F9/455;;H04L12/64,,0,0,,,,ACTIVE
531,DE,D1,DE 69032598 D1,131-783-637-070-959,1998-10-01,1998,DE 69032598 T,1990-06-22,US 37067389 A;;US 9003586 W,1989-06-23,ZUSAMMENSETZUNGEN UND METHODEN ZUR SYNTHESE DES B-REZEPTORS FÜR DAS NATRIURETISCHE PROTEIN UND VERWENDUNGSMETHODEN,"PCT No. PCT/US90/03586 Sec. 371 Date Dec. 19, 1991 Sec. 102(e) Date Dec. 19, 1991 PCT Filed Jun. 22, 1990 PCT Pub. No. WO91/00292 PCT Pub. Date Jan. 10, 1991.Described are the amino acid sequence of natriuretic peptide receptor B (NPRB) and DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.",GENENTECH INC,CHANG MING-SHI;;GOEDDEL DAVID;;LOWE DAVID,,https://lens.org/131-783-637-070-959,Granted Patent,no,0,0,11,11,0,A61K38/00;;C07K14/58;;C07K14/72;;C07K16/2869;;A61P43/00;;A61P7/10;;C07K16/2869;;C07K14/72;;C07K14/58;;A61K38/00,A61K38/00;;A61K38/22;;A61K39/395;;A61P7/10;;A61P43/00;;C07K1/00;;C07K1/22;;C07K14/00;;C07K14/435;;C07K14/575;;C07K14/58;;C07K14/705;;C07K14/72;;C07K16/00;;C07K16/28;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/53,,0,0,,,,EXPIRED
532,DE,T2,DE 69032598 T2,067-716-912-933-941,1999-03-11,1999,DE 69032598 T,1990-06-22,US 37067389 A;;US 9003586 W,1989-06-23,ZUSAMMENSETZUNGEN UND METHODEN ZUR SYNTHESE DES B-REZEPTORS FÜR DAS NATRIURETISCHE PROTEIN UND VERWENDUNGSMETHODEN,"PCT No. PCT/US90/03586 Sec. 371 Date Dec. 19, 1991 Sec. 102(e) Date Dec. 19, 1991 PCT Filed Jun. 22, 1990 PCT Pub. No. WO91/00292 PCT Pub. Date Jan. 10, 1991.Described are the amino acid sequence of natriuretic peptide receptor B (NPRB) and DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.",GENENTECH INC,CHANG MING-SHI;;GOEDDEL DAVID;;LOWE DAVID,,https://lens.org/067-716-912-933-941,Granted Patent,no,0,0,11,11,0,A61K38/00;;C07K14/58;;C07K14/72;;C07K16/2869;;A61P43/00;;A61P7/10;;C07K16/2869;;C07K14/72;;C07K14/58;;A61K38/00,A61K38/00;;A61K38/22;;A61K39/395;;A61P7/10;;A61P43/00;;C07K1/00;;C07K1/22;;C07K14/00;;C07K14/435;;C07K14/575;;C07K14/58;;C07K14/705;;C07K14/72;;C07K16/00;;C07K16/28;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/53,,0,0,,,,EXPIRED
533,EP,A4,EP 1773498 A4,127-155-372-858-561,2009-12-02,2009,EP 05764557 A,2005-07-06,US 2005/0023895 W;;US 58569704 P,2004-07-06,SPOTTING DEVICE AND METHOD FOR HIGH CONCENTRATION SPOT DEPOSITION ON MICROARRAYS AND OTHER MICROSCALE DEVICES,,UNIV UTAH RES FOUND,GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,,https://lens.org/127-155-372-858-561,Search Report,no,5,0,12,12,0,B01J19/0046;;B01J2219/00353;;B01J2219/00367;;B01J2219/00369;;B01J2219/00371;;B01J2219/00497;;B01J2219/00527;;B01J2219/00536;;B01J2219/00574;;B01J2219/00576;;B01J2219/00585;;B01J2219/00596;;B01J2219/00605;;B01J2219/0061;;B01J2219/00612;;B01J2219/00619;;B01J2219/00621;;B01J2219/00626;;B01J2219/00628;;B01J2219/0063;;B01J2219/00637;;B01J2219/00639;;B01J2219/00644;;B01J2219/00648;;B01J2219/00659;;B01J2219/00675;;B01J2219/00677;;B01J2219/00691;;B01J2219/00693;;B01J2219/00722;;B01J2219/00725;;B01J2219/00731;;B01J2219/00734;;B01J2219/00736;;B01J2219/00743;;B01L3/0293;;B01L3/5027;;B01L3/502707;;B01L3/502715;;B01L3/50273;;B01L3/502761;;B01L2200/0647;;B01L2200/147;;B01L2300/0636;;B01L2300/0654;;B01L2300/0822;;B01L2300/0877;;B01L2300/1827;;B01L2400/0415;;B01L2400/0487;;B82Y30/00;;C40B50/14;;C40B60/14;;G01N35/1002;;G01N35/1065;;G01N35/1074;;G01N2035/00158;;G01N2035/1034;;G01N2035/1039;;C12M23/16;;Y10T29/49;;B01L3/02;;G01D15/00;;B01L3/00;;Y10T29/49;;B01J19/0046;;B01J2219/00675;;B01L3/0293;;B01J2219/00734;;G01N35/1002;;B01J2219/00644;;B01J2219/00605;;B01L2300/1827;;B01J2219/00596;;B01J2219/00619;;B82Y30/00;;B01J2219/00497;;B01J2219/00736;;G01N2035/1039;;B01J2219/00612;;B01L3/502715;;B01L2300/0636;;C40B60/14;;B01J2219/00722;;B01L2300/0654;;B01L2300/0877;;B01L2200/147;;B01J2219/00369;;B01J2219/00693;;G01N2035/00158;;B01J2219/00367;;B01J2219/00585;;B01J2219/00677;;B01J2219/00536;;B01J2219/0063;;B01L2300/0822;;B01L3/50273;;B01J2219/00353;;B01L3/502707;;B01L2400/0487;;C40B50/14;;B01J2219/00659;;B01L2200/0647;;B01J2219/00725;;B01L3/5027;;G01N35/1074;;B01J2219/00637;;B01J2219/0061;;B01J2219/00527;;B01L2400/0415;;B01J2219/00648;;B01J2219/00731;;B01L3/502761;;B01J2219/00621;;B01J2219/00639;;B01J2219/00628;;B01J2219/00626;;G01N2035/1034;;B01J2219/00574;;G01N35/1065;;B01J2219/00743;;B01J2219/00371;;B01J2219/00691;;B01J2219/00576;;C12M23/16,B01L3/02;;G01D15/00,,0,0,,,,ACTIVE
534,CA,A1,CA 2571859 A1,086-943-328-727-072,2006-02-09,2006,CA 2571859 A,2005-07-06,US 58569704 P;;US 2005/0023895 W,2004-07-06,SPOTTING DEVICE AND METHOD FOR HIGH CONCENTRATION SPOT DEPOSITION ON MICROARRAYS AND OTHER MICROSCALE DEVICES,,UNIV UTAH RES FOUND,MYSZKA DAVID;;CHANG-YEN DAVID;;GALE BRUCE,,https://lens.org/086-943-328-727-072,Patent Application,no,0,2,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B01L3/02;;G01D15/00,,0,0,,,,DISCONTINUED
535,EP,B1,EP 1773498 B1,041-094-218-621-924,2012-06-13,2012,EP 05764557 A,2005-07-06,US 2005/0023895 W;;US 58569704 P,2004-07-06,SPOTTING DEVICE AND METHOD FOR HIGH CONCENTRATION SPOT DEPOSITION ON MICROARRAYS AND OTHER MICROSCALE DEVICES,,UNIV UTAH RES FOUND,GALE BRUCE;;CHANG-YEN DAVID;;MYSZKA DAVID,,https://lens.org/041-094-218-621-924,Granted Patent,yes,10,0,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B01J19/00;;B01L3/00;;C12M1/26;;G01N35/10,,0,0,,,,ACTIVE
536,CN,C,CN 100496749 C,194-314-957-944-84X,2009-06-10,2009,CN 200580023025 A,2005-07-06,US 58569704 P,2004-07-06,Spotting device and method for high concentration spot deposition on microarrays and other mini devices,,UNIV UTAH RES FOUND,BRUCE GALE;;DAVID CHANG YEN;;DAVID MYSZKA,,https://lens.org/194-314-957-944-84X,Granted Patent,no,0,0,12,12,0,B01J19/0046;;B01J19/0046;;B01L3/02;;B01J2219/00353;;B01J2219/00353;;B01J2219/00367;;B01J2219/00367;;B01J2219/00369;;B01J2219/00369;;B01J2219/00371;;B01J2219/00371;;B01J2219/00497;;B01J2219/00497;;B01J2219/00527;;B01J2219/00527;;B01J2219/00536;;B01J2219/00536;;B01J2219/00574;;B01J2219/00574;;B01J2219/00576;;B01J2219/00576;;B01J2219/00585;;B01J2219/00585;;B01J2219/00596;;B01J2219/00596;;B01J2219/00605;;B01J2219/00605;;B01J2219/0061;;B01J2219/0061;;B01J2219/00612;;B01J2219/00612;;B01J2219/00619;;B01J2219/00619;;B01J2219/00621;;B01J2219/00621;;B01J2219/00626;;B01J2219/00626;;B01J2219/00628;;B01J2219/00628;;B01J2219/0063;;B01J2219/0063;;B01J2219/00637;;B01J2219/00637;;B01J2219/00639;;B01J2219/00639;;B01J2219/00644;;B01J2219/00644;;B01J2219/00648;;B01J2219/00648;;B01J2219/00659;;B01J2219/00659;;B01J2219/00675;;B01J2219/00675;;B01J2219/00677;;B01J2219/00677;;B01J2219/00691;;B01J2219/00691;;B01J2219/00693;;B01J2219/00693;;B01J2219/00722;;B01J2219/00722;;B01J2219/00725;;B01J2219/00725;;B01J2219/00731;;B01J2219/00731;;B01J2219/00734;;B01J2219/00734;;B01J2219/00736;;B01J2219/00736;;B01J2219/00743;;B01J2219/00743;;B01L3/00;;B01L3/0293;;B01L3/0293;;B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/50273;;B01L3/50273;;B01L3/502761;;B01L3/502761;;B01L2200/0647;;B01L2200/0647;;B01L2200/147;;B01L2200/147;;B01L2300/0636;;B01L2300/0636;;B01L2300/0654;;B01L2300/0654;;B01L2300/0822;;B01L2300/0822;;B01L2300/0877;;B01L2300/0877;;B01L2300/1827;;B01L2300/1827;;B01L2400/0415;;B01L2400/0415;;B01L2400/0487;;B01L2400/0487;;B82Y30/00;;B82Y30/00;;C12M23/16;;C12M23/16;;C40B50/14;;C40B50/14;;C40B60/14;;C40B60/14;;G01D15/00;;G01N35/1002;;G01N35/1002;;G01N35/1065;;G01N35/1065;;G01N35/1074;;G01N35/1074;;G01N2035/00158;;G01N2035/00158;;G01N2035/1034;;G01N2035/1034;;G01N2035/1039;;G01N2035/1039;;Y10T29/49;;Y10T29/49,B01L3/02,,0,0,,,,ACTIVE
537,US,A1,US 2007/0174901 A1,066-689-175-734-805,2007-07-26,2007,US 33620506 A,2006-01-20,US 33620506 A,2006-01-20,System and method for automatic wireless network password update,"A system and method that allows an administrator to set a new password at a wireless access point, such as a traditional WAP or a wireless router. The wireless access point creates a message that includes the new password. The message is encrypted using the old password that was previously set for the wireless network. The encrypted message is wirelessly transmitted from the wireless access point to the active client devices (those clients currently accessing the wireless network). The clients decrypt the message using the old password that was previously provided to the clients. The clients retrieve the new password from the message. The clients construct a new message that is encrypted using the new password. The new message is wirelessly transmitted from the clients to the wireless access device and serves as an acknowledgement.",CHANG DAVID Y;;CHANG JOHN Y;;VENKATARAMAPPA VISHWANATH,CHANG DAVID Y;;CHANG JOHN Y;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2005-11-15),https://lens.org/066-689-175-734-805,Patent Application,yes,9,41,7,7,0,H04L63/0428;;H04L63/0846;;H04W12/06;;H04W12/033;;H04L63/0846;;H04L63/0428;;H04W12/06;;H04W12/033,H04L9/32;;G06F21/44,726/5,0,0,,,,DISCONTINUED
538,US,B2,US 9433773 B2,116-557-854-547-435,2016-09-06,2016,US 201414582554 A,2014-12-24,TW 103204412 U,2014-03-14,Cranial electrotherapy stimulation device,"A cranial electrotherapy stimulation (CES) device includes a head support, a control unit configured to provide a stimulating current, and a primary arm module. The primary arm module includes a primary arm and an electrode unit. The primary arm is pivotally connected to the head support and is longitudinally extendible. The electrode unit is disposed at the primary arm and includes an electrode that is electrically coupled to the control unit and that forms a path for transmission of the stimulating current to a stimulating point of a subject when the electrode is placed in direct contact with the stimulating point.",CONTOUR OPTIK INC,CHAO DAVID;;LIN CHIEN-HO;;CHANG YUNG-CHANG,CONTOUR OPTIK INC (2014-12-02),https://lens.org/116-557-854-547-435,Granted Patent,yes,10,4,3,3,0,A61N1/0472;;A61N1/0472;;A61N1/0456;;A61N1/0456;;A61N1/0484;;A61N1/0484;;A61N1/36025;;A61N1/36025,A61N1/00;;A61N1/04;;A61N1/36,,0,0,,,,ACTIVE
539,US,A1,US 2017/0010060 A1,117-519-087-071-358,2017-01-12,2017,US 201615202436 A,2016-07-05,US 201615202436 A;;US 201562189125 P,2015-07-06,"HETEROGENEOUS SURFACES FOR PATTERNED BUBBLE ARRAYS, ENHANCED HEAT TRANSFER, & ADVANCED HEAT EXHANGER APPLICATIONS","Heterogeneous surfaces to tailor bubble nucleation, bubble sites, and bubble dynamics. In some embodiments, piezoelectric inkjet printing is employed to deposit hydrophobic polymer dot arrays having any predetermined pattern. In some further embodiments, a field region comprising hydrophilic nanostructures further surrounds these dot arrays. The hydrophobic sites may be disposed at a crater bottom to enhancing wicking and replenishment of evaporate. In some embodiments, a heat exchanger comprises the heterogeneous surface for enhanced critical heat flux. In some embodiments, an apparatus for conveying information comprises the heterogeneous surface to generate a 2D binary image with each bubble serving as an image pixel that corresponds to one or more site within the heterogeneous surface.",CHANG CHIH-HUNG;;CHOI CHANG-HO;;DAVID MICHELE,CHANG CHIH-HUNG;;CHOI CHANG-HO;;DAVID MICHELE,OREGON STATE UNIVERSITY (2016-08-01),https://lens.org/117-519-087-071-358,Patent Application,yes,0,12,1,1,0,F28F13/187;;F28F13/187;;F28F21/06;;F28F21/081;;F28F2245/02;;F28F2245/02;;F28F2245/04;;F28F2245/04;;F28F2255/20;;F28F2255/20,F28F13/18;;B41J11/00;;F28F21/06;;F28F21/08,,0,0,,,,DISCONTINUED
540,US,B2,US 7105072 B2,011-774-927-123-208,2006-09-12,2006,US 8385102 A,2002-02-25,US 8385102 A;;US 34241699 A,1999-06-29,Method for processing a film,"A method for processing a film. The method impressing the whole surface or a selected surface of the film to form protuberant structures on the film by using a transfer and an impresser which has grain projections formed thereon, wherein the protuberant structures have a protuberant shape with an opening hole on the tip or without an opening hole on the tip.",FOUR PILLARS ENTPR CORP,LIN DAVID;;CHANG KUN-MING;;CHANG CHI-PING,,https://lens.org/011-774-927-123-208,Granted Patent,yes,18,1,8,8,0,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B29C2793/0045;;B29K2705/00;;B29L2031/722;;B31F1/07;;B31F2201/0702;;B60P1/26;;B62D33/0273;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;B31F1/07;;B31F2201/0702;;B29K2705/00;;B29C2793/0045;;B29C51/08;;B60P1/26;;B29C51/14;;B26F1/24;;B62D33/0273;;B29C59/02;;B29L2031/722;;B29C59/04,B21D31/00;;B26F1/24;;B29C51/08;;B29C51/14;;B29C59/00;;B29C59/02;;B29C59/04;;B31F1/07;;B60P1/26;;B62D33/027,156/219;;156/220;;156/252;;156/253;;156/289;;264/284;;264/293;;72/379.2,0,0,,,,EXPIRED
541,GB,B,GB 2364023 B,091-666-326-324-331,2003-06-04,2003,GB 0114438 A,1999-09-14,US 9920952 W;;US 34241699 A,1999-06-29,Method for processing a film,,FOUR PILLARS ENTPR CORP,LIN DAVID;;CHANG K M;;CHANG CHI-PING,,https://lens.org/091-666-326-324-331,Granted Patent,no,2,0,8,8,0,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B29C2793/0045;;B29K2705/00;;B29L2031/722;;B31F1/07;;B31F2201/0702;;B60P1/26;;B62D33/0273;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;B31F1/07;;B31F2201/0702;;B29K2705/00;;B29C2793/0045;;B29C51/08;;B60P1/26;;B29C51/14;;B26F1/24;;B62D33/0273;;B29C59/02;;B29L2031/722;;B29C59/04,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B31F1/07;;B60P1/26;;B62D33/027,B6J JF1           JF1;;B6J J201          JF1;;B6J J204          JF1;;B6J J803          JF1,0,0,,,,EXPIRED
542,GB,A,GB 2364023 A,182-489-556-334-943,2002-01-16,2002,GB 0114438 A,1999-09-14,US 9920952 W;;US 34241699 A,1999-06-29,Method for processing a film,"A method for processing a film. The method impressing the whole surface or a selected surface of the film (10) to form protuberant structures (12) on the film by using a transfer (106) and an impresser (104) which has grain projections (108) formed thereon, wherein the protuberant structures have a protuberant shape with an opening hole on the tip or without an opening hole on the tip.",FOUR PILLARS ENTPR CORP,LIN DAVID;;CHANG K M;;CHANG CHI-PING,,https://lens.org/182-489-556-334-943,Patent Application,no,2,0,8,8,0,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B29C2793/0045;;B29K2705/00;;B29L2031/722;;B31F1/07;;B31F2201/0702;;B60P1/26;;B62D33/0273;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;B31F1/07;;B31F2201/0702;;B29K2705/00;;B29C2793/0045;;B29C51/08;;B60P1/26;;B29C51/14;;B26F1/24;;B62D33/0273;;B29C59/02;;B29L2031/722;;B29C59/04,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B31F1/07;;B60P1/26;;B62D33/027,B6J JF1           JF1;;B6J J201          JF1;;B6J J204          JF1;;B6J J803          JF1,0,0,,,,EXPIRED
543,US,A1,US 2015/0258329 A1,146-676-450-599-108,2015-09-17,2015,US 201414582567 A,2014-12-24,TW 103204411 U,2014-03-14,ELECTRODE,"An electrode configured for use in a direct current electrical stimulation system, which includes a control circuit configured to provide a stimulating current, includes a main body and a plurality of pin members. The main body is electrically coupled to the control circuit to receive the stimulating current therefrom and includes a base wall and a surrounding wall cooperating with the base wall to define a receiving space for receiving an electrically conductive liquid. The pin members extend from the main body, are in fluid communication with the receiving space, and permit delivery of the electrically conductive liquid to a subject when the pin members are placed in direct contact with the subject.",CONTOUR OPTIK INC,CHAO DAVID;;LIN CHIEN-HO;;CHANG YUNG-CHANG,CONTOUR OPTIK INC (2014-12-02),https://lens.org/146-676-450-599-108,Patent Application,yes,4,2,3,3,0,A61N1/0456;;A61N1/0456;;A61N1/0448;;A61N1/0448;;A61N1/0472;;A61N1/0472;;A61N1/20;;A61N1/20;;A61N1/36025;;A61N1/36025,A61N1/05;;A61N1/08,,0,0,,,,INACTIVE
544,US,A1,US 2003/0034589 A1,077-823-770-447-409,2003-02-20,2003,US 8385102 A,2002-02-25,US 8385102 A;;US 34241699 A,1999-06-29,Method for processing a film,"
   A method for processing a film. The method impressing the whole surface or a selected surface of the film to form protuberant structures on the film by using a transfer and an impresser which has grain projections formed thereon, wherein the protuberant structures have a protuberant shape with an opening hole on the tip or without an opening hole on the tip. 
",LIN DAVID;;CHANG K. M.;;CHANG CHI-PING,LIN DAVID;;CHANG K M;;CHANG CHI-PING,,https://lens.org/077-823-770-447-409,Patent Application,yes,13,1,8,8,0,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B29C2793/0045;;B29K2705/00;;B29L2031/722;;B31F1/07;;B31F2201/0702;;B60P1/26;;B62D33/0273;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;B31F1/07;;B31F2201/0702;;B29K2705/00;;B29C2793/0045;;B29C51/08;;B60P1/26;;B29C51/14;;B26F1/24;;B62D33/0273;;B29C59/02;;B29L2031/722;;B29C59/04,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B31F1/07;;B60P1/26;;B62D33/027,26428;;264/284;;264/293;;264/154,0,0,,,,EXPIRED
545,TW,B,TW 580426 B,107-391-531-773-514,2004-03-21,2004,TW 88114609 A,1999-08-26,US 34241699 A,1999-06-29,Method for processing a film,"A method for processing a film. The method impressing the whole surface or a selected surface of the film to form protuberant structures on the film by using a transfer and an impresser which has grain projections formed thereon, wherein the protuberant structures have a protuberant shape with an opening hole on the tip or without an opening hole on the tip.",FOUR PILLARS ENTPR CO LTD,LIN DAVID;;CHANG KUEN-MING;;CHANG CHI-PING,,https://lens.org/107-391-531-773-514,Granted Patent,no,0,0,8,8,0,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B29C2793/0045;;B29K2705/00;;B29L2031/722;;B31F1/07;;B31F2201/0702;;B60P1/26;;B62D33/0273;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;B31F1/07;;B31F2201/0702;;B29K2705/00;;B29C2793/0045;;B29C51/08;;B60P1/26;;B29C51/14;;B26F1/24;;B62D33/0273;;B29C59/02;;B29L2031/722;;B29C59/04,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B31F1/07;;B60P1/26;;B62D33/027,,0,0,,,,EXPIRED
546,US,B2,US 9555233 B2,096-711-803-941-677,2017-01-31,2017,US 201414582567 A,2014-12-24,TW 103204411 U,2014-03-14,Electrode,"An electrode configured for use in a direct current electrical stimulation system, which includes a control circuit configured to provide a stimulating current, includes a main body and a plurality of pin members. The main body is electrically coupled to the control circuit to receive the stimulating current therefrom and includes a base wall and a surrounding wall cooperating with the base wall to define a receiving space for receiving an electrically conductive liquid. The pin members extend from the main body, are in fluid communication with the receiving space, and permit delivery of the electrically conductive liquid to a subject when the pin members are placed in direct contact with the subject.",CONTOUR OPTIK INC,CHAO DAVID;;LIN CHIEN-HO;;CHANG YUNG-CHANG,CONTOUR OPTIK INC (2014-12-02),https://lens.org/096-711-803-941-677,Granted Patent,yes,11,0,3,3,0,A61N1/0456;;A61N1/0456;;A61N1/0448;;A61N1/0448;;A61N1/0472;;A61N1/0472;;A61N1/20;;A61N1/20;;A61N1/36025;;A61N1/36025,A61N1/00;;A61N1/04;;A61N1/20;;A61N1/36,,0,0,,,,INACTIVE
547,WO,A1,WO 2001/000410 A1,196-568-763-775-155,2001-01-04,2001,US 9920952 W,1999-09-14,US 34241699 A,1999-06-29,METHOD FOR PROCESSING A FILM,"A method for processing a film. The method impressing the whole surface or a selected surface of the film (10) to form protuberant structures (12) on the film by using a transfer (106) and an impresser (104) which has grain projections (108) formed thereon, wherein the protuberant structures have a protuberant shape with an opening hole on the tip or without an opening hole on the tip.",FOUR PILLARS ENTPR CORP;;LIN DAVID;;CHANG K M;;CHANG CHI PING,LIN DAVID;;CHANG K M;;CHANG CHI-PING,,https://lens.org/196-568-763-775-155,Patent Application,yes,2,2,8,8,0,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B29C2793/0045;;B29K2705/00;;B29L2031/722;;B31F1/07;;B31F2201/0702;;B60P1/26;;B62D33/0273;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;Y10T156/1041;;Y10T156/1057;;Y10T156/1039;;Y10T156/1056;;B31F1/07;;B31F2201/0702;;B29K2705/00;;B29C2793/0045;;B29C51/08;;B60P1/26;;B29C51/14;;B26F1/24;;B62D33/0273;;B29C59/02;;B29L2031/722;;B29C59/04,B26F1/24;;B29C51/08;;B29C51/14;;B29C59/02;;B29C59/04;;B31F1/07;;B60P1/26;;B62D33/027,,0,0,,,,PENDING
548,US,A1,US 2007/0185875 A1,184-327-592-416-656,2007-08-09,2007,US 35103506 A,2006-02-09,US 35103506 A,2006-02-09,Extensible role based authorization for manageable resources,"Methods and systems are provided for dynamically altering the access capabilities to the data resources for users of a computer based application. The access capabilities are defined by a dynamic role that specifies which of the resources a user may access, and a set of permissions associated with the dynamic role to define. New dynamic roles may be created when additional resources and components are added to an application. Methods and systems are provided for creating new dynamic roles to temporarily access resources, and for deleting a dynamic role after it is no longer needed.",IBM,CHANG DAVID Y;;CHANG JOHN Y;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-01-05),https://lens.org/184-327-592-416-656,Patent Application,yes,6,74,3,3,0,G06F21/604;;G06F21/6218;;G06F21/604;;G06F21/6218,G06F17/30,707/9,0,0,,,,DISCONTINUED
549,US,A1,US 2015/0258327 A1,147-339-482-021-756,2015-09-17,2015,US 201414582554 A,2014-12-24,TW 103204412 U,2014-03-14,CRANIAL ELECTROTHERAPY STIMULATION DEVICE,"A cranial electrotherapy stimulation (CES) device includes a head support, a control unit configured to provide a stimulating current, and a primary arm module. The primary arm module includes a primary arm and an electrode unit. The primary arm is pivotally connected to the head support and is longitudinally extendible. The electrode unit is disposed at the primary arm and includes an electrode that is electrically coupled to the control unit and that forms a path for transmission of the stimulating current to a stimulating point of a subject when the electrode is placed in direct contact with the stimulating point.",CONTOUR OPTIK INC,CHAO DAVID;;LIN CHIEN-HO;;CHANG YUNG-CHANG,CONTOUR OPTIK INC (2014-12-02),https://lens.org/147-339-482-021-756,Patent Application,yes,6,14,3,3,0,A61N1/0472;;A61N1/0472;;A61N1/0456;;A61N1/0456;;A61N1/0484;;A61N1/0484;;A61N1/36025;;A61N1/36025,A61N1/04,,0,0,,,,ACTIVE
550,WO,A1,WO 1993/015531 A1,001-319-593-649-391,1993-08-05,1993,US 9300763 W,1993-01-26,US 82978892 A,1992-01-31,REDUCTION OF SIDELOBES IN OPTICAL ARRAYS,"To reduce the sidelobe levels in a beam produced by an optical phased array, the array is arranged so that the output fields of the emitters have the amplitude and phase given by the inverse Fourier transform of the desired radiation pattern.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,,https://lens.org/001-319-593-649-391,Patent Application,yes,3,2,4,4,0,H01Q21/22;;H01Q3/2676,H01Q3/26;;H01Q21/22;;H01S3/10;;H01S5/00,,2,1,011-118-399-496-32X,10.1109/22.85389,"IEEE TRANSACTIONS ON MICROWAVE THEORY AND TECHNIQUES vol. 39, no. 7, July 1991, NEW YORK US pages 1216 - 1219 GOFFER ET AL. 'Wide-Bandwidth Optical Phased Array Based on Remote Coding Configuration';;1988 INTERNATIONAL SYMPOSIUM DIGEST ANTENNAS AND PROPAGATION vol. III, June 1988, SYRACUSE,NY pages 1196 - 1199 PICAZO ET AL. 'SYNTHESIS OF SHAPED BEAM PATTERNS USING WINDOW CURRENTS'",PENDING
551,US,B2,US 10023432 B2,009-431-458-398-535,2018-07-17,2018,US 201315035043 A,2013-11-08,US 2013/0069068 W,2013-11-08,Guide rail for elevator,"A method of making a guide rail for an elevator system includes providing a metallic guide rail having a base portion and a blade portion extending from the base portion The blade portion includes one or more guide surfaces interactive with a safety brake of the elevator system. A protective layer is applied to the guide rail for corrosion protection and a perimeter of the protective layer is adhered to the guide rail to seal the guide surfaces from corrosive elements, while not adhering the protective layer to the guide surfaces.",OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,OTIS ELEVATOR COMPANY (2013-11-05),https://lens.org/009-431-458-398-535,Granted Patent,yes,19,0,7,7,0,B66B7/022;;B66B7/022;;B32B37/12;;B32B38/10;;B32B2307/752,B66B7/02;;B32B37/12;;B32B38/10,,3,0,,,"Notification of Transmittal of thr International Search Report and the Written Opinion of the International Searching Authority, or the Declaration; dated Aug. 13, 2014; 12 pages.;;European Search Report and Written Opinion; European Application No. 13896989.4; International Filing Date: Nov. 8, 2013; dated Jun. 7, 2017; 11 pages.;;Chinese Office Action Issued in CN Application No. 201380080796.X, dated Mar. 20, 2018, 9 Pages.",ACTIVE
552,US,B2,US 7408696 B2,015-086-893-467-673,2008-08-05,2008,US 84112204 A,2004-05-07,US 84112204 A;;US 24328002 A;;US 51848800 A;;US 32217301 P,2000-03-03,Three-dimensional electrophoretic displays,"This invention relates to three-dimensional (3-D) electrophoretic displays comprising individually sealed cells filled with optically active electrophoretic dispersions, and more particularly to bi-stable, low-power-consumption and sealed microcup-based electrophoretic displays for high-quality three-dimensional imagery applications.",SIPIX IMAGING INC,LIANG RONG-CHANG;;CHEN DAVID,E INK CALIFORNIA LLC (1999-06-01),https://lens.org/015-086-893-467-673,Granted Patent,yes,110,41,2,195,0,G02F1/133377;;G02F1/167;;H04N13/337;;G02F1/1677;;G02F1/167;;G02F1/133377;;H04N13/337;;G02F1/1677,G02B26/00;;G02B27/22;;G02F1/00;;G02F1/1333;;G02F1/167;;G02F1/1677;;G09G3/34;;H04N13/00,359/296;;359/322;;345/107,43,10,053-038-780-358-376;;091-370-983-199-144;;029-756-915-418-96X;;041-504-776-962-677;;105-423-081-876-129;;020-075-588-450-688;;026-622-073-982-026;;144-158-648-847-207;;040-378-122-966-854;;053-468-791-784-08X,10.1889/1.1833658;;10.1038/28349;;10.1109/t-ed.1977.18838;;10.1142/2337;;10.1109/t-ed.1979.19566;;10.1109/ted.2002.801432;;10.1063/1.325511;;10.1889/1.1832942;;10.1889/1.1832401;;10.1889/1.1825690,"U.S. Appl. No. 09/518,488, filed Mar. 2000, Liang et al.;;U.S. Appl. No. 09/606,654, filed Jun. 2000, Liang et al.;;Bryning et al., ""37.4: Reverse-Emulsion Electrophoretic Display (REED)"" SID 98 Digest pp. 1018-1021 (1998).;;Comiskey et al, ""An Electrophoretic Ink for All-printed Reflective Electronic Displays"", Letters to Nature, MIT, The Media Laboratory, 20 Ames Street, Cambridge, MA 02139-4307, USA, May 1998, pp. 253-255.;;Dalisa, A. L., ""Electrophoretic Display Technology"", IEEE Trans. Electron Devices, pp. 827-834 (1977).;;Drzaic, P.S., ""Liquid Crystal Disperions"", The PDLC Paradigm, pp. 1-9, (1995).;;Harvey, T.G., ""Replication Techniques for Micro-optics"", SPIE Proc., vol. 3099, pp. 76-82 (1997).;;Harbour, J. R., ""Subdivided Electrophoretic Display"" Xerox Disclosure Journal, US Xerox Corporation, Stamford, Conn., 4(6):705, Nov. 1979, XP002123212.;;Hopper, M. A. et al, ""An Electrophoretic Display, its Properties, Model and Addressing"", IEEE Transactions on Electron Devices, 26(8): 1148-1152 (1979).;;Inoue, S. et al., ""High Resolution Microencapsulated Electrophoretic Display (EPD) Driven by Poly-Si TFTs With Four-Level Grayscale"" IEEE Transactions on Electron Devices 49(8), pp. 1532-1539 (2002).;;Kazlas, P. et al., ""12.1: 12.1 SVGA Microencapsulated Electorphoretic Active Matrix Display for Information Applicances"" SID 01 Digest 152-155 (2001).;;Kishi, E et al, ""5.1 Development of In-Plane EPD"", Canon Research Center, SID 00 Digest, pp. 24-27.;;Lewis, J.C., ""Electrophoretic Displays"", Allen Clark Research Centre, The Plessey Company Ltd., Caswell, Towcester, Northants, England, pp. 223-240.;;Lewis, J.C., et al, ""Gravitational, Inter-Particle-Electrode Forces in Electrophoretic Display"", Proceedings of the S.I.D., vol. 18/3&4, 1977.;;Matsuda, Y. ""Newly designed, high resolution, active matrix addressing in plane EPD"" IDW 02 EP2-3 1341-1344 (2002).;;Murau and Singer, ""The Understanding the Elimination of Some Suspension Instabilities in an Electrophoretic Display"", Philips Laboratories, Briarcliff Manor, NY 10510, Apr. 10, 1978, J. Appl. Phys. 49(9), pp. 4820-4829.;;Nakamura, et al, ""Development of Electrophoretic Display using Microencapsulated Suspension"", NOK Corporation, Kanagawa, Japan & NOK Corporation, Ibaraki, Japan, SID 98 Digest, pp. 1014-1017.;;Ota et al., ""Developments in Electrophoretic Displays"" Proc. of SID, vol. 18/3&4, pp. 243-254 (1977).;;Ota, et al., ""Electrophoretic Image Display (EPID) Panel,"" Wireless Research Laboratory, Matsushita Electric Industrial Company, Ltd., Osaka, 571, Japan, received Feb. 7, 1973, pp. 832-836, Jul. 1973.;;Singer, B. et al, ""X-Y Addressable Electrophoretic Display"", Proc. SID 18(3/4), pp. 255-266 (1977).;;Slafer, W. D. et al, ""Continuous Manufacturing of Thin Cover Sheet Optical Media"", SPIE Proc., vol. 1663, pp. 324-335 (1992).;;Swanson et al., ""5.2: High Performance Electrophoretic Displays"" SID 00 Diges, pp. 29-31 (2000).;;Liang, L.C. (Apr. 2004). Microcup Electronic Paper by Roll-to-Roll Manufacturing Process. Presentation at the Flexible Displays & Electronics 2004 of Intertech, San Fransisco, California, USA.;;Society of Information Display. (2004). Information Display, SID 2004 Reivew Issue, 20(3&4), 37-38.;;Wang, X., Kiluk, S., Chang, C., Wu, Y., & Liang, R.C. (Feb. 2004). Mirocup (R) Electronic Paper and the Converting Processes. Paper presented at the ASID, Nanjing, China. (in Chinese, English translation attached.).;;Zang, H.M. (Feb. 2004). Microcup Electronic Paper. Presentation conducted at the Displays & Microelectronics Conference of U.S. Display Consortium, Phoenix, Arizona, USA.;;Zang, H.M, Hwang, J.J., Gu, H., Hou, J., Weng, X., Chen, Y., et al. (Jan. 2004). Threshold and Grayscale Stability of Microcup (R) Electronic Paper. Presentation conducted at the 16th Annual Symposium-Electronic Imaging Science and Technology of IS&T/SPIE, San Jose, California, USA.;;Ho, C.,& Liang, R.C. (Dec. 2003). Microcup (R) Electronic Paper by Roll-to-Roll Manufacturing Processes. Presentation conducted at FEG, Nei-Li, Taiwan.;;Chung, J., Hou, J., Wang, W., Chu, L.Y., Yao, W., & Liang, R.C. (Dec. 2003). Microcup(R) Electrophoretic Displays, Grayscale and Color Rendition. IDW, AMD2/EP1-2, 243-246.;;Zang, H.M (Oct. 2003). Microcup (R) Electronic Paper by Roll-to-Roll Manufacturing Processes. Presentation conducted at the Advisory Board Meeting, Bowling Green State University, Ohio, USA.;;Allen, K. (Oct. 2003). Electrophoretics Fulfilled. Emerging Displays Review: Emerging Display Technologies, Monthly Report Oct. 2003, 9-14.;;Zang, H.M., & Liang, R.C. (2003) Microcup Electronic Paper by Roll-to-Roll Manufacturing Processes. The Spectrum, 16(2), 16-21.;;Chen, S.M. (Jul. 2003) The Applications for the Revolutionary Electronic Paper Technology. OPTO News & Letters, 102, 37-41. (in Chinese, English abstract attached, full translation available upon request).;;Lee, H., & Liang, R.C. (Jun. 2003) SiPix Microcup(R) Electronic Paper-An Introduction, Advanced Display, 3, 4-9 (in Chinese, English abstract attached, full translation available upon request).;;Liang, R.C., Hou, J., Chung, J., Wang, X., Pereira, C., & Chen, Y. (2003). Microcup(R) Active and Passive Matrix Electrophoretic Displays by A Roll-to-Roll Manufacturing Processes. SID Digest, 20.1.;;Chen, S.M. (May 2003) The New Applications and the Dynamics of Companies. TRI. 1-10. (In Chinese, English abstract attached, full translation available upon request).;;Liang, R.C., Hou, J., Zang, H.M., Chung, J., & Tseng, S. (2003). Microcup(R) displays : Electronic Paper by Roll-to-Roll Manufacturing Processes. Journal of the SID, 11(4), 621-628.;;Liang, R.C., Hou, J., Zang, H.M., & Chung, J. (Feb. 2003). Passive Matrix Microcup(R) Electrophoretic Displays. Paper presented at the IDMC, Taipei, Taiwan.;;Liang, R.C., & Tseng, S. (Feb. 2003). Microcup(R) LCD, An New Type of Dispersed LCD by A Roll-to-Roll Manufacturing Process. Paper presented at the IDMC, Taipei, Taiwan.;;Liang, R.C. (Feb. 2003) Microcup(R) Electrophoretic and Liquid Crystal Displays by Roll-to-Roll Manufacturing Processes. Presentation conducted at the Flexible Microelectronics & Displays Conference of U.S. Display Consortium, Phoenix, Arizona, USA.;;Liang, R.C., Hou, J., & Zang, H.M. (Dec. 2002) Microcup Electrophoretic Displays by Roll-to-Roll Manufacturing Processes. IDW , EP2-2, 1337-1340.;;Nikkei Microdives. (Dec. 2002) Newly-Developed Color Electronic Paper Promises-Unbeatable Production Efficiency. Nikkei Microdevices, 3. (in Japanese, with English translation).;;Zang, et al., ""Threshold and Grayscale Stability of Microcup(R) Electronic Paper"", Electronic Imaging Science and Technology, SPIE vol. 5289: 102-108 (2004).",EXPIRED
553,US,B2,US 10426259 B2,011-595-504-138-05X,2019-10-01,2019,US 201715672022 A,2017-08-08,US 201715672022 A,2017-08-08,Adjustable height table,"A table having a table top having an upper surface and a lower surface. The table further having a first and second guide track located on the lower surface. A first leg is pivotally connected to a second leg, the first leg comprising a first slide adapted to slidably engage the first guide track, and the second leg comprising a second slide adapted to slidably engage the second guide track. The table further includes a first retainer adapted to engage the first slide and the first guide track to prevent sliding of the first slide with respect to the first guide track, and a second retainer adapted to engage the second slide and the second guide track to prevent sliding of the second slide with respect to the second guide track. The table may be an adjustable height table. Other features of the table are also described.",VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,VARIDESK LLC (2017-08-10),https://lens.org/011-595-504-138-05X,Granted Patent,yes,52,3,3,3,0,A47B87/002;;A47B9/16;;A47B87/002;;A47B9/14;;A47B9/16,A47B9/14;;A47B9/16;;A47B87/00,,2,0,,,"Ares Height Adjustable Folding Table (26″×18″), Mar. 5, 2016, obtained from https://www.youtube.com/watch?V=dYe-4OTbHkM.;;International Search Report and Written Opinion in corresponding International Application No. PCT/US2018/045802 dated Sep. 18, 2018 (10 pages).",INACTIVE
554,US,A1,US 2003/0048522 A1,026-304-613-520-823,2003-03-13,2003,US 24328002 A,2002-09-12,US 24328002 A;;US 32217301 P,2001-09-13,Three-dimensional electrophoretic displays,"
   This invention relates to three-dimensional (3-D) electrophoretic displays comprising individually sealed cells filled with optically active electrophoretic dispersions, and more particularly to bi-stable, low-power-consumption and sealed microcup-based electrophoretic displays for high-quality three-dimensional imagery applications. 
",LIANG RONG-CHANG;;CHEN DAVID,LIANG RONG-CHANG;;CHEN DAVID,SIPIX IMAGING INC (2002-08-12),https://lens.org/026-304-613-520-823,Patent Application,yes,52,45,10,195,0,G02F1/133377;;G02F1/1334;;G02F1/134363;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677;;G02F1/1334;;G02F1/134363;;G02F1/133377;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677,G02B27/22;;G02F1/1333;;G02F1/1334;;G02F1/1343;;G02F1/167;;G02F1/1677;;H04N13/00,359/296,0,0,,,,DISCONTINUED
555,US,B2,US 9434935 B2,040-388-807-253-418,2016-09-06,2016,US 201313792135 A,2013-03-10,US 201313792135 A,2013-03-10,Modified caspase polypeptides and uses thereof,"The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2023-11-21);;BELLICUM PHARMACEUTICALS INC (2013-04-29),https://lens.org/040-388-807-253-418,Granted Patent,yes,84,18,17,17,50,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,C07H21/04;;A01K67/00;;A61K31/4545;;C12N9/64;;C12N15/00;;C12N15/63,,99,96,180-396-298-490-664;;030-951-581-231-87X;;097-015-592-385-347;;143-034-905-707-627;;105-844-582-547-53X;;072-788-084-986-303;;053-945-880-920-206;;091-588-365-157-475;;048-793-449-009-473;;041-397-625-399-935;;036-034-789-927-905;;079-967-664-874-058;;044-471-795-926-496;;028-238-234-983-369;;068-696-141-407-273;;001-067-626-994-418;;018-751-914-040-764;;009-424-537-894-726;;047-867-313-375-928;;055-953-050-127-623;;004-852-459-781-732;;062-130-425-112-476;;003-381-030-696-215;;014-990-643-039-130;;054-914-540-977-067;;087-719-944-261-851;;064-213-235-179-334;;051-276-704-495-732;;010-511-607-738-720;;048-188-266-680-461;;034-955-588-990-231;;028-050-239-356-335;;015-253-633-954-147;;029-286-581-257-399;;019-211-471-107-876;;027-238-263-538-41X;;025-596-606-643-965;;011-194-249-913-209;;009-314-499-609-666;;020-437-829-589-898;;161-641-816-931-384;;010-091-785-487-524;;088-994-457-887-198;;003-297-281-928-568;;032-026-264-382-468;;094-435-086-030-641;;068-637-973-521-79X;;016-074-079-257-776;;083-532-409-044-411;;035-702-835-572-741;;015-184-046-646-194;;106-360-460-538-50X;;124-985-422-988-633;;045-538-880-672-523;;096-019-825-303-501;;081-133-875-946-817;;086-352-377-514-220;;039-038-627-486-120;;043-247-299-521-534;;001-116-270-494-591;;010-127-506-936-262;;026-459-663-632-774;;003-327-415-791-486;;091-582-343-202-549;;092-399-646-107-750;;035-011-400-015-37X;;105-358-520-980-924;;054-667-680-236-126;;017-120-321-828-436;;138-643-940-612-044;;094-151-485-006-097;;031-031-897-260-663;;193-603-995-859-640;;053-900-918-619-293;;121-068-294-761-014;;095-009-613-240-195;;105-045-276-085-540;;101-489-246-945-003;;010-380-189-167-20X;;034-273-672-763-762;;022-418-163-251-872;;086-707-718-808-930;;048-533-982-202-633;;034-194-200-419-642;;004-253-998-677-868;;061-213-774-521-865;;020-984-837-129-173;;127-348-232-397-557;;045-853-272-050-122;;107-198-277-230-121;;013-058-058-246-438;;001-186-331-594-208;;047-757-821-570-95X;;020-345-352-285-601;;015-812-924-415-969;;026-818-597-556-84X,10.2165/00126839-200607030-00006;;16752945;;10.1016/s0021-9258(18)95637-1;;7615552;;9192897;;10.1038/42716;;10.1016/j.coi.2005.01.004;;15766677;;10.1038/ni722;;11590405;;10880445;;pmc313930;;10.1093/emboj/19.13.3325;;9380684;;10.1073/pnas.94.20.10618;;pmc23423;;10.1038/36593;;9367155;;pmc336488;;10.1093/nar/16.8.3195;;3375054;;10.1182/blood.v96.3.1039.015k04_1039_1046;;10910920;;00010910920;;10.1182/blood.v96.3.1039;;10.1038/32588;;9521319;;10.1038/nri1592;;15803149;;10.1111/j.1749-6632.2003.tb06047.x;;12727638;;10837075;;10.1146/annurev.immunol.18.1.767;;15837970;;10.1200/jco.2005.05.160;;8939689;;10.1016/s1074-5521(96)90249-5;;7614713;;10.1161/01.res.77.2.266;;9624004;;10.1038/30996;;9833853;;10.1097/00002030-199816000-00007;;15241424;;10.1038/nature02761;;10.1016/s0022-5347(18)35293-5;;16278310;;10.1182/blood-2004-11-4250;;pmc20324;;10.1073/pnas.94.7.3076;;9096348;;pmc2702793;;10.1073/pnas.0901522106;;19528653;;10.1016/j.ceb.2003.10.009;;14644197;;12620239;;10.1016/s1097-2765(03)00051-0;;10.1016/s0264-410x(02)00081-6;;11983257;;10.1016/s0092-8674(00)81265-9;;8681376;;0008681376;;10.1104/pp.110.161232;;pmc2948987;;20921159;;2315699;;10.1126/science.2315699;;10.1128/mcb.25.23.10543-10555.2005;;pmc1291226;;16287866;;12538665;;10.1084/jem.20021790;;pmc2193806;;009812896;;10.1126/science.282.5392.1318;;9812896;;8570628;;pmc40126;;10.1073/pnas.93.2.749;;9286332;;10.1007/978-1-4757-9966-8_4;;8915674;;10.1007/s00282-996-0463-4;;12213402;;10.1016/s0264-410x(02)00310-9;;10.1126/science.288.5475.2351;;10875917;;10.1016/j.cyto.2007.03.005;;pmc1965282;;17449269;;10.1016/s0090-4295(00)01094-3;;11306418;;10537328;;18338032;;10.1371/journal.pone.0001317;;pmc2267039;;pmc1088972;;10.1371/journal.pbio.0030183;;15941357;;8597384;;10.1111/j.1749-6632.1995.tb31045.x;;10.1128/mcb.7.8.2745-2752.1987;;10.1128/mcb.7.8.2745;;pmc367891;;3670292;;9050879;;10.1073/pnas.94.5.1914;;pmc20017;;10.1016/j.vaccine.2004.07.010;;15542183;;10429676;;10.1084/jem.190.1.125;;pmc2195555;;15961631;;10.1126/science.1115253;;10.1158/1535-7163.mct-04-0171;;15897234;;10.4049/jimmunol.172.11.7162;;15153540;;pmc27912;;10.1073/pnas.95.18.10437;;9724721;;10.1111/j.1747-0285.2006.00403.x;;16882320;;10.1002/9783527619375.ch4b;;pmc2727290;;19506159;;10.1200/jco.2008.20.7944;;10810999;;10.1002/jlb.67.5.607;;10.1002/jmv.1890310109;;2198326;;pmc330768;;10.1093/nar/18.9.2807;;2111010;;12810728;;10.1074/jbc.m209993200;;2851485;;10.1016/0378-1119(88)90593-8;;10.1007/s00262-003-0432-5;;14648069;;2503724;;10.1056/nejm198908173210702;;12393586;;10.1182/blood-2002-01-0312;;15317891;;10.1056/nejmoa040766;;10.1126/science.286.5447.2098;;10617422;;11007363;;10.1016/s0952-7915(00)00146-1;;10.1073/pnas.0502101102;;15837926;;10.2210/pdb1z8l/pdb;;pmc556220;;10837408;;10.1093/intimm/12.6.807;;12391253;;10.4049/jimmunol.169.9.5322;;11198272;;12517769;;pmc114679;;11602739;;10.1128/jvi.75.22.10991-11001.2001;;10.1517/13543776.8.1.53;;10.1056/nejmoa1106152;;pmc3236370;;22047558;;10395322;;10.1038/10495;;10.1146/annurev.immunol.15.1.617;;9143702;;pmc1475951;;10.1200/jco.2005.00.240;;15800326;;10.1111/j.1600-065x.2009.00782.x;;pmc3826168;;19426221;;16357940;;pmc1312019;;10.1172/jci26169;;10.1089/10430349950016924;;10515447;;10.1038/383178a0;;8774884;;10.1126/science.272.5258.50;;8600536;;pmc299564;;10.1073/pnas.84.23.8463;;2446324;;10.1038/7403;;10202929;;pmc190186;;8627803;;10.1128/jvi.70.5.3227-3234.1996;;pmc189840;;10.1128/jvi.70.1.520-532.1996;;8523565;;pmc47827;;7504271;;10.1073/pnas.90.22.10613;;7584109;;8382676;;10.1007/bf00768066;;12114876;;10.1074/jbc.274.23.16349;;pmc3624707;;10347193;;7980434;;10.1042/bj3030697;;pmc1137601;;14978216;;10.1091/mbc.e03-07-0493;;pmc404016;;605383;;10.1007/bf01551818;;10.2174/138620707782507296;;18045079;;10.1111/j.0105-2896.2004.00139.x;;15233739,"""Sipuleucel-T:APC 8015, APC-8015, prostate cancer vaccine-Dendreon."" Drugs R D. 2006;7(3):197-201.;;Adam et al., ""Cross-linking of the p55 Tumor Necrosis Factor Receptor Cytoplasmic Domain by a Dimeric Ligand Induces nuclear Factor-kB and Mediates Cell Death,"" The Journal of Biological Chemistry vol. 270, No. 29, Jul. 21, 1995, pp. 17482-17487.;;Adema et al., ""A dendritic-cell-deprived C-C chemokine that preferentially attracts naïve T cells."" Nature Jun. 12, 1997;387(6634):713-717.;;Adema et al., ""Migration of dendritic cell based cancer vaccines: in vivo veritas?"" Curr Opin Immunol. Apr. 2005;17(2): 170-174.;;Albert et al., ""Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells."" Nat Immunol. Nov. 2001;2(11):1010-1017.;;AliPrantis et al., EMBO J. 19(13):3325-3336, 2000.;;Amara et al. ""A versatile synthetic dimerizer for the regulation of protein-protein interactions."" PNAS 1997:94:10618-10623.;;Anderson et al., ""A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function."" Nature. Nov. 13, 1997:390(6656):175-179.;;Arcone et al., ""Identification of sequences responsible for acute-phase induction of human C-reactive protein."" Nucleic Acids Res. Apr. 25, 1988;16(8):3195-3207.;;Ardeshna et al., ""The Pl3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells."" Blood. Aug. 1, 2000;96(3):1039-1046.;;Banchereau et al., ""Dendritic cells and the control of immunity."" Nature. Mar. 19, 1998;392(6673):245-252.;;Banchereau et al., ""Dendritic cells as therapeutic vaccines against cancer."" Nat Rev Immunol. Apr. 2005;5(4):296-306.;;Banchereau et al., ""Dendritic cells: controllers of the immune system and a new promise for immunotherapy."" Ann NY Acad Sci. Apr. 2003;987:180-187.;;Banchereau et al., ""Immunobiology of dendritic cells."" Annu Rev Immunol. 2000;18:767-811.;;Bander et al., ""Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer."" J Clin Oncol. Jul. 20, 2005;23(21):4591-601.;;Belshaw et al. (Sep. 1996). ""Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization."" Chemistry & Biology. 3(9): pp. 731-738.;;Bennett et al., ""Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways."" Circ Res. Aug. 1995:77(2):266-273.;;Bennett et al., ""Help for cytotoxic-T-cell responses is mediated by CD40 signalling."" Nature Jun. 4, 1998;393(6684):478-480.;;Bernard et al., ""HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons."" AIDS. Nov. 12, 1998;12(16):2125-2139.;;Beutler B., ""Inferences, questions and possibties in Toll-like receptor signalling"" Nature. Jul. 8, 2004;430(6996):257-263.;;Bianco FJ. et al., ""Natural History of Biochemically-Recurrent Castrate-Resistant Disease in Men treated with maximal androgen blockage for a Rising PSA after Radical Prostatectomy."" Cancer Symposium: Abstract 278, 2005.;;Bisping et al., ""Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically delined subgroups."" Blood. Mar. 1, 2006;107(5):2079-2089.;;Blau et al., ""A proliferation switch for genetically modified cells."" Proc Natl Acad Sci USA. Apr. 1, 1997;94(7):3076-3081.;;Bloom, J.D. and F.H. Arnold, In the light of directed evolution: pathways of adaptive protein evolution. Proc Natl Acad Sci U S A, 2009, 106 Suppl 1:p. 9995-10000.;;Boatright, K.M. and G.S. Salvesen, Mechanisms of Caspase activation. Curr Opin Cell Biol. 2003. 15(6): p. 725-31.;;Boatright, K.M., et al., A unified model for apical Caspase activation. Mol Cell, 2003. 11(2): p. 529-41.;;Bojak et al., ""Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis."" Vaccine. May 6, 2002;20(15):1975-1979.;;Boldin et al., ""Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death,"" Cell vol. 85, 803-815, Jun. 14, 1996.;;Bonnert et al., GeneBank: AAC50954.1: GI:1814020; Feb. 2, 1997.;;Boss, W.F., et al., Basal signaling regulates plant growth and development. Plant Physiol, 2010. 154(2): p. 439-43.;;Bowie et al, ""Deciphering the message in protein sequences: tolerance to amino acid substitutions."" Science Mar. 1990; 247:1306-1310.;;Brady, S.C., L.A. Allan, and P.R. Clarke, Regulation of Caspase-9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress. Mol Cell Biol, 2005. 25(23): p. 10543-55.;;Burns et al., J. Exp. Med 197(2):263-268, 2003.;;Cardone, M.H., et al., Regulation of cell death protease Caspase-9 by phosphorylation. Science, 1998. 282(5392): p. 1318-21.;;Carter et al., ""Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase."" Proc Natl Acad Sci U S A. Jan. 23, 1996;93(2):749-53.;;Caux et al., ""CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha."" Adv Exp Med Biol. 1997;417:21-25.;;Caux et al., ""In vitro regulation of development and function of dendritic cells."" Hematol Cell Ther. Oct. 1996;38(5):463.;;Cazeaux et al., ""Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter."" Vaccine. Sep. 10, 2002;20(27-28):3322-31.;;Chan et al., ""A Domain in TNF Receptors that mediates ligand-independent receptor assembly and signaling."" Science 288, 2351-2354, (2001).;;Chan, Francis Ka-Ming, ""Three is Better Than One: Pre-Ligand Receptor Assembly in the Regulation of TNF Receptor Signaling,"" Cytokine, Feb. 2007; 37(2) 101-107.;;Chang et al., ""Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen."" Urology. Apr. 2001;57(4):801-5.;;Chang et al., ""Prostate-specific membrane antigen is produced in tumor-associated neovasculature."" Clin Cancer Res. Oct. 1999;5(10):2674-81.;;Chang, W.C., et al., Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor. PLoS One, 2007. 2(12): p. e1317.;;Chao, Y., et al., Engineering a dimeric Caspase-9: a re-evaluation of the induced proximity model for Caspase activation. PLoS Biol, 2005. 3(6): p. e183. 1079-1087.;;Chatterjee et al., ""Strategies for efficient gene transfer into hematopoietic cells. The use of adeno-associated virus vectors in gene therapy."" Ann NY Acad Sci. Dec. 29, 1995;770:79-90.;;Chen C, Okayama H., ""High-efficiency transformation of mammalian cells by plasmid DNA."" Mol Cell Biol. Aug. 1987;7(8):2745-2752.;;Chen et al., ""A testicluar antigen aberrantly expressed in human cancers detected by autologous antibody screening."" Proc Natl Acad Sci USA. Mar. 4, 1997;94(5):1914-1918.;;Cheung et al., ""Plasmid encoding papillomavirus Type 16 (HPV16) DNA construced with codon optimization improved the immunogenicity against HPV infection."" Vaccine. Dec. 16, 2004;23(5):629-638.;;Chiodoni et al., ""Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating factor (GM-CSF) and CD40 Ligand Genes Take Up and Present Endo-genous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response,"" J. Exp. Med. vol. 190, No. 1, Jul. 5, 1999. pp. 125-133.;;Choe et al., ""Crystal structure of human toll-like receptor 3 (TLR3) ectodomain."" Science. Jul. 22, 2005;309(5734):581-585.;;Christiansen et al., ""N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy."" Mol Cancer Ther. May 2005;4(5):704-14.;;Cisco et al., ""Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4."" J Immunol. Jun. 1, 2004;172(11):7162-7168.;;Clackson et al., ""Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity."" Proc Natl Acad Sci USA. Sep. 1, 1998;95(18):10437-10442.;;Clackson T., ""Dissecting the functions of proteins and pathways using chemically induced dimerization."" Chem Biol Drug Des. Jun. 2006;67(6):440-442.;;Clackson, T., ""Controlling Protein-Protein interactions Using Chemical inducers and Disrupters of Dimerization"" Chapter 4.2, pp. 227-249 in Chemical Biology: From Small Molecules to Systems Biology and Drug Design (Schreiber, s., et al., eds., Wiley, 2007)).;;Clarke et al., ""Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma."" J Clin Oncol. Aug. 10, 2009;27(23):3861-7.;;Clarke SR., ""The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity."" J Leukoc Biol. May 2000;67(5):607-614.;;Clarke, S.J., et al., ""A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer."" 2009, J. Clin. Oncol. 27:15s (suppl.:abstr. 3025).;;Coffin ""Molecular Mechanisms of Nucleic Acid Integration,"" Journal of Mecical Virology, 31:43-19 (1990).;;Cohen et al., ""Nucleotide sequence of the cDNA encoding human tyrosinase-related protein."" Nucleic Acids Res. May 11, 1990:18(9):2807-2808.;;Contin et al., ""Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling."" J Biol Chem. Aug. 29, 2003:278(35):32801-32809.;;Coupar et al., ""A general methods for the construction of recombinant vaccinia viruses expressing multiple foreign genes."" Gene. Aug. 15, 1988;68(1):1-10.;;Cranmer et al., ""Clinical applications of dendritic cell vaccination in the treatment of cancer."" Cancer Immunol Immunother. Apr. 2004;54(4):275-306.;;Crawford et al., ""A controlled trial of leuprolide with and without flutamide in prostatic carcinoma."" N Engl J Med. Aug. 17, 1989;321(7):419-424, w/, erratum N Engl J Med Nov. 16, 1989;321(20):1420.;;Cremer et al., ""Long-lived immature dendritic cells mediated by TRANCE-RANK interaction."" Blood. Nov. 15, 2002;100(10):3646-3655.;;Cristofanilli et al., ""Circulating tumor cells, disease progression, and survival in metstatic breast cancer."" N Engl J Med. Aug. 19, 2004;351(8):781-91.;;Cyster JG., ""Chemokines and cell migration in secondary lymphoid organs."" Science. Dec. 10, 1999;286(5447):2098-2102.;;Dallal RM, Lotze MT., ""The dendritic cell and human cancer vaccines."" Curr Opin Immunol. Oct. 2000;12(5):583-588.;;David et al., ""Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase."" Proc Natl Acad Sci USA. Apr. 26, 2005;102(17):5981-5986.;;De Becker et al., ""The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells."" Int Immunol. Jun. 2000;12(6):807-815.;;de Gruiji et al, ""Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors,"" The Journal of Immunology vol. 169, 2002 PQS 5322-5331.;;de la Thilie et al., ""Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion."" Cancer Detect Prev. 2000;24(6):579-88.;;De Vries et al., ""Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state."" Cancer Res. Jan. 1, 2003;63(1):12-17.;;Deml et al. ""Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein,"" 2001, J. Virol. 75:10991-11001.;;Deonarain, ""Ligand-targeted receptor-mediated vectors for gene delivery,"" 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.;;Di Stasi, A., et al., Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med, 2011. 365(18): p. 1673-83.;;Diehl et al., ""CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy."" Nat. Med. Jul. 1999;5(7):774-779.;;Donnelly et al., ""DNA vaccines."" Annu Rev Immunol. 1997:15:617-48.;;Dudley et al., ""Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastic melanoma."" J Clin Oncol. Apr. 1, 2005;23(10):2346-2357.;;Elgueta et al., ""Molecular mechanism and function of CD40/CD40L engagement in the immune system,"" Immunological Reviews, 229, (2009) 152-172.;;Evel-Kabler et al., ""SOCS1 restricts dendritic cells ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling."" J Clin Invest. Jan. 2006;116(1):90-100.;;Fan et al., ""Improved artifical death switches based on caspases and FADD."" Hum Gene Ther. Sep. 20, 1999;10(14):2273-2285.;;Farrar et al., ""Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization,"" Nature Sep. 12, 1996:383(6596):178-181.;;Fearon et al., ""The instructive role of innate immunity in the acquired immune response,"" Science, Apr. 5, 1996;272(5258):50-53.;;Fechheimer et al., ""Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading."" Proc Natl Acad Sci USA. Dec. 1987;84(23):8463-8467.;;Fernandez et al., ""Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo."" Nat Med. Apr. 1999;5(4):405-411.;;Ferrari et al., ""Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-addociated virus vectors."" J Virol. May 1996:70(5):3227-3234.;;Fisher et al., ""Transduction with recombinant adeno-addociated virus for gene therapy is limited by leading-strand synthesis."" J Virol. Jan. 1996:70(1):520-532.;;Flotte et al., ""Stable in vivo expression of te cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector."" Proc Natl Acad Sci USA. Nov. 15, 1993:90(22):10613-10617.;;Flotte TR, Carter B.J. ""Adeno-associated virus vectors for gene therapy."" Gene Ther. Aug. 1995:2(6):357-362.;;Flotte, ""Prospects for Virus-Based Gene Therapy for Cystic Fibrosis,"" Journal of Bioenergetics and Bioinformatics, vol. 25, No. 1, 1993.;;Freeman et al., ""The role of (111)In Capromab Pendetide (Prosta-ScintR) Immunoscintigraphy in the management of prostate cancer."" Q J Nucl Med. Jun. 2002;46(2):131-7.;;Fujio Y, Walsh K., ""Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner."" J Biol Chem. Jun. 4, 1999;274(23):16349-16354.;;Galbiati et al., ""N-terminal fatty acylation of the alpha-subunit of the G-protein Gi1: only the myristoylated protein is a substrate for palmitoylation."" Biochem J. Nov. 1, 1994;303(Pt 3):697-700.;;Gauthier-Campbell et al., ""Regulation of dendritic branching and pilopodia formation in hippocampal neurons by specific acylated protein motifs."" Mol Biol Cell. May 2004;15(5):2205-2217.;;Gefter et al., ""A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells"" Somatic Cell Genet. Mar. 1977;3(2):231-236.;;GerBank Accession No. M29540, Nov. 1, 1994.;;Gestwicki JE, Marinec PS., Chemical control over protein-protein interactions: beyond inhibitors. Comb Chem High Throughput Screen. Sep. 2007;10(8):667-675.;;Gilboa E, Vieweg J., ""Cancer immunotherapy with mRNA-transfected dendritic cells."" Immunol Rev. Jun. 2004;199:251-263.",ACTIVE
556,CA,A1,CA 2103907 A1,052-363-690-475-862,1993-08-25,1993,CA 2103907 A,1993-02-08,US 84022392 A,1992-02-24,METHOD AND APPARATUS FOR COMPRESSING A LIGHT PULSE,"METHOD AND APPARATUS FOR COMPRESSING A LIGHT PULSE This invention discloses a method and apparatus for shortening the length of a pulse of light. Generally, the method entails altering the index of refraction of an optical medium (14) through which the pulse of light is traveling at an area of the medium (14) where the front end of the pulse of light is located, such that the front end of the pulse of light travels slower than the back end, thus enabling the back end to catch up with the front end in order to shorten the length of the pulse. To accomplish this, it is proposed to generate an electric field across the optical medium (14) by a charge carrying medium (12) positioned relative to the optical medium (14), such that the index of refraction is altered by the electro-optic effect. In addition, it is possible to alter the index of refraction of the optical medium (14) by surrounding the optical medium (14) with a piezoelectric material (20) and applying an electric field to the piezoelectric material (20) such that the piezoelectric material (20) compresses the optical medium (14), thus altering the index of refraction.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,,https://lens.org/052-363-690-475-862,Patent Application,no,0,0,5,5,0,G02F1/0134;;G02F1/0134;;G02F1/035;;G02F1/035;;G02F2203/26;;G02F2203/26;;H01S3/0057;;H01S3/0057,G02F1/01;;G02F1/035;;G02F2/00;;H01S3/00;;H01S3/10,,0,0,,,,DISCONTINUED
557,EP,B1,EP 0427971 B1,057-766-441-011-117,1993-04-07,1993,EP 90119924 A,1990-10-17,US 42383089 A,1989-10-19,GAMMA RAY DETECTING DEVICE USING DISLOCATION FREE CRYSTAL,,HUGHES AIRCRAFT COMPANY,"VALI, VICTOR;;CHANG, DAVID B.",,https://lens.org/057-766-441-011-117,Granted Patent,yes,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01N23/20;;G01T1/36,,3,0,,,"NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH, vol. A261, nos. 1-2, 1st November 1987, pages 72-74, Amsterdam, NL; V.V. ARISTOV et al.: ""Bragg zone plates for hard X-ray focusing"";;NUCLEAR INSTRUMENTS & METHODS, vol. 165, no. 3, October 1979, pages 463-467, Amsterdam, NL; J.G. PRONKO et al.: ""X-ray spectrograph with active readout"";;NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH, vol. A-254, no. 3, 1st March 1987, pages 570-577, Amsterdam, NL; D.H. DOWELL et al.: ""The response of a 24 cm X 36 cm NaI(Tl) spectrometer to gamma rays between 50 and 300 MeV""",EXPIRED
558,AU,B2,AU 593068 B2,071-581-420-146-473,1990-02-01,1990,AU 1987/069395 A,1987-01-07,US 81765986 A;;US 88966486 A,1986-01-10,BITUMINOUS COMPOSITIONS,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/071-581-420-146-473,Granted Patent,no,3,0,9,20,0,C08L95/00,C08L95/00,,0,0,,,,EXPIRED
559,WO,A1,WO 2015/069268 A1,090-578-023-790-451,2015-05-14,2015,US 2013/0069068 W,2013-11-08,US 2013/0069068 W,2013-11-08,GUIDE RAIL FOR ELEVATOR,"A method of making a guide rail for an elevator system includes providing a metallic guide rail having a base portion and a blade portion extending from the base portion The blade portion includes one or more guide surfaces interactive with a safety brake of the elevator system. A protective layer is applied to the guide rail for corrosion protection and a perimeter of the protective layer is adhered to the guide rail to seal the guide surfaces from corrosive elements, while not adhering the protective layer to the guide surfaces.",OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,,https://lens.org/090-578-023-790-451,Patent Application,yes,7,0,7,7,0,B66B7/022;;B66B7/022;;B32B37/12;;B32B38/10;;B32B2307/752,B66B7/02,,0,0,,,,PENDING
560,TW,A,TW 201228148 A,140-863-789-591-821,2012-07-01,2012,TW 99144854 A,2010-12-20,TW 99144854 A,2010-12-20,Cable connector assembly,"A cable connector assembly includes at least one connector (1), a shielding member (3) and a cable (4) connected to the connector (1) and a switch device (5) enclosed inside the shielding member (3). The switch device (5) has a button (51) and a printed circuit board assembly (54). The printed circuit board assembly (54) includes a board (540), a switch element (541) mounted onto the board (540) and a light emitting diode (542). The light emitting diode is located below the button and emits light via the button.",HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,,https://lens.org/140-863-789-591-821,Patent of Addition,no,0,0,1,1,0,,H01R13/703;;H01R31/06,,0,0,,,,PENDING
561,US,A1,US 2006/0228873 A1,167-970-434-080-292,2006-10-12,2006,US 37762906 A,2006-03-16,US 37762906 A;;US 7393805 A;;US 64772403 A;;US 871901 A;;US 30797601 P,2001-07-26,Electrostatic nanolithography probe actuation device and method,"Method and apparatus for selectively actuating a cantilevered probe for applying a compound to a substrate in nanolithography. A probe having a probe electrode and a substrate having a counter electrode are provided. Voltage applied to the probe electrode and/or counter electrode provides electrostatic attraction between them, moving a probe tip into sufficient proximity to the substrate to apply the patterning compound. Alternatively, a flexible cantilevered probe anchored to a holder includes a layer of conductive material forming a probe electrode. A counter electrode on the holder faces the probe electrode. The holder and probe are positioned so that a probe tip applies the compound to the substrate. The probe is disposed between the substrate and the counter electrode. An electrostatic attractive force generated between the probe electrode and the counter electrode flexes the probe and lifts the tip away from the substrate to suspend writing.",UNIV ILLINOIS,LIU CHANG;;BULLEN DAVID A,BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS THE (2006-04-24),https://lens.org/167-970-434-080-292,Patent Application,yes,14,31,5,5,0,G01Q80/00;;G03F7/0002;;G01Q70/06;;G01Q70/16;;G01Q70/06;;G03F7/0002;;G01Q80/00;;G01Q70/16,G01Q70/16;;G01Q80/00,438/496,0,0,,,,EXPIRED
562,NO,L,NO 904506 L,196-981-436-497-10X,1991-04-22,1991,NO 904506 A,1990-10-18,US 42383089 A,1989-10-19,GAMMASTRAALEDETEKTERINGSANORDNING SOM ANVENDER KRYSTALLBOELGELEDERE.,,HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/196-981-436-497-10X,Abstract,no,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01N23/20;;G01T1/36,,0,0,,,,PENDING
563,TW,A,TW 200601806 A,199-180-971-626-507,2006-01-01,2006,TW 93118244 A,2004-06-24,TW 93118244 A,2004-06-24,A method of setting and displaying the information of weather forecast on setting time,"A method of setting and displaying the information of weather forecast on setting time is disclosed. First, mobile phone users are able to receive the information of the latest weather forecast with their mobile phones. The information will be provided at the desired time of the day base on the starting date and the time setting by the users. And then, the mobile phone will decide the type of the weather based on the received message and displaying the information of weather forecast with icons or words at the same time. Thus, it will be more convenient in both receiving and comprehending the weather condition with the latest technology.",INVENTEC APPLIANCES CORP,HO DAVID;;CHANG SUNG-YAN,,https://lens.org/199-180-971-626-507,Patent of Addition,no,0,0,2,2,0,,,,0,0,,,,INACTIVE
564,TW,A,TW 200805398 A,001-251-437-845-835,2008-01-16,2008,TW 96109156 A,2007-03-16,US 37762906 A,2006-03-16,Electrostatic nanolithography probe actuation device and method,"Method and apparatus for selectively actuating a cantile-vered probe for applying a compound to a substrate in nanolithography. A probe having a probe electrode and a substrate having a counter electrode are provided. Voltage applied to the probe electrode and/or counter electrode provides electrostatic attraction between them, moving a probe tip into sufficient proximity to the substrate to apply the patterning compound. Alternatively, a flexible cantile-vered probe anchored to a holder includes a layer of con-ductive material forming a probe electrode. A counter elec-trode on the holder faces the probe electrode. The holder and probe are positioned so that a probe tip applies the com-pound to the substrate. The probe is disposed between the substrate and the counter electrode. An electrostatic attract-tive force generated between the probe electrode and the counter electrode flexes the probe and lifts the tip away from the substrate to suspend writing.",UNIV ILLINOIS,LIU CHANG;;BULLEN DAVID ANDREW,,https://lens.org/001-251-437-845-835,Patent of Addition,no,0,0,5,5,0,G01Q80/00;;G03F7/0002;;G01Q70/06;;G01Q70/16;;G01Q70/06;;G03F7/0002;;G01Q80/00;;G01Q70/16,G01Q70/16;;G01Q80/00,,0,0,,,,PENDING
565,NO,D0,NO 913604 D0,006-908-644-276-853,1991-09-12,1991,NO 913604 A,1991-09-12,NO 913604 A;;NO 873764 A;;US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BITUMINOES BLANDING.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/006-908-644-276-853,Patent Application,no,0,0,2,20,0,,C08L95/00,,0,0,,,,DISCONTINUED
566,EP,A1,EP 4308917 A1,075-684-299-187-026,2024-01-24,2024,EP 22715713 A,2022-03-18,US 202163163197 P;;IB 2022052502 W,2021-03-19,NON-CONTACT SAMPLER WITH AN OPEN-PORT INTERFACE FOR LIQUID CHROMATOGRAPHY SYSTEMS,,DH TECHNOLOGIES DEV PTE LTD,COX DAVID MICHAEL;;LIU CHANG,,https://lens.org/075-684-299-187-026,Patent Application,yes,0,0,3,3,0,H01J49/0404;;G01N30/20;;G01N30/72,G01N30/04;;G01N30/16;;G01N30/20;;G01N30/72;;H01J49/04,,0,0,,,,PENDING
567,NO,C,NO 168776 C,090-001-032-129-378,1992-04-01,1992,NO 873764 A,1987-09-09,US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BLANDINGER AV BITUMINOESE MATERIALER OG OLEFIN-KOPOLYMERER,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/090-001-032-129-378,Granted Patent,no,0,0,4,20,0,,C08L23/08;;C08L95/00,,0,0,,,,EXPIRED
568,BR,A,BR 9101589 A,127-988-515-722-052,1991-12-10,1991,BR 9101589 A,1991-04-19,US 51161890 A,1990-04-20,"DETECTOR DE VAZAMENTO DE LIQUIDO,PROCESSO PARA MEDIR A TAXA DE VARIACAO DE VOLUME DE UM LIQUIDO,E DETECTOR DE VAZAMENTO DE LIQUIDO PARA DETECTAR A PRESENCA DE UM LIQUIDO CONTAMINANTE",,HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/127-988-515-722-052,Patent Application,no,0,0,10,10,0,G01M3/3245;;G01F23/00;;G01M3/3245,G01F23/28;;G01M3/32;;G01M3/38,,0,0,,,,PENDING
569,AU,A1,AU 2014/249417 A1,135-780-829-523-803,2015-09-17,2015,AU 2014/249417 A,2014-03-07,US 201313792135 A;;US 2014/0022004 W,2013-03-10,Modified caspase polypeptides and uses thereof,"The technology relates in part to compositions comprising modified caspase-9 polypeptides, compositions comprising nucleic acids coding for modified caspase-9 polypeptides, chimeric modified caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/135-780-829-523-803,Patent Application,no,0,0,17,17,0,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,A01N65/00;;A61K31/4545;;A61K35/14;;C12N5/00;;C12N9/64;;C12P21/00,,0,0,,,,ACTIVE
570,WO,A1,WO 1987/004174 A1,172-619-996-636-873,1987-07-16,1987,US 8700016 W,1987-01-07,US 81765986 A;;US 88966486 A,1986-01-10,BITUMINOUS COMPOSITIONS,"A composition useful as a pavement material comprising a mixture of asphalt and a polymer of an α-olefin, or an interpolymer of an α-olefin, and at least one copolymer selected from the group consisting of an α,β-unsaturated carboxylic acid, a ionomer of an α,β-unsaturated carboxylic acid, a vinyl ester of alkanoic acid, and carbon monoxide. The composition may contain also an aggregate and/or a filler.",DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/172-619-996-636-873,Patent Application,yes,13,9,9,20,0,C08L95/00,C08L95/00,C3N N1QX          N1(A-H+Q),1,0,,,See also references of EP 0252142A4,PENDING
571,WO,A2,WO 2003/023511 A2,178-411-392-554-733,2003-03-20,2003,US 0229105 W,2002-09-12,US 32217301 P,2001-09-13,THREE-DIMENSIONAL ELECTROPHORETIC DISPLAYS,"This invention relates to three-dimensional (3-D) electrophoretic displays comprising individually sealed cells filled with optically active electrophoretic dispersions, and more particularly to bi-stable, low-power-consumption and sealed microcup-based electrophoretic displays for high-quality three-dimensional imagery applications.",SIPIX IMAGING INC,LIANG RONG-CHANG;;CHEN DAVID,,https://lens.org/178-411-392-554-733,Patent Application,yes,0,0,10,195,0,G02F1/133377;;G02F1/1334;;G02F1/134363;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677;;G02F1/1334;;G02F1/134363;;G02F1/133377;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677,G02B27/22;;G02F1/1333;;G02F1/1334;;G02F1/1343;;G02F1/167;;G02F1/1677;;H04N13/00,,0,0,,,,PENDING
572,NO,L,NO 913604 L,177-921-583-665-878,1987-09-09,1987,NO 913604 A,1991-09-12,NO 913604 A;;NO 873764 A;;US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BITUMINOES BLANDING.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/177-921-583-665-878,Abstract,no,0,0,2,20,0,,C08L95/00,,0,0,,,,DISCONTINUED
573,TW,A,TW 201143216 A,192-094-676-038-977,2011-12-01,2011,TW 99116579 A,2010-05-25,TW 99116579 A,2010-05-25,Cable connector assembly,"A cable connector assembly (1000) includes an insulative housing (11), a plurality of contacts (13), a magnetic member (14), a cover (15) and a cable (18). Each contact (13) has a main portion received in the insulative housing and a mating portion forwardly extending beyond a front surface of the insulative housing. The magnetic member is mounted to the insulative housing. The cover encloses the insulative housing and the magnetic member. The cover and the magnetic member together form an annular mating area therebetween. There is at least one of the contacts located in the annular mating area, and at least one of the contacts located inside the magnetic member.",HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,,https://lens.org/192-094-676-038-977,Patent of Addition,no,0,0,2,2,0,,H01R13/62;;H01R24/58,,0,0,,,,INACTIVE
574,DE,D1,DE 69001291 D1,194-154-897-526-098,1993-05-13,1993,DE 69001291 T,1990-10-17,US 42383089 A,1989-10-19,GERAET ZUR GAMMASTRAHLENFESTSTELLUNG UNTER VERWENDUNG VON VERSETZUNGSFREIEN KRISTALLEN.,,HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/194-154-897-526-098,Granted Patent,no,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01N23/20;;G01T1/36,,0,0,,,,EXPIRED
575,WO,A1,WO 2022/195559 A1,016-929-886-511-524,2022-09-22,2022,IB 2022052502 W,2022-03-18,US 202163163197 P,2021-03-19,NON-CONTACT SAMPLER WITH AN OPEN-PORT INTERFACE FOR LIQUID CHROMATOGRAPHY SYSTEMS,"A method of performing liquid chromatography (LC) with an LC system including an LC column and an analyzer includes delivering a transport liquid to an open port interface (OPI) of a sample receiving circuit, wherein the sample receiving circuit includes a sample transfer chamber. A sample is ejected from a sample holder into the OPI with a non-contact ejector. The transport liquid and the sample are received in the sample transfer chamber. The sample transfer chamber is decoupled from the sample receiving circuit. A solvent is delivered to the analysis circuit. The sample is pushed from the sample transfer chamber with the solvent. The sample and the solvent is passed through the LC column to produce an eluent. The eluent is analyzed with the analyzer.",DH TECHNOLOGIES DEV PTE LTD,COX DAVID MICHAEL;;LIU CHANG,,https://lens.org/016-929-886-511-524,Patent Application,yes,3,0,3,3,0,H01J49/0404;;G01N30/20;;G01N30/72,G01N30/04;;G01N30/16;;G01N30/20;;G01N30/72;;H01J49/04,,4,3,095-957-414-282-691;;025-429-388-499-476;;035-173-945-292-352,32550988;;pmc7294554;;10.1021/acsmedchemlett.0c00066;;10.1002/rcm.7274;;26331924;;10.1002/rcm.1020;;12720286,"DIRICO KENNETH J. ET AL: ""Ultra-High-Throughput Acoustic Droplet Ejection-Open Port Interface-Mass Spectrometry for Parallel Medicinal Chemistry"", ACS MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 6, 1 May 2020 (2020-05-01), US, pages 1101 - 1110, XP055827491, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.0c00066;;ZHANG HUI ET AL: ""Acoustic Ejection Mass Spectrometry for High-Throughput Analysis"", BIORXIV, 29 January 2020 (2020-01-29), XP055838995, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.01.28.923938v1.full.pdf> [retrieved on 20210908], DOI: 10.1101/2020.01.28.923938;;GARY J. VAN BERKEL ET AL: ""An open port sampling interface for liquid introduction atmospheric pressure ionization mass spectrometry : Open port sampling interface"", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 29, no. 19, 15 October 2015 (2015-10-15), GB, pages 1749 - 1756, XP055519679, ISSN: 0951-4198, DOI: 10.1002/rcm.7274;;JAMES W. HAGERJ. C. YVES LE BLANC: ""Product ion scanning using a Q-q-Q linear ion trap (Q TRAP) mass spectrometer"", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 37, 2003, pages 3056 - 1064",PENDING
576,HU,A2,HU P0301851 A2,042-351-050-796-878,2003-09-29,2003,HU P0301851 A,2000-04-12,US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P;;US 0009785 W,1999-10-29,DRY POWDER COMPOSITIONS HAVING IMPROVED DISPERSIVITY,"A találmány egy hatóanyagot és egy legalább két leucilmaradékottartalmazó dipeptidet vagy tripeptidet tartalmazó, igen magasdiszpergálhatóságú gyógyszerformát szolgáltat. A találmány szerintiösszetétel kiváló aeroszolos tulajdonságokkal rendelkezik, így előnyösa tüdőbe aeroszolképzéssel történő bejuttatásra. A találmány ezenkívül egy eljárást is szolgáltat (a) egy, a tüdőbe juttatandó,hatóanyag-tartalmú gyógyszerforma diszpergálhatóságának fokozására, és(b) az összetételnek egy alany tüdejébe történő bejuttatására. Ó",INHALE THERAPEUTIC SYST,KUO MEI-CHANG;;LECHUGABALLESTEROS DAVID,,https://lens.org/042-351-050-796-878,Patent Application,no,0,0,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K9/00;;A61K47/42;;A61K9/08;;A61K9/12;;A61K9/14;;A61K9/72;;A61K31/58;;A61K38/00;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,,0,0,,,,EXPIRED
577,US,A1,US 2013/0119918 A1,104-819-686-148-495,2013-05-16,2013,US 201213667625 A,2012-11-02,US 201213667625 A;;US 28471208 A,2008-09-23,PORTABLE STACKABLE SOLAR BATTERIES,"Portable stackable solar batteries are disclosed, in which the solar batteries can be connected in a planar arrangement for solar recharging and connected in a vertically stacked arrangement for powering an electrically powered device and/or for charging another rechargeable battery.",SOLARLEGO INC;;SOLARLEGO INC,CHANG DAVID;;COATES STEPHEN S,,https://lens.org/104-819-686-148-495,Patent Application,yes,13,2,5,5,0,H01M10/465;;H01M14/005;;H01M10/4207;;Y02E10/56;;Y02E60/10;;H01M10/465;;H01M14/005;;H01M10/4207;;H02J7/35;;H02J7/0045;;H02J7/0014,H02J7/00,320/101,0,0,,,,ACTIVE
578,US,A1,US 2004/0082019 A1,122-501-931-531-619,2004-04-29,2004,US 41201103 A,2003-04-11,US 41201103 A;;US 37243702 P,2002-04-16,In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes,"
   The present invention provides methods of quantitating recent secreted antigen specific antibodies from supernatant of antibody secreting cells (ASC) in vitro culture for evaluation of vaccine or antigen induced antigen specific antibody secretion without ex vivo antigen stimulation. 
",HUI SUNNY CHANG,CHANG HUI SUNNY;;SACK DAVID,,https://lens.org/122-501-931-531-619,Patent Application,yes,1,0,7,7,0,C07K16/1239;;Y10S530/866;;Y10S530/862;;Y10S530/863;;Y10S530/861;;G01N33/5091;;C07K16/1239;;Y10S530/862;;Y10S530/866;;Y10S530/861;;Y10S530/863;;G01N33/5091;;G01N33/6854,C07K16/12;;G01N33/50,435/7.21,0,0,,,,EXPIRED
579,EP,A1,EP 0252142 A1,130-045-731-509-058,1988-01-13,1988,EP 87900922 A,1987-01-07,US 81765986 A;;US 88966486 A,1986-01-10,BITUMINOUS COMPOSITIONS.,"Une composition utile comme matériau de pavage comprend un mélange d'asphalte et d'un polymère d'une alpha-oléfine ou d'un interpolymère d'une alpha-oléfine, et d'au moins un copolymère sélectionné dans le groupe formé d'un acide carboxyle alpha,beta-insaturé, d'un ionomère d'un acide carboxyle alpha,beta-insaturé, d'un ester de vinyle d'acide alcanoïque, et du monoxyde de carbone. La composition peut également contenir des agrégats et/ou des charges.",DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/130-045-731-509-058,Patent Application,yes,0,0,9,20,0,C08L95/00,C08L95/00,,0,0,,,,DISCONTINUED
580,WO,A1,WO 2019/032697 A1,135-428-982-892-784,2019-02-14,2019,US 2018/0045802 W,2018-08-08,US 201715672022 A,2017-08-08,ADJUSTABLE HEIGHT TABLE,"A table having a table top having an upper surface and a lower surface. The table further having a first and second guide track located on the lower surface. A first leg is pivotally connected to a second leg, the first leg comprising a first slide adapted to slidably engage the first guide track, and the second leg comprising a second slide adapted to slidably engage the second guide track. The table further includes a first retainer adapted to engage the first slide and the first guide track to prevent sliding of the first slide with respect to the first guide track, and a second retainer adapted to engage the second slide and the second guide track to prevent sliding of the second slide with respect to the second guide track. The table may be an adjustable height table. Other features of the table are also described.",VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,,https://lens.org/135-428-982-892-784,Patent Application,yes,4,0,3,3,0,A47B87/002;;A47B9/16;;A47B87/002;;A47B9/14;;A47B9/16,A47B9/14;;A47B9/16,,0,0,,,,PENDING
581,WO,A3,WO 1997/030103 A3,142-526-341-065-140,1997-08-21,1997,US US9702135,1997-02-10,"US 60/0/011,738",1996-02-15,PREPARATION OF POLYETHERAMINES AND POLYETHERAMINE DERIVATIVES,"Processes for preparing polyetheramines, polyetherpolyamines and their derivatives from ammonia capped polyethers are disclosed. Polyetheramines, polyetherpolyamines and their derivatives are prepared by reacting an ammonia capped polyether with an aldehyde or ketone to form an imine or reaction of an ammonia capped polyether with cyanide compound to form a nitrile intermediate, followed by subsequent hydrogenation of the intermediates to form the final polyetheramine products. A process for producing polyetheramine products by reaction of an ammonia capped polyether with an alkylene oxide followed by amination to produce a polyetheramine is also disclosed.",THE DOW CHEMICAL COMPANY,"CHANG, Dane;;WILSON, David, A.",,https://lens.org/142-526-341-065-140,Search Report,yes,0,0,1,1,0,,B01D19/04;;C08G65/325;;C08G65/333;;C10L1/22;;C10L1/238;;C10L1/24;;C10M149/12;;C23F11/173,,0,0,,,,UNKNOWN
582,AU,A8,AU 2003/230922 A8,148-078-217-217-33X,2003-11-03,2003,AU 2003/230922 A,2003-04-14,US 37243702 P;;US 41201103 A;;US 0311508 W,2002-04-16,Assay for quantitating secreted antibodies in lymphocytes supernatant,,CHANG HUI SUNNY,SACK DAVID;;CHANG HUI SUNNY,,https://lens.org/148-078-217-217-33X,Patent Application,no,0,0,7,7,0,C07K16/1239;;Y10S530/866;;Y10S530/862;;Y10S530/863;;Y10S530/861;;G01N33/5091;;C07K16/1239;;Y10S530/862;;Y10S530/866;;Y10S530/861;;Y10S530/863;;G01N33/5091;;G01N33/6854,C07K16/12;;G01N33/50,,0,0,,,,DISCONTINUED
583,US,A,US 5043299 A,148-713-249-905-313,1991-08-27,1991,US 44448589 A,1989-12-01,US 44448589 A,1989-12-01,Process for selective deposition of tungsten on semiconductor wafer,"An improved process for the selective deposition of tungsten on a masked semiconductor wafer is disclosed which comprises cleaning the surfaces of the wafer in an air-tight cleaning chamber, then transferring the cleaned wafer to a vacuum deposition chamber such as a CVD chamber for selective deposition of tungsten thereon without exposing the cleaned wafer to conditions which would recontaminate the cleaned wafer prior to said deposition, and then selectively depositing tungsten on the unmasked surfaces of the cleaned wafer.",APPLIED MATERIALS INC,CHANG MEI;;WANG DAVID N,APPLIED MATERIALS INC. A DE CORP (1990-01-17),https://lens.org/148-713-249-905-313,Granted Patent,yes,3,116,8,8,0,H01L21/28562;;H01L21/76879;;Y10S148/051;;Y10S438/906;;Y10S438/908;;H01L21/285;;H01L21/76879;;H01L21/28562;;Y10S438/906;;Y10S438/908;;Y10S148/051,C23C16/02;;C23C16/04;;C23C16/06;;C23C16/54;;H01L21/28;;H01L21/285;;H01L21/768,437/192;;437/200;;437/225;;437/228;;437/245;;X148DIG 51;;156/625;;156/646;;118/715;;118/733,2,1,141-789-486-030-537,10.1007/bf00566856,"Wolf, S., Silicon Processing for the VLSI Era, vol. 1, Lattice Press, 1986, pp. 399 404.;;Coburn, J., Plasma Assisted Etching, Plasma Chem. and Plasma Processing, vol. 2, No. 1, 1982, pp. 1 9, 28 29, 36 41.",EXPIRED
584,WO,A1,WO 2018/098469 A1,165-816-610-422-696,2018-05-31,2018,US 2017/0063431 W,2017-11-28,US 201615362324 A,2016-11-28,LEANING CHAIR,"A leaning chair can include a base defining a lower surface that rests on a floor, the base including a support surface; a shaft coupled to the base, the shaft defining a first end and a second end; a flexible mount coupling the first end of the shaft to the base, the shaft extending through the mount; a pivot pin located underneath the mount, the first end of the shaft resting on the pivot pin, and being configured to be housed inside the mount, the pivot pin being configured to pivot on the support surface; and a user support member coupled to the second end of the shaft.",VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,,https://lens.org/165-816-610-422-696,Patent Application,yes,5,0,3,3,0,A47C7/004;;A47C3/18;;A47C3/28;;A47C3/40;;A47C7/004;;A47C3/18;;A47C3/40;;A47C3/28;;A47C3/20;;A47C7/00;;A47C7/025;;A47C9/025;;F16C11/04;;F16C2314/70,A47C7/00,,0,0,,,,PENDING
585,EP,A4,EP 3066039 A4,160-610-645-850-863,2017-07-05,2017,EP 13896989 A,2013-11-08,US 2013/0069068 W,2013-11-08,GUIDE RAIL FOR ELEVATOR,,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,OTIS ELEVATOR COMPANY (2017-09-06),https://lens.org/160-610-645-850-863,Search Report,no,3,0,7,7,0,B66B7/022;;B66B7/022;;B32B37/12;;B32B38/10;;B32B2307/752,B66B7/02,,1,0,,,See also references of WO 2015069268A1,ACTIVE
586,CA,A1,CA 2027151 A1,174-572-289-938-001,1991-04-20,1991,CA 2027151 A,1990-10-09,US 42383089 A,1989-10-19,GAMMA RAY DETECTING DEVICE USING CRYSTAL WAVEGUIDES,,HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/174-572-289-938-001,Patent Application,no,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01T1/36;;G01N23/20,D13580032    M,0,0,,,,EXPIRED
587,CA,C,CA 2588624 C,195-157-336-106-835,2010-06-22,2010,CA 2588624 A,2007-05-15,CA 2588624 A,2007-05-15,POSTERIOR-FORM ENHANCEMENT DEVICE,"The posterior-form enhancement device includes a garment and two posterior-form pads. Each posterior-form pad is formed by attaching one first posterior-form piece to one second posterior-form piece. The garment is used for covering the lower body part of a person, and in its rear side has two pockets adjacent to the posteriors of wearers for placing the posterior-form pads respectively. Each first posterior-form piece includes a bag for encasing a volume of gel. The second posterior-form pieces are respectively adjacent to the first posterior-form pieces in the pockets, wherein the first posterior-form piece is near an external surface away from wearers' posteriors of while the second posterior-form piece is near an internal surface adjacent to wearers' posteriors. The shape and size of the pockets are determined by the shape and size of the posterior-form pad. The posterior-form pads can be put into or taken out of the pockets.",CHEN DAVID E;;CHANG JASPER,CHEN DAVID E;;CHANG JASPER,,https://lens.org/195-157-336-106-835,Granted Patent,no,0,0,2,2,0,A41B9/04,A41D27/26;;A41B9/00;;A41D13/00;;A41D27/12;;A41D27/20,,0,0,,,,INACTIVE
588,US,S,US D0846930 S,055-855-417-818-000,2019-04-30,2019,US 201629582820 F,2016-10-31,US 201629582820 F,2016-10-31,Chair,,VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,VARIDESK LLC (2016-11-01),https://lens.org/055-855-417-818-000,Design Right,no,0,17,1,1,0,,,0601;;D 6716;;D6/360,0,0,,,,ACTIVE
589,WO,A3,WO 2003/023511 A3,059-106-304-908-090,2004-01-29,2004,US 0229105 W,2002-09-12,US 32217301 P,2001-09-13,THREE-DIMENSIONAL ELECTROPHORETIC DISPLAYS,"This invention relates to three-dimensional (3-D) electrophoretic displays comprising individually sealed cells filled with optically active electrophoretic dispersions, and more particularly to bi-stable, low-power-consumption and sealed microcup-based electrophoretic displays for high-quality three-dimensional imagery applications.",SIPIX IMAGING INC,LIANG RONG-CHANG;;CHEN DAVID,,https://lens.org/059-106-304-908-090,Search Report,yes,4,0,10,195,0,G02F1/133377;;G02F1/1334;;G02F1/134363;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677;;G02F1/1334;;G02F1/134363;;G02F1/133377;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677,G02B27/22;;G02F1/1333;;G02F1/1334;;G02F1/1343;;G02F1/167;;G02F1/1677;;H04N13/00,,0,0,,,,PENDING
590,US,B2,US 10140573 B2,096-571-737-391-504,2018-11-27,2018,US 201414268372 A,2014-05-02,US 201414268372 A;;US 201461947149 P,2014-03-03,Neural network adaptation to current computational resources,"Methods and apparatus are provided for processing in an artificial nervous system. According to certain aspects, resolution of one or more functions performed by processing units of a neuron model may be reduced, based at least in part on availability of computational resources or a power target or budget. The reduction in resolution may be compensated for by adjusting one or more network weights.",QUALCOMM INC,JULIAN DAVID JONATHAN;;CHANG ILWOO,QUALCOMM INCORPORATED (2014-05-06),https://lens.org/096-571-737-391-504,Granted Patent,yes,13,3,8,8,0,G06N3/082;;G06N3/048;;G06N3/082;;G06N3/048;;G06N3/048;;G06N3/082,G06F15/18;;G06N3/04;;G06N3/08,,6,2,028-632-450-220-716;;176-825-485-539-61X,10.1109/82.964997;;10.1109/etcs.2010.448,"Djahanshahi H., et al., “Quantization noise improvement in a hybrid distributed-neuron ANN architecture”, IEEE Transactions on Circuits and Systems II: Analog and Digital Signal Processing, vol. 48, No. 9, Sep. 2001 (Sep. 2001), pp. 842-846, XP011813481, DOI: 10.1109/82.964997 section II.;;International Search Report and Written Opinion—PCT/US2015/017454—ISA/EPO—dated Sep. 8, 2015.;;BAO JIAN ; CHEN YU ; YU JINSHOU: ""Neural Networks with Limited Precision Weights and Its Application in Embedded Systems"", EDUCATION TECHNOLOGY AND COMPUTER SCIENCE (ETCS), 2010 SECOND INTERNATIONAL WORKSHOP ON, IEEE, PISCATAWAY, NJ, USA, 6 March 2010 (2010-03-06), Piscataway, NJ, USA, pages 86 - 91, XP031673183, ISBN: 978-1-4244-6388-6;;Krizhevsky A., et al., “ImageNet Classification with Deep Convolutional Neural Networks”, Proceedings of the 26th Annual Conference on Neural Information Processing Systems (NIPS'25), Dec. 6, 2012 (Dec. 86, 2012), pp. 1097-1105, XP055113686, ISBN: 978-1-62748-003-1 abstract and section 4.2.;;Mathieu M., et al., “Fast training of convolutional networks through FFTs”, arXiv:1312.5851v4, Feb. 18, 2014 (Feb. 18, 2014), pp. 1-9, XP055210204, Retrieved from the Internet: URL: http://arxiv.org/abs/1312.5851v4 [retrieved on Aug. 28, 2015] sections 2.2 and 3.;;Pham V., et al., “Dropout Improves Recurrent Neural Networks for Handwriting Recognition”, arXiv:1312.4569v1, Nov. 5, 2013 (Nov. 5, 2013), 6 Pages, XP055193460, Retrieved from the Internet: URL: http://arxiv.org/abs/1312.4569v1 [retrieved on Jun. 3, 2015].",ACTIVE
591,US,B2,US 8737459 B2,097-773-797-673-425,2014-05-27,2014,US 201113178500 A,2011-07-08,US 201113178500 A,2011-07-08,Transmitter equalizer optimization,A transmitter includes an equalizer for conditioning a data signal in response to a first and a second equalizer setting. The first and second equalizer settings are both associated with a selected point on a two-dimensional search grid. The search grid includes a first equalizer setting and a second equalizer setting for each point on the search grid. The transmitter transmits a data signal across a first channel medium using settings associated with a selected point on the search grid. A receiver analyzes the received signal from the transmitter to determine a signal quality metric. The search grid is used to select settings from neighboring points to produce signals that are evaluated to produce signal quality metrics. The results of the evaluations are used to efficiently search the search grid for optimum equalizer settings for the transmitter.,SAWEY DAVID CHRISTOPHER;;CHANG JIAN;;TEXAS INSTRUMENTS INC,SAWEY DAVID CHRISTOPHER;;CHANG JIAN,TEXAS INSTRUMENTS INCORPORATED (2011-07-06),https://lens.org/097-773-797-673-425,Granted Patent,yes,3,2,2,2,0,H04L25/028;;H04L25/03343;;H04L25/03885;;H04L25/028;;H04L25/03343;;H04L25/03885,H04W24/00,375/231;;375/232;;375/233,0,0,,,,ACTIVE
592,EP,A4,EP 2967081 A4,112-198-063-033-115,2017-01-04,2017,EP 14778378 A,2014-03-07,US 201313792135 A;;US 2014/0022004 W,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,,BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/112-198-063-033-115,Search Report,no,0,0,17,17,0,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,A01N65/00;;A61K31/4545;;C12N5/00;;C12N9/64;;C12P21/00,,2,1,106-502-063-725-273,pmc1895037;;15728125;;10.1182/blood-2004-11-4564,"KARIN C STRAATHOF ET AL: ""A inducible caspase 9 safety switch for T-cell therapy"", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 11, 1 June 2005 (2005-06-01), pages 4247 - 4254, XP008126232, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2004-11-4564;;See also references of WO 2014164348A2",ACTIVE
593,US,A,US 5155792 A,113-871-189-400-121,1992-10-13,1992,US 72456591 A,1991-06-27,US 72456591 A,1991-06-27,Low index of refraction optical fiber with tubular core and/or cladding,"An optical fiber having an index of refraction less than that conventionally available. The low index of refraction fiber 10 of the present invention includes a fiber core 20 of a first index of refraction. The fiber core 20 circumscribes a longitudinal axis, and is surrounded by a cladding layer 30 having a second index of refraction less than the first index of refraction. Included within the cladding layer 30 are a plurality of tube structures 40 arranged about the fiber core 20. The tube structures 40 create a plurality of channels 42 within the cladding layer 20, thereby engendering a low index of refraction therein.",HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,OL SECURITY LIMITED LIABILITY COMPANY (2012-07-30);;HUGHES AIRCRAFT COMPANY A CORP. OF DE (1991-06-27);;HE HOLDINGS INC (1997-12-16);;RAYTHEON COMPANY (1997-12-17),https://lens.org/113-871-189-400-121,Granted Patent,yes,6,71,3,3,0,G01D5/268;;G02B6/02338;;G02B6/02347;;G02B6/02338;;G02B6/02347;;G01D5/268,G01D5/26;;G01N21/27;;G02B6/00;;G02B6/02;;G02B6/036,G2J JGBC1         JGBC1,0,0,,,,EXPIRED
594,US,B2,US 7704120 B2,113-201-419-331-924,2010-04-27,2010,US 79764207 A,2007-05-04,US 79764207 A,2007-05-04,Posterior-form enhancement device,"The posterior-form enhancement device includes a garment and two posterior-form pads. Each posterior-form pad is formed by attaching one first posterior-form piece to one second posterior-form piece. The garment is used for covering the lower body part of a person, and in its rear side has two pockets adjacent to the posteriors of wearers for placing the posterior-form pads respectively. Each first posterior-form piece includes a bag for encasing a volume of gel. The second posterior-form pieces are respectively adjacent to the first posterior-form pieces in the pockets, wherein the first posterior-form piece is near an external surface away from wearers' posteriors of while the second posterior-form piece is near an internal surface adjacent to wearers' posteriors. The shape and size of the pockets are determined by the shape and size of the posterior-form pad. The posterior-form pads can be put into or taken out of the pockets.",CHEN DAVID E;;CHANG JASPER,CHEN DAVID E;;CHANG JASPER,,https://lens.org/113-201-419-331-924,Granted Patent,yes,11,13,2,2,0,A41B9/001;;A41B9/001;;A41B2400/38;;A41B2400/38,A41C1/00,450/99;;2/466,0,0,,,,INACTIVE
595,EP,A1,EP 0581948 A1,133-816-291-734-084,1994-02-09,1994,EP 93905835 A,1993-02-08,US 84022392 A,1992-02-24,METHOD AND APPARATUS FOR COMPRESSING A LIGHT PULSE.,"L'invention concerne un procédé et un appareil de raccourcissement de la longueur d'une impulsion de lumière. Le procéde consiste à modifier l'indice de réfraction d'un milieu optique (14) dans lequel l'impulsion de lumière se déplace sur une aire du milieu (14) où l'extrémité avant de l'impulsion de lumière se situe, de sorte que l'extrémité avant de l'impulsion de lumière se déplace plus lentement que l'extrémité arrière, permettant ainsi à cette dernière de rattraper l'extrémité avant afin de raccourcir la longueur de l'impulsion. Pour ce faire, on génère un champ électrique dans le milieu optique (14) au moyen d'un milieu porteur de charge (12) positionné par rapport audit milieu optique (14), de manière que l'indice de réfraction est modifié par l'effet électrooptique. De plus, il est possible de modifier l'indice de réfraction du milieu optique (14) en l'entourant d'un matériau piézo-électrique (20), et par application d'un champ électrique audit matériau piézo-électrique (20) de manière que celui-ci comprime le milieu optique (14), modifiant ainsi l'indice de réfraction.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,,https://lens.org/133-816-291-734-084,Patent Application,yes,0,0,5,5,0,G02F1/0134;;G02F1/0134;;G02F1/035;;G02F1/035;;G02F2203/26;;G02F2203/26;;H01S3/0057;;H01S3/0057,G02F1/01;;G02F1/035;;G02F2/00;;H01S3/00;;H01S3/10,,1,0,,,See references of WO 9317472A1,DISCONTINUED
596,WO,A3,WO 2008/054476 A3,142-162-641-060-195,2008-08-21,2008,US 2007/0006374 W,2007-03-14,US 37762906 A,2006-03-16,ELECTROSTATIC NANOLITHOGRAPHY PROBE ACTUATION DEVICE AND METHOD,"Method and apparatus for selectively actuating a cantilevered probe for applying a compound to a substrate in nanolithography. A probe having a probe electrode and a substrate having a counter electrode are provided. Voltage applied to the probe electrode and/or counter electrode provides electrostatic attraction between them, moving a probe tip into sufficient proximity to the substrate to apply the patterning compound. Alternatively, a flexible cantilevered probe anchored to a holder includes a layer of conductive material forming a probe electrode. A counter electrode on the holder faces the probe electrode. The holder and probe are positioned so that a probe tip applies the compound to the substrate. The probe is disposed between the substrate and the counter electrode. An electrostatic attractive force generated between the probe electrode and the counter electrode flexes the probe and lifts the tip away from the substrate to suspend writing.",UNIV ILLINOIS;;LIU CHANG;;BULLEN DAVID ANDREW,LIU CHANG;;BULLEN DAVID ANDREW,,https://lens.org/142-162-641-060-195,Search Report,yes,2,0,5,5,0,G01Q80/00;;G03F7/0002;;G01Q70/06;;G01Q70/16;;G01Q70/06;;G03F7/0002;;G01Q80/00;;G01Q70/16,G01Q70/16;;G01Q80/00,,2,2,056-227-951-021-164;;033-070-234-429-856,10.1016/j.sna.2005.09.001;;10.1088/0957-4484/13/2/315,"BULLEN ET AL.: ""Electrostatically actuated dip pen nanolithography probe arrays"", SENSORS AND ACTUATORS A, vol. 125, 10 October 2005 (2005-10-10), pages 504 - 511, XP005221348;;ZHANG ET AL.: ""A MEMS nanoplotter with high-density parallel dip-pen nanolithography probe arrays"", NANOTECHNOLOGY, vol. 13, 2002, pages 212 - 217, XP002346586",PENDING
597,AU,A1,AU 2002/324990 A1,173-044-860-261-875,2003-03-24,2003,AU 2002/324990 A,2002-09-12,US 32217301 P;;US 0229105 W,2001-09-13,Three-dimensional electrophoretic displays,,SIPIX IMAGING INC,CHEN DAVID;;LIANG RONG-CHANG,,https://lens.org/173-044-860-261-875,Patent Application,no,0,0,10,195,0,G02F1/133377;;G02F1/1334;;G02F1/134363;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677;;G02F1/1334;;G02F1/134363;;G02F1/133377;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677,G02B27/22;;G02F1/1333;;G02F1/1334;;G02F1/1343;;G02F1/167;;G02F1/1677;;H04N13/00,,0,0,,,,DISCONTINUED
598,DE,A1,DE 1817251 A1,168-305-298-828-150,1969-07-31,1969,DE 1817251 A,1968-12-27,US 69768068 A,1968-01-15,Schaltungsanordnung zur Steuerung eines elektrooptischen Kristalls,,IBM,CHING CHANG DAVID;;LIPP JAMES,,https://lens.org/168-305-298-828-150,Patent Application,no,0,0,6,6,0,G11C11/22;;G11C11/22,G11C11/22,,0,0,,,,DISCONTINUED
599,TW,U,TW M377731 U,183-804-410-340-498,2010-04-01,2010,TW 98216672 U,2009-09-10,TW 98216672 U,2009-09-10,Cable connector,"A cable connector includes an insulative housing, a plurality of termin-als mounted to the insulative housing (1), a metallic shell enclosing the insulative housing therein and a cable connected to the terminals. The insulative housing has a base portion and a tongue portion extending forwardly from the base portion, and a cavity is defind in the tongue por-tion, with contacting portions of the terminals accommodated therein. The terminals includes two pair of terminals adapted for transmitting dif-ferent signals and a pair of grounding terminals arranged between the two pair of terminals.",HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,,https://lens.org/183-804-410-340-498,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
600,US,B2,US 10298053 B2,027-367-467-787-486,2019-05-21,2019,US 201514956734 A,2015-12-02,US 201514956734 A;;US 201213667625 A;;US 28471208 A,2008-09-23,Interconnecting solar rechargeable batteries in a planar or vertical arrangement,"Techniques for connecting a plurality of solar rechargeable batteries in a planar arrangement or vertical arrangement are disclosed, wherein the plurality of solar rechargeable batteries are electrically connected, wherein each of the plurality of solar rechargeable batteries includes an integrated solar cell and a plurality of interconnections for electrically connecting with the plurality of solar rechargeable batteries in series and in parallel, and wherein the plurality of interconnections include a combination of male and female connectors that allow for electrically connecting the plurality of solar rechargeable batteries in series and in parallel; determining whether the plurality of solar rechargeable batteries are connected in series or in parallel; balancing the load of the plurality of solar rechargeable batteries so that each of the plurality of solar rechargeable batteries is equally charged; and wherein each of the plurality of solar rechargeable batteries can be connected standalone to an electrically powered device to power the electrically powered device.",SOLARLEGO INC,CHANG DAVID;;COATES STEPHEN S,,https://lens.org/027-367-467-787-486,Granted Patent,yes,14,0,5,5,0,H01M10/465;;H01M14/005;;H01M10/4207;;Y02E10/56;;Y02E60/10;;H01M10/465;;H01M14/005;;H01M10/4207;;H02J7/35;;H02J7/0045;;H02J7/0014,H01M10/46;;H01M10/42;;H01M14/00;;H02J7/00;;H02J7/35,,0,0,,,,ACTIVE
601,US,A1,US 2013/0010854 A1,047-859-482-941-601,2013-01-10,2013,US 201113178500 A,2011-07-08,US 201113178500 A,2011-07-08,TRANSMITTER EQUALIZER OPTIMIZATION,A transmitter includes an equalizer for conditioning a data signal in response to a first and a second equalizer setting. The first and second equalizer settings are both associated with a selected point on a two-dimensional search grid. The search grid includes a first equalizer setting and a second equalizer setting for each point on the search grid. The transmitter transmits a data signal across a first channel medium using settings associated with a selected point on the search grid. A receiver analyzes the received signal from the transmitter to determine a signal quality metric. The search grid is used to select settings from neighboring points to produce signals that are evaluated to produce signal quality metrics. The results of the evaluations are used to efficiently search the search grid for optimum equalizer settings for the transmitter.,SAWEY DAVID CHRISTOPHER;;CHANG JIAN,SAWEY DAVID CHRISTOPHER;;CHANG JIAN,TEXAS INSTRUMENTS INCORPORATED (2011-07-06),https://lens.org/047-859-482-941-601,Patent Application,yes,3,2,2,2,0,H04L25/028;;H04L25/03343;;H04L25/03885;;H04L25/028;;H04L25/03343;;H04L25/03885,H04W24/00,375/231,0,0,,,,ACTIVE
602,TW,U,TW M411725 U,060-678-935-001-785,2011-09-11,2011,TW 100201695 U,2011-01-26,TW 100201695 U,2011-01-26,Cable connector assembly,"A cable connector assembly includes an insulative housing having an accommodating groove, a number of conductive terminals accommodated in the insulative housing, a PCB connecting with the conductive terminals, a metal shell enclosing the insulative housing and the PCB and a cable connecting electrically the PCB. The conductive terminal has a mating portion located in the accommodating groove of the insulative housing, a bending exposing portion connecting with the PCB and a retaining portion between the exposing portion and the mating portion. The PCB has a number of through holes through the upper and lower surfaces. The exposing portion runs through one of the upper and lower surface of the PCB and welds on another surface of the PCB. The cable connector assembly can be a lower profile and weld the two rows conductive terminals at same time.",HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,,https://lens.org/060-678-935-001-785,Limited Patent,no,0,1,1,1,0,,,,0,0,,,,EXPIRED
603,CN,A,CN 101375288 A,077-158-626-746-992,2009-02-25,2009,CN 200780003453 A,2007-02-06,US 35103506 A,2006-02-09,Extensible role based authorization for manageable resources,"Methods and systems are provided for dynamically altering the access capabilities to the data resources for users of a computer based application. The access capabilities are defined by a dynamic role that specifies which of the resources a user may access, and a set of permissions associated with the dynamic role to define. New dynamic roles may be created when additional resources and components are added to an application. Methods and systems are provided for creating new dynamic roles to temporarily access resources, and for deleting a dynamic role after it is no longer needed.",IBM,YU CHANG DAVID;;VISHWANATH VENKATARAMAPPA,,https://lens.org/077-158-626-746-992,Patent Application,no,0,8,3,3,0,G06F21/604;;G06F21/6218;;G06F21/604;;G06F21/6218,G06F21/00,,0,0,,,,DISCONTINUED
604,DK,D0,DK 463187 D0,102-582-577-139-148,1987-09-04,1987,DK 463187 A,1987-09-04,US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BITUMINOESE MATERIALER.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/102-582-577-139-148,Patent Application,no,0,0,9,20,0,C08L95/00,C08L95/00,,0,0,,,,DISCONTINUED
605,AU,A,AU 1987/069395 A,113-647-177-711-604,1987-07-28,1987,AU 1987/069395 A,1987-01-07,US 81765986 A;;US 88966486 A,1986-01-10,BITUMINOUS COMPOSITIONS,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/113-647-177-711-604,Patent Application,no,0,2,9,20,0,C08L95/00,C08L95/00,,0,0,,,,EXPIRED
606,US,A,US 5723725 A,119-257-534-807-925,1998-03-03,1998,US 61935496 A,1996-03-21,US 61935496 A,1996-03-21,Inbred corn line ZS01101,"Broadly this invention provides inbred corn line ZS01101. The methods for producing a corn plant by crossing the inbred line ZS01101 are encompassed by the invention. Additionally, the invention relates to the various parts of inbred ZS01101 including culturable cells. This invention relates to hybrid corn seeds and plants produced by crossing the inbred line ZS01101 with at least one other corn line.",GARST SEED CO,WITHERSPOON DAVID;;CHANG MING-TANG,ADVANTA TECHNOLOGY LTD (1996-05-08);;SYNGENTA CROP PROTECTION AG (2008-09-22);;SYNGENTA PARTICIPATIONS AG (2009-01-01);;SYNGENTA (AT) LIMITED (2005-03-14),https://lens.org/119-257-534-807-925,Granted Patent,yes,0,7,1,1,0,A01H5/10;;Y10S47/01;;A01H6/4684;;A01H5/10;;A01H6/4684,A01H5/10,800/200;;800/235;;800/250;;X800DIG  56;;435/412;;435/424;;435/430;;435/430.1;;47/58;;X 47DIG  1,21,12,077-280-435-447-753;;056-164-704-356-332;;087-713-861-367-450;;059-935-368-980-858;;025-258-447-135-178;;145-546-326-243-559;;001-048-662-537-202;;001-374-855-146-80X;;159-003-895-450-782;;059-885-503-808-143;;039-165-764-634-646;;068-371-533-838-704,24248841;;10.1007/bf00269556;;24241136;;10.1007/bf00392228;;10.2135/1980.hybridizationofcrops.c4;;10.2135/cropsci1975.0011183x001500030040x;;10.2134/agronmonogr18.3ed.c8;;10.2135/cropsci1984.0011183x002400030028x;;10.1007/bf00272538;;24241762;;10.1007/bf00305983;;24253060;;10.2135/cropsci1985.0011183x002500040029x;;10.2135/cropsci1983.0011183x002300030033x;;10.2135/1980.hybridizationofcrops.c8;;10.2134/agronmonogr18.3ed.c9,"Testing Corn inbred Lines Agreement effective Nov. 1, 1994, by and between ICI Seeds Company and other party.;;Coe, E.H., Jr. and M.G. Neuffer. The Genetics of Corn, p. 111.;;Conger, B.V., F.J. Novak, R. Afza, and K. Erdelsky. Somatic embryogenesis from cultured leaf segments of Zea mays , Plant Cell Reports, 6:345 347 (1987).;;Duncan, D.R., M.E. Williams, B.E. Zehr and J.M. Widholm. The production of callus capable of plant regeneration from immature embryos of numerous Zea mays genotypes , Planta, 165:322 332 (1985).;;Edallo, et al., Chromosomal Variation and Frequency of Spontaneous Mutation Associated with in Vitro Culture and Plant Regeneration in Maize Maydica XXVI, pp. 39 56 (1981).;;Forsberg, R.A. and R.R. Smith. Sources, Maintenance, and Utilization of Parental Material , Hybridization of Crop Plants, Chapter 4, pp. 65 81 (1980).;;Green, C.E. and R.L. Phillips. Plant Regeneration from Tissue Cultures of Maize , Crop Science, vol. 15, pp. 417 421 (1975).;;Green, C.E. and C.A. Rhodes. Plant Regeneration in Tissue Cultures of Maize , Maize for Biological Research, pp. 367 372 (1982).;;Hallauer, et al, Corn Breeding , Corn and Corn Improvement pp. 463 564 (1988). Sprague et al, eds.;;Lowe, Keith. Patent Application 0 160 390.;;Meghji, M.R., J.W. Dudley, R.J. Lambert, and G.F. Sprague. Inbreeding Depression, Inbred and Hybrid Grain Yields, and Other Traits of Maize Genotypes Representing Three Eras . Crop Science, vol. 24, pp. 545 549 (1984).;;Phillips, et al., Cell/Tissue Culture and In Vitro Manipulation , In Corn & Corn Improvement, 3rd Ed., ASA Publication, 18, pp. 345 349 & 356 357 (1988).;;Poehlman, John Milton. Breeding Field Crop, AVI Publishing Company, Inc., Westport, Connecticut, pp. 237 246 (1987).;;Rao, K.V., et al., Somatic Embryogenesis in Glume Callus Cultures , Osmania University, Hyberabad, India.;;Sass (1977) Morphology . In Corn & Corn Improvement. ASA Publication. Madison, WI, pp. 89 109.;;Songstad, David D., David R. Duncan, and Jack M. Widholm. Effect of 1 aminocyclopropane 1 carboxylic acid, silver nitrate, and norbornadiene on plant regeneration from maize callus cultures , Plant Cell Reports, 7:262 265 (1988).;;Tomes, et al, the Effect of Parental Genotype on Initiation of Embryogenic Callus from Elite Maize ( Zea mays I. ) Germplasm . Theor. Appl. Genet. 70., pp. 505 509 (1985).;;Troyer, et al., Selection for Early Flowering in Corn: 10 Late Synthetics . Crop Science, vol. 25, pp. 695 697 (1985).;;Umbeck, et al. Reversion of Male Sterile T Cytoplasm Maize to Male Fertility in Tissue Culture , Crop Science vol. 23, pp. 584 588 (1983).;;Wright, H., Commercial Hybrid Seed Production , Hybridization of Crop Plants, pp. 161 176 (1980).;;Wych, R.D., Production of Hybrid Seed Corn ; Corn and Corn Improvement, pp. 565 607 (1988).",EXPIRED
607,US,A1,US 2023/0230825 A1,148-963-711-775-654,2023-07-20,2023,US 202117999569 A,2021-05-21,US 202117999569 A;;US 202063029226 P;;IB 2021054403 W,2020-05-22,Simplification of Method or System Using Scout MRM,"Each sample of a series of samples is ejected at an ejection time and according to a sample order. Each ejected sample of the series is ionized, producing ion beam. A list of different sets of MRM transitions is received. Each set of the list corresponds to a different sample. A group of one or more different sets is selected from the list. Initially, each set selected for the group corresponds to a different sample of one or more first samples of the series. A mass spectrometer is instructed to execute each transition of each set of the group on the ion beam until a transition of a set of the group is detected, upon which, one or more next sets are selected from the list to be monitored using the set of the detected transition and the sample order.",DH TECHNOLOGIES DEV PTE LTD,COX DAVID M;;LIU CHANG,DH TECHNOLOGIES DEVELOPMENT PTE. LTD (2020-06-23),https://lens.org/148-963-711-775-654,Patent Application,yes,0,0,5,5,0,H01J49/0031;;H01J49/004;;H01J49/0454;;H01J49/0404;;H01J49/0081;;H01J49/0404;;H01J49/0454;;H01J49/164,H01J49/00;;H01J49/04,,0,0,,,,PENDING
608,US,A1,US 2019/0337770 A1,033-866-885-523-225,2019-11-07,2019,US 201815971211 A,2018-05-04,US 201815971211 A,2018-05-04,COATED SHEAVE,An elevator sheave includes a sheave body and a coating on a surface of the sheave body. The coating includes microcracks and a filler in the microcracks. A method of making a sheave for an elevator system is also disclosed.,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,OTIS ELEVATOR COMPANY (2018-05-03),https://lens.org/033-866-885-523-225,Patent Application,yes,0,3,7,7,0,B66B7/02;;B66B15/04;;B66B15/04;;C09D191/06;;C25D3/04,B66B15/04;;C09D191/06;;C25D3/04,,0,0,,,,ACTIVE
609,US,B1,US 7345866 B1,065-495-157-859-565,2008-03-18,2008,US 12840705 A,2005-05-13,US 12840705 A,2005-05-13,Continuously tunable RF MEMS capacitor with ultra-wide tuning range,"A method is provided of continuously varying the capacitance of a MEMS varactor having a cantilever assembly mounted on a base portion, the cantilever assembly having a first capacitance plate and a dielectric element mounted thereon, and the base portion having a second capacitance plate mounted thereon. The method includes applying a first actuation voltage to deform the cantilever assembly until the dielectric element contacts the second capacitance plate leaving a gap therebetween, and applying a second actuation voltage larger than the first actuation voltage to further deform the cantilever assembly to reduce the gap between the dielectric element and the second capacitance plate.",HRL LAB LLC,HSU TSUNG-YUAN;;CHANG DAVID,HRL LABORATORIES LLC (2005-05-10),https://lens.org/065-495-157-859-565,Granted Patent,yes,10,18,1,1,0,H01G5/18;;H01G5/18,H01G5/00,361/277;;361/278;;361/283.1;;361/290;;361/291,0,0,,,,INACTIVE
610,WO,A3,WO 2015/134244 A3,077-977-996-408-260,2015-11-26,2015,US 2015/0017454 W,2015-02-25,US 201461947149 P;;US 201414268372 A,2014-03-03,NEURAL NETWORK ADAPTATION TO CURRENT COMPUTATIONAL RESOURCES,"Methods and apparatus are provided for processing in an artificial nervous system. According to certain aspects, resolution of one or more functions performed by processing units of a neuron model may be reduced, based at least in part on availability of computational resources or a power target or budget. The reduction in resolution may be compensated for by adjusting one or more network weights.",QUALCOMM INC,JULIAN DAVID JONATHAN;;CHANG ILWOO,,https://lens.org/077-977-996-408-260,Search Report,yes,0,0,8,8,0,G06N3/082;;G06N3/048;;G06N3/082;;G06N3/048;;G06N3/048;;G06N3/082,G06N3/08;;G06N3/04,,5,2,028-632-450-220-716;;176-825-485-539-61X,10.1109/82.964997;;10.1109/etcs.2010.448,"H. DJAHANSHAHI ET AL: ""Quantization noise improvement in a hybrid distributed-neuron ANN architecture"", IEEE TRANSACTIONS ON CIRCUITS AND SYSTEMS II: ANALOG AND DIGITAL SIGNAL PROCESSING, vol. 48, no. 9, September 2001 (2001-09-01), pages 842 - 846, XP011013481, DOI: 10.1109/82.964997;;B. JIAN ET AL: ""Neural networks with limited precision weights and its application in embedded systems"", PROCEEDINGS OF THE 2ND INTERNATIONAL WORKSHOP ON EDUCATION TECHNOLOGY AND COMPUTER SCIENCE (ETCS'10), 6 March 2010 (2010-03-06), pages 86 - 91, XP031673183, ISBN: 978-1-4244-6388-6;;A. KRIZHEVSKY ET AL: ""ImageNet classification with deep convolutional neural networks"", PROCEEDINGS OF THE 26TH ANNUAL CONFERENCE ON NEURAL INFORMATION PROCESSING SYSTEMS (NIPS'25), 6 December 2012 (2012-12-06), pages 1097 - 1105, XP055113686, ISBN: 978-1-62748-003-1;;V. PHAM ET AL: ""Dropout improves recurrent neural networks for handwriting recognition"", ARXIV:1312.4569V1, 5 November 2013 (2013-11-05), XP055193460, Retrieved from the Internet <URL:http://arxiv.org/abs/1312.4569v1> [retrieved on 20150603];;M. MATHIEU ET AL: ""Fast training of convolutional networks through FFTs"", ARXIV:1312.5851V4, 18 February 2014 (2014-02-18), XP055210204, Retrieved from the Internet <URL:http://arxiv.org/abs/1312.5851v4> [retrieved on 20150828]",PENDING
611,ZA,B,ZA 200202855 B,081-989-074-963-359,2003-10-29,2003,ZA 200202855 A,2002-04-11,US 16245199 P,1999-10-29,Dry powder compositions having improved dispersivity.,,INHALE THERAPEUTIC SYST,LECHUGABALLESTEROS DAVID;;KUO MEI-CHANG,,https://lens.org/081-989-074-963-359,Granted Patent,no,0,0,1,47,0,,A61K/,,0,0,,,,EXPIRED
612,US,A1,US 2011/0034083 A1,081-167-027-504-982,2011-02-10,2011,US 85329510 A,2010-08-10,CN 200920307646 U,2009-08-10,LOWER PROFILE CABLE ASSEMBLY,"A cable assembly includes an insulative housing, a number of contacts retained in the insulative housing and a metal shell covering the housing to form a receiving space with the tongue portion for receiving an electrical plug. The housing has a base portion and a tongue portion extending forwardly from the base portion. The contacts consist of two pairs of differential signal contacts and a pair of grounding contacts between the two pairs of differential signal contacts. Each contact has a contact portion. All contact portions are arranged in a row on one side of the tongue portion.",HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,HON HAI PRECISION INDUSTRY CO. LTD (2010-08-01),https://lens.org/081-167-027-504-982,Patent Application,yes,5,9,3,3,0,H01R13/506;;H01R13/506;;H01R13/6275;;H01R13/6275;;H01R13/6471;;H01R13/6471;;H01R13/6593;;H01R13/6593,H01R13/648;;H01R24/00,439/607.58;;439/660;;439/607.01,0,0,,,,INACTIVE
613,TW,U,TW M319663 U,096-359-745-499-39X,2007-10-01,2007,TW 96207129 U,2007-05-04,TW 96207129 U,2007-05-04,Posterior-form enhancement device,,CHEN DAVID E;;CHANG JASPER,CHEN DAVID E;;CHANG JASPER,,https://lens.org/096-359-745-499-39X,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
614,WO,A1,WO 1993/017472 A1,162-020-530-924-028,1993-09-02,1993,US 9301152 W,1993-02-08,US 84022392 A,1992-02-24,METHOD AND APPARATUS FOR COMPRESSING A LIGHT PULSE,"This invention discloses a method and apparatus for shortening the length of a pulse of light. Generally, the method entails altering the index of refraction of an optical medium (14) through which the pulse of light is traveling at an area of the medium (14) where the front end of the pulse of light is located, such that the front end of the pulse of light travels slower than the back end, thus enabling the back end to catch up with the front end in order to shorten the length of the pulse. To accomplish this, it is proposed to generate an electric field across the optical medium (14) by a charge carrying medium (12) positioned relative to the optical medium (14), such that the index of refraction is altered by the electro-optic effect. In addition, it is possible to alter the index of refraction of the optical medium (14) by surrounding the optical medium (14) with a piezoelectric material (20) and applying an electric field to the piezoelectric material (20) such that the piezoelectric material (20) compresses the optical medium (14), thus altering the index of refraction.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,,https://lens.org/162-020-530-924-028,Patent Application,yes,0,0,5,5,0,G02F1/0134;;G02F1/0134;;G02F1/035;;G02F1/035;;G02F2203/26;;G02F2203/26;;H01S3/0057;;H01S3/0057,G02F1/01;;G02F1/035;;G02F2/00;;H01S3/00;;H01S3/10,,5,5,020-855-628-847-346;;126-024-813-643-739;;041-318-182-675-401;;039-673-688-799-019;;050-966-442-345-76X,10.1364/ol.15.001023;;19770986;;10.1063/1.99181;;20490124;;10.1364/ao.26.003687;;10.1364/ol.14.000782;;19752966;;10.1109/3.135,"OPTICS LETTERS. vol. 15, no. 18, 15 September 1990, NEW YORK US pages 1023 - 1025 Q.Z. WANG ET AL. 'Degenerate cross-phase modulation for pulse compression and amplification of ultrashort laser pulses';;APPLIED PHYSICS LETTERS. vol. 52, no. 14, 4 April 1988, NEW YORK US pages 1122 - 1124 B.H. KOLNER 'Active pulse compression using an integrated electro-optic phase modulator';;APPLIED OPTICS. vol. 26, no. 17, 1 September 1987, NEW YORK US pages 3687 - 3694 M. HANER ET AL. 'Generation of arbitrarily shaped picosecond optical pulses using an integrated electrooptic waveguide modulator';;OPTICS LETTERS. vol. 14, no. 15, 1 August 1989, NEW YORK US pages 782 - 784 J.J CURRY ET AL. 'Generation of KrF laser pulses on a picosecond time scale using electro-optic modulation';;IEEE JOURNAL OF QUANTUM ELECTRONICS. vol. 24, no. 2, February 1988, NEW YORK US pages 382 - 387 T. KOBAYASHI ET AL. 'Optical pulse compression using high-frequency electrooptic phase modulation'",PENDING
615,US,A1,US 2012/0164886 A1,169-117-520-477-901,2012-06-28,2012,US 201113335244 A,2011-12-22,CN 201020674466 U,2010-12-22,LOWER PROFILE ELECTRICAL CONNECTOR ASSEMBLY,"An electrical connector assembly comprises: a housing, a plurality of conductive terminals received in the housing and arranged in two rows, each conductive terminal defining a front mating portion, a retaining portion retained in the housing, and an exposing portion located behind the housing, a PCB electrically connected to the conductive terminals, and having a number of through holes through an upper and a lower surfaces thereof; a metal shell enclosing the housing and the PCB; and a cable electrically connected to the PCB. At least a row of conductive terminals are bent and pass through the through holes, and two rows of exposing portions of the conductive terminals are soldered on a surface of the PCB.",KO DAVID;;LI CHANG-MAO;;HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,HON HAI PRECISION INDUSTRY CO. LTD (2011-12-15),https://lens.org/169-117-520-477-901,Patent Application,yes,10,10,2,2,0,H01R13/6658;;H01R13/6658;;H01R13/502;;H01R13/502;;H01R13/6581;;H01R13/6581;;H01R24/60;;H01R24/60;;H01R2107/00;;H01R2107/00,H01R24/28,439/626,0,0,,,,DISCONTINUED
616,DE,A1,DE 1774504 A1,171-508-849-754-53X,1971-10-14,1971,DE 1774504 A,1968-07-04,US 65153967 A,1967-07-06,Zerstoerungsfreies lesbares magnetisches Duennschicht-Speicherelement,,IBM,CHANG HSU;;ALLEN THOMPSON DAVID,,https://lens.org/171-508-849-754-53X,Patent Application,no,0,0,4,4,0,G11B5/00;;G11B5/66;;G11B11/10515;;G11B11/10584;;G11B11/10586;;G11B2005/0002;;G11B2005/0005;;G11B2005/0021;;G11C11/15;;G11C13/06;;Y10S428/926;;Y10T428/12438;;Y10T428/12958;;Y10T428/12771;;Y10T428/12438;;Y10T428/12958;;Y10T428/12771;;G11B5/00;;G11B11/10515;;G11C11/15;;G11B2005/0002;;G11B2005/0005;;G11B11/10584;;G11B2005/0021;;G11B11/10586;;G11C13/06;;Y10S428/926;;G11B5/672,G11B5/00;;G11B5/66;;G11B11/105;;G11C11/15;;G11C13/06,,0,0,,,,DISCONTINUED
617,US,A1,US 2010/0029176 A1,168-376-168-882-245,2010-02-04,2010,US 53336009 A,2009-07-31,US 53336009 A;;US 8581608 P,2008-08-01,ATTACHABLE BREAST FORM ENHANCEMENT SYSTEM,"A backless, strapless breast form system to be worn in place of a traditional bra including a pair of breast forms, wherein each breast form includes a volume of silicone gel encased between thermoplastic film material; an interior surface adapted to be attached to a user's breast, wherein substantially an entire interior surface from edge to edge comprises a pressure sensitive adhesive layer and wherein the interior surface has a plurality of bumps adapted to increase a push up effect of the breast form; a lateral side adapted to face the user's armpit and a medial side facing opposite the lateral side, wherein the breast form is adapted to be secured to the user's breast solely by the pressure sensitive adhesive layer; and a connector adapted to adjoin the pair of breast forms, wherein the connector is positioned between the medial side of each of the pair of breast forms.",CHEN DAVID E;;CHANG JASPER,CHEN DAVID E;;CHANG JASPER,BRAGEL INTERNATIONAL INC (2009-10-03),https://lens.org/168-376-168-882-245,Patent Application,yes,42,13,2,2,0,A41C3/065;;A41C3/065,A41C3/00,450/38;;450/81,0,0,,,,INACTIVE
618,US,B2,US 10376071 B2,183-167-296-564-615,2019-08-13,2019,US 201615362324 A,2016-11-28,US 201615362324 A,2016-11-28,Leaning chair,"A leaning chair can include a base defining a lower surface that rests on a floor, the base including a support surface; a shaft coupled to the base, the shaft defining a first end and a second end; a flexible mount coupling the first end of the shaft to the base, the shaft extending through the mount; a pivot pin located underneath the mount, the first end of the shaft resting on the pivot pin, and being configured to be housed inside the mount, the pivot pin being configured to pivot on the support surface; and a user support member coupled to the second end of the shaft.",VARIDESK LLC;;VARIADESK LLC,PATTON DAVID;;CHANG LIO YENWEI,VARIDESK LLC (2016-12-05),https://lens.org/183-167-296-564-615,Granted Patent,yes,123,9,3,3,0,A47C7/004;;A47C3/18;;A47C3/28;;A47C3/40;;A47C7/004;;A47C3/18;;A47C3/40;;A47C3/28;;A47C3/20;;A47C7/00;;A47C7/025;;A47C9/025;;F16C11/04;;F16C2314/70,A47C3/20;;A47C7/00;;A47C7/02;;A47C9/02;;F16C11/04,,1,0,,,"International Search Report and Written Opinion of the International Searching Authority in International Application No. PCT/US2017/063431, dated Feb. 2, 2018.",ACTIVE
619,TW,U,TW M383929 U,019-172-912-612-052,2010-07-11,2010,TW 99200195 U,2010-01-06,TW 99200195 U,2010-01-06,Adhesive bra cup,,BRAGEL INTERNAT INC,CHANG JASPER;;CHEN DAVID-E,,https://lens.org/019-172-912-612-052,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
620,CN,A,CN 103596802 A,055-221-168-113-098,2014-02-19,2014,CN 201280026406 A,2012-04-05,US 2012/0032338 W;;US 201161472502 P,2011-04-06,Vehicle seat track cover,"According to various embodiments, a vehicle seat track cover includes a substrate configured to be positioned over a seat track and a slot formed along the substrate. The slot is configured to facilitate passage of a seat support from the seat track to a vehicle seat.",JOHNSON CONTROLS TECH CO,CLARK KENNETH;;CHANG DAVID YU,,https://lens.org/055-221-168-113-098,Patent Application,no,5,7,5,5,0,B60N2/0725;;B60N2/90;;Y10T156/1052;;Y10T156/1052;;B60N2/0725;;B60N2/90;;B60N2/07,B60N2/07;;B60N2/90,,0,0,,,,DISCONTINUED
621,EP,A1,EP 0539877 A1,060-583-739-987-530,1993-05-05,1993,EP 92118152 A,1992-10-23,US 78379891 A,1991-10-30,Optical fiber having internal partial mirrors.,"An optical fiber (10) has an internal partial mirror (12) disposed to partially transmit and to partially reflect optical energy incident thereon. Said fiber (10) comprises a first fiber segment (14) having a first core region (22) which circumscribes a longitudinal axis (X), said first core region (22) being of a first cross-sectional area perpendicular to said longitudinal axis (X). Said fiber (10) further comprises a second fiber segment (18) in optical communication with said first fiber segment (14), said second fiber segment (18) having a second core region (24) which circumscribes said axis (X) wherein said second core region (24) is of a second cross-sectional area perpendicular to said axis (Fig. 1). Further described is a fiber optic interferometer comprising an optical energy source, photodetector and an improved optical fiber having dual internal partially reflected mirrors therebetween.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,,https://lens.org/060-583-739-987-530,Patent Application,yes,4,0,3,3,0,G02B6/02052;;G02B6/02052,G01B9/02;;G02B6/28;;G02B6/00;;G02B6/26,,2,1,084-204-109-446-244,10.1109/68.36033,"IEEE PHOTONICS TECHNOLOGY LETTERS vol. 1, no. 7, 1989, NEW YORK US pages 184 - 187 HORCHE ET AL.;;PROCEEDINGS OF THE SPIE VOL.1170: FIBER OPTIC SMART STRUCTURES AND SKINS II 1989, BELLINGHAM, US pages 113 - 122 LEE ET AL.",DISCONTINUED
622,WO,A3,WO 1997/030103 A3,087-198-972-209-080,1997-12-04,1997,US 9702135 W,1997-02-10,US 1173896 P,1996-02-15,PREPARATION OF POLYETHERAMINES AND POLYETHERAMINE DERIVATIVES,"Processes for preparing polyetheramines, polyetherpolyamines and their derivatives from ammonia capped polyethers are disclosed. Polyetheramines, polyetherpolyamines and their derivatives are prepared by reacting an ammonia capped polyether with an aldehyde or ketone to form an imine or reaction of an ammonia capped polyether with cyanide compound to form a nitrile intermediate, followed by subsequent hydrogenation of the intermediates to form the final polyetheramine products. A process for producing polyetheramine products by reaction of an ammonia capped polyether with an alkylene oxide followed by amination to produce a polyetheramine is also disclosed.",DOW CHEMICAL CO,CHANG DANE;;WILSON DAVID A,,https://lens.org/087-198-972-209-080,Search Report,yes,14,0,3,3,0,B01D19/0413;;C10L1/238;;C08G65/3255;;C08G65/33368;;C10L1/22;;C10L1/2225;;C10L1/2235;;C10L1/2283;;C10L1/2286;;C10L1/232;;C10L1/233;;C10L1/2443;;C10L1/2475;;C10M149/12;;C10M2215/042;;C10N2030/12;;C23F11/173,B01D19/04;;C08G65/325;;C08G65/333;;C10L1/22;;C10L1/238;;C10L1/24;;C10M149/12;;C23F11/173,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 013, no. 090 (M - 803) 2 March 1989 (1989-03-02)",PENDING
623,AU,B2,AU 2014/249417 B2,104-677-205-582-418,2017-07-13,2017,AU 2014/249417 A,2014-03-07,US 201313792135 A;;US 2014/0022004 W,2013-03-10,Modified caspase polypeptides and uses thereof,"The technology relates in part to compositions comprising modified caspase-9 polypeptides, compositions comprising nucleic acids coding for modified caspase-9 polypeptides, chimeric modified caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/104-677-205-582-418,Granted Patent,no,1,0,17,17,0,A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008;;A61P1/04;;A61P17/00;;A61P19/08;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P5/00;;A61P7/00;;A61P7/06;;A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008,A01N65/00;;A61K31/4545;;A61K35/14;;C12N5/00;;C12N9/64;;C12P21/00,,0,0,,,,ACTIVE
624,US,B2,US 9932572 B2,128-001-339-678-82X,2018-04-03,2018,US 201615224441 A,2016-07-29,US 201615224441 A;;US 201313792135 A,2013-03-10,Modified Caspase polypeptides and uses thereof,"The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2023-11-21);;BELLICUM PHARMACEUTICALS INC (2013-04-29),https://lens.org/128-001-339-678-82X,Granted Patent,yes,95,3,17,17,50,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,C07H21/04;;A01K67/00;;A61K31/4545;;A61K38/48;;A61K38/52;;A61K48/00;;C12N9/64;;C12N9/90,,479,470,180-396-298-490-664;;030-951-581-231-87X;;097-015-592-385-347;;143-034-905-707-627;;105-844-582-547-53X;;072-788-084-986-303;;053-945-880-920-206;;025-871-854-811-562;;089-335-215-220-013;;052-802-325-723-516;;091-588-365-157-475;;027-400-811-033-272;;046-399-217-299-346;;048-793-449-009-473;;041-397-625-399-935;;017-399-532-580-822;;023-512-064-153-73X;;036-034-789-927-905;;079-967-664-874-058;;044-471-795-926-496;;028-238-234-983-369;;068-696-141-407-273;;001-067-626-994-418;;018-751-914-040-764;;009-424-537-894-726;;013-872-547-066-215;;047-867-313-375-928;;055-953-050-127-623;;004-852-459-781-732;;062-130-425-112-476;;003-381-030-696-215;;075-057-846-638-250;;014-990-643-039-130;;054-914-540-977-067;;087-719-944-261-851;;064-213-235-179-334;;051-276-704-495-732;;001-247-987-939-340;;068-589-904-018-425;;066-722-514-892-229;;010-511-607-738-720;;048-188-266-680-461;;034-955-588-990-231;;029-640-383-431-180;;003-965-481-653-512;;028-050-239-356-335;;015-253-633-954-147;;053-160-570-826-935;;029-286-581-257-399;;019-211-471-107-876;;027-238-263-538-41X;;025-596-606-643-965;;115-972-294-054-30X;;011-194-249-913-209;;009-314-499-609-666;;020-437-829-589-898;;015-617-903-805-622;;161-641-816-931-384;;010-091-785-487-524;;088-994-457-887-198;;088-994-457-887-198;;003-297-281-928-568;;032-026-264-382-468;;094-435-086-030-641;;068-637-973-521-79X;;016-074-079-257-776;;083-532-409-044-411;;035-702-835-572-741;;035-675-543-762-067;;015-184-046-646-194;;106-360-460-538-50X;;124-985-422-988-633;;045-538-880-672-523;;096-019-825-303-501;;081-133-875-946-817;;086-352-377-514-220;;039-038-627-486-120;;043-247-299-521-534;;001-116-270-494-591;;010-127-506-936-262;;026-459-663-632-774;;003-327-415-791-486;;091-582-343-202-549;;092-399-646-107-750;;035-011-400-015-37X;;105-358-520-980-924;;054-667-680-236-126;;017-120-321-828-436;;138-643-940-612-044;;094-151-485-006-097;;103-276-080-854-913;;031-031-897-260-663;;039-931-356-007-897;;193-603-995-859-640;;008-797-776-310-121;;053-900-918-619-293;;121-068-294-761-014;;060-366-483-956-384;;095-009-613-240-195;;105-045-276-085-540;;060-824-980-876-559;;101-489-246-945-003;;010-380-189-167-20X;;034-273-672-763-762;;022-418-163-251-872;;086-707-718-808-930;;048-533-982-202-633;;034-194-200-419-642;;004-253-998-677-868;;075-924-048-888-91X;;012-803-875-488-163;;061-213-774-521-865;;020-984-837-129-173;;127-348-232-397-557;;045-853-272-050-122;;107-198-277-230-121;;006-840-326-353-915;;013-058-058-246-438;;001-186-331-594-208;;007-502-914-983-416;;047-757-821-570-95X;;020-345-352-285-601;;015-812-924-415-969;;069-990-053-764-194;;026-818-597-556-84X;;061-024-824-482-639;;015-918-618-160-633;;086-801-624-319-977;;007-174-956-711-777;;104-820-138-625-471;;005-256-565-741-692;;071-111-890-340-768;;077-658-154-371-483;;037-076-314-262-251;;072-366-322-919-406;;037-272-595-739-244;;056-887-460-397-507;;026-651-480-495-148;;054-084-981-000-462;;023-078-614-743-461;;049-300-737-849-942;;011-265-446-016-318;;004-990-754-720-540;;034-984-135-752-006;;014-527-453-484-407;;040-755-900-417-167;;022-721-164-690-713;;091-275-864-852-82X;;007-920-864-848-68X;;025-007-303-045-409;;038-217-001-867-586;;085-875-375-088-180;;017-442-312-120-833;;039-017-574-897-344;;128-119-661-218-34X;;086-170-866-192-229;;091-578-804-330-462;;044-459-274-575-625;;125-472-370-503-982;;039-539-237-346-160;;042-448-719-499-308;;012-604-366-279-425;;030-162-494-746-005;;071-429-593-853-516;;106-947-905-231-395;;097-361-810-716-194;;041-228-863-393-830;;116-106-866-304-85X;;006-692-394-149-981;;029-359-798-838-615;;052-585-729-017-070;;081-578-609-335-687;;013-047-069-985-371;;077-236-925-915-005;;016-695-531-786-749;;136-575-879-348-349;;029-496-615-483-112;;088-917-763-027-234;;023-654-025-246-048;;002-001-935-508-270;;014-015-599-953-342;;036-843-545-508-253;;028-186-015-540-38X;;144-600-240-796-177;;088-947-503-926-361;;027-975-358-037-407;;011-488-475-745-454;;008-073-363-539-995;;136-858-514-372-864;;024-439-638-297-07X;;106-951-989-469-238;;088-156-513-960-044;;115-723-032-291-789;;070-157-552-933-517;;009-509-198-473-232;;038-878-744-989-953;;062-825-278-526-054;;022-498-703-986-961;;048-218-069-440-383;;033-400-337-705-998;;005-657-092-506-111;;006-048-787-078-531;;065-826-406-353-842;;073-813-895-256-644;;043-619-194-006-282;;137-699-600-392-782;;023-350-295-989-674;;035-537-674-004-113;;082-978-884-755-116;;055-406-926-990-606;;106-753-778-592-300;;064-187-018-698-676;;032-051-999-499-063;;000-385-963-376-028;;067-339-109-223-755;;000-634-088-419-476;;167-577-652-745-132;;008-330-766-873-60X;;049-959-533-625-66X;;003-180-650-129-827;;002-292-913-195-296;;078-485-640-301-150;;007-888-139-067-445;;030-202-896-771-215;;023-881-689-236-424;;048-431-572-007-678;;186-364-529-195-761;;004-434-892-365-519;;103-691-552-833-183;;027-411-691-702-227;;002-377-847-209-110;;044-954-143-201-664;;038-798-666-682-058;;074-329-622-195-729;;007-204-099-352-136;;052-176-596-515-633;;057-689-969-307-462;;083-666-837-096-094;;012-920-215-541-005;;010-215-653-626-483;;035-068-894-998-018;;000-397-009-050-409;;069-658-664-429-198;;053-731-896-070-337;;100-916-770-919-108;;019-090-096-232-967;;015-609-843-238-59X;;081-727-758-133-68X;;085-009-706-976-342;;122-742-372-778-777;;010-956-444-271-709;;012-208-904-405-480;;072-682-318-815-262;;094-857-606-776-915;;044-967-162-851-665;;011-216-460-660-408;;025-599-819-137-904;;048-717-099-664-915;;065-795-579-066-770;;092-166-334-303-974;;011-271-172-397-985;;039-710-508-993-00X;;004-475-916-895-09X;;091-258-571-706-824;;013-951-100-691-597;;096-958-176-450-303;;047-872-994-235-117;;066-545-064-691-571;;103-350-396-206-093;;000-810-251-482-038;;049-021-985-873-114;;018-681-067-914-617;;045-364-218-979-507;;031-636-356-171-07X;;100-091-443-443-591;;007-041-645-879-370;;075-987-120-610-743;;124-907-585-224-730;;034-903-394-627-376;;040-573-961-841-570;;080-879-659-208-873;;017-762-302-959-224;;027-672-669-256-326;;032-286-250-571-912;;019-130-227-958-367;;123-672-572-481-850;;006-639-759-517-028;;005-058-719-114-708;;016-334-505-417-815;;007-421-226-677-859;;005-027-163-913-51X;;046-354-133-089-764;;056-375-645-149-64X;;057-103-385-862-082;;008-116-074-064-417;;020-287-887-014-506;;005-636-362-711-412;;089-856-988-028-203;;041-210-978-585-52X;;021-985-430-393-379;;030-236-804-821-445;;041-998-348-351-290;;141-276-141-946-220;;076-607-506-177-849;;097-076-899-446-449;;016-501-978-837-735;;036-533-475-472-422;;119-279-899-568-792;;000-380-208-347-204;;033-901-493-241-22X;;020-273-453-652-888;;015-639-251-167-350;;059-821-098-734-992;;063-854-944-766-893;;009-012-940-202-16X;;119-212-580-354-913;;006-770-979-895-067;;055-856-069-214-984;;028-834-504-937-401;;013-196-935-848-429;;125-327-916-677-079;;049-998-237-923-20X;;005-466-548-606-507;;087-247-552-844-019;;098-316-126-880-450;;006-258-294-728-546;;048-036-080-827-91X;;035-252-295-554-52X;;048-912-563-158-551;;041-809-608-159-532;;083-300-127-977-763;;006-320-575-424-025;;032-152-898-363-426;;007-709-585-201-038;;034-624-943-604-483;;122-689-697-267-422;;004-212-749-090-555;;038-226-770-301-063;;015-709-963-423-413;;007-664-139-814-196;;106-992-460-151-925;;019-622-793-830-57X;;027-326-505-837-755;;057-404-975-210-454;;000-671-283-072-01X;;063-710-398-275-735;;027-552-012-139-76X;;017-574-565-089-074;;012-510-167-851-671;;109-929-540-276-805;;088-927-854-299-269;;101-917-417-419-111;;009-073-833-235-053;;028-770-755-246-613;;040-507-217-146-638;;030-072-073-955-723;;056-073-530-503-473;;098-944-418-410-87X;;169-828-460-554-08X;;089-488-528-988-581;;002-030-548-108-94X;;028-025-167-151-693;;048-017-174-975-725;;044-729-181-568-490;;091-144-636-478-872;;124-781-955-523-893;;031-386-880-222-030;;017-807-482-658-328;;021-752-362-084-875;;153-254-671-972-061;;115-279-609-964-995;;005-362-487-902-647;;032-924-718-385-415;;022-691-846-812-525;;005-770-782-535-061;;031-032-421-240-450;;051-394-691-678-683;;019-361-384-066-918;;054-431-289-321-79X;;053-903-483-492-249;;000-906-844-677-689;;050-125-427-191-516;;006-523-154-140-614;;030-687-805-182-393;;032-882-065-353-850;;021-079-160-548-304;;026-045-531-189-395;;019-223-757-833-839;;124-073-715-271-423;;115-663-891-903-809;;003-718-487-856-435;;016-722-037-931-42X;;086-384-699-415-141;;116-489-634-006-248;;034-941-163-165-394;;106-502-063-725-273;;012-898-490-363-145;;054-965-596-624-412;;020-052-915-250-236;;034-084-208-857-228;;032-469-683-201-820;;021-725-944-006-945;;048-314-689-562-138;;092-090-153-273-042;;019-307-772-858-418;;086-439-822-197-06X;;068-977-389-569-007;;008-297-903-289-089;;019-846-871-242-611;;032-041-391-617-173;;000-446-253-604-686;;046-809-937-619-124;;058-997-183-544-854;;072-032-471-580-08X;;090-636-673-155-049;;049-897-709-904-769;;109-173-335-603-750;;122-165-725-168-150;;018-227-879-163-484;;022-700-685-856-667;;045-167-043-118-816;;000-427-962-971-581;;029-365-736-670-360;;007-883-666-419-470;;011-150-334-195-470;;035-130-340-511-487;;020-267-455-416-896;;039-142-275-859-279;;007-162-010-900-165;;092-475-980-877-170;;019-849-114-602-468;;031-815-721-025-163;;057-790-048-617-243;;065-709-522-043-46X;;050-960-928-763-817;;090-705-720-236-682;;049-893-011-590-675;;055-438-959-647-712;;005-744-458-310-160;;189-867-009-180-674;;007-044-567-892-660;;012-615-279-719-895;;107-273-667-679-802;;067-225-454-459-616;;177-603-936-164-523;;004-701-796-869-470;;025-627-126-037-64X;;011-294-598-583-277;;044-282-688-661-565;;080-275-967-332-334;;064-342-726-068-592;;144-915-082-232-945;;007-350-465-902-739;;020-703-580-582-672;;040-168-376-932-43X;;001-130-700-090-695;;038-404-519-135-404;;032-184-716-110-548;;026-288-202-084-572;;049-238-531-992-941;;049-238-531-992-941;;012-898-490-363-145;;077-906-081-143-534;;071-411-988-846-315;;009-431-727-846-405;;026-958-333-907-92X;;073-080-484-676-956;;010-407-523-122-611;;062-983-269-546-129;;037-223-423-261-423,10.2165/00126839-200607030-00006;;16752945;;10.1016/s0021-9258(18)95637-1;;7615552;;9192897;;10.1038/42716;;10.1016/j.coi.2005.01.004;;15766677;;10.1038/ni722;;11590405;;10880445;;pmc313930;;10.1093/emboj/19.13.3325;;9380684;;10.1073/pnas.94.20.10618;;pmc23423;;pmc1895537;;16741253;;10.1182/blood-2006-02-001909;;10.1182/blood-2002-11-3516;;12763937;;10.1182/blood.v72.3.1099.bloodjournal7231099;;3046681;;10.1038/36593;;9367155;;10.1016/j.stemcr.2015.07.011;;26321144;;pmc4624898;;12126823;;10.1016/s0140-6736(02)09413-8;;pmc336488;;10.1093/nar/16.8.3195;;3375054;;10.1182/blood.v96.3.1039.015k04_1039_1046;;10910920;;00010910920;;10.1182/blood.v96.3.1039;;10.1200/jco.2005.09.117;;15753458;;10.1056/nejm199810223391702;;9780338;;10.1038/32588;;9521319;;10.1038/nri1592;;15803149;;10.1111/j.1749-6632.2003.tb06047.x;;12727638;;10837075;;10.1146/annurev.immunol.18.1.767;;15837970;;10.1200/jco.2005.05.160;;8939689;;10.1016/s1074-5521(96)90249-5;;7614713;;10.1161/01.res.77.2.266;;9624004;;10.1038/30996;;14563634;;10.1182/blood-2003-08-2908;;9833853;;10.1097/00002030-199816000-00007;;15241424;;10.1038/nature02761;;10.1016/s0022-5347(18)35293-5;;16278310;;10.1182/blood-2004-11-4250;;pmc20324;;10.1073/pnas.94.7.3076;;9096348;;10.1038/nrc1365;;15122208;;pmc2702793;;10.1073/pnas.0901522106;;19528653;;10.1016/j.ceb.2003.10.009;;14644197;;12620239;;10.1016/s1097-2765(03)00051-0;;10.1016/s0264-410x(02)00081-6;;11983257;;10.1016/s0092-8674(00)81265-9;;8681376;;0008681376;;10.1182/blood.v99.9.3179;;11964281;;10.1084/jem.20040890;;15611290;;pmc2211993;;10.1126/science.276.5319.1719;;9180086;;10.1104/pp.110.161232;;pmc2948987;;20921159;;2315699;;10.1126/science.2315699;;10.1128/mcb.25.23.10543-10555.2005;;pmc1291226;;16287866;;17483296;;10.1182/blood-2006-12-063412;;23515080;;pmc3742551;;10.1126/scitranslmed.3005930;;12538665;;10.1084/jem.20021790;;pmc2193806;;009812896;;10.1126/science.282.5392.1318;;9812896;;pmc2651342;;19211796;;10.1073/pnas.0813101106;;8570628;;pmc40126;;10.1073/pnas.93.2.749;;9286332;;10.1007/978-1-4757-9966-8_4;;8915674;;10.1007/s00282-996-0463-4;;12213402;;10.1016/s0264-410x(02)00310-9;;17656645;;10.1634/stemcells.2007-0197;;10.1126/science.288.5475.2351;;10875917;;10.1016/j.cyto.2007.03.005;;pmc1965282;;17449269;;10.1016/s0090-4295(00)01094-3;;11306418;;16606790;;10.1161/circulationaha.105.593038;;10537328;;18338032;;10.1371/journal.pone.0001317;;pmc2267039;;pmc1088972;;10.1371/journal.pbio.0030183;;15941357;;pmc1088972;;10.1371/journal.pbio.0030183;;15941357;;8597384;;10.1111/j.1749-6632.1995.tb31045.x;;10.1128/mcb.7.8.2745-2752.1987;;10.1128/mcb.7.8.2745;;pmc367891;;3670292;;9050879;;10.1073/pnas.94.5.1914;;pmc20017;;10.1016/j.vaccine.2004.07.010;;15542183;;10429676;;10.1084/jem.190.1.125;;pmc2195555;;15961631;;10.1126/science.1115253;;10.1158/1535-7163.mct-04-0171;;15897234;;10.1016/s1470-2045(09)70074-9;;19345145;;10.3410/f.1160119.620403;;10.4049/jimmunol.172.11.7162;;15153540;;pmc27912;;10.1073/pnas.95.18.10437;;9724721;;10.1111/j.1747-0285.2006.00403.x;;16882320;;10.1002/9783527619375.ch4b;;pmc2727290;;19506159;;10.1200/jco.2008.20.7944;;10810999;;10.1002/jlb.67.5.607;;10.1002/jmv.1890310109;;2198326;;pmc330768;;10.1093/nar/18.9.2807;;2111010;;12810728;;10.1074/jbc.m209993200;;2851485;;10.1016/0378-1119(88)90593-8;;10.1007/s00262-003-0432-5;;14648069;;2503724;;10.1056/nejm198908173210702;;12393586;;10.1182/blood-2002-01-0312;;15317891;;10.1056/nejmoa040766;;10.1126/science.286.5447.2098;;10617422;;11007363;;10.1016/s0952-7915(00)00146-1;;10.1073/pnas.0502101102;;15837926;;10.2210/pdb1z8l/pdb;;pmc556220;;10837408;;10.1093/intimm/12.6.807;;12391253;;10.4049/jimmunol.169.9.5322;;11198272;;12517769;;10.4049/jimmunol.180.9.6365;;18424760;;pmc114679;;11602739;;10.1128/jvi.75.22.10991-11001.2001;;10.1042/bj20070288;;pmc1925235;;17437405;;10.1517/13543776.8.1.53;;16984391;;10.1111/j.1365-2141.2006.06300.x;;10.1056/nejmoa1106152;;pmc3236370;;22047558;;10395322;;10.1038/10495;;10.1080/14653240600855905;;16923606;;10.1146/annurev.immunol.15.1.617;;9143702;;pmc1475951;;10.1200/jco.2005.00.240;;15800326;;10.1126/science.1076514;;pmc1764179;;12242449;;10.1111/j.1600-065x.2009.00782.x;;pmc3826168;;19426221;;16357940;;pmc1312019;;10.1172/jci26169;;10.1089/10430349950016924;;10515447;;10.1038/383178a0;;8774884;;10.1126/science.272.5258.50;;8600536;;pmc299564;;10.1073/pnas.84.23.8463;;2446324;;10.1038/7403;;10202929;;pmc190186;;8627803;;10.1128/jvi.70.5.3227-3234.1996;;21266849;;10.4161/hv.7.0.14574;;10.4049/jimmunol.172.1.104;;14688315;;pmc189840;;10.1128/jvi.70.1.520-532.1996;;8523565;;pmc47827;;7504271;;10.1073/pnas.90.22.10613;;7584109;;8382676;;10.1007/bf00768066;;12114876;;12208748;;10.1074/jbc.274.23.16349;;pmc3624707;;10347193;;7980434;;10.1042/bj3030697;;pmc1137601;;10.1016/j.tetlet.2004.05.116;;14978216;;10.1091/mbc.e03-07-0493;;pmc404016;;605383;;10.1007/bf01551818;;10.2174/138620707782507296;;18045079;;1717600;;10.1016/0022-1759(91)90110-2;;10.1111/j.0105-2896.2004.00139.x;;15233739;;15122211;;10.1038/nrc1359;;10.1056/nejm199101243240406;;1985245;;10.1182/blood.v84.5.1492.1492;;8068942;;411876;;pmc2181914;;10.1084/jem.146.6.1719;;10.1016/0952-7915(89)90198-2;;2516446;;2987679;;pmc366838;;10.1128/mcb.5.5.1188-1190.1985;;10.1128/mcb.5.5.1188;;10.1126/science.7792603;;7792603;;pmc49329;;10.1073/pnas.89.12.5547;;1319065;;10.1146/annurev.med.56.082103.104727;;15660500;;4705382;;10.1016/0042-6822(73)90341-3;;10.1016/s1286-4579(99)00209-9;;10572310;;11526406;;10.1038/ni0901-882;;10.1002/eji.1830241039;;7925580;;10.1146/annurev.immunol.16.1.111;;9597126;;10.1096/fasebj.6.15.1464371;;1464371;;pmc4133482;;10.1182/blood-2013-10-535245;;24986688;;19796623;;10.1016/j.stem.2009.08.021;;10.1532/ijh97.06230;;17675260;;10.4049/jimmunol.169.3.1524;;12133980;;10.1038/nm1183;;15665830;;8072533;;10.1038/371080a0;;pmc549490;;15708970;;10.1073/pnas.0500187102;;10.1016/0022-2836(84)90181-5;;6737476;;10.4049/jimmunol.166.1.182;;11123291;;9482916;;pmc19394;;10.1073/pnas.95.5.2509;;pmc255695;;10.1128/jvi.61.8.2555-2558.1987;;3599182;;10.1016/s0022-2836(83)80112-0;;6876165;;10706699;;10.4049/jimmunol.164.6.3095;;23929832;;pmc3739034;;10.1182/blood-2013-06-509604;;8752278;;10.1038/382822a0;;12430632;;10.1016/s0361-090x(02)00095-8;;10725460;;10.1016/s0022-1759(99)00239-2;;pmc308317;;7937055;;7568223;;pmc40892;;10.1073/pnas.92.21.9810;;22697466;;10.1186/1752-0509-6-66;;pmc3436737;;11606776;;pmc60109;;10.1073/pnas.231471798;;10.1016/j.bbmt.2007.08.050;;pmc2153438;;18022571;;12084934;;pmc124401;;10.3410/f.723954163.793509207;;10.1073/pnas.132252399;;10086387;;10.1038/6529;;10.1016/j.bbmt.2006.10.016;;10201887;;10.4049/jimmunol.162.7.3749;;8757608;;15133508;;10.1038/ni1071;;10.1186/scrt52;;pmc3226282;;21375737;;17339194;;10.3324/haematol.10570;;18204965;;10.1007/s10875-007-9166-z;;14569557;;10.1016/j.bbmt.2003.08.009;;10724039;;10.1089/10430340050015798;;10.4049/jimmunol.168.2.926;;11777991;;7511053;;7527294;;8417812;;10.1177/00912700122010771;;11504275;;pmc556483;;1537334;;10.1002/j.1460-2075.1992.tb05083.x;;9300684;;10.4049/jimmunol.159.6.2652;;2700931;;10.1101/sqb.1989.054.01.003;;10.3322/ca.2007.0010;;18287387;;9464798;;10.1002/eji.1830271209;;10.1084/jem.191.3.495;;10662795;;pmc2195824;;12833128;;10.1038/sj.gt.3301977;;11561001;;pmc2195968;;10.1084/jem.194.6.863;;10.1016/j.cell.2006.03.047;;16751103;;3818598;;10.1016/s0021-9258(18)61660-6;;pmc2212425;;9858506;;10.1084/jem.188.12.2199;;10.1007/978-1-4757-9966-8_59;;9286387;;10.1182/blood.v97.11.3466;;11369638;;21832238;;pmc3393096;;10.1126/scitranslmed.3002842;;10.1006/excr.1999.4690;;10579924;;10.4049/jimmunol.167.7.3773;;11564794;;20848748;;10.1016/j.eururo.2010.07.016;;21067392;;21067391;;10.1056/nejmc1009982;;7842013;;10.1038/ng1094-148;;10.1016/s0003-4975(96)00946-0;;8957370;;10.1073/pnas.91.14.6458;;pmc44221;;8022805;;7516411;;pmc2191573;;10.1084/jem.180.1.347;;8786287;;10.1007/s11912-000-0058-0;;11122870;;10.1080/1061186031000072978;;12852436;;pmc2154351;;17062687;;10.1158/1078-0432.ccr-06-1183;;10.1073/pnas.93.24.14082;;8943064;;pmc19498;;10.1038/80498;;11017148;;pmc3254150;;19341619;;10.1016/j.stem.2009.03.010;;1422046;;12150927;;10.1016/s0092-8674(02)00827-9;;10.1073/pnas.94.4.1426;;9037069;;pmc19807;;1172191;;10.1038/256495a0;;825377;;10.1002/eji.1830060713;;12958064;;10.1182/blood-2003-02-0342;;10801470;;10.1016/s1074-5521(00)00109-5;;10.1006/mthe.2002.0538;;11863421;;10829082;;10.1073/pnas.130182597;;pmc16563;;10.1002/pros.20150;;15389777;;10.1089/dna.2006.25.383;;16848679;;15972637;;10.4049/jimmunol.175.1.112;;18781156;;10.1038/nrg2432;;pmc4317294;;10.1073/pnas.84.21.7473;;2823263;;pmc299318;;9886383;;10.4049/jimmunol.162.1.168;;18575608;;pmc2429965;;10.1371/journal.pone.0002517;;15528145;;10.1016/j.bcmd.2004.08.017;;11017102;;10.1038/79758;;11509174;;10.1016/s0092-8674(01)00455-x;;10.1126/science.290.5489.92;;11021806;;11093145;;10.1002/1521-4141(200011)30:11<3291::aid-immu3291>3.0.co;2-2;;10.1016/s1525-0016(16)38574-4;;17974997;;10.1158/0008-5472.can-07-0833;;10.1016/s0140-6736(08)60690-x;;18468541;;10.1016/s0264-410x(02)00382-1;;12477423;;14699116;;10.1074/jbc.m311564200;;10.1073/pnas.0608249103;;pmc1634835;;10.3410/f.1079797.532717;;17088535;;10.1021/cr60274a001;;10.1016/0378-1119(91)90411-4;;1829048;;10.1038/sj.gt.3301641;;11896462;;10.1006/viro.2000.0357;;10873786;;10.1371/journal.pone.0070543;;pmc3728319;;23936225;;9751609;;pmc2194226;;10.1084/jem.20030026;;14568984;;9288760;;11846609;;10.1006/meth.2001.1262;;10706088;;10.1074/jbc.c400613200;;15755740;;10.1182/blood-2001-12-0360;;12149219;;pmc3077556;;21251012;;10.1111/j.1749-6632.2010.05877.x;;10.1038/383181a0;;8774885;;10.1073/pnas.95.7.3655;;pmc19891;;9520421;;1652694;;10.1038/353090a0;;18794543;;10.1200/jco.2008.16.9524;;10.1016/s1286-4579(00)01323-x;;11137041;;10.1038/ni0805-749;;16034427;;10.1016/0092-8674(83)90344-6;;6678608;;10.1073/pnas.0530192100;;pmc151411;;12601144;;10.1016/j.immuni.2005.02.010;;15845453;;10.1074/jbc.m414325200;;15703181;;10.1084/jem.20030448;;12925677;;pmc2194169;;12747747;;10.1016/0006-8993(95)01488-8;;8724980;;10.1111/j.1365-2567.2006.02326.x;;16556265;;pmc1782249;;10411888;;pmc17529;;10.1073/pnas.96.15.8408;;10.1084/jem.194.5.657;;11535633;;pmc2195949;;10.1038/41131;;9237759;;10.1016/s1097-2765(00)80136-7;;9734363;;15319172;;10.1034/j.1600-065x.2002.18816.x;;12445291;;10.4049/jimmunol.171.8.3913;;14530307;;10.1038/nature04946;;16823444;;11241301;;10.1002/1521-4141(200103)31:3<959::aid-immu959>3.0.co;2-a;;19384291;;pmc2805264;;10.1038/mt.2009.83;;8599196;;10.1006/viro.1996.0099;;11706021;;10.1074/jbc.m106361200;;10363991;;10.1089/dna.1993.12.777;;8216848;;10.1126/science.1129003;;pmc2267026;;16946036;;20179677;;pmc2862534;;10.1038/mt.2010.24;;9892184;;12912979;;10.1074/jbc.m306440200;;10.1126/science.2499928;;2499928;;10.1111/j.1442-2042.2010.02544.x;;20438593;;10.1038/ni1223;;15995707;;pmc3760217;;pmc3069772;;21383499;;10.1172/jci44327;;10.1128/iai.69.12.7250-7253.2001;;11705894;;pmc98808;;17664353;;10.1182/blood-2007-02-069716;;11433329;;10.1038/89863;;10.1073/pnas.97.19.10395;;pmc27035;;10984535;;10.1016/0076-6879(87)49054-x;;3320679;;15899823;;10.1158/0008-5472.can-04-3119;;9692848;;10.1016/s0022-1759(98)00028-3;;12218115;;10.4049/jimmunol.169.6.3006;;10.1016/s0021-9258(19)50076-x;;1375228;;10.4049/jimmunol.159.8.3838;;9378971;;pmc553575;;2820712;;10.1002/j.1460-2075.1987.tb02450.x;;10.1182/blood-2003-12-4392;;15231572;;12906261;;10.1615/critrevimmunol.v23.i12.50;;10.1073/pnas.250476497;;pmc17650;;11095740;;9703872;;9020360;;10.1038/385537a0;;10.4049/jimmunol.168.1.5;;11751939;;12532024;;10.1126/science.1078231;;1172324;;10.1016/0042-6822(75)90421-3;;10.1038/334320a0;;2839775;;8171039;;pmc43728;;10.1073/pnas.91.9.4086;;17901396;;10.1634/stemcells.2007-0637;;8839444;;10.3109/10739689609148292;;9816319;;10102814;;10.1126/science.284.5411.143;;pmc298248;;2479021;;10.1073/pnas.86.21.8202;;10.1021/bi034999p;;pmc3110659;;14567692;;10.1056/nejmoa1103849;;pmc3387277;;21830940;;10.1073/pnas.81.22.7161;;pmc392097;;6438633;;16365406;;10.4049/jimmunol.176.1.157;;9082988;;10.1126/science.276.5309.71;;pmc443569;;2447485;;10.1128/mcb.8.1.42;;10.1128/mcb.8.1.42-51.1988;;10.1016/1074-5521(94)90006-x;;9383386;;7581076;;12803317;;10.1615/critrevimmunol.v22.i5-6.20;;12850789;;10.1080/14653240310001488;;10.1038/nm.1882;;18978797;;pmc2749734;;10318845;;10.1074/jbc.274.20.14246;;17638856;;pmc2018664;;10.1182/blood-2007-02-072843;;15657060;;10.1074/jbc.m413787200;;pmc3437189;;19898472;;10.1038/ni.1820;;11477091;;10.1074/jbc.m105927200;;10.1016/s1074-7613(01)00136-4;;11371351;;2149186;;10.1016/0167-8140(90)90148-p;;pmc64668;;11734640;;10.1073/pnas.231465798;;9841930;;10.1084/jem.188.11.2175;;pmc2212396;;12829610;;10.1182/blood-2003-01-0150;;16361568;;10.1158/1078-0432.ccr-05-1314;;10627446;;10.1182/blood.v95.2.430;;10.1038/nm0296-216;;8574968;;9624003;;10.1038/30989;;14735692;;10.1081/cnv-120025091;;15778365;;10.4049/jimmunol.174.7.4070;;2105458;;10.1128/mcb.10.2.689;;10.1128/mcb.10.2.689-695.1990;;pmc360867;;10.1038/nm0996-1028;;8782462;;9608512;;10.1006/meth.1998.0596;;10.1128/mcb.11.5.2887;;pmc360079;;10.1128/mcb.11.5.2887-2895.1991;;2017183;;9716582;;10.1182/blood.v92.5.1549.417k32_1549_1555;;10.1182/blood.v92.5.1549;;14624253;;10.1371/journal.pbio.0000053;;pmc261890;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1073/pnas.86.23.9079;;2556698;;pmc298437;;10.1128/mcb.00968-06;;pmc1636743;;16923964;;10.1007/978-1-349-02718-7_1;;pmc3667586;;23550147;;10.1158/2159-8290.cd-12-0548;;6420177;;10.1128/iai.65.8.3239-3247.1997;;9234781;;pmc175458;;9754563;;10.1002/(sici)1521-4141(199809)28:09<2760::aid-immu2760>3.0.co;2-n;;10.1128/jvi.61.10.3096-3101.1987;;pmc255885;;3041032;;16621978;;10.4049/jimmunol.176.9.5153;;21530212;;10.1016/j.coi.2011.03.008;;pmc3109217;;10.1007/s00262-003-0419-2;;13680192;;10.1182/blood-2003-05-1643;;14592837;;12149218;;10.1182/blood-2001-11-0017;;10.1016/s0022-5347(01)64846-8;;10.1097/00005392-199705000-00057;;9112515;;8931606;;10.1093/jnci/88.22.1623;;19209432;;10.1016/j.eururo.2008.04.086;;7687666;;10.1200/jco.1993.11.8.1566;;10.1128/jvi.71.7.4892-4903.1997;;pmc191719;;9188551;;10.1038/31002;;9624005;;18354197;;10.4049/jimmunol.180.7.4728;;10.1016/s0952-7915(03)00015-3;;12633662;;10.1038/nri841;;12094225;;10.1200/jco.2010.28.15_suppl.7631;;pmc2946157;;10.1021/jo00103a013;;20882116;;12382069;;10.1007/s00210-002-0588-0;;17404082;;10.1158/1078-0432.ccr-06-2701;;10.1038/nbt1035;;15558048;;10.1016/s1097-2765(02)00482-3;;11931755;;12620238;;10.1016/s1097-2765(03)00054-6;;10.1073/pnas.072544399;;pmc123625;;11904389;;9815541;;9753487;;10.1016/s0016-5085(98)70256-2;;10.1002/1097-0142(19951015)76:8<1428::aid-cncr2820760820>3.0.co;2-t;;8620419;;10.1200/jco.1997.15.1.382;;8996165;;15475958;;10.1038/ni1129;;10.1089/aid.2004.20.1335;;15650426;;6287286;;10.1038/299163a0;;pmc1895160;;15817673;;10.1182/blood-2005-01-0393;;22117050;;10.1182/blood-2011-03-344275;;10.1158/0008-5472.can-11-0422;;21546571;;pmc4140173;;10.1215/15228517-4-1-1;;11772427;;pmc1920634;;10.1093/neuonc/4.1.1;;10.1215/s1522851701000151;;pmc2895425;;19696798;;10.1038/nrm2748;;pmc40891;;10.1073/pnas.92.21.9805;;7568222;;7694365;;10.1126/science.7694365;;10.1016/s0960-9822(02)00607-3;;8805308;;8815789;;10.1146/annurev.physiol.58.1.143;;10.1146/annurev.ph.58.030196.001043;;10.1182/asheducation-2005.1.390;;16304409;;10.1038/ni1162;;15654341;;11242052;;11241997;;10.1038/35065125;;12615891;;10.1146/annurev.immunol.21.120601.141040;;pmc151021;;10.1172/jci15962;;10.1172/jci0215962;;12070296;;10085063;;10.1074/jbc.274.13.8359;;pmc1895037;;15728125;;10.1182/blood-2004-11-4564;;10.1083/jcb.152.1.65;;11149921;;pmc2193650;;10.1038/nri1747;;16493424;;12097260;;15523088;;10.1093/jnci/djh299;;7882349;;15749921;;10.4049/jimmunol.174.6.3798;;10.1371/journal.pone.0010192;;20419139;;pmc2855718;;10.1016/0092-8674(93)90326-l;;7505205;;15087402;;10.1158/0008-5472.can-03-3630;;18768149;;10.1016/j.pharmthera.2008.07.005;;pmc2668812;;17155934;;10.1042/bc20060071;;2522441;;10.1016/s0021-9258(18)83636-5;;10.4049/jimmunol.165.4.1863;;10925265;;10.1016/j.bbmt.2007.04.005;;pmc2040267;;17640595;;11222367;;10.1182/blood.v97.5.1249;;16204643;;10.1189/jlb.0305172;;902315;;10.1016/0092-8674(77)90202-1;;10.1182/blood.v97.1.63;;11133743;;pmc3350361;;10.3410/f.720026377.793531786;;10.1182/blood-2011-10-387969;;22308288;;10.1634/stemcells.2005-0620;;17038675;;pmc29329;;10.1073/pnas.98.4.1751;;11172023;;10.1038/sj.cgt.7700527;;12489023;;7665226;;10.1002/ijc.2910620511;;pmc367564;;3466023;;10.1128/mcb.6.2.716-718.1986;;10.1128/mcb.6.2.716;;19308035;;10.1038/bmt.2009.63;;15752064;;10.1371/journal.pbio.0030082;;pmc1059451;;pmc2191857;;7836930;;10.1084/jem.181.2.775;;15557192;;10.4049/jimmunol.173.11.6955;;pmc313954;;10.1093/emboj/19.13.3304;;10880443;;10.1007/s00281-004-0175-1;;15609005;;12858181;;10.1038/nbt844;;11562757;;10.3892/ijo.19.4.791;;14685154;;10.1038/sj.cgt.7700664;;pmc53910;;10.1073/pnas.87.9.3410;;2333290;;22008483;;10.1186/1756-0500-4-420;;pmc3208510;;7675046;;10.1056/nejm199510193331603;;16140431;;10.1016/j.vaccine.2005.08.023;;10.1074/jbc.m104994200;;11562359;;16528382;;10.1038/sj.cdd.4401890;;12193701;;10.4049/jimmunol.169.5.2354;;pmc362893;;2247055;;10.1128/mcb.10.12.6181-6191.1990;;10.1128/mcb.10.12.6181;;10.1126/science.2734614;;2734614;;10.1182/blood-2002-06-1688;;12393532;;7509828;;12705853;;10.1016/s1074-7613(03)00081-5;;8753752;;10.1016/s0090-4295(96)00184-7;;10.1016/0169-409x(93)90057-b;;10.1016/j.bbrc.2003.11.091;;14672702;;26052521;;pmc4448736;;10.1038/mtm.2014.53;;10.1016/s0021-9258(18)61209-8;;3558345;;10.1128/jvi.70.11.8098-8108.1996;;pmc190884;;8892935;;16490780;;10.1177/1087057105285440;;11559553;;10.1016/s0378-1119(01)00550-9;;11470520;;10.1128/iai.71.9.4961-4969.2003;;pmc187353;;12933838;;10.1038/sj.mt.6300036;;17235321;;12200351;;10.1182/blood-2002-01-0260;;pmc55213;;2175906;;10.1073/pnas.87.24.9568;;pmc2738518;;10.3201/eid0812.020224;;12498651;;15197139;;10.1161/01.cir.0000134696.08436.65;;3261386;;10.1128/mcb.8.6.2394-2401.1988;;10.1128/mcb.8.6.2394;;pmc363437;;20022954;;pmc2820784;;10.1074/jbc.m109.078113;;10.1016/s0014-5793(02)03669-4;;12459484;;16930549;;10.1016/j.bbrc.2006.07.209;;16930549;;10.1016/j.bbrc.2006.07.209;;10.1083/jcb.152.1.65;;11149921;;pmc2193650;;10.1038/mt.2009.210;;19773745;;pmc2839303;;21587213;;pmc3182363;;10.1038/mt.2011.51;;12135633;;10.1016/s0378-1135(02)00099-8;;pmc2192415;;10.1084/jem.183.1.87;;8551248;;10.1242/jcs.110.5.673;;9092949;;10.1074/jbc.m204783200;;12506111;;pmc154993;;10.1128/jvi.77.11.6197-6207.2003;;12743276;;10.1128/jvi.74.6.2628-2635.2000;;pmc111751;;10684277,"“Sipuleucel-T:APC 8015, APC-8015, prostate cancer vaccine—Dendreon.” Drugs R D. 2006;7(3):197-201.;;Adam et al., “Cross-linking of the p55 Tumor Necrosis Factor Receptor Cytoplasmic Domain by a Dimeric Ligand Induces nuclear Factor-kB and Mediates Cell Death,” The Journal of Biological Chemistry vol. 270, No. 29, Jul. 21, 1995, pp. 17482-17487.;;Addgene product literature Plasmid #15567, Feb. 22, 2016, pp. 1-4, https://www.addgene.org/15567/.;;Adema et al., “A dendritic-cell-deprived C-C chemokine that preferentially attracts naïve T cells.” Nature. Jun. 12, 1997;387(6634):713-717.;;Adema et al., “Migration of dendritic cell based cancer vaccines: in vivo veritas?” Curr Opin Immunol. Apr. 2005;17(2):170-174.;;Albert et al., “Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells.” Nat Immunol. Nov. 2001;2(11):1010-1017.;;AliPrantis et al., EMBO J. 19(13):3325-3336, 2000.;;Amara et al, “A versatile synthetic dimerizer for the regulation of protein-protein interactions.” PNAS 1997;94:10618-10623.;;Amrolia et al., “Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.” Blood. Sep. 15, 2006;108(6):1797-808.;;Amrolia et al., “Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.” Blood. Sep. 15, 2003;102(6):2292-9.;;Anasetti et al., Donor Buffy Coat Cell Infusion After Marrow Transplantation for Aplastic Anemia. Blood, 1988, 72: 1099-1100.;;Anderson et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.” Nature. Nov. 13, 1997;390(6656):175-179.;;Ando et al., “A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy” Stem Cell Reports (2015) 5:1-12.;;Andre-Schmutz et al., “Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase ½ study.” Lancet. Jul. 13, 2002;360(9327):130-7.;;Arcone et al., “Identification of sequences responsible for acute-phase induction of human C-reactive protein.” Nucleic Acids Res. Apr. 25, 1988;16(8):3195-3207.;;Ardeshna et al., “The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells.” Blood. Aug. 1, 2000;96(3):1039-1046.;;ARGENT™ Regulated Homodimerization Kit Instructions. Version 2.0 ARIAD Pharmaceuticals, Inc. Cambridge, MA. Sep. 9, 2002, p. 1-15.;;ARIAD Pharmaceuticals, Inc., “ARGENT Regulated Homodimerization Kit” Version 2.0, product brochure, Sep. 9, 2002.;;Aversa et al., “Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.” J Clin Oncol. May 20, 2005;23(15):3447-54.;;Aversa et al., “Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.” N Engl J Med. Oct. 22, 1998;339(17):1186-93.;;Banchereau et al., “Dendritic cells and the control of immunity.” Nature. Mar. 19, 1998;392(6673):245-252.;;Banchereau et al., “Dendritic cells as therapeutic vaccines against cancer.” Nat Rev Immunol. Apr. 2005;5(4):296-306.;;Banchereau et al., “Dendritic cells: controllers of the immune system and a new promise for immunotherapy.” Ann NY Acad Sci. Apr. 2003;987:180-187.;;Banchereau et al., “Immunobiology of dendritic cells.” Annu Rev Immunol. 2000; 18:767-811.;;Bander et al., “Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.” J Clin Oncol. Jul. 20, 2005;23(21):4591-601.;;Belshaw et al. (Sep. 1996). “Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization.” Chemistry & Biology. 3(9): pp. 731-738.;;Bennett et al., “Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways.” Circ Res. Aug. 1995;77(2):266-273.;;Bennett et al., “Help for cytotoxic-T-cell response is mediated by CD40 signalling.” Nature. Jun. 4, 1998;393(6684):478-480.;;Berger et al., “Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.” Blood. Feb. 15, 2004;103(4):1261-9.;;Bernard et al., “HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons.” AIDS. Nov. 12, 1998;12(16):2125-2139.;;Beutler B., “Inferences, questions and possibilities in Toll-like receptor signalling.” Nature. Jul. 8, 2004;430(6996):257-263.;;Bianco FJ, et al., “Natural History of Biochemically-Recurrent Castrate-Resistant Disease in Men treated with maximal androgen blockage for a Rising PSA after Radical Prostatectomy,” Cancer Symposium: Abstract 278, 2005.;;Bisping et al., “Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.” Blood. Mar. 1, 2006;107(5):2079-2089.;;Blau et al., “A proliferation switch for genetically modified cells.” Proc Natl Acad Sci USA. Apr. 1, 1997;94(7):3076-3081.;;Bleakley M, Riddell Sr., “Molecules and mechanisms of the graft-versus-leukaemia effect.” Nat Rev Cancer. May 2004;4(5):371-80.;;Bloom, J.D. and F.H. Arnold, In the light of directed evolution: pathways of adaptive protein evolution. Proc Natl Acad Sci U S A, 2009. 106 Suppl 1: p. 9995-10000.;;Boatright, K.M. and G.S. Salvesen, Mechanisms of Caspase activation. Curr Opin Cell Biol, 2003. 15(6): p. 725-31.;;Boatright, K.M., et al., A unified model for apical Caspase activation. Mol Cell, 2003. 11(2): p. 529-41.;;Bojak et al., “Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis.” Vaccine. May 6, 2002;20(15):1975-1979.;;Boldin et al., “Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death,” Cell vol. 85, 803-815, Jun. 14, 1996.;;Bollard CM, et al., Blood. 2002, 99:3179-3187.;;Bollard et al., “Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.” J Exp Med. Dec. 20, 2004;200(12):1623-33.;;Bonini et al., “HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.” Science. Jun. 13, 1997;276(5319):1719-24.;;Bonnert et al., GeneBank: AAC50954.1; GI: 1814020; Feb. 2, 1997.;;Boss, W.F., et al., Basal signaling regulates plant growth and development. Plant Physiol, 2010. 154(2): p. 439-43.;;Bowie et al, “Deciphering the message in protein sequences: tolerance to amino acid substitutions.” Science Mar. 1990; 247:1306-1310.;;Brady, S.C., L.A. Allan, and P.R. Clarke, Regulation of caspase-9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress. Mol Cell Biol, 2005. 25(23): p. 10543-55.;;Breitbach et al., “Potential risks of bone marrow cell transplantation into infarcted hearts.” Blood. Aug. 15, 2007;110(4):1362-9.;;Brentjens RJ, Davila ML, Riviere I, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38, 2013.;;Burns et al., J. Exp. Med 197(2):263-268, 2003.;;Cardone, M.H., et al., Regulation of cell death protease caspase-9 by phosphorylation. Science, 1998. 282(5392): p. 1318-21.;;Carpenito C, Milone MC, Hassan R, et al: Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106:3360-5, 2009.;;Carter et al., “Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.” Proc Natl Acad Sci U S A. Jan. 23, 1996;93(2):749-53.;;Caux et al., “CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha.” Adv Exp Med Biol. 1997;417:21-25.;;Caux et al., “In vitro regulation of development and function of dendritic cells.” Hematol Cell Ther. Oct. 1996;38(5):463.;;Cazeaux et al., “Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter.” Vaccine. Sep. 10, 2002;20(27-28):3322-31.;;Chamberlain et al., “Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing.” Stem Cells. Nov. 2007;25(11):2739-49.;;Chan et al., “A Domain in TNF Receptors that mediates ligand-independent receptor assembly and signaling,” Science 288, 2351-2354, (2001).;;Chan, Francis Ka-Ming, “Three is Better Than One: Pre-Ligand Receptor Assembly in the Regulation of TNF Receptor Signaling,” Cytokine, Feb. 2007; 37(2) 101-107.;;Chang et al., “Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.” Urology. Apr. 2001;57(4):801-5.;;Chang et al., “Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model.” Circulation. Apr. 18, 2006;113(15):1832-41.;;Chang et al., “Prostate-specific membrane antigen is produced in tumor-associated neovasculature.” Clin Cancer Res. Oct. 1999;5(10):2674-81.;;Chang, W.C., et al., Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor. PLoS One, 2007. 2(12): p. e1317.;;Chao et al., “Engineering a dimeric caspase-9: a re-evaluation of the induced proximity model for caspase activation” PLoS Biology (2005) 3(6):e183.;;Chao, Y., et al., Engineering a dimeric Caspase-9: a re-evaluation of the induced proximity model for Caspase activation. PLoS Biol, 2005. 3(6): p. e183. 1079-1087.;;Chatterjee et al., “Strategies for efficient gene transfer into hematopoietic cells. The use of adeno-associated virus vectors in gene therapy.” Ann NY Acad Sci. Dec. 29, 1995;770:79-90.;;Chen C, Okayama H., “High-efficiency transformation of mammalian cells by plasmid DNA.” Mol Cell Biol. Aug. 1987;7(8):2745-2752.;;Chen et al., “A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.” Proc Natl Acad Sci USA. Mar. 4, 1997;94(5):1914-1918.;;Cheung et al., “Plasmid encoding papillomavirus Type 16 (HPV16) DNA construced with codon optimization improved the immunogenicity against HPV infection.” Vaccine. Dec. 16, 2004;23(5):629-638.;;Chiodoni et ai, “Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating factor (GM-CSF) and CD40 Ligand Genes Take Up and Present Endo- genous Tumor-Associated Antigens, and Prime Naive Mice fora Cytotoxic T Lymphocyte Response,” J. Exp. Med. vol. 190, No. 1, Jul. 5, 1999. pp. 125-133.;;Choe et al., “Crystal structure of human toll-like receptor 3 (TLR3) ectodomain” Science. Jul. 22, 2005;309(5734):581-585.;;Christiansen et al., “N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.” Mol Cancer Ther. May 2005;4(5):704-14.;;Ciceri, F., et al., “Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study,” Lancet Oncol. 2009, vol. 10, No. 5, pp. 489-500.;;Cisco et al., “Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4.” J Immunol. Jun. 1, 2004;172(11):7162-7168.;;Clackson et al., “Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.” Proc Natl Acad Sci USA. Sep. 1, 1998;95(18):10437-10442.;;Clackson T., “Dissecting the functions of proteins and pathways using chemically induced dimerization.” Chem Biol Drug Des. Jun. 2006;67(6):440-442.;;Clackson, T. , “Controlling Protein-Protein interactions Using Chemical inducers and Disrupters of Dimerization” Chapter 4.2, pp. 227-249 in Chemical Biology: From Small Molecules to Systems Biology and Drug Design (Schreiber, s., et al., eds., Wiley, 2007)).;;Clarke et al., “Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.” J Clin Oncol. Aug. 10, 2009;27(23):3861-7.;;Clarke Sr., “The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity.” J Leukoc Biol. May 2000;67(5):607-614.;;Clarke, S.J., et al., “A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer ,” 2009, J. Clin. Oncol. 27:15s (suppl.; abstr. 3025).;;Coffin “Molecular Mechanisms of Nucleic Acid Integration,” Journal of Mecical Virology, 31:43-19 (1990).;;Cohen et al., “Nucleotide sequence of the cDNA encoding human tyrosinase-related protein.” Nucleic Acids Res. May 11, 1990;18(9):2807-2808.;;Contin et al., “Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling.” J Biol Chem. Aug. 29, 2003;278(35):32801-32809.;;Coupar et al., “A general methods for the construction of recombinant vaccinia viruses expressing multiple foreign genes.” Gene. Aug. 15, 1988;68(1):1-10.;;Cranmer et al., “Clinical applications of dendritic cell vaccination in the treatment of cancer.” Cancer Immunol Immunother. Apr. 2004;54(4):275-306.;;Crawford et al., “A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.” N Engl J Med. Aug. 17, 1989;321(7):419-424, w/, erratum N Engl J Med Nov. 16, 1989;321(20):1420.;;Cremer et al., “Long-lived immature dendritic cells mediated by TRANCE-RANK interaction.” Blood. Nov. 15, 2002;100(10):3646-3655.;;Cristofanilli et al., “Circulating tumor cells, disease progression, and survival in metastatic breast cancer.” N Engl J Med. Aug. 19, 2004;351(8):781-91.;;Cyster JG., “Chemokines and cell migration in secondary lymphoid organs.” Science. Dec. 10, 1999;286(5447):2098-2102.;;Dallal RM, Lotze MT., “The dendritic cell and human cancer vaccines.” Curr Opin Immunol. Oct. 2000;12(5):583-588.;;Davis et al., “Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.” Proc Natl Acad Sci USA. Apr. 26, 2005;102(17):5981-5986.;;De Becker et al., “The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells.” Int Immunol. Jun. 2000;12(6):807-815.;;de Gruijl et al, “Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors,” The Journal of Immunology vol. 169,2002 PQS 5322-5331.;;de la Thille et al., “Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion.” Cancer Detect Prev. 2000;24(6):579-88.;;De Vries et al., “Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.” Cancer Res. Jan. 1, 2003;63(1):12-17.;;de Witte et al., “An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease.” J Immunol. May 1, 2008;180(9):6365-73.;;Deml et al. “Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein,” 2001. J. Virol. 75:10991-11001.;;Denault et al., “Caspase 3 attenuates XIAP(X-linked inhibitor of apoptosis protein)-mediated inhibition of Caspase 9” Biochem. J. (2007) 11-19.;;Deonarain, “Ligand-targeted receptor-mediated vectors for gene delivery,” 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.;;Dey BR, Spitzer TR., “Current status of haploidentical stem cell transplantation.” Br J Haematol. Nov. 2006;135(4):423-37.;;Di Stasi, A., et al., Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med, 2011. 365(18): p. 1673-83.;;Diehl et al., “CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.” Nat Med. Jul. 1999;5(7):774-779.;;Dominici et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.” Cytotherapy. 2006;8(4):315-7.;;Donnelly et al., “DNA vaccines.” Annu Rev Immunol. 1997;15:617-48.;;Dudley et al., “Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastic melanoma.” J Clin Oncol. Apr. 1, 2005;23(10):2346-2357.;;Dudley et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.” Science. Oct. 25, 2002;298(5594):850-4.;;Elgueta et al., “Molecular mechanism and function of CD40/CD40L engagement in the immune system,” Immunological Reviews, 229, (2009) 152-172.;;Evel-Kabler et al., “SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.” J Clin Invest. Jan. 2006;116(1):90-100.;;Fan et al., “Improved artificial death switches based on caspases and FADD.” Hum Gene Ther. Sep. 20, 1999;10(14):2273-2285.;;Farrar et al., “Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization,” Nature Sep. 12, 1996;383(6596):178-181.;;Fearon et al., “The instructive role of innate immunity in the acquired immune response,” Science, Apr. 5, 1996;272(5258):50-53.;;Fechheimer et al., “Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading.” Proc Natl Acad Sci USA. Dec. 1987;84(23):8463-8467.;;Fernandez et al., “Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.” Nat Med. Apr. 1999;5(4):405-411.;;Ferrari et al., “Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.” J Virol. May 1996;70(5):3227-3234.;;Ferraro, B. et al., Human Vaccines 7:120-127 (2011).;;Finney HM, Akbar AN, Lawson AD: Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172:104-13, 2004.;;Fisher et al., “Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.” J Virol. Jan. 1996;70(1):520-532.;;Flotte et al., “Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.” Proc Natl Acad Sci USA. Nov. 15, 1993;90(22)10613-10617.;;Flotte TR, Carter BJ. “Adeno-associated virus vectors for gene therapy.” Gene Ther. Aug. 1995;2(6):357-362.;;Flotte, “Prospects for Virus-Based Gene Therapy for Cystic Fibrosis,” Journal of Bioenergetics and Bioinformatics, vol. 25, No. 1, 1993.;;Freeman et al., “The role of (111)in Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer.” Q J Nucl Med. Jun. 2002;46(2):131-7.;;Freytag et al., “Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.” Cancer Res. Sep. 1, 2002;62(17):4968-76.;;Fujio Y, Walsh K., “Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner.” J Biol Chem. Jun. 4, 1999;274(23):16349-16354.;;Galbiati et al., “N-terminal fatty acylation of the alpha-subunit of the G-protein Gi1: only the myristoylated protein is a substrate for palmitoylation.” Biochem J. Nov. 1, 1994;303(Pt 3):697-700.;;Gaubert, G.; Wengel, J. Tetrahedron Letters 2004, 45, 5629.;;Gauthier-Campbell et al., “Regulation of dendritic branching and pilopodia formation in hippocampal neurons by specific acylated protein motifs.” Mol Biol Cell. May 2004;15(5):2205-2217.;;Gefter et al., “A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells.” Somatic Cell Genet. Mar. 1977;3(2):231-236.;;GenBank Accession No. M29540, Nov. 1, 1994.;;Gestwicki JE, Marinec PS., Chemical control over protein-protein interactions: beyond inhibitors. Comb Chem High Throughput Screen. Sep. 2007;10(8):667-675.;;Ghetie et al., “The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.” J Immunol Methods. Sep. 13, 1991;142(2):223-30.;;Gilboa E, Vieweg J., “Cancer immunotherapy with mRNA-transfected dendritic cells.” Immunol Rev. Jun. 2004;199:251-263.;;Gilboa E., “The promise of cancer vaccines.” Nat Rev Cancer. May 2004;4(5):401-411.;;Gittes RF., “Carcinoma of the prostate.” N Engl J Med. Jan. 24, 1991;324(4):236-245.;;Goodman et al., “Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells.” Blood. Sep. 1, 1994;84(5):1492-1500.;;Goodwin et al., “Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell.” J Exp Med. Dec. 1, 1977;146(6):1719-1734.;;Goodwin JS., “Immunomodulation by eicosanoids and anti-anflammatory drugs.” Curr Opin Immunol. Dec. 1989;2(2):264-268.;;Gopal TV., “Gene transfer method for transient gene expression, stable transformation, and cotransformation of suspension cell cultures.” Mol Cell Biol. May 1985;5(5):1188-1190.;;Gossen et al., “Transcriptional activation by tetracyclines in mammalian cells.” Science. Jun. 23, 1995;268(5218):1766-1769.;;Gossen M, Bujard H., “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.” Proc Natil Acad Sci USA. Jun. 15, 1992;89(12):5547-5551.;;Gottschalk et al., “Post-transplant lymphoproliferative disorders.” Annu Rev Med. 2005;56:29-44.;;Graham FL, van der Eb AJ., “A new technique for the assay of infectivity of human adenovirus 5 DNA.” Virology. Apr. 1973;52(2):456-467.;;Granucci et al., “Eerly events in dendritic cell maturation induced by LPS.” Microbes Infect. Nov. 1999;1(13):1079-1084.;;Granucci et al., “Inducible IL-2 production by dendritic cells revealed by global gene expression analysis.” Nat Immunol. Sep. 2001;2(9):882-888.;;Granucci et al., “Modulation of cytokine expression in mouse dendritic cell clones.” Eur J Immunol. Oct. 1994;24(10):2522-2526.;;Grewal IS, Flavell RA., “CD40 and CD154 in cell-mediated immunity.” Annu Rev Immunol. 1998;16:111-135.;;Gross, G., and Eshar, Z., FASEB Journal 6:3370-3378 (1992).;;Guedan S, Chen X, Madar A, et al: ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood, 2014.;;Haase et al., “Generation of induced pluripotent stem cells from human cord blood” Cell Stem Cell (2009) 5:434-441.;;Hall et al., “Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.” Int J Hematol. Jul. 2007;86(1):8-16.;;Hammad et al., “Monocyte-derived dendritic cells induce a house dust mite-specific Th2 allergic inflammation in the lung of humanized SCID mice:involvement of CCR7.” J Immunol. Aug. 1, 2002;169(3):1524-1534.;;Hanks B.A., et al.. “Re-engIneered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo” Nature Medicine, vol. 11, No. 2. 2005 pp. 130-137.;;Harbury et al., “Crystal structure of an isoleucine-zipper trimer,” Nature, vol. 371, Sep. 1, 1994, 80-83.;;Hauer et al., “TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an Inhibitor of TRAF2 5-mediated activation of the noncanonical NF—B pathway by TRAF-binding TNFRs.” PNAS, vol. 102, No. 8, Feb. 22, 2005; pp. 2874-2879.;;Hay et al., “Replication of Adenovirus Mini-Chromasomes,” J. Mol. Biol. (1984) 175, 493-510.;;Haynes, N.M., et al. J. Immunol. 166:182-7 (2001).;;He et al., “A simplified system for generating recombinant adenoviruses.” Proc Natl Acad Sci USA. Mar. 3, 1998;95(5):2509-2514.;;Hearing et al., “Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome.” J Virol. Aug. 1987;61(8):2555-2558.;;Hearing P, Shenk T., “Functional analysis of the nucleotide sequence surrounding the cap site for adenovirus type 5 region E1A messenger RNAs.” J Mol Biol. Jul. 15, 1983;167(4):809-822.;;Hermans et al., “CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.” J Immunol. Mar. 15, 2000;164(6):3095-3101.;;Heslop, H.E., Blood 122:853-854 (2013).;;Ho et al., “Dimeric ligands define a role for transcriptional activation domains in reinitiation.” Nature. Aug. 29, 1996;382(6594):822-826.;;Hodge et al., “Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity,” Cancer Detect Prevent 2002; 26;275-291.;;Holler et al., “Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors,” Journal of Immunologial Methods 237(2000) 159-173.;;Hollstein et al., “Database of p53 gene somatic mutations in human tumors and cell lines.” Nucleic Acids Ress. Sep. 1994;22(17):3551-3555.;;Holsinger et al., “Signal transduction in T lymphocytes using a conditional allele of Sos.” Proc Natl Acad Sci USA. Oct. 10, 1995;92(21):9810-9814.;;Hong, T., et al., A simple theoretical framework for understanding heterogeneous differentiation of CD4+ T cells. BMC Syst Biol, 2012. 6: p. 66.;;Horng et al., PNAS 98(22):12654-12658, 2001.;;Horwitz et al., “Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.” Biol Blood Marrow Transplant. Dec. 2007;13(12):1422-6.;;Horwitz et al., “Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone.” Proc Natl Acad Sci U S A. Jun. 25, 2002;99(13):8932-7.;;Horwitz et al., “Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.” Nat Med. Mar. 1999;5(3):309-13.;;Horwitz, E. M., et al., (2007). Biol Blood Marrow Transplant 13: 53-57.;;Hoshino et al., “Cutting edge:Toll-like receptor 4(TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.” J Immunol. Apr. 1, 1999;162(7):3749-3752.;;Hostager et al., J. Immunol. 157:1047-1053 1996.;;Hou WS, Van Parijs L., “A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells.” Nat Immunol. Jun. 2004;5(6):583-589.;;Hsiao, E.C., et al., Constitutive Gs activation using a single-construct tetracycline-inducible expression system in embryonic stem cells and mice. Stem Cell Res Ther, 2011. 2(2): p. 11.;;Huang et al., “Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.” Haematologica. Mar. 2007;92(3):414-7.;;Huang et al., “Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia.” J Clin Immunol. May 2008;28(3):276-83.;;Hurley et al., “National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants.” Biol Blood Marrow Transplant. Oct. 2003;9(10):610-5.;;Introna et al., “Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies.” Hum Gene Ther. Mar 1, 2000;11(4):611-20.;;Ismaili et al., “Monophosphoryl lipid A activates both human dendritic cells and T cells.” J Immunol. Jan. 15, 2002;168(2):926-932.;;Israeli et al., “Expression of the prostate-specific membrane antigen.” Cancer Res. Apr. 1, 1994;54(7):1807-11.;;Israeli et al., “Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.” Cancer Res. Dec. 15, 1994;54(24):6306-10.;;Israeli et al., Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. Jan. 15, 1993;53(2):227-230.;;Iuliucci et al., “Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers.” J Clin Pharmacol. Aug. 2001;41(8):870-9.;;Jackson et al., “A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus.” EMBO J. Feb. 1992;11(2):527-535.;;Jacquot et al, “CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling,” J Immunol 1997; 159: 2652-2657.;;Janeway et al., “Approaching the asymptote? Evolution and revolution in immunology.” Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:1-13.;;Jemal et al., “Cancer statastics, 2008.” CA Cancer J Clin. Mar.-Apr. 2008;58(2):71-96.;;Jonuleit et al., Eur. J. Immunol 27:3135-3142, 1997.;;Josien et al., “TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo.” J Exp Med. Feb. 7, 2000;191(3):495-502.;;Junker et al., “Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes.” Gene Ther. Jul. 2003;10(14):1189-97.;;Kadowaki N. et al., “Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens,” J Exp Med. 2001, vol. 194, pp. 863-869.;;Kagan JC, Medzhitov R., “Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling.” Cell. Jun. 2, 2006;125(5):943-955.;;Kageyama et al., “Differing utilization of homologous transcription initiation sites of rat K and T kininogen genes under inflammation condition.” J Biol Chem. Feb. 15, 1987;262(5):2345-2351.;;Kalams et al., “The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses.” J Exp Med. Dec. 21, 1998;188(12):2199-2204.;;Kalinski et al., “Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses.” Adv Exp Med Biol. 1997;417:363-367.;;Kalinski et al., “Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer.” Blood. Jun. 1, 2001;97(11):3466-3469.;;Kalos M, Levine BL, Porter DL, et al: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73, 2011.;;Kandel ES, Hay N., “The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB.” Exp Cell Res. Nov. 25, 1999;253(1):210-229.;;Kanto et al., “Ceramide mediates tumor-induced dendritic cell apoptosis.” J Immunol. Oct. 1, 2001;167(7):3773-3784.;;Kantoff et al., “Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.” J Clin Oncol. Mar. 1, 2010;28(7):1099-105.;;Kantoff et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer.” N Engl J Med. Jul. 29, 2010;363(5):411-22.;;Kaplitt et al., “Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.” Nat Genet. Oct. 1994;8(2):148-154.;;Kaplitt et al., “Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector.” Ann Thorac Surg. Dec. 1996;62(6):1669-76.;;Kawakami et al., “Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.” Proc Natl Acad Sci USA. Jul. 5, 1994;91(14):6458-6462. et al.",ACTIVE
625,TW,U,TW M414724 U,124-994-275-921-299,2011-10-21,2011,TW 99224663 U,2010-12-20,TW 99224663 U,2010-12-20,Cable connector and complementary connector assembly,"A cable connector (100) is adapted for mating a complementary con-nector assembly conveniently. The cable connector (100) includes a first connector (1), a second connector (2), a shielding member (3) and a cable (4). The first connector (1) and the second connector (2) are disposed in juxtaposed manner. The first connector (1) and the second connector (2) held by the shielding member (3), and the first connector (1) is movable with respect to the shielding member (3).",HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,,https://lens.org/124-994-275-921-299,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
626,US,A,US 4839404 A,146-022-056-931-851,1989-06-13,1989,US 88966486 A,1986-07-28,US 88966486 A,1986-07-28,Bituminous compositions having high adhesive properties,"A composition useful as a pavement material comprising a mixture of asphalt, aggregate and an interpolymer of an .alpha.-olefin monomer selected from the group consisting of an .alpha.,.beta.-ethylenically unsaturated carboxylic acid or an ionomer of an .alpha.,.beta.-ethylenically unsaturated carboxylic acid.",DOW CHEMICAL CO,CHANG DANE;;WOLFE DAVID L,DOW CHEMICAL COMPANY THE (1986-07-16),https://lens.org/146-022-056-931-851,Granted Patent,yes,9,23,1,20,0,C08L95/00;;C08L95/00,C08L95/00,524/69;;524/70;;524/71;;524/68,0,0,,,,EXPIRED
627,US,A1,US 2018/0146789 A1,052-517-038-122-977,2018-05-31,2018,US 201615362324 A,2016-11-28,US 201615362324 A,2016-11-28,LEANING CHAIR,"A leaning chair can include a base defining a lower surface that rests on a floor, the base including a support surface; a shaft coupled to the base, the shaft defining a first end and a second end; a flexible mount coupling the first end of the shaft to the base, the shaft extending through the mount; a pivot pin located underneath the mount, the first end of the shaft resting on the pivot pin, and being configured to be housed inside the mount, the pivot pin being configured to pivot on the support surface; and a user support member coupled to the second end of the shaft.",VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,VARIDESK LLC (2016-12-05),https://lens.org/052-517-038-122-977,Patent Application,yes,0,1,3,3,0,A47C7/004;;A47C3/18;;A47C3/28;;A47C3/40;;A47C7/004;;A47C3/18;;A47C3/40;;A47C3/28;;A47C3/20;;A47C7/00;;A47C7/025;;A47C9/025;;F16C11/04;;F16C2314/70,A47C9/02;;A47C3/20;;A47C7/00;;A47C7/02;;F16C11/04,,0,0,,,,ACTIVE
628,US,A1,US 2016/0156221 A1,066-197-607-478-913,2016-06-02,2016,US 201514956734 A,2015-12-02,US 201514956734 A;;US 201213667625 A;;US 28471208 A,2008-09-23,INTERCONNECTING SOLAR RECHARGEABLE BATTERIES,"Portable stackable solar batteries are disclosed, in which the solar batteries can be connected in a planar arrangement for solar recharging and connected in a vertically stacked arrangement for powering an electrically powered device and/or for charging another rechargeable battery.",SOLARLEGO INC,CHANG DAVID;;COATES STEPHEN S,,https://lens.org/066-197-607-478-913,Patent Application,yes,0,0,5,5,0,H01M10/465;;H01M14/005;;H01M10/4207;;Y02E10/56;;Y02E60/10;;H01M10/465;;H01M14/005;;H01M10/4207;;H02J7/35;;H02J7/0045;;H02J7/0014,H02J7/35;;H02J7/00,,0,0,,,,ACTIVE
629,US,A,US 5164608 A,074-187-994-030-801,1992-11-17,1992,US 72258791 A,1991-06-27,US 72258791 A,1991-06-27,Plural wavelength fiber optic liquid level sensor for multiple liquids,"A fiber optic liquid level sensor for measuring the level of multiple immiscible liquids in a container (20). An end of an optical fiber (24) is immersed in the liquids in the container (20). Light is injected into the other end of the fiber. The ratio of transmitted to the reflected light is dependent on the evanescent mode losses to the liquids in the container. The levels of the liquids are derived from the losses, since the absorption per unit length of the fiber is different for each liquid. The relative amounts of liquids in the container are obtained from the amount of absorption.",HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,HUGHES AIRCRAFT COMPANY A DE CORPORATION (1991-06-27),https://lens.org/074-187-994-030-801,Granted Patent,yes,6,38,1,1,0,G01F23/292;;G01F23/292,G01F23/292,250/577;;250/227.23;;250/227.25,0,0,,,,EXPIRED
630,US,B1,US 7024569 B1,077-766-692-969-384,2006-04-04,2006,US 25443302 A,2002-09-24,US 25443302 A,2002-09-24,Method and apparatus for supplying auxiliary power to a bus coupled peripheral,"A method and apparatus for supplying auxiliary power to a peripheral is disclosed. The method includes supplying power from a first USB port of a host device to an input USB port of a USB hub device, supplying power through a downstream USB port of the USB hub device for use by a downstream USB device, supplying auxiliary power through a power output port of the USB hub device for use by a peripheral device that is coupled to an upstream port and supplying power from a second USB port of the host device to the peripheral device. The power received by the peripheral device is sufficient for its operation.",CYPRESS SEMICONDUCTOR CORP,WRIGHT DAVID G;;CHANG JEFF,QUILSTRAM SET II L.L.C (2010-06-22);;INTELLECTUAL VENTURES II LLC (2013-12-19);;CYPRESS SEMICONDUCTOR CORPORATION (2002-09-16),https://lens.org/077-766-692-969-384,Granted Patent,yes,11,49,1,1,0,G06F1/266;;G06F1/266,G06F13/14,713/300;;713/320;;713/321;;713/322;;713/323;;713/324,0,0,,,,EXPIRED
631,EP,A2,EP 2967081 A2,098-688-299-829-757,2016-01-20,2016,EP 14778378 A,2014-03-07,US 201313792135 A;;US 2014/0022004 W,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,,BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/098-688-299-829-757,Patent Application,yes,0,0,17,17,155,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,A01N65/00;;A61K31/4545;;C12N5/00;;C12N9/64;;C12P21/00,,0,0,,,,ACTIVE
632,NO,B,NO 168776 B,123-115-835-754-370,1991-12-23,1991,NO 873764 A,1987-09-09,US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BLANDINGER AV BITUMINOESE MATERIALER OG OLEFIN-KOPOLYMERER,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/123-115-835-754-370,Unknown,no,0,0,4,20,0,,C08L23/08;;C08L95/00,,0,0,,,,EXPIRED
633,US,A1,US 2012/0113573 A1,146-269-031-468-607,2012-05-10,2012,US 201113290151 A,2011-11-07,CN 201010533124 A,2010-11-05,CABLE ASSEMBLY ADAPTED FOR POWER AND SIGNAL TRANSMITTING,"A cable assembly ( 100 ) includes at least one connector ( 1 ) for transmitting power signal or optical signal; a cover ( 3 ) holding the connector; a cable electrically or optically connected with the connector; and a switch device ( 5 ) located inside the cover, the switch device includes a switch member, a LED, and a button partially exposed outward of the cover; wherein when the button is pressed to actuate the switch member and the LED is lighted to emit light through the button.",KO DAVID;;LI CHANG-MAO;;HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,HON HAI PRECISION INDUSTRY CO. LTD (2011-10-27),https://lens.org/146-269-031-468-607,Patent Application,yes,11,8,2,2,0,H01R13/641;;H01R13/70;;H01R13/7175;;H01R13/641;;H01R13/70;;H01R13/7175,H05K7/00;;H01R3/00,361/679.01;;439/489,0,0,,,,DISCONTINUED
634,EP,A1,EP 3564180 A1,167-439-749-975-633,2019-11-06,2019,EP 19172602 A,2019-05-03,US 201815971211 A,2018-05-04,COATED SHEAVE,An elevator sheave (28) includes a sheave body (28) and a coating (31) on a surface of the sheave body (28). The coating (31) includes microcracks (34) and a filler (33) in the microcracks (34). A method of making a sheave (28) for an elevator system is also disclosed.,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,,https://lens.org/167-439-749-975-633,Patent Application,yes,5,0,7,7,0,B66B7/02;;B66B15/04;;B66B15/04;;C09D191/06;;C25D3/04,B66B15/04,,0,0,,,,ACTIVE
635,US,B1,US 5043299 B1,004-738-161-800-276,1997-02-25,1997,US 44448589 A,1989-12-01,US 44448589 A,1989-12-01,Process for selective deposition of tungsten on semiconductor wafer,,APPLIED MATERIALS INC,CHANG MEI;;WANG DAVID N,APPLIED MATERIALS INC. A DE CORP (1990-01-17),https://lens.org/004-738-161-800-276,Granted Patent,no,0,1,8,8,0,H01L21/28562;;H01L21/76879;;Y10S148/051;;Y10S438/906;;Y10S438/908;;H01L21/285;;H01L21/76879;;H01L21/28562;;Y10S438/906;;Y10S438/908;;Y10S148/051,C23C16/02;;C23C16/04;;C23C16/06;;C23C16/54;;H01L21/28;;H01L21/285;;H01L21/768,43/719.2,0,0,,,,EXPIRED
636,WO,A3,WO 2003/089651 A3,028-021-889-019-063,2005-09-01,2005,US 0311508 W,2003-04-14,US 37243702 P;;US 41201103 A,2002-04-16,ASSAY FOR QUANTITATING SECRETED ANTIBODIES IN LYMPHOCYTES SUPERNATANT,The present invention provides methods of quantitating recent secreted antigen specific antibodies from supernatant of antibody secreting cells (ASC) in vitro culture for evaluation of vaccine or antigen induced antigen specific antibody secretion without ex vivo antigen stimulation.,CHANG HUI SUNNY;;SACK DAVID,CHANG HUI SUNNY;;SACK DAVID,,https://lens.org/028-021-889-019-063,Search Report,yes,4,0,7,7,0,C07K16/1239;;Y10S530/866;;Y10S530/862;;Y10S530/863;;Y10S530/861;;G01N33/5091;;C07K16/1239;;Y10S530/862;;Y10S530/866;;Y10S530/861;;Y10S530/863;;G01N33/5091;;G01N33/6854,C07K16/12;;G01N33/50,,0,0,,,,PENDING
637,US,A1,US 2019/0045920 A1,038-610-800-926-23X,2019-02-14,2019,US 201715672022 A,2017-08-08,US 201715672022 A,2017-08-08,ADJUSTABLE HEIGHT TABLE,"A table having a table top having an upper surface and a lower surface. The table further having a first and second guide track located on the lower surface. A first leg is pivotally connected to a second leg, the first leg comprising a first slide adapted to slidably engage the first guide track, and the second leg comprising a second slide adapted to slidably engage the second guide track. The table further includes a first retainer adapted to engage the first slide and the first guide track to prevent sliding of the first slide with respect to the first guide track, and a second retainer adapted to engage the second slide and the second guide track to prevent sliding of the second slide with respect to the second guide track. The table may be an adjustable height table. Other features of the table are also described.",VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,VARIDESK LLC (2017-08-10),https://lens.org/038-610-800-926-23X,Patent Application,yes,0,2,3,3,0,A47B87/002;;A47B9/16;;A47B87/002;;A47B9/14;;A47B9/16,A47B9/14;;A47B9/16,,0,0,,,,INACTIVE
638,EP,A2,EP 3114615 A2,033-752-887-134-180,2017-01-11,2017,EP 15710343 A,2015-02-25,US 201461947149 P;;US 201414268372 A;;US 2015/0017454 W,2014-03-03,NEURAL NETWORK ADAPTATION TO CURRENT COMPUTATIONAL RESOURCES,,QUALCOMM INC,JULIAN DAVID JONATHAN;;CHANG ILWOO,,https://lens.org/033-752-887-134-180,Patent Application,yes,0,0,8,8,0,G06N3/082;;G06N3/048;;G06N3/082;;G06N3/048;;G06N3/048;;G06N3/082,G06N3/08;;G06N3/04,,0,0,,,,DISCONTINUED
639,US,A,US 3095463 A,042-493-546-299-457,1963-06-25,1963,US 72100358 A,1958-03-12,US 72100358 A,1958-03-12,Temperature control apparatus,,CRUCIBLE STEEL CO AMERICA,CHANG MELVIN C;;DAVID GOLDSTEIN,,https://lens.org/042-493-546-299-457,Granted Patent,no,6,18,1,1,0,C23G1/02;;D06B23/22;;G05D9/12;;G05D23/00;;Y10T137/2534;;Y10T137/7368;;Y10T137/2534;;Y10T137/7368;;G05D23/00;;C23G1/02;;G05D9/12;;D06B23/22,C23G1/02;;D06B23/22;;G05D9/12;;G05D23/00,,0,0,,,,EXPIRED
640,US,A,US 3636838 A,056-851-270-982-858,1972-01-25,1972,US 3636838D A,1969-04-04,US 81344669 A,1969-04-04,BEAM MOTION COMPENSATION IN OPTICAL IMAGE TRANSFER SYSTEMS HAVING MOVING PARTS,,IBM,CHANG DAVID C;;LIPP JAMES,,https://lens.org/056-851-270-982-858,Granted Patent,no,0,19,6,6,0,B23K26/08;;G02B26/127;;G02B27/0025;;G02B27/0031;;H04N3/08;;B23K2101/007;;H04N3/08;;G02B27/0031;;G02B26/127;;B23K26/08;;G02B27/0025;;B23K2101/007,B23K26/08;;G02B26/12;;G02B27/00;;H04N3/08,95/4.5;;352/113;;340/378,0,0,,,,EXPIRED
641,WO,A2,WO 2015/134244 A2,069-245-877-409-830,2015-09-11,2015,US 2015/0017454 W,2015-02-25,US 201461947149 P;;US 201414268372 A,2014-03-03,NEURAL NETWORK ADAPTATION TO CURRENT COMPUTATIONAL RESOURCES,"Methods and apparatus are provided for processing in an artificial nervous system. According to certain aspects, resolution of one or more functions performed by processing units of a neuron model may be reduced, based at least in part on availability of computational resources or a power target or budget. The reduction in resolution may be compensated for by adjusting one or more network weights.",QUALCOMM INC,JULIAN DAVID JONATHAN;;CHANG ILWOO,,https://lens.org/069-245-877-409-830,Patent Application,yes,0,1,8,8,0,G06N3/082;;G06N3/048;;G06N3/082;;G06N3/048;;G06N3/048;;G06N3/082,,,0,0,,,,PENDING
642,WO,A3,WO 2014/164348 A3,083-366-481-919-058,2015-03-05,2015,US 2014/0022004 W,2014-03-07,US 201313792135 A,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,"The technology relates in part to compositions comprising modified caspase-9 polypeptides, compositions comprising nucleic acids coding for modified caspase-9 polypeptides, chimeric modified caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/083-366-481-919-058,Search Report,yes,2,0,17,17,0,A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008;;A61P1/04;;A61P17/00;;A61P19/08;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P5/00;;A61P7/00;;A61P7/06;;A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008,A01N65/00;;C12N5/00;;C12P21/00,,3,3,034-955-588-990-231;;039-931-356-007-897;;088-994-457-887-198,10.1128/mcb.25.23.10543-10555.2005;;pmc1291226;;16287866;;10.1042/bj20070288;;pmc1925235;;17437405;;pmc1088972;;10.1371/journal.pbio.0030183;;15941357,"BRADY ET AL.: ""Regulation of Caspase 9 through Phosphorylation by Protein Kinase C Zeta in Response to Hyperosmotic Stress"", MOLECULAR AND CELLULAR BIOLOGY, vol. 25, no. 23, 1 December 2005 (2005-12-01), pages 10543 - 10555, XP055293374, DOI: 10.1128/MCB.25.23.10543-10555.2005;;DENAULT ET AL.: ""Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9"", BIOCHEM. J., vol. 405, no. 1, 1 July 2007 (2007-07-01), pages 11 - 19, XP055293379, DOI: 10.1042/BJ20070288;;CHAO ET AL.: ""Engineering a Dimeric Caspase-9: A Re-evaluation of the Induced Proximity Model for Caspase Activation"", PLOS BIOL, vol. 3, no. 6, 1 June 2005 (2005-06-01), pages 1 - 9, XP055250949, DOI: 10.1371/JOURNAL.PBIO.0030183",PENDING
643,EP,A1,EP 0520653 A1,086-500-847-927-33X,1992-12-30,1992,EP 92305399 A,1992-06-12,US 72456591 A,1991-06-27,Low index of refraction optical fiber.,"An optical fiber having an index of refraction less than that conventionally available. The low index of refraction fiber 10 of the present invention includes a fiber core 20 of a first index of refraction. The fiber core 20 circumscribes a longitudinal axis, and is surrounded by a cladding layer 30 having a second index of refraction less than the first index of refraction. Included within the cladding layer 30 are a plurality of tube structures 40 arranged about the fiber core 20. The tube structures 40 create a plurality of channels 42 within the cladding layer 30, thereby engendering a low index of refraction therein.",HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/086-500-847-927-33X,Patent Application,yes,5,11,3,3,0,G01D5/268;;G02B6/02338;;G02B6/02347;;G02B6/02338;;G02B6/02347;;G01D5/268,G01N21/27;;G01D5/26;;G02B6/00;;G02B6/02;;G02B6/036,,0,0,,,,DISCONTINUED
644,EP,A1,EP 3440958 A1,094-454-782-613-940,2019-02-13,2019,EP 18186011 A,2018-07-27,US 201762538411 P,2017-07-28,MOTORIZED ADJUSTABLE HEIGHT TABLE,"A table includes a table top having a frame attached to a lower surface of the table top. The table also includes a first leg having lugs and a second leg having lugs. The lugs of the first leg and the second leg are received in slots of the frame to attach the legs to the table. The legs are telescopically movable to adjust the height of the table top.
",VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,,https://lens.org/094-454-782-613-940,Patent Application,yes,4,2,6,6,0,A47B3/06;;A47B13/021;;A47B13/023;;F16B12/52;;A47B9/20;;A47B2200/0059;;A47B13/003;;A47B9/20;;A47B2200/0059;;A47B2200/0057;;A47B13/003;;A47B13/021;;A47B3/06;;A47B13/023;;F16B12/52,A47B3/06;;A47B9/20;;A47B13/02;;F16B12/52,,0,0,,,,ACTIVE
645,CA,A1,CA 2459555 A1,089-513-596-285-88X,2004-02-12,2004,CA 2459555 A,2003-07-11,US 21111002 A;;US 0321665 W,2002-08-02,"AN IMPROVED BACKLESS, STRAPLESS BRA","A backless, strapless bra (10) comprising a pair of bra cups (12) having an interior surface facing towards a user's skin that comprises a pressure sensitive adhesive layer (33) disposed thereon for adjoining the bra cups to the user's skin. The bra cups are permanently or removably adjoined by a connector (14) that is positioned between inner side portions of the bra cup s. The connector can have a varierty of configurations that enable the user to attach the bra cups. The connector allows the user to create a desired amoun t of breast cleavage and breast push-up enhancement. The bra cup also includes a pull-up device (68) that attches to the top portion of the bra cups and allo ws the user to lift the bra cups and the user's breasts to provide additional breast push-up enhancement.",BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER,,https://lens.org/089-513-596-285-88X,Patent Application,no,0,0,29,29,0,A41C3/065;;A41C3/06;;A41C3/065,A41C3/06;;A41C3/10,,0,0,,,,EXPIRED
646,AU,A1,AU 2018/208763 A1,092-897-679-663-632,2019-02-14,2019,AU 2018/208763 A,2018-07-30,US 201762538411 P,2017-07-28,Motorized adjustable height table,A table includes a table top having a frame attached to a lower surface of the table top. The table also includes a first leg having lugs and a second leg having lugs. The lugs of the first leg and the second leg are received in slots of the frame to attach the legs to the table. The legs are telescopically movable to adjust the height of the table top. 46a 14b 26 14c 12a 1a18 44b 16 20 28 42 46b 16b 16 16c,VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,,https://lens.org/092-897-679-663-632,Patent Application,no,0,0,6,6,0,A47B3/06;;A47B13/021;;A47B13/023;;F16B12/52;;A47B9/20;;A47B2200/0059;;A47B13/003;;A47B9/20;;A47B2200/0059;;A47B2200/0057;;A47B13/003;;A47B13/021;;A47B3/06;;A47B13/023;;F16B12/52,A47B9/00,,0,0,,,,PENDING
647,US,A,US 3512865 A,102-950-747-152-262,1970-05-19,1970,US 3512865D A,1968-01-15,US 69768068 A,1968-01-15,D-C FREE ELECTRO-OPTIC CRYSTAL SYSTEM,,IBM,CHANG DAVID C;;LIPP JAMES,,https://lens.org/102-950-747-152-262,Granted Patent,no,5,1,6,6,0,G11C11/22;;G11C11/22,G11C11/22,350/150,0,0,,,,EXPIRED
648,EP,A2,EP 0427971 A2,097-790-928-806-203,1991-05-22,1991,EP 90119924 A,1990-10-17,US 42383089 A,1989-10-19,Gamma ray detecting device using dislocation free crystal.,"A γ-ray telescope that comprises a dislocation-free single crystal. Typical crystals include silicon and germanium, for example. The crystal is surrounded by an active shield that functions as an anticoincidence counter and a γ-ray detector is disposed adjacent the crystal in order to detect received γ-rays. The y-ray detector comprises an imaging proportional counter, scintillation counter, or a y-ray detecting charge coupled device, for example. The γ-ray detector is based on the Borrmann effect, which is the anomalous transmission of γ-rays through dislocation free single crystals at the Bragg angle. For extended sources, data processing is provided to separate the directional and wavelength dependence of the intensity variation. The y-ray telescope has angular resolution of at least one arc second and may have an effective aperture of several square meters. Reduction in background radiation, which is essentially determined by the crystal thickness, may be made quite large, greater than 10 12.  Consequently, the use of the present invention makes it possible to detect a weak y-ray source even in the presence of a large isotropic background.",HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/097-790-928-806-203,Patent Application,yes,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01N23/20;;G01T1/36,,0,0,,,,EXPIRED
649,HU,B1,HU 229310 B1,155-302-301-593-132,2013-10-28,2013,HU P0301851 A,2000-04-12,US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P;;US 0009785 W,1999-10-29,DRY POWDER COMPOSITIONS HAVING IMPROVED DISPERSIVITY,,NEKTAR THERAPEUTICS,LECHUGABALLESTEROS DAVID;;KUO MEI-CHANG,,https://lens.org/155-302-301-593-132,Granted Patent,no,0,0,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K9/12;;A61K9/00;;A61K47/42;;A61K9/08;;A61K9/14;;A61K9/72;;A61K31/58;;A61K38/00;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,,0,0,,,,EXPIRED
650,EP,A4,EP 0252142 A4,026-126-298-086-123,1988-06-08,1988,EP 87900922 A,1987-01-07,US 81765986 A;;US 88966486 A,1986-01-10,BITUMINOUS COMPOSITIONS.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/026-126-298-086-123,Search Report,no,6,0,9,20,0,C08L95/00,C08L95/00,,1,0,,,See also references of WO 8704174A1,DISCONTINUED
651,CN,A,CN 105705449 A,062-155-919-286-610,2016-06-22,2016,CN 201380080796 A,2013-11-08,US 2013/0069068 W,2013-11-08,Guide rail for elevator,"The invention provides a guide rail for an elevator. A method of making a guide rail for an elevator system includes providing a metallic guide rail having a base portion and a blade portion extending from the base portion. The blade portion includes one or more guide surfaces interactive with a safety brake of the elevator system. A protective layer is applied to the guide rail for corrosion protection and a perimeter of the protective layer is adhered to the guide rail to seal the guide surfaces from corrosive elements, while not adhering the protective layer to the guide surfaces.",OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,,https://lens.org/062-155-919-286-610,Patent Application,no,7,0,7,7,0,B66B7/022;;B66B7/022;;B32B37/12;;B32B38/10;;B32B2307/752,B66B7/02,,0,0,,,,DISCONTINUED
652,NZ,A,NZ 313386 A,084-409-474-079-701,1998-07-28,1998,NZ 31338696 A,1996-07-08,GB 9516372 A;;US 61986496 A;;US 9611409 W,1995-08-10,"PIGMENTED RHEOPECTIC CLEANING COMPOSITIONS WITH THIXOTROPIC PROPERTIES CONTAINING HYPOCHLORITE, BENTONITE, TERTIARY AMINE OXIDE, SARCOSINATE, AND ALKALI METAL ALKYLBENZENE",,RECKITT & COLMAN INC,CHANG DAVID;;CAVANAGH JAMES W,,https://lens.org/084-409-474-079-701,Patent Application,no,0,0,13,19,0,C11D3/3956;;C11D1/10;;C11D1/75;;C11D1/83;;C11D3/1266;;C11D3/40;;C11D3/42,C11D1/10;;C11D1/75;;C11D1/83;;C11D3/12;;C11D3/395;;C11D3/40;;C11D3/42,,0,0,,,,PENDING
653,US,A1,US 2010/0319044 A1,078-406-255-526-435,2010-12-16,2010,US 56440209 A,2009-09-22,US 56440209 A;;US 18744509 P,2009-06-16,Efficient Distribution of Remote Storage Data,"Described are apparatuses and methods for remote recording of digital data. A remote server digital video recorder (RS-DVR) server system includes one or more computer readable storage devices and a digital video recorder (DVR) server. The DVR server includes an input controller, a buffer unit, and a storage controller. The input controller receives an original data stream. The buffer unit is coupled to the input controller and receives and stores at least a portion of the original data stream from the input controller. The storage controller is coupled to the buffer unit and controls direct memory access to the one or more computer readable storage devices for writing one or more subscriber data streams copied from the original data stream. Each subscriber data stream is associated with a subscriber and written to a storage device location in the one or more computer readable storage devices associated with the subscriber.",SEACHANGE INTERNATIONAL INC,AGANS DAVID JOHN;;CHANG BANG,SEACHANGE INTERNATIONAL INC (2009-10-07),https://lens.org/078-406-255-526-435,Patent Application,yes,3,53,1,1,0,H04N5/76;;H04N5/76;;H04N5/765;;H04N5/765;;H04N21/231;;H04N21/231;;H04N21/2747;;H04N21/2747,H04N7/173;;H04N5/76,725/115;;X386E05068,0,0,,,,DISCONTINUED
654,US,B2,US 7524936 B2,079-464-036-440-780,2009-04-28,2009,US 71222207 A,2007-02-27,US 71222207 A;;US 85006004 A;;US 99924801 A;;US 24930500 P;;US 25136400 P;;US 28917201 P;;US 28953701 P,2000-11-16,Mitogenic oxygenase regulators,"The present invention relates to new genes encoding for the production of novel nox enzyme proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.",UNIV EMORY,LAMBETH J DAVID;;CHANG GUANGJIE,EMORY UNIVERSITY (2002-02-20),https://lens.org/079-464-036-440-780,Granted Patent,yes,4,0,16,16,34,A01K2217/05;;A01K2217/05;;A61P9/10;;A61P35/00;;A61P43/00;;C12N9/0036;;C12N9/0036;;C07K16/40;;C07K16/40;;C12N9/0004;;C12N9/0004;;C12N2799/026;;C12N2799/026;;G01N33/573;;G01N33/573;;G01N2333/90209;;G01N2333/90209,C12N15/09;;G01N33/53;;A61K38/44;;A61K48/00;;A61P9/10;;A61P35/00;;A61P43/00;;C07K16/18;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/02;;C12N5/10;;C12N9/02;;C12N9/04;;C12N15/53;;C12Q1/26;;G01N33/573,530/387.1;;530/388.26;;530/389.1;;530/391.3;;435/7.1;;435/7.2;;435/7.4,41,32,000-266-609-677-993;;013-427-269-155-107;;033-141-360-632-930;;030-371-969-594-350;;095-627-506-916-389;;049-709-867-052-126;;034-125-438-887-80X;;089-569-708-927-270;;016-001-136-237-206;;032-466-829-720-639;;040-717-516-643-277;;016-516-425-316-27X;;032-119-046-535-326;;026-220-476-537-814;;000-165-717-775-109;;070-878-789-668-942;;019-734-845-307-825;;009-166-673-375-315;;091-241-839-810-796;;014-772-124-562-944;;143-862-641-314-339;;111-213-245-621-301;;021-285-443-869-13X;;062-563-382-463-383;;027-363-992-605-988;;064-227-086-891-172;;057-496-115-428-497;;082-512-230-120-256;;075-700-958-880-084;;013-711-360-109-193;;002-784-353-737-376;;048-270-085-844-095,9600919;;10.1073/pnas.95.11.6073;;pmc27587;;11483596;;10.1074/jbc.m103034200;;10187835;;10.1074/jbc.274.15.10451;;10.1182/blood.v87.5.2005.2005;;8634451;;7750801;;10.1016/0891-5849(94)00198-s;;11376945;;10.1016/s0378-1119(01)00449-8;;8464931;;pmc46247;;10.1073/pnas.90.7.3113;;10.1111/j.1600-0609.1993.tb00635.x;;8243611;;6275983;;10.1161/01.res.80.1.45;;8978321;;7768942;;10.1074/jbc.270.22.13399;;10869423;;10.1073/pnas.130135897;;pmc16661;;10.1161/01.res.74.6.1141;;8187280;;10.1126/science.275.5306.1649;;9054359;;10.1016/s0021-9258(18)53574-2;;8382686;;10.1016/s0378-1119(00)00258-4;;10974555;;10.1016/s0968-0004(00)01658-3;;11050424;;3021851;;2556998;;pmc1133461;;10.1042/bj2630539;;10.1006/bbrc.1997.7704;;9398607;;9405639;;pmc25029;;10.1073/pnas.94.26.14483;;9931459;;10.1016/s0167-4781(98)00248-6;;9383399;;10.1016/1074-5521(95)90076-4;;2065663;;pmc452914;;10.1002/j.1460-2075.1991.tb07761.x;;11032835;;10.1074/jbc.m007597200;;10.1038/43459;;10485709;;7569979;;10.1126/science.270.5234.296;;1846317;;1657941;;10.1016/s0021-9258(18)54809-2;;10.1074/jbc.271.38.23317;;8798532;;8665527;;9341176;;10.1074/jbc.272.43.27288,"Brenner, SE et al. Proc. Natl. Acad. Sci. USA (1998) 95:6073-6078.;;Banfi, B. et al. ""A Ca(2+)-Activated NADPH Oxidase in Testis, Spleen, and Lymph Nodes"", Journal of Biological Chemistry, United States, Oct. 5, 2001, vol. 276, No. 40, pp. 37594-37601.;;Biberstine-Kinkade, K., et al., ""Mutagenesis of an Arginie- and Lysine-rich Domain in the gp91phox Subunit of the Phagocyte NADPH-oxidase Flavocytochrome b558,"" J. Biol. Chem., vol. 274, No. 15, pp. 10451-10457 (1999).;;Bjiorgvinsdottir et al., ""Cloning of murine gp91 (phox) and functional expression in a human X-liked . . . "" Blood, 87 (5), 2005-2010 (1996).;;Burdon, R. H., ""Superoxide and Hydrogen Peroxide in Relation to Mammalian Cell Proliferation,"" Free Radical Biol. Med., vol. 18, No. 4, pp. 775-794 (1995).;;Cheng Guangjie et al. Homologs of Gp91phox: Cloning and Tissue Expression of Nox3, Nox4 and Nox5, Gene (Amsterdam), vol. 269, No. 1-2, 23001, pp. 131-140.;;Cheng G. et al., ""NADPH Oxidase 4 (NOX4), a Homolog of gp91 and Mox1 (NOX1)"", May 10, 2000.;;Church, S. L., et al., ""Increased Manganese Superoxide Dismutase Expression Suppresses the Malignant Phenotype of Human Melanoma Cells,"" Proc. Natl. Acad. Sci. USA, vol. 90, pp. 3113-3117 (1993).;;Emmendörffer, A., et al., ""Production of Oxygen Radicals By Fibroblasts and Neutrophils from a Patient with X-Linked Chronic Granulomatous Disease,"" Eur. J. Haematol, vol. 51, pp. 223-227 (1993).;;Fernandez-Pol, J.A., et al., ""Correlation Between the Loss of the Transformed Phenotype and an Increase in Superoxide Dismutase Activity in a Revertant Subclone of Sarcoma Virus-infected Mammalian Cells,"" Can. Res., vol. 42, pp. 609-617 (1982).;;Fukui, T., et al., ""p22phox mRNA Expression and NADPH Oxidase Activity are Increased in Aortas from Hypertensive Rats,"" Cir. Res., vol. 80, No. 1, pp. 45-51, (1997).;;Gardner, P. R., et al., ""Superoxide Radical and Iron Modulate Aconitase Activity in Mammalian Cells,"" J. Biol. Chem., vol. 270, No. 22, pp. 13399-13405 (1995).;;Geiszt, M., et al., ""Identification of Renox, an NAD(P)H Oxidase in Kidney,"" PNAS, vol. 97, No. 14, pp. 8010-8014 (2000).;;Griendling, K. K., et al., ""Angiotensin II Stimulates NADH and NADPH Oxidase Activity in Cultured Vascular Smooth Muscle Cells,"" Cir. Res., vol. 74, No. 6, pp. 1141-1148 (1994).;;Irani, K., et al., ""Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts,"" Science, vol. 275, No. 5306, pp. 1649-1652 (1997).;;Isogai, Y., ""Superoxide-producing Cytochrome b: Enzymatic and Electron Paramagnetic Resonance Properties of Cytochrome b558 Purified from Neutrophils,"" J. Biol. Chem., vol. 268, No. 6, pp. 4025-4031 (1993).;;Kikuchi, H., et al., ""NADPH Oxidase Subunit, pg91phox Homologue, Preferentially Expressed in Human Colon Epithelial Cells,"" Gene, vol. 254, pp. 237-243 (2000).;;Lambeth, J.D., et al., ""Novel Homologs of gp91phox,"" Trends in Biochemical Sciences, vol. 25, pp. 459-461 (2000).;;Lambeth, J.D., ""Regulation of the Phagocyte Respiratory Burst Oxidase by Protein Interactions,"" Journal of Biochemistry and Molecular Biology, vol. 33, No. 6, pp. 427-439 (2000).;;Lloyd, D., ""Human DNA Sequence from Clone 146H21 on Chromosome Xq22"", Jan. 10, 1997.;;Mastsubara, T., et al., ""Increased Superoxide Anion Release from Human Endothelial Cells in Response to Cytokines,"" J. Immun., vol. 137, No. 10, pp. 3295-3298 (1986).;;Meier, B., et al., ""Human Fibroblasts Release Reactive Oxygen Species in Response to Interleukin-1 or Tumor Necrosis Factor-alpha,"" Biochem. J., vol. 263, No. 2, pp. 539-545 (1989).;;Merta, A. et al., ""The Rat S-Adenosylhomocysteine Hydrolase Promoter"", Biochemical and Biophysical Research Communications, United States, Nov. 26, 1997, vol. 240, No. 3, pp. 580-585.;;Pagano, P. J., et al., ""Localization of a Constitutively Active, Phagocyte-like NADPH Oxidase in Rabbit Aortic Adventitia: Enhancement by Angiotensin II,"" Proc. Natl. Acad. Sci. USA, vol. 94, No. 26, pp. 14483-14488 (1997).;;Pepe, G.J. et al. ""Cloning of the 11Beta Hydroxysteroid Dehydrogenase (11Beta-HSD)-2 Gene in the Baboon: Effects of Estradiol on Promoter Activity of 11Beta-HSD-1 and -2 in Placental JEG-3 Cells"", U.S. National Library of Medicine, Jan. 18, 1999.;;Schmidt, K. N., et al., ""The Roles of Hydrogen Peroxide and Superoxide as Messengers in the Activation of Transcription Factor NF-kappaB,"" Chem. & Bio., vol. 2, No. 1, pp. 13-22 (1995).;;Schreck, R., et al., ""Reactive Oxygen Intermediates as Apparently Widely Used Messengers in the Activation of the NF-kappaB Transcription Factor and HIV-1,"" EMBO J., vol. 10, No. 8, pp. 2247-2258 (1991).;;Shiose, A., et al., ""A Novel Superoxidase-producing NAD(P)H Oxidase in Kidney"", J. Biol. Chem., vol. 276, No. 2, pp. 1417-1423 (2001).;;Sugano, S. et al., ""NEDO Human cDNA Sequencing Project"", Sep. 29, 2000.;;Suh, Y., et al., ""Cell Transformation by the Superoxide-Generating Oxidase Mox1,"" Nature, vol. 401, No. 6748, pp. 79-82 (1999).;;Sundaresan, M., et al., ""Requirement for Generation of H2O2 for Platelet-Derived Growth Factor Signal Transduction,"" Science, vol. 270, pp. 296-299 (1995).;;Szatrowski, T.P., et al., ""Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells,"" Canc. Res., vol. 51, No. 3, pp. 794-798 (1991).;;Uhlinger, D.J., ""Nucleoside Triphosphate Requirements for Superoxide Generation and Phosphorylation in a Cell-Free System from Human Neutrophils,"" J. Biol. Chem., vol. 266, No. 31, pp. 20990-20997 (1991).;;Ushio-Fukai M., et al., ""p22phox is a Critical Component of the Superoxide-Generating NADH/NADPH Oxidase System and Regulates Angiotensin II-Induced Hypertrophy in Vascular Smooth Muscle Cells,"" J. Biol. Chem, vol. 271, No. 38, pp. 23317-23321 (1996).;;Yan, T., et al., ""Manganese-Containing Superoxide Dismutase Overexpression Causes Phenotypic Reversion in SV40-Transformed Human Lung Fibroblasts,"" Canc. Res., vol. 56, pp. 2864-2871 (1996).;;Yu, L., et al., ""Biosynthesis of the Phagocyte NADPH Oxidase Cytochrome b588: Role of Heme Incorporation and Heterodimer Formation in Maturation and Stability of gp91phox and p22phox Subunits,"" J. Biol. Chem, vol. 272, No. 43, pp. 27288-27294 (1997).;;Genbank Accession No. AF254621, May 9, 2001, (2 pages).;;Genbank Accession No. AAG33638, Sep. 6, 2005, (2 pages).;;Genbank Accession No. AF317889, Sep. 6, 2005, (2 pages).;;Genbank Accession No. BAB15319, Sep. 12, 2006, (2 pages).;;Genbank Accession No. AK026011, Sep. 12, 2006, (2 pages).",EXPIRED
655,CA,A1,CA 2101173 A1,100-661-870-478-424,1993-08-01,1993,CA 2101173 A,1993-01-26,US 82978892 A,1992-01-31,REDUCTION OF SIDELOBES IN OPTICAL ARRAYS,"2101173 9315531 PCTABS00024 To reduce the sidelobe levels in a beam produced by an optical phased array, the array is arranged so that the output fields of the emitters have the amplitude and phase given by the inverse Fourier transform of the desired radiation pattern.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,,https://lens.org/100-661-870-478-424,Patent Application,no,0,0,4,4,0,H01Q21/22;;H01Q3/2676,H01Q3/26;;H01Q21/22;;H01S3/10;;H01S5/00,,0,0,,,,DISCONTINUED
656,US,B2,US 7270961 B2,099-111-906-709-109,2007-09-18,2007,US 41201103 A,2003-04-11,US 41201103 A;;US 37243702 P,2002-04-16,In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes,The present invention provides methods of quantitating recent secreted antigen specific antibodies from supernatant of antibody secreting cells (ASC) in vitro culture for evaluation of vaccine or antigen induced antigen specific antibody secretion without ex vivo antigen stimulation.,CHANG HUI SUNNY;;SACK DAVID,CHANG HUI SUNNY;;SACK DAVID,,https://lens.org/099-111-906-709-109,Granted Patent,yes,1,2,7,7,0,C07K16/1239;;Y10S530/866;;Y10S530/862;;Y10S530/863;;Y10S530/861;;G01N33/5091;;C07K16/1239;;Y10S530/862;;Y10S530/866;;Y10S530/861;;Y10S530/863;;G01N33/5091;;G01N33/6854,G01N33/53;;C07K16/12;;G01N33/50,435/7.1;;530/380;;530/386;;530/387.1;;530/412;;530/413;;530/866;;530/861;;530/862;;530/863;;435/2;;435/340;;435/326;;435/327;;435/377;;435/383,4,4,051-701-837-466-323;;049-209-426-701-388;;061-342-499-241-033;;088-893-318-415-77X,6169778;;pmc2186486;;10.1084/jem.154.4.1043;;6184400;;10.1016/s0165-2427(01)00370-1;;11604164;;6972539;;pmc319381;;10.1073/pnas.78.4.2528,"Lane et al., Journal of Experimental Medicine. vol. 154, Oct. 1981, pp. 1043-1057.;;Peters et al., The Journal of Immunology. vol. 130, No. 2, Feb. 1983, pp. 678-680.;;Rebelatto et al., Veterinary Immunology and Immunopathology. vol. 83. 2001. pp. 93-105.;;Volkman et al., Proc. Natl. Acad. Sci. vol. 78, No. 4, pp. 2528-2531, Apr. 1981.",INACTIVE
657,CN,A,CN 117098991 A,167-597-053-058-38X,2023-11-21,2023,CN 202280021709 A,2022-03-18,US 202163163197 P;;IB 2022052502 W,2021-03-19,NON-CONTACT SAMPLER WITH OPEN PORT INTERFACE FOR LIQUID CHROMATOGRAPHY SYSTEMS,"A method of performing liquid chromatography (LC) with an LC system including a liquid chromatography (LC) column and an analyzer includes delivering a delivery liquid to an open port interface (OPI) of a sample receiving loop, where the sample receiving loop includes a sample transfer chamber. The sample is ejected from the sample holder into the OPI with a non-contact ejector. A transport liquid and a sample are received in a sample transfer chamber. The sample transfer chamber is decoupled from the sample receiving circuit. The solvent is transferred to an analysis loop. The sample is pushed out of the sample transfer chamber with a solvent. The sample and solvent are passed through an LC column to produce an eluate. And analyzing the eluate by using an analyzer.",DH TECHNOLOGIES DEV PTE LTD,COX DAVID M;;LIU CHANG,,https://lens.org/167-597-053-058-38X,Patent Application,no,0,0,3,3,0,H01J49/0404;;G01N30/20;;G01N30/72,G01N30/04,,0,0,,,,PENDING
658,US,A1,US 2019/0029413 A1,001-235-843-236-744,2019-01-31,2019,US 201816047246 A,2018-07-27,US 201816047246 A;;US 201762538411 P,2017-07-28,MOTORIZED ADJUSTABLE HEIGHT TABLE,A table includes a table top having a frame attached to a lower surface of the table top. The table also includes a first leg having lugs and a second leg having lugs. The lugs of the first leg and the second leg are received in slots of the frame to attach the legs to the table. The legs are telescopically movable to adjust the height of the table top.,VARIDESK LLC,PATTON DAVID;;CHANG LIO Y,VARIDESK LLC (2018-09-04),https://lens.org/001-235-843-236-744,Patent Application,yes,24,27,6,6,0,A47B9/20;;A47B9/20;;A47B3/06;;A47B3/06;;A47B13/003;;A47B13/003;;A47B13/021;;A47B13/021;;A47B13/023;;A47B13/023;;A47B2200/0057;;A47B2200/0059;;A47B2200/0059;;F16B12/52;;F16B12/52,A47B9/20;;A47B13/00,,0,0,,,,ACTIVE
659,US,B2,US 8221189 B2,011-445-040-382-375,2012-07-17,2012,US 53336009 A,2009-07-31,US 53336009 A;;US 8581608 P,2008-08-01,Attachable breast form enhancement system,"A backless, strapless breast form system to be worn in place of a traditional bra including a pair of breast forms, wherein each breast form includes a volume of silicone gel encased between thermoplastic film material; an interior surface adapted to be attached to a user's breast, wherein substantially an entire interior surface from edge to edge comprises a pressure sensitive adhesive layer and wherein the interior surface has a plurality of bumps adapted to increase a push up effect of the breast form; a lateral side adapted to face the user's armpit and a medial side facing opposite the lateral side, wherein the breast form is adapted to be secured to the user's breast solely by the pressure sensitive adhesive layer; and a connector adapted to adjoin the pair of breast forms, wherein the connector is positioned between the medial side of each of the pair of breast forms.",CHEN DAVID E;;CHANG JASPER;;BRAGEL INTERNATIONAL INC,CHEN DAVID E;;CHANG JASPER,BRAGEL INTERNATIONAL INC (2009-10-03),https://lens.org/011-445-040-382-375,Granted Patent,yes,48,14,2,2,0,A41C3/065;;A41C3/065,A41C3/00,450/81;;450/88;;450/54,3,0,,,"Abstract and Figures Only for French Patent No. 2505620 (Nov. 19, 1982).;;Figures Only for Italian Patent No. IT 0521811 (May 1955).;;Dr. Leonard's-America's Leading Discount Healthcare Catalog, p. 15, Natural Looking Breast Enhancer Pads, Silicone Covered with Film, 1998.",INACTIVE
660,EP,A1,EP 3066039 A1,051-057-618-232-477,2016-09-14,2016,EP 13896989 A,2013-11-08,US 2013/0069068 W,2013-11-08,GUIDE RAIL FOR ELEVATOR,,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,OTIS ELEVATOR COMPANY (2017-09-06),https://lens.org/051-057-618-232-477,Patent Application,yes,0,0,7,7,0,B66B7/022;;B66B7/022;;B32B37/12;;B32B38/10;;B32B2307/752,B66B7/02,,0,0,,,,ACTIVE
661,SG,A1,SG 52629 A1,080-890-709-018-136,1998-09-28,1998,SG 1996007012 A,1994-04-15,US 5287693 A,1993-04-26,A process for making an improved tantalum powder and high capacitance low leakage electromode made therefrom,"A process for producing capacitor grade powder, electrodes, and finished capacitors therefrom having reduced electrical leakage characteristics. The powder is prepared by reacting Group V-B base materials with quantities of between 500 to 7000 ppm of nitrogen and 700 to 3000 ppm of oxygen. Electrical leakage is reduced by at least 28% for electrodes anodized at 100 volts or greater in comparison with electrodes and finished capacitors made from undoped materials. A range of specific charge of up to 25,000 uFV/g is achieved for sintering temperatures of 1400 DEG C. to 1800 DEG C.",CABOT CORP,CHANG HONGJU;;KORIS DAVID J,,https://lens.org/080-890-709-018-136,Patent Application,no,0,0,24,24,0,C22C1/045;;H01G9/0525;;H01G9/0525;;C22C1/045,C22C1/04;;H01G9/052;;H01G9/00;;H01G9/02,,0,0,,,,PENDING
662,WO,A1,WO 2023/233328 A1,074-345-155-924-450,2023-12-07,2023,IB 2023055590 W,2023-05-31,US 202263347649 P,2022-06-01,SYSTEMS AND METHODS FOR DATA ACQUISITION METHOD SWITCHING,"A method and system of data acquisition in an acoustic ejection mass spectrometer including a plurality of reservoirs, each reservoir containing a sample, the method including scheduling a plurality of ejection events for the plurality of reservoirs, setting an analysis method for each ejection event, ejecting a first sample at a first ejection time, starting a first analysis method of the ejected first sample at a first start time, ejecting a second sample at a second ejection time, and starting a second analysis method of the ejected second sample at a second start time, the second start time being or equal to or earlier than the first end time. For example, before starting the first analysis method, it is determined whether an ejection of the first sample has occurred, and if the ejection of the first sample is determined not to have occurred, the second sample is ejected.",DH TECHNOLOGIES DEV PTE LTD,LIU CHANG;;COX DAVID MICHAEL,,https://lens.org/074-345-155-924-450,Patent Application,yes,4,0,1,1,0,H01J49/0454,H01J49/04,,3,2,082-031-406-612-530;;035-173-945-292-352,10.1021/acs.analchem.0c02999;;33063997;;10.1002/rcm.1020;;12720286,"LIU CHANG ET AL: ""Operational Modes and Speed Considerations of an Acoustic Droplet Dispenser for Mass Spectrometry"", ANALYTICAL CHEMISTRY, vol. 92, no. 24, 16 October 2020 (2020-10-16), US, pages 15818 - 15826, XP055827509, ISSN: 0003-2700, DOI: 10.1021/acs.analchem.0c02999;;ZHANG HUI ET AL: ""Acoustic Ejection Mass Spectrometry for High-Throughput Analysis"", BIORXIV, 29 January 2020 (2020-01-29), XP055838995, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.01.28.923938v1.full.pdf> [retrieved on 20210908], DOI: 10.1101/2020.01.28.923938;;JAMES W. HAGERJ. C. YVES LE BLANC: ""Product ion scanning using a Q-q-Q linear ion trap (Q TRAP) mass spectrometer"", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 17, 2003, pages 1056 - 1064, XP055199582, DOI: 10.1002/rcm.1020",PENDING
663,FI,A,FI 873900 A,082-579-399-599-975,1987-09-09,1987,FI 873900 A,1987-09-09,US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BITUMENINNEHAOLLANDE KOMPOSITIONER.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/082-579-399-599-975,Patent Application,no,0,0,9,20,0,C08L95/00,C08L95/00,,0,0,,,,DISCONTINUED
664,AU,A1,AU 2017/232045 A1,088-542-485-374-19X,2017-10-05,2017,AU 2017/232045 A,2017-09-19,AU 2017/232045 A;;AU 2014/249417 A;;US 201313792135 A;;US 2014/0022004 W,2013-03-10,Modified caspase polypeptides and uses thereof,"Abstract The technology relates in part to compositions comprising modified caspase-9 polypeptides, compositions comprising nucleic acids coding for modified caspase-9 polypeptides, chimeric modified caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/088-542-485-374-19X,Patent Application,no,0,0,17,17,0,A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008;;A61P1/04;;A61P17/00;;A61P19/08;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P5/00;;A61P7/00;;A61P7/06;;A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008,A01N65/00;;A61K31/4545;;A61K35/14;;C12N5/00;;C12N9/64;;C12P21/00,,0,0,,,,DISCONTINUED
665,US,A,US 4649828 A,096-279-812-714-281,1987-03-17,1987,US 82658686 A,1986-02-06,US 82658686 A,1986-02-06,Explosively forged penetrator warhead,"An ordnance device includes a submunition having a generally cylindrical case packed with an explosive charge. The rearmost end of the case is capped by a detonator that fires the explosive charge when a target is sensed. The front end of the case is capped by a liner that on detonation of the explosive charge converts to one or more explosively forged penetrators that speed toward the target at supersonic speed. By assembling the liner from a plurality of narrow metal strips arranged in parallel and weakly bonded together, the strips separate on detonation forming a plurality of aerodynamically stable slugs, each of which has undergone plastic deformation to form a projectile that is potentially lethal.",AVCO CORP,HENDERSON DAVID;;TING CHANG-SHENG,AVCO CORPORATION (1986-01-21);;TEXTRON IPMP L.P (2001-04-01);;TEXTRON SYSTEMS CORPORATION (1996-12-20),https://lens.org/096-279-812-714-281,Granted Patent,yes,4,17,1,1,0,F42B1/036;;F42B12/10;;F42B1/036;;F42B12/10,F42B1/036;;F42B12/10,102/476;;102/306;;102/501,0,0,,,,EXPIRED
666,CN,A,CN 1159553 A,108-937-649-053-190,1997-09-17,1997,CN 96102331 A,1996-06-19,AU PN364195 A,1995-06-19,Solar energy selective absorption surface coating,"A solar selective surface coating (13) that is deposited on a solar collector element (10). The surface coating (13) comprises a three-layer structure having an inner layer (14) in the form of a bright metal infrared reflective coating layer, a solar energy absorptive coating layer (15) deposited on the reflective coating layer, and an anti-reflective surface layer (16). The absorptive coating (15) is deposited as a cermet, typically a tungsten-aluminium nitride cermet, which is formed by sputtering material simultaneously from first and second metal electrodes (23 and 24) in the presence of a gas which is reactive with the metal from which the second electrode (24) is formed and substantially non-reactive with the metal from which the first electrode (23) is formed. That is, the solar energy absorptive coating (15) is formed by co-depositing materials from the first and second electrodes (23 and 24) in the presence of a gas which is reactive with the metal of one only of the electrodes.",AUSTRALIA SYDNEY UNIV,CHANG QI-CHU;;MILS DAVID,GLOBAL SOLAR POWER SURFACE TECHNOLOGY PTE LTD. (2011-11-04),https://lens.org/108-937-649-053-190,Patent Application,no,0,22,12,12,0,C23C14/0688;;C23C14/185;;Y02E10/40;;F24S70/30;;F24S70/225;;C23C14/185;;F24S70/225,F25C1/22;;C23C14/06;;C23C14/08;;C23C14/18;;C23C14/34;;C23C14/35;;C23C14/36;;F24J2/46;;F24J2/48;;F25C1/12;;F25C1/24;;F25C5/18,,0,0,,,,EXPIRED
667,EP,A3,EP 0427971 A3,117-266-003-892-27X,1991-05-29,1991,EP 90119924 A,1990-10-17,US 42383089 A,1989-10-19,GAMMA RAY DETECTING DEVICE USING CRYSTAL WAVEGUIDES,"A γ-ray telescope that comprises a dislocation-free single crystal. Typical crystals include silicon and germanium, for example. The crystal is surrounded by an active shield that functions as an anticoincidence counter and a γ-ray detector is disposed adjacent the crystal in order to detect received γ-rays. The y-ray detector comprises an imaging proportional counter, scintillation counter, or a y-ray detecting charge coupled device, for example. The γ-ray detector is based on the Borrmann effect, which is the anomalous transmission of γ-rays through dislocation free single crystals at the Bragg angle. For extended sources, data processing is provided to separate the directional and wavelength dependence of the intensity variation. The y-ray telescope has angular resolution of at least one arc second and may have an effective aperture of several square meters. Reduction in background radiation, which is essentially determined by the crystal thickness, may be made quite large, greater than 10 12.  Consequently, the use of the present invention makes it possible to detect a weak y-ray source even in the presence of a large isotropic background.",HUGHES AIRCRAFT COMPANY,"VALI, VICTOR;;CHANG, DAVID B.",,https://lens.org/117-266-003-892-27X,Search Report,yes,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01N23/20;;G01T1/36,,3,2,163-125-948-379-52X;;115-714-937-331-314,10.1016/0029-554x(79)90629-3;;10.1016/0168-9002(87)90031-3,"NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH, vol. A261, nos. 1-2, 1st November 1987, pages 72-74, Amsterdam, NL; V.V. ARISTOV et al.: ""Bragg zone plates for hard X-ray focusing"";;NUCLEAR INSTRUMENTS & METHODS, vol. 165, no. 3, October 1979, pages 463-467, Amsterdam, NL; J.G. PRONKO et al.: ""X-ray spectrograph with active readout"";;NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH, vol. A-254, no. 3, 1st March 1987, pages 570-577, Amsterdam, NL; D.H. DOWELL et al.: ""The response of a 24 cm X 36 cm NaI(Tl) spectrometer to gamma rays between 50 and 300 MeV""",EXPIRED
668,US,B1,US 8324857 B1,119-586-655-843-217,2012-12-04,2012,US 28471208 A,2008-09-23,US 28471208 A,2008-09-23,Portable stackable solar batteries,"Portable stackable solar batteries are disclosed, in which the solar batteries can be connected in a planar arrangement for solar recharging and connected in a vertically stacked arrangement for powering an electrically powered device and/or for charging another rechargeable battery.",CHANG DAVID;;COATES STEPHEN S;;SOLARLEGO INC,CHANG DAVID;;COATES STEPHEN S,SOLARLEGO INC (2008-11-18),https://lens.org/119-586-655-843-217,Granted Patent,yes,14,12,5,5,0,H01M10/465;;H01M14/005;;H01M10/4207;;Y02E10/56;;Y02E60/10;;H01M10/465;;H01M14/005;;H01M10/4207;;H02J7/35;;H02J7/0045;;H02J7/0014,H01M10/44,320/101;;136/244;;60/641.8,0,0,,,,ACTIVE
669,US,A,US 5870166 A,122-979-649-297-454,1999-02-09,1999,US 80628297 A,1997-02-25,US 80628297 A,1997-02-25,Versatile optical mounting assembly,"An optical mounting assembly includes a frame, preferably in the form of a shaped wire form, having a proximal section attachable to a headband or to the bridge portion of a pair of eyeglass frames, a mid-section extending downwardly along and in spaced-apart conformity with the ridge of a user's nose, and a distal section which is bent upwardly with respect to the mid section. Optionally, the mid-section may include an adjustable nose pad which is adapted to make contact against the ridge of the user's nose. This provides for improved weight distribution, with the distal section being configured to mountably receive one of a variety of accessories such as light sources, imaging apparatus, face shields, etc.",CHANG; BYUNG JIN;;NOWAK; DAVID,CHANG BYUNG JIN;;NOWAK DAVID,,https://lens.org/122-979-649-297-454,Granted Patent,yes,8,33,1,1,0,G02B7/002;;G02B7/002;;G02B25/004;;G02B25/004;;G02B27/0176;;G02B27/0176;;G02B2027/0138;;G02B2027/0138;;G02B2027/0156;;G02B2027/0156;;G02B2027/0158;;G02B2027/0158;;G02C7/088;;G02C7/088;;G02C11/04;;G02C11/04,G02B27/00;;G02B27/01;;G02C7/08;;G02C9/00,G2J JS2AX1        JS2AX1,0,0,,,,EXPIRED
670,EP,B1,EP 2967081 B1,142-454-787-496-535,2019-07-03,2019,EP 14778378 A,2014-03-07,US 201313792135 A;;US 2014/0022004 W,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,,BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/142-454-787-496-535,Granted Patent,yes,2,0,17,17,0,A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008;;A61P1/04;;A61P17/00;;A61P19/08;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P5/00;;A61P7/00;;A61P7/06;;A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008,A61K38/48;;A61K31/4545;;A61K38/52;;C12N9/64;;C12N9/90,,4,0,,,"KARIN C STRAATHOF ET AL: ""A inducible caspase 9 safety switch for T-cell therapy"", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 11, 1 June 2005 (2005-06-01) , pages 4247-4254, XP008126232, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2004-11-4564;;BRADY ET AL.: 'Regulation of Caspase 9 through Phosphorylation by Protein Kinase C Zeta in Response to Hyperosmotic Stress' MOLECULAR AND CELLULAR BIOLOGY vol. 25, no. 23, 01 December 2005, pages 10543 - 10555, XP055293374 DOI: 10.1128/MCB.25.23.10543-10555.2005;;DENAULT ET AL.: 'Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9' BIOCHEM. J. vol. 405, no. 1, 01 July 2007, pages 11 - 19, XP055293379 DOI: 10.1042/BJ20070288;;CHAO ET AL.: 'Engineering a Dimeric Caspase-9: A Re-evaluation of the Induced Proximity Model for Caspase Activation' PLOS BIOL vol. 3, no. 6, 01 June 2005, pages 1 - 9, XP055250949 DOI: 10.1371/JOURNAL.PBIO.0030183",ACTIVE
671,TW,U,TW M352902 U,164-798-659-003-545,2009-03-21,2009,TW 97217773 U,2008-10-03,TW 97217773 U,2008-10-03,Adhesive bra cup,,CHANG JASPER;;CHEN DAVID E,CHANG JASPER;;CHEN DAVID E,,https://lens.org/164-798-659-003-545,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
672,US,B2,US 11111108 B2,186-048-385-307-503,2021-09-07,2021,US 201815971211 A,2018-05-04,US 201815971211 A,2018-05-04,Coated sheave,An elevator sheave includes a sheave body and a coating on a surface of the sheave body. The coating includes microcracks and a filler in the microcracks. A method of making a sheave for an elevator system is also disclosed.,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,OTIS ELEVATOR COMPANY (2018-05-03),https://lens.org/186-048-385-307-503,Granted Patent,yes,26,1,7,7,0,B66B7/02;;B66B15/04;;B66B15/04;;C09D191/06;;C25D3/04,B66B15/04;;C09D191/06;;C25D3/04,,0,0,,,,ACTIVE
673,EP,A1,EP 0578815 A1,197-440-834-209-403,1994-01-19,1994,EP 93904698 A,1993-01-26,US 82978892 A,1992-01-31,REDUCTION OF SIDELOBES IN OPTICAL ARRAYS.,"Afin de réduire les niveaux des lobes latéraux d'un faisceau produit par un réseau optique, le réseau est agencé de sorte que les champs de sortie des émetteurs aient une amplitude et une phase données par la transformée inverse de Fourier du rayonnement désiré.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,,https://lens.org/197-440-834-209-403,Patent Application,yes,0,0,4,4,0,H01Q21/22;;H01Q3/2676,H01Q3/26;;H01Q21/22;;H01S3/10;;H01S5/00,,1,0,,,See references of WO 9315531A1,DISCONTINUED
674,TW,B,TW 341580 B,196-607-663-814-208,1998-10-01,1998,TW 86101735 A,1997-02-14,US 1173896 P,1996-02-15,PREPARATION OF POLYETHERAMINES AND POLYETHERAMINE DERIVATIVES,"A process for preparing a polyetheramine, which comprises reacting an ammonia capped polyether with an aldehyder or ketone to form an imine intermediate, followed by subsequent hydrogenation of the imine to form a polyetheramine product.",DOW CHEMICAL CO,DANE CHANG;;DAVID A WILSON,,https://lens.org/196-607-663-814-208,Granted Patent,no,0,2,3,3,0,B01D19/0413;;C10L1/238;;C08G65/3255;;C08G65/33368;;C10L1/22;;C10L1/2225;;C10L1/2235;;C10L1/2283;;C10L1/2286;;C10L1/232;;C10L1/233;;C10L1/2443;;C10L1/2475;;C10M149/12;;C10M2215/042;;C10N2030/12;;C23F11/173,B01D19/04;;C08G65/325;;C08G65/333;;C10L1/22;;C10L1/238;;C10L1/24;;C10M149/12;;C23F11/173,,0,0,,,,EXPIRED
675,NO,L,NO 873764 L,013-362-114-882-807,1987-09-09,1987,NO 873764 A,1987-09-09,US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BITUMINOESE MATERIALER.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/013-362-114-882-807,Abstract,no,0,0,4,20,0,,C08L23/08;;C08L95/00,,0,0,,,,EXPIRED
676,TW,A,TW 200524363 A,031-238-820-352-824,2005-07-16,2005,TW 93100404 A,2004-01-08,TW 93100404 A,2004-01-08,Method for query remote database at mobile communication device,"A method for query remote database at a mobile communication device, the mobile communication device queries the database by a server via a WAP network and obtain a data. The method first transmits an identification code and a password from the mobile communication device, and brings up a request for query. The server receives and checks the identification code and the password. When the checking result is correct, then query the database and obtain the data according the request for query and limits of authority of user. The server transmits the data via the WAP network. Finally, the mobile communication device receive the data.",INVENTEC APPLIANCES CORP,HO DAVID;;CHANG KAI-TAO,,https://lens.org/031-238-820-352-824,Patent of Addition,no,0,0,1,1,0,,H04L9/32,,0,0,,,,PENDING
677,AU,A1,AU 2013/273787 A1,041-915-666-211-676,2015-07-09,2015,AU 2013/273787 A,2013-12-20,AU 2013/273787 A,2013-12-20,Method of detecting regions in an edge-based representation,"- 41 METHOD OF DETECTING REGIONS IN AN EDGE-BASED REPRESENTATION A method (700) for graphics processing comprises receiving (701) an intermediate graphical representation (620) associated with a document, the intermediate graphical representation comprising a plurality of non-intersecting edges (101-103). The method determines (702) a plurality of vertices (311-320) using the intermediate graphical representation. The vertices comprises endpoints (311,312; 314, 313; 316,315; 317,320) of the edges and at least one split point (319), the split point being determined by splitting a first edge (204) into two or more portions (""sub-edges"", 404) using an endpoint (316) of at least one second edge (102,103), wherein the first edge and the second edge are from the plurality of non-intersecting edges. The method associates (903) vertices from the plurality of vertices with at least one edge (101) from the intermediate graphical representation using endpoints of the one edge, wherein the associating comprises selecting, from the determined plurality of vertices, a plurality of neighbouring vertices (320,319,314,313,318,317) to said one edge to define (904) a region (431) with the endpoints of the one edge. The method processes (e.g. rasterisation by RIP module 614) the region using at least the endpoints of said one edge and the associated neighbouring vertices (320, 319, 314, 313, 318 and 317). 8166189_1 P095024_speci lodge",CANON KK,CHANG WEN SHAN;;KARLOV DAVID,,https://lens.org/041-915-666-211-676,Patent Application,no,0,0,3,3,0,G06K15/1849;;G06K15/1849;;G06T11/203;;G06T11/203;;G06T11/60,H04N1/00,,0,0,,,,DISCONTINUED
678,CA,A1,CA 3012778 A1,048-060-394-942-945,2019-01-28,2019,CA 3012778 A,2018-07-27,US 201762538411 P,2017-07-28,MOTORIZED ADJUSTABLE HEIGHT TABLE,A table includes a table top having a frame attached to a lower surface of the table top. The table also includes a first leg having lugs and a second leg having lugs. The lugs of the first leg and the second leg are received in slots of the frame to attach the legs to the table. The legs are telescopically movable to adjust the height of the table top.,VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,,https://lens.org/048-060-394-942-945,Patent Application,no,0,2,6,6,0,A47B3/06;;A47B13/021;;A47B13/023;;F16B12/52;;A47B9/20;;A47B2200/0059;;A47B13/003;;A47B9/20;;A47B2200/0059;;A47B2200/0057;;A47B13/003;;A47B13/021;;A47B3/06;;A47B13/023;;F16B12/52,A47B9/00;;A47B13/06,,0,0,,,,PENDING
679,US,A,US 5920371 A,142-641-047-418-172,1999-07-06,1999,US 89389497 A,1997-07-11,US 89389497 A;;US 2125296 P,1996-07-12,Versatile headband optical mounting assembly,"A versatile optical mounting assembly utilizes a headband mount having a forward portion and a vertical member having upper and lower ends. The forward portion of the headband mount includes a slide assembly which receives the upper end of the vertical member, allowing the vertical member to be vertically adjusted and locked into place once a desired position is achieved. A multiple-degree-of freedom clamp assembly is further provided to connect the lower end of the vertical member to the top edge of the eyeglass frames, facilitating first and second rotational movements about separate axes. The invention may also be used in conjunction with an ocular mounting assembly, in which case a slide rail is centrally attached to the eyeglass frames at a point proximate to where the clamp assembly connects the lower end of the vertical member to the top edge of the eyeglass frames. A mounting pad is received by the slide rail which may be vertically adjusted and locked into place once a desired orientation is achieved, and a second multiple-degree-of freedom clamp assembly is preferably used to connect the mounting pad to the ocular mounting assembly.",CHANG; BYUNG JIN;;NOWAK; DAVID,CHANG BYUNG JIN;;NOWAK DAVID,,https://lens.org/142-641-047-418-172,Granted Patent,yes,19,31,1,1,0,G02B7/002;;G02B25/004;;G02B27/0176;;G02B2027/0159;;G02B7/002;;G02B25/004;;G02B27/0176;;G02B2027/0159,G02B27/00;;G02B27/01,351/158;;2/453;;359/409,0,0,,,,EXPIRED
680,US,S,US D0459413 S,150-829-361-612-170,2002-06-25,2002,US 13797301 F,2001-03-05,AU 200100161 F,2001-01-22,Toy Koala,,TEOW JOO PHAIK;;CHANG DAVID,TEOW JOO PHAIK;;CHANG DAVID,WARNER-LAMBERT COMPANY (2001-03-26),https://lens.org/150-829-361-612-170,Design Right,no,0,0,2,2,0,,,D21/605,0,0,,,,EXPIRED
681,KR,A,KR 20170054118 A,186-184-302-214-034,2017-05-17,2017,KR 20150156872 A,2015-11-09,KR 20150156872 A,2015-11-09,FLAT LAMP PANNEL,"The present invention relates to a detachable flat panel illumination device having a structure capable of easy installation and maintenance when an existing lighting device is replaced with an LED lighting device. A flat light emitting module using an LED can be easily and detachably attached to the frame of a lighting member without installing any additional equipment or a frame, thereby providing a lighting structure capable of greatly reducing the replacement cost.",KUMHO ELECTRIC INC,LEE CHANG HO;;DAVID NATARELLI,,https://lens.org/186-184-302-214-034,Patent Application,no,0,1,1,1,0,,F21V21/08;;F21K99/00;;F21S10/00;;F21V1/02;;F21V7/00;;F21V17/10;;F21V17/16;;F21V21/084,,0,0,,,,ACTIVE
682,EP,B1,EP 3440958 B1,069-620-824-165-969,2021-03-03,2021,EP 18186011 A,2018-07-27,US 201762538411 P,2017-07-28,MOTORIZED ADJUSTABLE HEIGHT TABLE,,VARIDESK LLC,PATTON DAVID;;CHANG LIO YENWEI,,https://lens.org/069-620-824-165-969,Granted Patent,yes,4,0,6,6,0,A47B3/06;;A47B13/021;;A47B13/023;;F16B12/52;;A47B9/20;;A47B2200/0059;;A47B13/003;;A47B9/20;;A47B2200/0059;;A47B2200/0057;;A47B13/003;;A47B13/021;;A47B3/06;;A47B13/023;;F16B12/52,A47B3/06;;A47B9/20;;A47B13/02;;F16B12/52,,0,0,,,,ACTIVE
683,US,B1,US 8135357 B1,065-185-859-529-217,2012-03-13,2012,US 30077305 A,2005-12-13,US 30077305 A,2005-12-13,Integrated transmitter/receiver switch with impedance matching network,"A switchable inductor-capacitor-inductor (L-C-L) network, which includes an integrated T/R switch, can advantageously bridge a PA and an LNA of a wireless device. The first inductor can function as an RF choke that provides power to the PA. In one embodiment, the first inductor can be advantageously implemented using the bond wires already attached to the PA, thereby requiring no additional inductors to provide the integrated T/R switch and minimizing use of valuable silicon area. The second inductor can function as a source inductor for and cancel an input parasitic capacitance of the LNA. A set of capacitors can act as blocking capacitors to provide DC isolation between the LNA and the PA, thereby protecting the LNA from high voltages. The L-C-L network can also advantageously function as an impedance matching network for at least one of the PA and the LNA.",CHANG RICHARD T;;WEBER DAVID;;QUALCOMM ATHEROS INC,CHANG RICHARD T;;WEBER DAVID,ATHEROS COMMUNICATIONS INC (2005-12-13);;QUALCOMM ATHEROS INC (2011-01-05);;QUALCOMM INCORPORATED (2012-10-22),https://lens.org/065-185-859-529-217,Granted Patent,yes,30,14,1,1,0,H04B1/48;;H04B1/48,H04B1/44,455/83;;455/78;;455/82;;455/73;;455/101;;363/62;;363/60;;363/44;;333/100;;333/101;;330/286;;330/302;;330/140;;331/167;;331/49;;323/341;;323/266;;345/89;;345/98,2,2,055-918-696-258-733;;169-133-423-572-413,10.1109/jssc.2004.827809;;10.1109/isscc.2003.1234336,"Talwalkar et al.: ""Integrated CMOS Transmit-Receive Switch Using LC-Tuned Substrate Bias for 2.4 GHz and 5.2 GHz Applications"", IEEE Journal of Solid-State Circuits, vol. 39, No. 6, Jun. 2004, pp. 863-870.;;Talwalkar et al.: ""An Integrated 5.2 GHz CMOS T/R Switch With LC-Tuned Substrate Bias"", 2003 IEEE International Solid-State Circuits Conference, Paper 20.7, 10 pages.",INACTIVE
684,WO,A1,WO 2016/007838 A1,080-806-355-701-346,2016-01-14,2016,US 2015/0039912 W,2015-07-10,US 201462023011 P,2014-07-10,MULTIPLE LEVEL CONTAINER,"Cosmetic containers having multiple levels (106, 108), a lid (102), and a base (104), in which the opening of the lid also provides access to at least first (106) and second (108) levels having one or more compartments (110, 112) for products and/or applicators. The base (104) may contain a first level (106), and be coupled via a first linkage (116) to a second level (108). The lid (102) may be coupled by a pivot assembly (119) to the base (104) and to the second level (108) by a second linkage (118). The overall assembly may allow access to both the first level and the second level on opening the lid.",HCT GROUP HOLDINGS LTD;;EBERLEIN DAVID JEFFREY;;CHANG DERRICK,EBERLEIN DAVID JEFFREY;;CHANG DERRICK,,https://lens.org/080-806-355-701-346,Patent Application,yes,2,0,3,3,0,A45D33/008;;A45D2040/225;;A45D33/20;;A45D40/22;;A45D33/008;;A45D2040/225;;A45D33/20;;A45D33/26;;A45D40/22,A45D33/00;;A45D33/20;;A45D40/22,,0,0,,,,PENDING
685,NO,D0,NO 904506 D0,078-593-385-846-679,1990-10-18,1990,NO 904506 A,1990-10-18,US 42383089 A,1989-10-19,GAMMASTRAALEDETEKTERINGSANORDNING SOM ANVENDER KRYSTALLBOELGELEDERE.,,HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/078-593-385-846-679,Patent Application,no,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01N23/20;;G01T1/36,,0,0,,,,PENDING
686,NO,D0,NO 873764 D0,090-618-393-182-158,1987-09-09,1987,NO 873764 A,1987-09-09,US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BITUMINOESE MATERIALER.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/090-618-393-182-158,Patent Application,no,0,0,4,20,0,,C08L23/08;;C08L95/00,,0,0,,,,EXPIRED
687,US,A1,US 2015/0248609 A1,101-174-031-697-456,2015-09-03,2015,US 201414268372 A,2014-05-02,US 201414268372 A;;US 201461947149 P,2014-03-03,NEURAL NETWORK ADAPTATION TO CURRENT COMPUTATIONAL RESOURCES,"Methods and apparatus are provided for processing in an artificial nervous system. According to certain aspects, resolution of one or more functions performed by processing units of a neuron model may be reduced, based at least in part on availability of computational resources or a power target or budget. The reduction in resolution may be compensated for by adjusting one or more network weights.",QUALCOMM INC,JULIAN DAVID JONATHAN;;CHANG ILWOO,QUALCOMM INCORPORATED (2014-05-06),https://lens.org/101-174-031-697-456,Patent Application,yes,2,3,8,8,0,G06N3/082;;G06N3/048;;G06N3/082;;G06N3/048;;G06N3/048;;G06N3/082,G06N3/08;;G06N3/06,,0,0,,,,ACTIVE
688,US,B2,US 9427062 B2,096-334-411-280-100,2016-08-30,2016,US 201514795903 A,2015-07-10,US 201514795903 A;;US 201462023011 P,2014-07-10,Multiple level container,"Cosmetic containers having multiple levels, a lid, and a base, in which the opening of the lid also provides access to at least first and second levels having one or more compartments for products and/or applicators. The base may contain a first level, and be coupled via a first linkage to a second level. The lid may be coupled by a pivot assembly to the base and to the second level by a second linkage. The overall assembly may allow access to both the first level and the second level on opening the lid.",HCT GROUP HOLDINGS LTD,EBERLEIN DAVID JEFFREY;;CHANG DERRICK,HCT GROUP HOLDINGS LIMITED (2015-07-07),https://lens.org/096-334-411-280-100,Granted Patent,yes,6,2,3,3,0,A45D33/20;;A45D33/20;;A45D33/008;;A45D33/008;;A45D33/26;;A45D40/22;;A45D40/22;;A45D2040/225;;A45D2040/225,B65D1/24;;A45D33/00;;A45D33/20;;A45D33/26;;A45D40/22,,1,0,,,"PCT Appl. No. US2015/039912, The International Search Report and the Written Opinion of the International Searching Authority mailed Sep. 25, 2015.",INACTIVE
689,US,A1,US 2017/0015987 A1,142-626-400-439-922,2017-01-19,2017,US 201615224441 A,2016-07-29,US 201615224441 A;;US 201313792135 A,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,"The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2023-11-21);;BELLICUM PHARMACEUTICALS INC (2013-04-29),https://lens.org/142-626-400-439-922,Patent Application,yes,0,6,17,17,50,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,C12N9/64;;A61K38/48;;A61K38/52;;C12N9/90,,0,0,,,,ACTIVE
690,WO,A2,WO 1997/030103 A2,139-523-384-525-029,1997-08-21,1997,US 9702135 W,1997-02-10,US 1173896 P,1996-02-15,PREPARATION OF POLYETHERAMINES AND POLYETHERAMINE DERIVATIVES,"Processes for preparing polyetheramines, polyetherpolyamines and their derivatives from ammonia capped polyethers are disclosed. Polyetheramines, polyetherpolyamines and their derivatives are prepared by reacting an ammonia capped polyether with an aldehyde or ketone to form an imine or reaction of an ammonia capped polyether with cyanide compound to form a nitrile intermediate, followed by subsequent hydrogenation of the intermediates to form the final polyetheramine products. A process for producing polyetheramine products by reaction of an ammonia capped polyether with an alkylene oxide followed by amination to produce a polyetheramine is also disclosed.",DOW CHEMICAL CO,CHANG DANE;;WILSON DAVID A,,https://lens.org/139-523-384-525-029,Patent Application,no,0,61,3,3,0,B01D19/0413;;C10L1/238;;C08G65/3255;;C08G65/33368;;C10L1/22;;C10L1/2225;;C10L1/2235;;C10L1/2283;;C10L1/2286;;C10L1/232;;C10L1/233;;C10L1/2443;;C10L1/2475;;C10M149/12;;C10M2215/042;;C10N2030/12;;C23F11/173,B01D19/04;;C08G65/325;;C08G65/333;;C10L1/22;;C10L1/238;;C10L1/24;;C10M149/12;;C23F11/173,,0,0,,,,PENDING
691,US,B2,US 9269031 B2,168-679-755-113-625,2016-02-23,2016,US 201414575973 A,2014-12-18,AU 2013/273787 A,2013-12-20,Method of detecting regions in an edge-based representation,"A method receives an intermediate graphical representation (IGR) of a document, the IGR including a plurality of non-intersecting edges and determines a plurality of vertices using the IGR. The vertices include endpoints of the edges and a split point, being determined by splitting a first edge into two or more portions using an endpoint of at least one second edge, wherein the first edge and the second edge are from the plurality of non-intersecting edges, associates vertices from the plurality of vertices with at least one edge from the IGR using endpoints of the one edge, wherein the associating includes selecting, from the determined plurality of vertices, a plurality of neighbouring vertices to said one edge to define a region with the endpoints of the one edge. The method processes the region using at least the endpoints of said one edge and the associated neighbouring vertices.",CANON KK,CHANG WEN SHAN;;KARLOV DAVID,CANON KABUSHIKI KAISHA (2015-01-16),https://lens.org/168-679-755-113-625,Granted Patent,yes,14,0,3,3,0,G06K15/1849;;G06K15/1849;;G06T11/203;;G06T11/203;;G06T11/60,G06K15/00;;G06K15/02;;G06T11/60,,1,1,136-091-125-647-958,10.1145/74334.74369,"M. Gangnet; J.-C. Hervé; T. Pudet; J.-M. van Thong. Incremental computation of planar maps. SIGGRAPH Comput. Graph. 1989, 23, pp. 345-354.",ACTIVE
692,US,A,US 5012499 A,162-378-758-457-59X,1991-04-30,1991,US 42383089 A,1989-10-19,US 42383089 A,1989-10-19,gamma -ray detecting device using dislocation-free crystal,"A .gamma.-ray detector that comprises a dislocation-free single crystal. Typical crystals include silicon and germanium, for example. The crystal is surrounded by an active shield that functions as an anticoincidence counter and a .gamma.-ray detector is disposed adjacent the crystal in order to detect received -65 -rays. The .gamma.-ray detector comprises an imaging proportional counter, scintillation counter, or a .gamma.-ray detecting charge coupled device, for example. The .gamma.-ray detector of the present invention is based on the Bormann effect, which is the anomalous transmission of .gamma.-rays through dislocation free single crystals at the Bragg angle. For extended sources, data processing is provided to separate the directional and wavelength dependence of the intensity variation. The .gamma.-ray detector has angular resolution of at least one arc second and may have an effective aperture of several square meters. Reduction in background radiation, which is essentially determined by the crystal thickness, may be made quite large, greater than 10.sup.12. Consequently, the use of the present invention makes it possible to detect a weak .gamma.-ray source even in the presence of a large isotropic background.",HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,HUGHES AIRCRAFT COMPANY A CORP. OF DE (1989-10-04),https://lens.org/162-378-758-457-59X,Granted Patent,yes,1,4,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01N23/20;;G01T1/36,378/84;;378/145,0,0,,,,EXPIRED
693,JP,A,JP 2018171075 A,160-870-318-254-977,2018-11-08,2018,JP 2018134247 A,2018-07-17,US 201313792135 A,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,"PROBLEM TO BE SOLVED: To provide modified caspase polypeptides and uses thereof.SOLUTION: The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. The methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of an inducer.SELECTED DRAWING: None",BELLICUM PHARMACEUTICALS INC,DAVID SPENCER;;CHANG WEI-CHUN,,https://lens.org/160-870-318-254-977,Patent Application,no,0,0,17,17,155,A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008;;A61P1/04;;A61P17/00;;A61P19/08;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P5/00;;A61P7/00;;A61P7/06;;A61K31/4545;;C12N9/6472;;A61K38/4873;;A61K38/52;;C12N9/90;;C12Y304/22062;;C12Y502/01008,C12N15/09;;A61K35/12;;A61K35/14;;A61K35/17;;A61K35/28;;A61K35/51;;A61K35/545;;A61K35/76;;A61K35/761;;A61K38/46;;A61K38/48;;A61K45/08;;A61K48/00;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C07K14/47;;C07K19/00;;C12N5/10;;C12N9/50,,0,0,,,,DISCONTINUED
694,US,A1,US 2021/0362981 A1,174-787-558-009-779,2021-11-25,2021,US 202117395881 A,2021-08-06,US 202117395881 A;;US 201815971211 A,2018-05-04,COATED SHEAVE,An elevator sheave includes a sheave body and a coating on a surface of the sheave body. The coating includes microcracks and a filler in the microcracks. A method of making a sheave for an elevator system is also disclosed.,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,,https://lens.org/174-787-558-009-779,Patent Application,yes,21,0,7,7,0,B66B7/02;;B66B15/04;;B66B15/04;;C09D191/06;;C25D3/04,B66B15/04;;C09D191/06;;C25D3/04,,0,0,,,,DISCONTINUED
695,WO,A2,WO 2003/089651 A2,025-359-675-887-075,2003-10-30,2003,US 0311508 W,2003-04-14,US 37243702 P;;US 41201103 A,2002-04-16,AN IN VITRO ASSAY FOR QUANTITATING SECRETED ANTIBODIES IN LYMPHOCYTE SUPERNATANT FOR EVALUATION OF VACCINE OR ANTIGEN INDUCED SPECIFIC ANTIBODY SECRETION FROM EX VIVO CIRCULATING ANTIBODY-SECRETING LYMPHOCYTES,The present invention provides methods of quantitating recent secreted antigen specific antibodies from supernatant of antibody secreting cells (ASC) in vitro culture for evaluation of vaccine or antigen induced antigen specific antibody secretion without ex vivo antigen stimulation.,CHANG HUI SUNNY;;SACK DAVID,CHANG HUI SUNNY;;SACK DAVID,,https://lens.org/025-359-675-887-075,Patent Application,yes,0,0,7,7,0,C07K16/1239;;Y10S530/866;;Y10S530/862;;Y10S530/863;;Y10S530/861;;G01N33/5091;;C07K16/1239;;Y10S530/862;;Y10S530/866;;Y10S530/861;;Y10S530/863;;G01N33/5091;;G01N33/6854,C07K16/12;;G01N33/50,,0,0,,,,PENDING
696,EP,B1,EP 3066039 B1,036-484-234-224-243,2021-07-21,2021,EP 13896989 A,2013-11-08,US 2013/0069068 W,2013-11-08,GUIDE RAIL FOR ELEVATOR,,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,OTIS ELEVATOR COMPANY (2017-09-06),https://lens.org/036-484-234-224-243,Granted Patent,yes,8,0,7,7,0,B66B7/022;;B66B7/022;;B32B37/12;;B32B38/10;;B32B2307/752,B66B7/02,,1,0,,,None,ACTIVE
697,US,A1,US 2005/0012881 A1,054-712-254-301-044,2005-01-20,2005,US 84112204 A,2004-05-07,US 84112204 A;;US 24328002 A;;US 51848800 A;;US 32217301 P,2000-03-03,Three-dimensional electrophoretic displays,"This invention relates to three-dimensional (3-D) electrophoretic displays comprising individually sealed cells filled with optically active electrophoretic dispersions, and more particularly to bi-stable, low-power-consumption and sealed microcup-based electrophoretic displays for high-quality three-dimensional imagery applications.",LIANG RONG-CHANG;;CHEN DAVID,LIANG RONG-CHANG;;CHEN DAVID,E INK CALIFORNIA LLC (1999-06-01),https://lens.org/054-712-254-301-044,Patent Application,yes,13,16,2,195,0,G02F1/133377;;G02F1/167;;H04N13/337;;G02F1/1677;;G02F1/167;;G02F1/133377;;H04N13/337;;G02F1/1677,G02B27/22;;G02F1/1333;;H04N13/00,349/115,0,0,,,,EXPIRED
698,US,A1,US 2012/0115359 A1,067-744-980-894-209,2012-05-10,2012,US 201113290152 A,2011-11-07,CN 201010533125 A,2010-11-05,CABLE ASSEMBLY ADAPTED FOR POWER AND SIGNAL TRANSMITTING,"A cable assembly ( 100 ) includes a first connector ( 1 ) for transmitting power; a second connector ( 2 ) for transmitting signal; a cover ( 3 ) holding the first connector and the second connector, the first connector and the second connector arranged in juxtaposed manner; and the first connector floatable with regarding to the cover, the second connector fixed to the cover.",KO DAVID;;LI CHANG-MAO;;HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,HON HAI PRECISION INDUSTRY CO. LTD (2011-10-27),https://lens.org/067-744-980-894-209,Patent Application,yes,12,13,3,3,0,H01R13/6315;;H01R13/6658;;H01R13/701;;H01R13/7175;;H01R27/02;;H01R27/02;;H01R13/6315;;H01R13/7175;;H01R13/701;;H01R13/6658,H02G3/00;;H01R9/05,439/578;;X174 70  R,0,0,,,,DISCONTINUED
699,DK,A,DK 463187 A,081-526-533-824-489,1987-09-04,1987,DK 463187 A,1987-09-04,US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BITUMINOESE MATERIALER.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/081-526-533-824-489,Patent Application,no,0,0,9,20,0,C08L95/00,C08L95/00,,0,0,,,,DISCONTINUED
700,US,A,US 5361383 A,106-365-017-098-434,1994-11-01,1994,US 78379891 A,1991-10-30,US 78379891 A,1991-10-30,Optical fiber having internal partial mirrors and interferometer using same,"An optical fiber disposed to partially internally reflect optical energy passing therethrough is disclosed herein. The optical fiber 10 of the present invention includes an internal partial mirror disposed to partially transmit and to partially reflect optical energy incident thereon. The internal mirror is effectively realized at an interface I of first and second fiber segments 14 and 18. The first fiber segment 14 includes a first core region 22 which circumscribes a longitudinal axis X. The first core region 22 is of a first cross-sectional area perpendicular to the longitudinal axis X. The inventive fiber 10 further includes a second fiber segment 18 in optical communication with the first fiber segment 14. The second fiber segment 18 includes a second core region 24 which circumscribes the longitudinal axis X, wherein the second core region 24 is of a second cross-sectional area perpendicular thereto.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,HUGHES AIRCRAFT COMPANY (1993-02-08);;OL SECURITY LIMITED LIABILITY COMPANY (2012-07-30);;HE HOLDINGS INC. A DELAWARE CORP (1997-12-17);;RAYTHEON COMPANY (1997-12-17),https://lens.org/106-365-017-098-434,Granted Patent,yes,19,26,3,3,0,G02B6/02052;;G02B6/02052,G01B9/02;;G02B6/00;;G02B6/28;;G02B6/26,385/27;;385/39;;385/12;;385/14;;385/43;;385/48;;385/95;;385/96;;385/98;;356/345;;356/352,2,0,,,"Lee et al., Fiber Optic Sensor Research . . . SPIE vol. 1170, Fiber Optic Smart Structures II (1989) pp. 113 122.;;Horche et al., Spectral Behavior of a Low Cost All Fiber . . . IEEE Photonics Tech. Lett., vol. I, No. 7, Jul. 1989 4 Pages.",EXPIRED
701,US,B2,US 7955137 B2,163-009-536-758-39X,2011-06-07,2011,US 85329510 A,2010-08-10,CN 200920307646 U,2009-08-10,Lower profile cable assembly,"A cable assembly includes an insulative housing, a number of contacts retained in the insulative housing and a metal shell covering the housing to form a receiving space with the tongue portion for receiving an electrical plug. The housing has a base portion and a tongue portion extending forwardly from the base portion. The contacts consist of two pairs of differential signal contacts and a pair of grounding contacts between the two pairs of differential signal contacts. Each contact has a contact portion. All contact portions are arranged in a row on one side of the tongue portion.",HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,HON HAI PRECISION INDUSTRY CO. LTD (2010-08-01),https://lens.org/163-009-536-758-39X,Granted Patent,yes,6,14,3,3,0,H01R13/506;;H01R13/506;;H01R13/6275;;H01R13/6275;;H01R13/6471;;H01R13/6471;;H01R13/6593;;H01R13/6593,H01R24/00,439/660;;439/607.45,0,0,,,,INACTIVE
702,CN,A,CN 110436306 A,179-291-430-682-887,2019-11-12,2019,CN 201910359988 A,2019-04-30,US 201815971211 A,2018-05-04,Coated sheave,An elevator sheave includes a sheave body and a coating on a surface of the sheave body. The coating includes microcracks and a filler in the microcracks. A method of making a sheave for an elevatorsystem is also disclosed.,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,,https://lens.org/179-291-430-682-887,Patent Application,no,9,0,7,7,0,B66B7/02;;B66B15/04;;B66B15/04;;C09D191/06;;C25D3/04,B66B7/02,,2,0,,,"宋小平等: ""《表面活性剂处理剂及润滑剂制造技术》"", 30 September 2006, 科学技术文献出版社;;潘梦秋等: ""“自修复防腐涂层研究进展”"", 《中国材料进展》",ACTIVE
703,US,A1,US 2014/0255360 A1,181-082-514-408-894,2014-09-11,2014,US 201313792135 A,2013-03-10,US 201313792135 A,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,"The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2023-11-21);;BELLICUM PHARMACEUTICALS INC (2013-04-29),https://lens.org/181-082-514-408-894,Patent Application,yes,2,46,17,17,50,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,A61K35/14;;A61K31/4545;;C12N9/64,424/93.21;;536/23.2;;435/325,0,0,,,,ACTIVE
704,US,B2,US 9231422 B2,194-427-609-965-223,2016-01-05,2016,US 201213667625 A,2012-11-02,US 201213667625 A;;US 28471208 A,2008-09-23,Interconnecting solar rechargeable batteries,"Portable stackable solar batteries are disclosed, in which the solar batteries can be connected in a planar arrangement for solar recharging and connected in a vertically stacked arrangement for powering an electrically powered device and/or for charging another rechargeable battery.",SOLARLEGO INC,CHANG DAVID;;COATES STEPHEN S,,https://lens.org/194-427-609-965-223,Granted Patent,yes,13,0,5,5,0,H01M10/465;;H01M14/005;;H01M10/4207;;Y02E10/56;;Y02E60/10;;H01M10/465;;H01M14/005;;H01M10/4207;;H02J7/35;;H02J7/0045;;H02J7/0014,H01M10/44;;H01M10/42;;H01M10/46;;H01M14/00;;H02J7/00,,0,0,,,,ACTIVE
705,CA,A1,CA 2588624 A1,195-490-070-844-302,2008-11-15,2008,CA 2588624 A,2007-05-15,CA 2588624 A,2007-05-15,POSTERIOR-FORM ENHANCEMENT DEVICE,"The posterior-form enhancement device includes a garment and two posterior- form pads. Each posterior-form pad is formed by attaching one first posterior-for m piece to one second posterior-form piece. The garment is used for covering the lower body part of a person, and in its rear side has two pockets adjacent to the posteriors of wearers for placing the posterior-form pads respectively. Each first posterior-form piec e includes a bag for encasing a volume of gel. The second posterior-form pieces are respectively adjacent to the first posterior-form pieces in the pockets, wherein the firs t posterior-form piece is near an external surface away from wearers' posteriors of while the second posterior-form piece is near an internal surface adjacent to wearers' posteriors. The shape and size of the pockets are determined by the shape and size of the posterio r- form pad. The posterior-form pads can be put into or taken out of the pockets.",CHEN DAVID E;;CHANG JASPER,CHEN DAVID E;;CHANG JASPER,,https://lens.org/195-490-070-844-302,Patent Application,no,0,0,2,2,0,A41B9/04,A41D27/26;;A41B9/00;;A41D13/00;;A41D27/12;;A41D27/20,,0,0,,,,INACTIVE
706,TW,U,TW M428576 U,004-327-248-279-333,2012-05-01,2012,TW 100211657 U,2011-06-27,TW 100211657 U,2011-06-27,Adaptor,"An adaptor includes a first connector, a second and a third connector both of which are electrically connected with the first connector. The ad-aptor includes a micro-switch. The micro-switch could control the first connector selectivity electrically connected with the second or the third connector. It need not push-pull the complementary connector plug in the adaptor again and again during switching to use. The adaptor would be used conveniently.",HON HAI PREC IND CO LTD,LI CHANG-MAO;;KO DAVID,,https://lens.org/004-327-248-279-333,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
707,US,B2,US 11096481 B2,044-156-431-751-816,2021-08-24,2021,US 201816047246 A,2018-07-27,US 201816047246 A;;US 201762538411 P,2017-07-28,Motorized adjustable height table,A table includes a table top having a frame attached to a lower surface of the table top. The table also includes a first leg having lugs and a second leg having lugs. The lugs of the first leg and the second leg are received in slots of the frame to attach the legs to the table. The legs are telescopically movable to adjust the height of the table top.,VARIDESK LLC,PATTON DAVID;;CHANG LIO Y,VARIDESK LLC (2018-09-04),https://lens.org/044-156-431-751-816,Granted Patent,yes,34,2,6,6,0,A47B9/20;;A47B9/20;;A47B3/06;;A47B3/06;;A47B13/003;;A47B13/003;;A47B13/021;;A47B13/021;;A47B13/023;;A47B13/023;;A47B2200/0057;;A47B2200/0059;;A47B2200/0059;;F16B12/52;;F16B12/52,A47B9/20;;A47B3/06;;A47B13/00;;A47B13/02;;F16B12/52,,8,0,,,"WO2019149296 Bucquetetal abstract and figure (Year: 2018).;;CN 108813946 Feng et al abstract and figure (Year: 2018).;;CN 107713329 Wang abstract and figure (Year: 2018).;;English translation for CN107981540 (Year: 2018).;;Extended European Search Report issued in counterpart European Patent Application No. 18186011.5 dated Jan. 11, 2019.;;Office Action issued in counterpart European Patent Application No. 18186011.5 dated Oct. 8, 2019.;;Office Action issued in counterpart European Patent Application No. 18186011.5 dated Apr. 1, 2020.;;European Communication of Intent to Grant for corresponding EP Application No. 18186011.5 dated Sep. 24, 2020.",ACTIVE
708,WO,A2,WO 2008/054476 A2,059-259-289-173-643,2008-05-08,2008,US 2007/0006374 W,2007-03-14,US 37762906 A,2006-03-16,ELECTROSTATIC NANOLITHOGRAPHY PROBE ACTUATION DEVICE AND METHOD,"Method and apparatus for selectively actuating a cantilevered probe for applying a compound to a substrate in nanolithography. A probe having a probe electrode and a substrate having a counter electrode are provided. Voltage applied to the probe electrode and/or counter electrode provides electrostatic attraction between them, moving a probe tip into sufficient proximity to the substrate to apply the patterning compound. Alternatively, a flexible cantilevered probe anchored to a holder includes a layer of conductive material forming a probe electrode. A counter electrode on the holder faces the probe electrode. The holder and probe are positioned so that a probe tip applies the compound to the substrate. The probe is disposed between the substrate and the counter electrode. An electrostatic attractive force generated between the probe electrode and the counter electrode flexes the probe and lifts the tip away from the substrate to suspend writing.",UNIV ILLINOIS;;LIU CHANG;;BULLEN DAVID ANDREW,LIU CHANG;;BULLEN DAVID ANDREW,,https://lens.org/059-259-289-173-643,Patent Application,yes,0,0,5,5,0,G01Q80/00;;G03F7/0002;;G01Q70/06;;G01Q70/16;;G01Q70/06;;G03F7/0002;;G01Q80/00;;G01Q70/16,G01Q70/16;;G01Q80/00,,0,0,,,,PENDING
709,US,A1,US 2008/0271225 A1,072-189-347-399-705,2008-11-06,2008,US 79764207 A,2007-05-04,US 79764207 A,2007-05-04,Posterior-form enhancement device,"The posterior-form enhancement device includes a garment and two posterior-form pads. Each posterior-form pad is formed by attaching one first posterior-form piece to one second posterior-form piece. The garment is used for covering the lower body part of a person, and in its rear side has two pockets adjacent to the posteriors of wearers for placing the posterior-form pads respectively. Each first posterior-form piece includes a bag for encasing a volume of gel. The second posterior-form pieces are respectively adjacent to the first posterior-form pieces in the pockets, wherein the first posterior-form piece is near an external surface away from wearers' posteriors of while the second posterior-form piece is near an internal surface adjacent to wearers' posteriors. The shape and size of the pockets are determined by the shape and size of the posterior-form pad. The posterior-form pads can be put into or taken out of the pockets.",CHEN DAVID E;;CHANG JASPER,CHEN DAVID E;;CHANG JASPER,,https://lens.org/072-189-347-399-705,Patent Application,yes,11,4,2,2,0,A41B9/001;;A41B9/001;;A41B2400/38;;A41B2400/38,A41D1/14;;A41B9/00;;A41D27/26,2/211;;2/267;;2/400,0,0,,,,INACTIVE
710,TW,B,TW I458194 B,087-922-275-897-919,2014-10-21,2014,TW 99116579 A,2010-05-25,TW 99116579 A,2010-05-25,CABLE CONNECTOR ASSEMBLY,,HON HAI PREC IND CO LTD,KO DAVID;;LI CHANG-MAO,,https://lens.org/087-922-275-897-919,Granted Patent,no,1,0,2,2,0,,,,0,0,,,,INACTIVE
711,TW,A,TW 200816560 A,109-413-250-839-510,2008-04-01,2008,TW 95136107 A,2006-09-28,TW 95136107 A,2006-09-28,An antenna for global positioning system,"An antenna for global positioning system includes a cap, a coil member, and a limiter. The cap defines an accommodation chamber. The coil member is a coil of metal wire accommodated in the accommodation chamber, having a first end formed of closely attached turns, a second end formed of closely attached turns, and a middle part formed of spirally extended turns of the metal wire and connected between the first end and the second end. The limiter comprises a body member and a T-shaped metal connecting member embedded in the body member. The T-shaped metal connecting member has a first end that extends out of one side of the body member and supports the second end of the coil member inside the cap, and a second end that extends out of the opposite side of the body member. Thus, a non-directional, circularly polarized antenna with high inductance and high gain antenna is obtained. The invention simplifies the antenna manufacturing process, and greatly reduces the manufacturing cost of the antenna.",DHARMA TECHNOLOGY CORP LTD,LIAO HONG-SYUAN;;CHANG DAVID,,https://lens.org/109-413-250-839-510,Patent of Addition,no,0,0,1,1,0,,H01Q1/22,,0,0,,,,PENDING
712,EP,B1,EP 3564180 B1,119-296-395-429-435,2022-06-29,2022,EP 19172602 A,2019-05-03,US 201815971211 A,2018-05-04,COATED SHEAVE,,OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,,https://lens.org/119-296-395-429-435,Granted Patent,yes,2,0,7,7,0,B66B7/02;;B66B15/04;;B66B15/04;;C09D191/06;;C25D3/04,B66B15/04,,0,0,,,,ACTIVE
713,US,A1,US 2015/0178605 A1,125-365-394-110-960,2015-06-25,2015,US 201414575973 A,2014-12-18,AU 2013/273787 A,2013-12-20,METHOD OF DETECTING REGIONS IN AN EDGE-BASED REPRESENTATION,"A method receives an intermediate graphical representation (IGR) of a document, the IGR comprising a plurality of non-intersecting edges and determines a plurality of vertices using the IGR. The vertices comprises endpoints of the edges and a split point, being determined by splitting a first edge into two or more portions using an endpoint of at least one second edge, wherein the first edge and the second edge are from the plurality of non-intersecting edges, associates vertices from the plurality of vertices with at least one edge from the IGR using endpoints of the one edge, wherein the associating comprises selecting, from the determined plurality of vertices, a plurality of neighbouring vertices to said one edge to define a region with the endpoints of the one edge. The method processes the region using at least the endpoints of said one edge and the associated neighbouring vertices.",CANON KK,CHANG WEN SHAN;;KARLOV DAVID,CANON KABUSHIKI KAISHA (2015-01-16),https://lens.org/125-365-394-110-960,Patent Application,yes,12,2,3,3,0,G06K15/1849;;G06K15/1849;;G06T11/203;;G06T11/203;;G06T11/60,G06K15/02,,0,0,,,,ACTIVE
714,US,A,US 3488167 A,152-154-850-928-002,1970-01-06,1970,US 3488167D A,1967-07-06,US 65153967 A,1967-07-06,MAGNETIC MEMORY ELEMENT WITH VARIABLE EXCHANGE COUPLING,,IBM,CHANG HSU;;THOMPSON DAVID A,,https://lens.org/152-154-850-928-002,Granted Patent,no,2,6,4,4,0,G11B5/00;;G11B5/66;;G11B11/10515;;G11B11/10584;;G11B11/10586;;G11B2005/0002;;G11B2005/0005;;G11B2005/0021;;G11C11/15;;G11C13/06;;Y10S428/926;;Y10T428/12438;;Y10T428/12958;;Y10T428/12771;;Y10T428/12438;;Y10T428/12958;;Y10T428/12771;;G11B5/00;;G11B11/10515;;G11C11/15;;G11B2005/0002;;G11B2005/0005;;G11B11/10584;;G11B2005/0021;;G11B11/10586;;G11C13/06;;Y10S428/926;;G11B5/672,G11B5/00;;G11B5/66;;G11B11/105;;G11C11/15;;G11C13/06,29/196.1,0,0,,,,EXPIRED
715,AU,A1,AU 2008/203041 A1,193-625-761-786-992,2009-01-29,2009,AU 2008/203041 A,2008-07-10,US 94958307 P,2007-07-13,Effect of cumulative overload on rope shovel reliability,,BUCYRUS INT INC,LANG DAVID;;CHANG SHYUE-SHENG,,https://lens.org/193-625-761-786-992,Patent Application,no,0,1,5,5,0,G06Q10/06;;E02F9/264;;E02F9/26;;G06Q10/06;;E02F9/26;;E02F9/264,E02F9/26;;E02F3/36;;E02F9/20,,0,0,,,,DISCONTINUED
716,CA,A1,CA 2903216 A1,195-275-767-632-48X,2014-10-09,2014,CA 2903216 A,2014-03-07,US 201313792135 A;;US 2014/0022004 W,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,"The technology relates in part to compositions comprising modified caspase-9 polypeptides, compositions comprising nucleic acids coding for modified caspase-9 polypeptides, chimeric modified caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/195-275-767-632-48X,Patent Application,no,0,0,17,17,155,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,,,0,0,,,,DISCONTINUED
717,WO,A2,WO 2014/164348 A2,022-555-926-648-634,2014-10-09,2014,US 2014/0022004 W,2014-03-07,US 201313792135 A,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,"The technology relates in part to compositions comprising modified caspase-9 polypeptides, compositions comprising nucleic acids coding for modified caspase-9 polypeptides, chimeric modified caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID;;CHANG WEI-CHUN,,https://lens.org/022-555-926-648-634,Patent Application,yes,9,49,17,17,0,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,A61K35/14;;A61K31/4545;;C12N9/64,,209,190,119-279-899-568-792;;060-366-483-956-384;;063-854-944-766-893;;074-329-622-195-729;;020-052-915-250-236;;034-084-208-857-228;;071-429-593-853-516;;115-972-294-054-30X;;097-076-899-446-449;;030-162-494-746-005;;004-990-754-720-540;;019-130-227-958-367;;002-377-847-209-110;;045-167-043-118-816;;106-947-905-231-395;;049-897-709-904-769;;001-130-700-090-695;;029-640-383-431-180;;015-617-903-805-622;;017-574-565-089-074;;077-906-081-143-534;;075-987-120-610-743;;001-247-987-939-340;;068-589-904-018-425;;081-578-609-335-687;;008-797-776-310-121;;023-512-064-153-73X;;017-399-532-580-822;;030-202-896-771-215;;032-051-999-499-063;;037-076-314-262-251;;075-057-846-638-250;;046-399-217-299-346;;000-906-844-677-689;;025-871-854-811-562;;089-335-215-220-013;;069-990-053-764-194;;031-636-356-171-07X;;083-300-127-977-763;;041-809-608-159-532;;006-770-979-895-067;;106-360-460-538-50X;;088-917-763-027-234;;000-446-253-604-686;;019-223-757-833-839;;034-273-672-763-762;;013-872-547-066-215;;088-947-503-926-361;;001-247-987-939-340;;007-162-010-900-165;;028-834-504-937-401;;091-144-636-478-872;;106-502-063-725-273;;085-009-706-976-342;;034-273-672-763-762;;000-385-963-376-028;;015-812-924-415-969;;124-985-422-988-633;;026-045-531-189-395;;003-381-030-696-215;;081-727-758-133-68X;;128-119-661-218-34X;;038-226-770-301-063;;021-079-160-548-304;;125-472-370-503-982;;036-843-545-508-253;;089-488-528-988-581;;056-073-530-503-473;;088-917-763-027-234;;077-658-154-371-483;;071-111-890-340-768;;095-009-613-240-195;;064-213-235-179-334;;025-596-606-643-965;;008-073-363-539-995;;048-793-449-009-473;;057-103-385-862-082;;000-380-208-347-204;;049-893-011-590-675;;009-012-940-202-16X;;038-404-519-135-404;;007-664-139-814-196;;003-180-650-129-827;;100-091-443-443-591;;003-180-650-129-827;;141-276-141-946-220;;122-742-372-778-777;;144-915-082-232-945;;068-637-973-521-79X;;054-431-289-321-79X;;009-431-727-846-405;;067-225-454-459-616;;049-238-531-992-941;;002-030-548-108-94X;;057-790-048-617-243;;037-223-423-261-423;;083-666-837-096-094;;080-275-967-332-334;;012-208-904-405-480;;040-168-376-932-43X;;008-330-766-873-60X;;057-790-048-617-243;;008-297-903-289-089;;007-888-139-067-445;;031-386-880-222-030;;055-438-959-647-712;;040-573-961-841-570;;015-639-251-167-350;;022-700-685-856-667;;009-073-833-235-053;;075-924-048-888-91X;;072-366-322-919-406;;032-026-264-382-468;;004-212-749-090-555;;005-256-565-741-692;;048-533-982-202-633;;004-701-796-869-470;;092-475-980-877-170;;076-607-506-177-849;;107-273-667-679-802;;005-058-719-114-708;;044-907-186-843-585;;020-703-580-582-672;;048-036-080-827-91X;;091-275-864-852-82X;;052-176-596-515-633;;058-997-183-544-854;;085-875-375-088-180;;094-857-606-776-915;;041-998-348-351-290;;057-404-975-210-454;;088-927-854-299-269;;003-297-281-928-568;;003-297-281-928-568;;004-253-998-677-868;;061-213-774-521-865;;020-984-837-129-173;;086-801-624-319-977;;022-498-703-986-961;;043-619-194-006-282;;055-406-926-990-606;;018-681-067-914-617;;092-166-334-303-974;;016-501-978-837-735;;025-627-126-037-64X;;023-260-533-682-872;;188-427-004-635-881;;001-116-270-494-591;;031-815-721-025-163;;106-992-460-151-925;;060-824-980-876-559;;044-967-162-851-665;;066-722-514-892-229;;072-032-471-580-08X;;032-152-898-363-426;;006-840-326-353-915;;013-047-069-985-371;;017-807-482-658-328;;019-622-793-830-57X;;000-427-962-971-581;;048-017-174-975-725;;087-247-552-844-019;;000-634-088-419-476;;039-539-237-346-160;;000-671-283-072-01X;;032-882-065-353-850;;015-609-843-238-59X;;010-511-607-738-720;;086-439-822-197-06X;;124-073-715-271-423;;005-362-487-902-647;;035-252-295-554-52X;;115-279-609-964-995;;032-924-718-385-415;;106-502-063-725-273;;085-009-706-976-342;;053-900-918-619-293;;010-091-785-487-524;;014-990-643-039-130;;054-914-540-977-067;;087-719-944-261-851;;088-994-457-887-198;;034-941-163-165-394;;034-955-588-990-231;;025-599-819-137-904;;015-253-633-954-147;;005-466-548-606-507;;019-223-757-833-839;;006-692-394-149-981;;019-849-114-602-468,10102814;;10.1126/science.284.5411.143;;10.1080/14653240600855905;;16923606;;9082988;;10.1126/science.276.5309.71;;10.1073/pnas.0608249103;;pmc1634835;;10.3410/f.1079797.532717;;17088535;;12097260;;15523088;;10.1093/jnci/djh299;;10086387;;10.1038/6529;;17656645;;10.1634/stemcells.2007-0197;;17901396;;10.1634/stemcells.2007-0637;;12084934;;pmc124401;;10.3410/f.723954163.793509207;;10.1073/pnas.132252399;;10.1532/ijh97.06230;;17675260;;17664353;;10.1182/blood-2007-02-069716;;10.1016/s0140-6736(08)60690-x;;18468541;;19308035;;10.1038/bmt.2009.63;;10.1016/j.bbmt.2006.10.016;;10.1634/stemcells.2005-0620;;17038675;;15197139;;10.1161/01.cir.0000134696.08436.65;;17483296;;10.1182/blood-2006-12-063412;;16606790;;10.1161/circulationaha.105.593038;;6420177;;10.1038/mt.2009.210;;19773745;;pmc2839303;;20179677;;pmc2862534;;10.1038/mt.2010.24;;10.1182/blood.v99.9.3179;;11964281;;10.1084/jem.20040890;;15611290;;pmc2211993;;14569557;;10.1016/j.bbmt.2003.08.009;;16984391;;10.1111/j.1365-2141.2006.06300.x;;10.1056/nejm199810223391702;;9780338;;10.1200/jco.2005.09.117;;15753458;;15528145;;10.1016/j.bcmd.2004.08.017;;12958064;;10.1182/blood-2003-02-0342;;10.1146/annurev.med.56.082103.104727;;15660500;;10.1038/nrc1365;;15122208;;12126823;;10.1016/s0140-6736(02)09413-8;;pmc1895160;;15817673;;10.1182/blood-2005-01-0393;;pmc1895537;;16741253;;10.1182/blood-2006-02-001909;;10.1182/blood-2002-11-3516;;12763937;;1717600;;10.1016/0022-1759(91)90110-2;;10363991;;16361568;;10.1158/1078-0432.ccr-05-1314;;12829610;;10.1182/blood-2003-01-0150;;7581076;;pmc27912;;10.1073/pnas.95.18.10437;;9724721;;10.1177/00912700122010771;;11504275;;11222367;;10.1182/blood.v97.5.1249;;10.1016/s0960-9822(02)00607-3;;8805308;;10.1089/10430349950016924;;10515447;;14563634;;10.1182/blood-2003-08-2908;;12833128;;10.1038/sj.gt.3301977;;10.1182/blood.v99.9.3179;;11964281;;14685154;;10.1038/sj.cgt.7700664;;12850789;;10.1080/14653240310001488;;10.1038/nri841;;12094225;;pmc1895037;;15728125;;10.1182/blood-2004-11-4564;;10.1073/pnas.95.7.3655;;pmc19891;;9520421;;10.1089/10430349950016924;;10515447;;10801470;;10.1016/s1074-5521(00)00109-5;;10.2174/138620707782507296;;18045079;;10.1111/j.1747-0285.2006.00403.x;;16882320;;7694365;;10.1126/science.7694365;;pmc20324;;10.1073/pnas.94.7.3076;;9096348;;10.1038/383181a0;;8774885;;8752278;;10.1038/382822a0;;10.1038/nm0996-1028;;8782462;;pmc40891;;10.1073/pnas.92.21.9805;;7568222;;7568223;;pmc40892;;10.1073/pnas.92.21.9810;;10.3322/ca.2007.0010;;18287387;;7687666;;10.1200/jco.1993.11.8.1566;;10.1016/s0022-5347(01)64846-8;;10.1097/00005392-199705000-00057;;9112515;;10.1177/00912700122010771;;11504275;;pmc49329;;10.1073/pnas.89.12.5547;;1319065;;10.1126/science.7792603;;7792603;;10.1146/annurev.immunol.15.1.617;;9143702;;10.1016/s0264-410x(02)00081-6;;11983257;;12213402;;10.1016/s0264-410x(02)00310-9;;3818598;;10.1016/s0021-9258(18)61660-6;;pmc336488;;10.1093/nar/16.8.3195;;3375054;;pmc553575;;2820712;;10.1002/j.1460-2075.1987.tb02450.x;;pmc298248;;2479021;;10.1073/pnas.86.21.8202;;pmc362893;;2247055;;10.1128/mcb.10.12.6181-6191.1990;;10.1128/mcb.10.12.6181;;pmc443569;;2447485;;10.1128/mcb.8.1.42;;10.1128/mcb.8.1.42-51.1988;;3261386;;10.1128/mcb.8.6.2394-2401.1988;;10.1128/mcb.8.6.2394;;pmc363437;;10.1128/mcb.11.5.2887;;pmc360079;;10.1128/mcb.11.5.2887-2895.1991;;2017183;;18781156;;10.1038/nrg2432;;pmc4317294;;10.1089/dna.1993.12.777;;8216848;;18781156;;10.1038/nrg2432;;pmc4317294;;10.1038/334320a0;;2839775;;1652694;;10.1038/353090a0;;10.1038/sj.mt.6300036;;17235321;;10.1016/j.vaccine.2004.07.010;;15542183;;10.1089/aid.2004.20.1335;;15650426;;12135633;;10.1016/s0378-1135(02)00099-8;;10.1016/j.bbrc.2003.11.091;;14672702;;16930549;;10.1016/j.bbrc.2006.07.209;;10.1128/jvi.71.7.4892-4903.1997;;pmc191719;;9188551;;16140431;;10.1016/j.vaccine.2005.08.023;;10.1128/jvi.74.6.2628-2635.2000;;pmc111751;;10684277;;10.1006/viro.2000.0357;;10873786;;10.1016/s0378-1119(01)00550-9;;11470520;;10.1016/s1286-4579(00)01323-x;;11137041;;pmc2738518;;10.3201/eid0812.020224;;12498651;;10.1089/dna.2006.25.383;;16848679;;16140431;;10.1016/j.vaccine.2005.08.023;;2522441;;10.1016/s0021-9258(18)83636-5;;18575608;;pmc2429965;;10.1371/journal.pone.0002517;;pmc2946157;;10.1021/jo00103a013;;20882116;;10.1126/science.2734614;;2734614;;10.1126/science.2499928;;2499928;;10.1073/pnas.81.22.7161;;pmc392097;;6438633;;pmc367564;;3466023;;10.1128/mcb.6.2.716-718.1986;;10.1128/mcb.6.2.716;;21530212;;10.1016/j.coi.2011.03.008;;pmc3109217;;21266849;;10.4161/hv.7.0.14574;;4705382;;10.1016/0042-6822(73)90341-3;;10.1128/mcb.7.8.2745-2752.1987;;10.1128/mcb.7.8.2745;;pmc367891;;3670292;;2105458;;10.1128/mcb.10.2.689;;10.1128/mcb.10.2.689-695.1990;;pmc360867;;2987679;;pmc366838;;10.1128/mcb.5.5.1188-1190.1985;;10.1128/mcb.5.5.1188;;pmc299564;;10.1073/pnas.84.23.8463;;2446324;;10.1016/s0021-9258(18)61209-8;;3558345;;pmc53910;;10.1073/pnas.87.9.3410;;2333290;;8171039;;pmc43728;;10.1073/pnas.91.9.4086;;10.1016/0169-409x(93)90057-b;;10.1016/0076-6879(87)49054-x;;3320679;;10.1038/327070a0;;pmc55213;;2175906;;10.1073/pnas.87.24.9568;;2149186;;10.1016/0167-8140(90)90148-p;;10.1016/0022-2836(84)90181-5;;6737476;;10.1016/0378-1119(91)90411-4;;1829048;;902315;;10.1016/0092-8674(77)90202-1;;10.1016/s0022-2836(83)80112-0;;6876165;;10.1016/0092-8674(83)90344-6;;6678608;;1172324;;10.1016/0042-6822(75)90421-3;;10.1073/pnas.86.23.9079;;2556698;;pmc298437;;10.1128/jvi.61.10.3096-3101.1987;;pmc255885;;3041032;;8597384;;10.1111/j.1749-6632.1995.tb31045.x;;8597384;;10.1111/j.1749-6632.1995.tb31045.x;;pmc190186;;8627803;;10.1128/jvi.70.5.3227-3234.1996;;pmc189840;;10.1128/jvi.70.1.520-532.1996;;8523565;;pmc47827;;7504271;;10.1073/pnas.90.22.10613;;10.1182/blood.v84.5.1492.1492;;8068942;;10.1016/s0003-4975(96)00946-0;;8957370;;10.1073/pnas.93.24.14082;;8943064;;pmc19498;;10.1073/pnas.94.4.1426;;9037069;;pmc19807;;8599196;;10.1006/viro.1996.0099;;10.1016/0006-8993(95)01488-8;;8724980;;8839444;;10.3109/10739689609148292;;10.1128/jvi.70.11.8098-8108.1996;;pmc190884;;8892935;;10.1016/0168-9525(88)90174-6;;10.1007/978-1-4684-5167-2_5;;2851485;;10.1016/0378-1119(88)90593-8;;7675046;;10.1056/nejm199510193331603;;9716582;;10.1182/blood.v92.5.1549.417k32_1549_1555;;10.1182/blood.v92.5.1549;;10.1126/science.1076514;;pmc1764179;;12242449;;10.1073/pnas.0530192100;;pmc151411;;12601144;;10.1126/science.276.5319.1719;;9180086;;10.1182/blood.v97.1.63;;11133743;;10.1038/nm0296-216;;8574968;;12208748;;10724039;;10.1089/10430340050015798;;12382069;;10.1007/s00210-002-0588-0;;14624253;;10.1371/journal.pbio.0000053;;pmc261890;;15752064;;10.1371/journal.pbio.0030082;;pmc1059451;;18354197;;10.4049/jimmunol.180.7.4728;;pmc3437189;;19898472;;10.1038/ni.1820;;10829082;;10.1073/pnas.130182597;;pmc16563;;22697466;;10.1186/1752-0509-6-66;;pmc3436737;;10.1128/mcb.00968-06;;pmc1636743;;16923964;;pmc2895425;;19696798;;10.1038/nrm2748;;pmc3077556;;21251012;;10.1111/j.1749-6632.2010.05877.x;;10.1104/pp.110.161232;;pmc2948987;;20921159;;18768149;;10.1016/j.pharmthera.2008.07.005;;pmc2668812;;8815789;;10.1146/annurev.physiol.58.1.143;;10.1146/annurev.ph.58.030196.001043;;12620238;;10.1016/s1097-2765(03)00054-6;;pmc64668;;11734640;;10.1073/pnas.231465798;;10.1016/s1097-2765(02)00482-3;;11931755;;10.1073/pnas.072544399;;pmc123625;;11904389;;pmc1895037;;15728125;;10.1182/blood-2004-11-4564;;10.1073/pnas.95.7.3655;;pmc19891;;9520421;;10.1056/nejmoa1106152;;pmc3236370;;22047558;;18338032;;10.1371/journal.pone.0001317;;pmc2267039;;pmc2702793;;10.1073/pnas.0901522106;;19528653;;10.1016/j.ceb.2003.10.009;;14644197;;12620239;;10.1016/s1097-2765(03)00051-0;;pmc1088972;;10.1371/journal.pbio.0030183;;15941357;;10085063;;10.1074/jbc.274.13.8359;;10.1128/mcb.25.23.10543-10555.2005;;pmc1291226;;16287866;;10.1074/jbc.m414325200;;15703181;;009812896;;10.1126/science.282.5392.1318;;9812896;;15657060;;10.1074/jbc.m413787200;;10.1016/s0960-9822(02)00607-3;;8805308;;10.1186/scrt52;;pmc3226282;;21375737;;22008483;;10.1186/1756-0500-4-420;;pmc3208510,"PITTENGER, M. F. ET AL., SCIENCE, vol. 284, 1999, pages 143 - 147;;DOMINICI, M. ET AL., CYTOTHERAPY, vol. 8, 2006, pages 315 - 317;;PROCKOP, D. J., SCIENCE, vol. 276, 1997, pages 71 - 74;;LEE, R. H. ET AL., PROC NATL ACAD SCI, vol. 103, 2006, pages 17438 - 17443;;STUDENY, M. ET AL., CANCER RES, vol. 62, 2002, pages 3603 - 3608;;STUDENY, M. ET AL., J NATL CANCER INST, vol. 96, 2004, pages 1593 - 1603;;HORWITZ, E. M. ET AL., NAT MED, vol. 5, 1999, pages 309 - 313;;CHAMBERLAIN, G. ET AL., STEM CELLS, vol. 25, 2007, pages 2739 - 2749;;PHINNEY, D. G.; PROCKOP, D. J., STEM CELLS, vol. 25, 2007, pages 2896 - 2902;;HORWITZ, E. M. ET AL., PROC NATL ACAD SCI, vol. 99, 2002, pages 8932 - 8937;;HALL, B. ET AL., INT J HEMATOL, vol. 86, 2007, pages 8 - 16;;NAUTA, A. J.; FIBBE, W. E., BLOOD, vol. 110, 2007, pages 3499 - 3506;;LE BLANC, K. ET AL., LANCET, vol. 371, 2008, pages 1579 - 1586;;TYNDALL, A.; UCCELLI, A., BONE MARROW TRANSPLANT, 2009;;HORWITZ, E. M. ET AL., BIOL BLOOD MARROW TRANSPLANT, vol. 13, 2007, pages 53 - 57;;TOLAR, J. ET AL., STEM CELLS, vol. 25, 2007, pages 371 - 379;;YOON, Y.-S. ET AL., CIRCULATION, vol. 109, 2004, pages 3154 - 3157;;BREITBACH, M. ET AL., BLOOD, vol. 110, 2007, pages 1362 - 1369;;CHANG, M. G. ET AL., CIRCULATION, vol. 113, 2006, pages 1832 - 1841;;SALE, G. E.; STORB, R., EXP HEMATOL, vol. 11, 1983, pages 961 - 966;;ZHONG, X.-S., MOLECULAR THERAPY, vol. 18, 2010, pages 413 - 420;;MORGAN, R.A. ET AL., MOLECULAR THERAPY, vol. 18, 2010, pages 843 - 851;;BOLLARD, C.J. ET AL., BLOOD, vol. 99, 2002, pages 3179 - 3187;;BOLLARD, C.M. ET AL., J. EXPTL. MED., vol. 200, 2004, pages 1623 - 1633;;HURLEY CK ET AL., BIOL BLOOD MARROW TRANSPLANT, vol. 9, 2003, pages 610 - 615;;DEY BR ET AL., BR.J HAEMATOL., vol. 135, 2006, pages 423 - 437;;AVERSA F ET AL., N ENGL J MED, vol. 339, 1998, pages 1186 - 1193;;AVERSA F ET AL., J C LIN.ON COL., vol. 23, 2005, pages 3447 - 3454;;LANG P, MOL.DIS., vol. 33, 2004, pages 281 - 287;;KOLB HJ ET AL., BLOOD, vol. 103, 2004, pages 767 - 776;;GOTTSCHALK S ET AL., ANNU.REV.MED, vol. 56, 2005, pages 29 - 44;;BLEAKLEY M ET AL., NAT.REV.CANCER, vol. 4, 2004, pages 371 - 380;;ANDRE-SCHMUTZ I ET AL., LANCET, vol. 360, 2002, pages 130 - 137;;SOLOMON SR ET AL., BLOOD, vol. 106, 2005, pages 1123 - 1129;;AMROLIA PJ ET AL., BLOOD, vol. 108, 2006, pages 1797 - 1808;;AMROLIA PJ ET AL., BLOOD, 2003;;GHETIE V ET AL., J IMMUNOL METHODS, vol. 142, 1991, pages 223 - 230;;MOLLDREM JJ ET AL., CANCER RES, vol. 59, 1999, pages 2675 - 2681;;REZVANI K ET AL., CLIN.CANCER RES., vol. 11, 2005, pages 8799 - 8807;;REZVANI K ET AL., BLOOD, vol. 102, 2003, pages 2892 - 2900;;PRZEPIORKA D ET AL.: ""1994 Consensus Conference on Acute GVHD Grading"", BONE MARROW TRANSPLANT, vol. 15, 1995, pages 825 - 828, XP009166128;;CLACKSON T ET AL., PROC NATL ACAD SCI, vol. 95, 1998, pages 10437 - 10442;;LULIUCCI JD ET AL., J CLIN PHARMACOL., vol. 41, 2001, pages 870 - 879;;THOMIS DC ET AL., BLOOD, vol. 97, 2001, pages 1249 - 1257;;SPENCER DM ET AL., CURR BIOL., vol. 6, 1996, pages 839 - 847;;FAN L ET AL., HUM GENE THER., vol. 10, 1999, pages 2273 - 2285;;BERGER C ET AL., BLOOD, vol. 103, 2004, pages 1261 - 1269;;JUNKER K ET AL., GENE THER., vol. 10, 2003, pages 1189 - 1197;;BOLLARD CM ET AL., BLOOD, vol. 99, 2002, pages 3179 - 3187;;WAGNER HJ ET AL., CANCER GENE THER., vol. 11, 2004, pages 81 - 91;;PULE M ET AL., CYTOTHERAPY, vol. 5, 2003, pages 211 - 226;;SCHUMACHER TN, NAT REV IMMUNOL., vol. 2, 2002, pages 512 - 519;;STRAATHOF, K.C. ET AL., BLOOD, vol. 105, 2005, pages 4248 - 4254;;MACCORKLE, R.A. ET AL., PROC. NATL. ACAD. SCI., vol. 95, 1998, pages 3655 - 3660;;FAN, L. ET AL., HUMAN GENE THERAPY, vol. 10, 1999, pages 2273 - 2285;;KOPYTEK, S.J. ET AL., CHEMISTRY & BIOLOGY, vol. 7, 2000, pages 313 - 321;;GESTWICKI, J.E. ET AL., COMBINATORIAL CHEM. & HIGH THROUGHPUT SCREENING, vol. 10, 2007, pages 667 - 675;;CLACKSON T, CHEM BIOL DRUG DES, vol. 67, 2006, pages 440 - 442;;CLACKSON, T. ET AL.: ""Chemical Biology: From Small Molecules to Systems Biology and Drug Design"", 2007, WILEY;;SPENCER, D. M. ET AL., SCIENCE, vol. 262, 1993, pages 1019 - 1024;;SPENCER D. M. ET AL., CURR BIOL, vol. 6, 1996, pages 839 - 847;;BLAU, C. A. ET AL., PROC NATL ACAD.SCI., vol. 94, 1997, pages 3076 - 3081;;LUO, Z. ET AL., NATURE, vol. 383, 1996, pages 181 - 185;;MACCORKLE, R. A. ET AL., PROC NATL ACAD SCI, vol. 95, 1998, pages 3655 - 3660;;HO, S. N. ET AL., NATURE, vol. 382, 1996, pages 822 - 826;;RIVERA, V. M. ET AL., NAT.MED., vol. 2, 1996, pages 1028 - 1032;;SPENCER D. M. ET AL., PROC.NATI.ACAD.SCI., vol. 92, 1995, pages 9805 - 9809;;HOLSINGER, L. J. ET AL., PROC.NATI.ACAD.SCI., vol. 95, 1995, pages 9810 - 9814;;JEMAL, A. ET AL., CA CANCER J. CLINIC., vol. 58, 2008, pages 71 - 96;;SCHER, H.I.; KELLY, W.K., JOURNAL OF CLINICAL ONCOLOGY, vol. 11, 1993, pages 1566 - 1572;;SCHELLHAMMER, P.F. ET AL., J. UROL., vol. 157, 1997, pages 1731 - 1735;;LULIUCCI JD ET AL., J CLIN PHARMACOL., vol. 41, 2001, pages 870 - 879;;GOSSEN; BUJARD, PROC. NATL. ACAD. SCI., vol. 89, 1992, pages 5547 - 5551;;GOSSEN ET AL., SCIENCE, vol. 268, 1995, pages 1766 - 1769;;DONNELLY, J.J. ET AL., ANNU. REV. IMMUNOL., vol. 15, 1997, pages 617 - 648;;BOJAK, A. ET AL., VACCINE, vol. 20, 2002, pages 1975 - 1979;;CAZEAUX., N. ET AL., VACCINE, vol. 20, 2002, pages 3322 - 3331;;KAGEYAMA ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 2345 - 2351;;ARCONE ET AL., NUCL. ACIDS RES., vol. 16, no. 8, 1988, pages 3195 - 3207;;OLIVIERO ET AL., EMBO J., vol. 6, 1987, pages 1905 - 1912;;POLI; CORTESE, PROC. NAT'L ACAD. SCI., vol. 86, 1989, pages 8202 - 8206;;WILSON ET AL., MOL. CELL. BIOL., 1990, pages 6181 - 6191;;PROWSE; BAUMANN, MOL CELL BIOL, vol. 8, 1988, pages 42 - 51;;ZECHNER ET AL., MOL. CELL. BIOL., 1988, pages 2394 - 2401;;RON ET AL., MOL. CELL. BIOL., 1991, pages 2887 - 2895;;KUTZLER, M.A.; WEINER, D.B., NATURE REVIEWS GENETICS, vol. 9, 2008, pages 776 - 788;;MONTGOMERY, D.L. ET AL., DNA CELL BIOL., vol. 12, 1993, pages 777 - 783;;KUTZLER, M.A.; WEINER, D.B., NATURE REV. GEN., vol. 9, 2008, pages 776 - 788;;PELLETIER; SONENBERG, NATURE, vol. 334, 1988, pages 320 - 325;;MACEJAK; SARNOW, NATURE, vol. 353, 1991, pages 90 - 94;;YAN, J. ET AL., MOL. THER., vol. 15, 2007, pages 411 - 421;;CHEUNG, Y.K. ET AL., VACCINE, vol. 23, 2004, pages 629 - 638;;YADAVA, A.; OCKENHOUSE, C.F., INFECT. IMMUN., vol. 71, 2003, pages 4962 - 4969;;SMITH., J.M. ET AL., AIDS RES. HUM. RETROVIRUSES, vol. 20, 2004, pages 1335 - 1347;;ZHOU, W. ET AL., VET. MICROBIOL., vol. 88, 2002, pages 127 - 151;;WU, X. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 313, 2004, pages 89 - 96;;ZHANG, W. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 349, 2006, pages 69 - 78;;DEMI, L.A. ET AL., J. VIROL., vol. 75, 2001, pages 1099 - 1101;;SCHNEIDER, R. M. ET AL., J. VIROL., vol. 71, 1997, pages 4892 - 4903;;WANG, S.D. ET AL., VACCINE, vol. 24, 2006, pages 4531 - 4540;;MEGEDE, J. ET AL., J. VIROL., vol. 74, 2000, pages 2628 - 2635;;LI, V. ET AL., VIROLOGY, vol. 272, 2000, pages 417 - 428;;XU, Z.L. ET AL., GENE, vol. 272, 2001, pages 149 - 156;;MALIN, A.S. ET AL., MICROBES INFECT., vol. 2, 2000, pages 1677 - 1685;;KUTZLER, M.A. ET AL., J. IMMUNOL., vol. 175, 2005, pages 112 - 125;;YANG, J.S. ET AL., EMERG. INFECT. DIS., vol. 8, 2002, pages 1379 - 1384;;KUMAR., S. ET AL., DNA CELL BIOL., vol. 25, 2006, pages 383 - 392;;WANG, S. ET AL., VACCINE, vol. 24, 2006, pages 4531 - 4540;;TEPLER, I ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 5912;;LADDY, D.J. ET AL., PLOS.ONE, vol. 3, 2008, pages e2517;;SCHWEITZER ET AL., J. ORG. CHEM., vol. 59, 1994, pages 7238 - 7242;;WILSON ET AL., SCIENCE, vol. 244, 1989, pages 1344 - 1346;;NABEL ET AL., SCIENCE, vol. 244, no. 4910, 1989, pages 1342 - 1344;;POTTER ET AL., PROC. NAT'L ACAD. SCI., vol. 81, 1984, pages 7161 - 7165;;TUR-KASPA ET AL., MOL. CELL BIOL., vol. 6, 1986, pages 716 - 718;;SARDESAI, N.Y.; WEINER, D.B., CURRENT OPINION IN IMMUNOTHERAPY, vol. 23, 2011, pages 421 - 429;;FERRARO, B. ET AL., HUMAN VACCINES, vol. 7, 2011, pages 120 - 127;;GRAHAM; VAN DER EB, VIROLOGY, vol. 52, 1973, pages 456 - 467;;CHEN; OKAYAMA, MOL. CELL BIOL., vol. 7, no. 8, 1987, pages 2745 - 2752;;RIPPE ET AL., MOL. CELL BIOL., vol. 10, 1990, pages 689 - 695;;GOPAL, T.V., MOL CELL BIOL., vol. 5, no. 5, May 1985 (1985-05-01), pages 1188 - 1190;;FECHHEIMER ET AL., PROC. NAT'L ACAD. SCI., vol. 84, 1987, pages 8463 - 8467;;GHOSH; BACHHAWAT, LIVER DISEASES, TARGETED DIAGNOSIS AND THERAPY USING SPECIFIC RECEPTORS AND LIGANDS, 1991, pages 87 - 104;;WU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432;;WAGNER ET AL., PROC. NATL. ACAD. SCI., vol. 87, no. 9, 1990, pages 3410 - 3414;;PERALES ET AL., PROC. NATL. ACAD. SCI., vol. 91, 1994, pages 4086 - 4090;;WU; WU, ADV. DRUG DELIVERY REV., vol. 12, 1993, pages 159 - 167;;NICOLAU ET AL., METHODS ENZYMOL., vol. 149, 1987, pages 157 - 176;;KLEIN ET AL., NATURE, vol. 327, 1987, pages 70 - 73;;YANG ET AL., PROC. NAT'L ACAD. SCI., vol. 87, 1990, pages 9568 - 9572;;RENAN, M. J., RADIOTHER ONCOL., vol. 19, 1990, pages 197 - 218;;HAY, R.T. ET AL., J MOL BIOL., vol. 175, no. 4, 5 June 1984 (1984-06-05), pages 493 - 510;;HEARING ET AL., VIROL., vol. 67, 1987, pages 2555 - 2558;;LEVRERO ET AL., GENE, vol. 101, 1991, pages 195 - 202;;TIBBETTS, CELL, vol. 12, 1977, pages 243 - 249;;HEARING; SHENK, J. MOL. BIOL., vol. 167, 1983, pages 809 - 822;;COFFIN: ""Virology"", 1990, RAVEN PRESS, pages: 1437 - 1500;;MANN ET AL., CELL, vol. 33, 1983, pages 153 - 159;;NICOLAS, J.F.; RUBENSTEIN, J.L.R.: ""Vectors: a Survey of Molecular Cloning Vectors and Their Uses"", 1988;;NICOLAS; RUBENSTEIN; TEMIN ET AL.: ""In: Gene Transfer"", 1986, PLENUM PRESS, pages: 149 - 188;;PASKIND ET AL., VIROLOGY, vol. 67, 1975, pages 242 - 248;;ROUX ET AL., PROC. NAT'L ACAD. SCI., vol. 86, 1989, pages 9079 - 9083;;SAMULSKI ET AL., J. VIROL., vol. 61, 1987, pages 3096 - 3101;;CARTER; FLOTTE, ANN. N.Y. ACAD. SCI., vol. 770, 1995, pages 79 - 90;;CHATTEIJEE ET AL., ANN. N.Y. ACAD. SCI., vol. 770, 1995, pages 79 - 90;;FERRARI ET AL., J. VIROL., vol. 70, 1996, pages 3227 - 3234;;FISHER ET AL., J. VIROL., vol. 70, 1996, pages 520 - 532;;FLOTTE ET AL., PROC. NAT'L ACAD. SCI., vol. 90, 1993, pages 10613 - 10617;;GOODMAN ET AL., BLOOD, vol. 84, 1994, pages 1492 - 1500;;KAPLITTET, NAT'L GENET., vol. 8, 1994, pages 148 - 153;;KAPLITT, M.G. ET AL., ANN THORAC SURG., vol. 62, no. 6, December 1996 (1996-12-01), pages 1669 - 1676;;KESSLER ET AL., PROC. NAT'L ACAD. SCI., vol. 93, 1996, pages 14082 - 14087;;KOEBERL ET AL., PROC. NAT'L ACAD. SCI., vol. 94, 1997, pages 1426 - 1431;;MIZUKAMI ET AL., VIROLOGY, vol. 217, 1996, pages 124 - 130;;MCCOWN ET AL., BRAIN RES., vol. 713, 1996, pages 99 - 107;;PING ET AL., MICROCIRCULATION, vol. 3, 1996, pages 225 - 228;;XIAO ET AL., J. VIROL., vol. 70, 1996, pages 8098 - 8108;;RIDGEWAY, IN: VECTORS: A SURVEY OF MOLECULAR CLONING VECTORS AND THEIR USES, 1988, pages 467 - 492;;BAICHWAL; SUGDEN, GENE TRANSFER, 1986, pages 117 - 148;;COUPAR ET AL., GENE, vol. 68, 1988, pages 1 - 10;;""Remington's Pharmaceutical Sciences"", pages: 1035 - 1038,1570-1580;;WALTER, E.A. ET AL., N. ENGL. J. MED., vol. 333, 1995, pages 1038 - 1044;;ROONEY, C.M. ET AL., BLOOD, vol. 92, 1998, pages 1549 - 1555;;DUDLEY, M.E. ET AL., SCIENCE, vol. 298, 2002, pages 850 - 854;;MARJIT, W.A. ET AL., PROC. NATL. ACAD. SCI., vol. 100, 2003, pages 2742 - 2747;;BONINI C ET AL., SCIENCE, vol. 276, 1997, pages 1719 - 1724;;TIBERGHIEN P ET AL., BLOOD, vol. 97, 2001, pages 63 - 72;;CICERI, F. ET AL., LANCET ONCOL., vol. 262, 2009, pages 1019 - 1024;;RIDDELL SR ET AL., NAT MED., vol. 2, 1996, pages 216 - 223;;FREYTAG SO ET AL., CANCER RES., vol. 62, 2002, pages 4968 - 4976;;INTRONA M ET AL., HUM GENE THER., vol. 11, 2000, pages 611 - 620;;DATABASE GenBank [O] retrieved from ncbi Database accession no. AH002 818;;DATABASE GenBank [O] retrieved from ncbi Database accession no. NM_001229;;DATABASE GenBank [O] retrieved from ncbi Database accession no. NM_001770;;SEIFERT, R.; K. WENZEL-SEIFERT: ""Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors"", NAUNYN SCHMIEDEBERGS ARCH PHARMACOL, vol. 366, no. 5, 2002, pages 381 - 416;;ROOSE, J.P. ET AL.: ""T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression"", PLOS BIOL, vol. 1, no. 2, 2003, pages E53;;TZE, L.E. ET AL.: ""Basal immunoglobulin signaling actively maintains developmental stage in immature B cells"", PLOS BIOL, vol. 3, no. 3, 2005, pages e82;;SCHRAM, B.R. ET AL.: ""B cell receptor basal signaling regulates antigen-induced Ig light chain rearrangements"", J IMMUNOL, vol. 180, no. 7, 2008, pages 4728 - 4741;;RANDALL, K.L. ET AL.: ""Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production"", NAT IMMUNOL, vol. 10, no. 12, 2009, pages 1283 - 1291;;KOUSKOFF, V. ET AL.: ""B cell receptor expression level determines the fate of developing B lymphocytes: receptor editing versus selection"", PROC NATL ACAD SCI, vol. 97, no. 13, 2000, pages 7435 - 7439;;HONG, T. ET AL.: ""A simple theoretical framework for understanding heterogeneous differentiation of CD4+ T cells"", BMC SYST BIOL, vol. 6, 2012, pages 66, XP021116947, DOI: doi:10.1186/1752-0509-6-66;;RUDD, M.L.; A. TUA-SMITH; D.B. STRAUS: ""Lck SH3 domain function is required for T-cell receptor signals regulating thymocyte development"", MOL CELL BIOL, vol. 26, no. 21, 2006, pages 7892 - 7900;;SORKIN, A.; M. VON ZASTROW: ""Endocytosis and signalling: intertwining molecular networks"", NAT REV MOL CELL BIOL, vol. 10, no. 9, 2009, pages 609 - 622;;LUNING PRAK, E.T.; M. MONESTIER; R.A. EISENBERG: ""B cell receptor editing in tolerance and autoimmunity"", ANN N Y ACAD SCI, vol. 1217, 2011, pages 96 - 121;;BOSS, W.F. ET AL.: ""Basal signaling regulates plant growth and development"", PLANT PHYSIOL, vol. 154, no. 2, 2010, pages 439 - 443;;TAO, Y.X.: ""Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics"", PHARMACOL THER, vol. 120, no. 2, 2008, pages 129 - 148, XP025545708, DOI: doi:10.1016/j.pharmthera.2008.07.005;;SPIEGEL, A.M.: ""Defects in G protein-coupled signal transduction in human disease"", ANNU REV PHYSIOL, vol. 58, 1996, pages 143 - 170, XP009059612, DOI: doi:10.1146/annurev.ph.58.030196.001043;;SHIOZAKI, E.N. ET AL.: ""Mechanism of XIAP-mediated inhibition of caspase-9"", MOL CELL, vol. 11, no. 2, 2003, pages 519 - 527;;RENATUS, M. ET AL.: ""Dimer formation drives the activation of the cell death protease caspase-9"", PROC NATL ACAD SCI, vol. 98, no. 25, 2001, pages 14250 - 14255;;SHI, Y.: ""Mechanisms of Caspase activation and inhibition during apoptosis"", MOL CELL, vol. 9, no. 3, 2002, pages 459 - 470;;SHIOZAKI, E.N.; J. CHAI; Y. SHI: ""Oligomerization and activation of caspase-9, induced by Apaf-1 CARD"", PROC NATL ACAD SCI, vol. 99, no. 7, 2002, pages 4197 - 4202, XP002978103;;STRAATHOF, K.C. ET AL.: ""An inducible caspase-9 safety switch for T-cell therapy"", BLOOD, vol. 105, no. 11, 2005, pages 4247 - 4254, XP008126232, DOI: doi:10.1182/blood-2004-11-4564;;MACCORKLE, R.A.; K.W. FREEMAN; D.M. SPENCER: ""Synthetic activation of Caspases: artificial death switches"", PROC NATL ACAD SCI, vol. 95, no. 7, 1998, pages 3655 - 3560;;DI STASI, A. ET AL.: ""Inducible apoptosis as a safety switch for adoptive cell therapy"", N ENGL J MED, vol. 365, no. 18, 2011, pages 1673 - 1683, XP055181696, DOI: doi:10.1056/NEJMoa1106152;;CHANG, W.C. ET AL.: ""Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor"", PLOS ONE, vol. 2, no. 12, 2007, pages e1317;;BLOOM, J.D.; F.H. ARNOLD: ""In the light of directed evolution: pathways of adaptive protein evolution"", PROC NATL ACAD SCI, vol. 106, no. 1, 2009, pages 9995 - 10000;;BOATRIGHT, K.M.; G.S. SALVESEN: ""Mechanisms of Caspase activation"", CURR OPIN CELL BIOL, vol. 15, no. 6, 2003, pages 725 - 731;;BOATRIGHT, K.M. ET AL.: ""A unified model for apical Caspase activation"", MOL CELL, vol. 11, no. 2, 2003, pages 529 - 541, XP002365111, DOI: doi:10.1016/S1097-2765(03)00051-0;;CHAO, Y. ET AL.: ""Engineering a dimeric caspase-9: a re-evaluation of the induced proximity model for Caspase activation"", PLOS BIOL, vol. 3, no. 6, 2005, pages e183;;STENNICKE, H.R. ET AL.: ""caspase-9 can be activated without proteolytic processing"", J BIOL CHEM, vol. 274, no. 13, 1999, pages 8359 - 8362, XP055310291, DOI: doi:10.1074/jbc.274.13.8359;;BRADY, S.C.; L.A. ALLAN; P.R. CLARKE: ""Regulation of caspase-9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress"", MOL CELL BIOL, vol. 25, no. 23, 2005, pages 10543 - 10555, XP055293374, DOI: doi:10.1128/MCB.25.23.10543-10555.2005;;MARTIN, M.C. ET AL.: ""Protein kinase A regulates caspase-9 activation by Apaf-1 downstream of cytochrome c"", J BIOL CHEM, vol. 280, no. 15, 2005, pages 15449 - 15455;;CARDONE, M.H. ET AL.: ""Regulation of cell death protease caspase-9 by phosphorylation"", SCIENCE, vol. 282, no. 5392, 1998, pages 1318 - 1321;;RAINA, D. ET AL.: ""c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage"", J BIOL CHEM, vol. 280, no. 12, 2005, pages 11147 - 11151;;PAPWORTH, C.; BAUER, J. C.; BRAMAN, J.; WRIGHT, D. A.: ""Site-directed mutagenesis in one day with >80% efficiency"", STRATEGIES, vol. 9, no. 3, 1996, pages 3 - 4;;SPENCER, D.M.: ""Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization"", CURR BIOL, vol. 6, no. 7, 1996, pages 839 - 847, XP001093782, DOI: doi:10.1016/S0960-9822(02)00607-3;;HSIAO, E.C. ET AL.: ""Constitutive Gs activation using a single-construct tetracycline-inducible expression system in embryonic stem cells and mice"", STEM CELL RES THER, vol. 2, no. 2, 2011, pages 11, XP021102331, DOI: doi:10.1186/scrt52;;WALDNER, C. ET AL.: ""Double conditional human embryonic kidney cell line based on FLP and PhiC31 mediated transgene integration"", BMC RES NOTES, vol. 4, 2011, pages 420, XP021114651, DOI: doi:10.1186/1756-0500-4-420;;See also references of EP 2967081A4",PENDING
718,FI,A0,FI 873900 A0,017-499-783-864-481,1987-09-09,1987,FI 873900 A,1987-09-09,US 81765986 A;;US 88966486 A;;US 8700016 W,1986-01-10,BITUMENINNEHAOLLANDE KOMPOSITIONER.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/017-499-783-864-481,Patent Application,no,0,0,9,20,0,C08L95/00,C08L95/00,,0,0,,,,DISCONTINUED
719,CA,C,CA 2027151 C,065-623-537-580-201,1993-11-09,1993,CA 2027151 A,1990-10-09,US 42383089 A,1989-10-19,GAMMA RAY DETECTING DEVICE USING CRYSTAL WAVEGUIDES,"GAMMA RAY DETECTING DEVICE USING CRYSTAL WAVEGUIDES A .gamma.-ray telescope that comprises a dislocation-free single crystal. Typical crystals include silicon and germanium, for example. The crystal is surrounded by an active shield that functions as an anticoincidence counter and a .gamma.-ray detector is disposed adjacent the crystal in order to detect received .gamma.-rays. The .gamma.-ray detector comprises an imaging proportional counter, scintillation counter, or a .gamma.-ray detecting charge coupled device, for example. The .gamma.-ray detector is based on the Borrmann effect, which is the anomalous transmission of .gamma.-rays through dislocation free single crystals at the Bragg angle. For extended sources, data processing is provided to separate the directional and wavelength dependence of the intensity variation. The .gamma.-ray telescope has angular resolution of at least one arc second and may have an effective aperture of several square meters. Reduction in background radiation, which is es-sentially determined by the crystal thickness, may be made quite large, greater than 1012. Consequently, the use of the present invention makes it possible to detect a weak .gamma.-ray source even in the presence of a large isotropic background.",HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/065-623-537-580-201,Granted Patent,no,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01T1/36;;G01N23/20,D13580032    M,0,0,,,,EXPIRED
720,DE,T2,DE 69001291 T2,065-866-580-580-262,1993-07-22,1993,DE 69001291 T,1990-10-17,US 42383089 A,1989-10-19,GERAET ZUR GAMMASTRAHLENFESTSTELLUNG UNTER VERWENDUNG VON VERSETZUNGSFREIEN KRISTALLEN.,,HUGHES AIRCRAFT CO,VALI VICTOR;;CHANG DAVID B,,https://lens.org/065-866-580-580-262,Granted Patent,no,0,0,13,13,0,G01T1/36;;G01T1/36,G01T1/00;;G01N23/20;;G01T1/36,,0,0,,,,EXPIRED
721,US,B2,US 7247895 B2,094-225-171-807-018,2007-07-24,2007,US 37762906 A,2006-03-16,US 37762906 A;;US 7393805 A;;US 64772403 A;;US 871901 A;;US 30797601 P,2001-07-26,Electrostatic nanolithography probe actuation device and method,"Method and apparatus for selectively actuating a cantilevered probe for applying a compound to a substrate in nanolithography. A probe having a probe electrode and a substrate having a counter electrode are provided. Voltage applied to the probe electrode and/or counter electrode provides electrostatic attraction between them, moving a probe tip into sufficient proximity to the substrate to apply the patterning compound. Alternatively, a flexible cantilevered probe anchored to a holder includes a layer of conductive material forming a probe electrode. A counter electrode on the holder faces the probe electrode. The holder and probe are positioned so that a probe tip applies the compound to the substrate. The probe is disposed between the substrate and the counter electrode. An electrostatic attractive force generated between the probe electrode and the counter electrode flexes the probe and lifts the tip away from the substrate to suspend writing.",UNIV ILLINOIS,LIU CHANG;;BULLEN DAVID ANDREW,BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS THE (2006-04-24),https://lens.org/094-225-171-807-018,Granted Patent,yes,14,8,5,5,0,G01Q80/00;;G03F7/0002;;G01Q70/06;;G01Q70/16;;G01Q70/06;;G03F7/0002;;G01Q80/00;;G01Q70/16,H01L27/148;;G01Q70/16;;G01Q80/00;;H01L29/768,257/226;;257/444,10,6,067-979-622-405-045;;016-551-533-043-292;;047-112-128-487-869;;031-101-045-789-242;;006-533-002-808-522;;168-660-388-592-977,10.1126/science.288.5472.1808;;0010846159;;10846159;;10.1002/1521-4095(200011)12:21<1600::aid-adma1600>3.3.co;2-y;;9924019;;10.1126/science.283.5402.661;;0009924019;;10.1557/s0883769400065015;;10521346;;10.1126/science.286.5439.523;;0010521346;;10.1021/la000079l,"Seunghun Hong, C.A. Mirkin, ""A nanoplotter with both parallel and serial writing capabilities"", Science, vol. 288, No. 5472, pp. 1808-1811, Jun. 9, 2000.;;Jin Zhu, ""Chemical and physical methods for the modification of high-temperature superconductors, nanoparticles and other inorganic substrates (Abstract)"", The Sciences and Engineering, vol. 60-12B, pp. 6102, 1999.;;Dana A. Weinberger, Seunghun Hong, Chad A. Mirkin, B.W. Wessels, Thomas B. Higgins, ""Combinatorial generation and analysis of nanometer-and micrometer-scale silicon features via 'dip-pen' nanolithography and wet chemical etching"", Advanced Materials, vol. 12, No. 21, pp. 1600-1603, Nov. 2000.;;R.D. Piner, Jin Zhu, Feng Xu, Seunghun Hong, C.A. Mirkin,"" ""Dip-Pen"" nanolithography"", Science, vol. 283, No. 5402, pp. 661-663, Jan. 29, 1999.;;Chad A. Mirkin, ""DNA-based Methodology for Preparing Nanocluster Circuits, Arrays, and Diagnostic Materials"", MRS Bulletin, vol. 25, No. 1, pp. 43-54, 2000.;;Michael Gross, ""Incredible nanoplotter"", Chemistry in Britain, vol. 36, No. 10, p. 25, Oct. 2000.;;S. Hong, J. Zhu, C.A. Mirkin, ""Multiple ink nanolithography: toward a multiple-pen nano-plotter"", Science, vol. 286, No. 5439, pp. 523-525, Oct. 15, 1999.;;David Rotman, ""Nanotech Goes to Work (Technology Information)"", Technology Review (Cambridge, Mass.), vol. 104, No. 1, pp. 62-68, Jan. 1, 2001.;;Ming Zhang, David Bullen, Kee S. Ryu, Chang Liu, (University of Illinois at Urbana-Champaign), Seunghun Hong, Sung-Wook Chung, and Chad A. Mirkin (Northwestern University), ""Passive and Active Probe Arrays for Dip-Pen Nanolithography"".;;N.A. Amro, S. Xu, Gang-Yu Liu, ""Patterning surfaces using tip-directed displacement and self-assembly"", Langmuir, vol. 16, No. 7, pp. 3006-3009, Apr. 4, 2000.",EXPIRED
722,US,A1,US 2016/0365908 A1,113-251-944-751-332,2016-12-15,2016,US 201615177963 A,2016-06-09,US 201615177963 A;;US 201562173833 P,2015-06-10,ANTENNA SWAP ARCHITECTURES FOR TIME-DIVISION DUPLEXING COMMUNICATION SYSTEMS,"Antenna swap architectures for time-division duplexing communication systems. In some embodiments, an antenna routing architecture can include first nodes including a transmit (Tx) node, a primary receive (PRx) node and a diversity receive (DRx) node. The antenna routing architecture can further include second nodes including a main antenna node and a diversity antenna node. The antenna routing architecture can further include a routing circuit configured to provide one or more radio-frequency (RF) signal paths between the first nodes and the second nodes. The routing circuit can be further configured such that each of the Tx node and the PRx node is capable of being independently coupled to the main antenna node or the diversity antenna node.",SKYWORKS SOLUTIONS INC,CHANG WEIHENG;;PEHLKE DAVID RICHARD,SKYWORKS SOLUTIONS INC (2016-12-15),https://lens.org/113-251-944-751-332,Patent Application,yes,3,19,1,1,0,H03F1/0277;;H03F3/72;;H03F2203/7215;;H03F2203/7221;;H03F2203/7236;;H03F3/19;;H03F3/245;;H04B7/0602;;H04L5/14;;H03F2200/451;;H03F2200/294;;H04B7/0602;;H04L5/14;;H03F2200/451;;H03F2200/294;;H03F1/0277;;H03F3/72;;H03F3/245;;H03F2203/7215;;H03F2203/7221;;H03F2203/7236;;H03F3/19,H04B7/06;;H03F3/19;;H04L5/14,,0,0,,,,DISCONTINUED
723,US,A,US 5222161 A,111-242-669-549-852,1993-06-22,1993,US 84022392 A,1992-02-24,US 84022392 A,1992-02-24,Method and apparatus for compressing a light pulse,"This invention discloses a method and apparatus for shortening the length of a pulse of light. Generally, the method entails altering the index of refraction of an optical medium (14) through which the pulse of light is traveling at an area of the medium (14) where the front end of the pulse of light is located, such that the front end of the pulse of light travels slower than the back end, thus enabling the back end to catch up with the front end in order to shorten the length of the pulse. To accomplish this, it is proposed to generate an electric field across the optical medium (14) by a charge carrying medium (12) positioned relative to the optical medium (14), such that the index of refraction is altered by the electro-optic effect. In addition, it is possible to alter the index of refraction of the optical medium (14) by surrounding the optical medium (14) with a piezoelectric material (20) and applying an electric field to the piezoelectric material (20) such that the piezoelectric material (20) compresses the optical medium (14), thus altering the index of refraction.",HUGHES AIRCRAFT CO,CHANG DAVID B;;VALI VICTOR,OL SECURITY LIMITED LIABILITY COMPANY (2012-07-30);;HE HOLDINGS INC (1997-12-16);;HUGHES AIRCRAFT COMPANY A CORP. OF DELAWARE (1992-05-04);;RAYTHEON COMPANY (1997-12-17),https://lens.org/111-242-669-549-852,Granted Patent,yes,3,3,5,5,0,G02F1/0134;;G02F1/0134;;G02F1/035;;G02F1/035;;G02F2203/26;;G02F2203/26;;H01S3/0057;;H01S3/0057,G02F1/01;;G02F1/035;;G02F2/00;;H01S3/00;;H01S3/10,385/2;;372/12,1,0,,,"C. L. Tang, Ultrashort Optical Pulses, Encyclopedia of Physics, Ed. R. G. Lerner & G. L. Trigg, N.Y.; VCH Publishers, Inc. (1991).",EXPIRED
724,AU,A1,AU 2003/230922 A1,113-943-281-550-747,2003-11-03,2003,AU 2003/230922 A,2003-04-14,US 37243702 P;;US 41201103 A;;US 0311508 W,2002-04-16,AN IN VITRO ASSAY FOR QUANTITATING SECRETED ANTIBODIES IN LYMPHOCYTE SUPERNATANT FOR EVALUATION OF VACCINE OR ANTIGEN INDUCED SPECIFIC ANTIBODY SECRETION FROM EX VIVO CIRCULATING ANTIBODY-SECRETING LYMPHOCYTES,,CHANG HUI SUNNY,CHANG HUI SUNNY;;SACK DAVID,,https://lens.org/113-943-281-550-747,Patent Application,no,0,0,7,7,0,C07K16/1239;;Y10S530/866;;Y10S530/862;;Y10S530/863;;Y10S530/861;;G01N33/5091;;C07K16/1239;;Y10S530/862;;Y10S530/866;;Y10S530/861;;Y10S530/863;;G01N33/5091;;G01N33/6854,C07K16/12;;G01N33/50,,0,0,,,,DISCONTINUED
725,US,A1,US 2016/0280512 A1,129-175-806-809-89X,2016-09-29,2016,US 201315035043 A,2013-11-08,US 2013/0069068 W,2013-11-08,GUIDE RAIL FOR ELEVATOR,"A method of making a guide rail for an elevator system includes providing a metallic guide rail having a base portion and a blade portion extending from the base portion The blade portion includes one or more guide surfaces interactive with a safety brake of the elevator system. A protective layer is applied to the guide rail for corrosion protection and a perimeter of the protective layer is adhered to the guide rail to seal the guide surfaces from corrosive elements, while not adhering the protective layer to the guide surfaces.",OTIS ELEVATOR CO,CHANG XIAOYUAN;;TORLAI DAVID R,OTIS ELEVATOR COMPANY (2013-11-05),https://lens.org/129-175-806-809-89X,Patent Application,yes,7,0,7,7,0,B66B7/022;;B66B7/022;;B32B37/12;;B32B38/10;;B32B2307/752,B66B7/02;;B32B37/12;;B32B38/10,,0,0,,,,ACTIVE
726,FI,A0,FI 913073 A0,151-298-975-457-01X,1991-06-24,1991,FI 913073 A,1991-06-24,FI 913073 A;;FI 873900 A;;US 81765986 A;;US 86966486 A;;US 8700016 W,1986-01-10,BITUMEN INNEHAOLLANDE KOMPOSITIONER.,,DOW CHEMICAL CO,WOLFE DAVID LEE;;CHANG DANE,,https://lens.org/151-298-975-457-01X,Patent Application,no,0,0,1,20,0,,C08L/,,0,0,,,,DISCONTINUED
727,CN,C,CN 1090308 C,163-189-189-249-072,2002-09-04,2002,CN 96102331 A,1996-06-19,AU PN364195 A,1995-06-19,Solar energy selective absorption surface coating and forming method thereof,"A solar selective surface coating (13) that is deposited on a solar collector element (10). The surface coating (13) comprises a three-layer structure having an inner layer (14) in the form of a bright metal infrared reflective coating layer, a solar energy absorptive coating layer (15) deposited on the reflective coating layer, and an anti-reflective surface layer (16). The absorptive coating (15) is deposited as a cermet, typically a tungsten-aluminium nitride cermet, which is formed by sputtering material simultaneously from first and second metal electrodes (23 and 24) in the presence of a gas which is reactive with the metal from which the second electrode (24) is formed and substantially non-reactive with the metal from which the first electrode (23) is formed. That is, the solar energy absorptive coating (15) is formed by co-depositing materials from the first and second electrodes (23 and 24) in the presence of a gas which is reactive with the metal of one only of the electrodes.",AUSTRALIA SYDNEY UNIV,QI-CHU CHANG;;MILS DAVID,GLOBAL SOLAR POWER SURFACE TECHNOLOGY PTE LTD. (2011-11-04),https://lens.org/163-189-189-249-072,Granted Patent,no,0,1,12,12,0,C23C14/0688;;C23C14/185;;Y02E10/40;;F24S70/30;;F24S70/225;;C23C14/185;;F24S70/225,F25C1/22;;C23C14/06;;C23C14/08;;C23C14/18;;C23C14/34;;C23C14/35;;C23C14/36;;F24J2/46;;F24J2/48;;F25C1/12;;F25C1/24;;F25C5/18,,0,0,,,,EXPIRED
728,EP,A2,EP 1425627 A2,183-310-207-967-519,2004-06-09,2004,EP 02759666 A,2002-09-12,US 0229105 W;;US 32217301 P,2001-09-13,THREE-DIMENSIONAL ELECTROPHORETIC DISPLAYS,,SIPIX IMAGING INC,LIANG RONG-CHANG;;CHEN DAVID,,https://lens.org/183-310-207-967-519,Patent Application,yes,0,0,10,195,0,G02F1/133377;;G02F1/1334;;G02F1/134363;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677;;G02F1/1334;;G02F1/134363;;G02F1/133377;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677,G02B27/22;;G02F1/1333;;G02F1/1334;;G02F1/1343;;G02F1/167;;G02F1/1677;;H04N13/00,,0,0,,,,DISCONTINUED
729,US,A1,US 2016/0007714 A1,177-253-003-753-134,2016-01-14,2016,US 201514795903 A,2015-07-10,US 201514795903 A;;US 201462023011 P,2014-07-10,MULTIPLE LEVEL CONTAINER,"Cosmetic containers having multiple levels, a lid, and a base, in which the opening of the lid also provides access to at least first and second levels having one or more compartments for products and/or applicators. The base may contain a first level, and be coupled via a first linkage to a second level. The lid may be coupled by a pivot assembly to the base and to the second level by a second linkage. The overall assembly may allow access to both the first level and the second level on opening the lid.",HCT GROUP HOLDINGS LTD,EBERLEIN DAVID JEFFREY;;CHANG DERRICK,HCT GROUP HOLDINGS LIMITED (2015-07-07),https://lens.org/177-253-003-753-134,Patent Application,yes,4,5,3,3,0,A45D33/20;;A45D33/20;;A45D33/008;;A45D33/008;;A45D33/26;;A45D40/22;;A45D40/22;;A45D2040/225;;A45D2040/225,A45D33/20;;A45D33/26;;A45D40/22,,0,0,,,,INACTIVE
730,TW,B,TW 562985 B,191-924-995-590-324,2003-11-21,2003,TW 91121010 A,2002-09-13,US 32217301 P,2001-09-13,Three-dimensional electrophoretic displays,"This invention relates to three-dimensional (3-D) electrophoretic displays comprising individually sealed cells filled with optically active electrophoretic dispersions, and more particularly to bi-stable, low-power-consumption and sealed microcup-based electrophoretic displays for high-quality three-dimensional imagery applications.",SIPIX IMAGING INC,LIANG RONG-CHANG;;CHEN DAVID,,https://lens.org/191-924-995-590-324,Granted Patent,no,0,2,10,195,0,G02F1/133377;;G02F1/1334;;G02F1/134363;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677;;G02F1/1334;;G02F1/134363;;G02F1/133377;;G02F1/167;;H04N13/337;;H04N13/324;;G02F1/1677,G02B27/22;;G02F1/1333;;G02F1/1334;;G02F1/1343;;G02F1/167;;G02F1/1677;;H04N13/00,,0,0,,,,EXPIRED
731,US,S,US D0802405 S,195-460-794-879-431,2017-11-14,2017,US 201629582631 F,2016-10-28,US 201629582631 F,2016-10-28,Leg extender,,VARIDESK LLC,CHANG LIO YENWEI;;PATTON DAVID,VARIDESK LLC (2016-11-02),https://lens.org/195-460-794-879-431,Design Right,no,0,6,1,1,0,,,0805;;D 8374,0,0,,,,ACTIVE
732,WO,A1,WO 2019/060607 A1,147-949-630-867-998,2019-03-28,2019,US 2018/0052040 W,2018-09-20,US 201762561169 P,2017-09-20,METHODS AND SYSTEMS FOR THE DETECTION OF ANALYTE MOLECULES,"Methods and systems for the detection of analyte molecules are generally described. In some embodiments, a method may comprise using a stabilizing agent prior to, during, and/or after one or more steps of a detection assay. The stabilizing agent may serve to maintain and/or increase the detectable signal indicative of the analyte during one or more assay steps and/or until the signal is measured. In such cases, the stabilizing agent may reduce and/or prevent one or more phenomena associated with signal decay, such as, e.g., dissociation between, aggregation of, and/or denaturation of analyte molecules and/or detection molecules. In some embodiments, the stabilizing agent can be used to improve the sensitivity of new and existing assays with little or no adverse effect on specificity. The methods and systems, described herein, may be used for a plethora of applications, including the detection or quantification of low levels of analyte molecules.",QUANTERIX CORP,WILSON DAVID;;RISSIN DAVID;;CHANG LEI;;RIVNAK ANDREW;;DUFFY DAVID,,https://lens.org/147-949-630-867-998,Patent Application,yes,39,9,2,2,0,G01N33/542;;G01N33/542;;G01N33/5306;;G01N33/5306;;G01N33/54393;;G01N33/573;;G01N33/58,G01N33/53;;G01N33/542;;G01N33/543;;G01N33/58,,7,6,045-811-386-859-514;;005-576-045-627-59X;;011-056-622-380-864;;011-975-136-144-855;;067-956-712-331-172;;011-975-136-144-855,10.1016/0009-8981(81)90124-8;;6976241;;12702728;;10.1074/jbc.m300815200;;20495550;;10.1038/nbt.1641;;pmc2919230;;21344864;;10.1021/ac103161b;;pmc3056883;;22179487;;10.1039/c2lc20744c;;21344864;;10.1021/ac103161b;;pmc3056883,"TOSS ET AL: ""An evaluation of stabilizing agents in competitive protein-binding assay for 25-hydroxyvitamin D"", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 117, no. 3, 24 December 1981 (1981-12-24), pages 361 - 364, XP023399630, ISSN: 0009-8981, [retrieved on 19811224], DOI: 10.1016/0009-8981(81)90124-8;;JAI K. KAUSHIK ET AL: ""Why Is Trehalose an Exceptional Protein Stabilizer? : AN ANALYSIS OF THE THERMAL STABILITY OF PROTEINS IN THE PRESENCE OF THE COMPATIBLE OSMOLYTE TREHALOSE"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 29, 18 July 2003 (2003-07-18), US, pages 26458 - 26465, XP055547280, ISSN: 0021-9258, DOI: 10.1074/jbc.M300815200;;RISSIN ET AL., NAT BIOTECHNOL, vol. 28, no. 6, 2010, pages 595 - 9;;RISSIN ET AL., ANAL CHEM, vol. 83, no. 6, 2011, pages 2279 - 85;;KAN ET AL., LAB CHIP, vol. 12, no. 5, 2012, pages 977 - 85;;VADIM DEMIDOV ET AL., DNA AMPLIFICATION: CURRENT TECHNOLOGIES AND APPLICATIONS, 2004;;RISSIN ET AL., ANAL. CHEM., vol. 83, no. 6, 2011, pages 2279 - 2285",PENDING
733,US,B2,US 9163568 B2,117-028-604-857-732,2015-10-20,2015,US 58230409 A,2009-10-20,US 58230409 A,2009-10-20,Cold start systems and methods,A cylinder deactivation system comprises a fuel injection module and a cold start control module. The fuel injection module injects a desired amount of fuel into a cylinder of an engine during engine cranking. The cold start control module maintains an intake valve and an exhaust valve associated with the cylinder in respective closed positions while the desired amount of fuel is injected when at least one of an air temperature and a coolant temperature is less than a predetermined cold start temperature.,SCZOMAK DAVID P;;CLEARY DAVID J;;CHANG JUNSEOK;;GM GLOBAL TECH OPERATIONS INC,SCZOMAK DAVID P;;CLEARY DAVID J;;CHANG JUNSEOK,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2009-07-22),https://lens.org/117-028-604-857-732,Granted Patent,yes,17,3,6,6,0,F02D13/06;;F02D13/06;;F02D13/0219;;F02D13/0219;;F02D41/0087;;F02D41/0087;;F02D41/064;;F02D41/064;;F02D41/3058;;F02D41/402;;F02D2013/0292;;F02D2013/0292;;F02D2041/001;;F02D2041/001;;F02D2041/0012;;F02D2041/0012;;F02D2200/021;;F02D2200/021;;F02D2200/0414;;F02D2200/0414;;F02N19/004;;F02N19/004;;F02P5/1506;;F02P5/1506;;Y02T10/12;;Y02T10/12;;Y02T10/40;;Y02T10/40,G06F7/00;;F02D13/02;;F02D13/06;;F02D41/00;;F02D41/06;;F02D41/30;;F02D41/40;;F02N19/00;;F02P5/15;;G06F17/00,,0,0,,,,ACTIVE
734,US,A1,US 2011/0088661 A1,191-701-602-863-830,2011-04-21,2011,US 58230409 A,2009-10-20,US 58230409 A,2009-10-20,COLD START SYSTEMS AND METHODS,A cylinder deactivation system comprises a fuel injection module and a cold start control module. The fuel injection module injects a desired amount of fuel into a cylinder of an engine during engine cranking. The cold start control module maintains an intake valve and an exhaust valve associated with the cylinder in respective closed positions while the desired amount of fuel is injected when at least one of an air temperature and a coolant temperature is less than a predetermined cold start temperature.,GM GLOBAL TECH OPERATIONS INC,SCZOMAK DAVID P;;CLEARY DAVID J;;CHANG JUNSEOK,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2009-07-22),https://lens.org/191-701-602-863-830,Patent Application,yes,17,35,6,6,0,F02D13/06;;F02D13/06;;F02D13/0219;;F02D13/0219;;F02D41/0087;;F02D41/0087;;F02D41/064;;F02D41/064;;F02D41/3058;;F02D41/402;;F02D2013/0292;;F02D2013/0292;;F02D2041/001;;F02D2041/001;;F02D2041/0012;;F02D2041/0012;;F02D2200/021;;F02D2200/021;;F02D2200/0414;;F02D2200/0414;;F02N19/004;;F02N19/004;;F02P5/1506;;F02P5/1506;;Y02T10/12;;Y02T10/12;;Y02T10/40;;Y02T10/40,F02D7/00;;F01L1/34;;F02D17/02;;F02M51/00,123/481;;123/491;;123/90.15;;X123198  F,0,0,,,,ACTIVE
735,DE,A1,DE 102010048355 A1,198-963-141-149-347,2011-05-12,2011,DE 102010048355 A,2010-10-13,US 58230409 A,2009-10-20,Kaltstartsysteme und -verfahren,"Ein Zylinderabschaltungssystem umfasst ein Kraftstoffinjektionsmodul und ein Kaltstartsteuermodul. Das Kraftstoffinjektionsmodul injiziert eine gewünschte Menge an Kraftstoff in einen Zylinder einer Maschine während eines Maschinenanlassvorganges. Das Kaltstartsteuermodul hält ein Ansaugventil und ein Abgasventil, die dem Zylinder zugeordnet sind, jeweils in geschlossenen Positionen, während die gewünschte Menge an Kraftstoff injiziert wird, wenn eine Lufttemperatur und/oder eine Kühlmitteltemperatur kleiner als eine vorbestimmte Kaltstarttemperatur ist.",GM GLOBAL TECH OPERATIONS INC,SCZOMAK DAVID P;;CLEARY DAVID J;;CHANG JUNSEOK,"GM GLOBAL TECHNOLOGY OPERATIONS LLC (N. D. GES, US (2011-03-23);;GM GLOBAL TECHNOLOGY OPERATIONS LLC , ( N. D. , US (2011-06-16)",https://lens.org/198-963-141-149-347,Patent Application,no,0,4,6,6,0,F02D13/06;;F02D13/06;;F02D13/0219;;F02D13/0219;;F02D41/0087;;F02D41/0087;;F02D41/064;;F02D41/064;;F02D41/3058;;F02D41/402;;F02D2013/0292;;F02D2013/0292;;F02D2041/001;;F02D2041/001;;F02D2041/0012;;F02D2041/0012;;F02D2200/021;;F02D2200/021;;F02D2200/0414;;F02D2200/0414;;F02N19/004;;F02N19/004;;F02P5/1506;;F02P5/1506;;Y02T10/12;;Y02T10/12;;Y02T10/40;;Y02T10/40,F02N19/00,,0,0,,,,ACTIVE
736,CN,A,CN 102042102 A,180-400-828-992-063,2011-05-04,2011,CN 201010516895 A,2010-10-20,US 58230409 A,2009-10-20,Cold start systems and methods,"The present invention relates to cold start systems and methods. Concretely, provided is a cylinder deactivation system comprising a fuel injection module and a cold start control module. The fuel injection module injects a desired amount of fuel into a cylinder of an engine during engine cranking. The cold start control module maintains an intake valve and an exhaust valve associated with the cylinder in respective closed positions while the desired amount of fuel is injected when at least one of an air temperature and a coolant temperature is less than a predetermined cold start temperature.",GM GLOBAL TECH OPERATIONS INC,SCZOMAK DAVID P;;CLEARY DAVID J;;JUNSEOK CHANG,,https://lens.org/180-400-828-992-063,Patent Application,no,4,10,6,6,0,F02D13/06;;F02D13/06;;F02D13/0219;;F02D13/0219;;F02D41/0087;;F02D41/0087;;F02D41/064;;F02D41/064;;F02D41/3058;;F02D41/402;;F02D2013/0292;;F02D2013/0292;;F02D2041/001;;F02D2041/001;;F02D2041/0012;;F02D2041/0012;;F02D2200/021;;F02D2200/021;;F02D2200/0414;;F02D2200/0414;;F02N19/004;;F02N19/004;;F02P5/1506;;F02P5/1506;;Y02T10/12;;Y02T10/12;;Y02T10/40;;Y02T10/40,F02D41/06;;F02D13/00;;F02D41/30,,0,0,,,,ACTIVE
737,DE,B4,DE 102010048355 B4,158-339-789-213-647,2016-01-28,2016,DE 102010048355 A,2010-10-13,US 58230409 A,2009-10-20,Kaltstartsysteme,"Zylinderabschaltungssystem, umfassend: ein Kraftstoffbestimmungsmodul, das während eines Maschinenanlassvorgangs eine in einem Zylinder einer Maschine eingeschlossene Luftmasse auf der Grundlage einer Lufttemperatur und eine gewünschte Menge an Kraftstoff zur Injektion in den Zylinder auf der Grundlage der in dem Zylinder eingeschlossenen Luftmasse bestimmt, wobei, wenn die Maschine für zumindest eine vorbestimmte Periode vor dem Maschinenanlassvorgang abgeschaltet war, das Kraftstoffbestimmungsmodul die gewünschte Menge an Kraftstoff zur Injektion in den Zylinder ferner auf der Grundlage einer Maschinenkühlmitteltemperatur bestimmt; ein Kraftstoffinjektionsmodul, das die gewünschte Menge an Kraftstoff in den Zylinder während des Maschinenanlassvorgangs injiziert; und ein Kaltstartsteuermodul, das ein Ansaugventil und ein Abgasventil, die dem Zylinder zugeordnet sind, jeweils in geschlossenen Positionen beibehält, während die gewünschte Menge an Kraftstoff injiziert wird, wenn die Lufttemperatur und/oder die Maschinenkühlmitteltemperatur kleiner als eine vorbestimmte Kaltstarttemperatur sind.",GM GLOBAL TECH OPERATIONS INC,SCZOMAK DAVID P;;CLEARY DAVID J;;CHANG JUNSEOK,"GM GLOBAL TECHNOLOGY OPERATIONS LLC (N. D. GES, US (2011-03-23);;GM GLOBAL TECHNOLOGY OPERATIONS LLC , ( N. D. , US (2011-06-16)",https://lens.org/158-339-789-213-647,Granted Patent,no,1,1,6,6,0,F02D13/06;;F02D13/06;;F02D13/0219;;F02D13/0219;;F02D41/0087;;F02D41/0087;;F02D41/064;;F02D41/064;;F02D41/3058;;F02D41/402;;F02D2013/0292;;F02D2013/0292;;F02D2041/001;;F02D2041/001;;F02D2041/0012;;F02D2041/0012;;F02D2200/021;;F02D2200/021;;F02D2200/0414;;F02D2200/0414;;F02N19/004;;F02N19/004;;F02P5/1506;;F02P5/1506;;Y02T10/12;;Y02T10/12;;Y02T10/40;;Y02T10/40,F02N19/00,,0,0,,,,ACTIVE
738,US,A1,US 2019/0199708 A1,160-408-804-136-407,2019-06-27,2019,US 201916291975 A,2019-03-04,US 201916291975 A;;US 201414268332 A,2014-05-02,METHODS AND SYSTEMS FOR ROLES AND MEMBERSHIP MANAGEMENT IN A MULTI-TENANT CLOUD ENVIRONMENT,"Systems and methods for allowing one or more users to access a number of tenant systems in a multi-tenant cloud environment are disclosed. The method includes registering a user to the tenant systems based on an identity information received from the user. The same identity information is associated with each of the tenant systems. The method also includes creating an account corresponding to each of the tenant systems for the user. The method further includes allowing the user to access one or more of the tenant systems based on the identity information entered by the user. The user accesses the tenant systems by entering the same identity information. Further, the same identity information is used for identifying the user in each of the tenant systems.",INGRAM MICRO INC,DAS SWARUP;;CHANG DAVID HOU;;WIPPICH DAVID J,ENSIM CORPORATION (2014-10-01);;CLOUDBLUE LLC (2021-10-29);;INGRAM MICRO INC (2017-03-09),https://lens.org/160-408-804-136-407,Patent Application,yes,11,4,2,3,0,H04L12/6418;;H04L63/0815;;H04L63/0815;;H04L63/105;;G06F2009/45595;;G06F9/45558;;H04L63/108,H04L29/06;;G06F9/455,,0,0,,,,ACTIVE
739,US,A1,US 2008/0159536 A1,045-026-295-281-290,2008-07-03,2008,US 4929408 A,2008-03-15,US 4929408 A;;US 33620506 A,2006-01-20,Automatic Wireless Network Password Update,"An approach is provided that allows an administrator to set a new password at a wireless access point, such as a traditional WAP or a wireless router. The wireless access point creates a message that includes the new password. The message is encrypted using the old password that was previously set for the wireless network. The encrypted message is wirelessly transmitted from the wireless access point to the active client devices (those clients currently accessing the wireless network). The clients decrypt the message using the old password that was previously provided to the clients. The clients retrieve the new password from the message. The clients construct a new message that is encrypted using the new password. The new message is wirelessly transmitted from the clients to the wireless access device and serves as an acknowledgement.",CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,,https://lens.org/045-026-295-281-290,Patent Application,yes,11,18,7,7,0,H04L63/0428;;H04L63/0846;;H04W12/06;;H04W12/033;;H04L63/0846;;H04L63/0428;;H04W12/06;;H04W12/033,H04L9/32;;G06F21/44;;H04K1/00,380/258;;380/270,0,0,,,,INACTIVE
740,US,B2,US 10897463 B2,090-469-346-013-486,2021-01-19,2021,US 201916436152 A,2019-06-10,US 201916436152 A;;US 201715627833 A;;US 201514593639 A;;US 85809010 A,2010-08-17,Managing and securing manageable resources in stateless web server architecture using servlet filters,"Access is controlled to managed resources in a stateless web server architecture including a stateless web server computing platform; a resource locator map portion of the stateless web server computing platform providing a unique resource locator code representing each managed resource in a stateless web server architecture, wherein the managed resource is assigned to a plurality of application program components; a set of servlet filters disposed in a portion of the stateless web server computing platform, each servlet filter associated with one of the application program components; a resource locator matcher portion of the stateless web server computing platform, responsive to a user request to a unique resource locator, matching a pattern in the user request to one or more of the application program components using a corresponding servlet filter; and a request dispatcher portion of the stateless web server computing platform sending the user request to the matched application program component, wherein the application program component receives and processes the user request.",IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-01-07),https://lens.org/090-469-346-013-486,Granted Patent,yes,18,0,8,8,0,G06F16/958;;G06F16/958;;H04L63/083;;H04L63/10,G06F15/16;;G06F16/958;;H04L29/06,,15,0,,,"IBM; “List of Co-Assigned Patent Applications to Be Treated as Related”.;;Costello, Roger L.; “Building Web Services the REST Way”, published online and retrieved from http://www.xfront.com/REST-Web-Services.html on May 21, 2010.;;Fielding, Roy Thomas; “Architectural Styles and the Design of Network-based Software Architectures”, Ph.D. dissertation at the University of California (Irvine), published online and retrieved from http://www.ics.uci.edu/-fielding/pubs/dissertation/fielding_dissertation_2up.pdf on May 21, 2010.;;Rodriguez, Alex;“ RESTful Web services: The basics”; published online and retrieved on Aug. 3, 2010 from http://download.boulder.ibm.com/ibmd1/pub/software/dw/webservices/ws-resffu1/ws-restfu1-pdf.;;Sun, Bruce;“A multi-tier architecture for building RESTful Web services”; published online and retrieved on Aug. 3, 2010 from http://download.boulder.ibm.com/ibmdl/pub/software/dw/ajax/wa-aj-multitier/wa-aj-multitier-pdf.;;Eugen; “Securing a RESTful Web Service with Spring Security 3.1”, posted on Oct. 31, 2011, retrieved on Apr. 15, 2012, from http://www.baeldung.com.;;US Army; “Wear and Appearance of Army Uniforms and Insignia”, May 11, 2012, Army Regulation 670-1, pp. 251-254.;;dictionary.com; definition of “hash mark”, accessed on Jan. 7, 2014.;;LSOFT; “5.7 Using Merged Parameters with URLs”, retrieved from http://www.lsof.com/manuals/Maestro/Maestro_Users on Jan. 7, 2014.;;pc.net; “What is the different between a backslash and a forward slash?”, retrieved from http://pc.net/helpcenter/print/backslash_vs_forward_slash on Jan. 7, 2014.;;W3 Consortium; “3 Protocol Parameters”, RFC 2616, retrieved from http:/fwww.w3.org/Protocols/rfc2616/rfc2616-sec3.html on Jan. 7, 2014.;;Stackoverflow; “what is the#! sign in the URL and what is [sic] it mean?”, retrieved from http:/fstackoverflow.com/questions/5395330/what-is-the-sign-in-the-url on Jul. 1, 2014.;;Wikipedia; “Number sign”, retrieved from http:/fen.wikipedia.org/wiki/Number_sign on Jan. 7, 2014.;;Wikipedia; “Slash (punctuation)”, retrieved from http://en.wikipedia.org/wiki/Slash_(punctuation) on Jan. 7, 2014.;;USPTO; final rejections in U.S. Appl. No. 10/955,449, (Perkins), dated Jul. 23, 2007.",ACTIVE
741,US,A1,US 2010/0067293 A1,095-215-072-062-177,2010-03-18,2010,US 21012608 A,2008-09-12,US 21012608 A,2008-09-12,Programmable and Redundant Circuitry Based On Magnetic Tunnel Junction (MTJ),"Techniques, apparatus and circuits based on magnetic or magnetoresistive tunnel junctions (MTJs). In one aspect, a programmable circuit device can include a magnetic tunnel junction (MTJ); a MTJ control circuit coupled to the MTJ to control the MTJ to cause a breakdown in the MTJ in programming the MTJ; and a sensing circuit coupled to the MTJ to sense a voltage under a breakdown condition of the MTJ.",YU DAVID CHANG-CHENG;;LUO XIAO;;CHANG JIA-HWANG,YU DAVID CHANG-CHENG;;LUO XIAO;;CHANG JIA-HWANG,GRANDIS INC (2008-09-17);;SAMSUNG SEMICONDUCTOR INC (2016-02-24),https://lens.org/095-215-072-062-177,Patent Application,yes,99,22,2,2,0,G11C11/161;;G11C11/1675;;G11C11/1675;;G11C11/161,G11C11/02,365/171,0,0,,,,ACTIVE
742,US,B2,US 8290163 B2,120-795-671-481-849,2012-10-16,2012,US 4929408 A,2008-03-15,US 4929408 A;;US 33620506 A,2006-01-20,Automatic wireless network password update,"An approach is provided that allows an administrator to set a new password at a wireless access point, such as a traditional WAP or a wireless router. The wireless access point creates a message that includes the new password. The message is encrypted using the old password that was previously set for the wireless network. The encrypted message is wirelessly transmitted from the wireless access point to the active client devices (those clients currently accessing the wireless network). The clients decrypt the message using the old password that was previously provided to the clients. The clients retrieve the new password from the message. The clients construct a new message that is encrypted using the new password. The new message is wirelessly transmitted from the clients to the wireless access device and serves as an acknowledgement.",CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH;;IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,,https://lens.org/120-795-671-481-849,Granted Patent,yes,13,9,7,7,0,H04L63/0428;;H04L63/0846;;H04W12/06;;H04W12/033;;H04L63/0846;;H04L63/0428;;H04W12/06;;H04W12/033,H04L29/06;;G06F21/44,380/273;;380/272;;380/279;;713/163,1,0,,,"Office Action for U.S. Appl. No. 11/336,205, mailed Jun. 18, 2009, 12 pages.",INACTIVE
743,US,A1,US 2008/0072316 A1,127-335-733-746-409,2008-03-20,2008,US 46806706 A,2006-08-29,US 46806706 A,2006-08-29,DYNAMICALLY CONFIGURING EXTENSIBLE ROLE BASED MANAGEABLE RESOURCES,"Methods and systems are provided for dynamically altering the capabilities of a software application in response to a request from a user to perform an action in the application. Based on the user's security role, the software application is reconfigured by either granting access to the user to an existing component of the application, or if no suitable component is available, adding an external vendor component to the software application which is suitable for performing the requested action.",CHANG DAVID YU;;CHANG JOHN YOW-CHUNG;;VENKATARAMAPPA VISHWANATH,CHANG DAVID YU;;CHANG JOHN YOW-CHUNG;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-08-29),https://lens.org/127-335-733-746-409,Patent Application,yes,8,113,2,2,0,G06F12/1458;;G06F12/1458,G06F12/14,726/21,0,0,,,,INACTIVE
744,JP,A,JP 2007213570 A,083-552-063-629-946,2007-08-23,2007,JP 2007007625 A,2007-01-17,US 33620506 A,2006-01-20,SYSTEM AND METHOD FOR UPDATING WIRELESS NETWORK PASSWORD,"<P>PROBLEM TO BE SOLVED: To allow a manager to set a new password to a wireless access point. <P>SOLUTION: The wireless access point 110 produces a message including the new password, encrypts it by use of an old password previously set to a wireless network, and wirelessly transmits it to an active client 130. The active client 130 releases the encryption of the message by use of the old password previously provided to the active client 130, and retrieves the new password from the message. The active client 130 forms a new message encrypted by use of the new password, and wirelessly transmits the new message to the wireless access point 110 to operate as an affirmative response. <P>COPYRIGHT: (C)2007,JPO&INPIT",IBM,VISHWANATH VENKATARAMAPPA;;CHANG JOHN YOW-CHUN;;DAVID YU CHANG,,https://lens.org/083-552-063-629-946,Patent Application,no,1,5,7,7,0,H04L63/0428;;H04L63/0846;;H04W12/06;;H04W12/033;;H04L63/0846;;H04L63/0428;;H04W12/06;;H04W12/033,G06F21/44;;H04L9/32;;H04L12/28,,0,0,,,,INACTIVE
745,US,B2,US 7731089 B2,004-097-035-835-059,2010-06-08,2010,US 46308906 A,2006-08-08,US 46308906 A,2006-08-08,Interactive physical mail content management,"A computer implemented method, apparatus, and computer usable program code for interactive mail management of physical mail. Physical mail is received in a mailbox. An identifier is read in response to receiving the physical mail in the mailbox. The physical mail contains the identifier. Information contained in the identifier is sent to the mail recipient. The mail recipient is able to identify instructions for communicating with a sender associated with the physical mail based on the information from the identifier.",IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-08-03);;TWITTER INC (2013-12-30),https://lens.org/004-097-035-835-059,Granted Patent,yes,68,16,2,2,0,A47G29/1214;;G06Q10/00;;G06Q10/087;;G06Q10/00;;A47G29/1214;;G06Q10/087,G06F19/00;;G06F17/00;;G06Q10/00;;G06Q90/00;;G07B17/02;;G08B13/08;;G08B13/12;;G08B13/14,235/385;;235/383;;235/487;;705/401;;340/545.6;;340/569;;340/572.1,4,3,025-898-209-273-300;;017-831-826-229-042;;057-578-508-570-565,10.1145/263479.263480;;10.1145/503376.503393;;10.1145/1027802.1027827,"U.S. Appl. No. 11/463,102, filed Aug. 8, 2006, Chang et al.;;Kimbrough el al., ""On Automated Message Processing in Electronic Commerce and Work Support Systems: Speech Act Theory and Expressive Felicity"", ACM Transactions on Information Systems, vol. 15, No. 4, Oct. 1997, pp. 321-367.;;Brush et al., ""Notification for Shared Annotation of Digital Documents"", CHI 2002, vol. 4, Issue 1, pp. 89-96.;;Kosatka et al, ""From Yellow Stickies to the World-Wide Web: The Evolution of Problem Tracking at the University of Houston"", SIGUCCS'04, Baltimore Maryland, 2004, pp. 94-100.",ACTIVE
746,US,A1,US 2019/0297070 A1,000-634-436-438-420,2019-09-26,2019,US 201916436152 A,2019-06-10,US 201916436152 A;;US 201715627833 A;;US 201514593639 A;;US 85809010 A,2010-08-17,Managing and Securing Manageable Resources in Stateless Web Server Architecture Using Servlet Filters,"Access is controlled to managed resources in a stateless web server architecture including a stateless web server computing platform; a resource locator map portion of the stateless web server computing platform providing a unique resource locator code representing each managed resource in a stateless web server architecture, wherein the managed resource is assigned to a plurality of application program components; a set of servlet filters disposed in a portion of the stateless web server computing platform, each servlet filter associated with one of the application program components; a resource locator matcher portion of the stateless web server computing platform, responsive to a user request to a unique resource locator, matching a pattern in the user request to one or more of the application program components using a corresponding servlet filter; and a request dispatcher portion of the stateless web server computing platform sending the user request to the matched application program component, wherein the application program component receives and processes the user request.",IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-01-07),https://lens.org/000-634-436-438-420,Patent Application,yes,0,0,8,8,0,G06F16/958;;G06F16/958;;H04L63/083;;H04L63/10,G06F16/958;;H04L29/06,,0,0,,,,ACTIVE
747,TW,U,TW M487746 U,123-148-502-425-211,2014-10-11,2014,TW 103204411 U,2014-03-14,TW 103204411 U,2014-03-14,Electrode,,CONTOUR OPTIK INC,CHAO DAVID YINKAI;;LIN CHIEN-HO;;CHANG YUNG-CHANG,,https://lens.org/123-148-502-425-211,Limited Patent,no,0,0,3,3,0,A61N1/0456;;A61N1/0456;;A61N1/0448;;A61N1/0448;;A61N1/0472;;A61N1/0472;;A61N1/20;;A61N1/20;;A61N1/36025;;A61N1/36025,,,0,0,,,,INACTIVE
748,US,A1,US 2015/0222626 A1,135-118-921-795-215,2015-08-06,2015,US 201514593639 A,2015-01-09,US 201514593639 A;;US 85809010 A,2010-08-17,Managing and Securing Manageable Resources in Stateless Web Server Architecture Using Servlet Filters,"Access is controlled to managed resources in a stateless web server architecture including a stateless web server computing platform; a resource locator map portion of the stateless web server computing platform providing a unique resource locator code representing each managed resource in a stateless web server architecture, wherein the managed resource is assigned to a plurality of application program components; a set of servlet filters disposed in a portion of the stateless web server computing platform, each servlet filter associated with one of the application program components; a resource locator matcher portion of the stateless web server computing platform, responsive to a user request to a unique resource locator, matching a pattern in the user request to one or more of the application program components using a corresponding servlet filter; and a request dispatcher portion of the stateless web server computing platform sending the user request to the matched application program component, wherein the application program component receives and processes the user request.",IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-01-07);;INTERNATIONAL BUSINESS MACHINES CORP (2015-03-12),https://lens.org/135-118-921-795-215,Patent Application,yes,3,1,8,8,0,G06F16/958;;G06F16/958;;H04L63/083;;H04L63/10,H04L29/06,,0,0,,,,ACTIVE
749,US,A1,US 2008/0040242 A1,077-833-434-757-167,2008-02-14,2008,US 46308906 A,2006-08-08,US 46308906 A,2006-08-08,INTERACTIVE PHYSICAL MAIL CONTENT MANAGEMENT,"A computer implemented method, apparatus, and computer usable program code for interactive mail management of physical mail. Physical mail is received in a mailbox. An identifier is read in response to receiving the physical mail in the mailbox. The physical mail contains the identifier. Information contained in the identifier is sent to the mail recipient. The mail recipient is able to identify instructions for communicating with a sender associated with the physical mail based on the information from the identifier.",CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATHAN,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATHAN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-08-03);;TWITTER INC (2013-12-30),https://lens.org/077-833-434-757-167,Patent Application,yes,66,73,2,2,0,A47G29/1214;;G06Q10/00;;G06Q10/087;;G06Q10/00;;A47G29/1214;;G06Q10/087,G06Q10/00,705/28,0,0,,,,ACTIVE
750,US,B2,US 7894248 B2,090-756-805-983-580,2011-02-22,2011,US 21012608 A,2008-09-12,US 21012608 A,2008-09-12,Programmable and redundant circuitry based on magnetic tunnel junction (MTJ),"Techniques, apparatus and circuits based on magnetic or magnetoresistive tunnel junctions (MTJs). In one aspect, a programmable circuit device can include a magnetic tunnel junction (MTJ); a MTJ control circuit coupled to the MTJ to control the MTJ to cause a breakdown in the MTJ in programming the MTJ; and a sensing circuit coupled to the MTJ to sense a voltage under a breakdown condition of the MTJ.",GRANDIS INC,YU DAVID CHANG-CHENG;;LUO XIAO;;CHANG JIA-HWANG,GRANDIS INC (2008-09-17);;SAMSUNG SEMICONDUCTOR INC (2016-02-24),https://lens.org/090-756-805-983-580,Granted Patent,yes,110,16,2,2,0,G11C11/161;;G11C11/1675;;G11C11/1675;;G11C11/161,G11C11/14;;G11C11/00;;G11C17/00;;G11C17/02;;G11C17/18,365/158;;365/96;;365/97;;365/171;;365/225.7,40,16,092-507-938-314-845;;001-964-410-559-695;;028-606-472-428-543;;011-659-853-578-299;;047-733-944-831-359;;015-044-893-099-14X;;106-021-691-052-543;;000-051-687-591-126;;150-503-316-929-937;;083-245-855-864-258;;100-707-567-954-580;;125-973-374-216-310;;014-667-806-558-382;;026-051-787-033-23X;;003-030-428-332-855;;157-280-370-501-21X,10.1063/1.1330562;;9984672;;10.1103/physrevb.54.9353;;10.1109/20.706281;;10.1063/1.372933;;10.1103/physrevb.71.184401;;10.1109/tmag.2004.830407;;10.1063/1.1568823;;11019116;;10.1103/physrevlett.84.3466;;10.1038/nature04036;;16163352;;10.1016/j.jmmm.2004.08.017;;10.1109/tmag.1981.1061755;;10.1016/0304-8853(96)00062-5;;12883551;;10.1038/nmat946;;10.1063/1.1828222;;10.1063/1.1846945;;10.1063/1.1356712,"Albert, et al., ""Spin-polarized current switching of a Co thin film nanomagnet"", Applied Physics Letters, vol. 77, No. 23, pp. 3809-3811, Dec. 4, 2000.;;Berger, ""Emission of spin waves by a magnetic multilayer traversed by a current"", Physical Review B, vol. 54, No. 13, pp. 9353-9358, Oct. 1, 1996.;;Cowache et al., ""Spin-valve structures with NiO pinning layers,"" IEEE Transactions on Magnetics, vol. 34, Iss. 4, part 1, pp. 843-845 (Jul. 1998).;;Cowburn et al., ""Lateral interface anisotropy in nanomagnets,"" Journal of Applied Physics, 87(9): 7067-7069 (May 1, 2000).;;Devolder, T. et al., ""Instability threshold versus switching threshold in spin-transfer-induced magnetization switching"", Physical Review B71, 184401-1-184401-6 (2005).;;Doi, et al., ""Magnetism of Coi1-xFex-NOL in Specular Spin-Valves"", IEEE Transactions on Magnetics, vol. 40, No. 4, pp. 2263-2265, Jul. 2004.;;Dokupil et al., Magnetostriction in combination with GMR/TMR-structures [online] Jun. 2, 2005, [retrieved pn Sep. 5, 2007] abstract.;;English language translation of Korean Office Action in Korean Application No. 10-2008-7009238, mailed Feb. 5, 2010, 8 pages.;;Korean Office Action in Korean Application No. 10-2008-7009238, mailed Feb. 5, 2010, 6 pages.;;USPTO Notice of Allowance in U.S. Appl. No. 11/232,356, mailed May 3, 2010, 16 pages.;;USPTO Final Office Action in U.S. Appl. No. 11/232,356, mailed Nov. 30, 2009, 29 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 12/210,126, mailed Mar. 1, 2010, 6 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/520,858, mailed Dec. 1, 2009, 24 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/271,208, mailed Oct. 6, 2006, 6 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/318,337, mailed Nov. 16, 2007, 10 pages.;;USPTO Final Office Action in U.S. Appl. No. 11/394,056, mailed Feb. 3, 2009, 8 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/394,056, mailed May 1, 2008, 9 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/394,056, mailed Sep. 30, 2009, 9 pages.;;Non-Final Office Action in U.S. Appl. No. 11/190,255, mailed Aug. 1, 2008, 24 pages.;;Korean Intellectual Property Office, Office Action in Korean Pat. App. No. KR 9-5-2009-035312920, mailed Aug. 25, 2009, 5 pages.;;English language translation of Korean Intellectual Property Office, Office Action in Korean Pat. App. No. KR 9-5-2009-035312920, mailed Aug. 25, 2009, 6 pages.;;International Search Report and Written Opinion dated Nov. 26, 2008 for Application No. PCT/US06/48793, 11 pages.;;International Search Report and Written Opinion dated Aug. 20, 2008 for Application No. PCT/US07/08203, 12 pages.;;International Search Report and Written Opinion dated Nov. 18, 2008 for Application No. PCT/US2008/068230, 9 pages.;;International Search Report and Written Opinion dated Nov. 21, 2008 for PCT/US2008/073512, 11 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/232,356, mailed Jan. 23, 2009, 42 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/769,645, mailed Mar. 6, 2009, 11 pages.;;Taiwanese Patent Office, Office Action dated Sep. 29, 2009 for Taiwanese Patent Application No. 95134547 (8 pages).;;English language translation of Taiwanese Patent Office, Office Action dated Sep. 29, 2009 for Taiwanese Patent Application No. 95134547 (7 pages).;;Supplementary European Search Report dated Oct. 8, 2009 for European Patent Application No. EP06814990.5 (9 pages).;;Inomata et al., ""Size-independent spin switching field using synthetic antiferromagnets,"" Applied Physics Letters 82(16): 2667-2669 (Apr. 21, 2003).;;Leighton et al., ""Coercivity Enhancement in Exchange Biased Systems Driven by Interfacial Magnetic Frustration,"" Physical Review Letters 84(15): 3466-3469 (Apr. 10, 2000).;;Mancoff, F.B. et al., ""Phase-locking in double-point-contact spin-transfer devices"", Nature, vol. 437:393-395 (2005).;;Queste, S. et al., ""Microwave permeability study for antiferromagnet thickness dependence on exchange bias field in NiFe/IrMn layers,"" Journal of Magnetism and Magnetic Materials, vol. 288, pp. 60-65 (Mar. 1, 2005).;;Sharrock, M.P. et al., ""Kinetic Effects in Coercivity Measurements"", IEEE Transactions on Magnetics, vol. Mag-17, No. 6:3020-3022 (1981).;;Slonczewski, et al., ""Current-driven excitation of Magnetic multilayers"", Journal of Magnetism and Magnetic Materials, vol. 159, pp. L1-L7, 1996.;;Thirion, C. et al., ""Switching of magnetization by nonlinear resonance studied in single nanoparticles"", Nature Materials, Nature Publishing Group www.nature.com/naturematerials, vol. 2, 524-527 (Aug. 2003).;;Tulapurkar, et al., ""Subnanosecond magnetization reversal in magnetic nanopillars by spin angular momentum transfer"", Applied Physics Letters, vol. 85, No. 22, pp. 5358-5360, Nov. 29, 2004.;;Xi, Haiwen et al., ""Spin-current effect on ferromagnetic resonance in patterned magnetic thin film structures"", J of Applied Physics 97, 033904-1-033904-5 (2005).;;Zhang, et al., ""40% tunneling magnetoresistance after anneal at 380 C for tunnel junctions with iron-oxide interface layers"", Journal of Applied Physics, vol. 89, No. 11, pp. 6665-6667, Jun. 1, 2001.",ACTIVE
751,US,A1,US 2012/0047258 A1,150-295-614-169-960,2012-02-23,2012,US 85809010 A,2010-08-17,US 85809010 A,2010-08-17,Managing and Securing Manageable Resources in Stateless Web Server Architecture Using Servlet Filters,"Access is controlled to managed resources in a stateless web server architecture including a stateless web server computing platform; a resource locator map portion of the stateless web server computing platform providing a unique resource locator code representing each managed resource in a stateless web server architecture, wherein the managed resource is assigned to a plurality of application program components; a set of servlet filters disposed in a portion of the stateless web server computing platform, each servlet filter associated with one of the application program components; a resource locator matcher portion of the stateless web server computing platform, responsive to a user request to a unique resource locator, matching a pattern in the user request to one or more of the application program components using a corresponding servlet filter; and a request dispatcher portion of the stateless web server computing platform sending the user request to the matched application program component, wherein the application program component receives and processes the user request.",CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH;;IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-08-16),https://lens.org/150-295-614-169-960,Patent Application,yes,6,0,8,8,0,G06F16/958;;G06F16/958;;H04L63/083;;H04L63/10,G06F15/173,709/225,0,0,,,,INACTIVE
752,TW,U,TW M488322 U,181-045-854-663-645,2014-10-21,2014,TW 103204412 U,2014-03-14,TW 103204412 U,2014-03-14,Transcranial direct current stimulation device,,CONTOUR OPTIK INC,CHAO DAVID YINKAI;;LIN CHIEN-HO;;CHANG YUNG-CHANG,,https://lens.org/181-045-854-663-645,Limited Patent,no,0,3,3,3,0,A61N1/0472;;A61N1/0472;;A61N1/0456;;A61N1/0456;;A61N1/0484;;A61N1/0484;;A61N1/36025;;A61N1/36025,,,0,0,,,,INACTIVE
753,TW,U,TW M476988 U,040-848-958-031-446,2014-04-21,2014,TW 102221929 U,2013-11-22,TW 102221929 U,2013-11-22,Touch panel,"A touch panel includes one first electrode serial disposed on a substrate and extending along a first direction. The first electrode serial includes a plurality of first electrodes and a first string wire. The first electrodes are arranged along the first direction, and the first string wire extends along the first direction, positioned at an upper side or a lower side of the first electrodes. The first string wire is electrically connected to the first electrodes of the first electrode serial.",WINTEK CORP,STEVENSON DAVID E;;LIU CHIN-CHANG;;SU KUO-CHANG,,https://lens.org/040-848-958-031-446,Limited Patent,no,0,0,3,3,0,G06F3/041;;G06F2203/04103,,,0,0,,,,EXPIRED
754,TW,B,TW I226666 B,171-827-727-575-945,2005-01-11,2005,TW 90129483 A,2001-11-28,TW 90129483 A,2001-11-28,Deep submicron T shaped gate semiconductor device and manufacturing the same,"Submicron T-gate formation using I-line stepper with phase shift mask (PSM) technique [1,2,3] has become very attractive due to its low capital investment and high throughput for GaAs MMIC technology. The present invention teaches a novel submicron (<0.2 mm) T-gate technology using shift mask technique. The 8% half-tone PSM was selected for the definition of the isolated narrow space. Before lithography, 2500 Å Si3N4 film was deposited on the wafer. After I-line PSM exposure and RIE etching of the silicon nitride film, openings with less than 0.25 mum wide were formed on the Si3N4 film. To further reduce the dimension of the openings, the wafer was then deposited addition 500 Å nitride and etched back using RIE without any mask. Less than 0.2 mum openings were formed on the wafer after the dry etch. The wafer was then coated with another layer of photoresist to form lift-off structure. This novel process is a high throughput T-gate process compared to conventional E-beam lithography technology for GaAs MMIC production.",UNIV NAT CHIAO TUNG,CHANG EDWARD Y;;CHANG HUANG-CHOUNG;;FU DAVID K,,https://lens.org/171-827-727-575-945,Granted Patent,no,0,0,1,1,0,,H01L21/335,,0,0,,,,EXPIRED
755,CN,U,CN 203720807 U,180-128-123-935-640,2014-07-16,2014,CN 201420062848 U,2014-02-12,TW 102221929 U,2013-11-22,Touchpad,"The utility model discloses a touchpad, which includes a first electrode serial, wherein the first electrode serial is arranged on a substrate and extends along a first direction; the first electrode serial includes multiple first electrodes and a first tandem conductor; the first electrodes are arranged along the first direction, and the first tandem conductor extends along the first direction and is arranged below or above the first electrodes; the first tandem conductor is electrically connected with the first electrodes of the first electrode serial respectively. The touchpad provided by the utility model has the beneficial effects that as the tandem conductors are in tandem connection with the electrodes arrayed and extended along the same direction, the problem of the prior art that the impedance is high as connecting electrodes or bridge connectors with small line widths are otherwise provided between the electrodes is solved, the impedance consistency of the whole electrode serial can be improved, the whole touching and sensing effect is improved, and the visual effect of the touchpad is improved at the same time.",WINTEK CORP,DAVID E STEVENSON;;CHIN-CHANG LIU;;KUO-CHANG SU,,https://lens.org/180-128-123-935-640,Limited Patent,no,0,2,3,3,0,G06F3/041;;G06F2203/04103,G06F3/041,,0,0,,,,EXPIRED
756,US,A1,US 2017/0302651 A1,075-939-581-548-368,2017-10-19,2017,US 201715627833 A,2017-06-20,US 201715627833 A;;US 201514593639 A;;US 85809010 A,2010-08-17,Managing and Securing Manageable Resources in Stateless Web Server Architecture Using Servlet Filters,"Access is controlled to managed resources in a stateless web server architecture including a stateless web server computing platform; a resource locator map portion of the stateless web server computing platform providing a unique resource locator code representing each managed resource in a stateless web server architecture, wherein the managed resource is assigned to a plurality of application program components; a set of servlet filters disposed in a portion of the stateless web server computing platform, each servlet filter associated with one of the application program components; a resource locator matcher portion of the stateless web server computing platform, responsive to a user request to a unique resource locator, matching a pattern in the user request to one or more of the application program components using a corresponding servlet filter; and a request dispatcher portion of the stateless web server computing platform sending the user request to the matched application program component, wherein the application program component receives and processes the user request.",IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-03-12),https://lens.org/075-939-581-548-368,Patent Application,yes,0,0,8,8,0,G06F16/958;;G06F16/958;;H04L63/083;;H04L63/10,H04L29/06;;G06F17/30,,0,0,,,,INACTIVE
757,CN,A,CN 104656967 A,043-477-066-400-188,2015-05-27,2015,CN 201410048884 A,2014-02-12,TW 102221929 U,2013-11-22,Touchpad,"The present invention discloses a touchpad, which includes a first electrode serial, wherein the first electrode serial is arranged on a substrate and extends along a first direction; the first electrode serial includes multiple first electrodes and a first tandem conductor; the first electrodes are arranged along the first direction, and the first tandem conductor extends along the first direction and is arranged below or above the first electrodes; the first tandem conductor is electrically connected with the first electrodes of the first electrode serial respectively. The touchpad provided by the present invention has the beneficial effects that as the tandem conductors are in tandem connection with the electrodes arrayed and extended along the same direction, the problem of the prior art that the impedance is high as connecting electrodes or bridge connectors with small line widths are otherwise provided between the electrodes is solved, the impedance consistency of the whole electrode serial can be improved, the whole touching and sensing effect is improved, and the visual effect of the touchpad is improved at the same time.",WINTEK CORP,DAVID E STEVENSON;;CHIN-CHANG LIU;;KUO-CHANG SU,,https://lens.org/043-477-066-400-188,Patent Application,no,7,2,3,3,0,G06F3/041;;G06F2203/04103,G06F3/041,,0,0,,,,DISCONTINUED
758,US,B2,US 9722995 B2,001-278-674-011-447,2017-08-01,2017,US 201514593639 A,2015-01-09,US 201514593639 A;;US 85809010 A,2010-08-17,Managing and securing manageable resources in stateless web server architecture using servlet filters,"Access is controlled to managed resources in a stateless web server architecture including a stateless web server computing platform; a resource locator map portion of the stateless web server computing platform providing a unique resource locator code representing each managed resource in a stateless web server architecture, wherein the managed resource is assigned to a plurality of application program components; a set of servlet filters disposed in a portion of the stateless web server computing platform, each servlet filter associated with one of the application program components; a resource locator matcher portion of the stateless web server computing platform, responsive to a user request to a unique resource locator, matching a pattern in the user request to one or more of the application program components using a corresponding servlet filter; and a request dispatcher portion of the stateless web server computing platform sending the user request to the matched application program component, wherein the application program component receives and processes the user request.",IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-01-07);;INTERNATIONAL BUSINESS MACHINES CORP (2015-03-12),https://lens.org/001-278-674-011-447,Granted Patent,yes,14,0,8,8,0,G06F16/958;;G06F16/958;;H04L63/083;;H04L63/10,G06F15/173;;G06F17/00;;G06F17/30;;H04L29/06,,14,0,,,"Costello, Roger L.; “Building Web Services the REST Way”, published online and retrieved from http://www.xfront.com/REST-Web-Services.html on May 21, 2010.;;Fielding, Roy Thomas; “Architectural Styles and the Design of Network-based Software Architectures”, Ph.D. dissertation at the University of California (Irvine), published online and retrieved from http://www.ics.uci.edu/˜fielding/pubs/dissertation/fielding—dissertation—2up.pdf on May 21, 2010.;;Rodriguez, Alex; “RESTful Web services: The basics”; published online and retrieved on Aug. 3, 2010 from http://download.boulder.ibm.com/ibmdl/pub/software/dw/webservices/ws-restful/ws-restful-pdf.pdf.;;Sun, Bruce; “A multi-tier architecture for building RESTful Web services”; published online and retrieved on Aug. 3, 2010 from http://download.boulder.ibm.com/ibmdl/pub/software/dw/ajax/wa-aj-multitier/wa-aj-multitier-pdf.pdf.;;Eugen; “Securing a RESTful Web Service with Spring Security 3.1”, posted on Oct. 31, 2011, retrieved on Apr. 15, 2012, from http://www.baeldung.com.;;US Army; “Wear and Appearance of Army Uniforms and Insignia”, May 11, 2012, Army Regulation 670-1, pp. 251-254.;;dictionary.com; definition of “hash mark”, accessed on Jan. 7, 2014.;;LSOFT; “5.7 Using Merged Parameters with URLs”, retrieved from http://www.lsof.com/manuals/Maestro/Maestro—Users on Jan. 7, 2014.;;PC.NET; “What is the different between a backslash and a forward slash?”, retrieved from http://pc.net/helpcenter/print/backslash—vs—forward—slash on Jan. 7, 2014.;;W3 Consortium; “3 Protocol Parameters”, RFC 2616, retrieved from http://www.w3.org/Protocols/rfc2616/rfc2616-sec3.html on Jan. 7, 2014.;;Stackoverflow; “what is the #! sign in the URL and what is [sic] it mean?”, retrieved from http://stackoverflow.com/questions/5395330/what-is-the-sign-in-the-url on Jan. 7, 2014.;;Wikipedia; “Number sign”, retrieved from http://en.wikipedia.org/wiki/Number—sign on Jan. 7, 2014.;;Wikipedia; “Slash (punctuation)”, retrieved from http://en.wikipedia.org/wiki/Slash—(punctuation) on Jan. 7, 2014.;;USPTO; final rejections in U.S. Appl. No. 10/955,449, (Perkins), mailed on Jul. 23, 2007.",ACTIVE
759,US,B2,US 7874008 B2,111-961-207-572-32X,2011-01-18,2011,US 46806706 A,2006-08-29,US 46806706 A,2006-08-29,Dynamically configuring extensible role based manageable resources,"Methods and systems are provided for dynamically altering the capabilities of a software application in response to a request from a user to perform an action in the application. Based on the user's security role, the software application is reconfigured by either granting access to the user to an existing component of the application, or if no suitable component is available, adding an external vendor component to the software application which is suitable for performing the requested action.",IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUNG;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-08-29),https://lens.org/111-961-207-572-32X,Granted Patent,yes,11,47,2,2,0,G06F12/1458;;G06F12/1458,G06F17/30;;G06F7/04;;H04N7/16,726/27;;726/21;;726/1,9,1,140-819-005-126-094,10.1109/mc.2004.1297300,"U.S. Appl. No. 11/351,035, Chang et al.;;""Using Java Security to Protect WebLogic Resources"" http://d-docs.bea.com/wls/docs90/security/server-prot.html, accessed Aug. 29, 2005.;;""Securing WebLogic Resources"" http://e-docs.bea.com/wls/docs81/secwires/secroles.html, accessed Aug. 29, 2005.;;""Context-Aware Dynamic Access Control for Pervasive Applications"", Zhang et al., http:www.caip.rutgers.edu/TASSL/Papers/automate-sesame-cnds-04.pdf, 2004.;;""Universal IdP(TM): Universal Identity Manager (IM),"" Open Network, cache of http://www.opennetwork.com/solutions/functionality/im/, accessed Aug. 29, 2005.;;Bhatti et al., ""XML-Based Specification for Web Services Document Security,"" IEEE, pp. 41-49, Apr. 2004, http://web.ics.purdue.edu/~bhattir/academics/research/papers/IEEE-Computer-APR04.pdf.;;Fernandez, ""Enterprise Dynamic Access Control (EDAC): Overview,"" Prepared for Commander, US Pacific Fleet, Pearl Harbor, May 1, 2005.;;Himanshu Khurana, ""Integrated Security Services for Dynamic Coalition Management,"" Electrical and Computer Engineering Dept., Univ. of Maryland, DARPA DC PI Meeting, Jul. 25, 2003, http//www.ece.umd.edu/~gligor/ISSDCM2003/DARPA-DC-PI-Meeting-07-2003.pdf.;;""Role and Rule-Based Provisioning,"" Beta Systems Software AG, 2003-2005, http://www2.betasystems.com/en/portfolio/products-solutions/securitymanagement/sam/ht-rolebased-prov.html.",INACTIVE
760,US,B2,US 10367806 B2,156-121-758-381-336,2019-07-30,2019,US 201715627833 A,2017-06-20,US 201715627833 A;;US 201514593639 A;;US 85809010 A,2010-08-17,Managing and securing manageable resources in stateless web server architecture using servlet filters,"Access is controlled to managed resources in a stateless web server architecture including a stateless web server computing platform; a resource locator map portion of the stateless web server computing platform providing a unique resource locator code representing each managed resource in a stateless web server architecture, wherein the managed resource is assigned to a plurality of application program components; a set of servlet filters disposed in a portion of the stateless web server computing platform, each servlet filter associated with one of the application program components; a resource locator matcher portion of the stateless web server computing platform, responsive to a user request to a unique resource locator, matching a pattern in the user request to one or more of the application program components using a corresponding servlet filter; and a request dispatcher portion of the stateless web server computing platform sending the user request to the matched application program component, wherein the application program component receives and processes the user request.",IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-03-12),https://lens.org/156-121-758-381-336,Granted Patent,yes,4,0,8,8,0,G06F16/958;;G06F16/958;;H04L63/083;;H04L63/10,G06F15/173;;G06F16/958;;H04L29/06,,2,0,,,"Co-assigned and co-pending U.S. Appl. No. 14/593,639, filed Jan. 9, 2015, by inventors David Yu Chang, et al.;;Co-assigned U.S. Appl. No. 12/858,090, filed Aug. 17, 2010, issued as U.S. Pat. No. 9,021,093, by inventors David Yu Chang, et al.",INACTIVE
761,WO,A1,WO 2007/090833 A1,193-883-516-908-29X,2007-08-16,2007,EP 2007051120 W,2007-02-06,US 35103506 A,2006-02-09,EXTENSIBLE ROLE BASED AUTHORIZATION FOR MANAGEABLE RESOURCES,"Methods and systems are provided for dynamically altering the access capabilities to the data resources for users of a computer based application. The access capabilities are defined by a dynamic role that specifies which of the resources a user may access, and a set of permissions associated with the dynamic role to define. New dynamic roles may be created when additional resources and components are added to an application. Methods and systems are provided for creating new dynamic roles to temporarily access resources, and for deleting a dynamic role after it is no longer needed.",IBM;;IBM UK;;CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,,https://lens.org/193-883-516-908-29X,Patent Application,yes,3,0,3,3,0,G06F21/604;;G06F21/6218;;G06F21/604;;G06F21/6218,G06F21/00,,0,0,,,,PENDING
762,US,B2,US 9021093 B2,132-380-107-298-286,2015-04-28,2015,US 85809010 A,2010-08-17,US 85809010 A,2010-08-17,Managing and securing manageable resources in stateless web server architecture using servlet filters,"Access is controlled to managed resources in a stateless web server architecture including a stateless web server computing platform; a resource locator map portion of the stateless web server computing platform providing a unique resource locator code representing each managed resource in a stateless web server architecture, wherein the managed resource is assigned to a plurality of application program components; a set of servlet filters disposed in a portion of the stateless web server computing platform, each servlet filter associated with one of the application program components; a resource locator matcher portion of the stateless web server computing platform, responsive to a user request to a unique resource locator, matching a pattern in the user request to one or more of the application program components using a corresponding servlet filter; and a request dispatcher portion of the stateless web server computing platform sending the user request to the matched application program component, wherein the application program component receives and processes the user request.",CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH;;IBM,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-08-16),https://lens.org/132-380-107-298-286,Granted Patent,yes,15,0,8,8,0,G06F16/958;;G06F16/958;;H04L63/083;;H04L63/10,G06F15/173;;G06F15/16;;G06F17/00;;G06F17/30,709/225;;709/245;;715/208,14,0,,,"Costello, Roger L.; ""Building Web Services the REST Way"", published online and retrieved from http://www.xfront.com/REST-Web-Services.html on May 21, 2010.;;Fielding, Roy Thomas; ""Architectural Styles and the Design of Network-based Software Architectures"", Ph.D. dissertation at the University of California (Irvine), published online and retrieved from http://www.ics.uci.edu/~fielding/pubs/dissertation/fielding-dissertation-2up.pdf on May 21, 2010.;;Rodriguez, Alex; ""RESTful Web services: The basics""; published online and retrieved on Aug. 3, 2010 from http://download.boulder.ibm.com/ibmdl/pub/software/dw/webservices/ws-restful/ws-restful-pdf.pdf.;;Sun, Bruce; ""A multi-tier architecture for building RESTful Web services""; published online and retrieved on Aug. 3, 2010 from http://download.boulder.ibm.com/ibmdl/pub/software/dw/ajax/wa-aj-multitier/wa-aj-multitier-pdf.pdf.;;Eugen; ""Securing a RESTful Web Service with Spring Security 3.1"", posted on Oct. 31, 2011, retrieved on Apr. 15, 2012, from http://www.baeldung.com.;;USPTO; final rejections in U.S. Appl. No. 10/955,449, (Perkins), mailed on Jul. 23, 2007.;;US Army; ""Wear and Appearance of Army Uniforms and Insignia"", May 11, 2012, Army Regulation 670-1, pp. 251-254.;;Dictionary.com; definition of ""hash mark"", accessed on Jan. 7, 2014.;;LSOFT; ""5.7 Using Merged Parameters with URLs"", retrieved from http://www.lsof.com/manuals/Maestro/Maestro-Users on Jan. 7, 2014.;;PC.net; ""What is the different between a backslash and a forward slash?"", retrieved from http://pc.net/helpcenter/print/backslash-vs-forward-slash on Jan. 7, 2014.;;W3 Consortium; ""3 Protocol Parameters"", RFC 2616, retrieved from http://www.w3.org/Protocols/rfc2616/rfc2616-sec3.html on Jan. 7, 2014.;;Stackoverflow; ""what is the #! sign in the URL and what is [sic] it mean?"", retrieved from http://stackoverflow.com/questions/5395330/what-is-the-sign-in-the-url on Jan. 7, 2014.;;Wikipedia; ""Number sign"", retrieved from http://en.wikipedia.org/wiki/Number-sign on Jan. 7, 2014.;;Wikipedia; ""Slash (punctuation)"", retrieved from http://en.wikipedia.org/wiki/Slash-(punctuation) on Jan. 7, 2014.",INACTIVE
763,US,A1,US 2008/0040243 A1,137-273-195-605-570,2008-02-14,2008,US 46310206 A,2006-08-08,US 46310206 A,2006-08-08,NOTIFICATION OF MAIL DELIVERIES IN REMOTE POST OFFICE MAILBOXES,"A computer implemented method, apparatus, and computer usable program code for mail notification. Physical mail is received in a mailbox. The physical mail includes an identifier indicating information about the physical mail. A presence of the physical mail is detected in the mailbox. The identifier is read in response to detecting the presence of the physical mail. A notification is sent to a mail recipient including the information in response to reading the identifier.",CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,CHANG DAVID YU;;CHANG JOHN YOW-CHUN;;VENKATARAMAPPA VISHWANATH,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-08-03),https://lens.org/137-273-195-605-570,Patent Application,yes,59,108,1,1,0,G06Q10/00;;G06Q10/087;;A47G29/1214;;G06Q10/00;;G06Q10/087;;A47G29/1214,G06Q10/00,705/28,0,0,,,,DISCONTINUED
764,WO,A1,WO 2013/170289 A1,164-104-750-665-719,2013-11-21,2013,AU 2012/001275 W,2012-10-12,GB 201208392 A,2012-05-14,AN INTERACTIVE SYSTEM,"An interactive system for creating, offering and processing a series of partial transactions between one or more nodes in substantially real time to establish a complete transaction between two nodes, the system comprising a delivery node for offering partial transactions, a central node configured to receive and collate partial transactions from the delivery node and to provide information regarding partial transactions simultaneously to one or more user nodes configured to receive and review partial transactions from the central node, a parsing module is provided which is configured to amend pre-selected details pertaining to the or each partial transaction delivered to it by the delivery node to generate at least one parsed partial transaction, the central node provides the or each parsed partial transaction to the or each user node, and the central node is configured to receive at least one reviewed parsed partial transaction from the or each user node and to convert the or each reviewed parsed partial transaction into a complete transaction, and to subsequently provide information regarding the or each completed transaction to the delivery node.",TAILORBET LTD;;MCKENZIE DAVID;;LO KEVIN YU-CHANG;;SILVA DAVID KIM;;ATICHIAN CHRISTIAN,MCKENZIE DAVID;;LO KEVIN YU-CHANG;;SILVA DAVID KIM,,https://lens.org/164-104-750-665-719,Patent Application,yes,4,0,4,5,0,G06Q10/047,G06Q30/00;;G06F17/00;;G06Q20/00,,0,0,,,,PENDING
765,DK,T3,DK 0479948 T3,178-593-887-686-172,1999-05-25,1999,DK 90917872 T,1990-06-22,US 37067389 A;;US 9003586 W,1989-06-23,Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder,"PCT No. PCT/US90/03586 Sec. 371 Date Dec. 19, 1991 Sec. 102(e) Date Dec. 19, 1991 PCT Filed Jun. 22, 1990 PCT Pub. No. WO91/00292 PCT Pub. Date Jan. 10, 1991.Described are the amino acid sequence of natriuretic peptide receptor B (NPRB) and DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.",GENENTECH INC,CHANG MING-SHI;;GOEDDEL DAVID V;;LOWE DAVID G,,https://lens.org/178-593-887-686-172,Granted Patent,no,0,0,11,11,0,A61K38/00;;C07K14/58;;C07K14/72;;C07K16/2869;;A61P43/00;;A61P7/10;;C07K16/2869;;C07K14/72;;C07K14/58;;A61K38/00,A61K38/00;;A61K38/22;;A61K39/395;;A61P7/10;;A61P43/00;;C07K1/00;;C07K1/22;;C07K14/00;;C07K14/435;;C07K14/575;;C07K14/58;;C07K14/705;;C07K14/72;;C07K16/00;;C07K16/28;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/53,,0,0,,,,EXPIRED
766,EP,A1,EP 2850573 A1,005-408-863-828-542,2015-03-25,2015,EP 12821224 A,2012-10-12,GB 201208392 A;;AU 2012/001275 W,2012-05-14,AN INTERACTIVE SYSTEM,,SB TECHNOLOGIES LTD,MCKENZIE DAVID;;LO KEVIN YU-CHANG;;SILVA DAVID KIM,,https://lens.org/005-408-863-828-542,Patent Application,yes,0,0,4,5,0,G06Q10/047,G06Q30/00;;G06F17/00;;G06Q20/00,,1,0,,,See references of WO 2013170289A1,DISCONTINUED
767,WO,A3,WO 2008/150539 A3,080-238-581-819-737,2009-03-26,2009,US 2008/0007040 W,2008-06-04,US 80998707 A,2007-06-04,HEAT CONDUCTING SLEEVE FOR A FUEL INJECTOR,"An engine comprises a block, a piston, a head, a fuel injector, and a sleeve (33). The fuel injector includes an actuator (32) extending between a first axial position (106) and a second axial position (104) along a longitudinal axis of the fuel injector. The sleeve (33) is coupled between the head and the fuel injector and extends between a third axial position (110) and a fourth axial position (108) along the axis of the fuel injector. The area between the first and second axial positions at least partially overlaps the area between the third and fourth axial positions.",CATERPILLAR INC;;CHANG DAVID Y;;PUSCH THOMAS G;;LIN DAVID J,CHANG DAVID Y;;PUSCH THOMAS G;;LIN DAVID J,,https://lens.org/080-238-581-819-737,Search Report,yes,6,0,3,3,0,F02M53/04;;F02M53/04;;F02M47/027;;F02M47/027;;F02M61/166;;F02M61/166;;F02M61/168;;F02M61/168,F02M53/04;;F02M47/02;;F02M61/16,,0,0,,,,PENDING
768,US,B2,US 7946276 B2,098-850-644-494-226,2011-05-24,2011,US 7998208 A,2008-03-31,US 7998208 A,2008-03-31,Protection device for a solenoid operated valve assembly,"A fuel injector is disclosed. The fuel injector includes an injector valve needle and a valve actuation assembly including a stator, an armature, and a valve, the valve in fluid communication with the injector valve needle. A stator protection device is positioned between the stator and at least a portion of the armature. The stator protection device is configured to prevent contact between the stator and the armature.",CATERPILLAR INC,PUSCH THOMAS G;;MARTIN DAVID E;;CHANG DAVID Y,CATERPILLAR INC (2008-03-12),https://lens.org/098-850-644-494-226,Granted Patent,yes,20,10,4,4,0,F02M61/166;;F02M63/0007;;F02M63/0019;;F02M63/0021;;F02M63/007;;F02M2200/02;;F02M2200/8084;;F02M2200/9007;;F02M2200/9053;;F02M63/0007;;F02M2200/9007;;F02M61/166;;F02M63/0021;;F02M2200/02;;F02M2200/8084;;F02M63/0019;;F02M63/007;;F02M2200/9053,B05B1/30;;F02M51/00;;F02M61/04,123/490;;123/472;;251/129.01,0,0,,,,ACTIVE
769,US,A1,US 2009/0242667 A1,152-098-813-630-115,2009-10-01,2009,US 7998208 A,2008-03-31,US 7998208 A,2008-03-31,Protection device for a solenoid operated valve assembly,"A fuel injector is disclosed. The fuel injector includes an injector valve needle and a valve actuation assembly including a stator, an armature, and a valve, the valve in fluid communication with the injector valve needle. A stator protection device is positioned between the stator and at least a portion of the armature. The stator protection device is configured to prevent contact between the stator and the armature.",CATERPILLAR INC,PUSCH THOMAS G;;MARTIN DAVID E;;CHANG DAVID Y,CATERPILLAR INC (2008-03-12),https://lens.org/152-098-813-630-115,Patent Application,yes,20,5,4,4,0,F02M61/166;;F02M63/0007;;F02M63/0019;;F02M63/0021;;F02M63/007;;F02M2200/02;;F02M2200/8084;;F02M2200/9007;;F02M2200/9053;;F02M63/0007;;F02M2200/9007;;F02M61/166;;F02M63/0021;;F02M2200/02;;F02M2200/8084;;F02M63/0019;;F02M63/007;;F02M2200/9053,F02M51/00;;B05B1/30;;F02M61/04;;F16K31/04,239/533.2;;239/585.1;;251/129.01;;123/472,0,0,,,,ACTIVE
770,US,A,US 5352587 A,153-305-885-093-932,1994-10-04,1994,US 77815791 A,1991-12-19,US 77815791 A;;US 9003586 W;;US 37067389 A,1989-06-23,Compositions and methods for the synthesis of natriuretic protein receptor B and methods of use,"Described are the amino acid sequence of natriuretic peptide receptor B (NPRB) and DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.",GENENTECH INC,CHANG MING-SHI;;GOEDDEL DAVID V;;LOWE DAVID G,GENENTECH INC (1991-12-11),https://lens.org/153-305-885-093-932,Granted Patent,yes,1,43,11,11,0,A61K38/00;;C07K14/58;;C07K14/72;;C07K16/2869;;A61P43/00;;A61P7/10;;C07K16/2869;;C07K14/72;;C07K14/58;;A61K38/00,A61K38/22;;A61K39/395;;A61K38/00;;A61P7/10;;A61P43/00;;C07K1/00;;C07K1/22;;C07K14/00;;C07K14/435;;C07K14/575;;C07K14/58;;C07K14/705;;C07K14/72;;C07K16/00;;C07K16/28;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/53,435/69.1;;435/172.1;;435/240.1;;435/320.1;;530/350;;514/12,19,19,009-821-941-052-239;;051-244-588-685-451;;047-681-817-594-029;;034-654-280-616-391;;070-626-621-092-336;;090-536-166-896-653;;035-603-542-584-796;;028-164-413-174-402;;009-082-998-909-954;;079-534-820-321-516;;007-012-861-045-431;;035-214-087-723-715;;072-119-719-864-134;;059-946-857-914-804;;047-910-872-444-839;;032-150-857-197-741;;030-965-127-204-465;;001-866-874-475-781;;099-035-931-483-672,2837487;;10.1016/s0021-9258(19)76554-5;;2903071;;10.1016/0014-5793(88)80539-8;;2901039;;10.1038/334708a0;;2896603;;10.1016/0014-5793(88)80400-9;;2823146;;10.1038/329836a0;;10.1016/s0889-8529(18)30496-1;;2892671;;10.1126/science.1672777;;1672777;;2522776;;10.1016/0006-291x(89)92268-7;;1660465;;10.1016/s0021-9258(18)54463-x;;2570641;;10.1016/0092-8674(89)90513-8;;10.1126/science.3500514;;3500514;;2563900;;10.1038/338078a0;;10.1038/341068a0;;2570358;;10.1002/j.1460-2075.1989.tb03518.x;;pmc400964;;2569967;;10.1038/nbt0588-529;;2542042;;10.1016/0014-2999(89)90838-8;;10.1016/0014-5793(88)80523-4;;2844607;;2845313;;10.1016/s0149-7634(88)80007-1;;2139780;;10.1016/0006-291x(90)92401-k,"Fuller et al., 1988, J. Biol. Chem., 263, 9395.;;Koesling et al., 1988, FEBS Letter, 239, 29.;;Singh et al., 1988, Nature, 334, 708.;;Song et al., 1988, FEBS Letter, 232, 125.;;Masu et al., 1987 Nature, 329, 836.;;Leitman, D. C. and Murad, F. Endocrinol. Metab. Clin. N. Am., 16:79 105 (1987).;;Koller et al., Selective Activation of the B Natriuretic Peptide Receptor by C Type Natriuretic Peptide (CNP) , Science, 252: 120 123 (1991).;;Kojima et al. Cloning and sequence analysis of cDNA encoding a precursor for rat brain natriuretic peptide , Biochem. Biophys. Res. Comm., 159(3): 1420 1426 (1989).;;Bennett et al., Extracellular domain IgG fusion proteins for three human natriuretic peptide receptors , J. Biol. Chem., 266(34):23060 23067 (1991).;;Schulz et al., Cell, vol. 58, 1155 1162, 1989.;;Smith et al., Science, 238, 1704 1707, 1987.;;Chinkers et al., Nature, 338:78 83 (1989).;;Chang et al., Nature, 341:68 72 (1989).;;Lowe et al., EMBO Journal, 8(5):1377 1384 (1989).;;Baxter et al., Biotechnology, 6:529 546 (1988).;;Oehlenschlager et al., Eur. Jour. of Pharmacology, 161:159 164 (1989).;;Hirata et al., FEB 238(2):415 418 (1988).;;Stewart et al., Neuroscience & Biobehavioral Reviews, 12:151 168 (1988).;;Sudoh et al., Biochem and Biophy Res Comm. 168(2):863 870 (1990).",EXPIRED
771,CA,A1,CA 2059131 A1,131-630-871-894-457,1990-12-24,1990,CA 2059131 A,1990-06-22,US 37067389 A,1989-06-23,COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF NATRIURETIC PROTEIN RECEPTOR B AND METHODS OF USE,"2059131 9100292 PCTABS00003 Described are the amino acid sequence of natriuretic peptide receptor B (NPRB) and DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.",GENENTECH INC,CHANG MING-SHI;;GOEDDEL DAVID V;;LOWE DAVID G,,https://lens.org/131-630-871-894-457,Patent Application,no,0,0,11,11,0,A61K38/00;;C07K14/58;;C07K14/72;;C07K16/2869;;A61P43/00;;A61P7/10;;C07K16/2869;;C07K14/72;;C07K14/58;;A61K38/00,A61K38/00;;A61K38/22;;A61K39/395;;A61P7/10;;A61P43/00;;C07K1/00;;C07K1/22;;C07K14/00;;C07K14/435;;C07K14/575;;C07K14/58;;C07K14/705;;C07K14/72;;C07K16/00;;C07K16/28;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/53,,0,0,,,,DISCONTINUED
772,US,A1,US 2008/0295806 A1,027-204-667-975-792,2008-12-04,2008,US 80998707 A,2007-06-04,US 80998707 A,2007-06-04,Heat conducting sleeve for a fuel injector,"An engine comprises a block, a piston, a head, a fuel injector, and a sleeve. The block includes at least one bore. The piston is configured to reciprocate within the bore. The head is coupled to the block and defines with the block and the piston a combustion chamber. The fuel injector is coupled to the head and is configured to deliver fuel to the combustion chamber. The fuel injector includes an actuator extending between a first axial position and a second axial position along a longitudinal axis of the fuel injector. The sleeve is coupled between the head and the fuel injector and extends between a third axial position and a fourth axial position along the axis of the fuel injector. The area between the first and second axial positions at least partially overlaps the area between the third and fourth axial positions.",CATERPILLAR INC,CHANG DAVID Y;;LIN DAVID J;;PUSCH THOMAS G,CATERPILLAR INC (2007-07-18),https://lens.org/027-204-667-975-792,Patent Application,yes,48,22,3,3,0,F02M53/04;;F02M53/04;;F02M47/027;;F02M47/027;;F02M61/166;;F02M61/166;;F02M61/168;;F02M61/168,F02M61/16,123/470,0,0,,,,DISCONTINUED
773,WO,A2,WO 2008/150539 A2,017-965-450-984-368,2008-12-11,2008,US 2008/0007040 W,2008-06-04,US 80998707 A,2007-06-04,HEAT CONDUCTING SLEEVE FOR A FUEL INJECTOR,"An engine comprises a block, a piston, a head, a fuel injector, and a sleeve. The block includes at least one bore. The piston is configured to reciprocate within the bore. The head is coupled to the block and defines with the block and the piston a combustion chamber. The fuel injector is coupled to the head and is configured to deliver fuel to the combustion chamber. The fuel injector includes an actuator extending between a first axial position and a second axial position along a longitudinal axis of the fuel injector. The sleeve is coupled between the head and the fuel injector and extends between a third axial position and a fourth axial position along the axis of the fuel injector. The area between the first and second axial positions at least partially overlaps the area between the third and fourth axial positions.",CATERPILLAR INC;;CHANG DAVID Y;;PUSCH THOMAS G;;LIN DAVID J,CHANG DAVID Y;;PUSCH THOMAS G;;LIN DAVID J,,https://lens.org/017-965-450-984-368,Patent Application,yes,0,0,3,3,0,F02M53/04;;F02M53/04;;F02M47/027;;F02M47/027;;F02M61/166;;F02M61/166;;F02M61/168;;F02M61/168,F02M53/04;;F02M47/02;;F02M61/16,,0,0,,,,PENDING
774,AT,T1,AT E170192 T1,119-063-105-214-19X,1998-09-15,1998,AT 90917872 T,1990-06-22,US 37067389 A,1989-06-23,ZUSAMMENSETZUNGEN UND METHODEN ZUR SYNTHESE DES B-REZEPTORS FÜR DAS NATRIURETISCHE PROTEIN UND VERWENDUNGSMETHODEN,"PCT No. PCT/US90/03586 Sec. 371 Date Dec. 19, 1991 Sec. 102(e) Date Dec. 19, 1991 PCT Filed Jun. 22, 1990 PCT Pub. No. WO91/00292 PCT Pub. Date Jan. 10, 1991.Described are the amino acid sequence of natriuretic peptide receptor B (NPRB) and DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.",GENENTECH INC,CHANG MING-SHI;;GOEDDEL DAVID V;;LOWE DAVID G,,https://lens.org/119-063-105-214-19X,Granted Patent,no,0,0,11,11,0,A61K38/00;;C07K14/58;;C07K14/72;;C07K16/2869;;A61P43/00;;A61P7/10;;C07K16/2869;;C07K14/72;;C07K14/58;;A61K38/00,A61K38/00;;A61K38/22;;A61K39/395;;A61P7/10;;A61P43/00;;C07K1/00;;C07K1/22;;C07K14/00;;C07K14/435;;C07K14/575;;C07K14/58;;C07K14/705;;C07K14/72;;C07K16/00;;C07K16/28;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/53,,0,0,,,,DISCONTINUED
775,US,A,US 5028565 A,135-214-635-144-438,1991-07-02,1991,US 39865389 A,1989-08-25,US 39865389 A,1989-08-25,Process for CVD deposition of tungsten layer on semiconductor wafer,"An improved process is disclosed for the deposition of a layer of tungsten on a semiconductor wafer in a vacuum chamber wherein the improvements comprise depositing tungsten on the semiconductor wafer in the presence of nitrogen gas to improve the reflectivity of the surface of the resulting layer of tungsten; maintaining the vacuum chamber at a pressure of from about 20 to 760 Torr to improve the deposition rate of the tungsten, as well as to improve the reflectivity of the tungsten surface; and, when needed, the additional step of forming a nucleation layer on the semiconductor layer prior to the step of depositing tungsten on the semiconductor wafer to improve the uniformity of the deposited tungsten layer.",APPLIED MATERIALS INC,CHANG MEI;;LEUNG CISSY;;WANG DAVID N;;CHENG DAVID,APPLIED MATERIALS INC (1989-09-20),https://lens.org/135-214-635-144-438,Granted Patent,yes,3,371,16,16,0,H01L21/283;;H01L21/76838;;H01L21/76838;;H01L21/28556;;H01L21/28556;;H01L21/32051;;H01L21/32051;;Y10S148/025;;Y10S148/025,C23C16/06;;C23C16/08;;C23C16/22;;C23C16/44;;H01L21/28;;H01L21/285;;H01L21/3205;;H01L21/768,437/192;;437/195;;437/190;;X148DIG 25,5,0,,,"Toshi et al, The Role of Process Parameters of Selective W Deposited by SiH 4 , H 2 , and WF 6 Chemistry in Terms of Shallow Junction Leakages , Materials Research Society, pp. 85 92, 1989.;;Broadbent et al, Selective Tungsten Processing by LPCUD , Solid State Tech., pp. 51 59 12/85.;;Morosami et al, Kinetics and Properties of CVD Tungsten Film on hion Substrates , pp. 181 203.;;Broadbent et al., Selective Low Pressure CVD of Tungsten , Solid State Science and Tech., vol. 131, No. 6, 6/84, pp. 1427 1433.;;Lifshntz et al., Shallow Shieded Diodes with LPCND Tungsten Plug , Materials Research SOciety 1988, pp. 225 229.",EXPIRED
776,US,B2,US 7088901 B2,002-405-082-148-437,2006-08-08,2006,US 63553103 A,2003-08-07,US 63553103 A,2003-08-07,Light guide apparatus and method for a detector array,"According to one aspect, the invention relates to a light guide which may include a first surface which receives light, a second surface which emits light, wherein the second surface is parallel to the first surface and the second surface has a smaller area than the first surface, at least one edge surface which extends between the first surface and the second surface, and a light barrier which extends between the first surface and the second surface, wherein the light barrier divides the light guide into separate regions and reduces the propagation of light between the separate regions. The light guide can be used in a positron emission tomography scanner.",KIM CHANG L;;MCDANIEL DAVID L,KIM CHANG L;;MCDANIEL DAVID L,GE MEDICAL SYSTEMS GLOBAL TECHNOLOGY CO. LLC (2003-09-04);;GENERAL ELECTRIC COMPANY (2008-10-08),https://lens.org/002-405-082-148-437,Granted Patent,yes,8,14,2,2,0,G02B6/10;;G02B6/10;;G02B6/08;;G02B6/08,G02B6/10;;F21V8/00;;G02B6/08,385/146;;250/363.3;;250/366;;250/367;;250/368,9,8,046-878-113-502-117;;111-201-087-957-329;;046-878-113-502-117;;031-069-869-742-52X;;111-201-087-957-329;;104-823-007-350-141;;039-052-198-269-494;;016-009-462-087-22X,10.1109/tns.1986.4337144;;10.1109/nssmic.2002.1239644;;10.1109/tns.1986.4337144;;10.1109/tns.1986.4337140;;10.1109/nssmic.2002.1239644;;10.1109/23.256693;;10.1109/nssmic.2001.1008424;;10.1109/tns.1986.4337143,"H.Uchida, et al., ""Design of a mosaic BGO detector system for positron CT"", IEEE Trans Nuclear Science, 33(1), pp. 464-467 (Feb. 1987).;;Photomultiplier Tubes Product Specification, Photonis XP1452 (abstract), Mar. 29, 2001 (3 pages).;;""High Spatial Resolution Detector Using and 8x8 MLS Crystal Array and a Quad Anode Photo-Multiplier."" by Chang L. Kim and David McDaniel, 1 page poster presented Nov. 15, 2002 at the 2002 IEEE Nuclear Science Symposium and Medical Imaging Conference, Norfolk, VA.;;""Design of a Mosaic BGO Detector System for Positron CT,"" by Uchida et al., IEEE Transactions on Nuclear Science, vol. 33, No. 1 Feb. 1986 ( 4 pages).;;""Figures of Merit for Different Detector Configurations Utilized in High Positron Cameras,"" by Eriksson et al., IEEE Transactions on Nuclear Science, vol. 33, No. 1, pp. 446-451, (Feb. 1986).;;""High Spatial Resolution Detector Using and 8x8 MLS Crystal Array and a Quad Anode Photo-Multiplier,"" by Chang L. Kim and David McDaniel (5 pages), distributed May, 2003 by IEEE to attendees of the Nov. 2002 IEEE Nuclear Sciences Symposium and Medical Imaging Conference, Norfolk, VA.;;Wai-Hoi Wong, ""A Positron Camera Detector Design with Cross-Coupled Scintillators and Quadrant Sharing Photomulipliers,"" IEEE Transactions on Nuclear Science, vol. 40, No. 4, pp. 962-966, (Aug. 1993).;;Catherine M. Pepin, ""Comparison of LSO, LGSO and MLS Scintillators,"" IEEE Nuclear Science Symposium, vol. 1, pp. 124-128, San Diego, Ca (Nov. 2001).;;M.E Casey and R. Nutt, ""A Multicrystal Two Dimensional BGO Detector System for Positron Emission Tomography,""IEEE Transactions on Nuclear Science, vol. 33, No. 1, Feb. 1986, p. 460-463.",EXPIRED
777,EP,A1,EP 0123485 A1,003-857-431-602-647,1984-10-31,1984,EP 84302549 A,1984-04-13,US 48498383 A;;US 59349284 A,1983-04-14,"Colon-specific prodrug, the preparation and uses thereof.","A colon-specific drug delivery system is based on the use of a synthetic drug glycoside prodrug composition which, when ingested by a mammal, undergoes reaction with glycosidases produced by colonic microflora to release a free drug capable of being absorbed to or absorbed by the intestinal mucosa. Hitherto, synthetic drug glycosides useful in the delivery of chemotherapeutic agents to the colon were not known.",UNIV CALIFORNIA,FRIEND DAVID ROBERT;;CHANG GEORGE WASHINGTON,,https://lens.org/003-857-431-602-647,Patent Application,yes,3,10,2,3,0,A61K31/704;;A61K47/549;;C07J17/005,C07J17/00,,2,2,046-301-940-698-129;;021-245-589-346-466,10.1002/jps.2600571202;;4974346;;10.1021/jm00369a005;;6699871,"JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 57, no. 12, December 1968, pages 2021-2037, Washington, D.C., US; R.R. SCHELINE: ""Drug metabolism by intestinal microorganisms"";;JOURNAL OF MEDICINAL CHEMISTRY, vol. 27, no. 3, March 1984, pages 261-265, American Chemical Society, Washington, D.C., US; D.R. FRIEND et al.: ""A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria""",DISCONTINUED
778,CN,A,CN 104919077 A,007-827-430-706-370,2015-09-16,2015,CN 201480004713 A,2014-01-10,US 2014/0011149 W;;US 201361752209 P;;US 201361752549 P;;US 201361897082 P;;US 201361907628 P,2013-01-14,METHOD AND SYSTEM FOR GRAPHENE FORMATION,A method of forming graphene includes placing a substrate in a processing chamber and introducing a cleaning gas including hydrogen and nitrogen into the processing chamber. The method also includes introducing a carbon source into the processing chamber and initiating a microwave plasma in the processing chamber. The method further includes subjecting the substrate to a flow of the cleaning gas and the carbon source for a predetermined period of time to form the graphene.,CALIFORNIA INST OF TECHN,BOYD DAVID A;;YEH NAI-CHANG,,https://lens.org/007-827-430-706-370,Patent Application,no,5,4,14,14,0,C23C16/26;;C23C16/4405;;C23C16/511;;H01L29/92;;C01B32/184;;C01B32/186;;Y10T428/24355;;C01B32/186;;C23C16/26;;C23C16/4405;;C23C16/511;;Y10T428/24355;;C01B32/184;;C01B32/186;;C23C16/26;;C23C16/4405;;C23C16/511,C23C14/02,,1,0,,,"N.-C. YEH ET AL.: ""Strain-induced pseudo-magnetic fields and charging effects on CVD-grown graphene"", 《SURFACE SCIENCE》",ACTIVE
779,WO,A1,WO 2011/123428 A1,024-196-853-899-889,2011-10-06,2011,US 2011/0030294 W,2011-03-29,US 32928210 P;;US 31990210 P,2010-04-01,ANTIBODY-BASED DEPLETION OF ANTIGEN-PRESENTING CELLS AND DENDRITIC CELLS,"Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8 + memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.",IMMUNOMEDICS INC;;CHANG CHIEN-HSING;;GOLDENBERG DAVID M,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/024-196-853-899-889,Patent Application,yes,4,0,8,8,100,C07K16/2803;;C07K16/2887;;C07K16/30;;C07K16/3007;;C07K16/44;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/52;;C07K2317/522;;C07K2317/55;;C07K2317/73;;C07K2317/77;;A61K31/4965;;C07K2317/734;;C07K2317/75;;C07K2319/70;;A61K47/6807;;A61K47/6813;;A61K47/6815;;A61K47/6849;;A61K47/6881;;A61K47/6885;;C07K16/2833;;A61P37/06;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/44;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/55;;C07K2317/73;;C07K2317/77;;C07K2319/70;;C07K16/2833;;C07K2317/522;;C07K2317/51;;C07K16/30;;C07K2317/52;;A61K31/4965;;C07K2317/75;;C07K2317/734;;A61K47/6813;;A61K47/6815;;A61K47/6807;;A61K47/6881;;A61K47/6849;;A61K47/6885;;Y02A50/30;;C07K16/18;;C07K16/2851;;C07K16/2863;;C07K16/3092;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32,A61K39/395,,5,3,051-227-177-237-633;;031-062-814-364-881;;037-982-835-914-459,10.1093/intimm/dxf073;;12202400;;10.1158/1078-0432.ccr-08-1953;;19351768;;pmc2681251;;15923369;;pmc3957538;;10.1369/jhc.4a6552.2005,"LOKSHIN ET AL.: ""Differential regulation of maturation and apoptosis of humen monocyte-derived dendritic celle mediated by MHC dass II"", INT IMMUNOL, vol. 14, no. 9, 2002, pages 1027 - 1037, XP008161720;;CHEN ET AL.: ""Differential Effects of Milatuzumab On Human Antigen-Pressenting Cells in Comparison to Malignant B Cells."", 51ST ASH ANNUAL MEETING, 2009, XP008161688, Retrieved from the Internet <URL:http://ash.corifex.com/ash/2009/webprogram/Paper23675.html> [retrieved on 20110802];;STEIN ET AL.: ""Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines."", CLIN CANCER RES, vol. 15, no. 8, 2009, pages 2808 - 2817, XP008161722;;BARRERA ET AL.: ""Polarized expression of CD74 by gastric epithellal cells."", J HISTOCHEM CYTOCHEM, vol. 53, no. 12, 2005, pages 1481 - 1489, XP008161721;;""HLA-DR."", WIKIPEDIA, 26 February 2010 (2010-02-26), XP008161685, Retrieved from the Internet <URL:http://en.wiklpedia.org/w/index.php?title=HLA-DR&oidid=346491680> [retrieved on 20100802]",PENDING
780,AU,A,AU 2001/079107 A,024-940-032-942-803,2002-02-13,2002,AU 2001/079107 A,2001-07-30,US 62968200 A;;US 0123983 W,2000-08-01,A tunneling sensor or switch and a method of making same,,HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,,https://lens.org/024-940-032-942-803,Patent Application,no,0,0,9,9,0,G01P15/0802;;G01P15/0802;;G01P15/0894;;G01P15/0894;;H01H1/0036;;H01H1/0036;;H01H59/0009;;H01H59/0009,B81B3/00;;B81C1/00;;G01P15/08;;H01H1/00;;H01H59/00;;H01L29/84,,0,0,,,,PENDING
781,WO,A3,WO 2014/194143 A3,017-612-182-762-254,2015-11-12,2015,US 2014/0040094 W,2014-05-29,US 201361828327 P,2013-05-29,DYNAMIC WAGER UPDATING GAMBLING HYBRID GAME,"A gambling hybrid game with dynamic wager updating is disclosed. The gambling hybrid game includes an entertainment system engine that provides an entertainment game to a user, a real world engine that provides gambling games to one or more users, and a game world engine that monitors the entertainment game and provides gambling games when appropriate. The gambling hybrid game during the course of game play may dynamically update a wager amount to be placed on a gambling event in the gambling game",GAMBLIT GAMING LLC,ARNONE MILES;;MEYERHOFER ERIC;;CHANG DAVID,,https://lens.org/017-612-182-762-254,Search Report,yes,3,0,8,8,0,G07F17/3227;;G07F17/3227;;G07F17/32;;G07F17/32;;G07F17/3204;;G07F17/3204;;G07F17/3286;;G07F17/3286;;G07F17/34;;G07F17/34,A63F9/24,,0,0,,,,PENDING
782,US,A1,US 2016/0000915 A1,019-833-427-707-029,2016-01-07,2016,US 201514861636 A,2015-09-22,US 201514861636 A;;US 201414243512 A;;US 201213693476 A;;US 201161566828 P;;US 201261609075 P;;US 201261682508 P;;US 201261718226 P;;US 201361808005 P;;US 201361832558 P;;US 201461941100 P;;US 201462054581 P,2011-12-05,CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS,"Extensive crosslinking of CD22 by plate-immobilized epratuzumab induced intracellular changes in Daudi cells similar to ligating B-cell antigen receptor (BCR) with a sufficiently high amount of anti-IgM. Either treatment leads to phosphorylation of CD22, CD79a and CD79b, along with their translocation to lipid rafts, both of which were needed to induce caspase-dependent apoptosis. Immobilization also induced stabilization of F-actin, phosphorylation of Lyn, ERKs and JNKs, generation of reactive oxygen species (ROS), decrease in mitochondria membrane potential (Δψ m ), upregulation of pro-apoptotic Bax, and downregulation of anti-apoptotic Bcl-xl and Mcl-1. Several of the in vitro effects of immobilized epratuzumab, including apoptosis, drop in Δψ m , and generation of ROS, were observed with soluble epratuzumab in Daudi cells co-cultivated with human umbilical vein endothelial cells. The in vivo mechanism of non-ligand-blocking epratuzumab may, in part, involve the unmasking of CD22 to facilitate the trans-interaction of B cells with vascular endothelium.",IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IMMUNOMEDICS INC (2016-01-06),https://lens.org/019-833-427-707-029,Patent Application,yes,7,5,3,17,20,A61K45/06;;A61K45/06;;A61K2039/505;;A61K2039/505;;C07K14/56;;C07K14/56;;C07K16/2803;;C07K16/2803;;C07K16/2833;;C07K16/2833;;C07K16/2887;;C07K16/2887;;C07K16/3007;;C07K16/3007;;C07K16/468;;C07K16/468;;C07K2317/24;;C07K2317/24;;C07K2317/31;;C07K2317/31;;C07K2317/54;;C07K2317/54;;C07K2317/55;;C07K2317/55;;C07K2317/73;;C07K2317/73;;C07K2317/732;;C07K2317/732;;C07K2317/734;;C07K2317/734;;C07K2317/77;;C07K2317/77;;C07K2317/92;;C07K2317/92;;C07K2317/94;;C07K2317/94;;C07K2319/00;;C07K2319/00,A61K39/395;;A61K45/06;;C07K16/28,,1,1,060-444-182-146-32X,10.1038/sj.onc.1210370;;17530024,"Leonard et al., Oncogene. 2007 May 28;26(25):3704-13.",ACTIVE
783,EP,A2,EP 0995186 A2,021-102-733-033-846,2000-04-26,2000,EP 98929094 A,1998-06-16,US 9812591 W;;US 87929697 A,1997-06-18,GRAPHICAL CLICK SURFACES FOR FORCE FEEDBACK APPLICATIONS,,IMMERSION CORP,ROSENBERG LOUIS B;;CHANG DAVID C,IMMERSION CORPORATION (2001-12-05),https://lens.org/021-102-733-033-846,Patent Application,yes,0,0,10,434,0,A63F2300/1025;;A63F2300/1037;;G05G9/047;;G05G2009/0477;;G06F3/011;;G06F3/016;;G06F3/0354;;G06F3/03543;;G06F3/03548;;G06F3/04812;;G06F3/0482;;G06F3/04842;;G06F2203/014;;H01H2003/008;;H04L67/131;;G06F3/016;;G06F3/011;;A63F2300/1025;;G06F3/04842;;G06F3/03548;;G06F3/0482;;G05G9/047;;G06F3/04812;;A63F2300/1037;;G05G2009/0477;;G06F3/0354;;G06F3/03543;;H01H2003/008;;G06F2203/014;;H04L67/131,G05G9/047;;G06F3/00;;G06F3/01;;G06F3/033;;G06F3/048;;H04L29/06,,0,0,,,,DISCONTINUED
784,DE,A1,DE 102017116711 A1,017-780-569-930-593,2018-01-25,2018,DE 102017116711 A,2017-07-24,US 201615218134 A,2016-07-25,KOLBEN,"Ein Kolben für einen Motor wird bereitgestellt. Der Kolben umfasst einen Körper mit einer Krone, die um eine Mittelachse herum angeordnet ist. Die Krone umfasst einen inneren Umfang und einen äußeren Umfang. Der Kolben umfasst eine Zentralkammer, die quer innerhalb des Körpers angeordnet ist und in Bezug auf die Krone vertieft ist. Der Kolben umfasst eine zentrale Erhöhung, die innerhalb der Zentralkammer um die Mittelachse herum angeordnet ist. Der Kolben umfasst auch eine Schale, die sich von der zentralen Erhöhung zu der Krone hin erstreckt. Der Kolben umfasst des Weiteren einen Durchgang, der an dem inneren Umfang der Krone vorgesehen ist. Der Durchgang umfasst einen Schlitz, der durch eine erste Oberfläche definiert wird, die mit einem ersten Winkel in Bezug auf die Mittelachse geneigt ist. Der Schlitz ist dazu geeignet, den Fluss eines Kraftstoffs von der Zentralkammer zu dem äußeren Umfang der Krone zu erlauben.",CATERPILLAR INC,GONG WEIDONG;;CHANG DAVID YU-ZHANG,,https://lens.org/017-780-569-930-593,Patent Application,no,0,2,3,3,0,F02B17/005;;F02B23/0627;;F02B23/0651;;Y02T10/12;;Y02T10/12;;F02B17/005;;F02B23/0627;;F02B23/0651;;F02F1/00;;F02F1/24;;F02F3/24,F02F3/28,,0,0,,,,PENDING
785,TW,B,TW 498410 B,043-038-966-014-560,2002-08-11,2002,TW 90116339 A,2001-07-04,US 62967900 A,2000-08-01,"A single crystal, dual wafer, tunneling gyroscope and a method of making same","A method of making a micro electro-mechanical gyroscope. A cantilevered beam structure, first portions of side drive electrodes and a mating structure are defined on a first substrate or wafer; and at least one contact structure, second portions of the side drive electrodes and a mating structure are defined on a second substrate or wafer, the mating structure on the second substrate or wafer being of a complementary shape to the mating structure on the first substrate or wafer and the first and second portions of the side drive electrodes being of a complementary shape to each other. A bonding layer, preferably a eutectic bonding layer, is provided on at least one of the mating structures and one or the first and second portions of the side drive electrodes. The mating structure of the first substrate is moved into a confronting relationship with the mating structure of the second substrate or wafer. Pressure is applied between the two substrates so as to cause a bond to occur between the two mating structures at the bonding or eutectic layer and also between the first and second portions of the side drive electrodes to cause a bond to occur there between. Then the first substrate or wafer is removed to free the cantilevered beam structure for movement relative to the second substrate or wafer. The bonds are preferably eutectic bonds.",HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,,https://lens.org/043-038-966-014-560,Granted Patent,no,0,1,11,11,0,B81B2201/0242;;B81C1/0015;;B81C2201/014;;B81C2201/0191;;B81C2203/036;;G01C19/5656;;G01P15/0802;;G01P15/0894;;B81C1/0015;;B81C2201/014;;G01C19/5656;;G01P15/0802;;B81B2201/0242;;B81C2201/0191;;G01P15/0894;;B81C2203/036,B81B3/00;;B81C1/00;;G01C19/5656;;G01P15/08,,0,0,,,,EXPIRED
786,US,B2,US 7571548 B2,033-825-410-466-991,2009-08-11,2009,US 82867107 A,2007-07-26,US 82867107 A,2007-07-26,Cycling pedal leg angle optimizer,Optimizing pedal angle for a cyclist is accomplished with a template having a central body with an aperture for positioning over the lateral condyle in a cyclist's knee. A fist alignment arm extends from the central body and incorporates an alignment indicia for positioning between the knee and hip of the cyclist. A second alignment arm extends from the central body at a predetermined angle with respect to the first alignment arm and employs an angular alignment indicia for relative placement over a malleolus bone of an ankle of the cyclist.,TAYLOR JOSHUA DAVID;;HERNANDEZ CHANG LOUISE,TAYLOR JOSHUA DAVID;;HERNANDEZ CHANG LOUISE,,https://lens.org/033-825-410-466-991,Granted Patent,yes,22,6,3,3,0,A61B5/1071;;A61B5/1071;;A61B5/4528;;A61B5/4528;;A61B5/6828;;A61B5/6828,G01B3/56;;B43L7/033,33/512;;X 33  1 N;;33/482,0,0,,,,INACTIVE
787,US,B2,US 9182506 B2,026-592-947-306-922,2015-11-10,2015,US 201313931569 A,2013-06-28,US 201313931569 A,2013-06-28,Methods and systems for signal communication in gamma ray detectors,"Methods and systems for signal communication in gamma ray detectors are provided. One gamma ray detector includes a scintillator block having a plurality of scintillator crystals and a plurality of light sensors coupled to the scintillator crystals and having a plurality of microcells. Each of the plurality of light sensors have a local summing point in each of a plurality of signal summing regions, wherein the local summing points are connected to the plurality of microcells. The plurality of light sensors also each include a main summing point connected to the plurality of local summing points, wherein the main summing point is located a same distance from each of the local summing points.",GEN ELECTRIC,KIM CHANG LYONG;;MCDANIEL DAVID LEO,GENERAL ELECTRIC COMPANY (2013-06-28),https://lens.org/026-592-947-306-922,Granted Patent,yes,8,6,3,3,0,G01T1/1642;;G01T1/2914;;G01T1/20;;G01T1/16;;G01T1/1641;;G01T1/20183;;G01T1/20182;;G01T1/2985;;G01T1/2914;;G01T1/20;;G01T1/16;;G01T1/1641;;G01T1/1642;;G01T1/20183;;G01T1/20182,G01T1/16;;G01T1/164;;G01T1/20;;G01T1/29,,1,0,,,"Search Report and Written Opinion from corresponding PCT Application No. PCT/US2014/041679 dated Aug. 22, 2014.",ACTIVE
788,CA,A1,CA 2772572 A1,029-187-252-235-339,2011-03-03,2011,CA 2772572 A,2010-08-27,US 23842409 P;;US 64414609 A;;US 73178110 A;;US 75264910 A;;US 75414010 A;;US 75474010 A;;US 2010/0046889 W,2009-08-31,BISPECIFIC IMMUNOCYTOKINE DOCK-AND-LOCK (DNL) COMPLEXES AND THERAPEUTIC USE THEREOF,"The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed on the same target cell. The bispecific immunocytokine DNL construct exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or even other types of cytokine-antibody DNL constructs. In a most preferred embodiment the construct comprises an anti-CD20 IgG antibody conjugated to an anti-HLA-DR Fab and IFNa2b, although other combinations of antibodies, antibody fragments and cytokines may be used to form the subject DNL complexes.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/029-187-252-235-339,Patent Application,no,0,0,12,1035,97,A61K2039/505;;A61P1/04;;A61P3/10;;A61P7/06;;A61P9/00;;A61P9/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;C07K14/52;;C07K16/249;;C07K16/2833;;C07K16/2887;;C07K2317/31;;C07K2317/55;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2319/30,C07K19/00;;C07K16/46,,0,0,,,,DISCONTINUED
789,EP,A1,EP 0996688 A1,033-326-450-344-589,2000-05-03,2000,EP 98935675 A,1998-07-16,US 9814641 W;;US 89564297 A,1997-07-17,AQUEOUS COATING COMPOSITION OF A SELF-STABILIZED CROSSLINKED LATEX,,DU PONT,CHANG DAVID C K;;FRYD MICHAEL,,https://lens.org/033-326-450-344-589,Patent Application,yes,0,0,18,18,0,C09D151/00;;C09D151/00;;C09D151/00;;C08F290/04;;C08F290/04;;C08F290/044;;C08F290/044;;C08F290/046;;C08F290/046,C08F290/04;;C09D5/02;;C09D151/00,,1,0,,,See references of WO 9903937A1,EXPIRED
790,US,B2,US 8883162 B2,041-899-426-276-764,2014-11-11,2014,US 201213688812 A,2012-11-29,US 201213688812 A;;US 201213483761 A;;US 94953610 A;;US 39660509 A;;US 63372906 A;;US 2006/0010762 W;;US 2006/0012084 W;;US 2006/0025499 W;;US 38935806 A;;US 39158406 A;;US 47802106 A;;US 72264510 A;;US 68933610 A;;US 201161566273 P;;US 201261616051 P;;US 78233206 P;;US 72829205 P;;US 75119605 P;;US 86453006 P;;US 14589609 P,2005-10-19,Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors,"The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) complex. Preferably, the DNL™ complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-α2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2013-02-28),https://lens.org/041-899-426-276-764,Granted Patent,yes,40,7,2,1035,123,A61K39/39558;;A61K39/39558;;A61K47/6897;;A61K47/6897;;A61K51/088;;A61K51/088;;A61P35/00;;A61P35/02;;B82Y5/00;;B82Y5/00;;B82Y10/00;;B82Y10/00;;C07K16/2863;;C07K16/2863;;C07K16/30;;C07K16/30;;C07K16/3007;;C07K16/3007;;C07K16/468;;C07K16/468;;C07K2317/24;;C07K2317/24;;C07K2317/35;;C07K2317/35;;C07K2317/522;;C07K2317/522;;C07K2317/526;;C07K2317/526;;C07K2317/53;;C07K2317/53;;C07K2317/55;;C07K2317/55;;C07K2317/64;;C07K2317/64;;C07K2317/73;;C07K2317/73;;C07K2317/77;;C07K2317/77;;C07K2317/92;;C07K2317/92;;C07K2319/00;;C07K2319/00;;C07K2319/30;;C07K2319/30;;C07K2319/70;;C07K2319/70,A61K39/395;;A61K39/44;;A61K47/48;;A61K51/08;;A61P35/00;;A61P35/02;;B82Y5/00;;B82Y10/00;;C07K16/28;;C07K16/30;;C07K16/46,424/181.1;;530/391.5;;530/391.9,111,106,010-908-907-218-597;;111-517-258-959-187;;113-073-836-369-700;;079-647-329-595-809;;014-440-266-315-016;;089-617-685-203-926;;044-833-204-245-310;;139-372-685-101-937;;012-396-951-553-305;;025-114-183-199-748;;027-713-460-602-505;;059-514-054-992-412;;009-382-346-030-754;;085-348-093-024-504;;084-363-781-757-911;;094-765-890-060-261;;040-727-613-160-452;;051-378-939-679-197;;046-717-070-604-887;;135-829-227-396-282;;033-159-596-168-05X;;023-972-612-906-083;;046-166-624-867-77X;;077-186-093-929-590;;012-139-204-135-647;;096-654-301-744-608;;006-692-005-939-614;;091-995-224-471-960;;046-723-641-666-637;;051-620-799-695-736;;000-687-583-450-12X;;030-424-581-071-330;;025-955-082-953-672;;043-565-065-226-050;;064-253-076-017-931;;073-213-551-327-892;;029-646-755-871-310;;015-399-642-762-43X;;142-686-487-823-912;;007-954-637-794-12X;;080-571-625-616-771;;013-580-733-777-26X;;046-220-521-080-741;;036-011-287-610-789;;046-650-803-614-561;;057-819-453-551-117;;020-829-015-080-665;;061-974-273-716-169;;073-910-564-236-619;;039-423-064-544-876;;037-506-957-000-949;;028-385-018-876-542;;078-950-298-931-296;;082-317-213-185-417;;061-716-650-834-485;;154-648-591-453-198;;138-142-682-110-803;;066-146-798-965-262;;032-799-656-305-036;;088-770-954-200-50X;;002-331-092-499-856;;052-302-906-314-226;;125-439-449-787-91X;;002-968-698-489-191;;003-133-671-061-524;;001-773-325-098-677;;001-438-265-785-943;;021-399-654-204-715;;013-495-040-538-497;;014-817-433-156-057;;006-606-859-520-426;;016-722-289-911-388;;055-567-629-980-222;;002-036-513-655-449;;099-307-614-319-429;;003-051-068-663-062;;023-678-010-672-059;;000-499-563-417-797;;023-833-986-552-400;;019-253-709-202-167;;103-932-348-507-545;;133-287-355-214-424;;091-341-936-846-342;;094-037-074-599-511;;101-663-979-767-604;;000-317-353-994-190;;052-947-986-013-690;;034-028-239-192-920;;040-142-822-097-134;;138-957-732-701-829;;027-215-950-157-668;;139-123-355-549-723;;038-215-831-671-137;;032-409-676-506-509;;044-988-808-395-48X;;019-736-899-818-187;;053-349-809-000-342;;008-956-301-309-595;;026-690-156-572-350;;066-342-559-427-246;;023-481-904-534-57X;;018-667-811-882-764;;007-072-874-769-097;;069-477-478-430-272;;006-680-826-675-902;;051-124-225-056-342,10.1158/1078-0432.ccr-06-1986;;17255306;;10.1200/jco.2007.11.1047;;17664477;;14695208;;23489099;;10.1517/17460441.3.4.441;;pmc2751307;;17408239;;10.1208/aapsj0901009;;10.1038/sj.gt.3301923;;12457277;;14585173;;10.1017/s1462399403006562;;10.1038/mt.2012.79;;pmc3392980;;22525514;;19491014;;10.1016/j.ejps.2009.02.013;;10.1172/jci114315;;2553774;;pmc304004;;10.1158/1078-0432.ccr-04-1070;;15756033;;10066081;;10.1023/a:1006127621512;;15928295;;10.1093/jnci/97.11.790;;10.1200/jco.2008.26.15_suppl.14510;;10.1210/er.16.1.3;;10.1210/edrv-16-1-3;;7758431;;12876069;;10.1152/ajprenal.00209.2003;;10.1042/bj20060890;;pmc1698672;;16981855;;16287993;;10.1158/0008-5472.can-05-2752;;10.1038/nrc1387;;15229476;;7758000;;10.1677/erc.1.01280;;17259557;;18245009;;10.1634/theoncologist.2007-0199;;10.1016/s0021-9258(18)42367-8;;1377676;;10889510;;10.1038/sj.cdd.4400693;;10.1158/1535-7163.mct-05-0048;;16093437;;10.1158/1078-0432.ccr-04-1586;;15837762;;10.1186/bcr50;;11250706;;pmc138771;;10.1073/pnas.0330734100;;12672969;;pmc153575;;16848397;;10.1021/bc060037u;;10.1016/j.febslet.2005.03.089;;15943971;;9857038;;10.1074/jbc.273.52.35048;;16704199;;10.1021/bc050322y;;10.1016/s1359-6101(01)00022-3;;11900988;;15375003;;10.1158/0008-5472.can-04-2048;;10.1016/0167-5699(96)10027-x;;8783497;;10358757;;10.1146/annurev.immunol.17.1.189;;6692364;;pmc2253242;;10.1110/ps.051687305;;16260760;;1860836;;10.1016/s0021-9258(18)98665-5;;11278869;;10.1074/jbc.m011252200;;pmc2118284;;16549598;;10.1084/jem.20060045;;10.1158/1078-0432.ccr-07-1217;;17875793;;pmc37461;;11447282;;10.1073/pnas.151260298;;10.1016/s0962-8924(99)01558-5;;10354567;;10.1016/s0021-9258(19)44263-4;;4348550;;10.1021/bc049781+;;15898716;;12657428;;10.1016/s1471-4914(03)00022-4;;pmc1373678;;10.1021/bc050172r;;16173810;;7963533;;17532550;;10.1016/j.biochi.2007.04.006;;10.1038/sj.tpj.6500204;;14569259;;10.1016/0022-1759(89)90093-8;;2514231;;10.1016/j.molimm.2007.06.151;;17768100;;18559529;;10.1158/0008-5472.can-08-0232;;10.1016/j.molcel.2006.09.006;;17081989;;10.2210/pdb2izy/pdb;;10.2967/jnumed.107.046185;;18077530;;10.1182/blood-2009-02-204289;;1366535;;10.1038/nbt0490-343;;10.1074/jbc.m412134200;;15596441;;9531615;;10.1182/blood.v91.8.3017.3017_3017_3027;;6159812;;10.7326/0003-4819-93-3-399;;8108387;;10.1073/pnas.91.4.1198;;pmc43124;;10.1038/nrd1033;;12612647;;10.1074/jbc.271.46.29016;;8910553;;11959956;;pmc122719;;10.1073/pnas.072685299;;10.4049/jimmunol.179.10.6881;;17982079;;pmc1462715;;10.1042/bj20051970;;16483255;;10.1080/10428190701704647;;18203019;;17081990;;pmc1855097;;10.1016/j.molcel.2006.09.015;;10.1023/a:1016042220817;;8842035;;6323591;;10.1089/jir.1983.3.425;;10.1016/s1074-7613(01)00126-1;;11336691;;10.1021/bc060245m;;17941681;;pmc392003;;6093118;;10.1073/pnas.81.21.6723;;9712065;;10.1210/mend.8.3.8015550;;8015550;;10.1210/me.8.3.325;;pmc1867205;;11943735;;10.1016/s0002-9440(10)62577-1;;10673721;;10.1038/sj.gt.3301059;;10.1093/emboj/20.7.1651;;pmc145475;;11285229;;10.2210/pdb1r2a/pdb;;10.1038/6663;;10074940;;0010074940;;10.1007/978-1-4684-6831-1_14;;12388634;;10.1124/jpet.102.037002;;2540040;;10.1016/0014-5793(89)80253-4;;9596485;;10.1023/a:1005934621940;;10.1002/jlb.64.3.358;;9738663;;6577942;;10.1007/bf00199167;;11356929;;10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-#;;10092109;;10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-;;pmc408104;;10.1172/jci5349;;10021462;;2411798;;10.1038/78966;;10966642;;10.1021/bc049713n;;15656592;;18922911;;10.1158/0008-5472.can-08-2033;;10.1073/pnas.0600982103;;16636283;;pmc1447525;;10.1021/bi972701n;;9485322;;10.3892/ijo.14.6.1143;;10339671;;18799723;;10.1182/blood-2008-04-153189;;10.1084/jem.191.10.1777;;pmc2193160;;10811870;;2147685;;10.1016/s0021-9258(18)45777-8;;10.1016/0163-7258(91)90075-w;;1653962;;pmc95154;;11274097;;10.1128/jb.183.8.2405-2410.2001;;10.1158/0008-5472.can-08-0037;;18593929;;pmc2585743;;18227543;;10.1148/radiol.2462070229;;2441862;;15102696;;10.1158/1078-0432.ccr-03-0493;;pmc1895595;;16778139;;10.1182/blood-2006-04-017921,"Cho, Clinical Cancer Research, vol. 13, p. 758s-763s, 2007.;;Ryan, Journal of Clinical Oncology, vol. 25, No. 22, p. 3296-3301, 2007.;;Burtrum, Cancer Research, vol. 63, p. 8912-8921, 2003.;;Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.;;Baxevanis, Expert Opinion Drug Discovery, vol. 3, No. 4, p. 441-452, 2008.;;Bendig, Methods: A Companion to Methods in Enzymology, vol. 8, p. 83-93, 1995.;;Eck and Wilson, Goodman & Gilman's The Pharmacological basis of Therapeutics, 1996, McGraw-Hill, New York, NY. p. 77-101.;;Gao, The AAPS Journal, vol. 9, No. 1, e92-e104, 2007.;;Niidome and Huang, Gene Therapy, vol. 9, p. 1647-1652, 2002.;;Parker, Expert Reviews in Molecular Medicine, vol. 5, p. 1-15, 2003.;;Zhang, Molecular Therapy, vol. 20, No. 7, p. 1298-1304, 2012.;;Moxley, European Journal of Pharmaceutical Sciences, vol. 37, p. 264-271, 2009.;;Arteaga et al., ""Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice"", J. Clin. Invest. Nov. 1989;84(5):1418-23.;;Benjamini et al., Immunology: A Short Course, 2nd Ed., 1991. p. 40.;;Cohen et al., ""Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti-Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871"", Clin. Cancer Res. Mar. 1, 2005;11(5):2063-73.;;Ellis et al, Insulin-like growth factors in human breast cancer, Breast Cancer Res. Treat. 1998;52(1-3):175-84.;;Garber et al., ""IGF-1: old growth factor shines as new drug target"", J. Natl. Cancer Inst. Jun. 1, 2005;97(11):790-2.;;Haluska et al., ""HER receptor signaling confers resistance to IGF-1R targeted therapy"", J. Clin. Oncol., 2008 ASCO Annual Meeting Proceedings, vol. 26, No. 15S (May 20 Suppl.), 2008: 14510.;;Jones et al., ""Insulin-like growth factors and their binding proteins: biological actions"", Endocr. Rev. Feb. 1995;16(1):3-34.;;Kang et al., ""IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose"", Am. J. Physiol. Renal Physiol. Nov. 2003;285(5):F1013-24.;;Keyhanfar et al., ""Precise mapping of an IGF-I-binding site on the IGF-1R"", Biochem J. Jan. 1, 2007;401(1):269-77.;;Miller et al., ""Type I insulin-like growth factor receptor as a therapeutic target in cancer"", Cancer Res. Nov. 15, 2005;65(22):10123-7.;;Pollak et al., ""Insulin-like growth factors and neoplasia"", Nat. Rev. Cancer Jul. 2004;4(7):505-18.;;Resnicoff et al., ""The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo"", Cancer Res. Jun. 1, 1995;55(11):2463-9.;;Riedemann et al., ""IGF1R signalling and its inhibition"", Endocr. Relat. Cancer Dec. 2006;13 Suppl 1:S33-43.;;Ryan and Goss, ""The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer"", Oncologist Jan. 2008;13(1):16-24.;;Soos et al., ""A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity"", J Biol Chem. Jun. 25, 1992;267(18):12955-63.;;Van Golen et al., ""IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma"", Cell Death Differ Jul. 2000;7(7):654-65.;;Wang et al.,Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody, Mol. Cancer Ther. 2005;4(8):1214-21.;;Wu et al., ""In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors"", Clin. Cancer Res. Apr. 15, 2005;11(8):3065-74.;;Zhang et al., ""Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer"", Breast Cancer Res. 2000;2(3):170-5.;;Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Comp. 1991, p. 43.;;Alto et al., ""Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring"" Proc. Natl. Acad. Sci USA Apr. 15, 2003; 100(8):4445-50.;;Backer et al., ""Self-Assembled ""Dock and Lock"" System for Linking Payloads to Targeting Proteins"" Bioconjugate Chem., 2006, 17(4):912-919.;;Baillie et al., ""Compartmentalisation of phospodiesterases and protein kinase A: opposites attract"" FEBS Letters 2005; 579:3264-3270.;;Banky et al., ""Dimerization/Docking Domain of the Type Ialpha Regulatory Subunit of cAMP-dependent Protein Kinase"" J. Biol. Chem. 273:35048-55, 1998.;;Basu et al., ""Structure-Function Engineering of Interferon-beta-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation"" Bioconjugate Chem. 2006; 17:618-630.;;Belardelli et al., ""Interferon-alpha in tumor immunity and immunotherapy"" Cytokine Growth Factor Rev. 13(2):119-134 (2002).;;Belardelli et al., ""International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?"" Cancer Res. 64:6827-6830 (2004).;;Belardelli et al., ""The neglected role of type I interferon in the T-cell response: implications for its clinical use"" Immunol. Today 17(8):369-72 (1996).;;Biron et al., ""Natural killer cells in antiviral defense: function and regulation by innate cytokines"" Annu. Rev. Immunol. 17:189-220 (1999).;;Brunda et al., ""Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons"" Cancer Res. 44:597-601 (1984).;;Burns-Hamuro et al., ""Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange"" Protein Science (2005), 14:2982-2992.;;Carr et al., ""Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif"" J. Biol. Chem. 266:14188-92 (1991).;;Carr et al., ""Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA"" J. Biol. Chem. 276(20):17332-17338 (2001).;;Carrero et al., ""Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes"" J. Exp. Med. 203(4):933-940 (2006).;;Chang et al., ""The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity"" Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.;;Chmura et al., ""Antibodies with infinite affinity"" Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).;;Colledge et al., ""AKAPs: from structure to function"" Trends Cell Biol. 6:216-21 (1999).;;Corbin et al., ""Regulation of Adenosine 3',5'-Monophosphate-dependent Protein Kinase"" J. Biol. Chem. 248:1813-21 (1973).;;Dhalluin et al., ""Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-alpha2a and Its Individual Positional Isomers"" Bioconjugate Chem. 2005;16:504-517.;;Dodart et al., ""Immunotherapy for Alzheimer's Disease: will vaccination work?"" Trends Mol. Med. 9(3):85-87 (2003).;;Doherty et al., ""Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor"" Bioconjugate Chem. 2005;16:1291-1298.;;Ferrantini et al., ""IFN-alpha1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity"" J. Immunol. 153:4604-15 (1994).;;Ferrantini et al., ""Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use"" Biochimie 89: 884-893 (2007).;;Foser et al., ""Improved biological and transcriptional activity of monopegylated interferon-alpha-2a isomers."" The Pharmacogenomics J 3:312-319 (2003).;;Gillies et al., ""High-level expression of chimeric antibodies using adapted cDNA variable region cassettes"" J. Immunol. Methods 125 (1989) 191-202.;;Glennie et al., ""Mechanisms of killing by anti-CD20 monoclonal antibodies"" Mol. Immunol. 44:3823-3837 (2007).;;Gold et al., ""A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma"", Cancer Res. 68:4819-26, 2008.;;Gold et al., ""Molecular Basis of AKAP Specificity for PKA Regulatory Subunits"" Mol. Cell Nov. 3, 2006;24(3):383-95.;;Goldenberg et al., ""Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting"" J. Nucl. Med. 49:158-63, 2008.;;Goldenberg et al., ""Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody"" Blood 113:1062-70 (2009).;;Goodson et al., ""Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site"" Nat. Biotechnology Apr. 1990;8(4):343-6.;;Grace et al., ""Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-alpha Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway"" J. Biol. Chem. 2005;280(8):6327-6336.;;Grimley et al., ""Prolonged STAT1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-alpha"" Blood 91(8):3017-27 (1998).;;Gutterman et al., ""Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma"" Ann. Intern. Med. 93(3):399-406 (1980).;;Gutterman et al., ""Cytokine therapeutics: Lessons from interferon alpha"" Proc. Natl. Acad. Sci. USA 91:1198-205 (1994).;;Harris et al., ""Effect of pegylation on pharmaceuticals"" Nat. Rev. Drug. Discov. 2:214-221 (2003).;;Hausken et al. ""Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII"" J. Biol. Chem. 271:29016-22 (1996).;;Hodneland et al., Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands, Proc. Natl. Acad. Sci. USA 2002; 99:5048-5052.;;Huang et al., ""Targeting IFN-alpha to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities"" J. Immunol. 179:6881-88 (2007).;;Hundsrucker et al., ""High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides"" Biochem. J. (2006) 396, 297-306.;;Kimby et al., ""Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group"" Leuk. Lymphoma 49(1):102-112 (2008).;;Kinderman et al., ""A Dynamic Mechanism for AKAP Binding to RII Isoforms of cAMP-Dependent Protein Kinase"" Mol. Cell 24(3):397-408 (2006).;;Kinstler et al., ""Characterization and Stability of N-terminally PEGylated rhG-CSF"" Pharm. Res. 1996;13(7):996-1002.;;Kramer et al., ""Cell and virus sensitivity studies with recombinant human alpha interferons"" J. Interferon. Res. 3(4):425-35 (1983).;;Le Bon et al., ""Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo"" Immunity 14:461-470 (2001).;;Lee et al., ""Solid-Phase PEGylation of Recombinant Interferon alpha-2a for Site-Specific Modification: Process Performance, Characterization, and in Vitro Bioactivity"" Bioconjugate Chem. 2007; 18:1728-34.;;Lohmann et al., ""High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins"" Proc. Natl. Acad. Sci. USA 81:6723-27 (1984).;;Luft et al., ""Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells"" J. Immunol. 161:1947-1953 (1998).;;Mason, Anthony J., ""Functional Analysis of the Cysteine Residues of Activin A"" Mol. Endocrinol. 8:325-32 (1994).;;Matarrese et al., ""Type I Interferon Gene Transfer Sensitizes Melanoma Cells to Apoptosis via a Target Activity on Mitochondrial Function"" Am. J. Pathol. 2002, 160(4):1507-1520.;;Mecchia et al., ""Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha"" Gene Ther. (2000) 7, 167-179.;;Newlon et al., ""A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes"" EMBO J. 2001; 20:1651-1662.;;Newlon et al., ""The molecular basis for protein kinase A anchoring revealed by solution NMR"" Nature Struct. Biol. 1999; 3:222-227.;;Ngo et al., ""Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox"", The Protein Folding Problem and Tertiary Structure Prediction, Ch. 14, pp. 492-495, (Mertz & Le Grand, Eds.), Birkhauser Boston, 1994.;;Osborn et al., ""Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-alpha Fusion Protein in Cynomolgus Monkeys"" J. Pharmacol. Exp. Ther. 303(2):540-548 (2002).;;Oyen et al., ""Human testis cDNA for the regulatory subunit RIIalpha of cAMP-dependent protein kinase encodes an alternate amino-terminal region"" FEBS Letters 246:57-64, 1989.;;Ozzello et al., ""Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3vl) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts"" Breast Cancer Res. Treat. 48: 135-147 (1998).;;Paquette et al., ""Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells"" J. Leukoc. Biol. 64:358-367; 1998.;;Pelham et al., ""Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36"" Cancer Immunol. Immuother 1983;15(3):210-216.;;Pepinsky et al., ""Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-beta-1a with Preserved in Vitro Bioactivity"" Pharmacol. Exp. Ther. 2001; 297(3):1059-1066.;;Pilling et al., ""Interferon-beta mediates stromal cell rescue of T cells from apoptosis"" Eur. J. Immunol. 29:1041-1050 (1999).;;Rabjohn et al., ""Molecular Cloning and Epitope Analysis of the Peanut Allergen Ara h 3"" J. Clinical Investigation 103 (4):535-542 (1999).;;Raefsky et al., ""Studies of Interferon as a regulator of hematopoietic cells proliferation"" J. Immunol. 135(4):2507-2512 (1985).;;Rose et al., ""Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1alpha"" Nature Struct. Biol. 2000; 7:744-748.;;Rosendahl et al., ""A Long-Acting, Highly Potent Interferon alpha-2 Conjugate Created Using Site-Specific PEGylation"" Bioconjugate Chem. 2005;16:200-207.;;Rossi et al., ""Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics"" Cancer Res. 68:8384-92 (2008).;;Rossi et al., ""Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting"" Proc. Natl. Acad. Sci. Epub Apr. 24, 2006, vol. 103, No. 18, pp. 6841-6846.;;Rustandi et al., ""The Ca2+-Dependent Interaction of S100B(betabeta) with a Peptide Derived from p53"", Biochemistry 1998; 37: 1951-1960.;;Sabaawy et al., ""Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer"" Int. J. Oncol. Jun. 1999; 14(6):1143-51.;;Salles et al., ""Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study"" Blood 2008; 112:4824-4831.;;Santini et al., ""Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vivo and in Hu-PBL-SCID Mice"" J. Exp. Med. 191(10):1777-1788 (2000).;;Scott et al., ""Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase"" J. Biol. Chem. 265:21561-66 (1990).;;Scott et al., ""Cyclic nucleotide-dependent protein kinases"" Pharmacol. Ther. 1991;50(1):123-45.;;Seffernick et al., ""Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different"" J. Bacteriol. 183(8):2405-2410 (2001).;;Sharkey et al., ""Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody"" Cancer Res. 68:5282-90 (2008).;;Sharkey et al., ""Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model"" Radiology 246:497-507 (2008).;;Sidky et al., ""Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses"" Cancer Res. 47:5155-5161, Oct. 1, 1987.;;Stein et al., ""Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma"" Clin. Cancer Res. vol. 10, 2868-2878, Apr. 15, 2004.;;Stein et al., ""Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab"" Blood 2006;108:2736-2744.",ACTIVE
791,EP,A1,EP 2326346 A1,040-538-008-976-91X,2011-06-01,2011,EP 09808814 A,2009-08-20,US 2009/0054441 W;;US 9048708 P,2008-08-20,DOCK-AND-LOCK (DNL) VACCINES FOR CANCER THERAPY,,IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/040-538-008-976-91X,Patent Application,yes,0,0,17,1035,35,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;A61K39/001129;;A61K39/001112;;A61K39/001113;;A61K39/001176;;A61K39/001194;;A61K39/00117;;A61K39/001191;;A61K39/00115;;A61K39/001163;;A61K39/001124;;A61K39/001166;;A61K39/001182;;A61K39/001114;;A61K39/001138;;A61K39/001189;;A61K39/001192;;A61K39/001104;;A61K39/001103;;A61K39/001184;;A61K39/001188;;A61K39/001151;;A61K39/001117;;A61K39/001181;;A61K39/001109;;A61K39/001149;;A61K39/00114;;A61K39/001102;;A61K39/00113;;A61K39/001126;;A61K39/001135;;A61K39/001153;;A61K39/001162;;A61K39/001186;;A61K39/001195;;A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/001189;;A61K39/001112;;A61K39/001153;;A61K39/001163;;A61K39/001135;;A61K39/00117;;A61K39/001113;;A61K39/001124;;A61K39/001192;;A61K39/001129;;A61K39/001117;;A61K39/001103;;A61K39/001195;;A61K39/001138;;A61K39/001149;;A61K39/001182;;A61K39/001114;;A61K39/001102;;A61K39/001104;;A61K39/001126;;A61K39/00113;;A61K39/00114;;A61K39/00115;;A61K39/001166;;A61K39/001181;;A61K39/001186;;A61K39/001191;;A61K39/001194;;A61K39/001162;;A61K39/001176;;A61K39/001188;;A61K39/001109;;A61K39/001184;;A61K39/001151;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011,A61K39/00;;C07K16/28;;C07K16/30,,0,0,,,,DISCONTINUED
792,WO,A1,WO 1991/012514 A1,048-879-123-655-026,1991-08-22,1991,US 9100871 W,1991-02-11,US 47889390 A,1990-02-12,NONCONTACT ON-LINE MEASUREMENT OF THE VISCOSITY OF LIQUID PAINT,"A method and apparatus for non-contact measurement of the viscosity of a liquid such as paint. In accordance with the method and apparatus, the surface of a liquid is perturbed with a standing wave of predetermined wavelength. This perturbation is effected by directing a burst of air against the surface of the liquid using periodically spaced air nozzles. The frequency and rate of decay of the induced surface wave is measured using typically optical means including a reflected light beam. The measured frequency and decay rate are combined with the known depth of the liquid sample in a computing circuit to provide a measurement of fluid viscosity.",HUGHES AIRCRAFT CO,PIERCE BRIAN M;;CHANG DAVID B,,https://lens.org/048-879-123-655-026,Patent Application,yes,2,0,7,7,0,G01N11/00;;G01N11/00;;G01N11/00,G01N11/00;;G01N11/16,,0,0,,,,PENDING
793,AU,A1,AU 2021/321214 A1,048-758-190-503-021,2023-02-23,2023,AU 2021/321214 A,2021-06-07,US 202016984486 A;;US 2021/0036128 W,2020-08-04,System and method for preventing or treating Alzheimer's and other neurodegenerative diseases,A protective therapy system for biological tissues or fluids includes applying a pulsed energy source to a target tissue or a target fluid having a chronic progressive disease or a risk of having a chronic progressive disease to therapeutically or prophylactically treat the target tissue or target fluid. A pulsed energy source having selected energy parameters may be applied to a brain of an individual who has Alzheimer's or other neurodegenerative disease or is at risk of developing such a neurodegenerative disease so as to prevent or treat the neurodegenerative disease.,OJAI RETINAL TECHNOLOGY LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/048-758-190-503-021,Patent Application,no,0,0,8,287,0,A61N1/40;;A61N5/02;;A61N5/025;;A61N1/403,A61N1/40,,0,0,,,,PENDING
794,US,B2,US 9492561 B2,045-364-905-323-809,2016-11-15,2016,US 201313908914 A,2013-06-03,US 201313908914 A;;US 96402110 A;;US 94953610 A;;US 39660509 A;;US 63372906 A;;US 38935806 A;;US 39158406 A;;US 47802106 A;;US 91551510 A;;US 87134510 A;;US 75474010 A;;US 75414010 A;;US 75264910 A;;US 73178110 A;;US 64414609 A;;US 54447609 A;;US 53780309 A;;US 47925009 A;;US 5618205 A;;US 46858909 A;;US 41887709 A;;US 41791709 A;;US 39696509 A;;US 86982310 A;;US 92540807 A;;US 78233206 P;;US 72829205 P;;US 75119605 P;;US 86453006 P;;US 25836909 P;;US 25872909 P;;US 37805910 P;;US 16680909 P;;US 16871509 P;;US 54422704 P;;US 23847309 P;;US 26630509 P;;US 31699610 P;;US 32396010 P;;US 23842409 P;;US 16829009 P;;US 16865709 P;;US 16866809 P;;US 16366609 P;;US 66860305 P;;US 9048708 P;;US 4393208 P;;US 10491608 P;;US 11954208 P;;US 26787709 P;;US 30268210 P;;US 41459210 P,2004-02-13,Dock-and-Lock (DNL) Complexes for delivery of interference RNA,"Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2011-03-10),https://lens.org/045-364-905-323-809,Granted Patent,yes,90,0,4,1035,82,B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2318/10;;C07K2319/00;;C07K2319/30;;A61K47/6849;;A61K47/6853;;A61K47/6891;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P9/00;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2318/10;;C07K2319/00;;C07K2319/30;;A61K47/6891;;A61K47/6849;;A61K47/6853,A61K47/48;;B82Y5/00;;C07K16/00;;C07K16/28;;C07K16/30;;C07K16/46,,109,103,029-611-134-469-353;;139-399-324-818-879;;037-719-830-241-939;;100-801-934-296-913;;043-779-209-608-781;;027-364-048-721-489;;034-038-300-119-191;;017-396-356-826-083;;091-995-224-471-960;;046-723-641-666-637;;051-620-799-695-736;;000-687-583-450-12X;;030-424-581-071-330;;025-955-082-953-672;;043-565-065-226-050;;064-253-076-017-931;;073-213-551-327-892;;029-646-755-871-310;;015-399-642-762-43X;;142-686-487-823-912;;007-954-637-794-12X;;080-571-625-616-771;;013-580-733-777-26X;;046-220-521-080-741;;036-011-287-610-789;;046-650-803-614-561;;057-819-453-551-117;;020-829-015-080-665;;061-974-273-716-169;;073-910-564-236-619;;039-423-064-544-876;;028-385-018-876-542;;078-950-298-931-296;;082-317-213-185-417;;061-716-650-834-485;;154-648-591-453-198;;138-142-682-110-803;;066-146-798-965-262;;032-799-656-305-036;;088-770-954-200-50X;;002-331-092-499-856;;052-302-906-314-226;;125-439-449-787-91X;;002-968-698-489-191;;003-133-671-061-524;;001-773-325-098-677;;001-438-265-785-943;;021-399-654-204-715;;013-495-040-538-497;;014-817-433-156-057;;006-606-859-520-426;;016-722-289-911-388;;055-567-629-980-222;;002-036-513-655-449;;099-307-614-319-429;;003-051-068-663-062;;023-678-010-672-059;;000-499-563-417-797;;023-833-986-552-400;;019-253-709-202-167;;103-932-348-507-545;;133-287-355-214-424;;091-341-936-846-342;;094-037-074-599-511;;101-663-979-767-604;;000-317-353-994-190;;052-947-986-013-690;;034-028-239-192-920;;040-142-822-097-134;;138-957-732-701-829;;027-215-950-157-668;;139-123-355-549-723;;038-215-831-671-137;;032-409-676-506-509;;125-571-073-159-031;;044-988-808-395-48X;;019-736-899-818-187;;053-349-809-000-342;;008-956-301-309-595;;026-690-156-572-350;;066-342-559-427-246;;023-481-904-534-57X;;018-667-811-882-764;;007-072-874-769-097;;069-477-478-430-272;;006-680-826-675-902;;051-124-225-056-342;;039-872-948-648-99X;;076-361-037-184-124;;049-603-242-735-802;;040-702-319-644-869;;151-391-931-864-381;;002-771-789-858-985;;132-695-844-930-786;;136-607-746-555-049;;033-802-631-358-941;;075-179-687-590-485;;056-957-879-544-490;;039-116-584-633-311;;020-799-430-434-219;;071-988-871-878-280;;007-026-394-144-883;;051-135-018-390-763,7516563;;10.1016/s0923-2494(94)80039-1;;22387378;;10.1016/j.abb.2012.02.011;;10.1354/vp.42-4-468;;16006606;;18234994;;10.1167/iovs.07-1175;;16873051;;10.1016/j.cell.2006.07.007;;pmc7125751;;23116517;;10.1021/bc300488f;;19846342;;pmc4441031;;10.1016/j.molmed.2009.09.001;;24406927;;10.1038/nbt.2786;;10.1073/pnas.0330734100;;12672969;;pmc153575;;16848397;;10.1021/bc060037u;;10.1016/j.febslet.2005.03.089;;15943971;;9857038;;10.1074/jbc.273.52.35048;;16704199;;10.1021/bc050322y;;10.1016/s1359-6101(01)00022-3;;11900988;;15375003;;10.1158/0008-5472.can-04-2048;;10.1016/0167-5699(96)10027-x;;8783497;;10358757;;10.1146/annurev.immunol.17.1.189;;6692364;;pmc2253242;;10.1110/ps.051687305;;16260760;;1860836;;10.1016/s0021-9258(18)98665-5;;11278869;;10.1074/jbc.m011252200;;pmc2118284;;16549598;;10.1084/jem.20060045;;10.1158/1078-0432.ccr-07-1217;;17875793;;pmc37461;;11447282;;10.1073/pnas.151260298;;10.1016/s0962-8924(99)01558-5;;10354567;;10.1016/s0021-9258(19)44263-4;;4348550;;10.1021/bc049781+;;15898716;;12657428;;10.1016/s1471-4914(03)00022-4;;pmc1373678;;10.1021/bc050172r;;16173810;;7963533;;17532550;;10.1016/j.biochi.2007.04.006;;10.1016/0022-1759(89)90093-8;;2514231;;10.1016/j.molimm.2007.06.151;;17768100;;18559529;;10.1158/0008-5472.can-08-0232;;10.1016/j.molcel.2006.09.006;;17081989;;10.2210/pdb2izy/pdb;;10.2967/jnumed.107.046185;;18077530;;10.1182/blood-2009-02-204289;;1366535;;10.1038/nbt0490-343;;10.1074/jbc.m412134200;;15596441;;9531615;;10.1182/blood.v91.8.3017.3017_3017_3027;;6159812;;10.7326/0003-4819-93-3-399;;8108387;;10.1073/pnas.91.4.1198;;pmc43124;;10.1038/nrd1033;;12612647;;10.1074/jbc.271.46.29016;;8910553;;11959956;;pmc122719;;10.1073/pnas.072685299;;10.4049/jimmunol.179.10.6881;;17982079;;pmc1462715;;10.1042/bj20051970;;16483255;;10.1080/10428190701704647;;18203019;;17081990;;pmc1855097;;10.1016/j.molcel.2006.09.015;;10.1023/a:1016042220817;;8842035;;6323591;;10.1089/jir.1983.3.425;;10.1016/s1074-7613(01)00126-1;;11336691;;10.1021/bc060245m;;17941681;;pmc392003;;6093118;;10.1073/pnas.81.21.6723;;9712065;;10.1210/mend.8.3.8015550;;8015550;;10.1210/me.8.3.325;;pmc1867205;;11943735;;10.1016/s0002-9440(10)62577-1;;10673721;;10.1038/sj.gt.3301059;;10.1093/emboj/20.7.1651;;pmc145475;;11285229;;10.2210/pdb1r2a/pdb;;10.1038/6663;;10074940;;0010074940;;10.1007/978-1-4684-6831-1_14;;12388634;;10.1124/jpet.102.037002;;2540040;;10.1016/0014-5793(89)80253-4;;9596485;;10.1023/a:1005934621940;;10.1002/jlb.64.3.358;;9738663;;6577942;;10.1007/bf00199167;;11356929;;10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-#;;10092109;;10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-;;pmc408104;;10.1172/jci5349;;10021462;;2411798;;10.1038/78966;;10966642;;10.1021/bc049713n;;15656592;;18922911;;10.1158/0008-5472.can-08-2033;;10.1073/pnas.0600982103;;16636283;;pmc1447525;;19710501;;10.1182/blood-2009-06-228890;;pmc2773491;;10.1021/bi972701n;;9485322;;10.3892/ijo.14.6.1143;;10339671;;18799723;;10.1182/blood-2008-04-153189;;10.1084/jem.191.10.1777;;pmc2193160;;10811870;;2147685;;10.1016/s0021-9258(18)45777-8;;10.1016/0163-7258(91)90075-w;;1653962;;pmc95154;;11274097;;10.1128/jb.183.8.2405-2410.2001;;10.1158/0008-5472.can-08-0037;;18593929;;pmc2585743;;18227543;;10.1148/radiol.2462070229;;2441862;;15102696;;10.1158/1078-0432.ccr-03-0493;;pmc1895595;;16778139;;10.1182/blood-2006-04-017921;;16948636;;pmc1698590;;10.1042/bj20060962;;12872134;;10.1038/nature01850;;10.1016/s0021-9258(18)81805-1;;2656679;;10.1016/s0021-9258(19)34204-8;;4298072;;6172550;;10.1099/0022-1317-57-1-233;;10.4049/jimmunol.165.8.4505;;11035090;;10.1021/bi990993h;;10512619;;15573134;;10.1038/nrm1527;;10665474;;10.1023/a:1006314501634;;12869693;;10.1073/pnas.1233578100;;pmc170940;;pmc2268497;;10.1128/jvi.01854-07;;18199639;;10706717;;10.4049/jimmunol.164.6.3246;;10.1016/0264-410x(90)90136-a;;2336874;;10.1128/jvi.72.2.1577-1585.1998;;pmc124638;;9445060;;10.1182/blood-2008-05-157396;;18669871;;pmc2556617;;pmc2675192;;19168105;;10.1016/j.vaccine.2009.01.010,"Colman et al., Research in Immunology (145(1):33-35, 1994.;;Golay et al., Archives of Biochemistry and Biophysics 526: 146-153, 2012.;;Jubala et al., Vet Pathol 42: 468-476, 2005.;;Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522-527, Feb. 2008.;;Dykxhoorn et al., cell 126: 231-235, Jul. 28, 2006.;;Rossi et al., Bioconjugate Chemistry 24: 63-71, Jan. 16, 2013.;;Kim et al., Trends in Molecular Medicine 15(11): 491-500, 2009.;;Eck et al., Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101.;;Hay et al., Nature Biotechnology 32(1): 40-51, Jan. 2014.;;Gupta et al., Cancer Res 70(8): Abstract No. LB-34, Apr. 15, 2010.;;Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Company, 1991, p. 43.;;Alto et al., ""Bioinformatic design of A-kinase anchoring protein-in silico: A potent and selective peptide antagonist of type II protein kinase A anchoring"", PNAS USA 100:4445-50, 2003.;;Backer et al., ""Self-Assembled ""Dock and Lock"" System for Linking Payloads to Targeting Proteins"", Bioconjugate Chem., 17 (4), pp. 912-919, 2006.;;Baillie et al., ""Compartmentalisation of phospodiesterases and protein kinase A: opposites attract"", FEBS Letters 2005; 579:3264-3270.;;Banky et al., ""Dimerization/Docking Domain of the Type Ialpha Regulatory Subunit of cAMP-dependent Protein Kinase"", J. Biol. Chem. 273:35048-55, 1998.;;Basu et al., ""Structure-Function Engineering of Interferon-beta-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation"", Bioconjugate Chem. 2006; 17:618-630.;;Belardelli et al., ""Interferon-alpha in tumor immunity and immunotherapy"" Cytokine Growth Factor Rev. 13(2):119-134 (2002).;;Belardelli et al., ""International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?"" Cancer Res. 64:6827-6830 (2004).;;Belardelli et al., ""The neglected role of type I interferon in the T-cell response: implications for its clinical use"" Immunol. Today 17(8):369-72 (1996).;;Biron et al., ""Natural killer cells in antiviral defense: function and regulation by innate cytokines"" Annu. Rev. Immunol. 17:189-220 (1999).;;Brunda et al., ""Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons"" Cancer Res. 44:597-601 (1984).;;Burns-Hamuro et al., ""Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange"" Protein Science (2005), 14:2982-2992.;;Carr et al., ""Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif"", J. Biol. Chem. 266:14188-92 (1991).;;Carr et al., ""Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA"" J. Biol. Chem. 276(20):17332-17338 (2001).;;Carrero et al., ""Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes"" J. Exp. Med. 203(4):933-940 (2006).;;Chang et al., ""The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity"" Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.;;Chmura et al., ""Antibodies with infinite affinity"" Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).;;Colledge et al., ""AKAPs: from structure to function"", Trends Cell Biol. 6:216-21 (1999).;;Corbin et al., ""Regulation of Adenosine 3',5'-Monophosphate-dependent Protein Kinase"", J. Biol. Chem. 248:1813-21 (1973).;;Dhalluin et al., ""Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-alpha2a and Its Individual Positional Isomers"" Bioconjugate Chem. 2005;16:504-517.;;Dodart et al., ""Immunotherapy for Alzheimer's Disease: will vaccination work?"" Trends Mol. Med. 9(3):85-87 (2003).;;Doherty et al., ""Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor"", Bioconjugate Chem. 2005;16:1291-1298.;;Ferrantini et al., ""IFN-alpha1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity"" J. Immunol. 153:4604-15 (1994).;;Ferrantini et al., ""Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use"" Biochimie 89: 884-893 (2007).;;Gillies et al., ""High-level expression of chimeric antibodies using adapted cDNA variable region cassettes"", J. Immunol. Methods 125 (1989) 191-202.;;Glennie et al., ""Mechanisms of killing by anti-CD20 monoclonal antibodies"" Mol. Immunol. 44:3823-3837 (2007).;;Gold et al., ""A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma"", Cancer Res. 68:4819-26, 2008.;;Gold et al., ""Molecular Basis of AKAP Specificity for PKA Regulatory Subunits"" Mol. Cell Nov. 3, 2006;24(3):383-95.;;Goldenberg et al., ""Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting"", J. Nucl. Med. 49:158-63, 2008.;;Goldenberg et al., ""Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody"" Blood 113:1062-70 (2009).;;Goodson et al., ""Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site"", Nat. Biotechnology Apr. 1990;8(4):343-6.;;Grace et al., ""Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-alpha Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway"" J. Biol. Chem. 2005;280(8):6327-6336.;;Grimley et al., ""Prolonged STAT1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-alpha"" Blood 91(8):3017-27 (1998).;;Gutterman et al., ""Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma"" Ann. Intern. Med. 93(3):399-406 (1980).;;Gutterman et al., ""Cytokine therapeutics: Lessons from interferon alpha"" Proc. Natl. Acad. Sci. USA 91:1198-205 (1994).;;Harris et al., ""Effect of pegylation on pharmaceuticals"" Nat. Rev. Drug. Discov. 2:214-221 (2003).;;Hausken et al. ""Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII"", J. Biol. Chem. 271:29016-22 (1996).;;Hodneland et al., ""Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands"", Proc. Natl. Acd. Sci. USA 2002; 99:5048-5052.;;Huang et al., ""Targeting IFN-alpha to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities"" J. Immunol. 179:6881-88 (2007).;;Hundsrucker et al., ""High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides"" Biochem. J. (2006) 396, 297-306.;;Kimby et al., ""Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group"" Leuk. Lymphoma 49(1):102-112 (2008).;;Kinderman et al., ""A Dynamic Mechanism for AKAP Binding to RII Isoforms of cAMP-Dependent Protein Kinase"" Mol. Cell 24(3):397-408 (2006).;;Kinstler et al., ""Characterization and Stability of N-terminally PEGylated rhG-CSF"" Pharm. Res. 1996;13 (7):996-1002.;;Kramer et al., ""Cell and virus sensitivity studies with recombinant human alpha interferons"" J. Interferon. Res. 3 (4):425-35 (1983).;;Le Bon et al., ""Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo"" Immunity 14:461-470 (2001).;;Lee et al., ""Solid-Phase PEGylation of Recombinant Interferon alpha-2a for Site-Specific Modification: Process Performance, Characterization, and in Vitro Bioactivity"" Bioconjugate Chem. 2007; 18:1728-34.;;Lohmann et al., ""High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins"", Proc. Natl. Acad. Sci. USA 81:6723-27 (1984).;;Luft et al., ""Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells"" J. Immunol. 161:1947-1953 (1998).;;Mason, Anthony J., ""Functional Analysis of the Cysteine Residues of Activin A"", Mol. Endocrinol. 8:325-32, 1994.;;Matarrese et al., ""Type I Interferon Gene Transfer Sensitizes Melanoma Cells to Apoptosis via a Target Activity on Mitochondrial Function"" Am. J. Pathol. 2002, 160(4):1507-1520.;;Mecchia et al., ""Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha"" Gene Ther. (2000) 7, 167-179.;;Newlon et al., ""A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes"", EMBO J. 2001; 20:1651-1662.;;Newlon et al., ""The molecular basis for protein kinase A anchoring revealed by solution NMR"", Nature Stud. Biol. 1999; 3:222-227.;;Ngo et al., ""Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox"", The Protein Folding Problem and Tertiary Structure Prediction, Ch. 14, pp. 492-495, (Mertz & Le Grand, Eds.), Birkhauser Boston, 1994.;;Nordstrom et al., ""First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-alpha2b) is Highly Toxic for Human Lymphoma Cells in Vitro"", 2009 ASH Annual Meeting Abstracts, Nov. 20, 2009; 114(22):675, Abstract # 1695.;;Osborn et al., ""Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-alpha Fusion Protein in Cynomolgus Monkeys"" J. Pharmacol. Exp. Ther. 303(2):540-548 (2002).;;Oyen et al., ""Human testis cDNA for the regulatory subunit RIIalpha of cAMP-dependent protein kinase encodes an alternate amino-terminal region"", FEBS Letters 246:57-64, 1989.;;Ozzello et al., ""Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3vl) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts"" Breast Cancer Res. Treat. 48: 135-147 (1998).;;Paquette et al., ""Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells"" J. Leukoc. Biol. 64:358-367; 1998.;;Pelham et al., ""Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36"" Cancer Immunol. Immuother. 1983;15(3):210-216.;;Pepinsky et al., ""Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-beta-1a with Preserved in Vitro Bioactivity"" Pharmacol. Exp. Ther. 2001; 297(3):1059-1066.;;Pilling et al., ""Interferon-beta mediates stromal cell rescue of T cells from apoptosis"" Eur. J. Immunol. 29:1041-1050 (1999).;;Rabjohn et al., ""Molecular Cloning and Epitope Analysis of the Peanut Allergen Ara h 3"" J. Clinical Investigation 103 (4):535-542 (1999).;;Raefsky et al., ""Studies of Interferon as a regulator of hematopoietic cells proliferation"" J. Immunol. 135 (4):2507-2512 (1985).;;Rose et al., ""Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1alpha"", Nature Struct. Biol. 2000; 7:744-748.;;Rosendahl et al., ""A Long-Acting, Highly Potent Interferon alpha-2 Conjugate Created Using Site-Specific PEGylation"" Bioconjugate Chem. 2005;16:200-207.;;Rossi et al., ""Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics"", Cancer Res. 68:8384-92, 2008.;;Rossi et al., ""Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting"" Proc. Natl. Acad. Sci. Epub Apr. 24, 2006, vol. 103, No. 18, pp. 6841-6846.;;Rossi et al., ""CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas"", Blood 2009;114:3864-3871.;;Rossi et al., ""A veltuzumab-IFNalpha2b conjugate with potent in vitro and in vivo anti-lymphoma activity"", Proceedings of the American Association for Cancer Research, Apr. 2009;50:783-784, Abstract # 3237.;;Rustandi et al., ""The Ca2+-Dependent Interaction of S100B(betabeta) with a Peptide Derived from p53"", Biochemistry 1998; 37: 1951-1960.;;Sabaawy et al., ""Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer"" Int. J. Oncol. Jun. 1999; 14(6):1143-51.;;Salles et al., ""Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the Gela-Goelams FL2000 study"" Blood 2008; 112:4824-4831.;;Santini et al., ""Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vivo and in Hu-PBL-SCID Mice"" J. Exp. Med. 191(10):1777-1788 (2000).;;Scott et al., ""Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase"", J. Biol. Chem. 265:21561-66 (1990).;;Scott et al., ""Cyclic nucleotide-dependent protein kinases"" Pharmacol. Ther. 1991;50(1):123-45.;;Seffernick et al., ""Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different"" J. Bacteriol. 183(8):2405-2410 (2001).;;Sharkey et al., ""Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody"", Cancer Res. 68:5282-90, 2008.;;Sharkey et al., ""Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model"", Radiology 246:497-507, 2008.;;Sidky et al., ""Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses"" Cancer Res. 47:5155-5161, Oct. 1, 1987.;;Stein et al., ""Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma"" Clin. Cancer Res. vol. 10, 2868-2878, Apr. 15, 2004.;;Stein et al., ""Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab"" Blood 2006;108:2736-2744.;;Stokka et al., ""Characterization of A-kinase-anchoring disruption using a solution-based assay"" Biochem. J. (2006) 400, 493-499.;;Stryer et al., ""Levels of Structure in Protein Architecture"", Biochemistry, 3rd Ed., pp. 31-33, W.H. Freeman & Co., New York, 1988.;;Takaoka et al., ""Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence"" Nature Jul. 31, 2003;424(6948):516-23.;;Taylor, S., ""cAMP-dependent Protein Kinase"" J. Biol. Chem. 1989;264(15):8443-8446.;;Walsh et al., ""An Adenosine 3', 5'-Monophosphate-dependant Protein Kinase from Rabbit Skeletal Muscle"" J. Biol. Chem. 243(13):3763-3774 (1968).;;Weck et al., ""Comparison of the Antiviral Activities of Various Cloned Human Interferon-alpha Subtypes in Mammalian Cell Cultures"" J. Gen. Virol. (1981), 57, 233-237.;;Winkler et al., ""Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody"", J. Immunol. 165:4505-14, 2000.;;Witkowski et al., ""Conversion of a beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine"" Biochemistry 38(36):11643-50 (1999).;;Wong et al., ""AKAP Signalling Complexes: Focal Points in Space and Time"", Nat. Rev. Mol. Cell Biol. 12:959-70 (2004).;;Zhu et al., ""Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor"", Invest. New Drugs 17:195-212, 1999.;;Belyakov et al., ""Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses"", Proc Natl Acad Sci U S A. Aug. 5, 2003;100(16):9458-63. Epub Jul. 17, 2003.;;Berhanu et al., Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge, J Virol. Apr. 2008;82(7):3517-29. Epub Jan. 16, 2008.;;Born et al., ""A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response"", J Immunol. Mar. 15, 2000;164(6):3246-54.;;Carayanniotis et al., ""Characterization of the adjuvant-free serological response to protein antigens coupled to antibodies specific for class II MHC determinants"", Vaccine. Apr. 1990;8(2):137-44.;;Chung et al., ""A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate"", J Virol. Feb. 1998;72(2):1577-85.;;Ding et al., ""Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1"", Blood. Oct. 1, 2008;112(7):2817-25. Epub Jul. 31, 2008.;;Grandpre et al., ""Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys"", Vaccine. Mar. 4, 2009;27(10):1549-56. Epub Jan. 23, 2009.",ACTIVE
795,TW,B,TW 591130 B,070-056-254-836-716,2004-06-11,2004,TW 89121049 A,2000-10-04,TW 89121049 A,2000-10-04,Method and apparatus for directly forming polycrystal silicon film,"A method and an apparatus for directly forming polycrystal silicon film are provided. In low pressure a silicon powder is injected to become atomized silicon liquid by a plasma spraying torch in order to directly become a polycrystal silicon film on a substrate. The method mainly comprises the steps of: placing a substrate on a pedestal in an airtight chamber, wherein the temperature of the substrate is controlled by the pedestal; controlling the pressure of the airtight chamber under 100 Torr; and plasma spraying silicon powder with high temperature plasma-forming gas onto the substrate for directly forming polycrystal silicon. Thus, that is a vacuum plasma spray (VPS) method to form a polycrystal silicon film.",DURATEK INC,TU DAVID;;CHANG CHARLIE;;HO PETER,,https://lens.org/070-056-254-836-716,Granted Patent,no,0,1,1,1,0,,C30B29/00;;H01L21/00,,0,0,,,,EXPIRED
796,US,A1,US 2022/0179772 A1,064-268-027-997-269,2022-06-09,2022,US 202217682160 A,2022-02-28,US 202217682160 A;;US 202017119279 A;;US 202016942486 A,2020-07-29,SYSTEMS AND METHODS FOR AUTOMATICALLY MODIFYING PIPELINED ENTERPRISE SOFTWARE,"Systems and methods for version control of pipelined enterprise software are disclosed. Exemplary implementations may: store information for executable code of software applications that are installed and executable by users, receive first user input from a first user that represents selection by the first user of a first software pipeline for execution; receive second user input from a second user that represents a second selection by the second user of a second software pipeline for execution, wherein the second software pipeline includes different versions of software applications that are included in the first software pipeline; facilitate execution of the first software pipeline for the first user; and facilitate execution of the second software pipeline for the second user at the same time as the execution of the first software pipeline for the first user.",INSTABASE INC,CHANG SHIH PING;;LLUNCOR DAVID EDGAR,INSTABASE INC (2020-07-28),https://lens.org/064-268-027-997-269,Patent Application,yes,1,0,5,5,0,G06F9/44536;;G06F11/3612;;G06F8/71;;G06F9/485;;G06F9/44505;;G06F8/4452,G06F11/36;;G06F8/41;;G06F8/71;;G06F9/445;;G06F9/48,,0,0,,,,ACTIVE
797,WO,A1,WO 2016/164925 A1,063-996-134-756-62X,2016-10-13,2016,US 2016/0026984 W,2016-04-11,US 201562145432 P,2015-04-09,DIGITAL MARKETPLACE FOR CASINO APPLICATIONS,"The invention comprises an application marketplace intended to aggregate real-money casino applications for Android, iOS, Windows Mobile, and any other suitable mobile ecosystem. The marketplace moderates and manages promotions for specific casino applications. The marketplace moderates and manages time-based promotions for live events, offers, casino offers, and specific casino applications. The marketplace incorporates a system for making in-application deposits, with consistent access to stored payment methods across casino applications and centralized access to billing transaction records. The marketplace links a store application or website to an embedded software element (SDK) within third-party casino applications which facilitates both application management and deposit of funds into casino applications. The marketplace personalizes user experience in ways specific to gambling based on declared preferences, observed consumer behavior, and individual or cohort deposit patterns within and across casino applications or categories of casino applications.",BETCADE LLC,CHANG DAVID BARBARINO;;FIATAL TREVOR ALAN,,https://lens.org/063-996-134-756-62X,Patent Application,yes,5,0,3,3,0,G06Q30/0207;;G07F17/3223;;G07F17/3225;;G07F17/3244;;G07F17/3255;;G06Q30/0207;;G07F17/3223;;G07F17/3225;;G07F17/3244;;G07F17/3255;;G06F3/0482;;G06Q20/102;;G06Q20/3672,G06Q30/06;;A63F3/06;;G06Q50/34,,0,0,,,,PENDING
798,CA,A1,CA 3145254 A1,061-973-690-710-329,2021-02-04,2021,CA 3145254 A,2020-07-27,US 201962879957 P;;US 2020/0043706 W,2019-07-29,METHOD OF CONTEXTUAL SPEECH DECODING FROM THE BRAIN,"Provided are methods of contextual decoding and/or speech decoding from the brain of a subject. The methods include decoding neural or optical signals from the cortical region of an individual, extracting context-related features and/or speech-related features from the neural or optical signals, and decoding the context-related features and/or speech-related features from the neural or optical signals. Contextual decoding and speech decoding systems and devices for practicing the subject methods are also provided.",UNIV CALIFORNIA,CHANG EDWARD F;;MOSES DAVID A,,https://lens.org/061-973-690-710-329,Patent Application,no,0,1,5,5,0,A61B5/372;;G10L15/24;;A61B5/4064;;A61B5/024;;A61F4/00;;G06F3/015;;G10L13/02;;G10L15/142;;G10L15/22;;G10L15/24;;G10L25/18;;G10L25/24;;G10L25/63;;G10L2015/227,A61B5/369;;A61B5/372;;A61B5/377,,0,0,,,,PENDING
799,WO,A1,WO 1996/030802 A1,077-057-861-852-346,1996-10-03,1996,GB 9600729 W,1996-03-27,GB 9506180 A,1995-03-27,PHASE-CONJUGATION APPARATUS AND METHOD OF PHASE CONJUGATING LIGHT,"A phase-conjugation apparatus comprises a photo-refractive crystal and means for directing one beam Iin of light in a self-pumped configuration (or a plurality of beams of light in a mutually-pumped configuration) into the crystal so that a phase-conjugation process takes place and a phase-conjugated beam Ipc is returned along the same path as the input beam. In order to enable improvements to be made in the range of input beam positions and/or beam orientations, and/or being the time to reach stability, and/or overall stability, and/or the phase-conjugation efficiency, the input beam is incident on the crystal at an obtuse angle to the direction in which a beam of any orientation would ultimately tend to bend in the crystal, which in the case of a barium titanate crystal equates to the so-called +C direction.",UNIV LONDON;;SELVIAH DAVID RICHARD;;CHANG CHI CHING,SELVIAH DAVID RICHARD;;CHANG CHI CHING,,https://lens.org/077-057-861-852-346,Patent Application,yes,0,0,2,2,0,G02F1/3538,G02F1/35,,7,7,088-500-948-719-786;;003-123-887-077-251;;034-202-574-772-181;;027-540-959-544-823;;024-679-328-255-774;;030-850-500-255-659;;017-556-189-552-010,10.1364/ol.10.000408;;19724464;;10.1364/ol.10.000627;;19730507;;19844388;;10.1364/ol.19.000610;;20556177;;10.1364/ao.29.000743;;10.1016/0030-4018(94)90501-0;;10.1016/0030-4018(95)00720-2;;19859294;;10.1364/ol.20.000677,"CHANG T Y ET AL: ""Optical phase conjugation by backscattering in barium titanate"", OPTICS LETTERS, AUG. 1985, USA, vol. 10, no. 8, ISSN 0146-9592, pages 408 - 410, XP002010376;;ANDERSON B T ET AL: ""Self-pumped phase conjunction in BaTiO/sub 3/ at 1.06 mu m"", OPTICS LETTERS, DEC. 1985, USA, vol. 10, no. 12, ISSN 0146-9592, pages 627 - 628, XP002010377;;YINGWU LIAN ET AL: ""Mechanism transformation with wavelength of self-pumped phase conjugation in BaTiO/sub 3/:Ce"", OPTICS LETTERS, 1 MAY 1994, USA, vol. 19, no. 9, ISSN 0146-9592, pages 610 - 612, XP002010378;;SHARP E J ET AL: ""Double phase conjugation in tungsten bronze crystals"", APPLIED OPTICS, 20 FEB. 1990, USA, vol. 29, no. 6, ISSN 0003-6935, pages 743 - 749, XP002010379;;TROTH R C ET AL: ""Greater than unity pulsed phase conjugate reflectivities using self-pumped four-wave mixing in a single BaTiO/sub 3/ crystal"", OPTICS COMMUNICATIONS, 15 JULY 1994, NETHERLANDS, vol. 109, no. 5-6, ISSN 0030-4018, pages 472 - 476, XP002010380;;CHI CHING CHANG ET AL: ""-C curve configuration (-C/sup 3/) photorefractive self-pumped phase conjugator"", OPTICS COMMUNICATIONS, 15 MARCH 1996, ELSEVIER, NETHERLANDS, vol. 124, no. 5-6, ISSN 0030-4018, pages 481 - 487, XP000583805;;CHI CHING CHANG ET AL: ""MUTUALLY PUMPED PHASE-CONJUGATE MIRROR: FISH-HEAD CONFIGURATION"", OPTICS LETTERS, vol. 20, no. 7, 1 April 1995 (1995-04-01), pages 677 - 679, XP000497420",PENDING
800,DE,D1,DE 69607865 D1,054-904-017-932-893,2000-05-31,2000,DE 69607865 T,1996-01-12,US 37670795 A,1995-01-23,System zum Senden von Nachrichten zwischen Makelprozessen,,IBM,CHANG DAVID Y;;SMITH MARC GREGORY,,https://lens.org/054-904-017-932-893,Granted Patent,no,0,0,7,7,0,G06F9/546;;G06F9/546,G06F15/16;;G06F9/46,,0,0,,,,EXPIRED
801,US,A,US 4999222 A,067-702-299-897-198,1991-03-12,1991,US 37768289 A,1989-07-10,US 37768289 A;;EP 91100492 A,1989-07-10,Metallized polyethylene plexifilamentary film-fibril sheet,"A metallized high specular gloss polyethylene plexifilamentary film-fibril sheet with very low emissivity is made by a process of calendering a polyethylene film-fibril sheet between a smooth metal roll and a soft, resilient roll to form a sheet of high specular gloss, followed by vacuum metallization of the smooth high specular gloss surface. Such metallized sheets are useful as radiant barriers or roof liners for energy savings purposes.",DU PONT,JONES DAVID C;;LEE CHI-CHANG,E.I. DU PONT DE NEMOURS AND COMPANY (1989-08-08),https://lens.org/067-702-299-897-198,Granted Patent,yes,5,53,10,14,0,B29C59/04;;B29C59/04;;C23C14/028;;C23C14/028;;C23C14/20;;C23C14/20;;D04H1/42;;D04H1/42;;D04H3/16;;D04H3/16;;D06M10/06;;D06M10/06;;D06M11/83;;D06M11/83;;D06M11/84;;D06M11/84,B29C59/04;;C23C14/02;;C23C14/20;;D04H1/42;;D04H3/16,427/250;;427/251;;427/316;;427/322;;X23C 1600,1,0,,,"Product Licensing Index, Research Disclosure, Tyvek Air Infiltration Barrier in Housing Construction, p. 556 (Oct. 1979).",EXPIRED
802,CA,A1,CA 2802516 A1,085-731-103-862-010,2011-12-22,2011,CA 2802516 A,2011-06-15,US 35480210 P;;US 2011/0040410 W,2010-06-15,METHODS OF REMOVING DEPOSITS IN OIL AND GAS APPLICATIONS,"This invention relates to compositions and methods for controlling and/or removing deposits in oil and/or gas handling equipment, and more specifically relates to controlling and/or removing deposits from the walls of oil and/or gas pipelines.",LUBRIZOL CORP,CHANG ZEN-YU;;ROBERTS C DAVID,,https://lens.org/085-731-103-862-010,Patent Application,no,0,0,3,3,0,C09K8/532;;C10L1/198;;C10L1/2383;;C10L1/2437;;C10L10/04;;C11D1/08;;C11D1/22;;C11D1/62;;C11D3/18;;C11D3/2082;;C11D3/30;;C11D3/3757;;C11D3/43;;C10L2270/10;;C10L1/143;;C10L1/1616;;C10L1/1824;;C10L10/00;;C10L10/18;;C10L2230/14;;C10L1/14;;C10L1/1826;;C10L1/1852;;C10L1/2387;;C10L3/101;;C09K8/52;;C11D2111/20;;C11D3/2082;;C10L1/198;;C11D3/43;;C11D3/18;;C10L1/2383;;C11D1/08;;C09K8/532;;C11D3/3757;;C11D1/22;;C11D1/62;;C10L10/04;;C11D3/30;;C10L1/2437;;C10L10/18;;C10L10/00;;C10L1/1616;;C10L2270/10;;C10L1/143;;C10L1/1826;;C10L1/14;;C10L1/1824;;C10L1/1852;;C10L2230/14;;C10L1/2387;;C10L3/101;;C11D2111/20;;C09K8/52,C09K8/52;;C10L1/18;;C10L1/22;;C10L1/24;;C10L10/04;;C11D1/08;;C11D1/22;;C11D1/40;;C11D3/20;;C11D3/30,,0,0,,,,DISCONTINUED
803,US,B2,US 8138016 B2,081-701-291-898-447,2012-03-20,2012,US 39968009 A,2009-03-06,US 39968009 A;;US 50233606 A,2006-08-09,Large area integration of quartz resonators with electronics,Methods for integrating quartz-based resonators with electronics on a large area wafer through direct pick-and-place and flip-chip bonding or wafer-to-wafer bonding using handle wafers are described. The resulting combination of quartz-based resonators and large area electronics wafer solves the problem of the quartz-electronics substrate diameter mismatch and enables the integration of arrays of quartz devices of different frequencies with the same electronics.,CHANG DAVID T;;KUBENA RANDALL L;;HRL LAB LLC,CHANG DAVID T;;KUBENA RANDALL L,HRL LABORATORIES LLC (2006-11-30),https://lens.org/081-701-291-898-447,Granted Patent,yes,110,8,7,7,0,H04R17/00;;H01L2924/0002;;Y10T29/42;;Y10T29/49005;;Y10T29/53178;;Y10T29/4908;;Y10T29/49007;;Y10T29/42;;Y10T29/49005;;Y10T29/53178;;Y10T29/4908;;Y10T29/49007;;H04R17/00;;H01L2924/0002,H01L21/44;;H01L23/34,438/107;;438/110;;438/118;;257/723;;X257E21598,17,9,049-549-900-425-669;;094-027-782-886-483;;093-683-868-693-489;;080-739-998-719-681;;026-469-527-179-37X;;052-680-114-184-468;;157-046-268-113-071;;015-390-078-907-560;;093-481-767-761-221,10.1109/ultsym.1994.401548;;10.1016/s0924-4247(99)00330-1;;10.1063/1.117548;;10.1063/1.1316071;;10.2514/6.1996-3709;;10.4271/950538;;10.1016/s0924-4247(99)00370-2;;10.1109/mikon.1998.742805;;10.1002/adma.200601995,"U.S. Appl. No. 12/026,486, filed Feb. 5, 2008, Kubena.;;Properties of SAW resonators fabricated on quartz substrates of various qualities; Greer, J.A.; Parker, T.E.; Montress, G.K.; Ultrasonics Symposium, 1994, Proceedings., 1994 IEEE, vol. 1, Nov. 1-4, 1994; pp. 31-36 vol. 1.;;Abe, Takashi, et al., ""One-chip multichannel quartz crystal microbalance (QCM) fabricated by Deep RIE,"" Sensors and Actuators, vol. 82, pp. 139-143 (2000).;;Cleland, A.N., et al., ""Fabrication of high frequency nanometer scale mechanical resonators from bulk Si crystals,"" Appl. Phys. Lett., vol. 69, No. 18, pp. 2653-2655 (Oct. 28, 1996).;;Evoy, S., et al., ""Temperature-dependent internal friction in silicon nanoelectromechanical systems,"" Applied Physics Letters, vol. 77, No. 15, pp. 2397-2399 (Oct. 9, 2000).;;Wright et al., ""The HRG Applied to a Satellite Attitude Reference System,"" Guidance and Control, AAS, 1994, 86: pp. 55-67.;;Putty et al., ""A Micromachined Vibrating Ring Gyroscope,"", Solid State Sensor and Actuator Workshop, Transducer Research Foundation, Hilton Head, 1994, pp. 213-220.;;Tang et al., ""A Packaged Silicon MEMS Vibratory Gyroscope for Microspacecraft,"" Proceedings IEEE, 10th Annual Int. Workshop on MEMS, Japan, 1997, pp. 500-505.;;Barbour et al., ""Micromechanical Silicon Instrument and Systems Development at Draper Laboratory,"" AIAA Guidance Navigation and Control Conference, 1996, Paper No. 96-3709 (20 pages).;;Johnson et al., ""Surface Micromachined Angular Rate Sensor,"" A1995 SAE Conference, Paper No. 950538, pp. 77-83.;;Fujita et al., ""Disk-shaped bulk micromachined gyroscope with vacuum sealing,"" Sensors and Actuators A:Physical, vol. 82, May 2000, pp. 198-204.;;Skulski et al., ""Planar resonator sensor for moisture measurements"", Microwaves and Radar, 1998, MIKON '98, 12th International Conf., vol. 3, May 20-22, 1998, pp. 692-695.;;Tang et al., ""Silicon Bulk Micromachined Vibratory Gyroscope,"" Jet Propulsion Lab.;;Sirbuly, Donald J. et al., Multifunctional Nanowire Evanescent Wave Optical Sensors, Advanced Materials, 2007 (published online: Dec. 5, 2006), 19, pp. 61-66.;;White, Lan M., et al., Increasing the Enhancement of SERS with Dielectric Microsphere Resonators, Spectroscopy-Eugene, Apr. 2006.;;Yan, Fei, et al., ""Surface-enhanced Raman scattering (SERS) detection for chemical and biological agents,"" IEEE Sensors Journal, vol. 5, No. 4, Aug. 2005.;;U.S. Appl. No. 11/818,797, filed Jun. 14, 2007, Kirby.",ACTIVE
804,US,A,US 5251482 A,084-914-130-249-663,1993-10-12,1993,US 55264290 A,1990-07-16,US 55264290 A,1990-07-16,Low frequency acoustic fuel sensor,"An acoustic fuel (or other liquid, powder or solid) sensor is disclosed. The sensor measures the volume of fuel in a container of known size. The air within the container is excited by an acoustic transducer. The transducer is driven by a frequency scanning source, and the frequency response of the air cavity within the container is monitored. This frequency response is then processed to determine the volume of air in the container, and the fuel volume is determined to be the total container volume less the air volume. In one embodiment, a tube connects the transducer through an orifice to the air volume, and the frequency response is observed to determine the resonant frequency of the air cavity within the container. The volume of the air cavity is then determined from the resonant frequency. The volume of the fuel is then determined from the tank volume minus the volume of the air cavity.",HUGHES AIRCRAFT CO,BATES KENN S;;CHANG DAVID B,HUGHES AIRCRAFT COMPANY A CORP OF DE (1990-06-25);;HE HOLDINGS INC. A DELAWARE CORP (1997-12-17);;RAYTHEON COMPANY (1997-12-17),https://lens.org/084-914-130-249-663,Granted Patent,yes,20,51,5,5,0,G01F22/00;;G01F23/2966;;G01F23/2966;;G01F17/00;;G01F17/00;;G01F22/02;;G01F22/02,G01F17/00;;G01F22/00;;G01F22/02;;G01F23/296,73290V;;73/149,9,2,049-398-359-196-267;;111-205-809-135-270,10.4271/710439;;10.4271/871961,"E. W. Pike et al, Investigation of Fuel Quantity Measuring Techniques, DTIC AD712120, USAF AMC Wright Patterson AFB, Ohio, Jun. 1952.;;W. B. Engle and R. M. Owen, Electrical and Physical Nature of Microbial Membranes Implicated in Aircraft Fuel Quantity Probe Malfunction, SAE 710439, National Air Transportation Meeting, Atlanta, Ga., May 1971.;;J. Huddart, An Alternative Approach to Fuel Gauging, SAE 790138, Society of Automotive Engineers, Detroit, Mich., Feb./Mar. 1979.;;E. Suzuki, T. Tomoda, and S. Momoo, A Highly Accurate Fuel Level Measuring System, SAE 871961, Passenger Car Meeting, Dearborn, Mich., Oct. 1987.;;P. Weitz and D. Slade, Effects of Anti Static Additives on Aircraft Capacitance Fuel Gauging Systems, AFWAL Wright Patterson AFB, Ohio, Technical Report AFWAL TR 80 2058, Jun. 1980.;;K. Wantanabe and Y. Takebayashi, Volume Measurement of Liquid in a Deformed Tank, SAE 8/1964, Passenger Meeting, Dearborn, Mich. Oct. 1987.;;H. Garner and H. Howell, Volumetric Fuel Quantity Gauge, Patent Application, NASA CASE Lar 13147 1, Aug. 1984.;;J. J. Singh, G. H. Mall, D. R. Sprinkel and H. Chegini, Feasibility of a Nuclear Gauge for Fuel Quantity Measurement Aboard Aircraft, NASA TM 87706, Aug. 1985.;;B. D. Keller, C. R. Mayer and B. Blanter, Acoustic Fuel Quantity Measurement System, NADC 78187 60, NADC Warminster, Pa., Feb. 1980.",EXPIRED
805,SG,A,SG 11202105023U A,080-474-654-941-034,2021-06-29,2021,SG 11202105023U A,2019-09-27,US 201816203970 A;;US 2019/0053553 W,2018-11-29,SYSTEM AND PROCESS FOR ADJUSTING TREATMENT PARAMETERS FOR RETINA PHOTOTHERAPY BASED ON RPE MELANIN LEVELS,,OJAI RETINAL TECHNOLOGY LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/080-474-654-941-034,Unknown,no,0,0,12,287,0,A61F9/008;;A61F2009/00863;;A61N5/0613;;A61N2005/0648;;A61N2005/0659;;A61N2005/0662,A61F9/00;;A61F9/008;;A61N5/06,,0,0,,,,PENDING
806,US,A,US 5164167 A,082-114-575-895-846,1992-11-17,1992,US 26122988 A,1988-10-24,US 26122988 A,1988-10-24,PROCESS FOR THE REMOVAL OF ACID FORMING GASES FROM EXHAUST GASES,"Exhaust gases are treated to remove NO or NO.sub.x and SO.sub.2 by contacting the gases with an aqueous emulsion or suspension of yellow phosphorus preferably in a wet scrubber. The pressure is not critical, and ambient pressures are used. Hot water temperatures are best, but economics suggest about 50.degree. C. are attractive. The amount of yellow phosphorus used will vary with the composition of the exhaust gas, less than 3% for small concentrations of NO, and 10% or higher for concentrations above say 1000 ppm. Similarly, the pH will vary with the composition being treated, and it is adjusted with a suitable alkali. For mixtures of NO.sub.x and SO.sub.2, alkalis that are used for flue gas desulfurization are preferred. With this process, 100% of the by-products created are usable, and close to 100% of the NO or NO and SO.sub.2 can be removed in an economic fashion.",UNIV CALIFORNIA,CHANG SHIH-GER;;LIU DAVID K,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE A CORP. OF CA (1988-10-21),https://lens.org/082-114-575-895-846,Granted Patent,yes,3,6,5,7,0,B01D53/60;;B01D53/60;;Y02A50/20;;Y02A50/20,B01D53/60,423/235;;423/239;;423/243.01;;423/244.01,0,0,,,,EXPIRED
807,US,A1,US 2009/0117193 A1,097-905-902-308-203,2009-05-07,2009,US 34336508 A,2008-12-23,US 34336508 A;;US 98550904 A;;US 31334302 A;;US 54875900 A;;US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P,1999-10-29,Compositions Comprising an Active Agent,"The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject.",NEKTAR THERAPEUTICS,KUO MEI-CHANG;;LECHUGA-BALLESTEROS DAVID,,https://lens.org/097-905-902-308-203,Patent Application,yes,44,3,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K9/14;;A61K9/00;;A61K47/42;;A61K9/08;;A61K9/12;;A61K9/72;;A61K31/58;;A61K38/00;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,424/489,3,3,071-359-051-194-156;;004-383-062-518-283;;108-739-752-465-233,10.1023/a:1016292232513;;7617520;;10.1021/js970308x;;9519146;;10.1111/j.1365-2265.1994.tb02491.x;;8187318,"Colthorpe et al (Pharmaceutical Research 12:356-359, 1995);;Maa et al (Journal of Pharmaceutical Sciences 87:152-159, 1998);;Møller et al (Clinical Endocrinology 40:511-513, 1994)",EXPIRED
808,US,B2,US 7901680 B2,115-838-568-831-149,2011-03-08,2011,US 54447609 A,2009-08-20,US 54447609 A;;US 39660509 A;;US 63372906 A;;US 38935806 A;;US 39158406 A;;US 47802106 A;;US 78233206 P;;US 72829205 P;;US 75119605 P;;US 86453006 P;;US 9048708 P,2005-10-19,Dock-and-lock (DNL) vaccines for cancer therapy,"The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 neg CD20 + MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2009-10-30),https://lens.org/115-838-568-831-149,Granted Patent,yes,70,91,17,1035,35,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;A61K39/001129;;A61K39/001112;;A61K39/001113;;A61K39/001176;;A61K39/001194;;A61K39/00117;;A61K39/001191;;A61K39/00115;;A61K39/001163;;A61K39/001124;;A61K39/001166;;A61K39/001182;;A61K39/001114;;A61K39/001138;;A61K39/001189;;A61K39/001192;;A61K39/001104;;A61K39/001103;;A61K39/001184;;A61K39/001188;;A61K39/001151;;A61K39/001117;;A61K39/001181;;A61K39/001109;;A61K39/001149;;A61K39/00114;;A61K39/001102;;A61K39/00113;;A61K39/001126;;A61K39/001135;;A61K39/001153;;A61K39/001162;;A61K39/001186;;A61K39/001195;;A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/001189;;A61K39/001112;;A61K39/001153;;A61K39/001163;;A61K39/001135;;A61K39/00117;;A61K39/001113;;A61K39/001124;;A61K39/001192;;A61K39/001129;;A61K39/001117;;A61K39/001103;;A61K39/001195;;A61K39/001138;;A61K39/001149;;A61K39/001182;;A61K39/001114;;A61K39/001102;;A61K39/001104;;A61K39/001126;;A61K39/00113;;A61K39/00114;;A61K39/00115;;A61K39/001166;;A61K39/001181;;A61K39/001186;;A61K39/001191;;A61K39/001194;;A61K39/001162;;A61K39/001176;;A61K39/001188;;A61K39/001109;;A61K39/001184;;A61K39/001151;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011,C07K16/46;;A61K38/17;;A61K39/38;;A61K39/395;;C07K16/18;;C12P21/00;;C12P21/02;;C12P21/08,424/134.1;;424/143.1;;424/144.1;;424/178.1;;424/179.1;;424/184.1;;424/192.1;;424/193.1;;530/387.3;;530/388.22;;530/324,102,98,013-580-733-777-26X;;009-038-716-796-026;;042-979-543-299-89X;;091-995-224-471-960;;046-723-641-666-637;;051-620-799-695-736;;000-687-583-450-12X;;030-424-581-071-330;;025-955-082-953-672;;043-565-065-226-050;;064-253-076-017-931;;073-213-551-327-892;;029-646-755-871-310;;015-399-642-762-43X;;142-686-487-823-912;;007-954-637-794-12X;;080-571-625-616-771;;013-580-733-777-26X;;046-220-521-080-741;;036-011-287-610-789;;046-650-803-614-561;;057-819-453-551-117;;020-829-015-080-665;;061-974-273-716-169;;073-910-564-236-619;;039-423-064-544-876;;028-385-018-876-542;;078-950-298-931-296;;082-317-213-185-417;;061-716-650-834-485;;154-648-591-453-198;;138-142-682-110-803;;066-146-798-965-262;;032-799-656-305-036;;088-770-954-200-50X;;002-331-092-499-856;;052-302-906-314-226;;125-439-449-787-91X;;002-968-698-489-191;;003-133-671-061-524;;001-773-325-098-677;;001-438-265-785-943;;021-399-654-204-715;;013-495-040-538-497;;014-817-433-156-057;;006-606-859-520-426;;016-722-289-911-388;;055-567-629-980-222;;002-036-513-655-449;;099-307-614-319-429;;003-051-068-663-062;;023-678-010-672-059;;003-108-249-997-920;;007-069-424-478-527;;038-825-262-077-725;;065-444-676-277-778;;012-784-512-058-868;;080-178-221-600-828;;047-005-302-967-531;;125-529-544-811-462;;018-006-598-852-321;;020-990-985-949-529;;011-995-316-086-363;;173-037-786-598-190;;016-166-700-584-053;;043-444-673-753-697;;061-936-806-789-399;;037-256-563-161-695;;032-644-566-775-628;;062-562-314-695-639;;036-691-203-666-761;;044-321-937-030-182;;020-668-088-701-771;;005-541-751-796-331;;049-772-226-734-591;;001-430-503-266-393;;085-654-388-708-810;;035-233-279-624-600;;011-935-449-060-496;;004-429-456-081-388;;015-339-909-605-122;;028-731-082-626-184;;050-194-893-837-23X;;078-879-327-122-588;;140-550-157-367-656;;062-046-556-389-561;;055-820-139-478-375;;042-089-225-863-796;;066-968-725-085-523;;040-346-598-938-318;;097-323-206-692-758;;078-011-985-450-368;;150-572-162-645-593;;028-439-318-566-993;;143-661-982-397-223;;061-149-695-178-188;;041-712-717-341-447;;034-368-738-281-179,10.1158/1078-0432.ccr-07-1217;;17875793;;10.4049/jimmunol.167.12.7150;;11739538;;2461992;;10.1073/pnas.0330734100;;12672969;;pmc153575;;16848397;;10.1021/bc060037u;;10.1016/j.febslet.2005.03.089;;15943971;;9857038;;10.1074/jbc.273.52.35048;;16704199;;10.1021/bc050322y;;10.1016/s1359-6101(01)00022-3;;11900988;;15375003;;10.1158/0008-5472.can-04-2048;;10.1016/0167-5699(96)10027-x;;8783497;;10358757;;10.1146/annurev.immunol.17.1.189;;6692364;;pmc2253242;;10.1110/ps.051687305;;16260760;;1860836;;10.1016/s0021-9258(18)98665-5;;11278869;;10.1074/jbc.m011252200;;pmc2118284;;16549598;;10.1084/jem.20060045;;10.1158/1078-0432.ccr-07-1217;;17875793;;pmc37461;;11447282;;10.1073/pnas.151260298;;10.1016/s0962-8924(99)01558-5;;10354567;;10.1016/s0021-9258(19)44263-4;;4348550;;10.1021/bc049781+;;15898716;;12657428;;10.1016/s1471-4914(03)00022-4;;pmc1373678;;10.1021/bc050172r;;16173810;;7963533;;17532550;;10.1016/j.biochi.2007.04.006;;10.1016/0022-1759(89)90093-8;;2514231;;10.1016/j.molimm.2007.06.151;;17768100;;18559529;;10.1158/0008-5472.can-08-0232;;10.1016/j.molcel.2006.09.006;;17081989;;10.2210/pdb2izy/pdb;;10.2967/jnumed.107.046185;;18077530;;10.1182/blood-2009-02-204289;;1366535;;10.1038/nbt0490-343;;10.1074/jbc.m412134200;;15596441;;9531615;;10.1182/blood.v91.8.3017.3017_3017_3027;;6159812;;10.7326/0003-4819-93-3-399;;8108387;;10.1073/pnas.91.4.1198;;pmc43124;;10.1038/nrd1033;;12612647;;10.1074/jbc.271.46.29016;;8910553;;11959956;;pmc122719;;10.1073/pnas.072685299;;10.4049/jimmunol.179.10.6881;;17982079;;pmc1462715;;10.1042/bj20051970;;16483255;;10.1080/10428190701704647;;18203019;;17081990;;pmc1855097;;10.1016/j.molcel.2006.09.015;;10.1023/a:1016042220817;;8842035;;6323591;;10.1089/jir.1983.3.425;;10.1016/s1074-7613(01)00126-1;;11336691;;10.1021/bc060245m;;17941681;;pmc392003;;6093118;;10.1073/pnas.81.21.6723;;9712065;;10.1210/mend.8.3.8015550;;8015550;;10.1210/me.8.3.325;;pmc1867205;;11943735;;10.1016/s0002-9440(10)62577-1;;10.1038/369113a0;;8177316;;10.1016/0092-8674(89)90943-4;;2528411;;3918797;;10.1016/0008-8749(85)90053-x;;9384709;;10.1007/bf01741317;;1760806;;1724446;;10.1002/jcb.240470404;;7983165;;10.1242/jcs.107.7.2021;;10.1007/978-1-4684-4949-5_7;;2850498;;10.1016/0161-5890(88)90128-9;;10.1126/science.8235605;;8235605;;10.1002/ijc.2910500525;;1544714;;pmc2149517;;2383478;;8421711;;pmc45737;;10.1073/pnas.90.2.720;;10.1007/bf01518521;;8348565;;8452154;;10.1016/0002-9343(93)90062-t;;8281471;;10.3322/canjclin.44.1.43;;2138514;;10.1016/0092-8674(90)90341-b;;2784887;;2513569;;10.1073/pnas.86.24.10024;;pmc298636;;1382844;;3878375;;10.1016/0022-1759(85)90271-6;;pmc299476;;10.1073/pnas.84.22.8055;;3500471;;1371822;;10.1016/0161-5890(92)90104-6;;8453790;;10.1006/clin.1993.1012;;6198721;;10.1126/science.6198721;;7541820;;2493487;;pmc303766;;10.1172/jci113976;;10.1002/eji.1830170118;;3102250;;1696564;;10.1002/ijc.2910460228;;1707540;;10.1073/pnas.88.8.3421;;pmc51459;;10.1002/ijc.2910560419;;7509323;;2384661;;6505692;;10.1126/science.6505692;;8275478;;10233730;;10.1046/j.1365-2567.1999.00676.x;;pmc2326754;;2908839;;7995933;;pmc345172;;6609369;;10.1073/pnas.81.9.2864;;7865356;;10.1007/bf01878491;;11208144;;10.1034/j.1600-0854.2000.010706.x;;2663143;;2536772;;6184152;;2971021;;10.1002/ijc.2910420324;;8171337;;10.1126/science.8171337;;10.1073/pnas.90.18.8581;;pmc47401;;8397411,"Chang et al, Clin Cancer Res 13 (18): 5586s-5591s; Sep. 15, 2007.;;Fong et al, J Immunology 167: 7150-7156, 2001.;;Tedder et al, J Immunol 141(12): 4388-4391, Dec. 1988.;;Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Comp. 1991, p. 43.;;Alto et al., ""Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring"" Proc. Natl. Acad. Sci USA Apr. 15, 2003; 100(8):4445-50.;;Backer et al., ""Self-Assembled ""Dock and Lock"" System for Linking Payloads to Targeting Proteins"" Bioconjugate Chem., 2006, 17(4):912-919.;;Baillie et al., ""Compartmentalisation of phospodiesterases and protein kinase A: opposites attract"", FEBS Letters 2005; 579:3264-3270.;;Banky et al., ""Dimerization/Docking Domain of the Type Ialpha Regulatory Subunit of cAMP-dependent Protein Kinase"", J. Biol. Chem. 273:35048-55, 1998.;;Basu et al., ""Structure-Function Engineering of Interferon-beta-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation"", Bioconjugate Chem. 2006; 17:618-630.;;Belardelli et al., ""Interferon-alpha in tumor immunity and immunotherapy"" Cytokine Growth Factor Rev. 13(2):119-134 (2002).;;Belardelli et al., ""International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?"" Cancer Res. 64:6827-6830 (2004).;;Belardelli et al., ""The neglected role of type I interferon in the T-cell response: implications for its clinical use"" Immunol. Today 17(8):369-72 (1996).;;Biron et al., ""Natural killer cells in antiviral defense: function and regulation by innate cytokines"" Annu. Rev. Immunol. 17:189-220 (1999).;;Brunda et al., ""Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons"" Cancer Res. 44:597-601 (1984).;;Burns-Hamuro et al., ""Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange"" Protein Science (2005), 14:2982-2992.;;Carr et al., ""Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif"", J. Biol. Chem. 266:14188-92 (1991).;;Carr et al., ""Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA"" J. Biol. Chem. 276(20):17332-17338 (2001).;;Carrero et al., ""Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes"" J. Exp. Med. 203(4):933-940 (2006).;;Chang et al., ""The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity"" Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.;;Chmura et al., ""Antibodies with infinite affinity"" Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).;;Colledge et al., ""AKAPs: from structure to function"", Trends Cell Biol. 6:216-21 (1999).;;Corbin et al., ""Regulation of Adenosine 3',5'-Monophosphate-dependent Protein Kinase"", J. Biol. Chem. 248:1813-21 (1973).;;Dhalluin et al., ""Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-alpha2a and Its Individual Positional Isomers"" Bioconjugate Chem. 2005;16:504-517.;;Dodart et al., ""Immunotherapy for Alzheimer's Disease: will vaccination work?"" Trends Mol. Med. 9(3):85-87 (2003).;;Doherty et al., ""Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor"", Bioconjugate Chem. 2005;16:1291-1298.;;Ferrantini et al., ""IFN-alpha1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity"" J. Immunol. 153:4604-15 (1994).;;Ferrantini et al., ""Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use"" Biochimie 89: 884-893 (2007).;;Gillies et al., ""High-level expression of chimeric antibodies using adapted cDNA variable region cassettes"", J. Immunol. Methods 125 (1989) 191-202.;;Glennie et al., ""Mechanisms of killing by anti-CD20 monoclonal antibodies"" Mol. Immunol. 44:3823-3837 (2007).;;Gold et al., ""A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma"", Cancer Res. 68:4819-26, 2008.;;Gold et al., ""Molecular Basis of AKAP Specificity for PKA Regulatory Subunits"" Mol. Cell Nov. 3, 2006;24(3):383-95.;;Goldenberg et al., ""Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting"", J. Nucl. Med. 49:158-63, 2008.;;Goldenberg et al., ""Properties and structure-function relationships of veltuzumab {hA20), a humanized anti-CD20 monoclonal antibody"" Blood 113:1062-70 (2009).;;Goodson et al., ""Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site"", Nat. Biotechnology Apr. 1990;8(4):343-6.;;Grace et al., ""Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-alpha Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway"" J. Biol. Chem. 2005;280(8):6327-6336.;;Grimley et al., ""Prolonged STAT1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-alpha"" Blood 91(8):3017-27 (1998).;;Gutterman et al., ""Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma"" Ann. Intern. Med. 93(3):399-406 (1980).;;Gutterman et al., ""Cytokine therapeutics: Lessons from interferon alpha"" Proc. Natl. Acad. Sci. USA 91:1198-205 (1994).;;Harris et al., ""Effect of pegylation on pharmaceuticals"" Nat. Rev. Drug. Discov. 2:214-221 (2003).;;Hausken et al. ""Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII"", J. Biol. Chem. 271:29016-22 (1996).;;Hodneland et al., ""Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands"", Proc. Natl. Acd. Sci. USA 2002; 99:5048-5052.;;Huang et al., ""Targeting IFN-alpha to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities"" J. Immunol. 179:6881-88 (2007).;;Hundsrucker et al., ""High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides"" Biochem. J. (2006) 396, 297-306.;;Kimby et al., ""Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group"" Leuk. Lymphoma 49(1):102-112 (2008).;;Kinderman et al., ""A Dynamic Mechanism for AKAP Binding to RII Isoforms of cAMP-Dependent Protein Kinase"" Mol. Cell 24(3):397-408 (2006).;;Kinstler et al., ""Characterization and Stability of N-terminally PEGylated rhG-CSF"" Pharm. Res. 1996;13 (7):996-1002.;;Kramer et al., ""Cell and virus sensitivity studies with recombinant human alpha interferons"" J. Interferon. Res. 3 (4):425-35 (1983).;;Le Bon et al., ""Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo"" Immunity 14:461-470 (2001).;;Lee et al., ""Solid-Phase PEGylation of Recombinant Interferon alpha-2a for Site-Specific Modification: Process Performance, Characterization, and in Vitro Bioactivity"" Bioconjugate Chem. 2007; 18:1728-34.;;Lohmann et al., ""High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins"", Proc. Natl. Acad. Sci. USA 81:6723-27 (1984).;;Luft et al., ""Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells"" J. Immunol. 161:1947-1953 (1998).;;Mason, Anthony J., ""Functional Analysis of the Cysteine Residues of Activin A"", Mol. Endocrinol. 8:325-32, 1994.;;Matarrese et al., ""Type I Interferon Gene Transfer Sensitizes Melanoma Cells to Apoptosis via a Target Activity on Mitochondrial Function"" Am. J. Pathol. 2002, 160(4):1507-1520.;;Amigorena et al., ""Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes"" Nature 369:113-120 (1994).;;Becker et al., ""Expression of a Hybrid Immunoglobulin-T Cell Receptor Protein in Transgenic Mice"", Cell, 58:911-921 (Sep. 1989).;;Becker, S., ""Inteferon-gamma Accelerates Immune Proliferation via Its Effect on Monocyte HLA-DR Expression"", Cell. Immunol. Mar. 1985;91(1):301-7.;;Bohlen et al., ""Idiotype vaccination strategies against a murine B-cell lymphoma: Dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth"", Cytokines Mol. Ther. Dec. 1996;2 (4):231-8.;;Bolhuis et al., ""T Cell Targeting in Cancer Therapy"", Cancer Immunol. Immunother., 34:1-8 (1991).;;Bolhuis et al., ""Engineering T Lymphocyte Antigen Specificity"", J. Cell. Biochem. 47:306-310, (1991).;;Bremnes et al., ""An LI and ML motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalization"", J. Cell. Science 107:2021-2032 (1994).;;Burnett et al., ""Human Monoclonal Antibodies to Defined Antigens"", Human Hybridomas & Monoclonal Antibodies (Engelman et al, eds.) Plenum Press, New York, 1985, pp. 114-115.;;Carayanniotis et al., ""Delivery of synthetic peptides by anti-class II MHC monovalent antibodies induces specific adjuvant-free IgG responses in vivo"", Mol. Immunol. 25(9):907-911 (1988).;;Cohen et al., ""Cancer Vaccines Get a Shot in the Arm"", Science 262:841-843 (1993).;;Durrant et al., ""An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours"", Int. J. Cancer 50:811-816 (1992).;;Eshhar et al., ""Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach"", Br. J. Cancer 62:27-29, 1990.;;Eshhar et al., ""Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors"", Proc. Natl. Acad. Sci. USA, 90:720-724 (1993).;;Fagerberg et al., ""Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1)"", Cancer Immunol. Immunother. 37:264-270 (1993).;;Goldenberg et al., ""Monoclonal Antibodies in Cancer Detection and Therapy"", Am. J. Med. 94(3):297-312 (1993).;;Goldenberg et al., ""New Developments in Monoclonal Antibodies for Cancer Detection and Therapy"", CA Cancer J. Clin. 44(1):43-64 (1994).;;Goverman et al., ""Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation"", Cell 60:929-939 (1993).;;Gross et al., ""Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity"", Transp. Proc. 21(1):127-130 (Feb. 1989).;;Gross et al., ""Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity"", Proc. Natl. Acad. Sci. USA 86:10024-10028 (Dec. 1989).;;Hefta et al., ""Expression of Carcinoembryonic Antigen and Its Predicted Immunoglobulin-like Domains in HeLa Cells for Epitope Analysis"", Cancer Res. 52:5647-5655 (1992).;;Herlyn et al., ""Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody"", J. Immunol. Methods 85:27-38 (1985).;;Herlyn et al., ""Anti-idiotype immunization of cancer patients: Modulation of the immune response"", Proc. Natl. Acad. Sci. USA 84:8055-8059 (1987).;;Ikeda et al., ""Epitope mapping of the carcinoembryonic antigen with various related recombinant proteins expressed in chinese hamster ovary cells and 25 distinct monoclonal antibodies"", Mol. Immunol. 29(2):229-240 (1992).;;Ioannides et al., ""T cell recognition of human tumors: implications for molecular immunotherapy of cancer"", Clin. Immunol. Immunopath. 66:91-106 (Feb. 1993).;;Irvine et al., ""Comparison of CEA-Recombinant Vaccinia Virus, Purified CEA, and an Anti-Idiotype Antibody Bearing the Image of a CEA Epitope in the Treatment and Prevention of CEA-Expressing Tumors"", Vaccine Res. 2(2):79-94 (1993).;;Kennedy et al., ""Antibody to Hepatitis B Virus Induced by Injecting Antibodies to the Idiotype"", Science 223:930-931 (1984).;;Kos et al., ""Requirement for Natural Killer Cells in the Induction of Cytotoxic T Cells"", J. Immunol. 155:578-584 (1995).;;Kresina et al., ""Antiidiotypic Antibody Vaccine in Murine Schistosomiasis mansoni Comprising the Internal Image of Antigen"", J. Clin. Invest. 83:912-920 (1989).;;Lanzavecchia et al., ""The use of hybrid hybridomas to target human cytotoxic T lymphocytes"", Eur. J. Immun. 17:105-111 (1987).;;Losman et al., ""Baboon anti-idiotype antibodies mimic a carcinoembryonic antigen epitope"", Int. J. Cancer 46:310-314 (1990).;;Losman et al., ""Human response against NP-4, a mouse antibody to carcinoembryonic antigen: Human anti-idiotype antibodies mimic an epitope on the tumor antigen"", Proc. Natl. Acad. Sci. USA 88:3421-3425 (Apr. 1991).;;Losman et al., ""Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotype antibody"", Int. J. Cancer 56:580-584 (1994).;;Machy et al., ""Endocytosis and recycling of MHC-encoded class II molecules by mouse B lymphocytes"", J. Immunol. 145(5):1350-1355 (1990).;;McNamara et al., ""Monoclonal Idiotype Vaccine Against Streptococcus pneumoniae Infection"", Science 226:1325-1326 (1984).;;Mittelman et al., ""Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23"", Cancer Res. 54:415-421(1994).;;Moldenhauer et al., ""Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments"", Immunol. 96:473-484 (1999).;;Monestier et al., ""Syngeneic Anti-idotype Monoclonal Antibodies to Murine Anticarcinoembryonic Antigen Monoclonal Antibodies"", Cancer Res. 49:123-126 (1989).;;Morton et al., Delivery of Nascent MHC Class II-Invariant Chain Complexes to Lysosomal Compartments and Proteolysis of Invariant Chain by Cysteine Proteases Preceded Peptide Binding in B-Lymphoblastoid Cells, J. Immunol. 154:137-150 (1995).;;Nepom et al., ""Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice"", Proc. Natl. Acad. Sci. USA 81:2864-2867 (1984).;;Nohria et al., ""Cytokines as potential vaccine adjuvants"", Biotherapy 7:261-269 (1994).;;Pathak et al., ""Endocytic Recycling is Required for the Presentation of an Exogenous Peptide via MHC Class II Molecules"", Traffic 1:561-569 (2000).;;Paul, W., (ed.), Fundamental Immunology, 3rd Ed., Raven Press, New York, 1993, p. 242.;;Pawlak-Byczkowska et al. ""Two New Monoclonal Antibodies, EPB-1 and EPB-2, Reactive with Human Lymphoma"", Cancer Res. 49:4568-4577 (1989).;;Powel et al., ""Induction of effective immunity to moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen"", J. Immunol. 142(4):1318-1324 (1989).;;Primus et al., ""Immunological Heterogeneity of Carcinoembryonic Antigen: Antigenic Determinants on Carcinoembryonic Antigen Distinguished by Monoclonal Antibodies"", Cancer Res. 43:686-692 (1983).;;Pupa et al., ""Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells"", Int. J. Cancer 42:455-459 (1988).;;Renner et al., ""Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells"", Science 264:833-835 (1994).;;Roche et al., ""Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization"", Proc. Natl. Acad. Sci. USA 90:8581-8585 (1993).;;Roitt et al., Immunology, 3rd Ed., Mosby, London, 1993, p. 6.9.",ACTIVE
809,EP,A3,EP 0203391 A3,114-735-015-662-981,1988-07-13,1988,EP 86105807 A,1986-04-26,US 72896685 A,1985-04-30,UNGELLED RESINS CONTAINING HYDROLYZABLE MOIETIES FROM ORGANOSILANE COMPOUNDS,"Disclosed is an ungelled resin composition comprising a compound having at least one group containing a silicon atom selected from:
    wherein
 Q represents the residue from an organic polyol selected from the group consisting of (1) simple diols, triols and higher hydric alcohols, (2) polyester polyols, (3) polyether polyols, (4) amide-containing polyols, (5) epoxy polyols and (6) polyhydric polyvinyl alcohols, and each R independently is selected from the group of moieties consisting of hydrogen, and a C 1 -C 10  group joined to Si through an Si-C linkage, and Y represents an easily hydrolyzable group. The ungelled resin composition contains an amount of easily hydrolyzable Y moieties directly bonded to silicon atoms such that the ratio of the number of grams of the ungelled resin composition to equivalents of easily hydrolyzable Y moieties in the ungelled resin composition is in a range of from 40 to 667. Preferred resin compositions of the invention can be cured in the presence of atmospheric moisture and a suitable catalyst at a temperature of less than or equal to 121 degrees Celsius within 3 hours. Disclosed is a method for producing the ungelled resin composition. Also disclosed is a nonaqueous composition, particularly a nonaqueous coating composition, containing an ungelled resin composition of the invention. Preferred coating compositions containing an ungelled resin composition of the invention can be cured in the presence of atmospheric moisture and a suitable catalyst at a temperature of less than or equal to 121 degrees C within 3 hours.","PPG INDUSTRIES, INC.","CHANG, WEN-HSUAN;;MCKEOUGH, DAVID THOMAS",,https://lens.org/114-735-015-662-981,Search Report,yes,4,0,12,12,0,C08G77/50;;C08G85/004;;C09D157/06;;C09D201/02;;C09D183/04;;C08G77/50;;C09D201/02;;C08G85/004;;C08G77/50;;C09D157/06,C08G59/00;;C08F8/42;;C08F16/00;;C08F16/02;;C08F16/06;;C08G59/14;;C08G63/00;;C08G63/91;;C08G65/48;;C08G69/00;;C08G69/48;;C08G77/50;;C08G85/00;;C09D157/06;;C09D183/00;;C09D183/05;;C09D201/02,,2,0,,,"PATENT ABSTRACTS OF JAPAN, Unexamined Applications, Field C, Vol. 7, No. 289, December 23, 1983 The Patent Office Japanese Government page 138 C 202; & JP-A-58 168 625 (Dainippon Ink Kagaku Kogyo K.K.);;PATENT ABSTRACTS OF JAPAN, Unexamined Applications, Field C, Vol. 8, No. 3, January 7, 1984 The Patent Office Japanese Government page 161 C 203; & JP-A-58 173 158 (Dainippon Ink Kagaku Kogyo K.K.)",DISCONTINUED
810,BR,A2,BR 112014001721 A2,125-403-956-605-151,2017-03-21,2017,BR 112014001721 A,2012-07-23,US 2012/0047789 W;;US 201161512050 P,2011-07-27,hidroprocessamento aperfeiçoado de matérias-primas biorenováveis,"resumo hidroprocessamento aperfeiçoado de matérias-primas biorenováveis a presente invenção fornece um processo aperfeiçoado para a produção de combustível na faixa de 5 ebulição do diesel ou de componentes combinando combustível a partir de matérias-primas renováveis, tais como óleos vegetais e graxas. o aperfeiçoamento envolveu a adição de um polissulfeto orgânico à matéria-prima renovável, antes da sua entrada na unidade de aquecimento da pré-reação do 10 processo resultando em incrustação reduzida na unidade de aquecimento da pré-reação. a invenção também proporciona o uso de tal polissulfeto orgânico em matérias-primas renováveis usadas em equipamentos de hidroprocessamento para reduzir incrustações nas unidades de aquecimento da 15 pré-reação de tais processos.",LUBRIZOL CORP,C DAVID ROBERTS;;ZEN-YU CHANG,,https://lens.org/125-403-956-605-151,Patent Application,no,0,0,12,12,0,C10G75/04;;C10L1/04;;C10L1/08;;C10G3/50;;C10G2300/1011;;C10G3/46;;C10G2300/1003;;C10G2300/1007;;C10G2300/1014;;C10G2300/1018;;C10G2300/202;;C10G2400/04;;Y02P30/20;;Y02E50/10;;C10L1/08;;C10G3/50;;C10G2300/1011;;C10L1/04;;C10G75/04;;C10G2300/1003;;C10G2300/1014;;C10G2300/202;;C10G2300/1007;;C10G2300/1018;;C10G3/46;;C10G2400/04;;Y02P30/20;;Y02E50/10;;C07C1/22;;C10L10/04,C10G3/00;;C10G65/04;;C10G75/04,,0,0,,,,DISCONTINUED
811,CA,A1,CA 2794499 A1,116-483-465-473-98X,2011-10-06,2011,CA 2794499 A,2011-03-29,US 31990210 P;;US 32928210 P;;US 2011/0030294 W,2010-04-01,ANTIBODY-BASED DEPLETION OF ANTIGEN-PRESENTING CELLS AND DENDRITIC CELLS,"Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.",IMMUMOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/116-483-465-473-98X,Patent Application,no,0,0,8,8,100,A61K31/4965;;A61K31/4965;;A61K47/6807;;A61K47/6807;;A61K47/6813;;A61K47/6813;;A61K47/6815;;A61K47/6815;;A61K47/6849;;A61K47/6849;;A61K47/6881;;A61K47/6881;;A61K47/6885;;A61K47/6885;;A61P37/06;;C07K16/2833;;C07K16/18;;C07K16/2803;;C07K16/2803;;C07K16/2833;;C07K16/2851;;C07K16/2863;;C07K16/2887;;C07K16/2887;;C07K16/30;;C07K16/30;;C07K16/3007;;C07K16/3007;;C07K16/3092;;C07K16/44;;C07K16/44;;C07K2317/24;;C07K2317/24;;C07K2317/31;;C07K2317/31;;C07K2317/35;;C07K2317/35;;C07K2317/51;;C07K2317/51;;C07K2317/52;;C07K2317/52;;C07K2317/522;;C07K2317/522;;C07K2317/55;;C07K2317/55;;C07K2317/73;;C07K2317/73;;C07K2317/734;;C07K2317/734;;C07K2317/75;;C07K2317/75;;C07K2317/77;;C07K2317/77;;C07K2319/70;;C07K2319/70;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32;;Y02A50/30,A61K39/395;;A61K47/48;;A61K51/10;;A61P37/06,,0,0,,,,DISCONTINUED
812,JP,A,JP 2012036898 A,135-498-997-942-450,2012-02-23,2012,JP 2011173190 A,2011-08-08,GB 201013266 A,2010-08-06,FAN ASSEMBLY,"PROBLEM TO BE SOLVED: To provide a fan assembly, particularly a fan heater.SOLUTION: The fan assembly includes: a motor-driven impeller for creating an air flow; at least one heater for heating a first portion of the air flow; and a casing comprising at least one air outlet for emitting the first portion of the air flow, and first channel means for conveying the first portion of the air flow to the at least one air outlet. To cool a part of the casing, the casing includes: means for diverting a second portion of the air flow in a direction away from the at least one heater; and second channel means for conveying the second portion of the air flow along an internal surface of the casing. The second portion of the air flow can merge with the first portion of the air flow within the casing, or can be emitted through at least one second air outlet of the casing, preferably over the external surface of the casing.",DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,,https://lens.org/135-498-997-942-450,Patent Application,no,4,3,23,23,0,F04D25/08;;F04D29/582;;F04D29/5826;;F04F5/16;;F24H3/0411;;F24H3/0417;;F24H9/0063;;F24H9/1872;;F24H2250/04;;F04D25/08;;F24H3/0417;;F04D29/58;;F04D25/08;;F04D25/08;;F04D29/5826;;F04D29/582;;F04F5/16;;F24H3/0417;;F24H9/0063;;F24H2250/04;;F24H3/0411;;F24H9/1872,F04F5/16;;F04D25/08;;F24H3/04,,0,0,,,,INACTIVE
813,US,B2,US 11395098 B2,131-363-060-425-434,2022-07-19,2022,US 201916373497 A,2019-04-02,US 201916373497 A;;US 201862652054 P,2018-04-03,Apparatus and method for container labeling,"An apparatus includes a communication device affixed to or placed within a transport container. The apparatus further includes processing circuitry configured to initiate display, via the communication device, of first routing information indicating a first destination along a geographic route from a first location to a second location and to, in response to a condition indicating movement of the container from the first location to an intermediate location, initiate display, via the at least one communication device, of second routing information indicating a second destination or a final destination that is different than the first destination.",MOTOGO LLC,RUTH DAVID BRIAN;;LO YUAN-CHANG,MOTOGO LLC (2019-04-02),https://lens.org/131-363-060-425-434,Granted Patent,yes,25,0,4,4,0,G06Q10/0833;;H04W4/024;;H04W4/029;;H04W4/35;;H04W4/024;;G06Q10/0833;;H04W4/029,H04W4/024;;G06Q10/08;;H04W4/029,,0,0,,,,ACTIVE
814,US,A1,US 2014/0045242 A1,123-907-107-438-826,2014-02-13,2014,US 201314027770 A,2013-09-16,US 201314027770 A;;US 75474010 A;;US 54447609 A;;US 39660509 A;;US 63372906 A;;US 38935806 A;;US 39158406 A;;US 47802106 A;;US 9048708 P;;US 78233206 P;;US 72829205 P;;US 75119605 P;;US 86453006 P;;US 16829009 P,2005-10-19,Novel Strategies for Improved Cancer Vaccines,"The present invention concerns methods and compositions for forming anti-cancer vaccine complexes. In preferred embodiments, the anti-cancer vaccine complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the vaccine complex. The anti-cancer vaccine complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 neg CD20 + MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2012-08-24),https://lens.org/123-907-107-438-826,Patent Application,yes,3,1,3,1035,35,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2833;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/646;;A61K47/6897;;A61P35/00;;A61K39/001124;;C07K16/468;;C07K16/3007;;C07K2319/00;;C07K16/2803;;C07K2319/30;;A61K2039/6056;;C07K2317/92;;C07K2317/31;;C07K2317/77;;C07K16/2887;;B82Y5/00;;A61K2039/625;;C07K16/2833;;C07K2317/55;;A61K47/646;;A61K47/6897;;A61K39/001124;;C07K16/46,C07K16/46,435/188;;530/391.9;;530/351,8,7,037-719-830-241-939;;017-396-356-826-083;;181-878-983-311-183;;050-929-392-993-933;;086-617-534-349-291;;139-399-324-818-879;;027-364-048-721-489,10.1354/vp.42-4-468;;16006606;;24406927;;10.1038/nbt.2786;;22998522;;10.1517/17460441.2012.722077;;16979786;;10.1016/j.addr.2006.05.004;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;22387378;;10.1016/j.abb.2012.02.011;;23116517;;10.1021/bc300488f,"Jubala et al., Vet Pathol 42: 468-476, 2005.;;Hay et al., Nature Biotechnology 32(1): 40-51, January 2014.;;Kumar et al., Expert Opinion Drug discov. 7(11): 1093-1106, 2012.;;Tabi et al., Advanced Drug Delivery Review 58: 902-915, 2006.;;Stancovski et al., PNAS 88: 8691-8695, 1991.;;Golay et al., Archives of Biochemistry and Biophysics 526: 146-153, 2012.;;Rossi et al., Bioconjugate Chemistry 24: 63-71, January 16, 2013.;;Martin et al., Leukemia & Lymphoma, 2015; Early Online: 1-6.",DISCONTINUED
815,US,B2,US 7454786 B2,126-034-769-302-310,2008-11-18,2008,US 40133403 A,2003-03-27,US 40133403 A,2003-03-27,Method for integrated security roles,"A method for integrated security roles is presented. An upstream application includes one or more role-mapping requirements that correspond to an upstream security role and a downstream security role. The upstream security role is expanded by adding an upstream security role identifier in a downstream application's role-mapping table or by adding upstream user-to-role mappings to a downstream application's role-mapping table. When an upstream security role is expanded, a user assigned to the upstream security role automatically has access to role-mapped downstream applications.",IBM,CHANG DAVID YU;;CHAO CHING-YUN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2003-03-18),https://lens.org/126-034-769-302-310,Granted Patent,yes,31,8,9,9,0,G06F21/6236;;G06F21/6236;;H04L63/102;;H04L63/102,G06F21/00;;G06F15/173;;H04L9/00;;H04L29/06,726/14;;709/238,4,0,,,"Epstein et al., ""Engineering of Role/Permission Assignments,"" Computer Security Applications Conference 17<SUP>th</SUP>, Dec. 10-14, 2001, p. 127-36.;;""Mapping Roles to Groups and Users,"" www.orionserver.com, downloaded Nov. 20, 2002 (2 pages).;;Lowy, J., ""Unify the Role-based Security Models for Enterprise and Application Domains with .Net"", msdn magazine, May 2002, p. 58-64 (missing page contains advertisements).;;A.C. Kapadia, ""A Dynamic Role Translation Model for Secure Interoperability,"" Internet: URL: http://citeseer.ist.psu.edu/kapadia01irbac.html, 2001 (41 pages).",INACTIVE
816,US,A1,US 2014/0049934 A1,133-618-168-592-634,2014-02-20,2014,US 201213589280 A,2012-08-20,US 201213589280 A,2012-08-20,SLAB INDUCTOR DEVICE PROVIDING EFFICIENT ON-CHIP SUPPLY VOLTAGE CONVERSION AND REGULATION,"A voltage conversion circuit such as a buck regulator circuit has a plurality of switches coupled to a voltage source; a slab inductor having a length, a width and a thickness, where the slab inductor is coupled between the plurality of switches and a load and carries a load current during operation of the plurality of switches. The voltage conversion circuit can also include means to reduce or cancel a detrimental effect of other wires on same chip, such as a power grid, that conduct a return current and thereby degrading the functionality of this slab inductor. In one embodiment the wires can be moved further away from the slab inductor and in another embodiment magnetic materials can be used to shield the slab inductor from at least one such interfering conductor.",CHANG LELAND;;GOREN DAVID;;WANG NAIGANG;;IBM,CHANG LELAND;;GOREN DAVID;;WANG NAIGANG,INTERNATIONAL BUSINESS MACHINES CORPORATION (2012-08-16),https://lens.org/133-618-168-592-634,Patent Application,yes,5,1,10,10,0,H02M3/155;;H02M3/156;;G06F1/26;;H02M3/155;;H02M3/158,H05K9/00,361/816,0,0,,,,ACTIVE
817,ES,T3,ES 2658153 T3,135-390-117-025-781,2018-03-08,2018,ES 12728898 T,2012-06-07,US 201113155136 A;;US 2012/0041349 W,2011-06-07,Métodos para la separación de óxido de alquileno mediante el uso de columnas de destilación extractiva,"Un método para separar óxido de propileno de una corriente de óxido de propileno crudo, que comprende el método para pasar la corriente de óxido de propileno en bruto a través de una columna de destilación extractiva, donde la columna de destilación funciona a una presión en un rango mayor que (25 a 50 psig) 273,69 a 446,06 kPa y donde la columna de destilación extractiva usa parafina C8-C20 como disolvente de extracción.",LYONDELL CHEMICAL TECH LP,LI XIANGMIN;;LEYSHON DAVID;;CHANG TE,,https://lens.org/135-390-117-025-781,Granted Patent,no,0,0,13,13,0,B01D3/40;;C07D301/32;;C07D303/04;;C07D303/04;;C07D301/19;;C07D301/19;;C07D301/19;;C07D301/32;;C07D301/32;;C07D303/04,B01D3/40;;C07D301/19;;C07D301/32;;C07D303/04,,0,0,,,,ACTIVE
818,WO,A2,WO 2002/010684 A2,134-959-171-614-656,2002-02-07,2002,US 0124200 W,2001-07-30,US 62968300 A,2000-08-01,THREE-AXES SENSOR AND A METHOD OF MAKING SAME,"A three axis MEM tunneling/capacitive sensor and method of making same. Cantilevered beamstructures for at least two orthogonally arranged sensors and associated mating structures aredefined on a first substrate or wafer, the at least two orthogonally arranged sensors havingorthogonal directions of sensor sensitivity. A resonator structure of at least a third sensor is alsodefined, the third sensor being sensitive in a third direction orthogonal to the orthogonal directions of sensor sensitivity of the two orthogonally arranged sensors and the resonatorstructure having a mating structure thereon. Contact structures for at least two orthogonallyarranged sensors are formed together with mating structures on a second substrate or wafer, themating structures on the second substrate or wafer being of a complementary shape to the matingstructures on the first substrate or wafer. The mating structures of the first substrate aredisposed in a confronting relationship with the mating structures of the second substrate orwafer. A eutectic bonding layer associated with one of the mating structures facilitates bondingbetween the respective mating structures. At least a portion of the first substrate or wafer is removed to release the cantilevered beam structures and the resonator structure.",HRL LAB LLC;;KUBENA RANDALL L;;CHANG DAVID T,KUBENA RANDALL L;;CHANG DAVID T,,https://lens.org/134-959-171-614-656,Patent Application,yes,0,3,10,10,0,B81B2201/0242;;B81B2201/025;;B81C3/002;;B81C2201/019;;B81C2203/036;;B81C2203/058;;G01C19/5656;;G01P15/0802;;G01P15/0894;;G01P15/18;;H01H1/0036;;H01H59/0009;;G01P2015/084;;G01P2015/0842;;B81C3/002;;B81B2201/0242;;B81C2201/019;;B81C2203/058;;B81B2201/025;;G01P15/0802;;H01H1/0036;;G01C19/5656;;H01H59/0009;;G01P15/0894;;G01P15/18;;B81C2203/036;;G01P2015/084;;G01P2015/0842,B81B3/00;;B81C1/00;;B81C3/00;;G01C19/5656;;G01P15/08;;G01P15/18;;H01H1/00;;H01H59/00;;H01L41/08,,0,0,,,,PENDING
819,US,A1,US 2011/0149866 A1,140-042-350-646-525,2011-06-23,2011,US 201113036322 A,2011-02-28,US 201113036322 A;;US 69889010 A;;US 14147805 A,2005-05-31,WIRELESS TERMINAL BASEBAND PROCESSOR HIGH SPEED TURBO DECODING MODULE,"A baseband processing module for use within a Radio Frequency (RF) transceiver includes a downlink/uplink interface, TX processing components, a processor, memory, RX processing components, and a turbo decoding module. The RX processing components receive a baseband RX signal from the RF front end, produce a set of IR samples from the baseband RX signal, and transfer the set of IR samples to the memory. The turbo decoding module receives a set of IR samples from the memory, forms a turbo code word from the set of IR samples, turbo decodes the turbo code word to produce inbound data, and outputs the inbound data to the downlink/uplink interface. The turbo decoding module performs metric normalization based upon a chosen metric, performs de-rate matching on the set of IR samples, performs error detection operations, and extracts information from a MAC packet that it produces.",BROADCOM CORP,HAHM MARK DAVID;;CHANG LI FUNG,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09),https://lens.org/140-042-350-646-525,Patent Application,yes,8,1,11,11,0,H03M13/09;;H03M13/1102;;H03M13/23;;H03M13/2975;;H03M13/3922;;H03M13/6306;;H03M13/6362;;H03M13/658;;H04L1/0051;;H04L1/0054;;H04L1/0066;;H04L1/1819;;H04L1/1845;;H03M13/658;;H03M13/6362;;H03M13/2975;;H04L1/0066;;H03M13/23;;H03M13/6306;;H04L1/1819;;H03M13/09;;H03M13/3922;;H04L1/0054;;H04L1/0051;;H04L1/1845;;H03M13/1102,H04W4/00,370/328,0,0,,,,ACTIVE
820,SG,A,SG 11202104948Q A,132-333-029-801-699,2021-06-29,2021,SG 11202104948Q A,2019-04-29,US 201816203970 A;;US 201916241812 A;;US 2019/0029660 W,2018-11-29,PROCESS FOR SAFELY PROVIDING RETINAL PHOTOTHERAPY BASED ON DETERMINATION OF RPE MELANIN LEVELS,,OJAI RETINAL TECHNOLOGY LLC,CHANG DAVID B;;LUTTRULL JEFFREY K,,https://lens.org/132-333-029-801-699,Unknown,no,0,0,11,287,0,A61B3/10;;A61N2005/0659;;A61N2005/0627;;A61N5/0613;;A61F9/00823;;A61F2009/00863;;A61F2009/00878;;A61F2009/00851;;A61B3/1225,A61N5/06;;A61B3/10,,0,0,,,,PENDING
821,US,B1,US 11841243 B1,146-105-552-109-510,2023-12-12,2023,US 202217668145 A,2022-02-09,US 202217668145 A,2022-02-09,Frequency multiplexed operation of vibratory gyroscopes for continuous self-calibration,"A Coriolis vibratory gyroscope having a resonator with at least a first and a second n=2 vibratory modes of same resonance frequency in a resonator plane; first and second sensing circuits for generating first and second sense signals in response to a motion of the resonator along a major axis of the first and second vibratory modes; a first drive circuit for driving the resonator in the first vibratory mode with a first drive signal; a second drive circuit for simultaneously driving the resonator in the second vibratory mode with a second drive signal; wherein said first signal has a first frequency equal to a resonant frequency of said resonator in said first vibratory mode, and said second signal has the same frequency as the first signal, modulated in amplitude with a second frequency.",HRL LAB LLC,PELLICCIONE MATTHEW;;SORENSON LOGAN;;CHANG DAVID,HRL LABORATORIES LLC (2022-01-24),https://lens.org/146-105-552-109-510,Granted Patent,yes,8,0,1,1,0,G01C19/5726;;G01C19/5726;;G01C25/00,G01C25/00;;G01C19/5726,,1,0,,,"“Coriolis Vibratory Gyros” D.D. Lynch, Symposium Gyro Technology 1998 Stuttgart, Germany.",ACTIVE
822,CN,A,CN 103328001 A,167-660-732-722-624,2013-09-25,2013,CN 201180051294 A,2011-11-03,US 2011/0059056 W;;US 40974010 P;;US 41459210 P;;US 94953610 A;;US 96893610 A;;US 201113021302 A;;US 201113036820 A;;US 201161487956 P,2010-11-03,Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy,"The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/167-660-732-722-624,Patent Application,no,3,2,8,1035,0,C07K16/00;;C07K2317/30;;C07K2317/90;;C07K2319/01;;C07K2319/73;;A61K47/6803;;A61K47/6807;;A61K47/6809;;A61K47/6811;;A61K47/6841;;A61P35/00;;A61P37/00,A61K39/00;;A61K39/42,,0,0,,,,ACTIVE
823,EP,A4,EP 1639516 A4,163-307-856-698-854,2009-07-15,2009,EP 04777587 A,2004-07-02,US 2004/0021550 W;;US 48446203 P;;US 76697604 A;;US 81376804 A,2003-07-02,METHOD AND APPARATUS FOR GROUND DETECTION AND REMOVAL IN VISION SYSTEMS,,SARNOFF CORP;;FORD MOTOR CO,CHANG PENG;;HIRVONEN DAVID;;CAMUS THEODORE,,https://lens.org/163-307-856-698-854,Search Report,no,5,0,8,15,0,G06V20/00;;G06V20/58;;G06V10/255;;G06V20/00;;G06V10/255;;G06V20/58,G06V20/00;;B60Q1/00;;G01C5/00;;G01C21/30;;G01S1/00;;G01V3/00;;G06F15/00;;G06F19/00;;G06K/;;G08B21/00,,4,4,013-510-237-011-317;;085-781-653-852-621;;042-282-337-878-196;;046-315-722-039-675,10.1016/s0921-8890(02)00175-6;;10.1109/icpr.1990.118108;;10.1109/irds.2002.1041368;;10.1016/0262-8856(90)90057-c,"SE S ET AL: ""Ground plane estimation, error analysis and applications"", ROBOTICS AND AUTONOMOUS SYSTEMS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 39, no. 2, 31 May 2002 (2002-05-31), pages 59 - 71, XP004352942, ISSN: 0921-8890;;LEUNG M K ET AL: ""Detecting wheels of vehicle in stereo images"", PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON PATTERN RECOGNITION. ATLANTIC CITY, JUNE 16 - 21, 1990. CONFERENCE A : COMPUTER VISION AND CONFERENCE B : PATTERN RECOGNITION SYSTEMS AND APPLICATIONS; [PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON PAT, vol. i, 16 June 1990 (1990-06-16), pages 263 - 267, XP010020271, ISBN: 978-0-8186-2062-1;;LOBO J ET AL: ""Segmentation of dense depth maps using inertial data a real-time implementation"", PROCEEDINGS OF THE 2002 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS. (IROS 2002). LAUSANNE, SWITZERLAND, SEPT. 30 - OCT. 4, 2002; [IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS], NEW YORK, NY : IEEE, US, vol. 1, 30 September 2002 (2002-09-30), pages 92 - 97, XP010609234, ISBN: 978-0-7803-7398-3;;ZHENG Y ET AL: ""SWITCHER: a stereo algorithm for ground plane obstacle detection"", IMAGE AND VISION COMPUTING, ELSEVIER, GUILDFORD, GB, vol. 8, no. 1, 1 February 1990 (1990-02-01), pages 57 - 62, XP024237889, ISSN: 0262-8856, [retrieved on 19900201]",DISCONTINUED
824,US,A1,US 2023/0079655 A1,164-701-711-532-775,2023-03-16,2023,US 202218050556 A,2022-10-28,US 202218050556 A;;US 202017038313 A;;US 201916247448 A;;US 201862617480 P,2018-01-15,SYSTEMS AND METHODS OF SECURING TRANSPORT CONTAINERS TO ATTACHMENT POINTS,"Securing systems and methods of securing a transport container to an attachment point. In one embodiment, the securing system includes an actuator, an attachment structure, and an electronic controller. The attachment structure is dimensioned to complement the actuator. The electronic controller is operably coupled to the actuator for attaching and releasing the actuator to the attachment structure.",MOTOGO LLC,RUTH DAVID BRIAN;;LO YUAN-CHANG,MOTOGO LLC (2019-01-14),https://lens.org/164-701-711-532-775,Patent Application,yes,6,0,7,7,0,A47G2029/146;;A47G2029/149;;A47G2029/144;;A47G29/141;;E05B73/00;;E05B73/00;;B60P7/0807;;F16M13/02;;A47G2029/144;;A47G29/141;;F16M2200/02;;E05Y2900/602;;E05B47/0002;;A47G2029/149;;A47G2029/146,E05B73/00;;A47G29/14;;B60P7/08;;E05B47/00;;F16M13/02,,0,0,,,,ACTIVE
825,CN,A,CN 102665758 A,165-453-990-898-265,2012-09-12,2012,CN 201080052690 A,2010-12-09,US 2010/0059660 W;;US 26787709 P;;US 64414609 A;;US 30268210 P;;US 73178110 A;;US 75264910 A;;US 75474010 A;;US 86982310 A;;US 87134510 A;;US 91551510 A;;US 41459210 P,2009-12-09,Dock-and-lock (DNL) Complexes For Delivery of Interference RNA,"Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.",IBC PHARMACEUTICALS INC,CHIEN-HSING CHANG;;GOLDENBERG DAVID M,,https://lens.org/165-453-990-898-265,Patent Application,no,2,6,8,1035,0,A61K2039/505;;A61P35/00;;C07K16/468;;C07K16/18;;C07K16/2803;;C07K16/2833;;C07K16/2887;;C07K16/30;;C07K16/303;;C07K16/3092;;C07K16/44;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2319/70;;C12N15/111;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32,A61K39/395,,0,0,,,,DISCONTINUED
826,CA,A1,CA 2046110 A1,163-860-624-414-174,1992-01-17,1992,CA 2046110 A,1991-07-03,US 55264290 A,1990-07-16,LOW FREQUENCY ACOUSTIC FUEL SENSOR,"LOW FREQUENCY ACOUSTIC FUEL SENSOR An acoustic fuel (or other liquid, powder or solid) sensor is disclosed. The sensor measures the volume of fuel in a container of known size. The air within the container is excited by an acoustic transducer. The transducer is driven by a frequency scanning source, and the frequency response of the air cavity within the container is monitored. This frequency response is then processed to determine the volume of air in the container, and the fuel volume is determined to be the total container volume less the air volume. In one embodiment, a tube connects the transducer through an orifice to the air volume, and the frequency response is observed to determine the resonant frequency of the air cavity within the container. The volume of the air cavity is then determined from the resonant frequency. The volume of the fuel is then determined from the tank volume minus the volume of the air cavity.",HUGHES AIRCRAFT CO,BATES KENN S;;CHANG DAVID B,,https://lens.org/163-860-624-414-174,Patent Application,no,0,0,5,5,0,G01F22/00;;G01F23/2966;;G01F23/2966;;G01F17/00;;G01F17/00;;G01F22/02;;G01F22/02,G01F17/00;;G01F22/00;;G01F22/02;;G01F23/296,,0,0,,,,DISCONTINUED
827,CA,A1,CA 2042092 A1,152-876-961-286-350,1991-12-12,1991,CA 2042092 A,1991-05-08,US 53579390 A,1990-06-11,INFRARED HOLOGRAPHIC DEFECT DETECTOR,"An infrared holographic defect detector (10) comprises a far infrared pulsed coherent source (14) of infrared radiation which provides infrared radiation. The radiation is directed at a generally non-reflective surface (12), for example, a surface of an automobile body having a matt grey pre-coat thereon. A semi-transparent mirror (15) is placed in the path of the radiation to provide a reference beam (17) therefrom. An infrared detector (18) and a charge-coupled device (20) receives the radiation reflected from the surface and the reference signal. A comparator (22) compares the received reflected information and the reference signal and, preferably, information from a source (24) which defines a desired surface configuration in order to derive a quantitative measurement of the surface. A monitor (26) visually displays the quantitative measurement and location of any dents in the surface. To avoid a requirement that sequential automobile doors containing the surface of investigation be three-dimensionally aligned to within microns of reference points, a detector of the reflected radiation can be translated and rotated. A number of sensed images of the surface are taken, one at each of the different positions of the detector. For each image a measure of its correlation with the standard image is made.",HUGHES AIRCRAFT CO,CHANG DAVID B;;DRUMMOND JAMES E,,https://lens.org/152-876-961-286-350,Patent Application,no,0,0,9,9,0,G01B9/021;;G01N21/3581;;G01N21/88;;G01N21/9515;;G01N2021/95615;;G03H2001/0413;;G03H2210/30;;G03H2222/16;;G03H2222/33;;G03H2226/11;;G01B11/24;;G01N21/88;;G03H2001/0413;;G03H2210/30;;G03H2222/16;;G01N21/3581;;G01N21/9515;;G03H2226/11;;G01N2021/95615;;G03H2222/33;;G01B9/021,G01B11/24;;G01B9/021;;G01N21/35;;G01N21/88;;G01N21/93;;G01N21/95;;G01N21/956,,0,0,,,,DISCONTINUED
828,US,B2,US 8366403 B2,158-132-179-615-747,2013-02-05,2013,US 201113188285 A,2011-07-21,GB 201013266 A,2010-08-06,Fan assembly,"A fan assembly includes a motor-driven impeller for creating an air flow, at least one heater for heating a first portion of the air flow, and a casing comprising at least one air outlet for emitting the first portion of the air flow, and first channel for conveying the first portion of the air flow to the at least one air outlet. To cool part of the casing, the casing diverts a second portion of the air flow away from the at least one heater, and comprises a second channel for conveying the second portion of the air flow along an internal surface of the casing. This second portion of the air flow may merge with the first portion within the casing, or it may be emitted through at least one second air outlet of the casing.",DYSON TECHNOLOGY LTD;;WALLACE JOHN DAVID;;CHOONG CHANG HIN,WALLACE JOHN DAVID;;CHOONG CHANG HIN,DYSON TECHNOLOGY LIMITED (2011-09-06),https://lens.org/158-132-179-615-747,Granted Patent,yes,103,10,23,23,0,F04D25/08;;F04D29/582;;F04D29/5826;;F04F5/16;;F24H3/0411;;F24H3/0417;;F24H9/0063;;F24H9/1872;;F24H2250/04;;F04D25/08;;F24H3/0417;;F04D29/58;;F04D25/08;;F04D25/08;;F04D29/5826;;F04D29/582;;F04F5/16;;F24H3/0417;;F24H9/0063;;F24H2250/04;;F24H3/0411;;F24H9/1872,F01D25/24;;F04F5/46;;F03B11/02;;F04D29/40,417/198;;417/179;;415/126;;416/117,23,1,005-409-660-034-800,10.1038/scientificamerican0666-84,"Gammack, P. et al., U.S. Office Action mailed Apr. 12, 2011, directed to U.S. Appl. No. 12/716,749; 8 pages.;;Gammack, P. et al., U.S. Office Action mailed Sep. 1, 2011, directed to U.S. Appl. No. 12/716,749; 9 pages.;;Gammack, P. et al., U.S. Office Action mailed May 24, 2011, directed to U.S. Appl. No. 12/716,613; 9 pages.;;Fitton et al., U.S. Office Action mailed Mar. 30, 2012, directed to U.S. Appl. No. 12/716,707; 7 pages.;;GB Search Report dated Nov. 22, 2010, directed towards counterpart application No. GB1013266.0; 2 pages.;;Reba, I., (Jun. 1966). ""Applications of the Coanda Effect."" Scientific American. 214:84-92.;;Gammack, P. et al., U.S. Office Action mailed Jun. 8, 2012, directed to U.S. Appl. No. 12/230,613; 15 pages.;;Gammack, P. et al., U.S. Office Action mailed Jun. 25, 2012, directed to U.S. Appl. No. 12/716,749; 11 pages.;;Fitton et al., U.S. Office Action mailed Nov. 30, 2010 directed to U.S. Appl. No. 12/560,232; 9 pages.;;Fitton, et al., U.S. Office Action mailed Mar. 8, 2011, directed to U.S. Appl. No. 12/716,780; 12 pages.;;Gammack, P et al., U.S. Final Office Action mailed Jun. 21, 2011, directed to U.S. Appl. No. 12/203,698; 11 pages.;;Gammack, P. et al., U.S. Final Office Action mailed Jun. 24, 2011, directed to U.S. Appl. No. 12/716,781; 19 pages.;;Gammack, P. et al., U.S. Office Action mailed Dec. 10, 2010, directed to U.S. Appl. No. 12/230,613; 12 pages.;;Gammack, P. et al., U.S. Office Action mailed Dec. 9, 2010, directed to U.S. Appl. No. 12/203,698; 10 pages.;;Gammack, P. et al., U.S. Office Action mailed Dec. 9, 2010, directed to U.S. Appl. No. 12/716,781; 17 pages.;;Gammack, P. et al., U.S. Office Action mailed May 13, 2011, directed to U.S. Appl. No. 12/230,613; 12 pages.;;Nicolas, F. et al., U.S. Office Action mailed Mar. 7, 2011, directed to U.S. Appl. No. 12/622,844; 10 pages.;;Third Party Submission Under 37 CFR 1.99 filed Jun. 2, 2011, directed towards U.S. Appl. No. 12/203,698; 3 pages.;;Gammack et al., Office Action mailed Sep. 17, 2012, directed to U.S. Appl. No. 13/114,707; 12 pages.;;Gammack et al., U.S. Office Action mailed Aug. 20, 2012, directed to U.S. Appl. No. 12/945,558; 15 pages.;;Gammack, P. et al., U.S. Office Action mailed Sep. 7, 2011, directed to U.S. Appl. No. 12/230,613; 15 pages.;;Nicolas, F. et al., U.S. Office Action mailed Sep. 8, 2011, directed to U.S. Appl. No. 12/622,844; 11 pages.;;Fitton, et al., U.S. Office Action mailed Sep. 6, 2011, directed to U.S. Appl. No. 12/716,780; 16 pages.",ACTIVE
829,WO,A1,WO 2019/099052 A1,160-136-948-410-130,2019-05-23,2019,US 2017/0062834 W,2017-11-21,US 201715818216 A,2017-11-20,MEASURING RPE AND CHOROID MELANIN LEVELS WITH REFLECTOMETER,"A process for determining levels or concentrations of melanin within an eye includes generating first and second light beams of a different wavelength. The first and second light beams are applied into the eye, such as a retinal pigment epithelium and choroid of the eye. The amount of light reflected from the eye from the first light beam and the second light beam is measured, such as using a reflectometer. A level or concentration of the melanin within the eye is calculated using the measured amount of light reflected from the eye from the first and second light beams.",OJAI RETINAL TECH LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/160-136-948-410-130,Patent Application,yes,10,0,5,287,0,A61B5/0082;;A61F9/00821;;A61B5/0066;;A61F2009/00863;;A61B3/12;;A61B3/0008;;A61B5/1455;;A61B5/14546;;A61B3/12;;A61B3/0008;;A61B5/1455;;A61B5/14546;;A61B5/0082;;A61B5/0066;;A61F9/00821;;A61F2009/00863,A61B3/12,,3,2,086-587-766-902-16X;;004-760-781-640-091,16877429;;10.1167/iovs.06-0122;;10.1088/0031-9155/47/16/303;;12222851,"""Near-Infrared Autofluorescence Imaging of the Fundus: Visualization of Ocular Melanin"", INVEST OPHTHALMOL VIS SCI., vol. 47, no. 8, 1 August 2006 (2006-08-01);;""Monte Carlo modelling of the spectral reflectance of the human eye"", PHYSICS IN MEDICINE AND BIOLOGY, vol. 47, no. 16, 21 August 2002 (2002-08-21);;See also references of EP 3713470A4",PENDING
830,EP,A1,EP 2635300 A1,174-166-758-374-998,2013-09-11,2013,EP 11838781 A,2011-11-03,US 201161487956 P;;US 201113036820 A;;US 201113021302 A;;US 96893610 A;;US 94953610 A;;US 41459210 P;;US 40974010 P;;US 2011/0059056 W,2010-11-03,DOCK-AND-LOCK (DNL) CONSTRUCTS FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) THERAPY,,IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/174-166-758-374-998,Patent Application,yes,0,0,8,1035,105,C07K16/00;;C07K2317/30;;C07K2317/90;;C07K2319/01;;C07K2319/73;;A61K47/6803;;A61K47/6807;;A61K47/6809;;A61K47/6811;;A61K47/6841;;A61P35/00;;A61P37/00,A61K47/50,,0,0,,,,DISCONTINUED
831,IN,A,IN 1331DEN2012 A,187-019-025-828-800,2015-06-05,2015,IN 1331DEN2012 A,2012-02-13,US 23842409 P;;US 64414609 A;;US 73178110 A;;US 75264910 A;;US 75414010 A;;US 75474010 A;;US 2010/0046889 W,2009-08-31,"""BISPECIFIC IMMUNOCYTOKINE DOCK-AND-LOCK (DNL) COMPLEXES AND THERAPEUTIC USE THEREOF""","The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed on the same target cell. The bispecific immunocytokine DNL construct exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or even other types of cytokine-antibody DNL constructs. In a most preferred embodiment the construct comprises an anti-CD20 IgG antibody conjugated to an anti-HLA-DR Fab and IFNα2b, although other combinations of antibodies, antibody fragments and cytokines may be used to form the subject DNL complexes.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/187-019-025-828-800,Patent Application,no,0,0,12,1035,0,A61K2039/505;;A61P1/04;;A61P3/10;;A61P7/06;;A61P9/00;;A61P9/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;C07K14/52;;C07K16/249;;C07K16/2833;;C07K16/2887;;C07K2317/31;;C07K2317/55;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2319/30,A61K39/00,,0,0,,,,PENDING
832,US,B2,US 9139649 B2,185-790-634-594-591,2015-09-22,2015,US 201514603011 A,2015-01-22,US 201514603011 A;;US 201461944295 P,2014-02-25,Humanized anti-CD22 antibody,"Disclosed are humanized RFB4 antibodies or antigen-binding fragments thereof. therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, hRFB4 comprises the light and heavy chain RFB4 CDR sequences with human antibody FR and constant region sequences, along with heavy chain framework region (FR) amino acid residues Q1, F27, V48, A49, F68, R98, T117 and light chain residues L4, S22, K39, G100, V104, and K107. More preferably, the heavy and light chain variable region sequences of hRFB4 comprise SEQ ID NO:7 and SEQ ID NO:8, respectively. In certain embodiments, trogocytosis (antigen shaving) induced by hRFB4 plays a significant role in determining antibody efficacy and disease responsiveness for treatment of B-cell diseases, such as hematopoietic cancers, immune system dysfunction and/or autoimmune disease.",IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IMMUNOMEDICS INC (2015-05-05),https://lens.org/185-790-634-594-591,Granted Patent,yes,64,11,14,14,144,A61K39/3955;;A61K39/39558;;A61K45/06;;A61K45/06;;A61K47/6803;;A61K47/6803;;A61K47/6809;;A61K47/6809;;A61K47/6849;;A61K47/6851;;A61K47/6867;;A61K47/6867;;A61K51/1027;;A61K51/1069;;A61K51/1069;;A61K2039/505;;A61K2039/505;;A61K2039/507;;A61P35/00;;A61P37/06;;C07K16/2803;;C07K16/2803;;C07K16/2851;;C07K2317/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/54;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/569;;C07K2317/622;;C07K2317/73;;C07K2317/73;;C07K2317/92,C07K1/00;;A61K39/00;;A61K39/395;;A61K45/06;;A61K47/48;;A61K51/10;;C07K16/00;;C07K16/28;;C07K16/44;;C12P21/08,,99,90,038-832-607-036-714;;022-888-592-525-153;;032-527-349-807-803;;102-203-552-913-675;;004-509-952-161-571;;044-747-359-082-359;;038-685-119-211-512;;135-702-726-061-040;;025-844-022-011-067;;045-085-794-005-733;;051-483-405-535-96X;;099-899-843-626-336;;018-859-577-017-321;;145-374-705-966-273;;055-398-771-003-487;;099-001-494-960-315;;006-749-329-100-094;;009-483-512-107-343;;031-719-370-148-435;;009-042-325-358-821;;034-772-288-124-313;;000-831-802-795-392;;112-824-579-660-422;;037-256-563-161-695;;085-277-440-303-853;;113-664-356-121-786;;006-574-964-805-278;;041-607-340-819-599;;033-722-471-924-608;;106-753-778-592-300;;093-013-896-320-935;;062-158-043-867-309;;109-401-140-187-082;;001-151-746-014-076;;032-820-729-763-323;;029-554-504-516-703;;015-339-909-605-122;;083-734-720-759-001;;088-656-447-551-373;;043-968-156-521-588;;020-760-687-853-074;;002-807-158-577-900;;050-098-928-030-605;;017-090-382-753-584;;150-572-162-645-593;;047-701-489-754-614;;022-559-088-437-181;;119-790-899-925-321;;042-233-175-582-26X;;148-566-474-884-523;;000-230-170-365-728;;042-867-392-672-290;;012-673-725-064-848;;079-806-459-580-360;;085-978-959-961-491;;051-675-358-865-830;;012-350-288-566-092;;012-966-135-253-576;;016-180-369-581-020;;057-621-847-128-836;;010-349-623-071-740;;065-513-767-113-281;;011-205-502-075-933;;048-845-629-081-271;;012-104-543-895-325;;010-111-903-745-914;;048-877-662-273-255;;016-530-506-730-457;;043-164-824-642-059;;114-983-664-284-645;;010-123-349-408-635;;052-305-448-483-99X;;051-619-987-703-90X;;025-423-697-450-900;;022-759-753-924-884;;012-426-427-709-70X;;024-475-520-305-36X;;129-380-899-533-361;;010-146-804-013-128;;081-786-494-160-86X;;020-855-322-534-259;;025-816-552-698-427;;037-017-089-132-994;;028-737-847-613-017;;076-183-945-466-427;;042-204-626-457-327;;034-368-738-281-179;;027-477-313-726-928;;034-930-328-000-261;;088-851-255-233-972,24097105;;10.1097/cco.0000000000000009;;21658624;;10.1016/j.beha.2011.03.005;;10.1158/1078-0432.ccr-04-0294;;15328168;;8373597;;15010151;;10.1016/s0268-960x(03)00039-0;;10.1182/blood-2011-02-336990;;pmc3204728;;21673350;;10.1016/j.coi.2005.03.005;;15886119;;22039078;;10.1158/1535-7163.mct-11-0632;;10.1186/ar2018;;16859536;;pmc1779377;;10.1093/rheumatology/ket378;;pmc3930886;;24273022;;10.1177/0961203312469692;;23553783;;8490132;;10.1007/bf00023609;;10.1002/0471142727.mb0802bs26;;23150297;;22351200;;10.1385/0-89603-204-3:79;;8443582;;10.1101/gr.2.3.266;;10.1002/1097-0142(19940201)73:3+<896::aid-cncr2820731322>3.0.co;2-h;;8306276;;7691963;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;10.1038/nbt0297-159;;9035142;;10.1385/0-89603-244-2:263;;21400284;;7693850;;10.1084/jem.178.5.1567;;pmc2191245;;2451562;;10.1200/jco.1991.9.4.548;;2066752;;8281471;;10.3322/canjclin.44.1.43;;10.1038/ng0594-13;;8075633;;1706642;;10.1007/bf01741331;;10.1038/321522a0;;3713831;;10.1056/nejm199308123290703;;7687326;;7594496;;10.4049/jimmunol.155.10.4917;;1172191;;10.1038/256495a0;;8428363;;7737671;;10.1089/hyb.1994.13.469;;10.1016/0161-5890(95)00080-1;;8643111;;10.1212/wnl.52.8.1701;;10331706;;8159246;;10.1038/368856a0;;8914801;;10.1097/00001622-199609000-00003;;1696564;;10.1002/ijc.2910460228;;10.1002/jps.2600830117;;8138914;;10.1016/0378-5173(96)04456-0;;pmc41463;;7624362;;10.1073/pnas.92.15.7021;;3101766;;10.1182/blood.v69.3.836.836;;10.1385/0-89603-204-3:105;;22351201;;23150298;;10.1007/bf00177365;;1618230;;10.1073/pnas.86.10.3833;;2726754;;pmc287235;;2663143;;10.1056/nejm199310213291702;;7692295;;7623531;;10.1016/s0140-6736(95)92225-3;;10556272;;10.1093/rheumatology/38.11.1150;;10.1016/s0022-1759(97)00192-0;;9692846;;9824507;;pmc1364410;;10.1046/j.1365-2567.1998.00615.x;;10.1002/ijc.2910560413;;8112889;;10.1007/bf01518451;;7691407;;7828367;;10.1006/clin.1995.1020;;10.1093/rheumatology/ket129;;23542611;;23313811;;pmc3888603;;10.1136/annrheumdis-2012-202760;;10.1007/s002770100340;;11669305;;8097878;;1966993;;16814387;;10.1016/j.molimm.2006.05.007;;10.2337/db11-0684;;pmc3237644;;22076927;;23927500;;10.1111/ejh.12183;;10981873;;10.1097/00129039-200009000-00007;;pmc2376077;;18473018;;10.1016/j.pharmthera.2010.01.001;;20097226;;7608568;;10.4049/jimmunol.155.2.925;;10.1111/j.1365-2141.1987.tb06162.x;;3122816;;7818255;;10.1002/ana.410370108;;11138697;;8947500;;pmc1217930;;10.1042/bj3200293;;pmc1003575;;2969703;;10.1136/ard.47.7.588;;9382890;;10.1084/jem.186.11.1923;;pmc2199156;;10679715;;10.1002/(sici)1097-4598(200003)23:3<385::aid-mus10>3.0.co;2-t;;10.1097/00000478-199601000-00007;;8540610;;10.1016/s0304-3835(01)00503-1;;11368882;;9076770;;10.1097/00006231-199702000-00009;;7493367;;10.1002/(sici)1097-0142(19970601)79:11<2115::aid-cncr8>3.0.co;2-n;;9179057;;10.1016/0008-8749(89)90359-6;;2463099;;10.1182/blood.v90.6.2188;;10.1182/blood.v90.6.2188.2188_2188_2195;;9310469;;10.1182/blood.v84.8.2457.2457;;10.1182/blood.v84.8.2457.bloodjournal8482457;;7522629;;1748994;;10.1016/0022-2836(91)90498-u;;11215825;;11410483;;10540230;;pmc2326920;;10.1046/j.1365-2567.1999.00868.x;;3536124;;10.1016/0092-8674(86)90506-4;;3127726;;10.1038/332323a0;;10.1073/pnas.90.18.8581;;pmc47401;;8397411;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1016/s0006-3495(89)82788-2;;pmc1330451;;2467696;;1423650;;10.3109/07388559209114235,"Hoelzer, D., ""Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia"", Curr Opin Oncol. Nov. 2013;25(6):701-6.;;Illidge et al., ""Radioimmunotherapy in follicular lymphoma"", Best Pract Res Clin Haematol. Jun. 2011;24(2):279-93.;;Leonard et al., ""Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results"", Clin Cancer Res. Aug. 15, 2004;10(16):5327-34.;;Leung et al., ""An extended primer set for PCR amplification of murine kappa variable regions"", Biotechniques. Aug. 1993;15(2):286-92.;;Mavromatis et al., ""Novel therapies for chronic lymphocytic leukemia"", Blood Rev. Jun. 2004;18(2):137-48.;;Micallef et al., ""Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma"", Blood. Oct. 13, 2011;118 (15):4053-61.;;Nitschke, L., ""The role of CD22 and other inhibitory co-receptors in B-cell activation"", Curr Opin Immunol. Jun. 2005;17(3):290-7.;;Sharkey et al., ""Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies"", Mol Cancer Ther. Jan. 2012;11(1):224-34.;;Steinfeld et al., ""Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study"", Arthritis Res Ther. 2006;8(4):R129.;;Strand et al., ""Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled Alleviate trials and extension study SL0006"", Rheumatology (Oxford). Mar. 2014;53(3):502-11.;;Wallace et al., ""Epratuzumab for systemic lupus erythematosus"", Lupus. Apr. 2013;22(4):400-5.;;Adang et al., The reconstruction and expression of a Bacillus thuringiensis cryIIIA gene in protoplasts and potato plants:, Plant Molec. Biol., 21:1131 (1993).;;Ausubel et al. (eds.), ""Gene Synthesis: Assembly of Target Sequences Using Mutually Priming Long Oligonucleotides"", Current Protocols in Molecular Biology, pp. 8.2.8-8.2.13 (1990).;;Ausubel et al. (eds.), ""Gene Synthesis: Assembly of Target Sequences Using Mutually Priming Long Oligonucleotides"", Short Protocols in Molec. Biol., 3rd ed., pp. 8.8-8.10, John Wiley & Sons, Inc. (1995).;;Baines et al., ""Purification of Immunoglobulin G (IgG)"", Methods in Molecular Biology, vol. 10, pp. 79-104, Manson (eds.), The Humana Press (1992).;;Bambot et al., ""Efficient Total Gene Synthesis of 1.35 kb Hybrid alpha-Lytic Protease Gene using the Polymerase Chain Reaction"", PCR Meth. Appl., 2:266 (1993).;;Baum et al., ""Initial Clinical Results with Technetium-99m-Labeled LL2 Monoclonal Antibody Fragment in the Radioimmunodetection of B-Cell Lymphomas"", Cancer 73 (Supp. 3):896 (1994).;;Bhat et al., ""Human Antilipid A Monoclonal Antibodies Bind to Human B Cells and the i Antigen on Cord Red Blood Cells"", J. Immunol., 151(9):5011 (1993).;;Carter et al., ""Humanization of an anti-P185HER2 antibody for human cancer therapy"", Proc. Nat'l Acad. Sci. USA, 89:4285 (1992).;;Coligan et al., (eds.), ""Production of Monoclonal Antibodies"", Current Protocols in Immunology, vol. 1, pp. 2.5.1-2.6.7, 2.7.1-2.7.12, 2.9.1-2.9.3, 2.10.1-2.10.4, John Wiley & Sons (1991).;;Coloma et al., ""Design and production of novel tetravalent bispecific antibodies"", Nature Biotech., 15:159 (1997).;;Dillon et al., ""Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes"", Methods in Molecular Biol., vol. 15:PCR Protocols: Curent Methods and Applications, White (ed.), pp. 263-268, Humana Press, Inc. (1993).;;Foy et al., ""In Vivo-CD40-gp39 Interactions are Essential for Thymus-Dependent Humoral Immunity. II. Prolonged Suppression of the Humoral Immune Response by an Antibody to the Ligand for CD40, gp39"", J. Exp. Med., 178:1567 (1993).;;Ghetie et al., ""Evaluation of Ricin A Chain-Containing Immunotoxins Directed Against CD19 and CD22 Antigens on Normal and Malignant Human B-Cells as Potential Reagents for in Vico Therapy"", Cancer Res. May 1, 1988;48 (9):2610-7.;;Goldenberg et al., ""Targeting, Dosimetry and Radioimmunotherapy of B-cell Lymphomas with Iodine 131-Labeled LL2 Monoclonal Antibody"", J. Clin. Oncol., 9:548 (1991).;;Goldenberg, ""New Developments in Monoclonal Antibodies for Cancer Detection and Therapy"", CA-A Cancer Journal for Clinicians, 44:43 (1994).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs"", Nature Genet., 7:13 (1994).;;Hekman et al., ""Initial Experience with Treatment of Human B Cell Lymphoma with Anti-CD19 Monoclonal Antibody"", Cancer Immunology Immunotherapy, 1991, pp. 364-372, vol. 32.;;IMURAN patient information leaflet, GlaxoSmithKline 7076598/5093, Oct. 2004.;;Jones et al., ""Replacing the complementarity-determining regions in a human antibody with those from a mouse"", Nature, 321:522 (1986).;;Kaminski et al., ""Radioimmunotherapy of B-Cell Lymphoma with [131l] Anti-B1 (Anti-CD20) Antibody"", The New England Journal of Medicine, 1993, pp. 459-465, vol. 329, No. 7.;;Kiener et al., ""Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes"", J. Immunol., 155(10):4917 (1995) (abstract only).;;Kohler et al., ""Continuous cultures of fused cells secreting antibody of predefined specificity"", Nature, 256:495 (1975).;;Kreitman et al., ""Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice"", Cancer Res. Feb. 15, 1993;53(4):819-25.;;Leung et al., ""Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma"", Hybridoma, 1994, pp. 469-476, vol. 13, No. 6.;;Leung et al., ""Construction and Characterization of a Humanized, Internalizing B-Cell (CD22)-Specific, Leukemina/Lymphoma Antibody, LL2"", Mol. Immunol. 1995, pp. 1413-1427, vol. 32, No. 17/18.;;Levine et al., ""IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab"", Neurology, vol. 52, No. 8, pp. 1701-1704, May 12, 1999.;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications"", Nature, 368:856 (1994).;;Longo, D., ""Immunotherapy for Non-Hodgkin's Lymphoma"", Current Opinion in Oncology, 1996, pp. 353-359, vol. 8, No. 5.;;Losman et al., ""Baboon Anti-Idiotype Antibodies Mimic a Carcinoembryonic Antigen Epitope"", Int. J. Cancer, 46:310 (1990).;;Lundberg, B., ""Preparation of Drug-Carrier Emulsions Stabilized with Phosphatidylcholine-Surfactant Mixtures"", J. Pharm. Sci., 83:72 (1993).;;Lundberg et al., ""Submicron lipid emulsions containing amphipathic polyethylene glycol for use as drug-carriers with prolonged circulation time"", Int. J. Pharm., 134:119 (1996).;;Mack et al., ""A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity"", Proc. Natl. Acad. Sci., 92:7021 (1995).;;Mason et al., ""Value of monoclonal anti-CD22 (P135) antibodies for the detection of normal and neoplastic B lymphoid cells"", Blood, 69:836 (1987) (abstract only).;;Mills et al., ""Diagnostic imaging of non-Hodgkin's B-cell lymphoma with anti-lymphomas antibody labeled with Tc-99m"", Proc. Am. Assoc. Cancer Res. 34:479 (1993) (Abstract #2857).;;Mole et al., ""Epitope Mapping"", Methods in Molecular Biology, vol. 10:Immunochemical Protocols, Manson (ed.), pp. 105-116, The Humana Press (1992).;;Murthy et al., ""Lymphoma imaging with a new technetium-99m labelled antibody, LL2"", Eur. J. Nucl. Med., 19:394 (1992).;;Orlandi et al., ""Cloning immunoglobulin variable domains for expression by the polymerase chain reaction"", Proc. Nat'l Acad. Sci. USA, 86:3833 (1989).;;Pawlak-Byczkowska et al., ""Two New Monoclonal Antibodies, EPB-1 and EPB-2, Reactive with Human Lymphoma""; Cancer Research, 1989, pp. 4568-4577, vol. 49, No. 16.;;Perrotta et al., ""Response to Chronic Relapsing ITP of 10 Years Duration of Retuximab"", Blood, vol. 92 (10 Suppl 1, part 1-2), p. 88b, 1998, abstract 3360.;;Press et al. ""Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support"", The New England Journal of Medicine, 1993, pp. 1219-1224, vol. 329, No. 17.;;Press et al., ""Phase II Trial of 131 I-B1 (anti-CD20) Antibody Therapy with Autologous Stem Cell Transplantation for Relapsed B Cell Lymphomas"", The Lancet, 1995, pp. 336-340, vol. 346, No. 8971.;;Protheroe et al., ""Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma"", Rheumatology, vol. 38, No. 11, pp. 1150-1152, Nov. 1999.;;Qu et al., ""Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates"", Journal of Immunological Methods, Apr. 15, 1998, pp. 131-144, vol. 213, No. 2.;;Rowan et al. ""Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequence emergence of CD52-deficient cells"", Immunology, vol. 95, No. 3, pp. 427-436, Nov. 1998.;;Shih et al., ""Internalization and intracellular Processing of an Anti-B-Cell Lymphoma Monoclonal Antibody, LL2""; Int. J. Cancer, 1994, pp. 538-545, vol. 56.;;Stein et al., ""Epitope specificity of the anti-(B cell lympoma) monocional antibody, LL2"", Cancer Immunology Immunotherapy, vol. 37, No. 5, pp. 293-298, 1993.;;The Merck Manual of Diagnosis and Therapy (Seventeenth Edition, Beers et al. eds., Merck Research Laboratoires, Whitehouse Station, NJ, 1999, Chapter 180, ""Demyelinating Diseases"", pp. 1473-1476.;;Theocharis et al., ""Charactarization of in Vivo Mutated T Cell Clones from Patients with Systemic Lupus Erythematosus"", Clinical immunology and Immunopathology, vol. 74, No. 2, pp. 135-142, Feb. 1995.;;Wallace et al., ""Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (Alleviate) and follow-up"", Rheumatology (Oxford). Jul. 2013;52(7):1313-22.;;Wallace et al., ""Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study"", Ann Rheum Dis. Jan. 2014;73(1):183-90.;;Abdel-Raheem et al., ""Severe Evan's syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody"", Annals of hematology (2001) 80:9 543-545.;;Aozasa, K. et al., ""The Occurrence of Monocytoid B-lymphocytes in Autoimmune Disorders"", Mod. Pathol., 6(2): 121-124, 1993.;;Bendig, ""Humanization of rodent monoclonal antibodies by CDR grafting"", Methods: A Companion to Methods in Enzymology 8:83-93 (1995).;;Brozek, C. M. et al., ""Anti-DR antibodies inhibit in vitro production of human rheumatoid factor"", J. Clin. Lab. Immunol., 31(3): 105-109, 1990.;;Carnahan et al., ""Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab"", Mol Immunol. Feb. 2007;44(6):1331-41.;;Carvello et al., ""Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses"", Diabetes. Jan. 2012;61(1):155-65.;;Chevallier et al., ""BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22 + Ph+ B-ALL: proof of principle"", Eur J Haematol. Dec. 2013;91(6):552-6.;;Datta et al., ""Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms"", Appl. Immunohistochem Mol. Morphol. 8(3):210-215, (2000).;;Dorner et al., ""Targeting CD22 as a strategy for treating systemic autoimmune diseases"", Ther Clin Risk Manag. Oct. 2007;3(5):953-9.;;Dorner et al., ""Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers"", Pharmacol Ther. Mar. 2010;125(3):464-75.;;Ellis et al., ""Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma"", Journal of Immunol. 155:925-937.;;Gondo et al., ""HLA class II antigen associated invariant chain gene expression in malignant lymphoma"", British J. of Haematology 67:413-417 (1987).;;Goodkin et al., ""Low-Dose (7.5 mg) Oral Methotrexate Reduces the Rate of Progression in Chronic Progressive Multiple Sclerosis"", Ann Neurol 1995;37:30-40.;;Govindan et al., ""Radionuclides Linked to a CD74 Antibody as Therapeutic Agents for B-Cell Lymphoma: Comparison of Auger Electron Emitters with b-Particle Emitters"", J. of Nuclear Med. 41(12):2089-2097 (2000).;;Hansen et al., ""Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas"", Biochem. J. 320:293-300, (1996).;;Hildebrandt, S. et al, ""Expression of CD21, CD22, and the mouse erythrocyte receptor on peripheral B lymphocytes in rheumatoid arthritis"", Annals of the Rheumatic Diseases, 47:588-594, 1988.;;Inaoki, M. et al., ""CD19-Regulated Signaling Thresholds Control Peripheral Tolerance and Autoantibody Production in B Lymphocytes"", J Exp. Med., 186(11):1923-1931, 1997.;;Inukai et al., ""Expression of HLA-DR and its enhancing molecules in muscle fibers in polymyositis"", Muscle Nerve 23 (3):385-392 (2000).;;Ioachim et al., ""Lymphoid Monoclonal Antibodies Reactive with Lung Tumors: Diagnostic Applications"", Am. J. Surg. Pathol. 20 (1); 64-71, (1996).;;Ishigami et al., ""Invariant chain expression in gastric cancer"", Cancer Letters 168:87-91, (2001).;;Juweid et al., ""99Tcm-LL1: a potential new bone marrow imaging agent"", Nucl. Med. Commun. 18(2):142-8 (1997).;;Juweid et al., ""Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody"", Cancer Res. 55(23 Suppl):5899s-5907s (1995).;;Lazova et al., ""LN-2 (CD74): A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma"", Cancer 79 (11) :2115-2124, (1997).;;Li et al., ""The Epitope Specificity and Tissue Reactivity of Four Murine Monoclonal Anti-CD22 Antibodies"",Cellular Immunology, 118:85-99, 1989.;;Maloney, D. G. et al., ""IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkins Lymphoma"", Blood, 90(6): 2188-2195, 1997.;;Maloney et al., ""Phase I Clinical Trial using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-cell Lymphoma"", Blood 84 (8): 2457-2466, (1994).;;Marks et al., ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"", J. Mol. biol. 222 (3): 581-597, (1991).;;Moller et al., ""CD74"", J. Biol. Regululators of Homeostatic Agents 14: 299-301, (2000).;;Ochakovskaya et al., ""Therapy of Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice with an Anti-CD74 Antibody Conjugated with 111Indium, 67Gallium, or 90Yttrium"", Clin Cancer Res; 7:1505-1510, (2001).;;Ong et al., ""Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines"", Immunology 98: 296-302, (1999).;;Pastan et al., ""Immunotoxins"", Cell, 47:641 (1986).;;Qu et al., ""Internalization and cytotoxic effects of a humanized anti-CD74 antibody, LL1"", Proc. annual meeting of Am. Assoc. for Cancer Res., vol. 43: 255 (abstract), Mar. 2002.;;Reichmann et al., ""Reshaping human antibodies for therapy"", Nature, 332:323 (1988).;;Roche et al., ""Cell Surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization"", Proc. Natl. Acad. Sci. USA 90: 8581-8585 (1993).;;Rudikoff et al., ""Single amino acid substitution altering antigen-binding specificity"", Proc. Natl. Acad. Sci. USA 79 (6):1979-83 (1982).;;Salopek et al., ""Anti-CD20 chimeric monoclonal antibody (Rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris: Implications for its use in other autoimmune antibody mediated diseases"", J. of Investigative Dermatology, 117: 2, p. 542, Abstract No. 916.;;Saltzman et al., ""Transport rates of proteins in porous materials with known microgeometry"", Biophys. J., 55:163 (1989).;;Sandhu, ""Protein Engineering of Antibodies"", Crit. Rev. Biotech., 12:437 (1992).",INACTIVE
833,US,A,US 4782494 A,192-664-466-671-733,1988-11-01,1988,US 86892986 A,1986-05-30,US 86892986 A,1986-05-30,Method of providing continuous lasing operation,The method of producing at least quasi-continuous lasing operation between initial and terminal lasing states comprising the steps of selecting a laser medium and cavity configuration (lasing frequency) with the laser medium containing upconverting material which provides for the exchange of energy between sufficient number of electrons at the terminal lasing state (manifold) so as to maintain population inversion between the initial and terminal lasing states during the lasing operation; and applying excitation energy of a suitable amount to the laser medium during at least a quasi-continuous time period.,HUGHES AIRCRAFT CO,POLLACK SLAVA A;;CHANG DAVID B,HUGHES AIRCRAFT COMPANY (1986-05-30),https://lens.org/192-664-466-671-733,Granted Patent,yes,1,19,9,9,0,H01S3/093;;H01S3/1608;;H01S3/1645;;H01S3/093;;H01S3/1608;;H01S3/1645,H01S3/091;;H01S3/093;;H01S3/16,372/91;;372/69;;372/39,2,0,,,"Batygov et al., Erbium Doped CaF 2 Crystal Laser Operating at Room Temperature , Sov. Jour. Quant. Elec., vol. 4, No. 12, Jun. 1975.;;Gomelauri et al., Single Mode Q Switched CaF 2 :Er 3 Laser , Sov. Jour. Quant. Electr., vol. 6, No. 3, p. 341, Mar. 1976.",EXPIRED
834,WO,A1,WO 2011/129866 A1,007-710-027-789-285,2011-10-20,2011,US 2011/0000601 W,2011-04-04,US 34259910 P,2010-04-16,DOUBLE WALLED CONTAINER AND CLOSURE THEREFOR,"A double-walled plastic jar for cosmetic materials, having an inner compartment to hold the cosmetic, and an annular outer side wall defining the exterior of the jar. The inner compartment carries the lip that seals with a screw cap, and also carries an external skirt, which latter has the screw threads for engagement by the cap. In addition, a weight is disposed in a-concealed manner in the base of the jar, between the walls, to give the jar a heft feel, characteristic of glass or thick plastic walls.",CHANG CHARLES;;MATOS DAVID;;DEVITO RALPH,CHANG CHARLES;;MATOS DAVID;;DEVITO RALPH,,https://lens.org/007-710-027-789-285,Patent Application,yes,15,6,1,1,0,A45D40/0068;;A45D40/0068,B65D90/02,,0,0,,,,PENDING
835,US,A1,US 2015/0344573 A1,003-052-196-995-04X,2015-12-03,2015,US 201514824751 A,2015-08-12,US 201514824751 A;;US 201514603011 A;;US 201461944295 P,2014-02-25,HUMANIZED ANTI-CD22 ANTIBODY,"Disclosed are humanized RFB4 antibodies or antigen-binding fragments thereof. therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, hRFB4 comprises the light and heavy chain RFB4 CDR sequences with human antibody FR and constant region sequences, along with heavy chain framework region (FR) amino acid residues Q1, F27, V48, A49, F68, R98, T117 and light chain residues L4, S22, K39, G100, V104, and K107. More preferably, the heavy and light chain variable region sequences of hRFB4 comprise SEQ ID NO:7 and SEQ ID NO:8, respectively. In certain embodiments, trogocytosis (antigen shaving) induced by hRFB4 plays a significant role in determining antibody efficacy and disease responsiveness for treatment of B-cell diseases, such as hematopoietic cancers, immune system dysfunction and/or autoimmune disease.",IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IMMUNOMEDICS INC (2015-05-05),https://lens.org/003-052-196-995-04X,Patent Application,yes,0,16,14,14,144,A61K39/3955;;A61K39/39558;;A61K45/06;;A61K45/06;;A61K47/6803;;A61K47/6803;;A61K47/6809;;A61K47/6809;;A61K47/6849;;A61K47/6851;;A61K47/6867;;A61K47/6867;;A61K51/1027;;A61K51/1069;;A61K51/1069;;A61K2039/505;;A61K2039/505;;A61K2039/507;;A61P35/00;;A61P37/06;;C07K16/2803;;C07K16/2803;;C07K16/2851;;C07K2317/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/54;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/569;;C07K2317/622;;C07K2317/73;;C07K2317/73;;C07K2317/92,C07K16/28;;A61K39/395;;A61K45/06;;A61K47/48;;A61K51/10,,0,0,,,,INACTIVE
836,US,B2,US 7264757 B2,006-973-022-785-662,2007-09-04,2007,US 78721204 A,2004-02-27,US 78721204 A,2004-02-27,Controllable microscopic bubble nucleation in fluid polymer material production method and its apparatus,"A controllable microscopic bubble nucleation in fluid polymer material production method and apparatus utilizing a gas pipe disposed in the conveyance screw shaft of an injection or extraction forming mechanism and a microbubble generating component, such as a microscopic perforation vented metal head or a microscopic perforation ceramic head, installed at the front extremity of the conveyance screw shaft. At the rear extremity of the gas pipe, a pressurization pump or a high pressure gas storage tank is admitted from an air intake opening, enabling the gas to be indirectly heated by an electric heater on the materials pipe. The high temperature gas is thereafter outputted from the microscopic perforations of the microbubble generating component such that high temperature microscopic bubbles are directly admitted into the section of liquid polymer material which is then uniformly amalgamated by the conveyance screw shaft and then deposited into a forming die.",EVERFOCUS WORLDWIDE CO LTD,CHANG CHIEN-TSUNG;;HIND DAVID WILLIAM,EVERFOCUS WORLDWIDE CO. LTD (2004-02-12),https://lens.org/006-973-022-785-662,Granted Patent,yes,2,12,2,2,0,B29C44/3469;;B29C44/3469;;B29C44/3446;;B29C44/3446;;B29C44/3449;;B29C44/3449,B29C44/20;;B29C39/10;;B29C44/34,264/50;;X425  4 C;;425/207;;425/208,0,0,,,,INACTIVE
837,AU,B2,AU 562197 B2,020-670-385-730-985,1987-06-04,1987,AU 1986/056704 A,1986-04-24,US 72896685 A,1985-04-30,RESINS CONTAINING HYUDROLYZABLE SILICON GROUPS,,PPG INDUSTRIES INC,CHANG WEN-HSUAN;;MCKEOUGH DAVID THOMAS,,https://lens.org/020-670-385-730-985,Granted Patent,no,0,1,12,12,0,C08G77/50;;C08G85/004;;C09D157/06;;C09D201/02;;C09D183/04;;C08G77/50;;C09D201/02;;C08G85/004;;C08G77/50;;C09D157/06,C08G59/00;;C08F8/42;;C08F16/00;;C08F16/02;;C08F16/06;;C08G59/14;;C08G63/00;;C08G63/91;;C08G65/48;;C08G69/00;;C08G69/48;;C08G77/50;;C08G85/00;;C09D157/06;;C09D183/00;;C09D183/05;;C09D201/02,,0,0,,,,EXPIRED
838,WO,A1,WO 2020/112234 A1,023-275-656-557-168,2020-06-04,2020,US 2019/0053553 W,2019-09-27,US 201816203970 A,2018-11-29,SYSTEM AND PROCESS FOR ADJUSTING TREATMENT PARAMETERS FOR RETINA PHOTOTHERAPY BASED ON RPE MELANIN LEVELS,"A system and process for safely providing retinal phototherapy includes generating first and second light beams of a different wavelength. The first and second light beams are applied to a retinal pigment epithelium (RPE) (24) and choroid (26) of an eye (10). The amount of light reflected from the eye from the first light beam and the second light beam is measured, such as using a reflectometer (110). A level or concentration of the melanin within the eye is calculated using the measured amount of light reflected from the eye from the first and second light beams. When the content or density of melanin in the RPE exceeds a predetermined amount, one or more treatment parameters of the retinal phototherapy is adjusted.",OJAI RETINAL TECH LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/023-275-656-557-168,Patent Application,yes,4,0,12,287,0,A61F9/008;;A61F2009/00863;;A61N5/0613;;A61N2005/0648;;A61N2005/0659;;A61N2005/0662,A61F9/00;;A61F9/008;;A61N5/06,,0,0,,,,PENDING
839,AU,B2,AU 775565 B2,018-384-727-614-943,2004-08-05,2004,AU 2000/042353 A,2000-04-12,US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P;;US 0009785 W,1999-10-29,Dry powder compositions having improved dispersivity,,NEKTAR THERAPEUTICS,LECHUGA-BALLESTEROS DAVID;;KUO MEI-CHANG,NEKTAR THERAPEUTICS (2003-07-10),https://lens.org/018-384-727-614-943,Granted Patent,no,1,0,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K47/42;;A61K9/00;;A61K9/08;;A61K9/12;;A61K9/14;;A61K9/72;;A61K31/58;;A61K38/00;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,,0,0,,,,EXPIRED
840,US,A,US 3624817 A,025-643-163-501-085,1971-11-30,1971,US 3624817D A,1969-07-11,US 84105769 A,1969-07-11,LIGHT-DEFLECTION SYSTEM,,HONEYWELL INC,LEE TZUO-CHANG;;ZOOK JAMES DAVID,,https://lens.org/025-643-163-501-085,Granted Patent,no,6,6,4,4,0,G02F1/31;;G02F1/31;;G02F1/29;;G02F1/29,G02F1/29;;G02F1/31,350/150,0,0,,,,EXPIRED
841,AU,A1,AU 2003/258130 A1,032-524-160-719-515,2004-02-23,2004,AU 2003/258130 A,2003-08-06,US 21358002 A;;US 41218003 A;;US 0324674 W,2002-08-06,PROCESS FOR THE PRODUCTION OF BISPHENOL-A,,CALGON CARBON CORP,CHANG CHEN-CHOU;;FAIR DAVID L,,https://lens.org/032-524-160-719-515,Patent Application,no,0,0,10,40,0,B01D15/1857;;B01D15/1864;;B01D2215/023;;B01D2215/028;;C07C37/20;;C07C37/20,B01D15/18;;C07B61/00;;C07C37/20;;C07C39/16,,0,0,,,,DISCONTINUED
842,CA,A1,CA 3116688 A1,030-595-650-259-844,2020-06-04,2020,CA 3116688 A,2019-04-29,US 201816203970 A;;US 201916241812 A;;US 2019/0029660 W,2018-11-29,PROCESS FOR SAFELY PROVIDING RETINAL PHOTOTHERAPY BASED ON DETERMINATION OF RPE MELANIN LEVELS,A process for safely providing retinal phototherapy includes generating an interferometric signal or pattern by applying a near infrared light beam to a retinal pigment epithelium of a retina of an eye. A level or concentration of melanin within the retinal pigment epithelium of the retina is compared to a normal level or concentration using the detected interferometric signal or pattern. One or more treatment parameters of the retinal phototherapy is adjusted if the level or concentration of melanin in the retinal pigment epithelium of the eye exceeds the normal level or concentration by a predetermined amount.,OJAI RETINAL TECH LLC,CHANG DAVID B;;LUTTRULL JEFFREY K,,https://lens.org/030-595-650-259-844,Patent Application,no,0,0,11,287,0,A61B3/10;;A61N2005/0659;;A61N2005/0627;;A61N5/0613;;A61F9/00823;;A61F2009/00863;;A61F2009/00878;;A61F2009/00851;;A61B3/1225,A61N5/06;;A61B3/10,,0,0,,,,PENDING
843,EP,A4,EP 2416807 A4,046-613-951-987-447,2012-06-13,2012,EP 10762283 A,2010-04-06,US 2010/0030045 W;;US 16829009 P;;US 54447609 A,2009-04-10,NOVEL STRATEGIES FOR IMPROVED CANCER VACCINES,,IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/046-613-951-987-447,Search Report,no,2,0,3,1035,0,A61K2039/6031;;C07K16/00;;C07K16/2833;;C07K16/2863;;C07K16/2887;;C07K16/3007;;C07K16/44;;C07K2317/55;;C07K2317/77;;C07K2319/00;;C07K2319/30;;C07K2319/70;;A61K39/001124;;A61K2039/80;;A61K39/001124;;A61K2039/80,A61K51/00;;A61K39/00;;C07K16/28;;C12P21/08,,7,6,024-508-415-038-739;;057-598-004-906-940;;032-409-676-506-509;;013-580-733-777-26X;;076-578-712-651-003;;009-038-716-796-026,10.1097/cji.0b013e318135472c;;17893564;;10.1046/j.1365-2141.2000.01958.x;;10792287;;10.1073/pnas.0600982103;;16636283;;pmc1447525;;10.1158/1078-0432.ccr-07-1217;;17875793;;10.1182/blood-2008-02-142430;;18535198;;10.4049/jimmunol.167.12.7150;;11739538,"KRETZ-ROMMEL ANKE ET AL: ""In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models"", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, vol. 30, no. 7, 1 October 2007 (2007-10-01), pages 715 - 726, XP009094216, ISSN: 1524-9557;;TITZER S ET AL: ""Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects."", BRITISH JOURNAL OF HAEMATOLOGY MAR 2000 LNKD- PUBMED:10792287, vol. 108, no. 4, March 2000 (2000-03-01), pages 805 - 816, XP002674551, ISSN: 0007-1048;;ROSSI E A ET AL: ""Stably Tethered Multifunctional Structures of Defined Composition Made by the Dock and Lock Method for Use in Cancer Targeting"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 103, no. 18, 2 May 2006 (2006-05-02), pages 6841 - 6846, XP008123542, ISSN: 0027-8424, [retrieved on 20060424], DOI: 10.1073/PNAS.0600982103;;CHANG C-H ET AL: ""The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retain Bioactivity"", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 18 SUPPL, 15 September 2007 (2007-09-15), pages 5586S - 5591S, XP008123543, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1217;;KIRSHNER JULIA ET AL: ""A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma"", BLOOD, vol. 112, no. 7, October 2008 (2008-10-01), pages 2935 - 2945, XP002674576, ISSN: 0006-4971;;FONG L ET AL: ""DENDRITIC CELL-BASED XENOANTIGEN VACCINATION FOR PROSTATE CANCER IMMUNOTHERAPY"", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 167, 1 January 2001 (2001-01-01), pages 7150 - 7156, XP008065266, ISSN: 0022-1767;;See also references of WO 2010117984A1",DISCONTINUED
844,GB,A,GB 2371305 A,043-026-931-059-701,2002-07-24,2002,GB 0130714 A,2001-04-24,US 0113207 W;;US 55976600 A,2000-04-27,Furan no-bake foundry binders and their use,"This invention relates to furan no-bake foundry binders comprising (a) a reactive furan resin, (b) furfuryl alcohol, and (c) a catalyst component comprising a catalytically effective amount of a Lewis acid furan catalyst. The invention also relates to foundry mixes prepared with the binder, foundry shapes prepared with the foundry mix, and metal castings prepared with the foundry shapes.",ASHLAND INC,CHANG KEN K;;HUTCHINGS DAVID A,,https://lens.org/043-026-931-059-701,Patent Application,no,5,0,12,12,0,B22C1/224;;B22C1/2246;;B22C1/2246;;C08K3/30;;C08K5/107;;C08K5/13;;C08K5/1535;;C08L71/00,B22C1/22,C3N N25J          N25;;C3N N25K1A        N25;;C3N N25K1B3       N25;;C3N N25K2F        N25;;C3N N25K3B        N25;;C3N N25L2A        N25;;C3N N25L2B        N25,0,0,,,,EXPIRED
845,CN,B,CN 102374660 B,036-576-998-609-651,2015-02-18,2015,CN 201110225536 A,2011-08-08,GB 201013263 A,2010-08-06,Fan assembly,,DYSON TECHNOLOGY LTD,JOHN DAVID WALLACE;;CHANG HIN CHOONG,,https://lens.org/036-576-998-609-651,Granted Patent,no,0,0,24,24,0,F04D25/08;;F24H3/0417;;F04D25/08;;F04D25/08;;F04D29/403;;F04D25/08;;F04D29/44;;F04D29/582;;F04D29/582;;F04D29/5826;;F04D29/5826;;F04D29/584;;F04F5/16;;F04F5/16;;F04F5/46;;F04F5/46;;F24F7/007;;F24F7/007;;F24F13/06;;F24F13/06;;F24F2013/0612;;F24F2013/0612;;F24F2221/28;;F24F2221/28;;F24H3/0417;;F24H3/0417;;F24H3/12;;F24H9/0063;;F24H9/0063;;F24H9/1872;;F24H9/1872;;F24H2250/04;;F24H2250/04,F24H9/00;;F04F5/16;;F24H9/18,,0,0,,,,ACTIVE
846,EP,A1,EP 0140896 A1,045-079-016-532-800,1985-05-15,1985,EP 84900261 A,1983-12-14,US 48573683 A,1983-04-18,PROTECTION OF ANTIBODY DURING CHEMICAL MODIFICATION.,"Réactifs améliorés et leurs procédés de préparation pour l'analyse de Streptococcus groupe A et d'autres organismes contenant des antigènes, où le fond important dérivant de la réaction croisée d'un groupe A anti-Streptococcique ou la réaction avec un Staphylococcus est éliminée, par modification chimique de l'anticorps. La réactivité de l'anticorps pour l'antigène est protégée pendant une telle modification. Les modifications comprennent le clivage de la partie Fc de l'anticorps et la liaison de l'anticorps ou d'un fragment de celui-ci sur un support à phase solide.",QUIDEL,KATZ DAVID H;;CHANG SHUNG-HO,,https://lens.org/045-079-016-532-800,Patent Application,yes,0,1,2,2,0,G01N33/563;;G01N33/531;;G01N33/56944;;G01N33/6857,G01N33/531;;G01N33/563;;G01N33/569;;G01N33/68,,1,0,,,See references of WO 8404170A1,DISCONTINUED
847,US,A,US 5706516 A,054-055-139-677-25X,1998-01-06,1998,US 37670795 A,1995-01-23,US 37670795 A,1995-01-23,System for communicating messages among agent processes,"Data processing application requests are processed in a computer system configured as a plurality of nodes with a plurality of interacting processes. Data is requested by an application request originating on a first node. The request data includes data located on a plurality of the nodes. A portion of computer memory on the nodes is established as agent message queues (""AMQ's""). A first process, acting as a coordinating agent, receives an application request on the first node. The coordinating agent generates a plurality of internal requests for the application request. The coordinating agent communicates the internal requests to a fast communication manager process (""FCM"") on the first node. The first FCM, sends the internal requests to FCM's on the nodes having the request data (""request data nodes""), for storage in selected AMQ's on the request data nodes. The internal requests are retrieved from the selected AMQ's by processes acting as subordinate agents on the request data nodes. The subordinate agents may currently process the internal requests.",IBM,CHANG DAVID YU;;SMITH MARC GREGORY,INTERNATIONAL BUSINESS MACHINES CORPORATION (1994-11-28),https://lens.org/054-055-139-677-25X,Granted Patent,yes,18,118,7,7,0,G06F9/546;;G06F9/546,G06F15/16;;G06F9/46,395/680;;395/601;;395/200.01,2,1,020-920-276-132-408,10.1109/icdcs.1991.148637,"Theimer et al, Heterogeneous Process Migration by Recompilation IEEE Distributed Computing Systems, Jul. 91 International Conference, pp. 18 25.;;Dineen et al, The Network Computing Architecture and System: An Environment for Developing Distributed Applications , IEEE, May 88.",EXPIRED
848,CA,C,CA 2807574 C,051-054-149-429-117,2016-04-05,2016,CA 2807574 A,2011-07-01,GB 201013265 A;;GB 2011051248 W,2010-08-06,A FAN ASSEMBLY,"A fan assembly includes a motor-driven impeller for creating an air flow, at least one heater for heating a first portion of the air flow, means for diverting a second portion of the air flow away from said at least one heater, and a casing comprising at least one first air outlet for emitting the first portion of the air flow and at least one second air outlet from emitting the second portion of the air flow. To cool an external surface of the casing, at least one second air outlet is arranged to direct at least part of the second portion of the air flow over the external surface.",DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,,https://lens.org/051-054-149-429-117,Granted Patent,no,0,0,22,22,0,F24F7/007;;F24F13/06;;F24F2013/205;;F24F2221/12;;F24F2221/28;;F24F2221/34;;F04F5/16;;F24H3/0411;;F24H3/0417;;F24H9/0063;;F24H9/1872;;F24H2250/04;;F04D25/08;;Y10T137/6525;;Y10T137/6552;;F04D25/08;;F24H3/0417;;F04D25/08;;F24H3/12;;F04D29/44;;Y10T137/6525;;Y10T137/6552;;F24F7/007;;F04D15/0218;;F24F2221/28;;F24F2221/12;;F24F2013/205;;F24F13/06;;F24F2221/34;;F24H9/0063;;F04F5/16;;F24H3/0417;;F24H2250/04;;F24H3/0411;;F24H9/1872;;F04D25/08,F24F7/007;;F04D25/08;;F04D29/58,,0,0,,,,INACTIVE
849,BR,A,BR 9102380 A,050-451-242-763-489,1992-01-14,1992,BR 9102380 A,1991-06-07,US 53579390 A,1990-06-11,"DETECTOR DE INFRAVERMELHO HOLOGRAFICO DE DEFEITOS,E,METODO PARA EXPLORAR UMA SUPERFICIE DE UM ARTIGO",,HUGHES AIRCRAFT CO,CHANG DAVID B;;DRUMMOND JAMES E,,https://lens.org/050-451-242-763-489,Patent Application,no,0,0,9,9,0,G01B9/021;;G01N21/3581;;G01N21/88;;G01N21/9515;;G01N2021/95615;;G03H2001/0413;;G03H2210/30;;G03H2222/16;;G03H2222/33;;G03H2226/11;;G01B11/24;;G01N21/88;;G03H2001/0413;;G03H2210/30;;G03H2222/16;;G01N21/3581;;G01N21/9515;;G03H2226/11;;G01N2021/95615;;G03H2222/33;;G01B9/021,G01B11/24;;G01B9/021;;G01N21/35;;G01N21/88;;G01N21/93;;G01N21/95;;G01N21/956,,0,0,,,,PENDING
850,US,A,US 5504886 A,052-438-392-276-332,1996-04-02,1996,US 8678593 A,1993-07-02,US 8678593 A,1993-07-02,System and method for applying user supplied relation definitions to application files for a relational database,"Disclosed is a system and method for applying structured query language on user application files not conforming to the definition of a base relation of a relational database management system. A relational database management system has a runtime supervisor and a data manager. For the use of the data manager a plurality of library procedures generalized for manipulation of user application files are provided installed with the database management system. Responsive to user selection, a class for user application files is defined by naming members of a set of the library procedures for use with member application files of the class and by naming the class. Further responsive to user selection, column definitions on an application file within the class are made to create a user defined table. The user defined table corresponds to a specified user application file and to the definition. To create a class of user application files, a class control block is created in which the members of the set of library procedures are named for the class. For the user defined table, a user defined table control block is created in which the column definitions are stored. Both control blocks are accessible to the runtime supervisor for use with an access plan generated from SQL statements. Special structured query language statements are provided for user invocation to define a class of user application files and for providing column definitions, as well as for deleting a class control block and a user defined table control block.",IBM,CHANG DAVID Y;;MALKEMUS TIMOTHY R,INTERNATIONAL BUSINESS MACHINES CORPORATION (1993-06-25),https://lens.org/052-438-392-276-332,Granted Patent,yes,12,43,5,5,0,G06F16/284;;G06F16/284;;Y10S707/99932,G06F17/30;;G06F12/00,395/600;;X364DIG 1;;364/282.1;;364/283.4,5,1,016-643-651-833-832,10.1145/125223.125228,"Power Tools , IBM Technical Disclosure Bulletin, New York, U.S., Sep., 1989, pp. 262 265.;;A Logical Table For User Defined Columns In Relational Databases , IBM Technical Disclosure Bulletin, New York, U.S. (Apr. 1992).;;User Defined Logical Relationship In Visual Query , IBM Technical Disclosure Bulletin, New York, U.S., Nov., 1990, pp. 221 222.;;Next Generation Database Systems, Communications Of The ACM, Oct., 1991, vol. 34, No. 10, pp. 95 109.;;L. M. Haas et al., Starburst Mid Flight: As The Dust Clears, Research Report, New York, U.S., Jan. 22, 1990, pp. 1 29.",EXPIRED
851,CN,B,CN 102374659 B,056-377-522-042-075,2014-05-14,2014,CN 201110225514 A,2011-08-08,GB 201013266 A,2010-08-06,Fan assembly,,DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,,https://lens.org/056-377-522-042-075,Granted Patent,no,0,0,23,23,0,F04D25/08;;F04D29/582;;F04D29/5826;;F04F5/16;;F24H3/0411;;F24H3/0417;;F24H9/0063;;F24H9/1872;;F24H2250/04;;F04D25/08;;F24H3/0417;;F04D29/58;;F04D25/08;;F04D25/08;;F04D29/5826;;F04D29/582;;F04F5/16;;F24H3/0417;;F24H9/0063;;F24H2250/04;;F24H3/0411;;F24H9/1872,F24H9/00;;F04F5/16;;F24H9/18,,0,0,,,,ACTIVE
852,CA,C,CA 2734265 C,065-219-175-310-76X,2017-12-19,2017,CA 2734265 A,2009-08-20,US 9048708 P;;US 2009/0054441 W,2008-08-20,DOCK-AND-LOCK (DNL) VACCINES FOR CANCER THERAPY,"The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti--cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 neg CD20+ MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/065-219-175-310-76X,Granted Patent,no,0,0,17,1035,35,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;A61K39/001129;;A61K39/001112;;A61K39/001113;;A61K39/001176;;A61K39/001194;;A61K39/00117;;A61K39/001191;;A61K39/00115;;A61K39/001163;;A61K39/001124;;A61K39/001166;;A61K39/001182;;A61K39/001114;;A61K39/001138;;A61K39/001189;;A61K39/001192;;A61K39/001104;;A61K39/001103;;A61K39/001184;;A61K39/001188;;A61K39/001151;;A61K39/001117;;A61K39/001181;;A61K39/001109;;A61K39/001149;;A61K39/00114;;A61K39/001102;;A61K39/00113;;A61K39/001126;;A61K39/001135;;A61K39/001153;;A61K39/001162;;A61K39/001186;;A61K39/001195;;A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/001189;;A61K39/001112;;A61K39/001153;;A61K39/001163;;A61K39/001135;;A61K39/00117;;A61K39/001113;;A61K39/001124;;A61K39/001192;;A61K39/001129;;A61K39/001117;;A61K39/001103;;A61K39/001195;;A61K39/001138;;A61K39/001149;;A61K39/001182;;A61K39/001114;;A61K39/001102;;A61K39/001104;;A61K39/001126;;A61K39/00113;;A61K39/00114;;A61K39/00115;;A61K39/001166;;A61K39/001181;;A61K39/001186;;A61K39/001191;;A61K39/001194;;A61K39/001162;;A61K39/001176;;A61K39/001188;;A61K39/001109;;A61K39/001184;;A61K39/001151;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011,A61K39/385;;A61K51/00;;A61P35/00;;A61P37/04,,0,0,,,,ACTIVE
853,US,B2,US 11734715 B2,071-995-301-383-900,2023-08-22,2023,US 202117154157 A,2021-01-21,US 202117154157 A;;US 201313756145 A;;US 201261593262 P,2012-01-31,Pre-feature promotion system,"A promotion offering system and method is disclosed. The promotion offering system and method selects consumers for a test promotion that has one or more attributes, and is configured to generate test data for multiple consumer groupings. The promotion offering system and method may use the test data in analyzing whether to send a promotion to a consumer. For example, the promotion offering system and method may use one algorithm to generate a list of ranked promotions, and may use the test data in order to adjust the list of ranked promotions (such as replacing a highest ranked promotion with another promotion).",GROUPON INC,THACKER DAVID;;AGGARWAL AMIT;;CHANG KEVIN,GROUPON INC (2013-08-13),https://lens.org/071-995-301-383-900,Granted Patent,yes,87,0,3,3,0,G06Q30/0254;;G06Q30/0254,G06Q30/02;;G06Q30/0251,,5,1,083-118-964-229-93X,10.1109/allerton.2011.6120295,"Distributed_collaborative_filtering_over_social_networks (Year: 2011).;;Increasing_Advertising_Value_of_Mobile_Marketing_-_An_Empirical_Study_of_Antecedents (Year: 2005).;;Monetizing_the_lnternet_Surely_There_Must_be_Something_other_than_Advertising (Year: 2009).;;U.S. Appl. No. 13/756,145, filed Jan. 31, 2013, U.S. Pat. No. 10,929,881.;;U.S. Appl. No. 61/695,857.",ACTIVE
854,AU,B2,AU 2010/286642 B2,074-750-079-938-453,2016-03-10,2016,AU 2010/286642 A,2010-08-27,US 75264910 A;;US 73178110 A;;US 64414609 A;;US 23842409 P;;US 75414010 A;;US 75474010 A;;US 2010/0046889 W,2009-08-31,Bispecific immunocytokine dock-and-lock (DNL) complexes and therapeutic use thereof,"The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed on the same target cell. The bispecific immunocytokine DNL construct exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or even other types of cytokine-antibody DNL constructs. In a most preferred embodiment the construct comprises an anti-CD20 IgG antibody conjugated to an anti-HLA-DR Fab and IFNα2b, although other combinations of antibodies, antibody fragments and cytokines may be used to form the subject DNL complexes.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/074-750-079-938-453,Granted Patent,no,1,0,12,1035,0,A61K2039/505;;C07K14/52;;C07K16/249;;C07K16/2833;;C07K16/2887;;C07K2317/31;;C07K2317/55;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2319/30;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P7/06;;A61P9/00;;A61P9/14;;A61P3/10,A61K39/00;;C12P21/08,,0,0,,,,ACTIVE
855,GB,A,GB 2482549 A,078-457-365-345-23X,2012-02-08,2012,GB 201013266 A,2010-08-06,GB 201013266 A,2010-08-06,A fan assembly with a heater,"A nozzle for a fan assembly and a fan assembly including said nozzle, comprises an air inlet, a heater 104 for heating a first portion of the air flow, a means for diverting a second portion of the air flow away from the heater, a first channel for conveying the first portion of the air flow to an air outlet, the nozzle defines an opening though which air from outside the nozzle is drawn by the airflow emitted from the air outlet and a second channel for conveying the second portion of the airflow along an internal surface of the nozzle. The fan assembly also includes a device for creating airflow, such as a motor-driven impeller. Preferably the nozzle is shaped to divide the air flow into a plurality of air streams each of which comprises part of the first portion and part of the second portion. Each air outlet may be a slot and the heater may be ceramic.",DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,,https://lens.org/078-457-365-345-23X,Patent Application,no,5,35,23,23,0,F04D25/08;;F04D29/582;;F04D29/5826;;F04F5/16;;F24H3/0411;;F24H3/0417;;F24H9/0063;;F24H9/1872;;F24H2250/04;;F04D25/08;;F24H3/0417;;F04D29/58;;F04D25/08;;F04D25/08;;F04D29/5826;;F04D29/582;;F04F5/16;;F24H3/0417;;F24H9/0063;;F24H2250/04;;F24H3/0411;;F24H9/1872,F24H3/04;;F04D25/08,,0,0,,,,DISCONTINUED
856,US,A1,US 2015/0016975 A1,084-107-348-638-927,2015-01-15,2015,US 201414505821 A,2014-10-03,US 201414505821 A;;GB 201013263 A;;US 201113192223 A,2010-08-06,FAN ASSEMBLY,"A fan assembly includes a motor-driven impeller for creating an air flow, a casing including an interior passage for receiving the air flow, and a plurality of air outlets for emitting the air flow from the casing. The casing defines and extends about an opening through which air from outside the casing is drawn by the air flow emitted from the air outlets. The fan assembly also includes at least one heater for heating at least a first portion of the air flow, and means for diverting at least a second portion of the air flow away from said at least one heater. The plurality of outlets includes at least one first air outlet for emitting the relatively hot first portion of the air flow and at least one second air outlet for emitting the relatively cold second portion of the air flow.",DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,,https://lens.org/084-107-348-638-927,Patent Application,yes,9,2,24,24,0,F04D25/08;;F24H3/0417;;F04D25/08;;F04D25/08;;F04D29/403;;F04D25/08;;F04D29/44;;F04D29/582;;F04D29/582;;F04D29/5826;;F04D29/5826;;F04D29/584;;F04F5/16;;F04F5/16;;F04F5/46;;F04F5/46;;F24F7/007;;F24F7/007;;F24F13/06;;F24F13/06;;F24F2013/0612;;F24F2013/0612;;F24F2221/28;;F24F2221/28;;F24H3/0417;;F24H3/0417;;F24H3/12;;F24H9/0063;;F24H9/0063;;F24H9/1872;;F24H9/1872;;F24H2250/04;;F24H2250/04,F04D29/40;;F04D29/58,415/177;;415/224,0,0,,,,INACTIVE
857,WO,A1,WO 1984/004041 A1,096-044-691-215-438,1984-10-25,1984,US 8400554 W,1984-04-10,US 48498383 A;;US 59349284 A,1983-04-14,COLON-SPECIFIC DRUG DELIVERY SYSTEM,"A colon-specific drug delivery system based on the use of a synthetic drug glycoside prodrug composition which, when ingested by a mammal, undergoes reaction with glycosidases produced by colonic microflora to release a free drug capable of being absorbed to or absorbed by the colonic mucosa. Synthesis of synthetic drug glycosides useful in the present drug delivery system is illustrated in figure 1. In that figure, ""a"" is Ag2CO3, molecular sieve, CCl4; ""b"" is 0.01 N NaOH, MeOH; and ""c"" is betaglucosidase; the numerals 3, 4, 23, 14, 15, 1 and 2 denote compounds 3, 4, 23, 14, 15, 1 and 2 respectively; the letter R means radical and the letters Ac mean acetyl. The other letters, e.g., O, H, F and Br denote the chemical elements oxygen, hydrogen, fluorine and bromine, respectively.",UNIV CALIFORNIA,FRIEND DAVID ROBERT;;CHANG GEORGE WASHINGTON,,https://lens.org/096-044-691-215-438,Patent Application,yes,2,3,2,3,0,A61K31/704;;A61K47/549;;C07J17/005,C07J17/00,C2U U2            U;;C2U U4A2A         U;;C2U U4B2B         U;;C2U U4C4A         U;;C2U U4C4B         U;;C2U U4C5          U;;C2U U4N16A        U;;C2U U4N9          U;;C2U U6A1          U;;C2U U8A1          U;;U1S S1318,1,0,,,"""Human Intestinal Flora"", Academic Press, London, 1974, PP. 54*71, Drasar et al:",PENDING
858,US,B1,US 6674141 B1,107-610-899-834-749,2004-01-06,2004,US 62968300 A,2000-08-01,US 62968300 A,2000-08-01,"Single crystal, tunneling and capacitive, three-axes sensor using eutectic bonding and a method of making same","
    A three axis MEM tunneling/capacitive sensor and method of making same. Cantilevered beam structures for at least two orthogonally arranged sensors and associated mating structures are defined on a first substrate or wafer, the at least two orthogonally arranged sensors having orthogonal directions of sensor sensitivity. A resonator structure of at least a third sensor is also defined, the third sensor being sensitive in a third direction orthogonal to the orthogonal directions of sensor sensitivity of the two orthogonally arranged sensors and the resonator structure having a mating structure thereon. Contact structures for at least two orthogonally arranged sensors are formed together with mating structures on a second substrate or wafer, the mating structures on the second substrate or wafer being of a complementary shape to the mating structures on the first substrate or wafer. The mating structures of the first substrate are disposed in a confronting relationship with the mating structures of the second substrate or wafer. A eutectic bonding layer associated with one of the mating structures facilitates bonding between the respective mating structures. At least a portion of the first substrate or wafer is removed to release the cantilevered beam structures and the resonator structure. 
",HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,HRL LABORATORIES LLC (2000-08-28),https://lens.org/107-610-899-834-749,Granted Patent,yes,28,22,10,10,0,B81B2201/0242;;B81B2201/025;;B81C3/002;;B81C2201/019;;B81C2203/036;;B81C2203/058;;G01C19/5656;;G01P15/0802;;G01P15/0894;;G01P15/18;;H01H1/0036;;H01H59/0009;;G01P2015/084;;G01P2015/0842;;B81C3/002;;B81B2201/0242;;B81C2201/019;;B81C2203/058;;B81B2201/025;;G01P15/0802;;H01H1/0036;;G01C19/5656;;H01H59/0009;;G01P15/0894;;G01P15/18;;B81C2203/036;;G01P2015/084;;G01P2015/0842,B81B3/00;;B81C1/00;;B81C3/00;;G01C19/5656;;G01P15/08;;G01P15/18;;H01H1/00;;H01H59/00;;H01L41/08,257/417;;257/587;;250/234;;216/11,11,6,068-279-650-120-61X;;030-642-585-316-273;;011-792-918-490-013;;067-585-851-384-039;;048-576-548-493-140;;069-012-973-020-326,10.1109/84.788627;;10.1109/sensor.1997.635453;;10.1063/1.104432;;10.1109/84.825770;;10.1109/55.496466;;10.1116/1.590931,"Gretillat et al., ""Improved Design of a Silicon Micromachined Gyroscope with Piezoresistive Detection and Electromagnetic Excitation"", IEEE Journal of Microelectromechanical Systems, vol. 8, No. 3, Sep. 1999, pp 243-250.*;;Grade, John, et al., ""Wafer-Scale Processing, Assembly, and Testing and Tunneling Infrared Detectors"", Transducers '97, 1997 International Conference on Solid State Sensors and Actuators, Chicago, Jun. 16-19, pp. 1241-1244.;;Kenny, T.W., et al., ""Micromachined Silicon Tunnel Sensor for Motion Detection"", Appl. Phys. Lett., vol. 58, No. 1, Jan. 7, 1991, pp. 100-102.;;Yeh, et al., ""A Low Voltage Bulk-Silicon Tunneling-Based Microaccelerometer"", IEEE, 1995 pp. 23.1.1-23.1.4.;;Cheng, Y.T. and Khalil Najafi, ""Localized Silicon Fusion and Eutectic Bonding for MEMS Fabrication and Packaging,"" Journal of Microelectromechanical Systems, vol. 9, No. 1, pp. 3-8 (Mar. 2000).;;Abstract of JP 04-369418, Patent Abstracts of Japan, vol. 017, No. 250, May 18, 1993.;;Abstract of JP 08-203417, Patent Abstracts of Japan, vol. 1996, No. 12, Dec. 26, 1996.;;Kubena, R.L., et al., ""A New Miniaturized Surface Micromachined Tunneling Accelerometer,"" IEEE Electron Device Letters, vol. 17, No. 6, pp. 306-308 (Jun. 1996).;;Kubena, R.L., et al., ""New miniaturized tunneling-based gyro for inetrial measurement applications,"" 43rd Journal of Vacuum Science & Technology B (Microelectronics and Nanometer Structures, vol. 17, No. 6, pp. 2948-2952 (Nov./Dec. 1999).;;Liu, C-H, et al., ""Characterization of a High-Sensitivity Micromachined Tunneling Accelerometer with Micro-g Resolution,"" Journal of Microelectromechanical Systems, vol. 7, No. 2, pp. 235-243 (Jun. 1998).;;Motamedi, M.E., et al., ""Tunneling Tip Engine for Microsensors Applications,"" Materials and Device Characterization in Micromachining II-Proceedings of the SPIE, Santa Clara, California, vol. 3875, pp. 192-199 (Sep. 1999).",EXPIRED
859,US,A1,US 2003/0186894 A1,119-746-814-595-469,2003-10-02,2003,US 31334302 A,2002-12-06,US 31334302 A;;US 54875900 A;;US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P,1999-10-29,Dry powder compositions having improved dispersivity,"
   The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject. 
",KUO MEI-CHANG;;LECHUGA-BALLESTEROS DAVID,KUO MEI-CHANG;;LECHUGA-BALLESTEROS DAVID,NEKTAR THERAPEUTICS (2003-01-13),https://lens.org/119-746-814-595-469,Patent Application,yes,2,36,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K9/00;;A61K9/08;;A61K47/42;;A61K9/12;;A61K9/14;;A61K9/72;;A61K31/58;;A61K38/00;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,514/18;;514/19;;424/46,0,0,,,,EXPIRED
860,TW,A,TW 200915317 A,112-651-167-035-492,2009-04-01,2009,TW 97129621 A,2008-08-05,US 83491707 A,2007-08-07,Method and system for providing a sense amplifier and drive circuit for spin transfer torque magnetic random access memory,"A method and system for providing a magnetic memory are described. The method and system include a plurality of magnetic storage cells, a plurality of bit lines, at least one reference line, and at least one sense amplifier. Each magnetic storage cell includes magnetic element(s) and selection device(s). The magnetic element(s) are programmable using write current(s) driven through the magnetic element. The bit and source lines correspond to the magnetic storage cells. The sense amplifier(s) are coupled with the bit lines and reference line(s), and include logic and a plurality of stages. The stages include first and second stages. The first stage converts at least current signal to at least one differential voltage signal. The second stage amplifies the at least one differential voltage signal. The logic selectively disablies at least one of the first and second stages in the absence of a read operation and enabling the first and second stages during the read operation.",GRANDIS INC;;RENESAS TECH CORP,LUO XIAO;;YU DAVID CHANG-CHENG,,https://lens.org/112-651-167-035-492,Patent of Addition,no,0,1,5,5,0,G11C11/1659;;G11C11/1673;;G11C11/1673;;G11C11/1659,G11C11/16;;G11C7/06,,0,0,,,,ACTIVE
861,AU,A,AU 2001/057219 A,135-498-516-002-75X,2001-11-07,2001,AU 2001/057219 A,2001-04-24,US 55976600 A;;US 0113207 W,2000-04-27,Furan no-bake foundry binders and their use,,ASHLAND INC,CHANG KEN K;;HUTCHINGS DAVID A,,https://lens.org/135-498-516-002-75X,Patent Application,no,0,0,12,12,0,B22C1/224;;B22C1/2246;;B22C1/2246;;C08K3/30;;C08K5/107;;C08K5/13;;C08K5/1535;;C08L71/00,B22C1/22,,0,0,,,,PENDING
862,DE,T2,DE 69115012 T2,128-214-406-167-317,1996-07-25,1996,DE 69115012 T,1991-01-17,EP 91100492 A;;US 37768289 A,1989-07-10,Verfahren zur Herstellung einer metallisierten plexifilamentaren Polyethylenfolie.,,DU PONT,JONES DAVID CHARLES;;LEE CHI-CHANG,,https://lens.org/128-214-406-167-317,Granted Patent,no,0,0,10,14,0,B29C59/04;;B29C59/04;;C23C14/028;;C23C14/028;;C23C14/20;;C23C14/20;;D04H1/42;;D04H1/42;;D04H3/16;;D04H3/16;;D06M10/06;;D06M10/06;;D06M11/83;;D06M11/83;;D06M11/84;;D06M11/84,B29C59/04;;C23C14/02;;C23C14/20;;D04H1/42;;D04H3/16,,0,0,,,,EXPIRED
863,US,A1,US 2009/0319666 A1,134-404-884-191-500,2009-12-24,2009,US 14159408 A,2008-06-18,US 14159408 A,2008-06-18,Method and Apparatus for Session Initiated Protocol (SIP) Based Information Uploading from an Optical Network Terminal (ONT),"Collecting diagnostic information from a remote device in today's networks is limited to system related information. However, of more interest to vendors of commercial products or services is information related to, for example, how their products, services or advertisement are perceived by end users. Accordingly, a method and corresponding apparatus according to an embodiment of the present invention are provided that extends the Session Initiated Protocol (SIP) NOTIFY mechanism. Originally defined for server to client or downstream notification of a state of a resource or of an event, the present invention extends this functionality to include uploading information other than a state of a resource or of an event from the client to the server or upstream. As such, information, such as usage behavior of a user, may now be collected to understand end user perception of products, services or advertisements.",LIANG SHIH-CHANG;;LIU DAVID H,LIANG SHIH-CHANG;;LIU DAVID H,TELLABS VIENNA INC (2008-06-14),https://lens.org/134-404-884-191-500,Patent Application,yes,3,9,1,1,0,H04L67/14;;H04L67/142;;H04L65/1104;;H04L67/535;;H04L67/14;;H04L67/142;;H04L65/1104;;H04L67/535,G06F15/16,709/227,0,0,,,,DISCONTINUED
864,WO,A1,WO 2012/061548 A1,125-251-811-974-992,2012-05-10,2012,US 2011/0059056 W,2011-11-03,US 201161487956 P;;US 201113036820 A;;US 201113021302 A;;US 96893610 A;;US 94953610 A;;US 41459210 P;;US 40974010 P,2010-11-03,DOCK-AND-LOCK (DNL) CONSTRUCTS FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) THERAPY,"The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.",IBC PHARMACEUTICALS INC;;CHANG CHIEN-HSING;;GOLDENBERG DAVID M,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/125-251-811-974-992,Patent Application,yes,3,2,8,1035,16,C07K16/00;;C07K2317/30;;C07K2317/90;;C07K2319/01;;C07K2319/73;;A61K47/6803;;A61K47/6807;;A61K47/6809;;A61K47/6811;;A61K47/6841;;A61P35/00;;A61P37/00,A61K39/00;;A61K39/42,,2,1,004-073-353-184-101,10.1006/jmbi.2000.3662;;10764601,"HERBERG ET AL.: ""Analysis of A-Kinase Anchoring Protein (AKAP) Interaction with Protein Kinase A (PKA) Regulatory Subunits: PKA Isoform Specificity in AKAP Binding."", J. MOL. BIOL., vol. 298, no. 2, 28 April 2000 (2000-04-28), pages 329 - 339, XP004465904;;See also references of EP 2635300A4",PENDING
865,US,S,US D0672023 S,145-650-323-067-529,2012-12-04,2012,US 201129385535 F,2011-02-15,GB 0016849 F,2010-09-01,Fan heater,,WALLACE JOHN DAVID;;CHOONG CHANG HIN;;DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,DYSON TECHNOLOGY LIMITED (2012-04-27);;DYSON LIMITED (2011-04-08),https://lens.org/145-650-323-067-529,Design Right,no,0,47,1,1,0,,,2304;;D23/370;;D23/332;;D23/378,0,0,,,,ACTIVE
866,JP,A,JP 2012037229 A,136-303-663-799-598,2012-02-23,2012,JP 2011173189 A,2011-08-08,GB 201013265 A,2010-08-06,FAN ASSEMBLY,"PROBLEM TO BE SOLVED: To provide a fan assembly, in particular, a fan heater for creating the flow of warm air in a room, an office and domestic circumferences.SOLUTION: This fan assembly includes a motor-driven impeller for creating the air flow, at least one heater for heating a first portion of the air flow, a means for diverting a second portion of the air flow to the direction separating from at least one heater, and a casing including at least one first air outlet for releasing the first portion of the air flow and at least one second air outlet for releasing the second portion of the air flow. At least one second air outlet is disposed to guide at least a part of the second portion of the air flow onto an outer face for cooling the outer face of the casing.",DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,,https://lens.org/136-303-663-799-598,Patent Application,no,16,6,22,22,0,F24F7/007;;F24F13/06;;F24F2013/205;;F24F2221/12;;F24F2221/28;;F24F2221/34;;F04F5/16;;F24H3/0411;;F24H3/0417;;F24H9/0063;;F24H9/1872;;F24H2250/04;;F04D25/08;;Y10T137/6525;;Y10T137/6552;;F04D25/08;;F24H3/0417;;F04D25/08;;F24H3/12;;F04D29/44;;Y10T137/6525;;Y10T137/6552;;F24F7/007;;F04D15/0218;;F24F2221/28;;F24F2221/12;;F24F2013/205;;F24F13/06;;F24F2221/34;;F24H9/0063;;F04F5/16;;F24H3/0417;;F24H2250/04;;F24H3/0411;;F24H9/1872;;F04D25/08,F04D29/54;;F24H3/04;;F04F5/16;;F24H3/00,,0,0,,,,INACTIVE
867,DE,D1,DE 69219141 D1,137-114-891-983-489,1997-05-22,1997,DE 69219141 T,1992-09-14,US 76334091 A;;US 9207773 W,1991-09-20,ÜBERTRAGUNGSEMULATOR FÜR LOKALES NETZ,A method and apparatus for using switched telecommunications services to emulate a local area network (LAN) medium. The method and apparatus convert a public switched network or an equivalent private network into a LAN cabling method for connecting distant devices using the same communications software as used in traditionally wired LANs.,MICROCOM SYSTEMS INC,CHANG EUGENE;;RICHARDSON DAVID;;BAKER BENNETT,,https://lens.org/137-114-891-983-489,Granted Patent,no,0,0,16,16,0,H04L12/18;;H04L12/1886;;H04L12/28;;Y10S370/904;;H04L12/18;;H04L12/1886;;H04L12/28,H04L12/18;;H04L12/28,,0,0,,,,EXPIRED
868,KR,A,KR 20150105404 A,147-105-472-685-442,2015-09-16,2015,KR 20157021210 A,2014-01-10,US 201361752209 P;;US 201361752549 P;;US 201361897082 P;;US 201361907628 P;;US 2014/0011149 W,2013-01-14,METHOD AND SYSTEM FOR GRAPHENE FORMATION,,CALIFORNIA INST OF TECHN,BOYD DAVID A;;YEH NAI CHANG,,https://lens.org/147-105-472-685-442,Patent Application,no,3,0,14,14,0,C23C16/26;;C23C16/4405;;C23C16/511;;H01L29/92;;C01B32/184;;C01B32/186;;Y10T428/24355;;C01B32/186;;C23C16/26;;C23C16/4405;;C23C16/511;;Y10T428/24355;;C01B32/184;;C01B32/186;;C23C16/26;;C23C16/4405;;C23C16/511,C23C16/26;;C23C16/44;;C23C16/511,,1,1,045-395-052-999-998,22316333;;10.1021/nl204088b,"Nano Lett. 2012, Vol. 12, pp. 1417-1423",ACTIVE
869,AU,A1,AU 2006/304418 A1,155-122-020-753-875,2007-04-26,2007,AU 2006/304418 A,2006-10-16,US 72829205 P;;US 2006/0040431 W,2005-10-19,Inhibition of placenta growth factor (PIGF) medicated metastasis and/or angiogenesis,,IMMUNOMEDICS INC;;CT MOLECULAR MED & IMMUNOLOGY,GOLDENBERG DAVID M;;CHANG CHIEN HSING,,https://lens.org/155-122-020-753-875,Patent Application,no,0,0,19,1035,0,A61K38/00;;A61K38/00;;A61K39/395;;A61P1/04;;A61P7/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/02;;A61P17/06;;A61P19/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/02;;A61P37/06;;A61P43/00;;C07K16/22;;C07K16/22;;C07K16/46;;C07K14/515;;C07K14/515,C07K16/46;;A61K39/395,,0,0,,,,INACTIVE
870,US,B2,US 11307963 B2,164-065-098-923-211,2022-04-19,2022,US 202017119279 A,2020-12-11,US 202017119279 A;;US 202016942486 A,2020-07-29,Systems and methods for automatically modifying pipelined enterprise software,"Systems and methods for version control of pipelined enterprise software are disclosed. Exemplary implementations may: store information for executable code of software applications that are installed and executable by users, receive first user input from a first user that represents selection by the first user of a first software pipeline for execution; receive second user input from a second user that represents a second selection by the second user of a second software pipeline for execution, wherein the second software pipeline includes different versions of software applications that are included in the first software pipeline; facilitate execution of the first software pipeline for the first user; and facilitate execution of the second software pipeline for the second user at the same time as the execution of the first software pipeline for the first user.",INSTABASE INC,CHANG SHIH PING;;LLUNCOR DAVID EDGAR,INSTABASE INC (2020-07-28),https://lens.org/164-065-098-923-211,Granted Patent,yes,16,0,5,5,0,G06F9/44536;;G06F11/3612;;G06F8/71;;G06F9/485;;G06F9/44505;;G06F8/4452,G06F11/36;;G06F8/41;;G06F8/71;;G06F9/445;;G06F9/48,,0,0,,,,ACTIVE
871,CA,A1,CA 2046109 A1,164-886-502-625-24X,1992-02-02,1992,CA 2046109 A,1991-07-03,US 56111890 A,1990-08-01,ENHANCED ELECTROSTATIC PAINT DEPOSITION METHOD AND APPARATUS,"An enhanced electrostatic paint deposition apparatus (10) comprising a nozzle (16), a conduit (14) coupled to the nozzle for supplying paint (12) thereto, and a plurality of electrically conductive whiskers (18) positioned within the nozzle for applying an electrostatic charge to droplets of the paint. Each of the whiskers terminates in a jagged end (30) for enabling the droplets to acquire an enhanced electric charge. The whiskers may be provided with lengths which are tailored to provide an array of whiskers with a desired three-dimensional curvature for controlling the focussing field on the paint droplets. Each whisker is secured to a holder (22) which is, in turn, secured to a porous grid (28) whose mesh size is selected to divide the paint into narrow streams of desired size, which exit nozzle 16 in droplet form. The holder is configured by decreasing its center portion (28) in dimension to tune the holder's current limiting capabilities. Pulsed negative high voltage is applied to the whiskers for enabling them to negatively charge the paint. Phased deflector plates 22, 24, 26 are provided to steer the paint stream.",HUGHES AIRCRAFT CO,CHANG DAVID B;;DRUMMOND JAMES E,,https://lens.org/164-886-502-625-24X,Patent Application,no,0,0,7,7,0,B05B5/0533;;B05B5/0536;;B05B5/00;;B05B5/0536;;B05B5/0533,B05B5/053;;B05D1/04,,0,0,,,,EXPIRED
872,EP,B1,EP 0723236 B1,160-710-017-406-460,2000-04-26,2000,EP 96300252 A,1996-01-12,US 37670795 A,1995-01-23,System for communicating messages among agent processes,,IBM,CHANG DAVID Y;;SMITH MARC GREGORY,,https://lens.org/160-710-017-406-460,Granted Patent,yes,0,0,7,7,0,G06F9/546;;G06F9/546,G06F15/16;;G06F9/46,,6,0,,,"IBM SYSTEMS JOURNAL, vol. 28, no. 2, 1 January 1989, pages 241-259, XP000122366 ASHFIELD J C ET AL: ""SYSTEM-INDEPENDENT FILE MANAGEMENT AND DISTRIBUTION SERVICES"";;IBM TECHNICAL DISCLOSURE BULLETIN, vol. 37, no. 4B, April 1994, NEW YORK, US, pages 331-332, XP002014669 ANONYMOUS: ""Sharing Application Control Data in the Parallel Database Manager"";;INFORMATION PROCESSING, SAN FRANCISCO, AUG. 28 - SEPT. 1, 1989, no. CONGRESS 11, 28 August 1989, RITTER G X, pages 827-832, XP000079775 SCHWARTZ M F: ""THE NETWORKED RESOURCE DISCOVERY PROJECT"";;IBM TECHNICAL DISCLOSURE BULLETIN, vol. 28, no. 2, July 1985, NEW YORK, US, pages 762-765, XP002014670 ANONYMOUS: ""Multiple IUCV Users on VM"";;IBM TECHNICAL DISCLOSURE BULLETIN, vol. 31, no. 8, January 1989, NEW YORK, US, pages 191-194, XP002014671 ANONYMOUS: ""Subcontractor Agent Service for a File Access Processor"";;PATENT ABSTRACTS OF JAPAN vol. 015, no. 047 (P-1162), 5 February 1991 & JP-A-02 281336 (NIPPON TELEGR & TELEPH CORP), 19 November 1990,",EXPIRED
873,US,A1,US 2012/0031509 A1,171-835-863-376-641,2012-02-09,2012,US 201113189012 A,2011-07-22,GB 201013265 A,2010-08-06,FAN ASSEMBLY,"A fan assembly includes a motor-driven impeller for creating an air flow, at least one heater for heating a first portion of the air flow, means for diverting a second portion of the air flow away from said at least one heater, and a casing comprising at least one first air outlet for emitting the first portion of the air flow and at least one second air outlet from emitting the second portion of the air flow. To cool an external surface of the casing, at least one second air outlet is arranged to direct at least part of the second portion of the air flow over the external surface.",WALLACE JOHN DAVID;;CHOONG CHANG HIN;;DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,DYSON TECHNOLOGY LIMITED (2011-09-06),https://lens.org/171-835-863-376-641,Patent Application,yes,3,66,22,22,0,F24F7/007;;F24F13/06;;F24F2013/205;;F24F2221/12;;F24F2221/28;;F24F2221/34;;F04F5/16;;F24H3/0411;;F24H3/0417;;F24H9/0063;;F24H9/1872;;F24H2250/04;;F04D25/08;;Y10T137/6525;;Y10T137/6552;;F04D25/08;;F24H3/0417;;F04D25/08;;F24H3/12;;F04D29/44;;Y10T137/6525;;Y10T137/6552;;F24F7/007;;F04D15/0218;;F24F2221/28;;F24F2221/12;;F24F2013/205;;F24F13/06;;F24F2221/34;;F24H9/0063;;F04F5/16;;F24H3/0417;;F24H2250/04;;F24H3/0411;;F24H9/1872;;F04D25/08,F04B53/08;;F04B39/06,137/338;;137/339,0,0,,,,ACTIVE
874,US,A1,US 2015/0238527 A1,167-791-375-930-23X,2015-08-27,2015,US 201314420856 A,2013-08-09,US 201314420856 A;;US 201261682056 P;;US 201361862024 P;;US 201361862026 P;;US 201361862027 P;;US 2013/0054421 W,2012-08-10,VITAMIN SUPPLEMENT COMPOSITIONS FOR INJECTION,"The embodiments relate to improved vitamin supplement compositions formulated for administration to patients, particularly improved vitamin compositions formulated for use in cosmetic or therapeutic applications. The compositions may be used to slow aging process and promote wellness including treating a vitamin deficiency, skin conditions, improving skin appearance, wound healing and scar prevention and hair loss.",AQUAVIT PHARMACEUTICALS INC,CHANG SOBIN;;FAGIEN STEVEN;;SHAFER DAVID,AQUAVIT PHARMACEUTICALS INC (2018-01-29),https://lens.org/167-791-375-930-23X,Patent Application,yes,3,15,5,42,0,A61Q19/08;;A61K31/197;;A61K31/315;;A61K31/375;;A61K31/4415;;A61K31/455;;A61K31/51;;A61K31/525;;A61K31/714;;A61K31/728;;A61K9/0019;;A61Q7/00;;A61K8/673;;A61K8/675;;A61K8/676;;A61Q19/00;;A61K2800/5922;;A61K2800/91;;A61K31/137;;A61K31/715;;A61P17/02;;A61P3/02;;A61Q19/08;;A61K31/197;;A61K31/375;;A61K31/4415;;A61K31/455;;A61K31/51;;A61K31/525;;A61K31/714;;A61K8/673;;A61K8/675;;A61K8/676;;A61K31/315;;A61K31/728;;A61K9/0019;;A61Q19/00;;A61Q7/00;;A61K2800/5922;;A61K2800/91;;A61K8/27;;A61K8/41;;A61K31/137;;A61K31/715;;A61K33/30;;A61K35/16;;A61K2800/10;;A61M5/30;;A61M37/0015,A61K35/16;;A61K8/27;;A61K8/41;;A61K8/67;;A61K31/137;;A61K31/197;;A61K31/375;;A61K31/4415;;A61K31/455;;A61K31/51;;A61K31/525;;A61K31/714;;A61K31/715;;A61K33/30;;A61M5/30;;A61M37/00;;A61Q19/08,,0,0,,,,ACTIVE
875,CN,A,CN 116322901 A,172-637-400-404-289,2023-06-23,2023,CN 202180067995 A,2021-06-07,US 202016984486 A;;US 2021/0036128 W,2020-08-04,Systems and methods for preventing or treating alzheimer's disease and other neurodegenerative diseases,A protective treatment system for a biological tissue or fluid includes applying a pulsed energy source to a target tissue or a target fluid having or at risk of developing a chronic progressive disease to treat or prophylactically treat the target tissue or the target fluid. A pulsed energy source with selected energy parameters may be applied to the brain of an individual having or at risk of developing Alzheimer's disease or other neurodegenerative disease to prevent or treat the neurodegenerative disease.,OJAI RETINAL TECH LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/172-637-400-404-289,Patent Application,no,0,0,8,287,0,A61N1/40;;A61N5/02;;A61N5/025;;A61N1/403,A61N1/40,,0,0,,,,PENDING
876,US,B2,US 7904049 B2,174-612-059-454-70X,2011-03-08,2011,US 69889010 A,2010-02-02,US 69889010 A;;US 14147805 A,2005-05-31,Wireless terminal baseband processor high speed turbo decoding module,"A baseband processing module for use within a Radio Frequency (RF) transceiver includes a downlink/uplink interface, TX processing components, a processor, memory, RX processing components, and a turbo decoding module. The RX processing components receive a baseband RX signal from the RF front end, produce a set of IR samples from the baseband RX signal, and transfer the set of IR samples to the memory. The turbo decoding module receives a set of IR samples from the memory, forms a turbo code word from the set of IR samples, turbo decodes the turbo code word to produce inbound data, and outputs the inbound data to the downlink/uplink interface. The turbo decoding module performs metric normalization based upon a chosen metric, performs de-rate matching on the set of IR samples, performs error detection operations, and extracts information from a MAC packet that it produces.",BROADCOM CORP,HAHM MARK DAVID;;CHANG LI FUNG,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09),https://lens.org/174-612-059-454-70X,Granted Patent,yes,6,2,11,11,0,H03M13/09;;H03M13/1102;;H03M13/23;;H03M13/2975;;H03M13/3922;;H03M13/6306;;H03M13/6362;;H03M13/658;;H04L1/0051;;H04L1/0054;;H04L1/0066;;H04L1/1819;;H04L1/1845;;H03M13/658;;H03M13/6362;;H03M13/2975;;H04L1/0066;;H03M13/23;;H03M13/6306;;H04L1/1819;;H03M13/09;;H03M13/3922;;H04L1/0054;;H04L1/0051;;H04L1/1845;;H03M13/1102,H04B1/26,455/324;;455/334;;370/442;;375/265;;714/792,0,0,,,,INACTIVE
877,WO,A1,WO 2001/018019 A1,164-866-716-830-398,2001-03-15,2001,US 0024689 W,2000-09-08,US 15302499 P,1999-09-08,EPITHELIAL PROTEIN LOST IN NEOPLASM (EPLIN),"Polynucleotide and polypeptide sequences encoding a novel tumor suppressor protein, EPLIN, are provided. Also included is a method for detecting a cell proliferative disorder associated with EPLIN. EPLIN is a marker that can be used diagnostically, prognostically and therapeutically over the course of cell proliferative disorders associated with EPLIN.",UNIV CALIFORNIA;;CHANG DAVID D;;MAUL RAYMOND S,CHANG DAVID D;;MAUL RAYMOND S,,https://lens.org/164-866-716-830-398,Patent Application,yes,1,2,2,4,0,A61K38/00;;C07K14/4703,A61K38/00;;C07K14/47,,2,2,079-248-564-289-395;;008-885-957-685-440,10618726;;10.1038/sj.onc.1203206;;10806352;;10.1016/s0378-1119(00)00144-x,"MAUL ET AL.: ""EPLIN, epithelial protein lost in neoplasm"", ONCOGENE, vol. 18, October 1999 (1999-10-01), pages 7838 - 7841, XP002933578;;CHEN ET AL.: ""Characterization of the human EPLIN (epithelial protein lost in neoplasm) gene reveals distinct promoters for the two EPLIN isoforms"", GENE, vol. 248, 2 May 2000 (2000-05-02), pages 69 - 76, XP002933577",PENDING
878,US,B2,US 9457072 B2,178-613-207-787-89X,2016-10-04,2016,US 201113010993 A,2011-01-21,US 201113010993 A;;US 54447609 A;;US 39660509 A;;US 63372906 A;;US 38935806 A;;US 39158406 A;;US 47802106 A;;US 78233206 P;;US 72829205 P;;US 75119605 P;;US 86453006 P;;US 9048708 P,2005-10-19,Dock-and-lock (DNL) vaccines for cancer therapy,"The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 neg CD20 + MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.",CHANG CHIEN-HSING;;GOLDENBERG DAVID M;;IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2009-10-30),https://lens.org/178-613-207-787-89X,Granted Patent,yes,87,0,17,1035,35,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;A61K39/001129;;A61K39/001112;;A61K39/001113;;A61K39/001176;;A61K39/001194;;A61K39/00117;;A61K39/001191;;A61K39/00115;;A61K39/001163;;A61K39/001124;;A61K39/001166;;A61K39/001182;;A61K39/001114;;A61K39/001138;;A61K39/001189;;A61K39/001192;;A61K39/001104;;A61K39/001103;;A61K39/001184;;A61K39/001188;;A61K39/001151;;A61K39/001117;;A61K39/001181;;A61K39/001109;;A61K39/001149;;A61K39/00114;;A61K39/001102;;A61K39/00113;;A61K39/001126;;A61K39/001135;;A61K39/001153;;A61K39/001162;;A61K39/001186;;A61K39/001195;;A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/001189;;A61K39/001112;;A61K39/001153;;A61K39/001163;;A61K39/001135;;A61K39/00117;;A61K39/001113;;A61K39/001124;;A61K39/001192;;A61K39/001129;;A61K39/001117;;A61K39/001103;;A61K39/001195;;A61K39/001138;;A61K39/001149;;A61K39/001182;;A61K39/001114;;A61K39/001102;;A61K39/001104;;A61K39/001126;;A61K39/00113;;A61K39/00114;;A61K39/00115;;A61K39/001166;;A61K39/001181;;A61K39/001186;;A61K39/001191;;A61K39/001194;;A61K39/001162;;A61K39/001176;;A61K39/001188;;A61K39/001109;;A61K39/001184;;A61K39/001151;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011,A61K39/00;;A61K47/48;;B82Y5/00;;C07K14/47;;C07K16/28;;C07K16/30;;C07K16/46,,108,105,100-801-934-296-913;;037-719-830-241-939;;043-472-027-972-076;;050-929-392-993-933;;033-802-631-358-941;;042-979-543-299-89X;;139-399-324-818-879;;086-617-534-349-291;;023-678-010-672-059;;000-499-563-417-797;;023-833-986-552-400;;019-253-709-202-167;;103-932-348-507-545;;133-287-355-214-424;;091-341-936-846-342;;094-037-074-599-511;;101-663-979-767-604;;000-317-353-994-190;;052-947-986-013-690;;034-028-239-192-920;;040-142-822-097-134;;138-957-732-701-829;;027-215-950-157-668;;139-123-355-549-723;;038-215-831-671-137;;032-409-676-506-509;;044-988-808-395-48X;;019-736-899-818-187;;053-349-809-000-342;;008-956-301-309-595;;026-690-156-572-350;;066-342-559-427-246;;023-481-904-534-57X;;018-667-811-882-764;;007-072-874-769-097;;069-477-478-430-272;;006-680-826-675-902;;051-124-225-056-342;;039-872-948-648-99X;;076-361-037-184-124;;049-603-242-735-802;;042-979-543-299-89X;;040-702-319-644-869;;151-391-931-864-381;;002-771-789-858-985;;132-695-844-930-786;;136-607-746-555-049;;033-802-631-358-941;;028-319-860-412-154;;065-166-447-091-438;;013-308-568-898-451;;027-753-296-155-34X;;043-594-248-563-810;;003-476-033-138-157;;136-729-689-116-079;;125-571-073-159-031;;016-515-175-785-422;;072-741-754-938-223;;014-703-386-292-316;;027-364-048-721-489;;036-248-996-518-788;;004-806-786-426-458;;091-995-224-471-960;;046-723-641-666-637;;051-620-799-695-736;;000-687-583-450-12X;;030-424-581-071-330;;025-955-082-953-672;;043-565-065-226-050;;064-253-076-017-931;;073-213-551-327-892;;029-646-755-871-310;;015-399-642-762-43X;;142-686-487-823-912;;007-954-637-794-12X;;080-571-625-616-771;;013-580-733-777-26X;;046-220-521-080-741;;036-011-287-610-789;;046-650-803-614-561;;057-819-453-551-117;;020-829-015-080-665;;061-974-273-716-169;;073-910-564-236-619;;039-423-064-544-876;;009-038-716-796-026;;028-385-018-876-542;;078-950-298-931-296;;082-317-213-185-417;;061-716-650-834-485;;154-648-591-453-198;;138-142-682-110-803;;066-146-798-965-262;;032-799-656-305-036;;088-770-954-200-50X;;002-331-092-499-856;;052-302-906-314-226;;125-439-449-787-91X;;002-968-698-489-191;;003-133-671-061-524;;001-773-325-098-677;;001-438-265-785-943;;021-399-654-204-715;;013-495-040-538-497;;014-817-433-156-057,18234994;;10.1167/iovs.07-1175;;10.1354/vp.42-4-468;;16006606;;10.1182/blood-2005-01-0318;;15878980;;10.3410/f.1025985.321890;;16979786;;10.1016/j.addr.2006.05.004;;10665474;;10.1023/a:1006314501634;;2461992;;22387378;;10.1016/j.abb.2012.02.011;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;pmc1867205;;11943735;;10.1016/s0002-9440(10)62577-1;;10673721;;10.1038/sj.gt.3301059;;10.1093/emboj/20.7.1651;;pmc145475;;11285229;;10.2210/pdb1r2a/pdb;;10.1038/6663;;10074940;;0010074940;;10.1007/978-1-4684-6831-1_14;;12388634;;10.1124/jpet.102.037002;;2540040;;10.1016/0014-5793(89)80253-4;;9596485;;10.1023/a:1005934621940;;10.1002/jlb.64.3.358;;9738663;;6577942;;10.1007/bf00199167;;11356929;;10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-#;;10092109;;10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-;;pmc408104;;10.1172/jci5349;;10021462;;2411798;;10.1038/78966;;10966642;;10.1021/bc049713n;;15656592;;18922911;;10.1158/0008-5472.can-08-2033;;10.1073/pnas.0600982103;;16636283;;pmc1447525;;10.1021/bi972701n;;9485322;;10.3892/ijo.14.6.1143;;10339671;;18799723;;10.1182/blood-2008-04-153189;;10.1084/jem.191.10.1777;;pmc2193160;;10811870;;2147685;;10.1016/s0021-9258(18)45777-8;;10.1016/0163-7258(91)90075-w;;1653962;;pmc95154;;11274097;;10.1128/jb.183.8.2405-2410.2001;;10.1158/0008-5472.can-08-0037;;18593929;;pmc2585743;;18227543;;10.1148/radiol.2462070229;;2441862;;15102696;;10.1158/1078-0432.ccr-03-0493;;pmc1895595;;16778139;;10.1182/blood-2006-04-017921;;16948636;;pmc1698590;;10.1042/bj20060962;;12872134;;10.1038/nature01850;;10.1016/s0021-9258(18)81805-1;;2656679;;2461992;;10.1016/s0021-9258(19)34204-8;;4298072;;6172550;;10.1099/0022-1317-57-1-233;;10.4049/jimmunol.165.8.4505;;11035090;;10.1021/bi990993h;;10512619;;15573134;;10.1038/nrm1527;;10665474;;10.1023/a:1006314501634;;10.1186/1471-2407-13-170;;pmc3623828;;23548153;;19736932;;10.1021/bc9001773;;22844444;;pmc3402531;;10.1371/journal.pone.0041235;;pmc3432068;;22952934;;10.1371/journal.pone.0044235;;10.1016/j.uct.2007.04.003;;pmc2034280;;18311322;;10.1517/14712598.2012.685153;;22679911;;10.1186/1476-4598-13-53;;pmc4015355;;24606732;;19710501;;10.1182/blood-2009-06-228890;;pmc2773491;;10.1182/blood-2008-10-187138;;pmc2699236;;19372261;;22168393;;10.1021/bc2004999;;22739259;;10.1016/j.tips.2012.06.001;;23116517;;10.1021/bc300488f;;24492297;;10.4161/mabs.27385;;pmc3984327;;pmc2883519;;10.1089/cbr.2009.0690;;20187791;;10.1073/pnas.0330734100;;12672969;;pmc153575;;16848397;;10.1021/bc060037u;;10.1016/j.febslet.2005.03.089;;15943971;;9857038;;10.1074/jbc.273.52.35048;;16704199;;10.1021/bc050322y;;10.1016/s1359-6101(01)00022-3;;11900988;;15375003;;10.1158/0008-5472.can-04-2048;;10.1016/0167-5699(96)10027-x;;8783497;;10358757;;10.1146/annurev.immunol.17.1.189;;6692364;;pmc2253242;;10.1110/ps.051687305;;16260760;;1860836;;10.1016/s0021-9258(18)98665-5;;11278869;;10.1074/jbc.m011252200;;pmc2118284;;16549598;;10.1084/jem.20060045;;10.1158/1078-0432.ccr-07-1217;;17875793;;pmc37461;;11447282;;10.1073/pnas.151260298;;10.1016/s0962-8924(99)01558-5;;10354567;;10.1016/s0021-9258(19)44263-4;;4348550;;10.1021/bc049781+;;15898716;;12657428;;10.1016/s1471-4914(03)00022-4;;pmc1373678;;10.1021/bc050172r;;16173810;;7963533;;17532550;;10.1016/j.biochi.2007.04.006;;10.4049/jimmunol.167.12.7150;;11739538;;10.1016/0022-1759(89)90093-8;;2514231;;10.1016/j.molimm.2007.06.151;;17768100;;18559529;;10.1158/0008-5472.can-08-0232;;10.1016/j.molcel.2006.09.006;;17081989;;10.2210/pdb2izy/pdb;;10.2967/jnumed.107.046185;;18077530;;10.1182/blood-2009-02-204289;;1366535;;10.1038/nbt0490-343;;10.1074/jbc.m412134200;;15596441;;9531615;;10.1182/blood.v91.8.3017.3017_3017_3027;;6159812;;10.7326/0003-4819-93-3-399;;8108387;;10.1073/pnas.91.4.1198;;pmc43124;;10.1038/nrd1033;;12612647;;10.1074/jbc.271.46.29016;;8910553;;11959956;;pmc122719;;10.1073/pnas.072685299;;10.4049/jimmunol.179.10.6881;;17982079;;pmc1462715;;10.1042/bj20051970;;16483255;;10.1080/10428190701704647;;18203019;;17081990;;pmc1855097;;10.1016/j.molcel.2006.09.015;;10.1023/a:1016042220817;;8842035,"Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522-527, Feb. 2008.;;Jubala et al., Vet Pathol 42: 468-476, 2005.;;Tacken et al., Blood 106(4): 1278-1284, Aug. 15, 2005.;;Tabi et al., Advanced Drug Delivery Review 58: 902-915, 2006.;;Zhu et al., Investigational New Drugs 17: 195-212, 1999.;;Tedder et al., J Immunol 141(12): 4388-4391, Dec. 1988.;;Golay et al., Archives of Biochemistry and Biophysics 526: 146-153, 2012.;;Stancovski et al., PNAS 88: 8691-8695, 1991.;;Martin et al., Leukemia & Lymphoma, 2015; Early Online: 1-6.;;Matarrese et al., ""Type I Interferon Gene Transfer Sensitizes Melanoma Cells to Apoptosis via a Target Activity on Mitochondrial Function"" Am. J. Pathol. 2002, 160(4):1507-1520.;;Mecchia et al., ""Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha"" Gene Ther. (2000) 7, 167-179.;;Newlon et al., ""A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes"", EMBO J. 2001; 20:1651-1662.;;Newlon et al., ""The molecular basis for protein kinase A anchoring revealed by solution NMR"", Nature Struct. Biol. 1999; 3:222-227.;;Ngo et al., ""Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox"", The Protein Folding Problem and Tertiary Structure Prediction, Ch. 14, pp. 492-495, (Mertz & Le Grand, Eds.), Birkhauser Boston, 1994.;;Osborn et al., ""Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-alpha Fusion Protein in Cynomolgus Monkeys"" J. Pharmacol. Exp. Ther. 303(2):540-548 (2002).;;Oyen et al., ""Human testis cDNA for the regulatory subunit Rllalpha of cAMP-dependent protein kinase encodes an alternate amino-terminal region"", FEBS Letters 246:57-64, 1989.;;Ozzello et al., ""Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3vl) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts"" Breast Cancer Res. Treat. 48:135-147 (1998).;;Paquette et al., ""Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells"" J. Leukoc. Biol. 64:358-367; 1998.;;Pelham et al., ""Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36"" Cancer Immunol. Immuother. 1983;15(3):210-216.;;Pepinsky et al., ""Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-beta-1a with Preserved in Vitro Bioactivity"" Pharmacol. Exp. Ther. 2001; 297(3):1059-1066.;;Pilling et al., ""Interferon-beta mediates stromal cell rescue of T cells from apoptosis"" Eur. J. Immunol. 29:1041-1050 (1999).;;Rabjohn et al., ""Molecular Cloning and Epitope Analysis of the Peanut Allergen Ara h 3"" J. Clinical Investigation 103 (4):535-542 (1999).;;Raefsky et al., ""Studies of Interferon as a regulator of hematopoietic cells proliferation"" J. Immunol. 135(4):2507-2512 (1985).;;Rose et al., ""Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1alpha"", Nature Struct. Biol. 2000; 7:744-748.;;Rosendahl et al., ""A Long-Acting, Highly Potent Interferon alpha-2 Conjugate Created Using Site-Specific PEGylation"" Bioconjugate Chem. 2005;16:200-207.;;Rossi et al. ""Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics"", Cancer Res. 68:8384-92, 2008.;;Rossi et al., ""Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting"" Proc. Natl. Acad. Sci. Epub Apr. 24, 2006, vol. 103, No. 18, pp. 6841-6846.;;Rustandi et al., ""The Ca2+-Dependent Interaction of S100B(betabeta) with a Peptide Derived from p53"", Biochemistry 1998; 37: 1951-1960.;;Sabaawy et al., ""Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer"" Int. J. Oncol. Jun. 1999; 14(6):1143-51.;;Salles et al., ""Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study"" Blood 2008; 112:4824-4831.;;Santini et al., ""Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vivo and in Hu-PBL-SCID Mice"" J. Exp. Med. 191(10):1777-1788 (2000).;;Scott et al., ""Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase"", J. Biol. Chem. 265:21561-66 (1990).;;Scott et al., ""Cyclic nucleotide-dependent protein kinases"" Pharmacol. Ther. 1991;50(1):123-45.;;Seffernick et al., ""Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different"" J. Bacteriol. 183(8):2405-2410 (2001).;;Sharkey et al., ""Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody"", Cancer Res. 68:5282-90, 2008.;;Sharkey et al., ""Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model"", Radiology 246:497-507, 2008.;;Sidky et al., ""Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses"" Cancer Res. 47:5155-5161, Oct. 1, 1987.;;Stein et al., ""Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma"" Clin. Cancer Res. vol. 10, 2868-2878, Apr. 15, 2004.;;Stein et al., ""Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab"" Blood 2006;108:2736-2744.;;Stokka et al., ""Characterization of A-kinase-anchoring disruption using a solution-based assay"" Biochem. J. (2006) 400, 493-499.;;Stryer et al., ""Levels of Structure in Protein Architecture"", Biochemistry, 3rd Ed., pp. 31-33, W.H. Freeman & Co., New York, 1988.;;Takaoka et al., ""Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence"" Nature Jul. 31, 2003;424(6948):516-23.;;Taylor, S., ""cAMP-dependent Protein Kinase"" J. Biol. Chem. 1989;264(15):8443-8446.;;Tedder et al., ""Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19"", J Immunol. Dec. 15, 1988;141(12):4388-94.;;Walsh et al., ""An Adenosine 3', 5'-Monophosphate-dependant Protein Kinase from Rabbit Skeletal Muscle"" J. Biol. Chem. 243(13):3763-3774 (1968).;;Weck et al., ""Comparison of the Antiviral Activities of Various Cloned Human Interferon-alpha Subtypes in Mammalian Cell Cultures"" J. Gen. Virol. (1981), 57, 233-237.;;Winkler et al., ""Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody"", J. Immunol. 165:4505-14, 2000.;;Witkowski et al., ""Conversion of a beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine"" Biochemistry 38(36):11643-50 (1999).;;Wong et al., ""AKAP Signalling Complexes: Focal Points in Space and Time"", Nat. Rev. Mol. Cell Biol. 12:959-70 (2004).;;Zhu et al., ""Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor"", Invest. New Drugs 17:195-212, 1999.;;Cardillo et al., ""Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro"", BMC Cancer. Apr. 1, 2013;13:170.;;Chang et al., ""A new method to produce monoPEGylated dimeric cytokines shown with human interferon-alpha2b"", Bioconjug Chem. Oct. 21, 2009;20(10):1899-907.;;Chang et al., ""A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro"", PLoS One. 2012;7(7):e41235.;;Chang et al., ""Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines"", PLoS One. 2012;7(8):e44235.;;Goldenberg et al., ""Cancer Imaging and Therapy with Bispecific Antibody Pretargeting"", Update Cancer Ther. Mar. 2007;2(1):19-31.;;Govindan et al., ""Designing immunoconjugates for cancer therapy"", Expert Opin Biol Ther. Jul. 2012;12(7):873-90.;;Liu et al., ""Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer"", Mol Cancer. Mar. 10, 2014;13:53.;;Rossi et al., ""CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas"", Blood. Oct. 29, 2009;114(18):3864-71.;;Rossi et al., ""Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma"", Blood. Jun. 11, 2009;113(24):6161-71.;;Rossi et al., ""The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures"", Bioconjug Chem. Mar. 21, 2012;23(3):309-23.;;Rossi et al., ""Complex and defined biostructures with the dock-and-lock method"", Trends Pharmacol Sci. Sep. 2012;33(9):474-81.;;Rossi et al., ""Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties"", Bioconjug Chem. Jan. 16, 2013;24(1):63-71.;;Rossi et al., ""A new class of bispecific antibodies to redirect T cells for cancer immunotherapy"", MAbs. Mar.-Apr. 2014;6(2):381-91.;;Sharkey et al., ""Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies"", Cancer Biother Radiopharm. Feb. 2010;25(1):1-12.;;Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Comp. 1991, p. 43.;;Alto et al., ""Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring"" Proc. Natl. Acad. Sci USA Apr. 15, 2003; 100(8):4445-50.;;Backer et al., ""Self-Assembled ""Dock and Lock"" System for Linking Payloads to Targeting Proteins"" Bioconjugate Chem., 2006, 17(4):912-919.;;Baillie et al., ""Compartmentalisation of phospodiesterases and protein kinase A: opposites attract"", FEBS Letters 2005; 579:3264-3270.;;Banky et al., ""Dimerization/Docking Domain of the Type lalpha Regulatory Subunit of cAMP-dependent Protein Kinase"", J. Biol. Chem. 273:35048-55, 1998.;;Basu et al., ""Structure-Function Engineering of Interferon-beta-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation"", Bioconjugate Chem. 2006; 17:618-630.;;Belardelli et al., ""Interferon-alpha in tumor immunity and immunotherapy"" Cytokine Growth Factor Rev. 13(2):119-134 (2002).;;Belardelli et al., ""International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?"" Cancer Res. 64:6827-6830 (2004).;;Belardelli et al., ""The neglected role of type I interferon in the T-cell response: implications for its clinical use"" Immunol. Today 17(8):369-72 (1996).;;Biron et al., ""Natural killer cells in antiviral defense: function and regulation by innate cytokines"" Annu. Rev. Immunol. 17:189-220 (1999).;;Brunda et al., ""Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons"" Cancer Res. 44:597-601 (1984).;;Burns-Hamuro et al., ""Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange"" Protein Science (2005), 14:2982-2992.;;Carr et al., ""Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif"", J. Biol. Chem. 266:14188-92 (1991).;;Carr et al., ""Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA"" J. Biol. Chem. 276(20):17332-17338 (2001).;;Carrero et al., ""Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes"" J. Exp. Med. 203(4):933-940 (2006).;;Chang et al., ""The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity"" Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.;;Chmura et al., ""Antibodies with infinite affinity"" Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).;;Colledge et al., ""AKAPs: from structure to function"", Trends Cell Biol. 6:216-21 (1999).;;Corbin et al., ""Regulation of Adenosine 3',5'-Monophosphate-dependent Protein Kinase"", J. Biol. Chem. 248:1813-21 (1973).;;Dhalluin et al., ""Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-alpha2a and Its Individual Positional Isomers"" Bioconjugate Chem. 2005;16:504-517.;;Dodart et al., ""Immunotherapy for Alzheimer's Disease: will vaccination work?"" Trends Mol. Med. 9(3):85-87 (2003).;;Doherty et al., ""Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor"", Bioconjugate Chem. 2005;16:1291-1298.;;Ferrantini et al., ""IFN-alpha1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity"" J. Immunol. 153:4604-15 (1994).;;Ferrantini et al., ""Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use"" Biochimie 89: 884-893 (2007).;;Fong et al., ""Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy"", J Immunol. Dec. 15, 2001;167(12):7150-6.;;Gillies et al., ""High-level expression of chimeric antibodies using adapted cDNA variable region cassettes"", J. Immunol. Methods 125 (1989) 191-202.;;Glennie et al., ""Mechanisms of killing by anti-CD20 monoclonal antibodies"" Mol. Immunol. 44:3823-3837 (2007).;;Gold et al., ""A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma"", Cancer Res. 68:4819-26, 2008.;;Gold et al., ""Molecular Basis of AKAP Specificity for PKA Regulatory Subunits"" Mol. Cell Nov. 3, 2006;24(3):383-95.;;Goldenberg et al., ""Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting"", J. Nucl. Med. 49:158-63, 2008.;;Goldenberg et al., ""Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody"" Blood 113:1062-70 (2009).;;Goodson et al., ""Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site"", Nat. Biotechnology Apr. 1990;8(4):343-6.;;Grace et al., ""Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-alpha Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway"" J. Biol. Chem. 2005;280(8):6327-6336.;;Grimley et al., ""Prolonged STAT1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-alpha"" Blood 91(8):3017-27 (1998).;;Gutterman et al., ""Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma"" Ann. Intern. Med. 93(3):399-406 (1980).;;Gutterman et al., ""Cytokine therapeutics: Lessons from interferon alpha"" Proc. Natl. Acad. Sci. USA 91:1198-205 (1994).;;Harris et al., ""Effect of pegylation on pharmaceuticals"" Nat. Rev. Drug. Discov. 2:214-221 (2003).;;Hausken et al. ""Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII"", J. Biol. Chem. 271:29016-22 (1996).;;Hodneland et al., ""Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands"", Proc. Natl. Acd. Sci. USA 2002; 99:5048-5052.;;Huang et al., ""Targeting IFN-alpha to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities"" J. Immunol. 179:6881-88 (2007).;;Hundsrucker et al., ""High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides"" Biochem. J. (2006) 396, 297-306.;;Kimby et al., ""Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group"" Leuk. Lymphoma 49(1):102-112 (2008).;;Kinderman et al., ""A Dynamic Mechanism for AKAP Binding to RII Isoforms of cAMP-Dependent Protein Kinase"" Mol. Cell 24(3):397-408 (2006).;;Kinstler et al., ""Characterization and Stability of N-terminally PEGylated rhG-CSF"" Pharm. Res. 1996;13(7):996-1002.",ACTIVE
879,US,A,US 4187193 A,179-808-451-149-511,1980-02-05,1980,US 90313478 A,1978-05-05,US 90313478 A;;US 50883474 A;;US 61120575 A,1974-09-24,Micro-capsules containing ureido fluoran chromogenic compounds,"A chromogenic compound having the structural formula ##STR1## wherein R.sup.1 and R.sup.2 each represent an alkyl group; R.sup.3 and R.sup.4 each represent a hydrogen atom, a halogen atom, an alkyl group, a nitro group, an amino group, an acyl group, or a carboalkoxy group; R.sup.5 represents a hydrogen atom or an alkyl group, with the proviso that R.sup.5 represents an alkyl group only when R.sup.4 represents a hydrogen atom; R.sup.6 represents an alkyl group, an aryl group or an aralkyl group; and X and Y each represent a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, an aryl group, an alkoxy group or a carboalkoxy group. The aforesaid compound may be provided in a pressure-sensitive copy system wherein a visible image is formed upon reaction of the above chromogenic compound with an electron-accepting material of the Lewis acid type.",CHAMPION INT CORP,CHANG CHENG-HSIUNG;;VINCENT DAVID N,,https://lens.org/179-808-451-149-511,Granted Patent,yes,8,1,1,10,0,B41M5/1455;;B41M5/1455;;C07D493/10;;C07D493/10;;Y10S428/914;;Y10S428/914;;Y10T428/254;;Y10T428/254;;Y10T428/2984;;Y10T428/2984;;Y10T428/2987;;Y10T428/2987,B41M5/145;;C07D493/10,252/316,0,0,,,,EXPIRED
880,DE,T2,DE 69121053 T2,188-006-752-086-835,1997-03-06,1997,DE 69121053 T,1991-05-22,US 52798290 A;;US 9103553 W,1990-05-24,ENTSCHWEFELUNG VON TRIAZOLOTHIADIAZINEN,,EASTMAN KODAK CO,KIM CHANG;;LAMICELA WAYNE;;ALLEN DAVID,,https://lens.org/188-006-752-086-835,Granted Patent,no,0,0,7,7,0,C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D487/04;;C07D513/04,,0,0,,,,EXPIRED
881,EP,A4,EP 2473186 A4,180-715-426-327-892,2013-07-10,2013,EP 10812633 A,2010-08-27,US 23842409 P;;US 64414609 A;;US 73178110 A;;US 75264910 A;;US 75414010 A;;US 75474010 A;;US 2010/0046889 W,2009-08-31,BISPECIFIC IMMUNOCYTOKINE DOCK-AND-LOCK (DNL) COMPLEXES AND THERAPEUTIC USE THEREOF,,IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/180-715-426-327-892,Search Report,no,10,0,12,1035,0,A61K2039/505;;A61P1/04;;A61P3/10;;A61P7/06;;A61P9/00;;A61P9/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;C07K14/52;;C07K16/249;;C07K16/2833;;C07K16/2887;;C07K2317/31;;C07K2317/55;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2319/30,C07K16/46;;A61K39/395;;A61P35/00;;C07K14/52;;C07K14/56;;C07K16/24;;C07K16/28,,2,1,154-648-591-453-198,10.2967/jnumed.107.046185;;18077530,"D. M. GOLDENBERG ET AL: ""Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting"", THE JOURNAL OF NUCLEAR MEDICINE, vol. 49, no. 1, 1 January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185;;See also references of WO 2011025904A1",DISCONTINUED
882,US,A1,US 2012/0254507 A1,184-002-409-538-300,2012-10-04,2012,US 201113077842 A,2011-03-31,US 201113077842 A,2011-03-31,WRITE-ABSORBING BUFFER FOR NON-VOLATILE MEMORY,"A write-absorbing, volatile memory buffer for use with a processor module and a non-volatile memory is disclosed. The write-absorbing buffer operates as a dirty cache that can be used to look up both read and write requests, although allocating new blocks only for write requests and not read requests. The blocks are small sized, and a write-only least-recently used cache replacement policy is used to transfer data in the blocks to the non-volatile memory. The write-absorbing buffer can be used to store copy-on-write pages for at least one virtual machine associated with the processor module and reduce write overhead to the non-volatile memory.",CHANG JICHUAN;;RANGANATHAN PARTHASARATHY;;ROBERTS DAVID,CHANG JICHUAN;;RANGANATHAN PARTHASARATHY;;ROBERTS DAVID,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2011-03-31),https://lens.org/184-002-409-538-300,Patent Application,yes,6,41,2,2,0,G06F11/1441;;G06F11/2015;;G06F12/0804;;G06F2212/2024;;G06F12/0868;;Y02D10/00;;G06F11/1441;;G06F11/2015;;G06F2212/2024;;G06F12/0804;;Y02D10/00;;G06F12/0868,G06F12/02,711/103;;X711E12008,0,0,,,,INACTIVE
883,US,B1,US 6463202 B1,188-347-995-869-768,2002-10-08,2002,US 59108400 A,2000-06-09,US 59108400 A,2000-06-09,Optimization of curved waveguide design to reduce transmission losses,"
    A waveguide designed to minimize bend-induced losses. The waveguide has three regions of varying indices of refraction. The indices of refraction are chosen so that the field is a trigonometric function in the core region, evanescent in the intermediate region, and trigonometric again in the outer region. The widths of each region are calculated to further reduce losses. 
",SOUTHWEST RES INST,CERWIN STEPHEN A;;CHANG DAVID B,SOUTHWEST RESEARCH INSTITUTE (2000-07-31),https://lens.org/188-347-995-869-768,Granted Patent,yes,8,5,1,1,0,G02B6/125;;G02B6/125;;G02B6/02;;G02B6/02;;G02B2006/12119;;G02B2006/12119,G02B6/02;;G02B6/12;;G02B6/125,385/124;;385/127,0,0,,,,EXPIRED
884,CN,A,CN 102374660 A,186-277-510-516-945,2012-03-14,2012,CN 201110225536 A,2011-08-08,GB 201013263 A,2010-08-06,Fan assembly,"A fan assembly includes a motor-driven impeller for creating an air flow, a casing including an interior passage for receiving the air flow, and a plurality of air outlets for emitting the air flow from the casing. The casing defines and extends about an opening through which air from outside the casing is drawn by the air flow emitted from the air outlets. The fan assembly also includes at least one heater for heating at least a first portion of the air flow, and means for diverting at least a second portion of the air flow away from said at least one heater. The plurality of outlets includes at least one first air outlet for emitting the relatively hot first portion of the air flow and at least one second air outlet for emitting the relatively cold second portion of the air flow. The second portion of the air flow is directed over an external surface of the casing to keep that surface cool during use of the heater.",DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,,https://lens.org/186-277-510-516-945,Patent Application,no,6,5,24,24,0,F04D25/08;;F24H3/0417;;F04D25/08;;F04D25/08;;F04D29/403;;F04D25/08;;F04D29/44;;F04D29/582;;F04D29/582;;F04D29/5826;;F04D29/5826;;F04D29/584;;F04F5/16;;F04F5/16;;F04F5/46;;F04F5/46;;F24F7/007;;F24F7/007;;F24F13/06;;F24F13/06;;F24F2013/0612;;F24F2013/0612;;F24F2221/28;;F24F2221/28;;F24H3/0417;;F24H3/0417;;F24H3/12;;F24H9/0063;;F24H9/0063;;F24H9/1872;;F24H9/1872;;F24H2250/04;;F24H2250/04,F24H9/00;;F04F5/16;;F24H9/18,,0,0,,,,ACTIVE
885,WO,A3,WO 2005/004035 A3,192-323-045-484-563,2005-06-09,2005,US 2004/0021550 W,2004-07-02,US 48446203 P;;US 76697604 A;;US 81376804 A,2003-07-02,METHOD AND APPARATUS FOR GROUND DETECTION AND REMOVAL IN VISION SYSTEMS,"A vision system that forms a map of a scene proximate a platform (410), e.g., a vehicle, that determines the actual ground plane form the map (414), and that corrects the map for differences between the actual ground plane (416) and an assumed ground plane. The vision system may remove the actual ground plane from the map to prevent false positives. The vision system can further identify and classify objects and, if appropriate, take evasive action.",SARNOFF CORP;;FORD MOTOR CO;;CHANG PENG;;HIRVONEN DAVID;;CAMUS THEODORE,CHANG PENG;;HIRVONEN DAVID;;CAMUS THEODORE,,https://lens.org/192-323-045-484-563,Search Report,yes,10,0,8,15,0,G06V20/00;;G06V20/58;;G06V10/255;;G06V20/00;;G06V10/255;;G06V20/58,B60Q1/00;;G01C5/00;;G01C21/30;;G01S1/00;;G01V3/00;;G06F15/00;;G06F19/00;;G06K/;;G08B21/00;;G06V20/00,,0,0,,,,PENDING
886,WO,A1,WO 2016/168829 A1,004-376-439-907-268,2016-10-20,2016,US 2016/0028128 W,2016-04-18,US 201562149154 P;;US 201562187980 P,2015-04-17,SMART HEADSET AND METHOD OF ROUTING SERVICE IN RESPONSE TO PROXIMITY TO MOBILE DEVICE,A smart headset communicates through the cellular transceiver with a cellular network when the smart headset in a first mode and communicates through a Bluetooth transceiver with a smart handset when the smart headset is in a second mode. A controller pf the smart headset is configured to place the smart headset in the first mode when the smart handset is determined to be farther than a maximum proximity from the smart headset and configured to place the headset in the second mode when the smart handset is determined to be within the maximum proximity to the smart headset.,KYOCERA CORP;;KALHAN AMIT;;COMSTOCK DAVID;;CHANG HENRY,KALHAN AMIT;;COMSTOCK DAVID;;CHANG HENRY,,https://lens.org/004-376-439-907-268,Patent Application,yes,5,1,6,6,0,H04R5/04;;H04R5/04;;H04L69/22;;H04M1/6066;;H04R5/033;;H04R5/033;;H04R25/55;;H04R25/55;;H04R2227/003;;H04R2227/003;;H04W4/023;;H04W4/023;;H04W4/80;;H04W40/38,H04R1/10;;H04R5/033,,0,0,,,,PENDING
887,CA,C,CA 1286212 C,013-558-422-926-95X,1991-07-16,1991,CA 524061 A,1986-11-28,US 80854685 A,1985-12-13,SEMICONDUCTOR GAS SENSOR HAVING THERMALLY ISOLATED SITE,SEMICONDUCTOR GAS SENSOR HAVING THERMALLY ISOLATED SITE A preferred semiconductor gas sensor of this invention features a gas interaction site comprising a gas sensitive semiconductor thin film and means for heating the film to an operative temperature. The thin film and heating means are carried upon a region of a substrate that is etched opposite the site to reduce the thickness of the region and thereby reduce heat flow from the region into a surrounding region.,GEN MOTORS CORP,CHANG SHIH-CHIA;;HICKS DAVID B,,https://lens.org/013-558-422-926-95X,Granted Patent,no,0,0,6,6,0,G01N27/12;;G01N27/12,G01N27/12,D21500020    M,0,0,,,,EXPIRED
888,AU,B2,AU 2010/328136 B2,018-497-736-246-936,2016-02-25,2016,AU 2010/328136 A,2010-12-09,US 26787709 P;;US 86982310 A;;US 94953610 A;;US 75264910 A;;US 64414609 A;;US 87134510 A;;US 91551510 A;;US 30268210 P;;US 75474010 A;;US 73178110 A;;US 41459210 P;;US 2010/0059660 W,2009-12-09,Dock-and-lock (DNL) complexes for delivery of interference RNA,"Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/018-497-736-246-936,Granted Patent,no,1,0,8,1035,0,A61K2039/505;;C07K16/18;;C07K16/2803;;C07K16/2833;;C07K16/2887;;C07K16/30;;C07K16/303;;C07K16/3092;;C07K16/44;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2319/70;;C12N15/111;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32;;A61P35/00,A61K39/395,,0,0,,,,ACTIVE
889,EP,A4,EP 0859826 A4,028-513-401-429-431,1999-11-24,1999,EP 96925280 A,1996-07-08,GB 9516372 A;;US 9611409 W;;US 61986496 A,1995-08-10,PIGMENTED RHEOPECTIC CLEANING COMPOSITIONS WITH THIXOTROPIC PROPERTIES,,RECKITT & COLMAN INC,CHANG DAVID A;;CAVANAGH JAMES W,RECKITT BENCKISER INC. (2001-04-18),https://lens.org/028-513-401-429-431,Search Report,no,1,0,13,19,0,C11D3/3956;;C11D1/10;;C11D1/75;;C11D1/83;;C11D3/1266;;C11D3/40;;C11D3/42,C11D1/10;;C11D1/75;;C11D1/83;;C11D3/12;;C11D3/395;;C11D3/40;;C11D3/42,,2,0,,,"DATABASE WPI Week 9431, Derwent World Patents Index; AN 253131, XP002117097, ""Liquid Bleacher composition having good viscosity.."";;See also references of WO 9706233A1",DISCONTINUED
890,GB,A,GB 2482548 A,029-471-240-867-732,2012-02-08,2012,GB 201013265 A,2010-08-06,GB 201013265 A,2010-08-06,A fan assembly with a heater,"Fan assembly including a impeller for creating an air flow, at least one heater 104 for heating a first portion of the air flow, means for diverting a second portion of the air flow away from said at least one heater, and a casing with at least one first air outlet for emitting the first portion of the air flow and at least one second air outlet for emitting the second portion of the air flow, with at least part of the second portion of the air flow being directed over an external surface of the casing. Preferably the casing is shaped to divide the air flow into a plurality of air streams each of which comprises part of the first portion and part of the second portion. Each air outlet may be a slot and the heater may be ceramic.",DYSON TECHNOLOGY LTD,WALLACE JOHN DAVID;;CHOONG CHANG HIN,,https://lens.org/029-471-240-867-732,Patent Application,no,4,41,22,22,0,F24F7/007;;F24F13/06;;F24F2013/205;;F24F2221/12;;F24F2221/28;;F24F2221/34;;F04F5/16;;F24H3/0411;;F24H3/0417;;F24H9/0063;;F24H9/1872;;F24H2250/04;;F04D25/08;;Y10T137/6525;;Y10T137/6552;;F04D25/08;;F24H3/0417;;F04D25/08;;F24H3/12;;F04D29/44;;Y10T137/6525;;Y10T137/6552;;F24F7/007;;F04D15/0218;;F24F2221/28;;F24F2221/12;;F24F2013/205;;F24F13/06;;F24F2221/34;;F24H9/0063;;F04F5/16;;F24H3/0417;;F24H2250/04;;F24H3/0411;;F24H9/1872;;F04D25/08,F04D25/08;;F24H3/04,,0,0,,,,DISCONTINUED
891,WO,A2,WO 2005/004035 A2,031-417-450-589-050,2005-01-13,2005,US 2004/0021550 W,2004-07-02,US 48446203 P;;US 76697604 A;;US 81376804 A,2003-07-02,METHOD AND APPARATUS FOR GROUND DETECTION AND REMOVAL IN VISION SYSTEMS,"A vision system that forms a map of a scene proximate a platform (410), e.g., a vehicle, that determines the actual ground plane form the map (414), and that corrects the map for differences between the actual ground plane (416) and an assumed ground plane. The vision system may remove the actual ground plane from the map to prevent false positives. The vision system can further identify and classify objects and, if appropriate, take evasive action.",SARNOFF CORP;;FORD MOTOR CO;;CHANG PENG;;HIRVONEN DAVID;;CAMUS THEODORE,CHANG PENG;;HIRVONEN DAVID;;CAMUS THEODORE,,https://lens.org/031-417-450-589-050,Patent Application,yes,0,6,8,15,0,G06V20/00;;G06V20/58;;G06V10/255;;G06V20/00;;G06V10/255;;G06V20/58,B60Q1/00;;G06V20/00;;G01C5/00;;G01C21/30;;G01S1/00;;G01V3/00;;G06F15/00;;G06F19/00;;G06K/;;G08B21/00,,0,0,,,,PENDING
892,CA,A1,CA 3082447 A1,030-048-771-608-622,2019-05-23,2019,CA 3082447 A,2017-11-21,US 201715818216 A;;US 2017/0062834 W,2017-11-20,MEASURING RPE AND CHOROID MELANIN LEVELS WITH REFLECTOMETER,"A process for determining levels or concentrations of melanin within an eye includes generating first and second light beams of a different wavelength. The first and second light beams are applied into the eye, such as a retinal pigment epithelium and choroid of the eye. The amount of light reflected from the eye from the first light beam and the second light beam is measured, such as using a reflectometer. A level or concentration of the melanin within the eye is calculated using the measured amount of light reflected from the eye from the first and second light beams.",OJAI RETINAL TECH LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/030-048-771-608-622,Patent Application,no,0,0,5,287,0,A61B5/0082;;A61F9/00821;;A61B5/0066;;A61F2009/00863;;A61B3/12;;A61B3/0008;;A61B5/1455;;A61B5/14546;;A61B3/12;;A61B3/0008;;A61B5/1455;;A61B5/14546;;A61B5/0082;;A61B5/0066;;A61F9/00821;;A61F2009/00863,,,0,0,,,,PENDING
893,US,B2,US 7127498 B2,038-823-504-223-635,2006-10-24,2006,US 24482502 A,2002-09-16,US 24482502 A;;US 24468602 A;;US 24469402 A;;US 24470402 A;;US 24481602 A;;US 24482702 A,2002-09-16,Software application domain and storage domain constraining process and method,"A method for constraining access to a storage system includes assigning a permanent bus identification to a storage device included in the storage system, creating a zone including a switch and the storage device included in the storage system such that data only passes to the storage device from the switch, and restricting access to the storage device from a server included in the storage system.",HEWLETT PACKARD DEVELOPMENT CO,CHANG DAVID FU-TIEN;;ASHUTOSH ASHUTOSH,APPIQ (2002-10-08);;HEWLETT-PACKARD COMPANY (2005-12-01);;HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2006-02-01),https://lens.org/038-823-504-223-635,Granted Patent,yes,1,3,14,14,0,G06F3/0635;;G06F3/067;;G06F11/323;;G06Q40/00;;G06Q40/04;;G06Q40/06;;G06Q40/08;;H04L41/046;;H04L41/06;;H04L41/0853;;H04L41/22;;H04L43/045;;H04L43/0888;;H04L67/1097;;H04L69/329;;G06Q40/03;;G06F11/323;;G06F3/067;;G06Q40/00;;H04L41/06;;H04L41/22;;H04L43/045;;G06Q40/06;;G06F3/0635;;H04L41/12;;H04L41/046;;H04L43/0888;;G06Q40/08;;H04L41/0853;;G06Q40/04;;H04L69/329;;H04L67/1097;;G06Q40/03,G06F12/14;;G06F/;;G06F3/06;;G06F9/44;;G06F11/32;;G06F13/00;;G06F13/16;;G06F15/00;;G06F15/16;;G06F15/173;;G06Q40/00;;H04L12/24;;H04L12/26;;H04L29/08,709/217;;710/9;;710/316;;711/152;;711/163,0,0,,,,ACTIVE
894,BR,A,BR 9609898 A,046-633-592-020-135,1999-05-25,1999,BR 9609898 A,1996-07-08,GB 9516372 A;;US 61986496 A;;US 9611409 W,1995-08-10,Composição aquosa de hipoclorito pigmentada espessada,,RECKITT & COLMAN INC,CHANG DAVID A;;CAVAGH JAMES W,,https://lens.org/046-633-592-020-135,Patent Application,no,0,0,13,19,0,C11D3/3956;;C11D1/10;;C11D1/75;;C11D1/83;;C11D3/1266;;C11D3/40;;C11D3/42,C11D1/10;;C11D1/75;;C11D1/83;;C11D3/12;;C11D3/395;;C11D3/40;;C11D3/42,,0,0,,,,DISCONTINUED
895,CN,A,CN 107419236 A,042-847-104-614-398,2017-12-01,2017,CN 201710654905 A,2014-01-10,US 201361752209 P;;US 201361752549 P;;US 201361897082 P;;US 201361907628 P;;CN 201480004713 A,2013-01-14,Method and system for graphene formation,The application relates to a method and system for graphene formation. A method of forming graphene includes placing a substrate in a processing chamber and introducing a cleaning gas including hydrogen and nitrogen into the processing chamber. The method also includes introducing a carbon source into the processing chamber and initiating a microwave plasma in the processing chamber. The method further includes subjecting the substrate to a flow of the cleaning gas and the carbon source for a predetermined period of time to form the graphene.,CALIFORNIA INST OF TECHN,BOYD DAVID A;;YEH NAI-CHANG,,https://lens.org/042-847-104-614-398,Patent Application,no,8,5,14,14,0,C23C16/26;;C23C16/4405;;C23C16/511;;H01L29/92;;C01B32/184;;C01B32/186;;Y10T428/24355;;C01B32/186;;C23C16/26;;C23C16/4405;;C23C16/511;;Y10T428/24355;;C01B32/184;;C01B32/186;;C23C16/26;;C23C16/4405;;C23C16/511,C23C16/26;;C23C16/44;;C23C16/511;;H01L29/92,,0,0,,,,ACTIVE
896,AU,B2,AU 2009/282830 B2,044-249-965-125-53X,2013-11-28,2013,AU 2009/282830 A,2009-08-20,US 9048708 P;;US 2009/0054441 W,2008-08-20,Dock-and-lock (DNL) vaccines for cancer therapy,"The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/044-249-965-125-53X,Granted Patent,no,1,0,17,1035,0,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;A61K39/001129;;A61K39/001112;;A61K39/001113;;A61K39/001176;;A61K39/001194;;A61K39/00117;;A61K39/001191;;A61K39/00115;;A61K39/001163;;A61K39/001124;;A61K39/001166;;A61K39/001182;;A61K39/001114;;A61K39/001138;;A61K39/001189;;A61K39/001192;;A61K39/001104;;A61K39/001103;;A61K39/001184;;A61K39/001188;;A61K39/001151;;A61K39/001117;;A61K39/001181;;A61K39/001109;;A61K39/001149;;A61K39/00114;;A61K39/001102;;A61K39/00113;;A61K39/001126;;A61K39/001135;;A61K39/001153;;A61K39/001162;;A61K39/001186;;A61K39/001195;;A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/001189;;A61K39/001112;;A61K39/001153;;A61K39/001163;;A61K39/001135;;A61K39/00117;;A61K39/001113;;A61K39/001124;;A61K39/001192;;A61K39/001129;;A61K39/001117;;A61K39/001103;;A61K39/001195;;A61K39/001138;;A61K39/001149;;A61K39/001182;;A61K39/001114;;A61K39/001102;;A61K39/001104;;A61K39/001126;;A61K39/00113;;A61K39/00114;;A61K39/00115;;A61K39/001166;;A61K39/001181;;A61K39/001186;;A61K39/001191;;A61K39/001194;;A61K39/001162;;A61K39/001176;;A61K39/001188;;A61K39/001109;;A61K39/001184;;A61K39/001151;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011,A61K39/00,,1,1,009-038-716-796-026,10.4049/jimmunol.167.12.7150;;11739538,"FONG L. et al., Journal of Immunology, 2001, vol. 167, pages 7150-7156",ACTIVE
897,WO,A2,WO 1998/058323 A2,054-638-331-169-364,1998-12-23,1998,US 9812591 W,1998-06-16,US 87929697 A,1997-06-18,GRAPHICAL CLICK SURFACES FOR FORCE FEEDBACK APPLICATIONS,"A method and apparatus for providing a click surface in a graphical environment, such as a graphical user interface, implemented on a host computer for use with a force feedback interface device. A displayed cursor is controlled by a user-moveable user object, such as a mouse, of the interface device. A click surface is displayed with an associated graphical object, such as a graphical button or an edge of a window, icon, or other object. When the click surface is contacted by the cursor, a force is output opposing movement of the user object in a direction into the click surface and into the graphical object. When the user object has moved to or past a trigger position past the contact with the click surface, a command gesture signal is provided to the host computer indicating that the graphical object has been selected as if a physical input device on the user object, such as a button, has been activated by the user. Preferably, the host computer displays the graphical environment including the click surface and cursor, while a microprocessor local to the interface device controls the force output of the click surface in parallel with the host display.",IMMERSION HUMAN INTERFACE CORP,ROSENBERG LOUIS B;;CHANG DAVID C,,https://lens.org/054-638-331-169-364,Patent Application,no,0,13,10,434,0,A63F2300/1025;;A63F2300/1037;;G05G9/047;;G05G2009/0477;;G06F3/011;;G06F3/016;;G06F3/0354;;G06F3/03543;;G06F3/03548;;G06F3/04812;;G06F3/0482;;G06F3/04842;;G06F2203/014;;H01H2003/008;;H04L67/131;;G06F3/016;;G06F3/011;;A63F2300/1025;;G06F3/04842;;G06F3/03548;;G06F3/0482;;G05G9/047;;G06F3/04812;;A63F2300/1037;;G05G2009/0477;;G06F3/0354;;G06F3/03543;;H01H2003/008;;G06F2203/014;;H04L67/131,G05G9/047;;G06F3/00;;G06F3/01;;G06F3/033;;G06F3/048;;H04L29/06,,0,0,,,,PENDING
898,US,A1,US 2020/0222640 A1,054-923-185-528-033,2020-07-16,2020,US 201816628970 A,2018-06-22,US 201816628970 A;;US 201762529926 P;;US 201762530001 P;;US 2018/0039030 W,2017-07-07,MEDICAL SHARP REMOVAL AND STORAGE DEVICE,"An apparatus for entirely removing a medical sharp from a holder to which it is connected, including a body ( 102 ), a heating unit ( 104 ) disposed in the body, a receiving unit ( 114 ) fixedly disposed in the body and configured to receive the holder, and a collet ( 122 ) movably disposed within the body and configured to receive the medical sharp. The apparatus also includes a first biasing member ( 130 ) disposed within the body, and a user interface ( 136 ) coupled to the collet and configured to displace the collet away from the receiving unit, actuate the first biasing member to increase a bias on the collet toward the receiving unit, and actuate the heating unit.",BECTON DICKINSON CO,LIMAYE AMIT;;SCHIFF DAVID;;CHANG ERIC,BECTON DICKINSON AND COMPANY (2019-12-06),https://lens.org/054-923-185-528-033,Patent Application,yes,3,1,18,24,0,B09B3/0075;;A61M5/3278;;A61M2005/3283;;A61M2205/368;;A61B2017/00734;;A61B50/36;;A61B50/362;;H01F5/00;;H01F2005/006;;A61L2/04;;A61L2202/24;;H05B1/025;;A61M5/3205;;A61M5/3205;;A61M2005/3209;;A61M2205/50;;A61M2205/8206;;A61M2205/8243;;H05B6/06;;H05B6/101;;A61M2005/3206;;H05B6/36;;A61B50/362;;A61B2050/364;;B09B3/00,A61M5/32;;B09B3/00;;H05B6/06;;H05B6/10,,0,0,,,,ACTIVE
899,EP,A3,EP 0633538 A3,046-072-496-105-094,1995-03-22,1995,EP 94304630 A,1994-06-24,US 8678593 A,1993-07-02,Relational database management system.,"A relational database management system 10 has a runtime supervisor 22 and a data manager 30. Typically user application files do not conform to the definition of a base relation of the relational database management system. Therefore, for the use of the data manager a plurality of library procedures generalized for manipulation of user application files are provided installed with the database management system. Responsive to user selection, a class for user application files is defined by naming members of a set of the library procedures for use with member application files of the class and by naming the class. Further responsive to user selection, column definitions on an application file within the class are made to create a user defined table 28. The user defined table corresponds to a specified user application file and to the definition. A class control block 26 is created in which the members of the set of library procedures are named for the class and a user defined table control block 28 is created in which the column definitions are stored. Both control blocks are accessible to the runtime supervisor for use with an access plan generated from SQL statements. Special structured query language statements are provided for user invocation to define a class of user application files and for providing column definitions, as well as for deleting a class control block and a user defined table control block.",IBM,CHANG DAVID YU;;MALKEMUS TIM R,,https://lens.org/046-072-496-105-094,Search Report,yes,1,0,5,5,0,G06F16/284;;G06F16/284;;Y10S707/99932,G06F12/00;;G06F17/30,,2,1,184-513-052-311-22X,10.1109/icde.1990.113446,"M. KAUL ET AL :: ""ViewSystem: Integrating Heterogeneous Information Bases by Object-Oriented Views"", 6TH INTERNATIONAL CONFERENCE ON DATA ENGINEERING, 5 February 1990 (1990-02-05), LOS ANGELES, USA, pages 2 - 10, XP010018186, DOI: doi:10.1109/ICDE.1990.113446;;L. LEVY :: ""Generalized technique for storage-independent data-accessing interface"", IBM TECHNICAL DISCLOSURE BULLETIN., vol. 19, no. 11, April 1977 (1977-04-01), NEW YORK US, pages 4404 - 4406",DISCONTINUED
900,WO,A1,WO 2011/025904 A1,044-101-344-869-818,2011-03-03,2011,US 2010/0046889 W,2010-08-27,US 23842409 P;;US 64414609 A;;US 73178110 A;;US 75264910 A;;US 75414010 A;;US 75474010 A,2009-08-31,BISPECIFIC IMMUNOCYTOKINE DOCK-AND-LOCK (DNL) COMPLEXES AND THERAPEUTIC USE THEREOF,"The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed on the same target cell. The bispecific immunocytokine DNL construct exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or even other types of cytokine-antibody DNL constructs. In a most preferred embodiment the construct comprises an anti-CD20 IgG antibody conjugated to an anti-HLA-DR Fab and IFNα2b, although other combinations of antibodies, antibody fragments and cytokines may be used to form the subject DNL complexes.",IBC PHARMACEUTICALS INC;;CHANG CHIEN-HSING;;GOLDENBERG DAVID M,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/044-101-344-869-818,Patent Application,yes,3,43,12,1035,0,A61K2039/505;;C07K14/52;;C07K16/249;;C07K16/2833;;C07K16/2887;;C07K2317/31;;C07K2317/55;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2319/30;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P7/06;;A61P9/00;;A61P9/14;;A61P3/10,A61K39/00;;C12P21/08,,0,0,,,,PENDING
901,WO,A1,WO 2014/026161 A1,049-022-108-750-432,2014-02-13,2014,US 2013/0054421 W,2013-08-09,US 201261682056 P;;US 201361862026 P;;US 201361862024 P;;US 201361862027 P,2012-08-10,VITAMIN SUPPLEMENT COMPOSITIONS FOR INJECTION,"The embodiments relate to improved vitamin supplement compositions formulated for administration to patients, particularly improved vitamin compositions formulated for use in cosmetic or therapeutic applications. The compositions may be used to slow aging process and promote wellness including treating a vitamin deficiency, skin conditions, improving skin appearance, wound healing and scar prevention and hair loss.",AQUAVIT PHARMACEUTICALS INC;;CHANG SOBIN;;FAGIEN STEVEN;;SHAFER DAVID,CHANG SOBIN;;FAGIEN STEVEN;;SHAFER DAVID,,https://lens.org/049-022-108-750-432,Patent Application,yes,3,34,5,42,0,A61Q19/08;;A61K31/197;;A61K31/315;;A61K31/375;;A61K31/4415;;A61K31/455;;A61K31/51;;A61K31/525;;A61K31/714;;A61K31/728;;A61K9/0019;;A61Q7/00;;A61K8/673;;A61K8/675;;A61K8/676;;A61Q19/00;;A61K2800/5922;;A61K2800/91;;A61K31/137;;A61K31/715;;A61P17/02;;A61P3/02;;A61Q19/08;;A61K31/197;;A61K31/375;;A61K31/4415;;A61K31/455;;A61K31/51;;A61K31/525;;A61K31/714;;A61K8/673;;A61K8/675;;A61K8/676;;A61K31/315;;A61K31/728;;A61K9/0019;;A61Q19/00;;A61Q7/00;;A61K2800/5922;;A61K2800/91;;A61K8/27;;A61K8/41;;A61K31/137;;A61K31/715;;A61K33/30;;A61K35/16;;A61K2800/10;;A61M5/30;;A61M37/0015,A61K31/714;;A61K8/67;;A61K9/08;;A61K31/197;;A61K31/315;;A61K31/375;;A61K31/4415;;A61K31/455;;A61K31/51;;A61K31/525;;A61K31/728;;A61P3/02;;A61P17/02;;A61Q19/08,,1,1,047-507-779-274-900,10.1201/9780203500231,"MOLNAR, J., NUTRITION AND WOUND HEALING, 2006, pages 8 AND 10",PENDING
902,US,B2,US 8501240 B2,056-254-785-911-674,2013-08-06,2013,US 34336508 A,2008-12-23,US 34336508 A;;US 98550904 A;;US 31334302 A;;US 54875900 A;;US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P,1999-10-29,Compositions comprising an active agent,"The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject.",KUO MEI-CHANG;;LECHUGA-BALLESTEROS DAVID;;NOVARTIS AG,KUO MEI-CHANG;;LECHUGA-BALLESTEROS DAVID,,https://lens.org/056-254-785-911-674,Granted Patent,yes,63,0,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K9/14;;A61K9/00;;A61K47/42;;A61K9/08;;A61K9/12;;A61K9/72;;A61K31/58;;A61K38/00;;A61K38/05;;A61K38/06;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,424/499;;424/489;;514/21.9;;514/21.91,17,12,071-359-051-194-156;;004-383-062-518-283;;108-739-752-465-233;;095-469-979-804-765;;085-701-811-082-528;;019-068-939-900-361;;020-837-463-625-374;;024-058-308-364-488;;002-798-676-955-666;;035-640-193-796-338;;011-709-743-461-084;;086-956-680-335-820,10.1023/a:1016292232513;;7617520;;10.1021/js970308x;;9519146;;10.1111/j.1365-2265.1994.tb02491.x;;8187318;;1963411;;10.1128/aac.40.7.1617;;pmc163383;;8807050;;10.1093/jac/35.2.317;;7759395;;8124763;;10.1248/cpb.42.19;;10086990;;8913469;;pmc163580;;10.1128/aac.40.11.2582;;10.1128/aac.40.10.2375;;8891147;;pmc163537;;10.1210/en.138.10.4330;;9322947;;10.1210/endo.138.10.5440;;8843287;;10.1128/aac.40.8.1817;;pmc163423,"Colthorpe et al (Pharmaceutical Research 12:356-359, 1995).;;Maa et al (Journal of Pharmaceutical Sciences 87:152-159, 1998).;;Møller et al (Clinical Endocrinology 40:511-513, 1994).;;Baldwin Dr et al ""Azithromycin concentrations at the sites of pulmonary infection"" Eur Respir J 3:886 (1990).;;Conte John E Jr et al ""Single-Dose Intrapulmonary Pharmacokinetics of Azithromycin, Clarithromycin, Ciprofloxacin, and Cefuroxime in Volunteer Subjects"" Antimicrob Agents Chemother 40(7):1617 (1996).;;Cook Peter J et al ""Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments"" J Antimicrob Chemother 35:317 (1995).;;Kobayashi Motomasa et al ""Marine Natural Products. XXXI. Structure-Activity Correlation of a Potent Cytotoxic Dimeric Macrolide Swinholide A, from the Okinawan Marine Sponge Theonella swinhoei, and Its Isomers"" Chem Pharm Bull 42(1)19 (1994).;;Murata Mitsuo et al ""Carrier-Mediated Lung Distribution of HSR-903, a New Quinolone Antibacterial Agent"" J Pharmacol Exp Ther 289(1):79 (1999) 1:1.;;Olsen Keith M et el ""Intrapulmonary Pharmacokinetics of Azithromycin in Healthy Volunteers Given Five Oral Doses"" Antimicrob Agents Chemother 40(11):2582 (1996).;;Patel Kalpana B et al ""Comparison of Bronchopulmonary Pharmacokinetics of Clarithromycin and Azithromycin"" Antimicrob Agents Chemother 40(10):2375 (1996).;;Sato Masahiko et al ""Biosynthetic Human Parathryoid Hormone (1-34) Effects on Bone Quality in Aged Ovariectomized Rats"" Endocrinology 138(10):4330 (1997).;;Sutcliffe Joyce et al ""Streptococcus pneumoniaeand Streptococcus pyogenesResistant to Macrolides but Sensitive to Clindamycin: a Common Resistance Pattern Mediated by an Efflux System"" Antimicrob Agents Chemother 40(8):1817 (1996).;;International Search Report, PCT/US00/09785 (Nov. 30, 2000).;;Written Opinion, PCT/US00/09785 (Aug. 28, 2001).;;Bibliographic data: EP 0472598 (Mar. 4, 1992).;;Bibliographic data: EP 0869816 (Oct. 14, 1998).;;Bibliographic data: EP 1223915 (Jul. 24, 2002).",EXPIRED
903,EP,A1,EP 0806110 A1,061-404-552-636-351,1997-11-12,1997,EP 95936272 A,1995-09-29,US 9512904 W;;US 31616794 A,1994-09-30,FLICKER REDUCTION AND SIZE ADJUSTMENT FOR VIDEO CONTROLLER WITH INTERLACED VIDEO OUTPUT,,CIRRUS LOGIC INC,KEENE DAVID;;YANG JIMMY;;CHANG KEVIN,,https://lens.org/061-404-552-636-351,Patent Application,yes,0,0,6,6,0,G09G5/395;;G09G5/395;;G09G2310/0224;;G09G2310/0224;;G09G2340/0414;;G09G2340/0414;;H04N7/012;;H04N7/012,G09G5/395;;H04N5/44,,1,0,,,See references of WO 9610887A1,EXPIRED
904,MX,A,MX PA00000106 A,065-667-856-613-992,2000-05-01,2000,MX PA00000106 A,2000-01-03,US 89564297 A,1997-07-17,MX PA00000106 A,,DU PONT,CHANG DAVID C K;;FRYD MICHAEL,,https://lens.org/065-667-856-613-992,Patent Application,no,0,0,18,18,0,C09D151/00;;C09D151/00;;C09D151/00;;C08F290/04;;C08F290/04;;C08F290/044;;C08F290/044;;C08F290/046;;C08F290/046,C08F290/04;;C09D5/02;;C09D151/00,,0,0,,,,EXPIRED
905,FI,A,FI 752646 A,076-067-776-330-52X,1976-03-25,1976,FI 752646 A,1975-09-22,US 50883474 A;;US 61120575 A,1974-09-24,FI 752646 A,,CHAMPION PAPER CO LTD,VINCENT DAVID M;;CHANG CHENG-HSIUNG,,https://lens.org/076-067-776-330-52X,Patent Application,no,0,0,9,10,0,B41M5/1455;;B41M5/1455;;C07D493/10;;C07D493/10;;Y10S428/914;;Y10S428/914;;Y10T428/254;;Y10T428/254;;Y10T428/2984;;Y10T428/2984;;Y10T428/2985;;Y10T428/2985;;Y10T428/2987;;Y10T428/2987,B41M5/145;;C07D493/10;;C09B11/28,,0,0,,,,EXPIRED
906,JP,A,JP 2011093922 A,065-855-981-110-049,2011-05-12,2011,JP 2010294308 A,2010-12-28,US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P,1999-10-29,DRY POWDER COMPOSITION HAVING IMPROVED DISPERSIBILITY,"<P>PROBLEM TO BE SOLVED: To provide a formulation possible to highly disperse, having an activator and a dipeptide or a tripeptide, containing at least two leucyl residues. <P>SOLUTION: The composition has an excellent aerosol property and therefore is preferable for aerosolized administration to a lung. Then, a method for (i) improving the dispersibility of the activator-containing formulation for administration to the lung, and (ii) transporting the composition to the lung of a subject, are provided. Based on a specific class of an excipient, if the excipient is taken in the dry powder formulation for aerosolization and transportation to the lung, dispersibility and aerosolization property of the dried powder is remarkably improved regardless of a type of the activator contained in the formulation. <P>COPYRIGHT: (C)2011,JPO&INPIT",NEKTAR THERAPEUTICS,LECHUGA-BALLESTEROS DAVID;;KUO MEI-CHANG,,https://lens.org/065-855-981-110-049,Patent Application,no,2,0,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K47/42;;A61K9/00;;A61K9/08;;A61K9/12;;A61K9/14;;A61K9/72;;A61K31/496;;A61K31/58;;A61K31/7036;;A61K38/00;;A61K38/04;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,,0,0,,,,DISCONTINUED
907,CN,C,CN 1090333 C,068-183-381-894-767,2002-09-04,2002,CN 95193691 A,1995-06-14,US 26214794 A,1994-06-20,Apparatus for coupling optical energy source to fiber optic,,COGENT LIGHT TECH,BAKER GLENN S;;CHANG DAVID D,,https://lens.org/068-183-381-894-767,Granted Patent,no,0,0,17,17,0,G02B6/36;;G02B6/4296;;G02B6/4296;;G02B6/02033;;G02B6/02033,G02B6/42;;G02C5/08;;G02C5/20,,0,0,,,,EXPIRED
908,US,A1,US 2012/0094146 A1,072-249-176-283-266,2012-04-19,2012,US 201113185958 A,2011-07-19,US 201113185958 A;;US 36558410 P,2010-07-19,Metallic Composite Material,"A roll bonded, composite metallic material utilizing a Magnesium (Mg) core to take advantage of its extreme light weight. The clad composite consist of roll bonded metal layers such as Al, stainless steel, copper and titanium on the surfaces of Mg. A multitude of clad combinations are available to combine the unique surface properties of various alloys to suit the particular application or design needs, with the light weight and strength characteristics of Mg.",HARDY MICHAEL DAVID;;CHANG CHENCHUNG STEVE,HARDY MICHAEL DAVID;;CHANG CHENCHUNG STEVE,EMS ENGINEERED MATERIALS SOLUTIONS LLC (2011-11-10),https://lens.org/072-249-176-283-266,Patent Application,yes,2,6,2,2,0,B22D11/008;;Y10T428/12729;;Y10T29/49002;;Y10T428/12729;;Y10T29/49002;;B22D11/008,B32B15/01;;H05K13/00,428/649;;29/592.1,0,0,,,,DISCONTINUED
909,US,A1,US 2021/0025199 A1,073-170-688-167-423,2021-01-28,2021,US 202017038313 A,2020-09-30,US 202017038313 A;;US 201916247448 A;;US 201862617480 P,2018-01-15,SYSTEMS AND METHODS OF SECURING TRANSPORT CONTAINERS TO ATTACHMENT POINTS,"Securing systems and methods of securing a transport container to an attachment point. In one embodiment, the securing system includes an actuator, an attachment structure, and an electronic controller. The attachment structure is dimensioned to complement the actuator. The electronic controller is operably coupled to the actuator for attaching and releasing the actuator to the attachment structure.",MOTOGO LLC,RUTH DAVID BRIAN;;LO YUAN-CHANG,MOTOGO LLC (2019-01-14),https://lens.org/073-170-688-167-423,Patent Application,yes,0,2,7,7,0,A47G2029/146;;A47G2029/149;;A47G2029/144;;A47G29/141;;E05B73/00;;E05B73/00;;B60P7/0807;;F16M13/02;;A47G2029/144;;A47G29/141;;F16M2200/02;;E05Y2900/602;;E05B47/0002;;A47G2029/149;;A47G2029/146,E05B73/00;;A47G29/14;;B60P7/08;;E05B47/00;;F16M13/02,,0,0,,,,ACTIVE
910,EP,A1,EP 3662515 A1,085-035-763-466-380,2020-06-10,2020,EP 17808074 A,2017-12-01,US 201715669139 A;;EP 2017081187 W,2017-08-04,JOSEPHSON JUNCTIONS FOR IMPROVED QUBITS,,IBM,ABRAHAM DAVID;;CHANG JOSEPHINE;;GAMBETTA JAY,,https://lens.org/085-035-763-466-380,Patent Application,yes,0,0,11,11,0,G06N10/00;;H03K19/1952;;H10N69/00;;H10N60/12;;H10N60/0912;;H10N60/10;;H10N60/805;;H10N60/815;;H10N60/0912;;H10N69/00;;H10N60/12;;G06N10/00;;G11C11/44;;G11C16/02;;H03K19/1952,H01L27/18;;G06N99/00;;H01L39/22;;H01L39/24,,0,0,,,,ACTIVE
911,CA,A1,CA 3011372 A1,090-700-848-637-941,2017-08-17,2017,CA 3011372 A,2017-02-10,US 201662293530 P;;US 201662329788 P;;US 201662336985 P;;US 2017/0017435 W,2016-02-10,COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS,The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.,IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/090-700-848-637-941,Patent Application,no,0,0,9,9,55,A61K45/06;;A61K39/3955;;A61K51/1057;;C07K16/2887;;C07K16/3007;;C07K16/3092;;C07K2317/732;;C07K2317/77;;C07K2317/90;;C07K2317/92;;A61K47/6889;;A61K47/6803;;A61K47/6851;;A61K31/4535;;A61K31/473;;A61K31/4985;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;A61K45/06;;A61K39/3955;;A61K51/1057;;C07K16/2887;;C07K16/3007;;C07K16/3092;;C07K2317/732;;C07K2317/77;;C07K2317/90;;C07K2317/92;;A61K47/6889;;A61K47/6803;;A61K47/6851;;A61K31/4535;;A61K31/473;;A61K31/4745;;A61K31/4985;;A61K41/0038;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/565,A61K45/06;;C07K16/30,,0,0,,,,PENDING
912,EP,A4,EP 4185376 A4,093-307-178-676-455,2023-11-15,2023,EP 21854336 A,2021-06-07,US 202016984486 A;;US 2021/0036128 W,2020-08-04,SYSTEM AND METHOD FOR PREVENTING OR TREATING ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES,,OJAI RETINAL TECH LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/093-307-178-676-455,Search Report,no,2,0,8,287,0,A61N1/40;;A61N5/02;;A61N5/025;;A61N1/403,A61N1/40;;A61N5/04,,0,0,,,,PENDING
913,US,A1,US 2006/0243909 A1,095-388-631-097-524,2006-11-02,2006,US 38457406 A,2006-03-20,US 38457406 A;;US 66506505 P,2005-03-24,System and method for sensitive photon detection,"A sensitive photon detection system generates an electronic photon sensor signal as a K factor times a number N photons per unit time. The system is configured by combining a separate optical amplifier with a gain factor K 1 with a photo detector with a gain factor K 2 such that K may be realized as the product of K 1 and K 2 . The values of K 1 and K 2 are chosen to meet a predetermined K while optimizing a signal quality of the photon sensor signal. The optical amplifier may be preceded by a photon gathering device and/or a light chopping device to further optimize system performance. Further, the photon sensor signal may be further processed analog circuitry or may be digitized and processed using digital signal processing to generate an enhanced photon sensor signal with enhanced signal quality by adding gain and/or bandwidth limiting.",SOUTHWEST RES INST,CERWIN STEPHEN A;;CHANG DAVID B,SOUTHWEST RESEARCH INSTITUTE (2006-06-28),https://lens.org/095-388-631-097-524,Patent Application,yes,1,4,2,2,0,G01J1/02;;G01J1/0295;;G01J1/04;;G01J1/0422;;G01J1/044;;G01J1/0459;;G01J1/42;;G01J1/42;;G01J1/02;;G01J1/0422;;G01J1/044;;G01J1/04;;G01J1/0459;;G01J1/0295,G01J1/00,250/336.1,0,0,,,,ACTIVE
914,DK,T3,DK 1666028 T3,099-890-878-021-467,2010-06-21,2010,DK 05027610 T,2000-04-12,US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P;;EP 00922117 A,1999-10-29,Tørre pulversammensætninger med forbedret dispersitet,,NOVARTIS AG,LECHUGA-BALLESTEROS DAVID;;KUO MEI-CHANG,,https://lens.org/099-890-878-021-467,Granted Patent,no,0,0,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K9/12;;A61K9/00;;A61K47/42;;A61K9/08;;A61K9/14;;A61K9/72;;A61K31/58;;A61K38/00;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,,0,0,,,,EXPIRED
915,US,A1,US 2003/0013246 A1,109-121-342-517-768,2003-01-16,2003,US 22387402 A,2002-08-19,US 22387402 A;;US 62967900 A,2000-08-01,Method of manufacturing a dual wafer tunneling gyroscope,"
   A method of making a micro electromechanical gyroscope. A cantilevered beam structure, first portions of side drive electrodes and a mating structure are defined on a first substrate or wafer; and at least one contact structure, second portions of the side drive electrodes and a mating structure are defined on a second substrate or wafer, the mating structure on the second substrate or wafer being of a complementary shape to the mating structure on the first substrate or wafer and the first and second portions of the side drive electrodes being of a complementary shape to each other. A bonding layer, preferably a eutectic bonding layer, is provided on at least one of the mating structures and one or the first and second portions of the side drive electrodes. The mating structure of the first substrate is moved into a confronting relationship with the mating structure of the second substrate or wafer. Pressure is applied between the two substrates so as to cause a bond to occur between the two mating structures at the bonding or eutectic layer and also between the first and second portions of the side drive electrodes to cause a bond to occur therebetween. Then the first substrate or wafer is removed to free the cantilevered beam structure for movement relative to the second substrate or wafer. The bonds are preferably eutectic bonds. 
",HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,HRL LABORATORIES LLC (2000-07-27),https://lens.org/109-121-342-517-768,Patent Application,yes,0,4,11,11,0,B81B2201/0242;;B81C1/0015;;B81C2201/014;;B81C2201/0191;;B81C2203/036;;G01C19/5656;;G01P15/0802;;G01P15/0894;;B81C1/0015;;B81C2201/014;;G01C19/5656;;G01P15/0802;;B81B2201/0242;;B81C2201/0191;;G01P15/0894;;B81C2203/036,B81B3/00;;B81C1/00;;G01C19/5656;;G01P15/08,4382,0,0,,,,EXPIRED
916,US,A1,US 2017/0118748 A1,118-304-405-128-11X,2017-04-27,2017,US 201515311799 A,2015-05-22,US 201515311799 A;;US 201462002037 P;;US 201462002041 P;;US 2015/0032279 W,2014-05-22,PHYSICAL CHANNEL STRUCTURE FOR COMMUNICATION IN UNLICENSED FREQUENCY BAND,Communication equipment communicates in a licensed frequency band using a licensed band physical channel structure (licensed structure) and communicates in an unlicensed frequency communication band using an unlicensed band physical channel structure (unlicensed structure) where the unlicensed structure includes at least the same symbol times and subcarrier frequency divisions as in the licensed structure. The symbol times and subcarriers form a plurality of time-frequency communication resource elements. A set of symbol times and subcarrier frequency divisions form a licensed reference subset of communication resource elements that are allocated for reference signal transmission in the licensed structure. The same set of symbol times and subcarrier frequency divisions form an unlicensed reference subset of communication resource elements that are allocated for reference signal transmission in the unlicensed structure.,KYOCERA CORP,KALHAN AMIT;;CHANG HENRY;;COMSTOCK DAVID,KYOCERA CORPORATION (2014-09-16),https://lens.org/118-304-405-128-11X,Patent Application,yes,1,14,37,37,0,H04W88/06;;H04L5/001;;H04L27/0006;;H04W74/0808;;H04W74/0866;;H04B7/2615;;H04W76/14;;H04W4/70;;H04W72/1215;;H04L5/0048;;H04L5/0053;;H04W76/14;;H04W4/70;;H04W88/06;;H04L5/001;;H04L27/0006;;H04W74/0808;;H04W74/0866;;H04W84/12;;H04B7/2615;;H04W72/21;;H04W72/23;;H04W72/541;;H04W72/1215;;H04W16/14;;H04W24/10;;H04W72/0453;;H04W88/08;;H04L5/0048;;H04W72/0446;;H04W24/08;;H04W72/02,H04W72/04;;H04L5/00;;H04W4/70;;H04W72/12,,0,0,,,,ACTIVE
917,CA,A1,CA 2781717 A1,142-005-686-633-875,2011-06-16,2011,CA 2781717 A,2010-12-09,US 26787709 P;;US 64414609 A;;US 30268210 P;;US 73178110 A;;US 75264910 A;;US 75474010 A;;US 86982310 A;;US 87134510 A;;US 91551510 A;;US 41459210 P;;US 94953610 A;;US 2010/0059660 W,2009-12-09,DOCK-AND-LOCK (DNL) COMPLEXES FOR DELIVERY OF INTERFERENCE RNA,"Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/142-005-686-633-875,Patent Application,no,0,0,8,1035,82,A61K2039/505;;A61P35/00;;C07K16/468;;C07K16/18;;C07K16/2803;;C07K16/2833;;C07K16/2887;;C07K16/30;;C07K16/303;;C07K16/3092;;C07K16/44;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2319/70;;C12N15/111;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32,,,0,0,,,,ACTIVE
918,US,S,US D0392021 S,130-479-793-950-365,1998-03-10,1998,US 6541697 F,1997-01-27,US 6541697 F,1997-01-27,In-tank toilet dispenser,,RECKITT & COLMAN INC,BODKER ALAN N;;CHANG DAVID A,RECKITT BENCKISER LLC (1997-06-03),https://lens.org/130-479-793-950-365,Design Right,yes,4,1,1,1,0,,,D23/208;;2301,0,0,,,,EXPIRED
919,US,B1,US 6428754 B1,129-015-845-584-82X,2002-08-06,2002,US 38229695 A,1995-02-01,US 38229695 A,1995-02-01,Method and Apparatus for treating exhaust gases,"
    An exhaust gas treatment system and method for treating the exhaust gas of an internal combustion engine includes a catalytic converter and a catalytic preheater or igniter upstream of the catalytic converter. A bypass passage extends around the igniter such that during the ignition period about two-thirds of the exhaust gas is bypassed around the igniter and one-third passes through the igniter. The igniter raises the temperature of the exhaust gases passing therethrough to an adiabatic temperature of about 900 K. Accordingly, the flow through the igniter combined with the flow through the bypass passage raises the average temperature of the combined exhaust gases to approximately 700 K., which is sufficient to ignite the catalytic converter at substantially the leading edge thereof. Accordingly, normal convective flow of the exhaust gases through the catalytic converter assists in propagating ignition of the converter. A temperature sensor in the catalytic converter causes a controller to operate a valve to divert substantially all of the exhaust gas flow through the bypass passage after the catalytic converter has ignited. 
",UNIV NOTRE DAME DU LAC,CHANG HSUEH-CHIA;;LEIGHTON DAVID T,NOTRE DAME UNIVERSITY OF (1995-01-25),https://lens.org/129-015-845-584-82X,Granted Patent,yes,7,8,1,1,0,B01D53/9454;;Y02T10/12;;B01D53/9454;;Y02T10/12,B01D53/94,422/168;;423/213.2,0,0,,,,EXPIRED
920,WO,A1,WO 2022/031362 A1,144-417-293-672-973,2022-02-10,2022,US 2021/0036128 W,2021-06-07,US 202016984486 A,2020-08-04,SYSTEM AND METHOD FOR PREVENTING OR TREATING ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES,A protective therapy system for biological tissues or fluids includes applying a pulsed energy source to a target tissue or a target fluid having a chronic progressive disease or a risk of having a chronic progressive disease to therapeutically or prophylactically treat the target tissue or target fluid. A pulsed energy source having selected energy parameters may be applied to a brain of an individual who has Alzheimer's or other neurodegenerative disease or is at risk of developing such a neurodegenerative disease so as to prevent or treat the neurodegenerative disease.,OJAI RETINAL TECH LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/144-417-293-672-973,Patent Application,yes,4,1,8,287,0,A61N1/40;;A61N5/02;;A61N5/025;;A61N1/403,A61N1/40,,1,1,029-251-072-345-999,pmc6839500;;31403948;;10.3233/jad-190367,"ARENDASH GARY, CAO CHUANHAI, ABULABAN HAITHAM, BARANOWSKI ROB, WISNIEWSKI GARY, BECERRA LINO, ANDEL ROSS, LIN XIAOYANG, ZHANG XIAO: ""A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging"", JOURNAL OF ALZHEIMER`S DISEASE, IOS PRESS, NL, vol. 71, no. 1, 3 September 2019 (2019-09-03), NL , pages 57 - 82, XP055907092, ISSN: 1387-2877, DOI: 10.3233/JAD-190367",PENDING
921,EP,A2,EP 1305257 A2,143-911-029-373-197,2003-05-02,2003,EP 01957352 A,2001-07-30,US 0123983 W;;US 62968200 A,2000-08-01,A TUNNELING SENSOR OR SWITCH AND A METHOD OF MAKING SAME,,HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,,https://lens.org/143-911-029-373-197,Patent Application,yes,0,0,9,9,0,G01P15/0802;;G01P15/0802;;G01P15/0894;;G01P15/0894;;H01H1/0036;;H01H1/0036;;H01H59/0009;;H01H59/0009,B81B3/00;;B81C1/00;;G01P15/08;;H01H1/00;;H01H59/00;;H01L29/84,,1,0,,,See references of WO 0210063A3,DISCONTINUED
922,US,B2,US 10820634 B2,142-552-400-019-371,2020-11-03,2020,US 201815915165 A,2018-03-08,US 201815915165 A;;US 201762468620 P,2017-03-08,Vaporizer,"It is the object of the present invention to eliminate the disadvantages in currently available Vaporizers. The present invention is adapted for use with semi-solid Extracts, which are immune to leakage and do not contain solvents. Furthermore, the present invention is easily operated by users and does not require Dabbing.",VUBER TECH;;VUBER TECH INC,CROWE DAVID;;DISANTO ANTHONY;;CHANG TONY,VUBER TECHNOLOGIES LLC (2017-01-26);;VUBER TECHNOLOGIES INC (2020-09-11),https://lens.org/142-552-400-019-371,Granted Patent,yes,5,1,4,4,0,H05B1/0227;;A24B15/167;;A24F40/46;;A24F40/10;;A24F40/44;;A24F40/60;;A24F40/42;;H05B3/44;;A24B15/167;;H05B1/0227;;A24F40/42;;A24F40/10;;A24F40/44;;A24F40/46;;A24F40/60,A24F40/42;;A24B15/167;;A24F40/10;;A24F40/44;;A24F40/46;;A24F40/60;;H05B1/02;;H05B3/44,,0,0,,,,ACTIVE
923,CN,A,CN 102481348 A,141-711-955-402-445,2012-05-30,2012,CN 201080038548 A,2010-08-27,US 2010/0046889 W;;US 23842409 P;;US 64414609 A;;US 73178110 A;;US 75264910 A;;US 75414010 A;;US 75474010 A,2009-08-31,Bispecific immunocytokine dock-and-lock (DNL) complexes and therapeutic use thereof,"The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed on the same target cell. The bispecific immunocytokine DNL construct exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or even other types of cytokine-antibody DNL constructs. In a most preferred embodiment the construct comprises an anti-CD20 IgG antibody conjugated to an anti-HLA-DR Fab and IFNa2b, although other combinations of antibodies, antibody fragments and cytokines may be used to form the subject DNL complexes.",IBC PHARMACEUTICALS INC,CHIEN-HSING CHANG;;GOLDENBERG DAVID M,,https://lens.org/141-711-955-402-445,Patent Application,no,4,6,12,1035,0,A61K2039/505;;A61P1/04;;A61P3/10;;A61P7/06;;A61P9/00;;A61P9/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;C07K14/52;;C07K16/249;;C07K16/2833;;C07K16/2887;;C07K2317/31;;C07K2317/55;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2319/30,A61K39/00;;C12P21/08,,4,3,154-648-591-453-198;;032-409-676-506-509;;013-580-733-777-26X,10.2967/jnumed.107.046185;;18077530;;10.1073/pnas.0600982103;;16636283;;pmc1447525;;10.1158/1078-0432.ccr-07-1217;;17875793,"DAVID M.GOLDENBERG: ""Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting"", 《THE JOURNAL OF NUCLEAR MEDICINE》, vol. 49, no. 1, 31 January 2008 (2008-01-31), pages 158 - 163, XP055028152, DOI: doi:10.2967/jnumed.107.046185;;PHUONG H.NGUYEN: ""Monomer adds to preformed structured oligomers of Aβ-peptides by a two-stage dock–lock mechanism"", 《PNAS》, vol. 104, no. 1, 2 January 2007 (2007-01-02), pages 111 - 116;;EDMUND A.ROSSI: ""Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting"", 《PNAS》, vol. 103, no. 18, 2 May 2006 (2006-05-02), pages 6841 - 6846, XP008123542, DOI: doi:10.1073/PNAS.0600982103;;CHIEN-HSING CHANG ET.AL.: ""“The dock and lock method：a novel platform technology for building multivalent，multifunctional structures of defined composition with retained bioactivity”"", 《CLINICAL CANCER RESEARCH》, vol. 13, no. 18, 15 September 2007 (2007-09-15)",DISCONTINUED
924,US,B2,US 9087110 B2,150-681-890-617-032,2015-07-21,2015,US 201314094651 A,2013-12-02,US 201314094651 A;;US 201361893801 P,2013-10-21,Prioritizing online relationships,Systems and methods for generating a set of priority contacts based on their strength of relationship with a user. Contacts of users and communications from those contacts are aggregated across multiple online accounts into a single set of communications. An affinity score is calculated for each of the user's contacts based on adding up the total weight and frequency of communications with the user and a predetermined number of contacts having the highest affinity score can be identified as priority contacts. The affinity score is used to filter the news feed in a user interface display so that only communications from priority contacts are displayed in the news feed.,MYLIFE COM INC,RANA SUMEET;;CHANG DONG;;WOLFE DAVID,MYLIFE.COM INC (2013-11-15),https://lens.org/150-681-890-617-032,Granted Patent,yes,27,2,2,2,0,G06F16/24578;;G06F16/248;;G06F16/24578,G06F17/30,,6,2,123-635-016-881-420;;005-418-410-129-764,10.1145/2399016.2399126;;10.1109/socialinformatics.2012.88,"Shlomo Berkovsky et al., ""Personalized Network Updates: Increasing Social Interactions and Contributions in Social Networks"", Jul. 20, 2012, Springer Berlin Heidelberg, UMAP 2012, LNCS, pp. 1-13.;;Mikko Honkala & Yanqing Cui, ""Automatic On-Device Filtering of Social Networking Feeds"", Oct. 17, 2012, ACM NordiCHI '12, pp. 721-730.;;Netvibes, ""Netvibes General Documentation"", 124 pages, crawled by the Internet Archive Wayback Machine on Jan. 24, 2011.;;Rana et al., ""Supporting Ubiquitous Interaction in Dynamic Shared Spaces through Automatic Group Formation Based on Social Context."", 2012, 2012 ASE International Conference on Social Informatics (SociallInformatics 2012) / 2012 ASE International Conference on Cyber Security (CyberSecurity 2012) / 2012 ASE International Conference on BioMedical Computing, pp. 121-130.;;Related Academic Work: Contacts Priority Ranking Algorithm | Group 7: OrientExpress Blog, downloaded Jul. 29, 2013, 4 pages. http://blog.soton.ac.uk/orientexpress/2012/04/17/related-academic-work-1/.;;""Smarter makes your overwhelming contact list a whole lot (yep) smarter"". May 2, 2012, Downloaded Jul. 29, 2013, 11 pages. http://www.coolmomtech.com/2012/05/smartr-app-contact-list-management.php.",ACTIVE
925,US,B2,US 11044737 B2,162-381-399-484-349,2021-06-22,2021,US 202015930115 A,2020-05-12,US 202015930115 A;;US 201816215986 A;;US 201615311799 A;;US 2015/0032279 W;;US 201462002041 P;;US 201462002037 P,2014-05-22,Physical channel structure for communication in unlicensed frequency band,Communication equipment communicates in a licensed frequency band using a licensed band physical channel structure (licensed structure) and communicates in an unlicensed frequency communication band using an unlicensed band physical channel structure (unlicensed structure) where the unlicensed structure includes at least the same symbol times and subcarrier frequency divisions as in the licensed structure. The symbol times and subcarriers form a plurality of time-frequency communication resource elements. A set of symbol times and subcarrier frequency divisions form a licensed reference subset of communication resource elements that are allocated for reference signal transmission in the licensed structure. The same set of symbol times and subcarrier frequency divisions form an unlicensed reference subset of communication resource elements that are allocated for reference signal transmission in the unlicensed structure.,KYOCERA CORP,KALHAN AMIT;;CHANG HENRY;;COMSTOCK DAVID,KYOCERA CORPORATION (2014-09-16),https://lens.org/162-381-399-484-349,Granted Patent,yes,21,0,37,37,0,H04W88/06;;H04L5/001;;H04L27/0006;;H04W74/0808;;H04W74/0866;;H04B7/2615;;H04W76/14;;H04W4/70;;H04W72/1215;;H04L5/0048;;H04L5/0053;;H04W76/14;;H04W4/70;;H04W88/06;;H04L5/001;;H04L27/0006;;H04W74/0808;;H04W74/0866;;H04W84/12;;H04B7/2615;;H04W72/21;;H04W72/23;;H04W72/541;;H04W72/1215;;H04W16/14;;H04W24/10;;H04W72/0453;;H04W88/08;;H04L5/0048;;H04W72/0446;;H04W24/08;;H04W72/02,H04W72/12;;H04B7/26;;H04L5/00;;H04L27/00;;H04W4/70;;H04W16/14;;H04W24/08;;H04W24/10;;H04W72/02;;H04W72/04;;H04W72/08;;H04W74/08;;H04W76/14;;H04W84/12;;H04W88/06;;H04W88/08,,2,0,,,"Samsung; “Physical Channel Design for Scheduling Assignment”; R1-141851; 3GPP TSG RAN WG1 Meeting #76bis; Mar. 31-Apr. 4, 2014; Shenzhen, China.;;Kyocera, “Design Details of Scheduling Assignments”; R1-141459; 3GPP TSG RAN WG1 Meeting #76bis; Mar. 31-Apr. 4, 2014; Shenzhen, China.",ACTIVE
926,US,A1,US 2011/0123436 A1,166-165-761-798-404,2011-05-26,2011,US 96402110 A,2010-12-09,US 96402110 A;;US 94953610 A;;US 39660509 A;;US 63372906 A;;US 38935806 A;;US 39158406 A;;US 47802106 A;;US 91551510 A;;US 87134510 A;;US 75474010 A;;US 75414010 A;;US 75264910 A;;US 73178110 A;;US 64414609 A;;US 54447609 A;;US 53780309 A;;US 47925009 A;;US 5618205 A;;US 46858909 A;;US 41887709 A;;US 41791709 A;;US 39696509 A;;US 86982310 A;;US 92540807 A;;US 78233206 P;;US 72829205 P;;US 75119605 P;;US 86453006 P;;US 37805910 P;;US 25872909 P;;US 25836909 P;;US 16680909 P;;US 16871509 P;;US 54422704 P;;US 23847309 P;;US 26630509 P;;US 31699610 P;;US 32396010 P;;US 23842409 P;;US 16829009 P;;US 16866809 P;;US 16865709 P;;US 16366609 P;;US 66860305 P;;US 9048708 P;;US 4393208 P;;US 10491608 P;;US 11954208 P;;US 26787709 P;;US 30268210 P;;US 41459210 P,2004-02-13,Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA,"Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2011-03-10),https://lens.org/166-165-761-798-404,Patent Application,yes,67,14,4,1035,82,B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2318/10;;C07K2319/00;;C07K2319/30;;A61K47/6849;;A61K47/6853;;A61K47/6891;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P9/00;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2318/10;;C07K2319/00;;C07K2319/30;;A61K47/6891;;A61K47/6849;;A61K47/6853,A61K39/395;;A61K51/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;C07K17/02,424/1.11;;530/391.1;;424/178.1;;424/181.1,3,3,043-779-209-608-781;;034-038-300-119-191;;100-801-934-296-913,16873051;;10.1016/j.cell.2006.07.007;;pmc7125751;;19846342;;pmc4441031;;10.1016/j.molmed.2009.09.001;;18234994;;10.1167/iovs.07-1175,"Dykxhoorn et al, Cell 126: 231-235, July 28, 2006.;;Kim et al, Trends in Molecular Medicine 15(11): 491-500, 2009.;;Yu et al, Investigative Ophthalmology & Visual Science 49(2): 522-527, February 2008.",ACTIVE
927,WO,A1,WO 2021/234644 A1,153-841-718-101-666,2021-11-25,2021,IB 2021054401 W,2021-05-21,US 202063029237 P,2020-05-22,IDENTIFICATION OF A FIRST SAMPLE IN A SERIES OF SEQUENTIAL SAMPLES,"An ADE device identifies an identifiable sequence of one or more ejections from at least one sample using a different value or pattern of values for one or more ADE parameters. The identifiable one or more ejections are performed to produce one or more mass peaks that have a different feature value or pattern of feature values for one or more peak features than other mass peaks produced. Ejection times are stored. One or more detected peaks with the different feature values or pattern of feature values are identified as produced by the identifiable one or more ejections. A delay time is calculated from the time of the identifiable ejections and the time of the identified detected peaks and the peaks are aligned with samples using delay time, stored times, and order of the samples.",DH TECHNOLOGIES DEV PTE LTD,COX DAVID;;LIU CHANG;;TATE STEPHEN,,https://lens.org/153-841-718-101-666,Patent Application,yes,7,3,5,5,0,H01J49/0454;;H01J49/0027;;H01J49/0009;;H01J49/0404;;H01J49/0009;;H01J49/0027;;H01J49/0404;;H01J49/0454,H01J49/00;;H01J49/04,,3,2,082-031-406-612-530;;035-173-945-292-352,10.1021/acs.analchem.0c02999;;33063997;;10.1002/rcm.1020;;12720286,"LIU CHANG ET AL: ""Operational Modes and Speed Considerations of an Acoustic Droplet Dispenser for Mass Spectrometry"", ANALYTICAL CHEMISTRY, vol. 92, no. 24, 16 October 2020 (2020-10-16), US, pages 15818 - 15826, XP055827509, ISSN: 0003-2700, DOI: 10.1021/acs.analchem.0c02999;;ANONYMOUS: ""Voyager (TM) Biospectrometry (TM) Workstation With Delayed Extraction"", 1 January 2000 (2000-01-01), XP055286306, Retrieved from the Internet <URL:http://www.niu.edu/analyticallab/_pdf/maldi/voyager-v51-usersguide.pdf> [retrieved on 20160706];;JAMES W. HAGERJ. C. YVES LE BLANC, RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 17, 2003, pages 1056 - 1064",PENDING
928,WO,A1,WO 2010/022225 A1,159-739-650-644-759,2010-02-25,2010,US 2009/0054441 W,2009-08-20,US 9048708 P,2008-08-20,DOCK-AND-LOCK (DNL) VACCINES FOR CANCER THERAPY,"The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 neg CD20 + MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.",IBC PHARMACEUTICALS INC;;CHANG CHIEN-HSING;;GOLDENBERG DAVID M,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/159-739-650-644-759,Patent Application,yes,3,12,17,1035,0,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;A61K39/001129;;A61K39/001112;;A61K39/001113;;A61K39/001176;;A61K39/001194;;A61K39/00117;;A61K39/001191;;A61K39/00115;;A61K39/001163;;A61K39/001124;;A61K39/001166;;A61K39/001182;;A61K39/001114;;A61K39/001138;;A61K39/001189;;A61K39/001192;;A61K39/001104;;A61K39/001103;;A61K39/001184;;A61K39/001188;;A61K39/001151;;A61K39/001117;;A61K39/001181;;A61K39/001109;;A61K39/001149;;A61K39/00114;;A61K39/001102;;A61K39/00113;;A61K39/001126;;A61K39/001135;;A61K39/001153;;A61K39/001162;;A61K39/001186;;A61K39/001195;;A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/001189;;A61K39/001112;;A61K39/001153;;A61K39/001163;;A61K39/001135;;A61K39/00117;;A61K39/001113;;A61K39/001124;;A61K39/001192;;A61K39/001129;;A61K39/001117;;A61K39/001103;;A61K39/001195;;A61K39/001138;;A61K39/001149;;A61K39/001182;;A61K39/001114;;A61K39/001102;;A61K39/001104;;A61K39/001126;;A61K39/00113;;A61K39/00114;;A61K39/00115;;A61K39/001166;;A61K39/001181;;A61K39/001186;;A61K39/001191;;A61K39/001194;;A61K39/001162;;A61K39/001176;;A61K39/001188;;A61K39/001109;;A61K39/001184;;A61K39/001151;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011,A61K39/00,,1,0,,,See also references of EP 2326346A4,PENDING
929,US,B1,US 8242865 B1,176-202-601-583-212,2012-08-14,2012,US 35291409 A,2009-01-13,US 35291409 A,2009-01-13,Planar RF electromechanical switch,"A micromachined switch is provided including a base substrate, a bond pad on the base substrate, a cantilever arm connected to the bond pad, the cantilever arm having a conductive via from the bond pad, a first actuation electrode on the base substrate, and a second actuation electrode on the cantilever arm connected to the bond pad by way of the conductive via, positioned such that an actuation voltage applied between the first actuation electrode and the second actuation electrode will deform the cantilever arm, wherein the first actuation electrode is facing a side of the cantilever arm opposite the second actuation electrode.",CHANG DAVID T;;HSU TSUNG-YUAN;;HRL LAB LLC,CHANG DAVID T;;HSU TSUNG-YUAN,HRL LABORATORIES LLC (2009-01-05),https://lens.org/176-202-601-583-212,Granted Patent,yes,5,0,2,2,0,H01H2057/006;;H01H57/00;;H01H55/00,H01H51/22,335/78;;200/181,2,0,,,"Huang, X.M.H., et al., ""Free-Free Beam Silicon Nananomechanical Resoantors,"" IEEE, The 12th International Conference on solid State Seanators, Actuators and Microsystems (Jun. 8-12, 2003).;;Seki, T., et al., ""Low-Loss RF MEMES Metal Contact Switch with CSP Structure,"" IEEE, The 12th International Conference on solid State Seanators, Actuators and Microsystems (Jun. 8-12, 2003).",ACTIVE
930,US,A1,US 2013/0163606 A1,178-663-688-304-291,2013-06-27,2013,US 201113337379 A,2011-12-27,US 201113337379 A,2011-12-27,Architecture for Scalable Virtual Network Services,"Techniques are provided to start a virtual service node that is configured to provide network traffic services for one or more virtual machines. The virtual service node has at least one associated service profile comprising identifiers for corresponding service policies for network traffic services. The service policies identified in the at least one associated service profile are retrieved. A virtual machine is started with an associated virtual interface and a port profile is applied to the virtual interface, including information identifying the service profile. Information is provided to the virtual service node that informs the virtual service node of network parameters and assigned service profile of the virtual machine. Network traffic associated with the virtual machine is intercepted and redirected to the virtual service node. A virtual service data path is provided that enables dynamic service binding, virtual machine mobility support, and virtual service node chaining and/or clustering.",BAGEPALLI NAGARAJ;;PATRA ABHIJIT;;CHANG DAVID;;CISCO TECH INC,BAGEPALLI NAGARAJ;;PATRA ABHIJIT;;CHANG DAVID,CISCO TECHNOLOGY INC (2011-12-21),https://lens.org/178-663-688-304-291,Patent Application,yes,4,129,2,2,0,H04L49/70;;H04L49/356;;H04L49/356;;H04L49/70,H04L12/56,370/409,0,0,,,,ACTIVE
931,SG,A1,SG 51711 A1,176-912-618-773-481,1998-09-28,1998,SG 1996011461 A,1996-11-29,SG 1996011461 A;;CA 2191279 A;;GB 9624553 A;;US 75850696 A,1996-11-26,An intelligent telephone system,,INVENTEC CORP,CHANG JACKSON;;LIN DAVID;;CAO JAMES,,https://lens.org/176-912-618-773-481,Patent Application,no,0,0,7,7,0,H04M1/247;;H04M1/27;;H04M1/27;;H04M1/247,H04M1/247;;H04M1/27,,0,0,,,,PENDING
932,EP,B1,EP 2785382 B1,191-018-270-278-670,2019-01-02,2019,EP 12854231 A,2012-11-29,US 201161566273 P;;US 201261616051 P;;US 201213483761 A;;US 2012/0067005 W,2011-12-02,MULTIVALENT ANTIBODY COMPLEXES TARGETING IGF-1R SHOW POTENT TOXICITY AGAINST SOLID TUMORS,,IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/191-018-270-278-670,Granted Patent,yes,6,0,5,1035,0,A61K39/3955;;C07K16/249;;C07K16/2803;;C07K16/2833;;C07K16/2863;;C07K16/2887;;C07K16/3007;;C07K16/3092;;A61K2039/507;;C07K2317/31;;C07K2317/35;;C07K2317/73;;C07K2317/77;;A61K47/6813;;A61K47/6849;;A61P35/00;;A61P37/02,A61K39/395;;A61K39/00;;A61K47/68;;C07K16/24;;C07K16/28;;C07K16/30,,8,0,,,"A. NAING ET AL: ""Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer"", CLINICAL CANCER RESEARCH, vol. 17, no. 18, 15 September 2011 (2011-09-15), pages 6052-6060, XP055061603, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2979;;E. ANDERS KOLB ET AL: ""R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts"", PEDIATRIC BLOOD & CANCER, 1 January 2010 (2010-01-01), pages n/a-n/a, XP055196541, ISSN: 1545-5009, DOI: 10.1002/pbc.22479;;R. T. KURMASHEVA ET AL: ""The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma"", CANCER RESEARCH, vol. 69, no. 19, 29 September 2009 (2009-09-29), pages 7662-7671, XP055185259, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-09-1693;;SRIRAM SATHYANARAYANAN ET AL: ""Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity"", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING; 100TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; DENVER, CA, USA; APRIL 18 -22, 2009, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 50, 1 April 2009 (2009-04-01), page 679, XP002687423, ISSN: 0197-016X;;X WAN ET AL: ""Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism"", ONCOGENE, vol. 26, no. 13, 25 September 2006 (2006-09-25), pages 1932-1940, XP055196548, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1209990;;COULTER DON W; BLATT JULIE; D'ERCOLE A JOSEPH; MOATS-STAATS BILLIE M: ""IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth"", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, vol. 28, no. 3A, 1 May 2008 (2008-05-01), pages 1509-1516, XP055196566, GR ISSN: 0250-7005;;THAKUR M L ET AL: ""IMPROVED ANTIBODY TARGETING WITH INTERFERON-ALPHA-2B CONJUGATE"", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, vol. 20, no. 3, 1 January 1997 (1997-01-01), pages 194-201, XP002945738, ISSN: 1524-9557;;QUEK ET AL.: 'Combination mTOR and IGF-1 inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.' CLIN CANCER RES. vol. 17, no. 4, 22 December 2010, pages 871 - 879, XP055070644",ACTIVE
933,WO,A9,WO 2010/022225 A9,198-426-156-014-193,2011-04-28,2011,US 2009/0054441 W,2009-08-20,US 9048708 P,2008-08-20,DOCK-AND-LOCK (DNL) VACCINES FOR CANCER THERAPY,"The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 neg CD20 + MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.",IBC PHARMACEUTICALS INC;;CHANG CHIEN-HSING;;GOLDENBERG DAVID M,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/198-426-156-014-193,Search Report,yes,0,0,17,1035,0,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;A61K39/001129;;A61K39/001112;;A61K39/001113;;A61K39/001176;;A61K39/001194;;A61K39/00117;;A61K39/001191;;A61K39/00115;;A61K39/001163;;A61K39/001124;;A61K39/001166;;A61K39/001182;;A61K39/001114;;A61K39/001138;;A61K39/001189;;A61K39/001192;;A61K39/001104;;A61K39/001103;;A61K39/001184;;A61K39/001188;;A61K39/001151;;A61K39/001117;;A61K39/001181;;A61K39/001109;;A61K39/001149;;A61K39/00114;;A61K39/001102;;A61K39/00113;;A61K39/001126;;A61K39/001135;;A61K39/001153;;A61K39/001162;;A61K39/001186;;A61K39/001195;;A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/001189;;A61K39/001112;;A61K39/001153;;A61K39/001163;;A61K39/001135;;A61K39/00117;;A61K39/001113;;A61K39/001124;;A61K39/001192;;A61K39/001129;;A61K39/001117;;A61K39/001103;;A61K39/001195;;A61K39/001138;;A61K39/001149;;A61K39/001182;;A61K39/001114;;A61K39/001102;;A61K39/001104;;A61K39/001126;;A61K39/00113;;A61K39/00114;;A61K39/00115;;A61K39/001166;;A61K39/001181;;A61K39/001186;;A61K39/001191;;A61K39/001194;;A61K39/001162;;A61K39/001176;;A61K39/001188;;A61K39/001109;;A61K39/001184;;A61K39/001151;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011,A61K39/00,,0,0,,,,PENDING
934,US,B2,US 9686888 B2,004-938-250-310-726,2017-06-20,2017,US 201514856836 A,2015-09-17,US 201514856836 A;;US 201213672413 A,2012-11-08,Heat dissipation lid having direct liquid contact conduits,"A heat dissipation lid that includes a plate having a first surface, an opposing second surface, and at least one sidewall extending from the plate second surface. The heat dissipation lid also includes at least one fluid delivery conduit and at least one fluid removal conduit, each extending between the plate first and second surface, and at least one spacing projection extending from the plate second surface to establish and maintain a desired distance between the plate second surface and a microelectronic device, when the heat dissipation lid is positioned to remove heat from the microelectronic device.",INTEL CORP,SONG DAVID W;;CHANG JE-YOUNG,,https://lens.org/004-938-250-310-726,Granted Patent,yes,15,3,4,4,0,H01L23/427;;H05K7/20272;;H01L23/473;;H01L23/473;;H01L2224/16;;H01L2224/73253;;H05K1/0209;;H05K1/0209;;H05K7/20218;;H05K7/2039;;H05K2201/066;;H05K2201/066;;Y10T29/4913;;Y10T29/4913,H05K7/20;;H01L23/427;;H01L23/473;;H05K1/02,,0,0,,,,ACTIVE
935,WO,A1,WO 2018/217227 A1,000-426-161-219-424,2018-11-29,2018,US 2017/0059940 W,2017-11-03,US 201715604153 A,2017-05-24,NOVEL ANTI-PD-1 CHECKPOINT INHIBITOR ANTIBODIES THAT BLOCK BINDING OF PD-L1 TO PD-1,"The present invention concerns compositions and methods of use of anti-PD-1 antibodies comprising CDR sequences corresponding to SEQ ID NO:1 to SEQ ID NO:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of SEQ ID NO: 9 and SEQ ID NO:10. The antibodies are of use to treat cancer and may be administered alone or with another standard anti-cancer therapy. The methods may comprise administering the anti-PD-1 antibody or antigen-binding fragment thereof in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or other checkpoint inhibitor antibodies.",IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/000-426-161-219-424,Patent Application,yes,3,19,1,72,14,A61P35/00;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2809;;C07K16/2818;;C07K16/30;;C07K16/3007;;C07K2317/24;;C07K2317/31;;C07K2317/76;;C07K2317/77;;C07K2317/92,C07K16/28;;A61K39/395;;A61P35/00;;C12N15/63;;G01N33/577,,0,0,,,,PENDING
936,US,A1,US 2018/0251746 A1,006-614-314-648-606,2018-09-06,2018,US 201815901556 A,2018-02-21,US 201815901556 A;;US 201615224441 A;;US 201313792135 A,2013-03-10,MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF,"The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.",BELLICUM PHARMACEUTICALS INC,SPENCER DAVID M;;CHANG WEI-CHUN,BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2023-11-21);;BELLICUM PHARMACEUTICALS INC (2013-04-29),https://lens.org/006-614-314-648-606,Patent Application,yes,4,4,17,17,50,A61K31/4545;;A61K31/4545;;A61K38/4873;;A61K38/4873;;A61K38/52;;A61K38/52;;A61P1/04;;A61P3/00;;A61P3/06;;A61P5/00;;A61P7/00;;A61P7/06;;A61P17/00;;A61P19/08;;A61P35/00;;A61P37/06;;A61P43/00;;C12N9/6472;;C12N9/6472;;C12N9/90;;C12N9/90;;C12Y304/22062;;C12Y304/22062;;C12Y502/01008;;C12Y502/01008,C12N9/64;;A61K31/4545;;A61K38/48;;A61K38/52;;C12N9/90,,0,0,,,,DISCONTINUED
937,US,B2,US 8481041 B2,014-214-990-684-992,2013-07-09,2013,US 201113288202 A,2011-11-03,US 201113288202 A;;US 74569207 A;;US 201113036820 A;;US 201113021302 A;;US 41791709 A;;US 47802106 A;;US 96893610 A;;US 39696509 A;;US 39158406 A;;US 96402110 A;;US 94953610 A;;US 39660509 A;;US 63372906 A;;US 75474010 A;;US 46858909 A;;US 38935806 A;;US 40974010 P;;US 201161487956 P;;US 80034206 P;;US 66860305 P;;US 72829205 P;;US 75119605 P;;US 78233206 P;;US 26787709 P;;US 30268210 P;;US 41459210 P;;US 86453006 P;;US 16829009 P,2005-04-06,Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy,"The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.",CHANG CHIEN-HSING;;GOLDENBERG DAVID M;;IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2012-02-06),https://lens.org/014-214-990-684-992,Granted Patent,yes,54,43,6,1035,105,A61K2039/505;;C07K16/1063;;C07K16/2887;;C07K2317/35;;C07K2317/51;;C07K2317/55;;C07K2317/64;;C07K2317/73;;C07K2317/732;;C07K2317/76;;A61K47/6809;;A61K47/6839;;A61K47/6879;;A61K47/60;;A61K47/6803;;A61K31/00;;A61P31/18;;A61K39/42;;A61K39/44;;A61K47/6809;;A61K47/6839;;A61K2039/505;;C07K16/1063;;C07K16/2887;;C07K2317/35;;C07K2317/51;;C07K2317/55;;C07K2317/64;;C07K2317/73;;C07K2317/732;;C07K2317/76;;A61K47/6879;;A61K39/3955;;A61K47/60;;A61K47/6803;;A61K31/00;;A61K31/704;;A61K39/39575,A61K39/00;;C07K16/08;;C07K19/00,424/179.1;;424/181.1;;530/391.1;;530/391.7,103,95,056-878-829-166-369;;055-097-669-167-865;;078-716-104-760-324;;033-666-351-337-122;;031-892-095-159-875;;085-345-104-578-809;;060-907-400-240-84X;;069-530-037-600-651;;049-041-058-538-276;;038-389-375-568-493;;069-564-057-074-164;;003-395-139-112-524;;087-676-232-841-375;;087-447-391-383-00X;;009-416-320-508-847;;046-007-655-283-621;;091-995-224-471-960;;046-723-641-666-637;;051-620-799-695-736;;000-687-583-450-12X;;030-424-581-071-330;;025-955-082-953-672;;043-565-065-226-050;;064-253-076-017-931;;073-213-551-327-892;;029-646-755-871-310;;015-399-642-762-43X;;142-686-487-823-912;;007-954-637-794-12X;;080-571-625-616-771;;013-580-733-777-26X;;046-220-521-080-741;;036-011-287-610-789;;046-650-803-614-561;;057-819-453-551-117;;020-829-015-080-665;;061-974-273-716-169;;073-910-564-236-619;;039-423-064-544-876;;028-385-018-876-542;;078-950-298-931-296;;082-317-213-185-417;;061-716-650-834-485;;154-648-591-453-198;;138-142-682-110-803;;066-146-798-965-262;;032-799-656-305-036;;088-770-954-200-50X;;002-331-092-499-856;;052-302-906-314-226;;125-439-449-787-91X;;002-968-698-489-191;;042-601-433-468-58X;;003-133-671-061-524;;001-773-325-098-677;;001-438-265-785-943;;021-399-654-204-715;;013-495-040-538-497;;014-817-433-156-057;;006-606-859-520-426;;016-722-289-911-388;;055-567-629-980-222;;002-036-513-655-449;;099-307-614-319-429;;003-051-068-663-062;;004-073-353-184-101;;023-678-010-672-059;;000-499-563-417-797;;023-833-986-552-400;;019-253-709-202-167;;103-932-348-507-545;;133-287-355-214-424;;091-341-936-846-342;;094-037-074-599-511;;101-663-979-767-604;;000-317-353-994-190;;052-947-986-013-690;;034-028-239-192-920;;040-142-822-097-134;;138-957-732-701-829;;077-950-844-586-930;;027-215-950-157-668;;139-123-355-549-723;;038-215-831-671-137;;032-409-676-506-509;;125-571-073-159-031;;044-988-808-395-48X;;019-736-899-818-187;;053-349-809-000-342;;008-956-301-309-595;;026-690-156-572-350;;066-342-559-427-246;;023-481-904-534-57X;;018-667-811-882-764;;007-072-874-769-097,10.2174/157489106775244046;;18221135;;15640162;;10.1074/jbc.m411141200;;10.1111/j.1749-6632.2001.tb03909.x;;11762983;;10.1002/cmdc.200500062;;16892368;;10.1093/jac/dkh428;;15456731;;8522171;;10.1016/0378-1119(95)00444-b;;10.1002/prot.1148;;11599031;;pmc249194;;10.1128/jvi.64.2.936-940.1990;;2296090;;10.2174/0929866013409201;;pmc2190574;;11331297;;10.1083/jcb.153.3.449;;16988511;;10.1097/01.aids.0000247111.58961.60;;10.1083/jcb.143.7.1883;;9864362;;pmc2175217;;10.1016/s0006-2952(99)00272-5;;10571253;;8627264;;10.1099/0022-1317-77-4-753;;9305836;;10.1038/38410;;10.1126/science.1126766;;16690857;;10.1073/pnas.0330734100;;12672969;;pmc153575;;16848397;;10.1021/bc060037u;;10.1016/j.febslet.2005.03.089;;15943971;;9857038;;10.1074/jbc.273.52.35048;;16704199;;10.1021/bc050322y;;10.1016/s1359-6101(01)00022-3;;11900988;;15375003;;10.1158/0008-5472.can-04-2048;;10.1016/0167-5699(96)10027-x;;8783497;;10358757;;10.1146/annurev.immunol.17.1.189;;6692364;;pmc2253242;;10.1110/ps.051687305;;16260760;;1860836;;10.1016/s0021-9258(18)98665-5;;11278869;;10.1074/jbc.m011252200;;pmc2118284;;16549598;;10.1084/jem.20060045;;10.1158/1078-0432.ccr-07-1217;;17875793;;pmc37461;;11447282;;10.1073/pnas.151260298;;10.1016/s0962-8924(99)01558-5;;10354567;;10.1016/s0021-9258(19)44263-4;;4348550;;10.1021/bc049781+;;15898716;;12657428;;10.1016/s1471-4914(03)00022-4;;pmc1373678;;10.1021/bc050172r;;16173810;;7963533;;17532550;;10.1016/j.biochi.2007.04.006;;10.1016/0022-1759(89)90093-8;;2514231;;10.1016/j.molimm.2007.06.151;;17768100;;18559529;;10.1158/0008-5472.can-08-0232;;10.1016/j.molcel.2006.09.006;;17081989;;10.2210/pdb2izy/pdb;;10.2967/jnumed.107.046185;;18077530;;10.1182/blood-2009-02-204289;;1366535;;10.1038/nbt0490-343;;10.1074/jbc.m412134200;;15596441;;9531615;;10.1182/blood.v91.8.3017.3017_3017_3027;;6159812;;10.7326/0003-4819-93-3-399;;8108387;;10.1073/pnas.91.4.1198;;pmc43124;;10.1038/nrd1033;;12612647;;10.1074/jbc.271.46.29016;;8910553;;15520207;;10.1158/0008-5472.can-04-1722;;11959956;;pmc122719;;10.1073/pnas.072685299;;10.4049/jimmunol.179.10.6881;;17982079;;pmc1462715;;10.1042/bj20051970;;16483255;;10.1080/10428190701704647;;18203019;;17081990;;pmc1855097;;10.1016/j.molcel.2006.09.015;;10.1023/a:1016042220817;;8842035;;6323591;;10.1089/jir.1983.3.425;;10.1016/s1074-7613(01)00126-1;;11336691;;10.1021/bc060245m;;17941681;;pmc392003;;6093118;;10.1073/pnas.81.21.6723;;9712065;;10.1210/mend.8.3.8015550;;8015550;;10.1210/me.8.3.325;;10.1006/jmbi.2000.3662;;10764601;;pmc1867205;;11943735;;10.1016/s0002-9440(10)62577-1;;10673721;;10.1038/sj.gt.3301059;;10.1093/emboj/20.7.1651;;pmc145475;;11285229;;10.2210/pdb1r2a/pdb;;10.1038/6663;;10074940;;0010074940;;10.1007/978-1-4684-6831-1_14;;12388634;;10.1124/jpet.102.037002;;2540040;;10.1016/0014-5793(89)80253-4;;9596485;;10.1023/a:1005934621940;;10.1002/jlb.64.3.358;;9738663;;6577942;;10.1007/bf00199167;;11356929;;10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-#;;10092109;;10.1002/(sici)1521-4141(199903)29:03<1041::aid-immu1041>3.0.co;2-;;pmc408104;;10.1172/jci5349;;10021462;;2411798;;10.1016/j.molimm.2004.11.003;;15829301;;10.1038/78966;;10966642;;10.1021/bc049713n;;15656592;;18922911;;10.1158/0008-5472.can-08-2033;;10.1073/pnas.0600982103;;16636283;;pmc1447525;;19710501;;10.1182/blood-2009-06-228890;;pmc2773491;;10.1021/bi972701n;;9485322;;10.3892/ijo.14.6.1143;;10339671;;18799723;;10.1182/blood-2008-04-153189;;10.1084/jem.191.10.1777;;pmc2193160;;10811870;;2147685;;10.1016/s0021-9258(18)45777-8;;10.1016/0163-7258(91)90075-w;;1653962;;pmc95154;;11274097;;10.1128/jb.183.8.2405-2410.2001;;10.1158/0008-5472.can-08-0037;;18593929;;pmc2585743;;18227543;;10.1148/radiol.2462070229,"Veiga et al., Recent Patents on Anti-Infective Drug Discovery, 2006, 1:67-73.;;Liu et al., The Journal of Biological Chemistry, 2005, 280(12):11259-11273.;;Tozser, Annals New York Academy of Sciences, 2001, 946:145-159.;;Dervillez et al., ChemMedChem, 2006, 1:330-339.;;Armbruster et al., ""Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12"", J Antimicrob Chemother. Nov. 2004;54(5):915-20.;;Backstrom et al., ""Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli"", Gene. Nov. 20, 1995;165(2):163-71.;;Bergamini et al., ""Adriamycin selectively inhibits HIV replication in resting macrophages"", Int Conf AIDS. Jun. 16-21, 1991;7(2):109 (abstract No. W.A.1071).;;Berry et al., ""Structure of an anti-HIV monoclonal Fab antibody fragment specific to a gp120 C-4 region peptide"", Proteins. Nov. 15, 2001;45(3):281-2.;;Broliden et al., ""A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization"", J Virol. Feb. 1990;64(2):936-40.;;Bryson et al., ""Cross-netralizing human monoclonal Anti-HIV-1 antibody 2F5: preparation and crystallographic analysis of the free and epitope-complexed forms of its Fab' fragment"", Protein and Peptide Letter, 8(5):413-428 (2001).;;Eck et al., ""Gene-Based Therapy"", The Pharmacological Bases of Therapeutics, Goodman and Gilman, Eds., pp. 77-101 (1996).;;Heath et al., ""Aggresomes resemble sites specialized for virus assembly"", J Cell Biol. Apr. 30, 2001;153(3):449-55.;;Johansson et al., ""Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody"", AIDS. Oct. 3, 2006;20(15):1911-5.;;Johnston et al., ""Aggresomes: a cellular response to misfolded proteins"", J Cell Biol. Dec. 28, 1998;143(7):1883-98.;;Orkin et al., Report and recommendation of the panel to assess the HIH investment in research on gene therapy, HIH, 1995.;;Paulik et al., ""Drug-antibody conjugates with anti-HIV activity"", Biochem Pharmacol. Dec. 1, 1999;58(11):1781-90.;;Sato K., ""Integration of cell experiment system"", KAST Annual Research Report, 2003, Abstract only.;;Schonning et al. ""Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1"", J Gen Virol. Apr. 1996;77 ( Pt 4):753-8.;;Verma et al., ""Gene therapy-promises, problems and prospects"", Nature. Sep. 18, 1997;389(6648):239-42.;;Wileman et al., ""Aggresomes and autophagy generate sites for virus replication"", Science. May 12, 2006;312 (5775):875-8.;;Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Company, 1991, p. 43.;;Alto et al., ""Bioinformatic design of A-kinase anchoring protein-in silico: A potent and selective peptide antagonist of type II protein kinase A anchoring"", PNAS USA 100:4445-50, 2003.;;Backer et al., ""Self-Assembled ""Dock and Lock"" System for Linking Payloads to Targeting Proteins"", Bioconjugate Chem., 17 (4), pp. 912-919, 2006.;;Baillie et al., ""Compartmentalisation of phospodiesterases and protein kinase A: opposites attract"", FEBS Letters 2005; 579:3264-3270.;;Banky et al., ""Dimerization/Docking Domain of the Type Ialpha Regulatory Subunit of cAMP-dependent Protein Kinase"", J. Biol. Chem. 273:35048-55, 1998.;;Basu et al., ""Structure-Function Engineering of Interferon-beta-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation"", Bioconjugate Chem. 2006; 17:618-630.;;Belardelli et al., ""Interferon-alpha in tumor immunity and immunotherapy"" Cytokine Growth Factor Rev. 13(2):119-134 (2002).;;Belardelli et al., ""International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?"" Cancer Res. 64:6827-6830 (2004).;;Belardelli et al., ""The neglected role of type I interferon in the T-cell response: implications for its clinical use"" Immunol. Today 17(8):369-72 (1996).;;Biron et al., ""Natural killer cells in antiviral defense: function and regulation by innate cytokines"" Annu. Rev. Immunol. 17:189-220 (1999).;;Brunda et al., ""Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons"" Cancer Res. 44:597-601 (1984).;;Burns-Hamuro et al., ""Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange"" Protein Science (2005), 14:2982-2992.;;Carr et al., ""Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif"", J. Biol. Chem. 266:14188-92 (1991).;;Carr et al., ""Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA"" J. Biol. Chem. 276(20):17332-17338 (2001).;;Carrero et al., ""Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes"" J. Exp. Med. 203(4):933-940 (2006).;;Chang et al., ""The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity"" Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.;;Chmura et al., ""Antibodies with infinite affinity"" Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).;;Colledge et al., ""AKAPs: from structure to function"", Trends Cell Biol. 6:216-21 (1999).;;Corbin et al., ""Regulation of Adenosine 3',5'-Monophosphate-dependent Protein Kinase"", J. Biol. Chem. 248:1813-21 (1973).;;Dhalluin et al., ""Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-alpha2a and Its Individual Positional Isomers"" Bioconjugate Chem. 2005;16:504-517.;;Dodart et al., ""Immunotherapy for Alzheimer's Disease: will vaccination work?"" Trends Mol. Med. 9(3):85-87 (2003).;;Doherty et al., ""Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor"", Bioconjugate Chem. 2005;16:1291-1298.;;Ferrantini et al., ""IFN-alpha1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity"" J. Immunol. 153:4604-15 (1994).;;Ferrantini et al., ""Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use"" Biochimie 89: 884-893 (2007).;;Gillies et al., ""High-level expression of chimeric antibodies using adapted cDNA variable region cassettes"", J. Immunol. Methods 125 (1989) 191-202.;;Glennie et al., ""Mechanisms of killing by anti-CD20 monoclonal antibodies"" Mol. Immunol. 44:3823-3837 (2007).;;Gold et al., ""A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma"", Cancer Res. 68:4819-26, 2008.;;Gold et al., ""Molecular Basis of AKAP Specificity for PKA Regulatory Subunits"" Mol. Cell Nov. 3, 2006;24(3):383-95.;;Goldenberg et al., ""Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting"", J. Nucl. Med. 49:158-63, 2008.;;Goldenberg et al., ""Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody"" Blood 113:1062-70 (2009).;;Goodson et al., ""Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site"", Nat. Biotechnology Apr. 1990;8(4):343-6.;;Grace et al., ""Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-alpha Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway"" J. Biol. Chem. 2005;280(8):6327-6336.;;Grimley et al., ""Prolonged STAT1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-alpha"" Blood 91(8):3017-27 (1998).;;Gutterman et al., ""Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma"" Ann. Intern. Med. 93(3):399-406 (1980).;;Gutterman et al., ""Cytokine therapeutics: Lessons from interferon alpha"" Proc. Natl. Acad. Sci. USA 91:1198-205 (1994).;;Harris et al., ""Effect of pegylation on pharmaceuticals"" Nat. Rev. Drug. Discov. 2:214-221 (2003).;;Hausken et al. ""Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII"", J. Biol. Chem. 271:29016-22 (1996).;;Henry et al., ""A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer"", Cancer Res. Nov. 1, 2004;64(21):7995-8001.;;Hodneland et al., ""Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands"", Proc. Natl. Acd. Sci. USA 2002; 99:5048-5052.;;Huang et al., ""Targeting IFN-alpha to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities"" J. Immunol. 179:6881-88 (2007).;;Hundsrucker et al., ""High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides"" Biochem. J. (2006) 396, 297-306.;;Kimby et al., ""Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group"" Leuk. Lymphoma 49(1):102-112 (2008).;;Kinderman et al., ""A Dynamic Mechanism for AKAP Binding to RII Isoforms of cAMP-Dependent Protein Kinase"" Mol. Cell 24(3):397-408 (2006).;;Kinstler et al., ""Characterization and Stability of N-terminally PEGylated rhG-CSF"" Pharm. Res. 1996;13(7):996-1002.;;Kramer et al., ""Cell and virus sensitivity studies with recombinant human alpha interferons"" J. Interferon. Res. 3(4):425-35 (1983).;;Le Bon et al., ""Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo"" Immunity 14:461-470 (2001).;;Lee et al., ""Solid-Phase PEGylation of Recombinant Interferon alpha-2a for Site-Specific Modification: Process Performance, Characterization, and in Vitro Bioactivity"" Bioconjugate Chem. 2007; 18:1728-34.;;Lohmann et al., ""High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins"", Proc. Natl. Acad. Sci. USA 81:6723-27 (1984).;;Luft et al., ""Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells"" J. Immunol. 161:1947-1953 (1998).;;Mason, Anthony J., ""Functional Analysis of the Cysteine Residues of Activin A"", Mol. Endocrinol. 8:325-32, 1994.;;Herberg et al., ""Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP binding"", J Mol Biol. Apr. 28, 2000;298(2):329-39.;;International Search Report for PCT/US11/59056, filed Nov. 3, 2011. Date of mailing Mar. 6, 2012.;;Matarrese et al., ""Type I Interferon Gene Transfer Sensitizes Melanoma Cells to Apoptosis via a Target Activity on Mitochondrial Function"" Am. J. Pathol. 2002, 160(4):1507-1520.;;Mecchia et al., ""Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha"" Gene Ther. (2000) 7, 167-179.;;Newlon et al., ""A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes"", EMBO J. 2001; 20:1651-1662.;;Newlon et al., ""The molecular basis for protein kinase A anchoring revealed by solution NMR"", Nature Stud. Biol. 1999; 3:222-227.;;Ngo et al., ""Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox"", The Protein Folding Problem and Tertiary Structure Prediction, Ch. 14, pp. 492-495, (Mertz & Le Grand, Eds.), Birkhauser Boston, 1994.;;Nordstrom et al., ""First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-alpha2b) is Highly Toxic for Human Lymphoma Cells in Vitro"", 2009 ASH Annual Meeting Abstracts, Nov. 20, 2009; 114(22):675, Abstract #1695.;;Osborn et al., ""Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-alpha Fusion Protein in Cynomolgus Monkeys"" J. Pharmacol. Exp. Ther. 303(2):540-548 (2002).;;Oyen et al., ""Human testis cDNA for the regulatory subunit RIIalpha of cAMP-dependent protein kinase encodes an alternate amino-terminal region"", FEBS Letters 246:57-64, 1989.;;Ozzello et al., ""Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3vl) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts"" Breast Cancer Res. Treat. 48: 135-147 (1998).;;Paquette et al., ""Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells"" J. Leukoc. Biol. 64:358-367; 1998.;;Pelham et al., ""Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36"" Cancer Immunol. Immuother. 1983;15(3):210-216.;;Pepinsky et al., ""Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-beta-1a with Preserved in Vitro Bioactivity"" Pharmacol. Exp. Ther. 2001; 297(3):1059-1066.;;Pilling et al., ""Interferon-beta mediates stromal cell rescue of T cells from apoptosis"" Eur. J. Immunol. 29:1041-1050 (1999).;;Rabjohn et al., ""Molecular Cloning and Epitope Analysis of the Peanut Allergen Ara h 3"" J. Clinical Investigation 103(4):535-542 (1999).;;Raefsky et al., ""Studies of Interferon as a regulator of hematopoietic cells proliferation"" J. Immunol. 135(4):2507-2512 (1985).;;Riemer et al., ""Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition"", Mol Immunol. May 2005;42(9):1121-4.;;Rose et al., ""Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1alpha"", Nature Struct. Biol. 2000; 7:744-748.;;Rosendahl et al., ""A Long-Acting, Highly Potent Interferon alpha-2 Conjugate Created Using Site-Specific PEGylation"" Bioconjugate Chem. 2005;16:200-207.;;Rossi et al., ""Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics"", Cancer Res. 68:8384-92, 2008.;;Rossi et al., ""Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting"" Proc. Natl. Acad. Sci. Epub Apr. 24, 2006, vol. 103, No. 18, pp. 6841-6846.;;Rossi et al., ""CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas"", Blood 2009;114:3864-3871.;;Rossi et al., ""A veltuzumab-IFNalpha2b conjugate with potent in vitro and in vivo anti-lymphoma activity"", Proceedings of the American Association for Cancer Research, Apr. 2009;50:783-784, Abstract # 3237.;;Rustandi et al., ""The Ca2+-Dependent Interaction of S100B(betabeta) with a Peptide Derived from p53"", Biochemistry 1998; 37: 1951-1960.;;Sabaawy et al., ""Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer"" Int. J. Oncol. Jun. 1999; 14(6):1143-51.;;Salles et al., ""Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study"" Blood 2008; 112:4824-4831.;;Santini et al., ""Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vivo and in Hu-PBL-SCID Mice"" J. Exp. Med. 191(10):1777-1788 (2000).;;Scott et al., ""Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase"", J. Biol. Chem. 265:21561-66 (1990).;;Scott et al., ""Cyclic nucleotide-dependent protein kinases"" Pharmacol. Ther. 1991;50(1):123-45.;;Seffernick et al., ""Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different"" J. Bacteriol. 183(8):2405-2410 (2001).;;Sharkey et al., ""Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody"", Cancer Res. 68:5282-90, 2008.;;Sharkey et al., ""Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model"", Radiology 246:497-507, 2008.",ACTIVE
938,US,A,US 5688435 A,006-933-664-162-997,1997-11-18,1997,US 61986496 A,1996-03-18,GB 9516372 A,1995-08-10,Pigmented rheopectic cleaning compositions with thixotropic properties,"A pigmented bleach-containing hard surface cleaner comprises an alkali metal hypochlorite, bentonite clay, a mono-(long chain alkyl)-tertiary amine oxide, an alkali metal salt, a pH stabilizer to attain a pH of 11 or higher, an alkali metal alkyl sarcosinate, an alkylbenzene sulphonate, and an inorganic pigment which is preferably ultramarine blue. The cleaning composition has excellent colour stability as well as phase stability and hypochlorite stability.",RECKITT & COLMAN INC,CHANG DAVID A;;CAVANAGH JAMES W,RECKITT BENCKISER LLC (1996-03-29),https://lens.org/006-933-664-162-997,Granted Patent,yes,14,25,6,19,0,C11D1/83;;C11D1/83;;C11D1/10;;C11D1/10;;C11D1/75;;C11D1/75;;C11D3/1266;;C11D3/1266;;C11D3/3956;;C11D3/3956;;C11D3/40;;C11D3/40;;C11D3/42;;C11D3/42,C11D1/10;;C11D1/75;;C11D1/83;;C11D3/12;;C11D3/395;;C11D3/40;;C11D3/42,252/187.25;;252/187.24;;252/187.26;;252/186.36;;510/191;;510/373;;510/490;;510/503,0,0,,,,EXPIRED
939,EP,A1,EP 0267942 A1,025-015-503-790-112,1988-05-25,1988,EP 87903522 A,1987-05-01,US 86927086 A,1986-05-30,UPCONVERSION PUMPED LASERS.,Le laser décrit comprend un milieu laser disposé dans une cavité à laser et un agencement de pompage pour appliquer sélectivement une énergie excitatrice au milieu laser. Le milieu laser contient un matériau de conversion incrémentielle du type permettant l'échange d'énergie entre des électrons des ions à effet laser à un état d'énergie donné inférieur à l'état laser initial métastable de sorte que certains des électrons d'échange sont convertis de manière incrémentielle à des états d'énergie égaux ou supérieurs à l'état laser initial métastable. L'agencement de pompage applique un énergie de longueur d'onde et d'intensité appropriées pour élever des électrons depuis des niveaux d'énergie inférieurs à l'état donné jusqu'à cet état en question en nombres suffisants pour supporter une conversion incrémentielle substantielle ainsi que l'effet laser résultant.,HUGHES AIRCRAFT CO,POLLACK SLAVA A;;CHANG DAVID B,,https://lens.org/025-015-503-790-112,Patent Application,yes,0,0,7,8,0,H01S3/08072;;H01S3/094038;;H01S3/094092;;H01S3/1608;;H01S3/1611;;H01S3/165;;H01S3/17;;H01S3/1123;;H01S3/1061;;H01S3/2391;;H01S3/1123;;H01S3/094092,H01S3/091;;H01S3/0933;;H01S3/094;;H01S3/11;;H01S3/121;;H01S3/16,,0,0,,,,EXPIRED
940,CA,C,CA 2781717 C,029-432-081-113-113,2017-09-12,2017,CA 2781717 A,2010-12-09,US 26787709 P;;US 64414609 A;;US 30268210 P;;US 73178110 A;;US 75264910 A;;US 75474010 A;;US 86982310 A;;US 87134510 A;;US 91551510 A;;US 41459210 P;;US 94953610 A;;US 2010/0059660 W,2009-12-09,DOCK-AND-LOCK (DNL) COMPLEXES FOR DELIVERY OF INTERFERENCE RNA,"Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/029-432-081-113-113,Granted Patent,no,0,0,8,1035,82,A61K2039/505;;C07K16/18;;C07K16/2803;;C07K16/2833;;C07K16/2887;;C07K16/30;;C07K16/303;;C07K16/3092;;C07K16/44;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2319/70;;C12N15/111;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32;;A61P35/00,A61K47/68,,0,0,,,,ACTIVE
941,US,A1,US 2020/0360709 A1,039-651-534-108-695,2020-11-19,2020,US 202016984486 A,2020-08-04,US 202016984486 A;;US 201715583096 A;;US 201615214726 A;;US 201514922885 A;;US 201514607959 A;;US 201313798523 A;;US 201213481124 A;;US 201615232320 A;;US 201615188608 A;;US 201615148842 A;;US 201514921890 A;;US 201562153616 P,2012-05-25,SYSTEM AND METHOD FOR PREVENTING OR TREATING ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES,A process that provides protective therapy for biological tissues or fluids includes applying a pulsed energy source to a target tissue or a target fluid having a chronic progressive disease or a risk of having a chronic progressive disease to therapeutically or prophylactically treat the target tissue or target fluid. A pulsed energy source having selected energy parameters may be applied to a brain of an individual who has Alzheimer's or other neurodegenerative disease or is at risk of developing such a neurodegenerative disease so as to prevent or treat the neurodegenerative disease.,OJAI RETINAL TECH LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,OJAI RETINAL TECHNOLOGY LLC (2020-07-27),https://lens.org/039-651-534-108-695,Patent Application,yes,0,5,2,287,0,A61N1/403;;A61N5/04;;A61N1/403;;A61N2/02;;A61N5/00;;A61N5/022;;A61N5/025;;A61N5/04;;A61N5/0622,A61N1/40;;A61N5/00,,0,0,,,,ACTIVE
942,US,A1,US 2013/0142942 A1,041-230-300-775-58X,2013-06-06,2013,US 201213678110 A,2012-11-15,US 201213678110 A;;US 201161561135 P,2011-11-17,Methods of Making a Reference Electrode for an Electrochemical Sensor,"Aspects of the present disclosure include methods for making an electrode for an electrochemical sensor. In practicing methods according to certain embodiments, a conductive layer is deposited on a substrate by high voltage electron beam thermal evaporation followed by depositing a reactive layer on a surface of the conductive layer by low-voltage resistive thermal evaporation using a sequential step, single production chamber. Also provided are methods for a producing a multi-layered reference electrode having silver or ITO and silver chloride thereon in the absence of a separate curing stage. Systems for practicing the subject methods are also described.",ABBOTT DIABETES CARE INC;;ABBOTT DIABETES CARE INC,WANG YI;;CHANG-YEN DAVID A,ABBOTT DIABETES CARE INC (2013-02-12),https://lens.org/041-230-300-775-58X,Patent Application,yes,9,5,1,1,0,G01N27/3272;;A61B5/00;;G01N27/3272,A61B5/00,427/8;;427/593;;427/535,0,0,,,,DISCONTINUED
943,CN,A,CN 101188718 A,045-563-242-233-424,2008-05-28,2008,CN 200710169382 A,2007-11-26,EP 06301177 A,2006-11-24,Method and apparatus for automatic fine tuning based on sync detection,,THOMSON LICENSING,DAVID CHANG CHIEW MUN;;HONG LI,,https://lens.org/045-563-242-233-424,Patent Application,no,0,3,5,6,0,H04N5/08;;H04N5/50;;H04N21/4302;;H04N21/4383;;H04N5/50;;H04N5/08;;H04N21/4383;;H04N21/4302,H04N5/50,,0,0,,,,INACTIVE
944,CA,C,CA 2191277 C,046-760-854-592-718,2001-02-27,2001,CA 2191277 A,1996-11-26,CA 2191277 A;;GB 9624542 A;;SG 1996011462 A,1996-11-26,METHOD AND APPARATUS FOR AUTOMATIC REDIALING,"An apparatus and a method for the automatic redialing by storing the dialed telephone numbers and the time sequence of the dialed numbers into RAM to result in successful redialing. The automatic redialing apparatus comprises; a timer, a RO M, a microprocessor, a RAM, and a telephone interface which consists of a dial keyboa rd, a automatic redial key, and a telephone receiver.",INVENTEC CORP,CHANG JACKSON;;LIN DAVID;;XU KENT,,https://lens.org/046-760-854-592-718,Granted Patent,no,0,0,6,6,0,H04M1/2725;;H04M1/27485,H04M1/272;;H04M1/27485,,0,0,,,,EXPIRED
945,US,B2,US 11797916 B2,051-068-804-153-32X,2023-10-24,2023,US 202117336892 A,2021-06-02,US 202117336892 A;;US 201916433471 A,2019-06-06,Systems and methods of package container return,A package container includes a processor that is configured to store a trial end time based at least in part on receiving a return request. The processor is also configured to determine a trial duration based on a comparison of a trial start time and the trial end time. The processor is further configured to initiate sending of a transportation request to a delivery management server in response to the processor determining that the trial duration is less than or equal to a trial duration threshold. The transportation request indicates a request to initiate sending of a transportation vehicle to a delivery location to retrieve the package container from the delivery location.,MOTOGO LLC,RUTH DAVID BRIAN;;LO YUAN-CHANG,MOTOGO LLC (2019-06-04),https://lens.org/051-068-804-153-32X,Granted Patent,yes,13,0,5,5,0,G06Q10/087;;G06Q10/0837;;G06Q10/0837;;G06F9/542;;G06Q10/087;;B65D55/02;;B65D43/16;;G07C9/00;;G06Q50/40,G06Q10/0837;;B65D43/16;;B65D55/02;;G06F9/54;;G06Q10/087;;G06Q50/30;;G07C9/00,,1,0,,,"Re-Turnz website <http://re-turnz.com/> (<http://web.archive.org/web/20190531023144/http://re-turnz.com/> captured on May 31, 2019 using Wayback Machine) (Year: 2019).",ACTIVE
946,US,A1,US 2016/0007499 A1,055-462-356-774-237,2016-01-07,2016,US 201514856836 A,2015-09-17,US 201514856836 A;;US 201213672413 A,2012-11-08,HEAT DISSIPATION LID HAVING DIRECT LIQUID CONTACT CONDUITS,"A heat dissipation lid that includes a plate having a first surface, an opposing second surface, and at least one sidewall extending from the plate second surface. The heat dissipation lid also includes at least one fluid delivery conduit and at least one fluid removal conduit, each extending between the plate first and second surface, and at least one spacing projection extending from the plate second surface to establish and maintain a desired distance between the plate second surface and a microelectronic device, when the heat dissipation lid is positioned to remove heat from the microelectronic device.",INTEL CORP,SONG DAVID W;;CHANG JE-YOUNG,,https://lens.org/055-462-356-774-237,Patent Application,yes,7,8,4,4,0,H01L23/427;;H05K7/20272;;H01L23/473;;H01L23/473;;H01L2224/16;;H01L2224/73253;;H05K1/0209;;H05K1/0209;;H05K7/20218;;H05K7/2039;;H05K2201/066;;H05K2201/066;;Y10T29/4913;;Y10T29/4913,H05K7/20,,0,0,,,,ACTIVE
947,US,A,US 4216112 A,057-312-266-064-089,1980-08-05,1980,US 83516577 A,1977-09-21,US 83516577 A,1977-09-21,Pressure-sensitive microcapsules containing alkylnaphthalene solvent and process for their production,"Pressure-sensitive microcapsules containing a solvent composition for use in carbonless copy systems for use in the absence of a halogenated solvent consisting essentially of a combination of a mono-alkyl naphthalene, wherein said alkyl group contains from 1 to 3 carbon atoms per molecule and a di-alkyl naphthalene, wherein each of said alkyl groups in said di-alkyl naphthalene contains from 2 to 4 carbon atoms per molecule, said mono-alkyl naphthalene being present in an amount between about 25 and about 40 percent by weight of the alkylated naphthalenes present in the solvent, and an isocyanate cross-linking agent.",CHAMPION INT CORP,CHANG CHENG H;;VINCENT DAVID N,,https://lens.org/057-312-266-064-089,Granted Patent,yes,5,2,1,1,0,B01J13/16;;B41M5/1655;;Y10S428/914;;Y10T428/2987;;Y10T428/2984;;Y10T428/2987;;Y10T428/2984;;B01J13/16;;B41M5/1655;;Y10S428/914,B01J13/16;;B41M5/165,252/316,0,0,,,,EXPIRED
948,US,A,US 4810474 A,063-818-920-045-575,1989-03-07,1989,US 8928587 A,1987-08-25,US 8928587 A,1987-08-25,"Method of removing nitrogen monoxide from a nitrogen monoxide-containing gas using a water-soluble iron ion-dithiocarbamate, xanthate or thioxanthate","A method of removing nitrogen monoxide from a nitrogen monoxide-containing gas, which method comprises: (a) contacting a nitrogen oxide-containing gas with an aqueous solution of water soluble organic compound-iron ion chelate of the formula: ##STR1## wherein the water-soluble organic compound is selected from compounds of the formula: ##STR2## wherein: R is selected from hydrogen or an organic moiety having at least one polar functional group; Z is selected from oxygen, sulfur, or --N--A wherein N is nitrogen and A is hydrogen or lower alkyl having from one to four carbon atoms; and M is selected from hydrogen, sodium or potassium; and n is 1 or 2, in a contacting zone for a time and at a temperature effective to reduce the nitrogen monoxide. These mixtures are useful to provide an unexpensive method of removing NO from gases, thus reducing atmospheric pollution from flue gases.",US ENERGY,LIU DAVID K;;CHANG SHIH-GER,UNITED STATES OF AMERICA THE AS REPRESENTED BY THE DEPARTMENT OF ENERGY (1987-08-21),https://lens.org/063-818-920-045-575,Granted Patent,yes,12,3,5,5,0,B01D53/56;;B01D53/56,B01D53/56;;B01D53/77,423/235,1,1,083-026-684-783-532,10.1002/ep.670060124,"Tu et al, Chemistry of a Flue Gas Combined NO x and SO 2 Scrubber Employing Ferrous Cysteine Additives, Apr. 1986.",EXPIRED
949,WO,A1,WO 1996/039661 A1,051-979-297-105-901,1996-12-12,1996,US 9609041 W,1996-06-05,US 46536795 A,1995-06-05,ERROR DETECTION AND CORRECTION METHOD AND APPARATUS,"A method and apparatus are disclosed for detecting and correcting errors in the data stored within the entries of a memory table. Each time data is entered into the memory table, an error code generator generates a corresponding error code using the data. This error code is stored in the memory table along with the corresponding data. When an entry in the memory table is read out, an error detector receives the outputted data and its corresponding error code and processes the data and the error code to determine whether the outputted data contains any errors. If the outputted data contains any errors, the outputted data and error code are sent to an error correction unit. In response, the correction unit attempts to find single and double bit errors in the data by way of a compact and efficient computer program. If either a single or double bit error is found, the error correction unit corrects the error or errors to derive a set of corrected data. This corrected data is then written back to the proper entry within the memory table to correct the error or errors in the data. Data errors within the memory table are thus detected and corrected.",HAL COMPUTER SYSTEMS INC,SAXENA NIRMAL;;CHANG CHIH-WEI DAVID,,https://lens.org/051-979-297-105-901,Patent Application,yes,0,0,8,8,0,G06F11/1008;;H03M13/15;;G06F11/1008;;H03M13/15,G06F11/10;;G06F12/16;;H03M13/01;;H03M13/15,,1,1,089-507-895-789-067,10.1109/ftcs.1993.627366,"CHANG D C-W, ET AL: ""Concurrent Error Detection/Correction in the HAL MMU Chip"", 23RD INT. SYMPOSIUM ON FAULT-TOLERANT COMPUTING, 22 June 1993 (1993-06-22), TOULOUSE, FRANCE, pages 630 - 635, XP000437282",PATENTED
950,CA,C,CA 2191279 C,060-681-667-001-611,2000-03-07,2000,CA 2191279 A,1996-11-26,CA 2191279 A;;GB 9624553 A;;SG 1996011461 A;;US 75850696 A,1996-11-26,AN INTELLIGENT TELEPHONE SYSTEM,"The present invention relates to an intelligent telephone system, operating methods related to the system are also disclosed. The intelligent telephone is c apable of programming operating procedures as a shortcut for re-operating in the future . Furthermore, achieve the purpose of conveniently operating some complicated oper ating processes for a user, and being capable of automatically performing in a preset time limit. The intelligent telephone system includes storage means, a ROM (Read Only Memory ), an LCD (Liquid Crystal Display), a telephone interface a CPU (Central Processing Unit), and a user inputting interface. The user interface is used for receiving audio information and commands for controlling operations to shortcuts. In software structure, the intelligent system includes a system control module, a shortcut f unctional module, and lots of software modules. The system control module gives control ri ghts and relative messages to the shortcut functional module. The shortcut functional module then control actions of the software modules for the purpose of completel y handling shortcut operations.",,LIN DAVID;;CAO JAMES;;CHANG JACKSON,,https://lens.org/060-681-667-001-611,Granted Patent,no,0,0,7,7,0,H04M1/247;;H04M1/27;;H04M1/27;;H04M1/247,H04M1/247;;H04M1/27,,0,0,,,,EXPIRED
951,US,S,US D0395071 S,069-047-093-092-815,1998-06-09,1998,US 7482097 F,1997-08-11,US 7482097 F,1997-08-11,In-tank toilet dispenser,,RECKITT & COLMAN INC,BODKER ALAN N;;CHANG DAVID A,RECKITT BENCKISER LLC (2010-12-31),https://lens.org/069-047-093-092-815,Design Right,yes,4,2,2,2,0,,,D23/208;;2301,0,0,,,,EXPIRED
952,EP,A3,EP 0723236 A3,060-990-670-431-830,1996-12-11,1996,EP 96300252 A,1996-01-12,US 37670795 A,1995-01-23,System for communicating messages among agent processes,"Data processing application requests are processed in a computer system configured as a plurality of nodes with a plurality of interacting processes. Data is requested by an application request originating on a first node. The request data includes data located on a plurality of the nodes. A portion of computer memory on the nodes is established as agent message queues (""AMQ's""). A first process, acting as a coordinating agent, receives an application request on the first node. The coordinating agent generates a plurality of internal requests for the application request. The coordinating agent communicates the internal requests to a fast communication manager process (""FCM"") on the first node. The first fast communications manager process, sends the internal requests to fast communications manager process's on the nodes having the request data (""request data nodes""), for storage in selected AMQ's on the request data nodes. The internal requests are retrieved from the selected AMQ's by processes acting as subordinate agents on the request data nodes. The subordinate agents may currently process the internal requests.",IBM,CHANG DAVID Y;;SMITH MARC GREGORY,,https://lens.org/060-990-670-431-830,Search Report,yes,0,0,7,7,0,G06F9/546;;G06F9/546,G06F15/16;;G06F9/46,,6,1,098-978-322-012-688,10.1147/sj.282.0241,"ASHFIELD J C ET AL: ""SYSTEM-INDEPENDENT FILE MANAGEMENT AND DISTRIBUTION SERVICES"", IBM SYSTEMS JOURNAL, vol. 28, no. 2, 1 January 1989 (1989-01-01), pages 241 - 259, XP000122366;;ANONYMOUS: ""Sharing Application Control Data in the Parallel Database Manager"", IBM TECHNICAL DISCLOSURE BULLETIN, vol. 37, no. 4B, April 1994 (1994-04-01), NEW YORK, US, pages 331 - 332, XP002014669;;SCHWARTZ M F: ""THE NETWORKED RESOURCE DISCOVERY PROJECT"", INFORMATION PROCESSING, SAN FRANCISCO, AUG. 28 - SEPT. 1, 1989, no. CONGRESS 11, 28 August 1989 (1989-08-28), RITTER G X, pages 827 - 832, XP000079775;;ANONYMOUS: ""Multiple IUCV Users on VM"", IBM TECHNICAL DISCLOSURE BULLETIN, vol. 28, no. 2, July 1985 (1985-07-01), NEW YORK, US, pages 762 - 765, XP002014670;;ANONYMOUS: ""Subcontractor Agent Service for a File Access Processor"", IBM TECHNICAL DISCLOSURE BULLETIN, vol. 31, no. 8, January 1989 (1989-01-01), NEW YORK, US, pages 191 - 194, XP002014671;;PATENT ABSTRACTS OF JAPAN vol. 015, no. 047 (P - 1162) 5 February 1991 (1991-02-05)",EXPIRED
953,GB,A,GB 2319692 A,056-784-210-030-575,1998-05-27,1998,GB 9624542 A,1996-11-26,GB 9624542 A;;CA 2191277 A;;SG 1996011462 A,1996-11-26,A telephone re-dialling facility,A method and apparatus are disclosed for automatically re-dialling a stored telephone number in which the apparatus stores the digits of a telephone number dialled by a caller and also the time intervals which elapse between digits as they are dialled. When the number is then re-dialled the stored intervals are automatically inserted between the digits. This is important when making long distance calls which require the caller to pause during the dialling sequence.,INVENTEC CORP,CHANG JACKSON;;LIN DAVID;;XU KENT,,https://lens.org/056-784-210-030-575,Patent Application,no,2,0,6,6,0,H04M1/2725;;H04M1/27485,H04M1/272;;H04M1/27485,H4K KBNX          KBNX,2,0,,,"Patent Abstracts of Japan, vol. 18, no. 509, page 148, (E1610) & JP-A-06 177 952 (SEKISUI CHEM);;Patent Abstracts of Japan, vol. 17, no. 404, page 66, (E1405) & JP-A-05 075 685 (MEISEI ELECTRIC)",EXPIRED
954,US,A1,US 2017/0088619 A1,060-445-078-947-586,2017-03-30,2017,US 201615378972 A,2016-12-14,US 201615378972 A;;US 201213656159 A;;US 201113074351 A;;US 201213567226 A;;US 201113004349 A;;US 31990210 P;;US 32928210 P;;US 29384610 P;;US 32300110 P;;US 37444910 P,2010-01-11,Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells,"Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8 + memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.",IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IMMUNOMEDICS INC (2013-02-08),https://lens.org/060-445-078-947-586,Patent Application,yes,0,0,8,8,100,A61K31/4965;;A61K31/4965;;A61K47/6807;;A61K47/6807;;A61K47/6813;;A61K47/6813;;A61K47/6815;;A61K47/6815;;A61K47/6849;;A61K47/6849;;A61K47/6881;;A61K47/6881;;A61K47/6885;;A61K47/6885;;A61P37/06;;C07K16/2833;;C07K16/18;;C07K16/2803;;C07K16/2803;;C07K16/2833;;C07K16/2851;;C07K16/2863;;C07K16/2887;;C07K16/2887;;C07K16/30;;C07K16/30;;C07K16/3007;;C07K16/3007;;C07K16/3092;;C07K16/44;;C07K16/44;;C07K2317/24;;C07K2317/24;;C07K2317/31;;C07K2317/31;;C07K2317/35;;C07K2317/35;;C07K2317/51;;C07K2317/51;;C07K2317/52;;C07K2317/52;;C07K2317/522;;C07K2317/522;;C07K2317/55;;C07K2317/55;;C07K2317/73;;C07K2317/73;;C07K2317/734;;C07K2317/734;;C07K2317/75;;C07K2317/75;;C07K2317/77;;C07K2317/77;;C07K2319/70;;C07K2319/70;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32;;Y02A50/30,C07K16/28;;C07K16/18;;C07K16/30;;C07K16/44;;C12N15/113,,1,1,031-138-099-455-044,8888491;;10.1002/stem.140501,"Marland et al., 1996, Stem Cells, VOl. 14: 501-507",DISCONTINUED
955,AU,A,AU 1996/065431 A,068-168-639-046-816,1997-03-05,1997,AU 1996/065431 A,1996-07-08,GB 9516372 A;;US 61986496 A;;US 9611409 W,1995-08-10,Pigmented rheopectic cleaning compositions with thixotropic properties,,RECKITT BENCKISER INC,CHANG DAVID A;;CAVANAGH JAMES W,RECKITT BENCKISER INC. (2002-08-22),https://lens.org/068-168-639-046-816,Patent Application,no,0,0,13,19,0,C11D3/3956;;C11D1/10;;C11D1/75;;C11D1/83;;C11D3/1266;;C11D3/40;;C11D3/42,C11D1/10;;C11D1/75;;C11D1/83;;C11D3/12;;C11D3/395;;C11D3/40;;C11D3/42,,0,0,,,,EXPIRED
956,US,A1,US 2011/0189083 A1,065-304-454-055-876,2011-08-04,2011,US 201113010993 A,2011-01-21,US 201113010993 A;;US 54447609 A;;US 39660509 A;;US 63372906 A;;US 38935806 A;;US 39158406 A;;US 47802106 A;;US 78233206 P;;US 72829205 P;;US 75119605 P;;US 86453006 P;;US 9048708 P,2005-10-19,Dock-and-Lock (DNL) Vaccines for Cancer Therapy,"The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 neg CD20 + MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.",IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2009-10-30),https://lens.org/065-304-454-055-876,Patent Application,yes,77,49,17,1035,35,A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;A61K39/001129;;A61K39/001112;;A61K39/001113;;A61K39/001176;;A61K39/001194;;A61K39/00117;;A61K39/001191;;A61K39/00115;;A61K39/001163;;A61K39/001124;;A61K39/001166;;A61K39/001182;;A61K39/001114;;A61K39/001138;;A61K39/001189;;A61K39/001192;;A61K39/001104;;A61K39/001103;;A61K39/001184;;A61K39/001188;;A61K39/001151;;A61K39/001117;;A61K39/001181;;A61K39/001109;;A61K39/001149;;A61K39/00114;;A61K39/001102;;A61K39/00113;;A61K39/001126;;A61K39/001135;;A61K39/001153;;A61K39/001162;;A61K39/001186;;A61K39/001195;;A61K2039/6056;;A61K2039/625;;B82Y5/00;;C07K16/2803;;C07K16/2887;;C07K16/3007;;C07K16/468;;C07K2317/31;;C07K2317/55;;C07K2317/77;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K47/6897;;A61K39/001189;;A61K39/001112;;A61K39/001153;;A61K39/001163;;A61K39/001135;;A61K39/00117;;A61K39/001113;;A61K39/001124;;A61K39/001192;;A61K39/001129;;A61K39/001117;;A61K39/001103;;A61K39/001195;;A61K39/001138;;A61K39/001149;;A61K39/001182;;A61K39/001114;;A61K39/001102;;A61K39/001104;;A61K39/001126;;A61K39/00113;;A61K39/00114;;A61K39/00115;;A61K39/001166;;A61K39/001181;;A61K39/001186;;A61K39/001191;;A61K39/001194;;A61K39/001162;;A61K39/001176;;A61K39/001188;;A61K39/001109;;A61K39/001184;;A61K39/001151;;A61K39/0011;;A61K2039/505;;C07K16/2833;;C07K2317/24;;C07K2317/51;;C07K2317/522;;C07K2317/526;;C12Y207/11011,A61K38/19;;A61K39/395;;A61K38/20;;A61K38/21;;A61K51/00;;A61P35/00;;A61P35/02;;A61P37/04,424/1.11;;424/178.1;;424/85.2;;424/85.6;;424/85.7;;424/85.5;;424/130.1;;424/85.1;;424/85.4,9,8,100-801-934-296-913;;037-719-830-241-939;;043-472-027-972-076;;050-929-392-993-933;;033-802-631-358-941;;042-979-543-299-89X;;139-399-324-818-879;;086-617-534-349-291,18234994;;10.1167/iovs.07-1175;;10.1354/vp.42-4-468;;16006606;;10.1182/blood-2005-01-0318;;15878980;;10.3410/f.1025985.321890;;16979786;;10.1016/j.addr.2006.05.004;;10665474;;10.1023/a:1006314501634;;2461992;;22387378;;10.1016/j.abb.2012.02.011;;pmc52575;;10.1073/pnas.88.19.8691;;1717984,"Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522-527, February 2008.;;Jubala et al., Vet Pathol 42: 468-476, 2005.;;Tacken et al., Blood 106(4): 1278-1284, August 15, 2005.;;Tabi et al., Advanced Drug Delivery Review 58: 902-915, 2006.;;Zhu et al., Investigational New Drugs 17: 195-212, 1999.;;Tedder et al., J Immunol 141(12): 4388-4391, December 1988.;;Golay et al., Archives of Biochemistry and Biophysics 526: 146-153, 2012.;;Stancovski et al., PNAS 88: 8691-8695, 1991.;;Martin et al., Leukemia & Lymphoma, 2015; Early Online: 1-6.",ACTIVE
957,WO,A1,WO 2016/033163 A1,087-490-736-368-256,2016-03-03,2016,US 2015/0046910 W,2015-08-26,US 201462043601 P,2014-08-29,IDENTIFICATION OF CANCER GENES BY IN-VIVO FUSION OF HUMAN CANCER CELLS AND ANIMAL CELLS,"The present invention concerns compositions and methods for detecting and identifying novel cancer genes. The technique involves in vivo fusion of human cancer cells and animal cells, preferably hamster stromal cells, to form hybrid human cancer-animal cells, followed by identification of genes that are overexpressed in the hybrid cells compared to normal or transformed animal cells. The novel oncogenes or their protein products may be utilized for detection and/or diagnosis of human cancer or for development of new cancer therapies targeted against the novel oncogenes or their expressed proteins.",IMMUNOMEDICS INC,GOLDENBERG DAVID M;;CHANG CHIEN-HSING,,https://lens.org/087-490-736-368-256,Patent Application,yes,3,9,5,5,86,C12Q1/6886;;C12Q1/6886;;C12Q2600/158;;C12Q2600/158,C12N5/28;;C12Q1/68,,5,4,137-101-026-198-432;;034-098-591-018-837;;028-569-460-877-835;;071-475-138-092-070,10.1371/journal.pone.0055324;;pmc3566191;;23405135;;1101764;;10.7326/0003-4819-83-4-553;;16572121;;10.1038/nature04687;;10.1158/0008-5472.can-06-1456;;16912208,"GOLDENBERG, DM ET AL.: ""Horizontal Transmission Of Malignancy: In-Vivo Fusion Of Human Lymphomas With Hamster Stroma Produces Tumors Retaining Human Genes And Lymphoid Pathology."", PLOS ONE., vol. 8, no. 2, February 2013 (2013-02-01), pages e553249, XP055412135;;KUCHERLAPATI, RS ET AL.: ""Mammalian Somatic Hybrids and Human Gene Mapping."", ANNALS OF INTERNAL MEDICINE., vol. 83, 1975, pages 553 - 560, XP009500540;;NGO, VN ET AL.: ""A Loss-Of-Function RNA Interference Screen For Molecular Targets In Cancer."", NATURE, vol. 441, 4 May 2006 (2006-05-04), pages 106 - 110, XP009500539;;JACOBSEN, BM ET AL.: ""Spontaneous Fusion with, And Transformation Of Mouse Stroma By, Malignant Human Breast Cancer Epithelium."", CANCER RES., vol. 66, no. 16, 2006, pages 8274 - 8279, XP055412148;;See also references of EP 3186365A4",PENDING
958,DE,A1,DE 2405242 A1,080-040-327-905-345,1974-08-08,1974,DE 2405242 A,1974-02-04,US 32929473 A;;US 43014174 A,1973-02-05,"CHROMOGENE BISFLUORAN-VERBINDUNGEN, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG",,CHAMPION PAPER CO LTD,VINCENT DAVID N;;CHANG CHENG HSIUNG,,https://lens.org/080-040-327-905-345,Patent Application,no,0,0,8,8,0,B41M5/1455;;C09B11/24;;Y10S428/914;;C09B11/24;;B41M5/1455;;Y10S428/914,B41M5/145;;C09B11/24,,0,0,,,,DISCONTINUED
959,US,A,US 5086972 A,084-783-767-603-976,1992-02-11,1992,US 56111890 A,1990-08-01,US 56111890 A,1990-08-01,ENHANCED ELECTROSTATIC PAINT DEPOSITION METHOD AND APPARATUS,"An enhanced electrostatic paint deposition apparatus (10) comprising a nozzle (16), a conduit (14) coupled to the nozzle for supplying paint (12) thereto, and a plurality of electrically conductive whiskers (18) positioned within the nozzle for applying an electrostatic charge to droplets of the paint. Each of the whiskers terminates in a jagged end (30) for enabling the droplets to acquire an enhanced electric charge. The whiskers may be provided with lengths which are tailored to provide an array of whiskers with a desired three-dimensional curvature for controlling the focussing field on the paint droplets. Each whisker is secured to a holder (22) which is, in turn, secured to a porous grid (20) whose mesh size is selected to divide that paint into narrow streams of desired size, which exit nozzle 16 in droplet form. The holder is configured by decreasing its center portion (28) in dimension to tume the holder's current limiting capabilities. Pulsed negative high voltage is applied to the whiskers for enabling them to negatively charge the paint. Phased deflector plates 22, 24, 26 are provided to steer the paint stream.",HUGHES AIRCRAFT CO,CHANG DAVID B;;DRUMMOND JAMES E,HUGHES AIRCRAFT COMPANY A CORP. OF DE (1990-07-09);;HE HOLDINGS INC. A DELAWARE CORP (1997-12-17);;RAYTHEON COMPANY (1997-12-17),https://lens.org/084-783-767-603-976,Granted Patent,yes,13,33,7,7,0,B05B5/0533;;B05B5/0536;;B05B5/00;;B05B5/0536;;B05B5/0533,B05B5/053;;B05D1/04,239/3;;239/690;;239/698;;239/708,0,0,,,,EXPIRED
960,US,B2,US 10809745 B2,099-635-934-067-200,2020-10-20,2020,US 201916247470 A,2019-01-14,US 201916247470 A;;US 201862617479 P,2018-01-15,System and method of last mile delivery,A vehicle includes a storage unit configured to store a plurality of package containers. Each package container of the plurality of package containers is associated with a corresponding destination. The vehicle includes a package manipulator configured to move a first package container of the plurality of package containers from the storage unit to a first drone. The first drone is configured to move the first package container to a first destination corresponding to the first package container.,MOTOGO LLC,RUTH DAVID BRIAN;;LO YUAN-CHANG,MOTOGO LLC (2019-01-14),https://lens.org/099-635-934-067-200,Granted Patent,yes,12,3,5,5,0,G05D1/0295;;G06Q10/083;;B64U80/86;;B64U2101/64;;B64U10/13;;G06Q10/08;;G06Q50/40;;G05D1/12;;G05D1/0276;;G05D1/0287;;G05D1/104;;G05D1/0206;;G05D1/0295;;B60P3/06;;B64C39/024;;G06Q10/00;;G06Q10/083;;B64U2101/60;;G06Q10/08;;G06Q50/40,G05D1/12;;B60P3/06;;B64C39/02;;G05D1/02;;G05D1/10;;G06Q10/00;;G06Q10/08;;G06Q50/28;;G06Q50/30,,0,0,,,,ACTIVE
961,AU,A,AU 1991/078216 A,093-177-360-356-041,1992-02-27,1992,AU 1991/078216 A,1991-06-05,US 53579390 A,1990-06-11,INFRARED HOLOGRAPHIC DEFECT DETECTOR,,HUGHES AIRCRAFT CO,CHANG DAVID B;;DRUMMOND JAMES E,,https://lens.org/093-177-360-356-041,Patent Application,no,0,0,9,9,0,G01B9/021;;G01N21/3581;;G01N21/88;;G01N21/9515;;G01N2021/95615;;G03H2001/0413;;G03H2210/30;;G03H2222/16;;G03H2222/33;;G03H2226/11;;G01B11/24;;G01N21/88;;G03H2001/0413;;G03H2210/30;;G03H2222/16;;G01N21/3581;;G01N21/9515;;G03H2226/11;;G01N2021/95615;;G03H2222/33;;G01B9/021,G01B11/24;;G01B9/021;;G01N21/35;;G01N21/88;;G01N21/93;;G01N21/95;;G01N21/956,,0,0,,,,EXPIRED
962,US,A1,US 2014/0053004 A1,097-397-528-198-076,2014-02-20,2014,US 201213595016 A,2012-08-27,US 201213595016 A;;US 201213589280 A,2012-08-20,SLAB INDUCTOR DEVICE PROVIDING EFFICIENT ON-CHIP SUPPLY VOLTAGE CONVERSION AND REGULATION,"A method is disclosed to operate a voltage conversion circuit such as a buck regulator circuit that has a plurality of switches coupled to a voltage source; a slab inductor having a length, a width and a thickness, where the slab inductor is coupled between the plurality of switches and a load and carries a load current during operation of the plurality of switches; and a means to reduce or cancel the detrimental effect of other wires on same chip, such as a power grid, potentially conducting return current and thereby degrading the functionality of this slab inductor. In one embodiment the wires can be moved further away from the slab inductor and in another embodiment magnetic materials can be used to shield the slab inductor from at least one such interfering conductor.",CHANG LELAND;;GOREN DAVID;;WANG NAIGANG;;IBM,CHANG LELAND;;GOREN DAVID;;WANG NAIGANG,,https://lens.org/097-397-528-198-076,Patent Application,yes,5,2,10,10,0,H02M3/155;;H02M3/156;;G06F1/26;;H02M3/155;;H02M3/158,G06F1/26;;G05F3/04,713/300;;323/311,0,0,,,,INACTIVE
963,US,B2,US 10954305 B2,097-476-597-778-141,2021-03-23,2021,US 201916393213 A,2019-04-24,US 201916393213 A;;US 201715429671 A;;US 201662293530 P;;US 201662329788 P;;US 201662336985 P,2016-02-10,Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers,The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.,IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IMMUNOMEDICS INC (2017-04-05),https://lens.org/097-476-597-778-141,Granted Patent,yes,154,1,9,9,55,A61K45/06;;A61K39/3955;;A61K51/1057;;C07K16/2887;;C07K16/3007;;C07K16/3092;;C07K2317/732;;C07K2317/77;;C07K2317/90;;C07K2317/92;;A61K47/6889;;A61K47/6803;;A61K47/6851;;A61K31/4535;;A61K31/473;;A61K31/4985;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;A61K45/06;;A61K39/3955;;A61K51/1057;;C07K16/2887;;C07K16/3007;;C07K16/3092;;C07K2317/732;;C07K2317/77;;C07K2317/90;;C07K2317/92;;A61K47/6889;;A61K47/6803;;A61K47/6851;;A61K31/4535;;A61K31/473;;A61K31/4745;;A61K31/4985;;A61K41/0038;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/565,C07K16/30;;A61K31/4535;;A61K31/473;;A61K31/4745;;A61K31/4985;;A61K39/395;;A61K41/00;;A61K45/06;;A61K47/68;;A61K51/10;;C07K16/28,,299,241,042-547-777-341-035;;108-600-785-855-282;;084-406-081-121-709;;056-084-479-750-455;;032-854-664-208-42X;;034-891-431-823-507;;065-623-261-799-738;;015-642-848-867-795;;096-236-862-413-065;;043-968-156-521-588;;081-786-494-160-86X;;010-146-804-013-128;;020-760-687-853-074;;030-607-398-087-475;;050-098-928-030-605;;037-017-089-132-994;;017-090-382-753-584;;076-183-945-466-427;;150-572-162-645-593;;047-701-489-754-614;;022-559-088-437-181;;058-762-950-947-317;;119-790-899-925-321;;042-233-175-582-26X;;030-323-674-660-051;;017-885-420-491-431;;042-204-626-457-327;;034-368-738-281-179;;148-566-474-884-523;;027-477-313-726-928;;039-694-062-725-758;;034-930-328-000-261;;088-851-255-233-972;;025-452-211-728-128;;000-230-170-365-728;;062-178-034-712-346;;042-867-392-672-290;;020-753-772-581-741;;012-673-725-064-848;;007-975-732-459-031;;052-921-940-379-720;;011-629-453-765-864;;019-168-971-708-423;;010-887-119-494-005;;130-195-552-916-671;;064-584-104-378-002;;134-307-095-921-860;;098-896-386-065-00X;;013-949-512-224-407;;015-025-443-148-609;;011-772-978-286-710;;153-953-439-011-20X;;035-271-391-847-828;;016-057-597-802-813;;004-502-302-666-605;;014-461-807-764-133;;056-939-871-131-764;;077-540-261-874-947;;136-729-689-116-079;;086-494-726-333-342;;044-726-527-887-779;;000-981-138-819-15X;;003-475-422-937-054;;059-477-415-607-736;;145-091-110-316-853;;014-036-481-584-548;;065-049-126-712-747;;166-719-967-077-903;;012-246-090-378-416;;042-944-947-577-761;;041-489-007-310-663;;043-342-385-609-124;;100-765-335-491-455;;079-726-622-008-509;;062-070-522-483-445;;174-478-515-506-055;;042-547-777-341-035;;145-374-705-966-273;;055-398-771-003-487;;099-001-494-960-315;;042-867-392-672-290;;006-749-329-100-094;;009-483-512-107-343;;031-719-370-148-435;;009-042-325-358-821;;012-104-543-895-325;;068-263-202-843-607;;034-772-288-124-313;;026-030-068-135-86X;;000-831-802-795-392;;112-824-579-660-422;;037-256-563-161-695;;010-111-903-745-914;;085-277-440-303-853;;035-104-987-435-228;;043-164-824-642-059;;068-702-049-290-007;;113-664-356-121-786;;051-482-033-723-112;;114-983-664-284-645;;010-123-349-408-635;;006-574-964-805-278;;022-759-753-924-884;;012-426-427-709-70X;;041-607-340-819-599;;033-722-471-924-608;;090-608-096-845-681;;106-753-778-592-300;;093-013-896-320-935;;062-158-043-867-309;;109-401-140-187-082;;001-151-746-014-076;;129-380-899-533-361;;032-820-729-763-323;;029-554-504-516-703;;015-339-909-605-122;;083-734-720-759-001;;088-656-447-551-373;;036-730-021-282-133;;046-361-760-081-927;;010-767-236-613-732;;020-127-117-763-794;;016-264-988-597-177;;007-493-367-998-675;;031-068-903-800-566;;018-179-351-202-058;;033-076-217-897-938;;153-207-578-081-22X;;143-294-391-188-188;;064-095-005-847-857;;148-991-600-782-331;;148-991-600-782-331;;053-889-348-645-937;;057-109-097-264-085;;069-321-339-177-245;;020-247-708-537-98X;;023-353-382-712-677;;019-559-136-556-09X;;137-205-442-514-613;;010-355-722-618-087;;171-017-539-947-823;;013-324-562-069-273;;010-627-479-628-985;;058-941-200-408-297;;038-000-152-109-072;;064-187-084-636-385;;031-068-903-800-566;;086-529-876-159-009;;087-031-646-027-148;;077-993-437-813-956;;060-998-747-543-379;;059-350-421-627-620;;165-041-812-797-428;;084-077-881-948-187;;002-492-039-627-908;;030-787-855-460-273;;045-498-624-517-619;;020-292-102-950-30X;;096-963-332-973-023;;057-128-712-606-686;;136-975-822-416-307;;058-859-503-377-384;;011-586-406-038-755;;128-836-441-705-236;;058-002-244-207-299;;025-301-087-308-039;;053-519-394-609-859;;051-717-130-010-96X;;030-794-989-593-325;;019-970-046-472-407;;046-603-564-693-861;;136-702-292-558-987;;030-479-327-358-342;;006-255-114-636-027;;000-547-741-855-41X;;037-584-917-369-18X;;003-838-960-550-412;;047-696-403-759-235;;065-684-269-783-203;;006-502-021-606-385;;191-033-722-441-201;;086-043-006-762-621;;079-255-923-000-756;;048-933-493-818-958;;002-759-423-576-375;;097-793-301-869-669;;014-902-168-422-911;;001-597-371-627-98X;;020-948-757-199-739;;055-324-436-521-365;;035-555-079-782-964;;039-290-617-350-793;;012-205-385-297-196;;029-917-637-507-800;;093-013-896-320-935;;022-312-164-847-613;;135-436-322-557-657;;020-534-534-925-756;;011-957-336-554-446;;101-048-885-765-283;;026-221-045-144-327;;008-407-960-911-73X;;135-702-726-061-040;;081-015-235-385-866;;044-329-054-302-873;;053-066-550-722-310;;067-697-834-670-531;;024-850-071-089-623;;029-906-660-886-630;;038-412-408-668-355;;023-954-641-765-962;;006-214-050-266-758;;009-974-066-299-096;;130-375-486-019-144;;112-393-806-936-598;;053-780-397-247-24X;;010-488-902-861-235;;099-832-503-419-14X;;018-172-135-113-876;;011-391-078-348-438;;109-659-920-419-356;;082-050-684-115-538;;047-167-336-592-24X;;037-864-263-908-59X;;012-973-893-068-586;;012-883-895-542-617;;032-905-075-079-620;;030-276-673-639-075;;003-552-514-905-777;;053-126-944-220-622;;091-200-508-488-826;;019-133-244-582-473;;112-393-806-936-598;;000-490-184-388-374;;030-178-438-506-054;;101-564-289-320-086;;001-291-021-947-017;;026-538-606-321-414;;004-859-401-621-244;;010-208-025-594-921;;064-189-123-360-414,21566063;;10.1158/1535-7163.mct-10-0874;;10.1002/cncr.22402;;17154393;;324671;;pmc1540873;;2692037;;16760006;;10.1007/s12094-006-0177-7;;10.1038/442739a;;16915261;;10.1053/beha.2002.0222;;12468399;;2362198;;10.1211/0022357991776787;;10579680;;pmc41463;;7624362;;10.1073/pnas.92.15.7021;;10.1182/blood.v84.8.2457.2457;;10.1182/blood.v84.8.2457.bloodjournal8482457;;7522629;;10.1182/blood.v90.6.2188;;10.1182/blood.v90.6.2188.2188_2188_2195;;9310469;;3101766;;10.1182/blood.v69.3.836.836;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1007/bf00177365;;1618230;;11410483;;10.1073/pnas.86.10.3833;;2726754;;pmc287235;;3536124;;10.1016/0092-8674(86)90506-4;;2663143;;10.1056/nejm199310213291702;;7692295;;7623531;;10.1016/s0140-6736(95)92225-3;;9672771;;10556272;;10.1093/rheumatology/38.11.1150;;10.1016/s0022-1759(97)00192-0;;9692846;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;9178842;;3127726;;10.1038/332323a0;;10.1073/pnas.90.18.8581;;pmc47401;;8397411;;9824507;;pmc1364410;;10.1046/j.1365-2567.1998.00615.x;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;pmc2902227;;19409036;;10.1089/cbr.2009.0627;;10.1016/s0006-3495(89)82788-2;;pmc1330451;;2467696;;1423650;;10.3109/07388559209114235;;10.1038/nbt1192-1446;;1369022;;10.1002/ijc.2910560413;;8112889;;10.4049/jimmunol.150.7.2844;;8095956;;10.1007/bf01518451;;7691407;;10.1093/intimm/6.4.579;;8018598;;7828367;;10.1006/clin.1995.1020;;10.1016/s0024-3205(03)00566-6;;12899928;;2472198;;10.1084/jem.173.1.137;;pmc2118772;;1985119;;8496602;;3126097;;10.1016/0378-1119(87)90219-8;;9679970;;1459581;;10.1089/hyb.1992.11.539;;23151048;;pmc3534488;;10.1186/1472-6890-12-22;;10.1158/1535-7163.mct-10-0338;;20663928;;10.1007/s00428-013-1475-4;;23979406;;19683559;;10.1016/j.bbcan.2009.08.001;;pmc3503378;;10.4103/1947-2714.103319;;23181231;;8417827;;10.1146/annurev.cb.08.110192.000435;;1282354;;10.1007/s13277-012-0586-x;;23150179;;10.1016/j.yexmp.2012.08.004;;23031786;;10.1002/ijc.28451;;23982827;;10.1073/pnas.78.8.5147;;pmc320350;;7029529;;24086649;;pmc3785439;;10.1371/journal.pone.0075864;;10.1186/1476-4598-13-53;;pmc4015355;;24606732;;23207686;;10.1007/s11605-012-2105-1;;10.1007/s10072-013-1326-8;;23397225;;10.1186/1477-7819-10-53;;22482828;;pmc3342122;;9610724;;10.1002/(sici)1097-0215(19980529)76:5<671::aid-ijc10>3.0.co;2-7;;10.1158/1535-7163.mct-12-0603;;23223830;;23564776;;26319086;;10.1158/1078-0432.ccr-15-1166;;10.18632/genesandcancer.40;;pmc4426947;;26000093;;11390564;;pmc3201164;;10.1369/0022155411410430;;21551320;;20079406;;10.1016/j.bbcan.2009.12.002;;pmc3237457;;10.1371/journal.pone.0028607;;22194864;;10.1016/j.ygyno.2010.12.018;;23872121;;10.1016/j.pep.2013.07.006;;18281513;;10.1158/1535-7163.mct-07-2003;;pmc3243826;;21970857;;10.1158/1541-7786.mcr-11-0241;;22987366;;10.1002/hed.23138;;21566063;;10.1158/1535-7163.mct-10-0874;;23150297;;22351200;;10.1385/0-89603-204-3:79;;8443582;;10.1101/gr.2.3.266;;10.1002/1097-0142(19940201)73:3+<896::aid-cncr2820731322>3.0.co;2-h;;8306276;;10.1007/bf01518451;;7691407;;7691963;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;10.1038/nbt0297-159;;9035142;;10.1385/0-89603-244-2:263;;21400284;;7608568;;10.4049/jimmunol.155.2.925;;9354445;;7693850;;10.1084/jem.178.5.1567;;pmc2191245;;8795695;;10.1016/0145-2126(96)00007-0;;2451562;;10.1200/jco.1991.9.4.548;;2066752;;8281471;;10.3322/canjclin.44.1.43;;10.1111/j.1365-2141.1987.tb06162.x;;3122816;;10.1038/ng0594-13;;8075633;;1762576;;10.1016/0076-6879(91)03007-4;;8947500;;pmc1217930;;10.1042/bj3200293;;6490581;;1706642;;10.1007/bf01741331;;9058745;;10.1182/blood.v89.6.2203;;pmc1003575;;2969703;;10.1136/ard.47.7.588;;9382890;;10.1084/jem.186.11.1923;;pmc2199156;;10.1038/321522a0;;3713831;;9076770;;10.1097/00006231-199702000-00009;;7493367;;10.1056/nejm199308123290703;;7687326;;7594496;;10.4049/jimmunol.155.10.4917;;3320581;;10.1016/0145-2126(87)90166-4;;1172191;;10.1038/256495a0;;8428363;;7737671;;10.1089/hyb.1994.13.469;;10.1016/0161-5890(95)00080-1;;8643111;;10.1212/wnl.52.8.1701;;10331706;;10.1016/0008-8749(89)90359-6;;2463099;;8159246;;10.1038/368856a0;;8914801;;10.1097/00001622-199609000-00003;;1696564;;10.1002/ijc.2910460228;;10.1002/jps.2600830117;;8138914;;10.1016/0378-5173(96)04456-0;;10.1158/1538-7445.sabcs14-p5-19-27;;10.1200/jco.2015.33.15_suppl.1016;;10.1158/0008-5472.can-07-1589;;18339868;;10.1200/jco.2015.33.15_suppl.2505;;10.1016/j.clgc.2015.10.002;;26541586;;10.1158/1538-7445.am2011-3619;;10.1158/1538-7445.am10-2438;;10.1021/mp5006195;;25402018;;19789330;;pmc2769088;;10.1158/1078-0432.ccr-09-0586;;10.1200/jco.2015.33.3_suppl.625;;10.1158/1538-7445.am10-5543;;17942826;;10.1096/fj.07-9574lsf;;10.1158/1538-7445.am2014-ct211;;10.1158/1538-7445.am2014-ct211;;10.1158/1078-0432.ccr-15-0124;;26473191;;24577941;;10.1158/1535-7163.mct-13-0683;;10.1158/1535-7163.targ-15-lb-c16;;10.1002/ijc.2910620419;;7635574;;10.1158/1538-7445.am10-5346;;10.1158/1535-7163.targ-15-c166;;10.1158/1538-7445.sabcs15-p6-15-02;;10.1021/acs.bioconjchem.5b00223;;25915780;;10.1158/1538-7445.am2014-2904;;10.1200/jco.2014.32.15_suppl.3107;;10.1158/1538-7445.sabcs14-p5-19-08;;26101915;;10.18632/oncotarget.4318;;pmc4673178;;10.1158/1538-7445.am2012-2526;;14999147;;10.1023/b:brea.0000018417.02580.ef;;10.1158/1538-7445.am10-2438;;10.1200/jco.2015.33.15_suppl.2504;;10.1158/1538-7445.am2012-4636;;10.1093/annonc/mdv233.162;;26106073;;10.1158/1078-0432.ccr-15-0670;;10.1097/00002371-199408000-00093;;10.1158/1538-7445.am2015-ct236;;10.1158/1535-7163.targ-13-c67;;10.1158/1538-7445.am2014-ct206;;10.1200/jco.2015.33.15_suppl.3546;;10.1158/1078-0432.ccr-14-3321;;pmc4558321;;25944802;;10.1200/jco.2015.33.3_suppl.703;;8253531;;10.1002/ijc.2910550611;;8306265;;10.1002/1097-0142(19940201)73:3+<816::aid-cncr2820731311>3.0.co;2-t;;2153458;;7606734;;11418314;;10.1016/s1040-8428(01)00106-8;;10541364;;10.1002/ijc.2910570721;;10.2967/jnumed.110.086520;;21865288;;pmc7100438;;17516710;;10.2165/00063030-200721030-00002;;17375082;;pmc2013952;;10.1038/sj.bjp.0707218;;10.1016/j.addr.2008.11.003;;pmc3105088;;19135109;;21118093;;10.2174/138920111795163913;;pmc3091815;;15255290;;10.1158/1535-7163.mct-12-0146;;pmc3462004;;22784709;;10.1007/s101470200035;;12202977;;pmc3028588;;10.1016/j.bbcan.2010.08.002;;20708654;;19469529;;10.1021/bc9001097;;18048937;;10.1099/mic.0.2007/008417-0;;9815155;;10.1021/bc980044l;;pmc10766325;;10.1158/1078-0432.ccr-10-2939;;21372224;;1727373;;15931214;;10.1038/nature03727;;10.1016/0169-5002(95)90663-0;;16131447;;10.1007/bf02710170;;16428500;;10.1158/1078-0432.ccr-05-1892;;10.1158/1535-7163.mct-12-1170;;23427296;;10.4324/9781315825151-97;;10.1021/jm00107a017;;1672159;;11212270;;9381203;;10.1126/science.278.5340.1041;;16767259;;10.1039/b516551b;;15246077;;10.1016/j.bmc.2004.06.003;;1725255;;10.1021/bc00012a008;;10.1128/aac.2.5.395;;4363789;;pmc444326;;10.1074/jbc.273.11.6395;;9497370;;10.1126/science.313.5792.1370;;16959977;;10077478;;10.1021/bc980100i;;8428363;;21333700;;10.1016/j.addr.2011.02.002;;pmc3132824;;10.1016/j.addr.2010.05.008;;20561951;;18939816;;10.1021/jm800719t;;pmc2661425;;10.1182/blood.v97.2.528;;11154233;;10.1016/s0014-2999(98)00541-x;;9774255;;10657642;;10.4049/jimmunol.164.4.1925;;10.1097/00001622-199212000-00020;;1457528;;22039078;;10.1158/1535-7163.mct-11-0632;;10.1158/1535-7163.mct-11-0115;;pmc5654622;;21467164;;8176479;;7493360;;11003162;;10.1016/s0968-0896(00)00157-7;;11853934;;10.1016/s0168-3659(01)00554-5;;pmc1864878;;17322365;;10.2353/ajpath.2007.060929;;10.1016/j.addr.2008.04.012;;18541331;;pmc2820307;;10.1016/s0074-7696(08)62137-3;;9348670;;10.1016/s0960-894x(01)00707-7;;11755358;;10.1158/2159-8290.cd-nb2019-034;;30867160;;10.1158/2159-8290.cd-nb2015-162;;26577300;;10.1056/nejmc1903943;;31189049;;31189048;;10.1200/jco.2016.70.8297;;28291390;;pmc5559902;;10.3410/f.727407789.793559069;;10.1016/s1470-2045(17)30232-2;;28343977;;10.1158/1535-7163.mct-17-0354;;29133623;;28069724;;10.1158/1078-0432.ccr-16-2401;;27207776;;10.1158/1535-7163.mct-16-0219;;10.1016/j.ejmech.2019.02.017;;30822636;;pmc8259133;;28817371;;10.1200/jco.2017.73.9011;;29989029;;pmc6034748;;10.18632/oncotarget.25615;;31208270;;10.1080/19420862.2019.1632115;;pmc6748572;;28679770;;10.1158/1078-0432.ccr-17-0933;;10.3410/f.727782010.793565218;;29977989;;10.1016/j.gore.2018.05.009;;pmc6030029;;28548889;;10.1200/jco.2016.72.1894;;30516432;;10.1080/19420862.2018.1556465;;pmc6380461;;pmc5825203;;29300693;;10.1080/19420862.2018.1415671;;10.17219/acem/70159;;29790694;;29116596;;10.1007/s11523-017-0535-0;;28558150;;10.1002/cncr.30789;;10.1056/nejmc1903943;;31189049;;31189048;;30931493;;10.1007/s11864-019-0633-6;;10.1080/14712598.2017.1331214;;28503956;;10.1158/1535-7163.mct-17-0442;;29079710;;30827748;;10.1016/s1470-2045(19)30074-9;;10.2217/fon-2018-0131;;30175620;;10.3233/blc-180169;;30112436;;pmc6087439;;30268765;;10.1016/j.clbc.2018.09.001;;10.1080/13543784.2019.1555239;;30507322,"Yannazaki et al. (Mol Cancer Ther, 10:1252-1263, 2011).;;US 6,558,648 B1, 05/2003, Griffiths et al. (withdrawn);;Beckman et al., “Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors”, Cancer. Jan. 15, 2007;109(2):170-9.;;Berenbaum, MC., “Synergy, additivism and antagonism in immunosuppression. A critical review”, Clin Exp Immunol. Apr. 1977;28(1):1-18.;;Berenbaum, MC., “What is synergy?”, Pharmacol Rev. Jun. 1989;41(2):93-141.;;Cespedes et al., “Mouse models in oncogenesis and cancer therapy”, Clin Transl Oncol. May 2006;8(5):318-29.;;Dennis, C., “Cancer: off by a whisker”, Nature. Aug. 17, 2006;442(7104):739-41.;;Foran, JM., “Antibody-based therapy of non-Hodgkin's lymphoma”, Best Pract Res Clin Haematol. Sep. 2002;15(3):449-65.;;Fujimori et al., “A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier”, J Nucl Med. Jul. 1990;31(7):1191-8.;;Lundberg et al., “Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions”, J. Pharm. Pharmacol. 51(10):1099-105 (1999).;;Mack et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity”, Proc. Natl. Acad. Sci. USA 92:7021-7025 (1995).;;Maloney et al., “Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma”, Blood 84(8):2457-66 (1994).;;Maloney et al., “IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma”, Blood. Sep. 15, 1997;90(6):2188-95.;;Mason et al., “Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells”, Blood. Mar. 1987;69(3):836-40.;;Mills et al., “Diagnostic imaging of non-Hodgkin's lymphoma with anti-lymphomas antibody labeled with Tc-99m”, Proc Am Assoc Cancer Res 1993; 34:479, Abstract #2857.;;Mole S. E., “Epitope Mapping”, Methods in Molecular Biology, vol. 10: Immunochemical Protocols, Manson (Ed.), Humana Press, Inc. (1992).;;Morrison et al., “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains”, Proc Natl Acad Sci USA Nov. 1984;81(21):6851-5.;;Murthy et al., “Lymphoma imaging with a new technetium-99m labelled antibody, LL2”, Eur J Nucl Med. 1992;19 (6):394-401.;;Ochakovskaya et al., Therapy of Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice with an Anti-CD74 Antibody Conjugated with (111)Indium, (67)Gallium, or (90)Yttrium, Clin. Cancer Res. 7(6):1505-1510 (2001).;;Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction”, Proc. Natl. Acad. Sci. USA 86:3833-3837 (1989).;;Pastan et al., “Immunotoxins”, Cell 47:641-648 (1986).;;Pawlak-Byczkowska et al., “Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human ymphoma”, Cancer Res. 49(16):4568-77 (1989).;;Perrota et al., “Response of chronic relapsing ITP of 10 years duration to Rituximab”, Blood, vol. 92(10 Suppl.), p. 88b, 1998, Abstract# 3360.;;Press et al., “Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support”, N. Engl. J. Med. 329(17):1219-24 (1993).;;Press et al., “Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas”, Lancet 346:336-40 (1995).;;Press et al., “Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates”, Cancer J. Sci. Am. 4(Suppl 2):S19-26 (1998).;;Brotheroe et al., “Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma”, Rheumatology (Oxford) 38(11):1150-2 (1999).;;Qu et al., “Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates”, J. Immunol. Methods 213(2):131-44 (1998).;;Qu et al., “Internalization and cytotoxic effects of a humanized anti-CD74 antibody, LL1”, Proc Am Assoc Cancer Res 2002;43:255, Abstract # 1269.;;Queen et al., “A humanized antibody that binds to the interleukin 2 receptor”, Proc Natl Acad Sci U S A. Dec. 1989;86(24):10029-33.;;Renner et al., “Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospects”, Leukemia 11(Suppl 2):S55-9 (1997).;;Riechmann et al., “Reshaping human antibodies for therapy”, Nature 332(6162):323-7 (1988).;;Roche et al., “Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization”, Proc Natl Acad Sci U S A. Sep. 15, 1993;90(18):8581-5.;;Rowan et al., “Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells”, Immunology 95(3):427-36 (1998).;;Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci. USA 79(6):1979-83 (1982).;;Rudnick et al., “Affinity and avidity in antibody-based tumor targeting”, Cancer Biother Radiopharm. Apr. 2009;24(2):155-61.;;Saltzman et al., “Transport rates of proteins in porous materials with known microgeometry”, Biophys. J. 55(1):163-71 (1989).;;Sandhu, J. S., “Protein engineering of antibodies”, Crit. Rev. Biotechnol. 12(5-6):437-62 (1992).;;Schwarts-Albiez et al., “The carbohydrate moiety of the CD22 antigen can be modulated by inhibitors of the glycosylation pathway”, Leukocyte Typing IV. White Cell Differentiation Antigens, Knapp et al., (Eds.), p. 65-67, Oxford University Press, 1989.;;Sherwood et al., “Controlled antibody delivery systems”, Biotechnology 10(11):1446-9 (1992).;;Shin et al., “Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2”, Int J Cancer 56(4):538-45 (1994).;;Singer et al., “Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences”, J. Immunol. 150(7):2844-57 (1993).;;Stein et al., “Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2”, Cancer Immunol. Immunother. 37(5):293-8 (1993).;;Tallarida, RJ., Drug Synergism and Dose Effect Analysis, Ed. Chapman & Hall, 2000, pp. 1-8; 10-13; 57-71.;;Taylor et al., “Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM”, Int Immunol. Apr. 1994;6(4):579-91.;;Theocharis et al., “Characterization of in vivo mutated T cell clones from patients with systemic lupus erythematosus”, Clin. Immunol. Immunopathol. 74(2):135-42 (1995).;;Tsang et al.,“Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis”, Life Sci. Sep. 5, 2003;73(16):2047-58.;;Vuist et al., “Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model”, Cancer Res. 49(14):3783-8 (1989).;;Wilson et al., “cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions”, J Exp Med. Jan. 1, 1991;173(1):137-46.;;Wilson et al., “Genomic structure and chromosomal mapping of the human CD22 gene”, J Immunol. Jun. 1, 1993;150(11):5013-24.;;Wosnik et al., “Rapid construction of large synthetic genes: total chemical synthesis of two different versions of the bovine prochymosin gene”, Gene. 1987;60(1):115-27.;;Wurflein et al., “Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells”, Cancer Res. Jul. 15, 1998;58(14):3051-8.;;Alberti et al., “Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2”, Hybridoma. Oct. 1992;11(5):539-45.;;Bignotti et al., “Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma”, BMC Clin Pathol. Nov. 14, 2012;12:22.;;Chang et al., “Ranpimase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells”, Mol Cancer Ther. Aug. 2010;9(8):2276-86.;;Chen et al., “Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type”, Virchows Arch. Nov. 2013;463(5):713-9.;;Cubas et al., “Trop2: a possible therapeutic target for late stage epithelial carcinomas”, Biochim Biophys Acta. Dec. 2009;1796(2):309-14.;;Fang et al., “Different effects of ERβ and TROP2 expression in Chinese patients with early-stage colon cancer”, Tumour Biol. Dec. 2012;33(6):2227-35.;;Farivar et al., “Nano—drug Delivery of Apoptosis Activator 2 to AGS Cells by Liposomes Conjugated with Anti-TROP2 Antibody”, N Am J Med Sci. Nov. 2012;4(11):582-5.;;Friedman et al., “BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells”, Cancer Res. Jan. 15, 1993;53(2):334-9.;;Higgins S.F., “ABC transporters: from microorganisms to man”, Annu Rev Cell Biol. 1992;8:67-113.;;Kapoor, S., “TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors”, Tumour Biol. Jun. 2013;34(3):1967-8.;;Lin et al., “Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer”, Exp Mol Pathol. Feb. 2013;94(1):73-8.;;Lin et al., “A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo”, Int J Cancer. Mar. 1, 2014;134(5):1239-49.;;Lipinski et al., “Human trophoblast cell-surface antigens defined by monoclonal antibodies”, Proc Natl Acad Sci U S A. Aug. 1981;78(8):5147-50.;;Liu et al., “Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway”, PLoS One. Sep. 27, 2013;8(9): e5864.;;Liu et al., “Trop-2-targeting tetrakis-ranpimase has potent antitumor activity against triple-negative breast cancer”, Mol Cancer. Mar. 10, 2014;13:53.;;Ning et al., “TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma”, J Gastrointest Surg. Feb. 2013;17(2):360-8.;;Ning et al., “TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas”, Neurol Sci. Oct. 2013;34(10):1745-50.;;Pak et al., “Significance of EpCAM and TROP2 expression in non-small cell lung cancer”, World J Surg Oncol. Apr. 6, 2012;10:53.;;Ripani et al., “Human Trop-2 is a tumor-associated calcium signal transducer”, Int J Cancer. May 29, 1998;76(5):671-6.;;Sapra et al., “Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells”, Mol Cancer Ther. Jan. 2013;12(1):38-47.;;Shishido et al., “ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan”, Anticancer Res. Apr. 2013;33(4):1379-86.;;Shor et al., “Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes”, Clin Cancer Res. Jan. 15, 2016;22(2):383-94.;;Shvartsur et al., “Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications”, Genes Cancer. Mar. 2015;6(3-4):84-105.;;Stein et al., “Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I”, J Nucl Med. Jun. 2001;42(6):967-74.;;Stepan et al., “Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target”, J Histochem Cytochem. Jul. 2011;59(7):701-10.;;Stoyanova et al., “Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling”, Genes Dev. Oct. 15, 2012;26(20):2271-85.;;Trerotola et al., “Letter to the editor: efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309-1”, Biochim Biophys Acta. Apr. 2010;1805(2):119-20.;;Tsukahara et al., “TROP2 expressed in the trunk of the ureteric duct regulates branching morphogenesis during kidney development”, PLoS One. 2011;6(12):e28607.;;Varughese et al., “Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody”, Am J Obstet Gynecol. Dec. 2011;205(6):567.e1-7.;;Vidmar et al., “Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain”, Protein Expr Purif. Sep. 2013;91(1):69-76.;;Wang et al., “Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers”, Mol Cancer Ther. Feb. 2008;7(2):280-5.;;Wang et al., “Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma”, Mol Cancer Res. Dec. 2011;9(12):1686-95.;;Wu et al., “Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell aarcinoma”, Head Neck. Oct. 2013;35(10):1373-8.;;Yamazaki et al., “Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo”, Mol Cancer Ther. Jul. 2011;10(7):1252-63.;;Ausubel et al., (eds.), Current Protocols in Molecular Biology, pp. 8.2.8-8.2.13, John Wiley & Sons, Inc. (1990).;;Ausubel et al., (eds.), Short Protocols in Molecular Biology, pp. 8.8-8.10, John Wiley & Sons, Inc. (1995).;;Baines et al., “Purification of Immunoglobulin G (IgG)”, Methods in Molecular Biology, vol. 10, pp. 79-104, Manson et al., (eds.), The Human Press (1992).;;Bambot et al., “Efficient total gene synthesis of 1.35-kb hybrid alpha-lytic protease gene using the polymerase chain reaction”, PCR Methods Appl. Feb. 1993;2(3):266-71.;;Baum et al., “Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas”, Cancer Feb. 1, 1994;73(3 Suppl):896-9.;;Beers et al., The Merck Manual of Diagnosis and Therapy, Ch. 180, p. 1474-1476; 17th Ed., Whitehouse Station, NJ, Merck Research Labs (1999).;;Belisle et al., “Epitope specificity of the anti-B-cell lymphoma monoclonal antibody, LL2”, Proc Am Assoc Cancer Res 1993; 34:481, Abstr #2873.;;Bendig, M., “Humanization of Rodent Monoclonal Antibodies by CDR Grafting”, Academic Press Inc., New York, Ny, vol. 8, (1995), pp. 83-93.;;Bhat et al., “Human antilipid a monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells”, J Immunol. Nov. 1, 1993;151(9):5011-21.;;Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy”, Proc. Natl. Acad. Sci. USA 89(10):4285-9 (1992).;;Coligan et al., (Eds.), Current Protocols in Immunology, vol. 1, pp. 2.5.1-2.6.7; pp. 2.7.1.-2.7.12; pp. 2.8.1-2.8.10; pp. 2.9.1-2.9.3; pp. 2.10.-2.10.4; John Wiley & Sons, Inc., 1991.;;Coloma et al., “Design and production of novel tetravalent bispecific antibodies”, Nat. Biotechnol. 15(2):159-63 (1997).;;Dillon et al., “Use of Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes”, Methods in Molecular Biology, vol. 15: PCR Protocols: Current Methods and Applications, White (Ed.), pp. 263-268, Humana Press, Inc. (1993).;;Ellis et al., “Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma”, J Immunol. Jul. 15, 1995;155(2):925-37.;;Flavell et al., “Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice”, Cancer Res. 57:4824-9 (1997).;;Foy et al., “In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39”, J Exp Med. Nov. 1, 1993;178(5):1567-75.;;French et al., “Response of B-cell lymphoma to a combination of bispecific antibodies and saporin”, Leuk. Res. 20 (7):607-17 (1996).;;Ghetie et al., “Evaluation of ricin a chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy”, Cancer Res. 48(9):2610-7 (1988).;;Goldenberg et al., “Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody”, J Clin Oncol. Apr. 1991;9(4):548-64.;;Goldenberg, D. M., “New Developments in Monoclonal Antibodies for Cancer Detection and Therapy”, CA Cancer J. Clin. 44(1):43-64 (1994).;;Goldenberg et al., “Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb”, Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 3941.;;Gondo et al., “HLA class II antigen associated invariant chain gene expression in malignant lymphoma”, Br. J. Haematol. 67(4):413-7 (1987).;;Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs”, Nature Genetics 7:13-21 (1994).;;Gussow et al., “Humanization of monoclonal antibodies”, Methods Enzymol. 1991;203:99-121.;;Hansen et al., “Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas”, Biochem. J. 1996, 320:293-300.;;Hashida et al., “More useful maleimide compounds for the conjugation of Fab' to horseradish peroxidase through thiol groups in the hinge”, J Appl Biochem. Feb.-Apr. 1984;6(1-2):56-63.;;Hekman et al., “Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody”, Cancer Immunol. Immunother. 1991;32(6):364-72.;;Hess et al., “Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompabbility complex class II invariant chain peptide”, Blood 89(6):2203-9 (1997).;;Hildebrandt et al., “Expression of CD 21, CD 22, and the mouse erythrocyte receptor on peripheral B lymphocytes in rheumatoid arthritis”, Ann Rheum Dis. Jul. 1988;47(7):588-94.;;Muran patient information leaflet, GlaxoSmithKline 7076598/5093, Oct. 2004.;;Inaoki et al., “CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes”, J Exp Med. Dec. 1, 1997;186(11):1923-31.;;Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse” Nature 321(6069):522-5 (1986).;;Juweid et al., “99Tcm-LL1: a potential new bone marrow imaging agent”, Nucl. Med. Commun. 18(2):142-8 (1997).;;Juweid et al., “Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody”, Cancer Res. 55(23 Suppl):5899s-5907s (1995).;;Kaminski et al., “Radioimmunotherapy of B-cell lymphoma with [131]anti-B1 (anti-CD20) antibody”, N. Engl. J. Med. 329(7):459-65 (1993).;;Kiener et al., “Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes”, J Immunol. Nov. 15, 1995;155(10):4917-25.;;Kiesel et al., “Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis”, Leuk. Res. 11(12):1119-25 (1987).;;Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature 256:495-7 (1975).;;Kreitman et al., “Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice”, Cancer Res. 53(4):819-25 (1993).;;Leonard et al., “Epratuzumab, a new Anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results”, Blood 94:92a-93a, Abstract # 404, (1999).;;Leung et al., “Chimerization and humanization of a B-cell Lymphoma specific antibody, LL2”, Proc Am Assoc Cancer Res 1993; 34:481, Abstr #2872.;;Leung et al., “Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma”, Hybridoma 13 (6):469-476 (1994).;;Leung et al., “Construction and characterization of a humanized, internalizing, b-cell (CD22)-specific, leukemia/lymphma antibody, LL2”, Mol. Immunol. 32(17/18):1413-1427 (1995).;;Levine et al., “IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab”, Neurology 52 (8):1701-4 (1999).;;Li et al., “The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies”, Cell Immunol. 118(1):85-99 (1989).;;Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Nature 368:856-9 (1994).;;Longo, D. L., “Immunotherapy for non-Hodgkin's lymphoma”, Curr. Opin. Oncol. 8(5):353-9 (1996).;;Losman et al., “Baboon anti-idiotype antibodies mimic a carcinoembryonic antigen epitope”, Int J Cancer. Aug. 15, 1990;46(2):310-4.;;Lundberg, B., “Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures”, J. Pharm. Sci. 83(1):72-5 (1994).;;Lundberg et al., “Submicron lipid emulsions containing amphipathic polyethylene glycol for use as drug-carriers with prolonged circulation time”, Int. J. Pharm. 134:119-127 (1996).;;Bardia et al., “IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)”, Poster, San Antonio Breast Cancer Symposium, Dec. 9-13, 2014.;;Bardia et al., “Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience”, J Clin Oncol 33, 2015 (suppl; abstr 1016), Retrieved from http://meetinglibrary.asco.org/content/150673-156.;;Dang et al., “Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition”, Cancer Res. Mar. 15, 2008;68(6):1872-80.;;Declaration under 37 C.F.R. 1.132 by David M. Goldenberg, filed in U.S. Appl. No. 13/948,732, filed Jun. 20, 2014.;;Declaration under 37 C.F.R. 1.132 by David M. Goldenberg, filed in U.S. Appl. No. 14/204,698, filed Jan. 7, 2015.;;Dotan et al., “A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic mlorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study”, J Clin Oncol 33, 2015 (suppl; abstr 2505), Retrieved from http://meetinglibrary.asco.org/content/148390-156.;;Faltas et al., “Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma”, Clin Genitourin Cancer. Feb. 2016;14(1):e75-9.;;Goldenberg et al., “Selective in vivo therapeutic efficacies of SN-38 conjugates of an anti-CEACAM5 antibody in preclinical models of human colon carcinoma”, Presentation, ASCO 2009 Gastrointestinal Cancers Symposium, San Francisco, CA, Jan. 15-17, 2009.;;Goldenberg, D.M., “Challenging the Dogmas: Clinical Efficacy of SN-38-Conjugated Antibodies in Solid Tumors”, 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, Nov. 18-21, 2014.;;Goldenberg, D.M., “SN-38 Conjugates for Therapy of Advanced Solid Cancers”, 5th Annual World ADC Summit in San Diego, CA, Oct. 26-29, 2014.;;Goldenberg et al., “Therapy of human solid tumor xenografts with CD74-targeted milatuzumab-SN-38 immunoconjugates”, Poster, 2012 ASCO Annual Meeting, Chicago, IL, Jun. 1-5, 2012.;;Goldenberg et al., “Improved Therapeutic Index of IMMU-132 ADC vs. Irinotecan in Preclinical Studies”, Presentation, AACR Annual Meeting, San Diego, CA, Apr. 5-9, 2014.;;Goldenberg et al., “Tolerability in mice, monkeys, and rabbits of new antibody (MAb)-drug (SN-38) immunoconjugates”, Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; Apr. 2-6, 2011; Orlando, FL Cancer Res 2011;71(8 Suppl):Abstract # 3619.;;Gorman, G., “Focused on Therapy: Cancer, Autoimmune & Other Serious Diseases”, Presentation, Oppenheimer 23rd Annual Healthcare Conference, NYC, Dec. 12, 2012.;;Govindan et al., “Targeted therapy of human colonic, lung, and pancreatic cancer xenografts, growing in nude mice, with potent antibody conjugates of SN-38”, Poster, AACR 100th Annual Meeting, Denver, CO, Apr 18-22, 2009.;;Govindan et al., “Efficacious therapies of two human pancreatic cancer xenografts and an aggressive human lymphoma xenograft with redesigned antibody-SN-38 conjugates”, Poster, AACR 101st Annual Meeting, Washington, DC, Apr. 17-21, 2010.;;Govindan et al., “Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug”, Mol Pharm. Nov. 25, 2014. [Epub ahead of print].;;Govindan et al., “Optimal cleavable linker for antibody-SN-38 conjugates for cancer therapy: Impact of linker's stability on efficacy”, Poster, AACR 103rd Annual Meeting, Chicago, IL, Mar. 31-Apr. 4, 2012.;;Govindan et al., “CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates”, Clin Cancer Res. Oct. 1, 2009;15(19):6052-61.;;Govindan et al., “IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38 targeting CEACAM5 antigen: Preclinical basis for clinical activity in metastatic colorectal cancer (mCRC)”, J Clin Oncol 33, 2015 (suppl 3; abstr 625), Retrieved from http://meetinglibrary.asco.org/content/139777-158.;;Karacay et al., “Combining antibody-targeted radiation (radioimmunotherapy) and antibody-SN-38 conjugates (ADC) improves pancreatic cancer therapy”, Poster, AACR 101st Annual Meeting, Washington, DC, Apr. 17-21, 2010.;;Moon et al., “Cross-linker evaluation in the design of antibody-SN-38 conjugates for cancer therapy”, Poster, AACR 101st Annual Meeting, Washington, DC, Apr. 17-21, 2010.;;Reagan-Shaw et al., “Dose translation from animal to human studies revisited”, FASEB J. Mar. 2008;22(3):659-61.;;Segal et al., “IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies”, Presentation, AACR Annual Meeting, San Diego, CA, Apr. 5-9, 2014.;;Segal et al., “IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies”, 2014 AACR Meeting Apr. 5-9, 2-14, San Diego, CA (Abstract No. CT211).;;Seruga et al., “Failures in Phase III: Causes and Consequences”, Clin Cancer Res. Oct. 15, 2015;21(20):4552-60.;;Starodub et al., “IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results”, Poster, the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30-Jun. 3, 2014.;;Tahara et al. “The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks”, Mol Cancer Ther; 13(5); 1170-80 (2014).;;Bardia et al., “Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC”, Poster presented at San Antonio Breast Cancer Symposium, Dec. 10, 2015, San Antonio, TX.;;Bardia et al., “Safety and tumor responses of the anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in refractory, metastatic, triple-negative breast cancer (TNBC): An ongoing Phase II trial”, Poster presented at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Nov. 8, 2015, Boston, MA.;;Basu et al., “The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303”, Int J Cancer. Aug. 9, 1995;62(4):472-9.;;Basu et al., “Epithelial glycoprotein EGP-1 recognized by MAb RS7-3G11 is phosphorylated on serine 303”, Proc. Amer. Assoc. Cancer Res. 36: 439 (Abstr. #2621), 1995.;;Camidge et al., “Therapy of Advanced Metastatic Lung Cancers with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132: Interim Phase II Clinical Results”, Oral presentation at 16th World Conference on Lung Cancer (WCLC), Sep. 7, 2015, Denver, CO.;;Cardillo et al., “A novel immunotoxin comprising quadruple RNase tethered to an internalizing anti-TROP-2 humanized MAb shows potent cytotoxicity against diverse solid tumors in vitro”, Proc. Amer. Assoc. Cancer Res. Annual Meeting, 51:1296 (Abstr. #5346), 2010.;;Cardillo et al., “Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)”, Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C166.;;Cardillo et al., “Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib”, Poster presented at San Antonio Breast Cancer Symposium, Dec. 10, 2015, San Antonio, TX.;;Cardillo et al., “Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers”, Bioconjug Chem. May 20, 2015;26(5):919-31, Epub May 8, 2015.;;Chang et al., “In vitro and in vivo evaluation of a novel recombinant immunotoxin of ranpirnase fused to a humanized anti-EGP-1 antobody, HRS7, for the potential treatment of prostate and lung cancers”, Proc. Amer. Assoc. Cancer Res. Annual Meeting, 48: (Abstr. #4795), 2007.;;Goldenberg et al., Tolerability in mice, monkeys, and rabbits of new antibody (MAb)-drug (SN-38) immunoconjugates. Proc. Amer. Assoc. Cancer Res. 102nd Annual Meeting, 52: 865 (Abstr. #3619), 2011.;;Goldenberg et al., “SN-38 antibody-drug conjugates as a novel platform for solid cancer therapy: preclinical science”, American Association for Cancer Research (AACR) 2014 Annual Meeting, Abstr. #2904, Apr. 7, 2014.;;Goldenberg et al., “Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers”, American Society of Clinical Oncology (ASCO) 50th Annual Meeting. J Clin Oncol 32:5s, 2014 (suppl; abstr #3107), 2014.;;Goldenberg et al., “IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results”, Poster P5-19-08 presented at San Antonio Breast Cancer Symposium, Dec. 9-13, 2014.;;Goldenberg et al., “Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)”, Oncotarget Jun. 18, 2015. [Epub ahead of print].;;Govindan et al., “Optimal cleavable linker for antibody-SN-38 conjugates for cancer therapy: Impact of linker's stability on efficacy”, Proc. Amer. Assoc. Cancer Res. 103rd Annual Meeting, 53: 611 (Abstr. #2526), 2012.;;Govindan et al., “Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel”, Breast Cancer Res Treat Mar. 2004;84(2):173-82.;;Govindan et al., “Conjugation of SN-38 to an anti-EGP-1 MAB, HRS7, via a cleavable linker shows selective therapeutic activity in a preclinical model of non-small cell lung cancer (NSCLC)”, Proc. Eleventh Conf. on Cancer Therapy, Cancer Biotherapy & Radiopharmaceuticals, 21(4):401 (Abstr. #56), 2006. et al.",ACTIVE
964,EP,A2,EP 0203391 A2,099-394-527-718-710,1986-12-03,1986,EP 86105807 A,1986-04-26,US 72896685 A,1985-04-30,Ungelled resins containing hydrolyzable moieties from organosilane compounds.,"Disclosed is an ungelled resin composition comprising a compound having at least one group containing a silicon atom selected from:
  
  
  wherein
 Q represents the residue from an organic polyol selected from the group consisting of (1) simple diols, triols and higher hydric alcohols, (2) polyester polyols, (3) polyether polyols, (4) amide-containing polyols, (5) epoxy polyols and (6) polyhydric polyvinyl alcohols, and each R independently is selected from the group of moieties consisting of hydrogen, and a C 1 -C 10  group joined to Si through an Si-C linkage, and Y represents an easily hydrolyzable group. The ungelled resin composition contains an amount of easily hydrolyzable Y moieties directly bonded to silicon atoms such that the ratio of the number of grams of the ungelled resin composition to equivalents of easily hydrolyzable Y moieties in the ungelled resin composition is in a range of from 40 to 667. Preferred resin compositions of the invention can be cured in the presence of atmospheric moisture and a suitable catalyst at a temperature of less than or equal to 121 degrees Celsius within 3 hours. Disclosed is a method for producing the ungelled resin composition. Also disclosed is a nonaqueous composition, particularly a nonaqueous coating composition, containing an ungelled resin composition of the invention. Preferred coating compositions containing an ungelled resin composition of the invention can be cured in the presence of atmospheric moisture and a suitable catalyst at a temperature of less than or equal to 121 degrees C within 3 hours.",PPG INDUSTRIES INC,CHANG WEN-HSUAN;;MCKEOUGH DAVID THOMAS,,https://lens.org/099-394-527-718-710,Patent Application,yes,0,6,12,12,0,C08G77/50;;C08G85/004;;C09D157/06;;C09D201/02;;C09D183/04;;C08G77/50;;C09D201/02;;C08G85/004;;C08G77/50;;C09D157/06,C08G59/00;;C08F8/42;;C08F16/00;;C08F16/02;;C08F16/06;;C08G59/14;;C08G63/00;;C08G63/91;;C08G65/48;;C08G69/00;;C08G69/48;;C08G77/50;;C08G85/00;;C09D157/06;;C09D183/00;;C09D183/05;;C09D201/02,,0,0,,,,DISCONTINUED
965,DK,T3,DK 1223915 T3,107-086-705-210-009,2006-03-06,2006,DK 00922117 T,2000-04-12,US 16245199 P;;US 16423699 P;;US 17276999 P;;US 17838300 P;;US 17841500 P,1999-10-29,Törpulverpræparater med forbedret dispersivitet,,NEKTAR THERAPEUTICS,LECHUGA-BALLESTEROS DAVID;;KUO MEI-CHANG,,https://lens.org/107-086-705-210-009,Granted Patent,no,0,0,46,47,0,A61K9/0075;;A61K9/008;;A61K9/145;;A61K47/183;;A61K47/20;;A61P1/04;;A61P1/08;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P3/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P3/06;;A61P37/00;;A61P39/06;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P3/10;;A61K47/18;;A61K9/0075;;A61K9/008;;A61K47/183;;A61K9/145;;A61K47/20,A61K9/12;;A61K9/00;;A61K47/42;;A61K9/08;;A61K9/14;;A61K9/72;;A61K31/58;;A61K38/00;;A61K38/21;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/43;;A61K38/55;;A61K39/395;;A61K45/00;;A61K47/12;;A61K47/16;;A61K47/18;;A61K47/26;;A61K47/30;;A61P1/04;;A61P1/08;;A61P3/02;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/00;;A61P5/28;;A61P7/02;;A61P7/12;;A61P9/00;;A61P9/06;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/08;;A61P15/18;;A61P19/02;;A61P21/00;;A61P25/02;;A61P25/06;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/26;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/06;;A61P33/10;;A61P35/00;;A61P37/00;;A61P39/06,,0,0,,,,EXPIRED
966,US,B2,US 9243203 B2,106-739-398-460-348,2016-01-26,2016,US 201213691628 A,2012-11-30,US 201213691628 A,2012-11-30,Copolymers of polyaminopolyolefins and polyanhydrides and methods of their preparation,"Provided herein are copolymers of a polyaminopolymer and polyanhydride, wherein the polyaminopolymer comprises a polyaminopolyolefin; and methods of their preparation.",CHEVRON ORONITE CO,CHANG YOUNG;;STOKES CASEY;;MORGAN DAVID,CHEVRON ORONITE COMPANY LLC (2013-02-12),https://lens.org/106-739-398-460-348,Granted Patent,yes,37,0,12,12,0,C10M149/18;;C10M2217/044;;C08G73/1042;;C08G73/1046;;C08G73/105;;C08G73/1082;;C10M149/14;;C10M2217/041;;C10N2020/04;;C10N2030/02;;C10N2040/25;;C10N2070/02;;C10M149/02;;C10M149/10;;C08G73/1042;;C08G73/1046;;C08G73/105;;C08G73/1082;;C10M149/18;;C10M2217/044;;C10M2217/041;;C10M149/14;;C10N2020/04;;C10N2030/02;;C10N2040/25;;C10N2070/02;;C08F8/00;;C08G81/024,C10M159/12;;C08F8/00;;C08G73/10;;C08G81/02;;C10M149/02;;C10M149/10;;C10M149/12;;C10M149/18,,6,6,000-122-658-288-190;;099-210-329-864-443;;066-204-075-157-133;;068-673-716-408-970;;150-071-832-149-818;;180-223-277-713-878,10.1021/ma060817y;;10.1002/pola.10905;;10.1081/ma-100101631;;10.1007/bf00275564;;10.1002/pola.22716;;10.1002/pola.20566,"Higashihara et al., ""Synthesis of poly(isobutylene-block-methyl methacrylate) by a novel coupling approach,"" Macromolecules, 39:5275-5279 (2006).;;Keki et al., ""Aminotelechelics: A convenient synthesis and characterization of primary amino-terminated telechelic poly(propylene glycol) and polyisobutylene"" J. Polymer Science: Part A: Polymer Chemistry, 42:587-596 (2004).;;Koroskenyi et al, ""Initiation via haloboration in living cationic polymerization. 6. A novel method for the synthesis of primary amine functional polyisobutylenes,"" J. Macromol. Chem. Pure Appl. Chem., A36:1879-1893 (1999).;;Percec et al., ""New Telechelic polymers and sequential copolymers by polyfunctional initiator-transfer agens (Inifers) 29. Synthesis of alpha,omega-di(amino)polysobutylenes,"" Polymer Bulletin, 9:27-32 (1983).;;Ummadisetty et al., ""Quantitative synthesis of novel polyisobutylenes fitted with termianl primary -Br, -Oh, -NH2, and methacrylate termini,"" J. Polymer Science: Part A: Polymer Chemistry, 46:4236-4242 (2008).;;Wollyung et al., ""Synthesis and mass spectrometry characterization of centrally and terminally amine-functionalized polyisobutylenes,"" J. Polymer Science: Part A: Polymer Chemistry, 43:946-958 (2005).",ACTIVE
967,US,A1,US 2016/0086438 A1,109-806-153-158-825,2016-03-24,2016,US 201514954922 A,2015-11-30,US 201514954922 A;;US 2014/0040093 W;;US 201361828566 P,2013-05-29,USER SELECTABLE GAMBLNG GAME HYBRID GAME,"A hybrid game having a user selectable gambling game is provided. The hybrid game includes a real world engine constructed to provide a randomly generated payout of real world credits from a real credit wager for a plurality of gambling games, an entertainment software engine constructed to execute an entertainment game providing outcomes based upon skillful execution of the entertainment game to earn a payout of game world credits, and a game world engine constructed to manage the entertainment software engine and communicate gameplay gambling event occurrences based upon skillful execution of the entertainment game that trigger at least one wager in the gambling game to the gambling game, receive entertainment game variable data from the entertainment software engine to determine what type of gambling game to execute, from a plurality of gambling games, and initiate a gambling game, from the plurality of gambling games, in the real world engine utilizing the real credit wager, based upon the entertainment game variable data received from the entertainment software engine.",GAMBLIT GAMING LLC,ARNONE MILES;;MEYERHOFER ERIC;;CHANG DAVID,,https://lens.org/109-806-153-158-825,Patent Application,yes,3,2,7,7,0,G07F17/3227;;G07F17/3227;;G07F17/3223;;G07F17/3223;;G07F17/3244;;G07F17/3244;;G07F17/3246;;G07F17/3246;;G07F17/3248;;G07F17/3248;;G07F17/3251;;G07F17/3251;;G07F17/3262;;G07F17/3262;;G07F17/3286;;G07F17/3286;;G07F17/3293;;G07F17/3293;;G07F17/3295;;G07F17/3295;;G07F17/34;;G07F17/34,G07F17/32;;G07F17/34,,0,0,,,,INACTIVE
968,US,A1,US 2012/0261256 A1,118-802-179-252-666,2012-10-18,2012,US 201213402592 A,2012-02-22,US 201213402592 A;;US 201161474952 P,2011-04-13,SAMPLE HOLDERS AND ANALYTICAL INSTRUMENT FOR POINT-OF-CARE QUALIFICATION OF CLINICAL SAMPLES,"This invention has two synergistic elements for simultaneous use in point-of-care or field analyses of diverse substances important to clinical medicine and other applications. The first element is a sample holder in which are stored the several reagents need for quantification of target molecules. The onboard storage of reagents in a water soluble plastic obviates the need for purchase, storage, measuring and mixing of the required reagents prior to analyses. The second part of the invention is a compact hand-held analyzer made of modern miniature optical components, into which the holder is inserted right after it is loaded with a sample by capillary action. The combination of the holder and analyzer permits analyses that are ten times faster than those done with current analyzers, and equally accurate. Analyses can be performed by diverse people, who require only a few minutes of training in the use of the entire invention.",CHANG CHIA-PIN;;NAGEL DAVID J,CHANG CHIA-PIN;;NAGEL DAVID J,GEORGE WASHINGTON UNIVERSITY THE (2012-05-23),https://lens.org/118-802-179-252-666,Patent Application,yes,6,30,2,2,0,B01L3/50273;;B01L3/50273;;B01L3/527;;B01L3/527;;B01L2200/04;;B01L2200/04;;B01L2200/0684;;B01L2200/0684;;B01L2200/0689;;B01L2200/0689;;B01L2200/141;;B01L2200/141;;B01L2200/142;;B01L2200/142;;B01L2200/148;;B01L2200/148;;B01L2300/023;;B01L2300/023;;B01L2300/027;;B01L2300/027;;B01L2300/0636;;B01L2300/0636;;B01L2300/0645;;B01L2300/0645;;B01L2300/0654;;B01L2300/0654;;B01L2300/069;;B01L2300/069;;B01L2300/0822;;B01L2300/0822;;B01L2300/0867;;B01L2300/0867;;B01L2300/0887;;B01L2300/0887;;B01L2300/089;;B01L2300/089;;B01L2300/161;;B01L2300/161;;B01L2300/163;;B01L2300/163;;B01L2400/0406;;B01L2400/0406;;B01L2400/0472;;B01L2400/0472;;B01L2400/0677;;B01L2400/0677;;G01N21/03;;G01N21/03;;G01N21/278;;G01N21/278;;G01N21/51;;G01N21/51;;G01N21/645;;G01N21/645;;G01N21/76;;G01N21/76;;G01N27/3272;;G01N27/3272;;G01N2021/0346;;G01N2021/0346;;G01N2021/495;;G01N2021/495;;G01N2021/6421;;G01N2021/6421;;G01N2021/6482;;G01N2021/6482,B01L3/00;;G01N21/59;;G01N21/64;;G01N21/75;;G01N21/76;;G01N27/00;;G01N27/26,204/400;;422/547;;422/82.05;;422/82.09;;422/82.08;;422/52;;422/82.01;;422/82.02,0,0,,,,DISCONTINUED
969,US,A,US 4628076 A,108-922-072-912-592,1986-12-09,1986,US 68264484 A,1984-12-17,US 68264484 A,1984-12-17,Curable coating vehicle based upon aminoalkyloxy silanes and organic isocyanates,"Disclosed is an ungelled resin comprising a compound corresponding to a specified formula (I) which compound typically is prepared by reaction of an aminoalkyloxy silane with an organic isocyanate. The ungelled resin contains a hydrolyzable group that is attached directly to Silicon. The ungelled resin can be utilized in coating compositions. The ungelled resin can be cured with moisture and/or with polyols, and can be used to provide protective and/or decorative films on a variety of substrates. The novel compounds contained in the ungelled resin for convenience can be thought of as prepared from an organic isocyanate having an average functionality of at least 1; a silicon-containing compound corresponding to a specified formula (III) infra, the silicon-containing compound having at least one hydrolyzable group; and a compound containing at least 2 carbon atoms, at least 1 functional group reactive with a moiety on the silicon-containing compound and at least one amino group. A compound of the resin contains at least one hydrolyzable group from the silicon-containing compound. A compound of the resin also contains a residue of the silicon-containing compound bonded to a residue of the compound containing at least 2 carbon atoms through an oxygen-silicon linkage.",PPG INDUSTRIES INC,CHANG WEN-HSUAN;;MCKEOUGH DAVID T,PPG INDUSTRIES INC (1984-12-12),https://lens.org/108-922-072-912-592,Granted Patent,yes,9,37,1,1,0,C09D183/10;;C09D183/10;;C08G18/0823;;C08G18/0823;;C08G18/10;;C08G18/10;;C08G18/831;;C08G18/831;;C08G18/837;;C08G18/837;;C08G77/455;;C08G77/455,C08G18/08;;C08G18/10;;C08G18/83;;C08G77/455;;C09D183/10,525/440;;525/446;;525/460;;525/453;;556/419;;528/15;;528/17;;528/18;;528/20;;528/21;;528/23;;528/26;;528/28,0,0,,,,EXPIRED
970,US,B2,US 6835587 B2,115-008-067-909-777,2004-12-28,2004,US 63928903 A,2003-08-11,US 63928903 A;;US 62968300 A;;US 35847103 A;;US 62968400 A;;US 42998803 A;;US 62967900 A;;US 22387402 A;;US 62968000 A;;US 37012403 A,2000-08-01,"Single crystal, tunneling and capacitive, three-axes sensor using eutectic bonding and a method of making same","
    A first axis MEM tunneling/capacitive sensor and method of making same. Cantilever beam structures for at least two orthogonally arranged sensors and associated mating structures are defined on a first substrate or wafer, the at least two orthogonally arrange sensors having orthogonal directions of sensor sensitivity. A resonator structure of at least a third sensor is also defined, the third sensor being sensitive in a third direction orthogonal to the orthogonal directions of sensor sensitivity of the two orthogonally arranged sensors and the resonator structure having a mating structure thereon. Contact structures for at least two orthogonally arranged sensors are formed together with mating structures on a second substrate or wafer, the mating structures on the second substrate or wafer being of a complementary shape to the mating structures on the first substrate or wafer. 
",HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,HRL LABORATORIES LLC (2000-08-28),https://lens.org/115-008-067-909-777,Granted Patent,yes,33,5,10,10,0,B81B2201/0242;;B81B2201/025;;B81C3/002;;B81C2201/019;;B81C2203/036;;B81C2203/058;;G01C19/5656;;G01P15/0802;;G01P15/0894;;G01P15/18;;H01H1/0036;;H01H59/0009;;G01P2015/084;;G01P2015/0842;;B81C3/002;;B81B2201/0242;;B81C2201/019;;B81C2203/058;;B81B2201/025;;G01P15/0802;;H01H1/0036;;G01C19/5656;;H01H59/0009;;G01P15/0894;;G01P15/18;;B81C2203/036;;G01P2015/084;;G01P2015/0842,B81B3/00;;B81C1/00;;B81C3/00;;G01C19/5656;;G01P15/08;;G01P15/18;;H01H1/00;;H01H59/00;;H01L41/08,438/48;;257/414,16,6,067-585-851-384-039;;030-642-585-316-273;;068-279-650-120-61X;;011-792-918-490-013;;048-576-548-493-140;;069-012-973-020-326,10.1109/84.825770;;10.1109/sensor.1997.635453;;10.1109/84.788627;;10.1063/1.104432;;10.1109/55.496466;;10.1116/1.590931,"U.S. patent application Ser. No. 10/223,874, Kubena et al., filed Aug. 19, 2002.;;U.S. patent application Ser. No. 10/358,471, Kubena et al., filed Feb. 4, 2003.;;U.S. patent application Ser. No. 10/370,124, Kubena et al., filed Feb. 18, 2003.;;U.S. patent application Ser. No. 10/429,988, Kubena et al., filed May 6, 2003.;;Abstract of JP 04-369418, Patent Abstracts of Japan, vol. 017, No. 250, May 18, 1983.;;Abstract of JP 08-203417, Patent Abstracts of Japan, vol. 1996, No. 12, Dec. 26, 1996.;;Cheng, Y.T., et al., ""Localized Silicon Fusion and Eutectic Bonding for MEMS Fabrication and Packaging,"" Journal of Microelectromechanical Systems, vol. 9, No. 1, pp. 3-8 (Mar. 2000).;;Grade, John, et al., ""Wafer-Scale Processing, Assembly, and Testing of Tunneling Infrared Detectors,"" Transducers '97, 1997 International Conference on Solid State Sensors and Actuators, Chicago, Jun. 16-19, pp. 1241-1244.;;Gretillat, et al., ""Improved Design of a Silicon Micromachined Gyroscope with Piezoresisitve Detection and Electromagnetic Excitation,"" IEEE Journal of Microelectromechanical Systems, vol. 8, No. 3, Sep. 1999, pp. 243-250.;;Kenny, T.W., et al., ""Micromachined Silicon Tunnel Sensor for Motion Detection,"" Appl., Phys. Lett., vol. 58, No. 1, Jan. 7, 1991, pp. 100-102.;;Kubena, R.L., et al., ""A New Miniaturized Surface Micromachined Tunneling Accelerometer,"" IEEE Electron Device Letters, vol. 17, No. 6, pp. 306-308 (Jun. 1996).;;Kubena, R.L., et al., ""New Miniaturized Tunneling-Based Gyro for Inertial Measurement Applications,"" 43rd Journal of Vacuum Science & Technology B (Microelectronics and Nanometer Structure, vol. 17, No. 6, pp. 2948-2952 (Nov./Dec. 1999).;;Liu, C-H, et al., ""Characterization of a High-Sensitivity Micromachined Tunneling Accelerometer with Micro-g Resolution,"" Journal of Microelectromechanical Systems, vol. 7, No. 2, pp. 235-243 (Jun. 1998).;;Motamedi, M.E., et al., ""Tunneling Tip Engine for Microsensors Applications,"" Materials and Device Characterization in Micromachining II-Proceedings of the SPIE, Santa Clara, California, vol. 3875, pp. 192-199 (Sep. 1999).;;Yeh, et al., ""A Low Voltage Bulk-Silicon Tunneling-Based Microaccelerometer,"" IEEE, 1995, pp. 23.1.1-23.1.4.;;Zavracky, P.M., et al., ""Design and Process Considerations For A Tunneling Tip Accelerometer,"" J. Micromech. Microeng., vol. 6, No. 3, pp. 192-199 (Sep. 1996).",EXPIRED
971,EP,B1,EP 0495143 B1,132-513-754-573-578,1995-11-29,1995,EP 91100492 A,1991-01-17,EP 91100492 A;;US 37768289 A,1989-07-10,Process for making metallized polyethylene plexifilamentary film-fibril sheet.,,DU PONT,JONES DAVID CHARLES;;LEE CHI-CHANG,,https://lens.org/132-513-754-573-578,Granted Patent,yes,0,0,10,14,0,B29C59/04;;B29C59/04;;C23C14/028;;C23C14/028;;C23C14/20;;C23C14/20;;D04H1/42;;D04H1/42;;D04H3/16;;D04H3/16;;D06M10/06;;D06M10/06;;D06M11/83;;D06M11/83;;D06M11/84;;D06M11/84,B29C59/04;;C23C14/02;;C23C14/20;;D04H1/42;;D04H3/16,,1,0,,,"DATABASE WPIL Section Ch, Week 45, Derwent Publications Ltd., London, GB; Class A, AN 85-281265 & RD-258025 (ANONIMOUS) 10 October 1985",EXPIRED
972,US,A,US 5510843 A,132-447-860-047-747,1996-04-23,1996,US 31616794 A,1994-09-30,US 31616794 A,1994-09-30,Flicker reduction and size adjustment for video controller with interlaced video output,"An apparatus and method are provided for reducing flicker and/or vertically scaling an interlaced video image. In a first embodiment, a sequence controller selectively addresses a video memory to retrieve pixel data from adjacent scan lines. The pixel data is multiplexed and converted into RGB data in a look up table and stored in upper and lower latches as upper and lower pixel data. The upper and lower pixel data is then weighted using a predetermined weighting scheme to produce hybrid pixel color data for an even or odd field. By reducing relative contrast between even and odd field lines, flicker is reduced. In a second embodiment, vertical resolution is reduced, for example, from 480 lines to 400 lines, by applying a series of weighting schemes or filters to weight data from six input lines into five output lines. To reduce flicker in the output lines, data from adjacent lines may weighted to reduce relative contrast. Due to the 6:5 reduction, a discontinuity in the output lines may exist where adjacent line data is not weighted. Luminance data from a third adjacent line may be weighted with pixel data from adjacent lines to reduce flicker at the discontinuity.",CIRRUS LOGIC INC,KEENE DAVID;;YANG JIMMY;;CHANG KEVIN,CIRRUS LOGIC INC (1994-11-09),https://lens.org/132-447-860-047-747,Granted Patent,yes,34,82,6,6,0,G09G5/395;;G09G5/395;;G09G2310/0224;;G09G2310/0224;;G09G2340/0414;;G09G2340/0414;;H04N7/012;;H04N7/012,G09G5/395;;H04N5/44,348/446;;348/441;;348/447,0,0,,,,EXPIRED
973,ES,A1,ES 2204264 A1,134-281-467-765-377,2004-04-16,2004,ES 200150090 A,2001-04-24,US 55976600 A,2000-04-27,FURAN NO-BAKE FOUNDRY BINDERS AND THEIR USE,"This invention relates to furan no-bake foundry binders comprising (a) a reactive furan resin, (b) furfuryl alcohol, and (c) a catalyst component comprising a catalytically effective amount of a Lewis acid furan catalyst. The invention also relates to foundry mixes prepared with the binder, foundry shapes prepared with the foundry mix, and metal castings prepared with the foundry shapes.",ASHLAND INC,CHANG KEN K;;HUTCHINGS DAVID A,,https://lens.org/134-281-467-765-377,Patent Application,no,4,0,12,12,0,B22C1/224;;B22C1/2246;;B22C1/2246;;C08K3/30;;C08K5/107;;C08K5/13;;C08K5/1535;;C08L71/00,B22C1/22,,0,0,,,,EXPIRED
974,US,A1,US 2020/0066091 A1,129-890-851-037-764,2020-02-27,2020,US 201916667344 A,2019-10-29,US 201916667344 A;;US 201816049029 A;;US 201514954922 A;;US 2014/0040093 W;;US 201361828566 P,2013-05-29,USER SELECTABLE GAMBLING GAME HYBRID GAME,"A hybrid game having a user selectable gambling game is provided. The hybrid game includes a real world engine constructed to provide a randomly generated payout of credits from a wager for a plurality of gambling games, an entertainment software engine constructed to execute an entertainment game providing outcomes based upon skillful execution of the entertainment game to earn a payout of game world credits, and a game world engine constructed to manage the entertainment software engine and communicate gameplay gambling event occurrences based upon skillful execution of the entertainment game that trigger at least one wager in the gambling game to the gambling game, receive entertainment game variable data from the entertainment software engine to determine what type of gambling game to execute, from a plurality of gambling games, and initiate a gambling game, from the plurality of gambling games, in the real world engine utilizing the wager, based upon the entertainment game variable data received from the entertainment software engine.",GAMBLIT GAMING LLC,ARNONE MILES;;MEYERHOFER ERIC;;CHANG DAVID,,https://lens.org/129-890-851-037-764,Patent Application,yes,0,0,7,7,0,G07F17/3227;;G07F17/3227;;G07F17/3223;;G07F17/3223;;G07F17/3244;;G07F17/3244;;G07F17/3246;;G07F17/3246;;G07F17/3248;;G07F17/3248;;G07F17/3251;;G07F17/3251;;G07F17/3262;;G07F17/3262;;G07F17/3286;;G07F17/3286;;G07F17/3293;;G07F17/3293;;G07F17/3295;;G07F17/3295;;G07F17/34;;G07F17/34,G07F17/32;;G07F17/34,,0,0,,,,ACTIVE
975,US,B2,US 7830074 B2,133-872-158-980-055,2010-11-09,2010,US 88146107 A,2007-07-27,US 88146107 A;;US 83660006 P,2006-08-08,Integrated quartz oscillator on an active electronic substrate,"An oscillator having a quartz resonator, and a base wafer containing active electronics, wherein the quartz resonator is bonded directly to the base wafer and subsequently hermetically capped.",HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,HRL LABORATORIES LLC (2007-07-23),https://lens.org/133-872-158-980-055,Granted Patent,yes,29,16,3,5,0,B81B2201/0271;;B81B2201/0271;;B81B2207/012;;B81B2207/012;;B81C1/00253;;B81C1/00253;;H04R17/10;;H04R17/10;;H04R31/00;;H04R31/00;;Y10T29/42;;Y10T29/42,H01L41/09,310/361;;310/348;;310/365,7,5,094-027-782-886-483;;077-367-259-404-333;;093-683-868-693-489;;049-549-900-425-669;;160-631-102-346-209,10.1016/s0924-4247(99)00330-1;;10.1149/1.1940507;;10.1063/1.117548;;10.1109/ultsym.1994.401548;;10.1063/1.2234846,"Abe,T., et al., ""One-Chip Multichannel Quartz crystal microbalance (QCM) Fabricated by Deep RIE,"" Sensors and Actuators, 2000, pp. 139-143.;;Aaltonen, T., et al., ""ALD of Rhodium thin films from Rh(acac)3 and Oxygen,"" Electrochemical and Solid-State Lett. 8, C99 (2005).;;Cleland, A.N., et al., ""Fabrication of High Frequency Nanometer Scale Mechanical Resonators From Bulk Si Crystals, ""applied Physics Letters, Oct. 28, 1996.;;Evoy, S., et al., ""Temperature-dependent Internal Friction in Silicon Nanoelectromechanical Systems,"" Applied Physics Letters, vol. 77, No. 15.;;Greer, J.A., et al., ""Properties of SAW resonators fabricated on quartz substrates of various qualities,"" Ultrasonics Symposium, 1994 IEEE, vol. 1, Nov. 1-4, 1994, pp. 31-36.;;Lin, J.W, et al., ""A Robust High-Q Micromachined RF Inductor for RFIC Applications,"" IEEE Transactions on Electronic Devices, vol. 52, No. 7, pp. 1489-1496 (Jul. 2005).;;Park, K.J., et al., ""Selective area atomic layer deposition of rhodium and effective work function characterization in capacitor structures,"" Applied Physics Letters 89, 043111 (2006).",ACTIVE
976,WO,A1,WO 1995/035517 A1,143-709-745-622-562,1995-12-28,1995,US 9507573 W,1995-06-14,US 26214794 A,1994-06-20,APPARATUS COUPLING POWER SOURCE TO FIBER OPTIC,"The present invention provides a fiber optic coupling apparatus for coupling light from a high power light source into a fiber optic (2) while preventing thermal damage to the fiber optic at the fiber-to-light source coupling. The light source comprises a housing having a fiber input structure with inner surfaces defining a through-hole (29) for receiving the fiber optic (2). The fiber input structure has outer surfaces (63) which define a substantially conical profile of the structure that extends within the housing such that an axis of symmetry of the fiber input structure is substantially coincident with the light input to the fiber optic (2). The fiber input structure is further made from a high heat conductivity material and has a reflective coating on an input end face for reflecting light that is outside the acceptance angle of the fiber optic (2), but incident upon the fiber input structure.",COGENT LIGHT TECH,BAKER GLENN S;;CHANG DAVID D,,https://lens.org/143-709-745-622-562,Patent Application,yes,5,5,17,17,0,G02B6/36;;G02B6/4296;;G02B6/4296;;G02B6/02033;;G02B6/02033,G02B6/42;;G02C5/08;;G02C5/20,,1,0,,,See also references of EP 0801752A4,PATENTED
977,EP,A4,EP 2552483 A4,141-554-737-034-211,2013-09-25,2013,EP 11763313 A,2011-03-29,US 31990210 P;;US 32928210 P;;US 2011/0030294 W,2010-04-01,ANTIBODY-BASED DEPLETION OF ANTIGEN-PRESENTING CELLS AND DENDRITIC CELLS,,IMMUNOMEDICS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,,https://lens.org/141-554-737-034-211,Search Report,no,4,0,8,8,0,A61K31/4965;;A61K31/4965;;A61K47/6807;;A61K47/6807;;A61K47/6813;;A61K47/6813;;A61K47/6815;;A61K47/6815;;A61K47/6849;;A61K47/6849;;A61K47/6881;;A61K47/6881;;A61K47/6885;;A61K47/6885;;A61P37/06;;C07K16/2833;;C07K16/18;;C07K16/2803;;C07K16/2803;;C07K16/2833;;C07K16/2851;;C07K16/2863;;C07K16/2887;;C07K16/2887;;C07K16/30;;C07K16/30;;C07K16/3007;;C07K16/3007;;C07K16/3092;;C07K16/44;;C07K16/44;;C07K2317/24;;C07K2317/24;;C07K2317/31;;C07K2317/31;;C07K2317/35;;C07K2317/35;;C07K2317/51;;C07K2317/51;;C07K2317/52;;C07K2317/52;;C07K2317/522;;C07K2317/522;;C07K2317/55;;C07K2317/55;;C07K2317/73;;C07K2317/73;;C07K2317/734;;C07K2317/734;;C07K2317/75;;C07K2317/75;;C07K2317/77;;C07K2317/77;;C07K2319/70;;C07K2319/70;;C12N15/113;;C12N2310/14;;C12N2310/3513;;C12N2320/32;;Y02A50/30,A61K39/395;;C07K16/28;;C07K19/00,,4,2,064-270-377-561-388;;051-227-177-237-633,15701868;;10.1158/1078-0432.777.11.2;;10.1093/intimm/dxf073;;12202400,"CHEN XIAOCHUAN ET AL: ""Depletion of Blood Antigen-Presenting Cells by IMMU-114: Therapeutic Potential Against Graft-Versus-Host Disease"", vol. 116, no. 21, 1 November 2010 (2010-11-01), pages 1053, XP008164120, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/>;;MICHEL ROSANA B ET AL: ""Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 JAN 2005, vol. 11, no. 2 Pt 1, 15 January 2005 (2005-01-15), pages 777 - 786, XP002711318, ISSN: 1078-0432;;ANNA E LOKSHIN ET AL: ""Differential regulation of maturation and apoptosis of humen monocyte-derived dendritic celle mediated by MHC dass II"", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 14, no. 9, 1 September 2002 (2002-09-01), pages 1027 - 1037, XP008161720, ISSN: 0953-8178, DOI: 10.1093/INTIMM/DXF073;;See also references of WO 2011123428A1",DISCONTINUED
978,TW,B,TW 529060 B,141-590-573-871-352,2003-04-21,2003,TW 90116335 A,2001-07-04,US 62968300 A,2000-08-01,"A single crystal, tunneling and capacitive, three-axes sensor using eutectic bonding and a method of making same","A three axis MEM tunneling/capacitive sensor and method of making same. Cantilevered beam structures for at least two orthogonally arranged sensors and associated mating structures are defined on a first substrate or wafer, the at least two orthogonally arranged sensors having orthogonal directions of sensor sensitivity. A resonator structure of at least a third sensor is also defined, the third sensor being sensitive in a third direction orthogonal to the orthogonal directions of sensor sensitivity of the two orthogonally arranged sensors and the resonator structure having a mating structure thereon. Contact structures for at least two orthogonally arranged sensors are formed together with mating structures on a second substrate or wafer, the mating structures on the second substrate or wafer being of a complementary shape to the mating structures on the first substrate or wafer. The mating structures of the first substrate are disposed in a confronting relationship with the mating structures of the second substrate or wafer. A eutectic bonding layer associated with one of the mating structures facilitates bonding between the respective mating structures. At least a portion of the first substrate or wafer is removed to release the cantilevered beam structures and the resonator structure.",HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,,https://lens.org/141-590-573-871-352,Granted Patent,no,0,0,10,10,0,B81B2201/0242;;B81B2201/025;;B81C3/002;;B81C2201/019;;B81C2203/036;;B81C2203/058;;G01C19/5656;;G01P15/0802;;G01P15/0894;;G01P15/18;;H01H1/0036;;H01H59/0009;;G01P2015/084;;G01P2015/0842;;B81C3/002;;B81B2201/0242;;B81C2201/019;;B81C2203/058;;B81B2201/025;;G01P15/0802;;H01H1/0036;;G01C19/5656;;H01H59/0009;;G01P15/0894;;G01P15/18;;B81C2203/036;;G01P2015/084;;G01P2015/0842,B81B3/00;;B81C1/00;;B81C3/00;;G01C19/5656;;G01P15/08;;G01P15/18;;H01H1/00;;H01H59/00;;H01L41/08,,0,0,,,,EXPIRED
979,CA,A1,CA 2955254 A1,141-860-280-614-202,2016-03-03,2016,CA 2955254 A,2015-08-26,US 201462043601 P;;US 2015/0046910 W,2014-08-29,IDENTIFICATION OF CANCER GENES BY IN-VIVO FUSION OF HUMAN CANCER CELLS AND ANIMAL CELLS,"The present invention concerns compositions and methods for detecting and identifying novel cancer genes. The technique involves in vivo fusion of human cancer cells and animal cells, preferably hamster stromal cells, to form hybrid human cancer-animal cells, followed by identification of genes that are overexpressed in the hybrid cells compared to normal or transformed animal cells. The novel oncogenes or their protein products may be utilized for detection and/or diagnosis of human cancer or for development of new cancer therapies targeted against the novel oncogenes or their expressed proteins.",IMMUNOMEDICS INC,GOLDENBERG DAVID M;;CHANG CHIEN-HSING,,https://lens.org/141-860-280-614-202,Patent Application,no,0,0,5,5,86,C12Q1/6886;;C12Q1/6886;;C12Q2600/158;;C12Q2600/158,C12N5/28;;C12Q1/68,,0,0,,,,DISCONTINUED
980,US,A1,US 2004/0054504 A1,144-238-982-710-759,2004-03-18,2004,US 24481602 A,2002-09-16,US 24481602 A;;US 24468602 A;;US 24469402 A;;US 24470402 A;;US 24482502 A;;US 24482702 A,2002-09-16,Software application domain and storage domain characterization process and method,"
   A method for characterizing a data path in a computer system includes collecting data from a software application, the data represents a data path between the software application and a storage system, collecting data from the storage system, the data represents the data path between the software application and the storage system, selecting the data path between the software application and the storage system, and determining a characterization measure of the selected data path. 
",CHANG DAVID FU-TIEN;;ASHUTOSH ASHUTOSH,CHANG DAVID FU-TIEN;;ASHUTOSH ASHUTOSH,APPIQ (2002-10-08);;HEWLETT-PACKARD COMPANY (2005-12-01);;HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2006-02-01),https://lens.org/144-238-982-710-759,Patent Application,yes,5,9,14,14,0,G06F3/0635;;G06F3/067;;G06F11/323;;G06Q40/00;;G06Q40/04;;G06Q40/06;;G06Q40/08;;H04L41/046;;H04L41/06;;H04L41/0853;;H04L41/22;;H04L43/045;;H04L43/0888;;H04L67/1097;;H04L69/329;;G06Q40/03;;G06F11/323;;G06F3/067;;G06Q40/00;;H04L41/06;;H04L41/22;;H04L43/045;;G06Q40/06;;G06F3/0635;;H04L41/12;;H04L41/046;;H04L43/0888;;G06Q40/08;;H04L41/0853;;G06Q40/04;;H04L69/329;;H04L67/1097;;G06Q40/03,G06F/;;G06F3/06;;G06F9/44;;G06F11/32;;G06F13/00;;G06F15/00;;G06F15/16;;G06F15/173;;G06Q40/00;;H04L12/24;;H04L12/26;;H04L29/08,702/186,0,0,,,,EXPIRED
981,US,A1,US 2003/0141562 A1,154-670-246-755-954,2003-07-31,2003,US 35847103 A,2003-02-04,US 35847103 A;;US 62968200 A,2000-08-01,"Single crystal, dual wafer, tunneling sensor or switch with silicon on insulator substrate and a method of making same","
   A method of making a micro electro-mechanical switch or tunneling sensor. A cantilevered beam structure and a mating structure are defined on an etch stop layer on a first substrate or wafer; and at least one contact structure and a mating structure are defined on a second substrate or wafer, the mating structure on the second substrate or wafer being of a complementary shape to the mating structure on the first substrate or wafer. A bonding layer, preferably a eutectic bonding layer, is provided on at least one of the mating structures. The mating structure of the first substrate is moved into a confronting relationship with the mating structure of the second substrate or wafer. Pressure is applied between the two substrates so as to cause a bond to occur between the two mating structures at the bonding or eutectic layer. Then the first substrate or wafer and the etch stop layer are removed to free the cantilevered beam structure for movement relative to the second substrate or wafer. 
",HRL LAB LLC,KUBENA RANDALL L;;CHANG DAVID T,HRL LABORATORIES LLC (2000-07-27),https://lens.org/154-670-246-755-954,Patent Application,yes,25,2,9,9,0,G01P15/0802;;G01P15/0802;;G01P15/0894;;G01P15/0894;;H01H1/0036;;H01H1/0036;;H01H59/0009;;H01H59/0009,B81B3/00;;B81C1/00;;G01P15/08;;H01H1/00;;H01H59/00;;H01L29/84,257/415,0,0,,,,EXPIRED
982,CA,C,CA 2046109 C,159-563-680-124-889,1994-06-28,1994,CA 2046109 A,1991-07-03,US 56111890 A,1990-08-01,ELECTROSTATIC PAINT DEPOSITION METHOD AND APPARATUS,"An enhanced electrostatic paint deposition apparatus (10) comprising a nozzle (16), a conduit (14) coupled to the nozzle for supplying paint (12) thereto, and a plurality of electrically conductive whiskers (18) positioned within the nozzle for applying an electrostatic charge to droplets of the paint. Each of the whiskers terminates in a jagged end (30) for enabling the droplets to acquire an enhanced electric charge. The whiskers may be provided with lengths which are tailored to provide an array of whiskers with a desired three-dimensional curvature for controlling the focussing field on the paint droplets. Each whisker is secured to a holder (22) which is, in turn, secured to a porous grid (28) whose mesh size is selected to divide the paint into narrow streams of desired size, which exit nozzle 16 in droplet form. The holder is configured by decreasing its center portion (28) in dimension to tune the holder's current limiting capabilities. Pulsed negative high voltage is applied to the whiskers for enabling them to negatively charge the paint. Phased deflector plates 22, 24, 26 are provided to steer the paint stream.",HUGHES AIRCRAFT CO,CHANG DAVID B;;DRUMMOND JAMES E,,https://lens.org/159-563-680-124-889,Granted Patent,no,0,0,7,7,0,B05B5/0533;;B05B5/0536;;B05B5/00;;B05B5/0536;;B05B5/0533,B05B5/053;;B05D1/04,,0,0,,,,EXPIRED
983,US,B2,US 8883160 B2,185-182-721-342-078,2014-11-11,2014,US 201113036820 A,2011-02-28,US 201113036820 A;;US 201113004349 A;;US 96893610 A;;US 39696509 A;;US 39158406 A;;US 96402110 A;;US 94953610 A;;US 39660509 A;;US 63372906 A;;US 91551510 A;;US 87134510 A;;US 86982310 A;;US 75414010 A;;US 75474010 A;;US 75264910 A;;US 73178110 A;;US 64414609 A;;US 92540807 A;;US 54447609 A;;US 46858909 A;;US 38935806 A;;US 41887709 A;;US 41791709 A;;US 47802106 A;;US 5618205 A;;US 29384610 P;;US 32300110 P;;US 37444910 P;;US 66860305 P;;US 72829205 P;;US 75119605 P;;US 78233206 P;;US 26787709 P;;US 30268210 P;;US 41459210 P;;US 86453006 P;;US 25836909 P;;US 25872909 P;;US 37805910 P;;US 23847309 P;;US 26630509 P;;US 31699610 P;;US 32396010 P;;US 23842409 P;;US 16680909 P;;US 16871509 P;;US 16829009 P;;US 16865709 P;;US 16866809 P;;US 16366609 P;;US 9048708 P;;US 4393208 P;;US 10491608 P;;US 11954208 P;;US 54422704 P,2004-02-13,Dock-and-lock (DNL) complexes for therapeutic and diagnostic use,"The prediction of protein function as well as the reconstruction of evolutionary genesis employing sequence comparison at large is still the most powerful tool in sequence analysis. Due to the exponential growth of the number of known protein sequences and the subsequent quadratic growth of the similarity matrix, the computation of the Similarity Matrix of Proteins (SIMAP) becomes a computational intensive task. The SIMAP database provides a comprehensive and up-to-date pre-calculation of the protein sequence similarity matrix, sequence-based features and sequence clusters. As of September 2009, SIMAP covers 48 million proteins and more than 23 million non-redundant sequences. Novel features of SIMAP include the expansion of the sequence space by including databases such as ENSEMBL as well as the integration of metagenomes based on their consistent processing and annotation. Furthermore, protein function predictions by Blast2GO are pre-calculated for all sequences in SIMAP and the data access and query functions have been improved. SIMAP assists biologists to query the up-to-date sequence space systematically and facilitates large-scale downstream projects in computational biology. Access to SIMAP is freely provided through the web portal for individuals (http://mips.gsf.de/simap/) and for programmatic access through DAS (http://webclu.bio.wzw.tum.de/das/) and Web-Service (http://mips.gsf.de/webservices/services/SimapService2.0?wsd1).",CHANG CHIEN-HSING;;GOLDENBERG DAVID M;;IBC PHARMACEUTICALS INC,CHANG CHIEN-HSING;;GOLDENBERG DAVID M,IBC PHARMACEUTICALS INC (2011-05-02),https://lens.org/185-182-721-342-078,Granted Patent,yes,107,6,2,1035,176,A61K51/1027;;A61K51/1045;;C07K14/47;;C07K2317/31;;C07K2317/55;;C07K2317/732;;C07K2317/734;;C07K2319/70;;C12N9/12;;A61K47/6811;;A61K47/6849;;A61K47/6851;;A61K51/08;;A61P25/28;;A61P35/00;;A61P35/02;;A61P37/02;;A61P9/00;;A61K51/1027;;A61K51/1045;;C07K14/47;;C07K2317/31;;C07K2317/55;;C07K2317/732;;C07K2317/734;;C07K2319/70;;C12N9/12;;A61K47/6849;;A61K47/6851;;A61K47/6811;;A61K51/08;;C07K16/46,C07K16/28;;A61K47/48;;A61K51/08;;A61K51/10;;C07K14/47;;C12N9/12,424/178.1;;424/134.1;;424/143.1;;424/185.1;;424/192.1;;424/193.1;;530/387.3;;530/388.22;;530/391.1,111,97,033-802-631-358-941;;042-601-433-468-58X;;086-617-534-349-291;;077-950-844-586-930;;024-820-331-109-719;;000-687-583-450-12X;;063-640-832-834-034;;045-755-768-073-724;;060-563-142-402-87X;;037-719-830-241-939;;120-950-961-102-189;;074-418-525-034-370;;049-307-661-382-363;;006-319-589-046-67X;;012-773-412-555-417;;043-577-073-203-164;;003-849-961-384-35X;;009-483-512-107-343;;017-428-931-050-781;;029-611-134-469-353;;031-719-370-148-435;;063-753-305-188-393;;017-441-437-559-036;;068-263-202-843-607;;026-030-068-135-86X;;000-831-802-795-392;;005-122-111-501-762;;037-256-563-161-695;;010-111-903-745-914;;036-610-307-697-565;;085-277-440-303-853;;003-290-569-958-617;;043-164-824-642-059;;105-301-367-397-929;;113-664-356-121-786;;043-564-423-480-477;;051-482-033-723-112;;031-717-021-147-961;;023-490-128-029-654;;033-797-614-829-293;;027-167-517-598-362;;004-895-233-734-212;;006-574-964-805-278;;022-759-753-924-884;;012-426-427-709-70X;;041-607-340-819-599;;090-608-096-845-681;;012-022-955-975-269;;106-753-778-592-300;;014-072-411-037-328;;067-124-478-098-066;;041-495-698-646-422;;093-013-896-320-935;;019-941-060-457-50X;;007-822-064-014-928;;062-158-043-867-309;;044-057-452-243-446;;109-401-140-187-082;;001-151-746-014-076;;129-380-899-533-361;;032-820-729-763-323;;029-554-504-516-703;;000-028-529-904-953;;103-193-594-949-908;;083-734-720-759-001;;065-016-072-737-955;;088-656-447-551-373;;145-603-218-835-045;;080-067-458-689-961;;096-236-862-413-065;;015-744-591-120-019;;081-504-981-453-784;;043-968-156-521-588;;081-786-494-160-86X;;090-763-979-480-516;;030-630-100-818-462;;016-219-576-017-946;;090-802-635-099-729;;171-783-818-492-895;;072-397-724-288-290;;025-816-552-698-427;;088-509-278-000-721;;021-287-408-826-053;;001-611-067-071-049;;111-624-689-261-964;;037-017-089-132-994;;017-090-382-753-584;;110-257-679-203-818;;072-815-769-820-104;;007-560-918-954-044;;076-183-945-466-427;;072-817-270-335-125;;150-572-162-645-593;;005-440-177-324-600;;053-053-565-640-630;;009-566-304-236-232;;099-900-812-708-588,10665474;;10.1023/a:1006314501634;;15520207;;10.1158/0008-5472.can-04-1722;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;10.1016/j.molimm.2004.11.003;;15829301;;10.1056/nejmoa0808268;;19196673;;9857038;;10.1074/jbc.273.52.35048;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1038/sj.tpj.6500017;;11911439;;10.2174/138161206777585238;;16796556;;10.1354/vp.42-4-468;;16006606;;10.1016/s0952-7915(99)00004-7;;10508703;;10.3109/08982109809035537;;10.2165/00063030-200115040-00002;;11437687;;1367550;;10.1016/s0168-3659(01)00343-1;;11489514;;10.1016/s1521-6616(03)00214-6;;14597210;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;10969772;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1038/nbt0297-159;;9035142;;10.1023/a:1007565230130;;10751032;;9488147;;10.1093/protein/10.10.1221;;9354445;;8795695;;10.1016/0145-2126(96)00007-0;;2451562;;10.1016/s0001-2998(89)80025-x;;2678484;;8281471;;10.3322/canjclin.44.1.43;;10.1111/j.1365-2141.1987.tb06162.x;;3122816;;10.1182/blood.v84.6.1922.bloodjournal8461922;;8080996;;10.1182/blood.v84.6.1922.1922;;10.1038/ng0594-13;;8075633;;14695162;;8947500;;pmc1217930;;10.1042/bj3200293;;2717640;;10.1117/12.960183;;1706642;;10.1007/bf01741331;;20574049;;10.1182/blood-2009-11-253203;;pmc2953888;;9058745;;10.1182/blood.v89.6.2203;;10.1211/0022357021771913;;11829129;;9865830;;10.1016/s0046-8177(98)90013-2;;2531466;;10.1126/science.2531466;;10.1016/s0006-3495(99)77059-1;;pmc1300499;;10512838;;10.1016/0959-440x(93)90084-x;;10.1038/321522a0;;3713831;;9076770;;10.1097/00006231-199702000-00009;;7493367;;10.1056/nejm199308123290703;;7687326;;3320581;;10.1016/0145-2126(87)90166-4;;8993319;;10.1021/bi962148u;;1172191;;10.1038/256495a0;;3495036;;10.1126/science.3495036;;10.1016/s0005-2736(99)00091-7;;10446299;;10706520;;10.1615/critrevtherdrugcarriersyst.v16.i3.10;;8428363;;10.1016/s1046-2023(05)80210-5;;10.1128/mcb.8.3.1247-1252.1988;;10.1128/mcb.8.3.1247;;pmc363269;;3285178;;7737671;;10.1089/hyb.1994.13.469;;7751635;;10.1016/0161-5890(95)00080-1;;8643111;;10.1212/wnl.52.8.1701;;10331706;;10.1016/0008-8749(89)90359-6;;2463099;;8159246;;10.1038/368856a0;;8914801;;10.1097/00001622-199609000-00003;;9699662;;10.3109/08982109909024786;;10.1002/jps.2600830117;;8138914;;10.1016/0378-5173(94)90122-8;;10.1016/0378-5173(96)04456-0;;10.1111/j.2042-7158.1997.tb06744.x;;9120763;;9702210;;10.1211/0022357991776787;;10579680;;10.1016/s0378-5173(00)00492-0;;11000546;;14684279;;10.1016/j.jconrel.2003.09.016;;pmc41463;;7624362;;10.1073/pnas.92.15.7021;;10.1182/blood.v84.8.2457.2457;;10.1182/blood.v84.8.2457.bloodjournal8482457;;7522629;;10.1007/s00280-002-0437-3;;12107554;;10.1038/348552a0;;2247164;;10.1038/ng0297-146;;9020839;;6185591;;10.4049/jimmunol.130.3.1473;;4028022;;11342146;;10.1016/s0005-2736(00)00334-5;;11215825;;6606682;;10.1016/0022-1759(83)90303-4;;15772702;;10.1038/sj.leu.2403716;;10778733;;10.1023/a:1006373905428;;14427334;;10.1016/0003-9861(60)90049-7;;11410483;;10.1073/pnas.86.10.3833;;2726754;;pmc287235;;pmc387008;;10.1073/pnas.83.22.8744;;2877461;;3615636;;10.1111/j.1751-1097.1987.tb04740.x;;2189957;;10.1200/jco.1990.8.6.956;;3536124;;10.1016/0092-8674(86)90506-4;;10.1111/j.1600-0609.1993.tb00599.x;;8348940;;2663143;;2015553;;10.1002/1097-0142(19910515)67:10<2529::aid-cncr2820671024>3.0.co;2-b;;10845683;;10.1016/s0378-5173(00)00329-x;;10.1172/jci112082;;pmc424036;;3930572;;pmc1197021;;10.1042/bj0730119;;14434282,"Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.;;Ngo et al, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.;;Zhu et al, Investigational New Drugs 17: 195-212, 1999.;;Henry et al, Cancer Res. 64: 7995-8001, Nov. 1, 2004.;;Stancovski et al, Proceedings of the National Academy of Science USA 88: 8691-8695, 1991.;;Riemer et al, Mol. Immunol. 42: 1121-1124, 2005.;;Tol et al, N Engl J Med. 360(6):563-72, Feb. 5, 2009.;;Banky et al, J Biol Chem 273(52): 35048-35055, 1998.;;Skolnick et al., Trends in Biotechnology, 18: 34-39, 2000.;;Jones et al., Pharmacogenomics Journal, 1:126-134, 2001.;;Tosatto et al., Current Pharmaceutical Design, 12:2067-2086, 2006.;;Jubala et al., Vet Pathol 42: 468-476, 2005.;;US 6,558,648, 5/2003, Griffiths et al. (withdrawn).;;Bagshawe et al., ""Developments with targeted enzymes in cancer therapy"", Curr. Opin. Immunol. 11(5):579-83 (1999).;;Bally et al. (Eds.), ""Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations"", Journal of Liposome Research, 1998, vol. 8, No. 3, pp. 299-335.;;Beers et al., The Merck Manual of Diagnosis and Therapy, Ch. 180, p. 1474-1476; 17th Ed., Whitehouse Station, NJ, Merck Research Labs (1999).;;Bendas et al., ""Immunoliposomes: a promising approach to targeting cancer therapy"", BioDrugs 15(4):215-24 (2001).;;Bendig, M., ""Humanization of Rodent Monoclonal Antibodies by CDR Grafting"", Academic Press Inc., New York, NY, vol. 8, (1995), pp. 83-93.;;Bird et al., ""Single chain antibody variable regions"", Trends Biotechnol. 9(4):132-7 (1991).;;Bom et al., ""The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity"", J. Control Release 74(1-3):325-33 (2001).;;Breen et al., ""Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype"", Clin. Immunol. 109(2):119-29 (2003).;;Burgess et al., ""Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue"", J. Cell Biol. 111:2129-2138 (1990).;;Carter et al., ""Humanization of an anti-p185HER2 antibody for human cancer therapy"", Proc. Natl. Acad. Sci. USA 89(10):4285-9 (1992).;;Chen et al., ""Differential Effects of Milatuzumab on Human Antigen-Presenting Cells in Comparison to Malignant B Cells"", 2009 ASH Annual Meeting Abstracts, vol. 114(22):1073; Abstr # 2744 (Nov. 20, 2009).;;Cochlovius et al., ""Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation"", Cancer Res. 60(16):4336-41 (2000).;;Coligan et al., (Eds.), Current Protocols in Immunology, vol. 1, pp. 2.5.1-2.6.7; pp. 2.7.1.-2.7.12; pp. 2.8.1-2.8.10; pp. 2.9.1-2.9.3; pp. 2.10.-2.10.4; John Wiley & Sons, Inc., 1991.;;Colman, P., ""Effects of amino acid sequence changes on antibody-antigen interactions"", Res. Immunol. 1994, 145:33-36.;;Coloma et al., ""Design and production of novel tetravalent bispecific antibodies"", Nat. Biotechnol. 15(2):159-63 (1997).;;Constantinides et al., ""Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel"", Pharm. Res. 17(2):175-82 (2000).;;Courtenay-Luck, N. S., ""Genetic manipulation of monoclonal antibodies"", Monoclonal Antibodies: Production, Engineering and Clinical Application, p. 166-179, Ritter et al. (Eds.), Cambridge University Press (1995).;;Fitzgerald et al., ""Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris"", Protein Eng. 10(10):1221-5 (1997).;;Flavell et al., ""Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice"", Cancer Res. 57:4824-9 (1997).;;Freedman et al., ""Non-Hodgkin's Lymphomas"", Cancer Medicine, 3rd Ed., vol. 2, p. 2028-2068, Holland et al., (Eds.), Lea & Febiger (1993).;;French et al., ""Response of B-cell lymphoma to a combination of bispecific antibodies and saporin"", Leuk. Res. 20 (7):607-17 (1996).;;Ghetie et al., ""Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy"", Cancer Res. 48(9):2610-7 (1988).;;Gold et al., ""Expression of CD74 in pancreatic and colorectal carcinomas as a basis for milatuzumab immunotherapy"", Abstract #5485; Proceeding of the American Association for Cancer Research, vol. 50, p. 1322-1323; Apr. 2009.;;Goldenberg, D. M. ""Radiolabeled antibodies"", Science & Medicine, 1(1):64 (Apr. 1994).;;Goldenberg, D. M. ""Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy"", Semin. Nucl. Med. 19(4):332-9 (1989).;;Goldenberg, D. M. ""New Developments in Monoclonal Antibodies for Cancer Detection and Therapy"", CA Cancer J. Clin. 44(1):43-64 (1994).;;Gondo et al., ""HLA class II antigen associated invariant chain gene expression in malignant lymphoma"", Br. J. Haematol. 67(4):413-7 (1987).;;Goto et al. ""A novel membrane antigen selectively expressed on terminally differentiated human B cells"", Blood 84 (6):1922-30 (1994).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs"", Nature Genetics 7:13-21 (1994).;;Greenwood et al., ""Effector functions of matched sets of recombinant human IgG subclass antibodies"", Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Clark (Ed.), p. 89; p. 97; Academic Titles (1993).;;Griffiths et al., ""Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate"", vol. 9, 6567-6571, Dec. 15, 2003.;;Hansen et al., ""Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas"", Biochem. J. 1996, 320:293-300.;;Hasan et al., ""Laser-induced selective cytotoxicity using monoclonal antibody-chromophore conjugates"", Prog. Clin. Biol. Res. 288:471-7 (1989).;;Hekman et al., ""Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody"", Cancer Immunol. Immunother. 1991;32(6):364-72.;;Hertlein et al., ""Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor on the Surface of B Cells"" 2009 ASH Annual Meeting Abstracts, vol. 114(22):301; Abstr # 721 (Nov. 20, 2009).;;Hertlein et al., ""Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells"", Blood. Jun. 23, 2010. [Epub ahead of print].;;Hess et al., ""Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide"", Blood 89(6):2203-9 (1997).;;Hong et al., ""pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system"", J. Pharm. Pharmacol. 54(1):51-8 (2002).;;Hua et al., ""Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung"", Hum. Pathol. 29(12):1441-6 (1998).;;Huse et al., ""Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda"", Science 246:1275-1281 (1989).;;Ibragimova et al., ""Stability of the beta-sheet of the WW domain: A molecular dynamics simulation study"", Biophys. J. 77(4):2191-8 (1999).;;Johnson et al., ""Human antibody engineering"", Current Opin. Struct. Biol. 3:564-571 (1993).;;Jones et al., ""Replacing the complementarity-determining regions in a human antibody with those from a mouse"" Nature 321(6069):522-5 (1986).;;Juweid et al., ""99Tcm-LL1: a potential new bone marrow imaging agent"", Nucl. Med. Commun. 18(2):142-8 (1997).;;Juweid et al., ""Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody"", Cancer Res. 55(23 Suppl):5899s-5907s (1995).;;Kaminski et al., ""Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody"", N. Engl. J. Med. 329(7):459-65 (1993).;;Kiesel et al., ""Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis"", Leuk. Res. 11(12):1119-25 (1987).;;Kirpotin et al., ""Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro"", Biochemistry 36(1):66-75 (1997).;;Kohler et al., ""Continuous cultures of fused cells secreting antibody of predefined specificity"", Nature 256:495-7 (1975).;;Kolata, G., ""Clinical promise with new hormones"", Science 236:517-519 (1987).;;Koning et al., ""Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells"", Biochim. Biophys. Acta. 1420(1-2):153-67 (1999).;;Kratz et al., ""Drug-polymer conjugates containing acid-cleavable bonds"", Crit. Rev. Ther. Drug Carrier Syst. 16 (3):245-88 (1999).;;Kreitman et al., ""Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice"", Cancer Res. 53(4):819-25 (1993).;;Larrick et al., ""PCR Amplification of Antibody Genes"", Methods: A Companion to methods in Enzymology 2 (2):106-110 (1991).;;Lazar et al.,""Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities"", Mol. Cell. Biol. 8(3):1247-1252 (1988).;;Leonard et al., ""Epratuzumab, a new Anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results"", Blood 94:92a-93a, Abstract # 404, (1999).;;Leung et al., ""Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma"", Hybridoma 13 (6):469-476 (1994).;;Leung et al., ""Engineering a Unique Glycosylation Site for Site-Specific Conjugation of Haptens to Antibody Fragments"", J. Immunol. 154:5919-5926 (1995).;;Leung et al., ""Construction and characterization of a humanized, internalizing, b-cell (CD22)-specific, leukemia/lymphma antibody, LL2"", Mol. Immunol. 32(17/18):1413-1427 (1995).;;Levine et al., ""IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab"", Neurology 52 (8):1701-4 (1999).;;Li et al., ""The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies"", Cell Immunol. 118(1):85-99 (1989).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications"", Nature 368:856-9 (1994).;;Longo, D. L. ""Immunotherapy for non-Hodgkin's lymphoma"", Curr. Opin. Oncol. 8(5):353-9 (1996).;;Lopez De Menezes et al., ""In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma"", Cancer Res. 58(15):3320-30 (1998).;;Lopez De Menezes et al., ""Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells"", J. Liposome Research 1999, vol. 9, No. 2 , pp. 199-228.;;Lundberg, B. ""Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures"", J. Pharm. Sci. 83(1):72-5 (1994).;;Lundberg, B. ""The solubilization of lipophilic derivatives of podophyllotoxins in sub-micron sized lipid emulsions and their cytotoxic activity against cancer cells in culture"", Int. J. Pharm. 109:73-81 (1994).;;Lundberg et al., ""Submicron lipid emulsions containing amphipathic polyethylene glycol for use as drug-carriers with prolonged circulation time"", Int. J. Pharm. 134:119-127 (1996).;;Lundberg et al., A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol), J Pharm Pharmacol. 49:16-21 (1997).;;Lundberg et al., ""Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions"", Anticancer Drug Des. 13(5):453-61 (1998).;;Lundberg et al., ""Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions"", J. Pharm. Pharmacol. 51(10):1099-105 (1999).;;Lundberg et al., ""Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin"", Int. J. Pharm. 205(1-2):101-8 (2000).;;Lundberg et al., ""Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells"", J. Control. Release 94(1):155-61 (2004).;;Mack et al., ""A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity"", Proc. Natl. Acad. Sci. USA 92:7021-7025 (1995).;;Maloney et al., ""Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma"", Blood 84(8):2457-66 (1994).;;Maranhao et al., ""Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients"", Cancer Chemother. Pharmacol. 49(6):487-98 (2002).;;McCafferty et al., ""Phage antibodies: filamentous phage displaying antibody variable domains"", Nature 348:552-553 (1990).;;Mendez et al., ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice"", Nature Genetics 15:146-156 (1997).;;Mew et al., ""Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates"", J. Immunol. 130(3):1473-7 (1983).;;Mew et al., ""Ability of Specific Monoclonal Antibodies and Conventional Antisera Conjugated to Hematoporphyrin to Label and Kill Selected Cell Lines Subsequent to Light Activation"", Cancer Res. 45:4380-4386 (1985).;;Moase et al., ""Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer"", Biochim. Biophys. Acta. 1510(1-2):43-55 (2001).;;Moller et al., ""CD74"", J. Biol. Regul. Homeost. Agents 14(4):299-301 (2000).;;Mosmann, T., ""Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays"", J. Immunol. Methods 65(1-2):55-63 (1983).;;Nagel et al., ""HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3"", Leukemia 19(5):841-6 (2005).;;Nakagawa et al., ""Clinical trial of intrathecal administration of 5-fluoro-2'-deoxyuridine for treatment of meningeal dissemination of malignant tumors"", J. Neurooncol. 45(2):175-83 (1999).;;Nisonoff et al., ""Separation of Univalent Fragments from the Bivalent Rabbit Antibody Molecule by Reduction of Disulfide Bonds"", Arch. Biochem. Biophys. 89:230-244 (1960).;;Ochakovskaya et al., Therapy of Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice with an Anti-CD74 Antibody Conjugated with (111)Indium, (67)Gallium, or (90)Yttrium, Clin. Cancer Res. 7(6):1505-1510 (2001).;;Orlandi et al., ""Cloning immunoglobulin variable domains for expression by the polymerase chain reaction"", Proc. Natl. Acad. Sci. USA 86:3833-3837 (1989).;;Oseroff et al., ""Antibody-targeted photolysis: Selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates"", Proc. Natl. Acad. Sci. USA 83:8744-8748 (1986).;;Oseroff et al., ""Strategies for selective cancer photochemotherapy: antibody-targeted and selective carcinoma cell photolysis"", Photochem. Potobiol. 46(1):83-96 (1987).;;Oster et al., ""Erythropoietin for the Treatment of Anemia of Malignancy Associated with Neoplastic Bone Marrow Infiltration"", J. Clin. Oncol. 8(6):956-962 (1990).;;Pastan et al., ""Immunotoxins"", Cell 47:641-648 (1986).;;Patti et al., ""High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas"", Eur. J. Haematol. 51(1):18-24 (1993).;;Pawlak-Byczkowska et al., ""Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma"", Cancer Res. 49(16):4568-77 (1989).;;Pelegrin et al., ""Antibody-Fluorescein Conjugates for Photoimmunodiagnosis of Human Colon Carcinoma in Nude Mice"", Cancer 67:2529-2537 (1991).;;Perkins et al., ""Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds"", Int. J. Pharm. 200(1):27-39 (2000).;;Pirker et al., ""Characterization of immunotoxins active against ovarian cancer cell lines"", J. Clin. Invest. 76(3):1261-7 (1985).;;Porter et al., ""The Hydrolysis of Rabbit gamma-Globulin and Antibodies with Crystalline Papain"", Biochem. J. 73 (1):119-127 (1959).",ACTIVE
984,EP,A1,EP 0268670 A1,188-744-819-772-480,1988-06-01,1988,EP 87904335 A,1987-05-01,US 86892986 A,1986-05-30,METHOD OF PROVIDING CONTINUOUS LASING OPERATION.,"Le procédé de mise en oeuvre d'une opération au laser au moins quasi continu entre des états de laser initial et terminal comprend les étapes de sélection d'un milieu laser et d'une configuration de cavité (fréquence du laser), le milieu laser contenant un matériau de conversion incrémentielle permettant l'échange d'énergie entre un nombre suffisant d'électrons au niveau de l'état laser terminal (connecteur) de manière à maintenir une inversion de population entre les états laser initial et terminal pendant l'opération au laser, et d'application d'une énergie excitatrice d'une intensité appropriée au milieu laser pendant au moins une période de temps quasi continue.",HUGHES AIRCRAFT CO,POLLACK SLAVA A;;CHANG DAVID B,,https://lens.org/188-744-819-772-480,Patent Application,yes,0,1,9,9,0,H01S3/093;;H01S3/1608;;H01S3/1645;;H01S3/093;;H01S3/1608;;H01S3/1645,H01S3/091;;H01S3/093;;H01S3/16,,0,0,,,,EXPIRED
985,CA,A,CA 1068517 A,198-771-596-273-540,1979-12-25,1979,CA 241897 A,1975-12-11,CA 241897 A,1975-12-11,METALLIC COATING POWDER CONTAINING A1 AND HF,A coating powder for a metallic article provides improved resistance to high temperature environmental conditions through the inclusion of about 0.1 - 10 weight percent Hf in the coated article surface. A method for providing such a coating includes application of the Hf alone or in combination with other surface protective means.,GEN ELECTRIC,CHANG DAVID R;;GRISIK JOHN J,,https://lens.org/198-771-596-273-540,Granted Patent,no,0,0,1,1,0,,,75-33,0,0,,,,EXPIRED
986,CN,A,CN 113365585 A,196-925-400-518-734,2021-09-07,2021,CN 201980090619 A,2019-09-27,US 201816203970 A;;US 2019/0053553 W,2018-11-29,SYSTEM AND PROCESS FOR ADJUSTING TREATMENT PARAMETERS FOR RETINA PHOTOTHERAPY BASED ON RPE MELANIN LEVELS,"A system and process for safely providing retinal phototherapy includes generating first and second light beams of a different wavelength. The first and second light beams are applied to a retinal pigment epithelium (RPE) (24) and choroid (26) of an eye (10). The amount of light reflected from the eye from the first light beam and the second light beam is measured, such as using a reflectometer (110). A level or concentration of the melanin within the eye is calculated using the measured amount of light reflected from the eye from the first and second light beams. When the content or density of melanin in the RPE exceeds a predetermined amount, one or more treatment parameters of the retinal phototherapy is adjusted.",OJAI RETINAL TECH LLC,LUTTRULL JEFFREY K;;CHANG DAVID B,,https://lens.org/196-925-400-518-734,Patent Application,no,4,0,12,287,0,A61F9/008;;A61F2009/00863;;A61N5/0613;;A61N2005/0648;;A61N2005/0659;;A61N2005/0662,A61F9/00;;A61F9/008;;A61N5/06,,0,0,,,,PENDING
987,US,A1,US 2005/0031293 A1,006-656-338-064-598,2005-02-10,2005,US 63553103 A,2003-08-07,US 63553103 A,2003-08-07,Light guide apparatus and method for a detector array,"According to one embodiment, the invention relates to a light guide comprising a first surface which receives light, a second surface which emits light, wherein the second surface is parallel to the first surface and the second surface has a smaller area than the first surface, at least one edge surface which extends between the first surface and the second surface, and a light barrier which extends between the first surface and the second surface, wherein the light barrier divides the light guide into separate regions and reduces the propagation of light between the separate regions. The light guide can be used in a positron emission tomography scanner.",KIM CHANG L.;;MCDANIEL DAVID L.,KIM CHANG L;;MCDANIEL DAVID L,GE MEDICAL SYSTEMS GLOBAL TECHNOLOGY CO. LLC (2003-09-04);;GENERAL ELECTRIC COMPANY (2008-10-08),https://lens.org/006-656-338-064-598,Patent Application,yes,8,10,2,2,0,G02B6/10;;G02B6/10;;G02B6/08;;G02B6/08,F21V8/00;;G02B6/08;;G02B6/10,385/146,0,0,,,,EXPIRED
988,AU,A,AU 1984/023466 A,001-198-286-980-350,1984-11-07,1984,AU 1984/023466 A,1983-11-28,US 48606683 A;;US 8301877 W,1983-04-18,REMOVAL OF SELF-BINDING AND STAPH A CROSS-REACTIVITY OF ANTI-STREP ANTIBODY,,QUIDEL,KATZ DAVID H;;SHUNG-HO CHANG,,https://lens.org/001-198-286-980-350,Patent Application,no,0,1,1,3,0,,C12Q1/14,,0,0,,,,DISCONTINUED
989,US,A1,US 2004/0064543 A1,016-724-254-805-226,2004-04-01,2004,US 24482702 A,2002-09-16,US 24482702 A;;US 24468602 A;;US 24469402 A;;US 24470402 A;;US 24481602 A;;US 24482502 A,2002-09-16,Software application domain and storage domain management process and method,"
   A system monitoring process for monitoring data flow includes an application level agent process that collects configuration data from a software application, the configuration data represents configuration dependencies between the software application and a storage system, and a storage system level agent process that collects configuration data from the storage system, the configuration data represents the configuration dependencies between the software application and the storage system. 
",ASHUTOSH ASHUTOSH;;CHANG DAVID FU-TIEN,ASHUTOSH ASHUTOSH;;CHANG DAVID FU-TIEN,APPIQ (2002-10-08);;HEWLETT-PACKARD COMPANY (2005-12-01);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2005-12-05),https://lens.org/016-724-254-805-226,Patent Application,yes,16,84,14,14,0,G06F3/0635;;G06F3/067;;G06F11/323;;G06Q40/00;;G06Q40/04;;G06Q40/06;;G06Q40/08;;H04L41/046;;H04L41/06;;H04L41/0853;;H04L41/22;;H04L43/045;;H04L43/0888;;H04L67/1097;;H04L69/329;;G06Q40/03;;G06F11/323;;G06F3/067;;G06Q40/00;;H04L41/06;;H04L41/22;;H04L43/045;;G06Q40/06;;G06F3/0635;;H04L41/12;;H04L41/046;;H04L43/0888;;G06Q40/08;;H04L41/0853;;G06Q40/04;;H04L69/329;;H04L67/1097;;G06Q40/03,G06F/;;G06F3/06;;G06F9/44;;G06F11/32;;G06F13/00;;G06F15/00;;G06F15/16;;G06F15/173;;G06Q40/00;;H04L12/24;;H04L12/26;;H04L29/08,709/224,0,0,,,,DISCONTINUED
990,US,A,US 5832074 A,016-932-588-038-035,1998-11-03,1998,US 75850696 A,1996-12-02,US 75850696 A;;CA 2191279 A;;GB 9624553 A;;SG 1996011461 A,1996-11-26,Intelligent telephone system,"The present invention relates to an intelligent telephone system, operating methods related to the system are also disclosed. The intelligent telephone is capable of programming operating procedures as a shortcut for re-operating in the future. Furthermore, achieve the purpose of conveniently operating some complicated operating processes for a user, and being capable of automatically performing in a preset time limit. The intelligent telephone system includes storage means, a ROM (Read Only Memory), an LCD (Liquid Crystal Display), a telephone interface, a CPU (Central Processing Unit), and a user inputting interface. The user interface is used for receiving audio information and commands for controlling operations to shortcuts. In software structure, the intelligent system includes a system control module, a shortcut functional module, and lots of software modules. The system control module gives control rights and relative messages to the shortcut functional module. The shortcut functional module then control actions of the software modules for the purpose of completely handling shortcut operations.",INVENTEC CORP,CHANG JACKSON;;LIN DAVID;;CAO JAMES,INVENTEC CORPORATION (1996-11-14),https://lens.org/016-932-588-038-035,Granted Patent,yes,7,8,7,7,0,H04M1/247;;H04M1/27;;H04M1/27;;H04M1/247,H04M1/247;;H04M1/27,379/355;;379/356;;379/368;;364/189;;364/709.01;;340/407.2,0,0,,,,EXPIRED
991,US,B2,US 9287780 B2,020-744-137-752-877,2016-03-15,2016,US 201514753530 A,2015-06-29,US 201514753530 A;;US 201213589280 A,2012-08-20,Slab inductor device providing efficient on-chip supply voltage conversion and regulation,"A method is disclosed to operate a voltage conversion circuit such as a buck regulator circuit that has a plurality of switches coupled to a voltage source; a slab inductor having a length, a width and a thickness, where the slab inductor is coupled between the plurality of switches and a load and carries a load current during operation of the plurality of switches; and a means to reduce or cancel the detrimental effect of other wires on same chip, such as a power grid, potentially conducting return current and thereby degrading the functionality of this slab inductor. In one embodiment the wires can be moved further away from the slab inductor and in another embodiment magnetic materials can be used to shield the slab inductor from at least one such interfering conductor.",IBM,CHANG LELAND;;GOREN DAVID;;WANG NAIGANG,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-05-15),https://lens.org/020-744-137-752-877,Granted Patent,yes,11,0,10,10,0,H02M3/155;;H02M3/156;;G06F1/26;;H02M3/155;;H02M3/158,G06F1/26;;H02M3/155;;H02M3/156;;H02M3/158,,0,0,,,,ACTIVE
992,US,A,US 4104437 A,023-238-178-770-155,1978-08-01,1978,US 61120575 A,1975-09-08,US 61120575 A;;US 50883474 A,1974-09-24,Pressure-sensitive copy system including ureido fluoran chromogenic compounds,"A chromogenic compound having the structural formula ##STR1## wherein R.sup.1 and R.sup.2 each represent an alkyl group; R.sup.3 and R.sup.4 each represent a hydrogen atom, a halogen atom, an alkyl group, a nitro group, an amino group, an acyl group, or a carboalkoxy group; R.sup.5 represents a hydrogen atom or an alkyl group, with the proviso that R.sup.5 represents an alkyl group only when R.sup.4 represents a hydrogen atom; R.sup.6 represents an alkyl group, an aryl group or an aralkyl group; and X and Y each represent a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, an aryl group, an alkoxy group or a carboalkoxy group. The aforesaid compound may be provided in a pressure-sensitive copy system wherein a visible image is formed upon reaction of the above chromogenic compound with an electron-accepting material of the Lewis acid type.",CHAMPION INT CORP,VINCENT DAVID N;;CHANG CHENG-HSIUNG,,https://lens.org/023-238-178-770-155,Granted Patent,yes,8,16,9,10,0,B41M5/1455;;B41M5/1455;;C07D493/10;;C07D493/10;;Y10S428/914;;Y10S428/914;;Y10T428/254;;Y10T428/254;;Y10T428/2984;;Y10T428/2984;;Y10T428/2985;;Y10T428/2985;;Y10T428/2987;;Y10T428/2987,B41M5/145;;C07D493/10;;C09B11/28,428/307,0,0,,,,EXPIRED
993,WO,A1,WO 2007/109927 A1,009-778-875-717-798,2007-10-04,2007,CN 2006000804 W,2006-04-26,CN 200610025041 A,2006-03-24,A KEY CONFIGURATION OF A TOUCHING PAD AND A METHOD TO USE IT,"The present invention discloses a key configuration of a touching pad and a method to use it. It can be adapted to digital handheld products like a cell phone. The said key configuration of a touching pad is that the mechanical keys are mainly set under the touching pad, carrying out a call function. The mechanical key is implemented by elastic metal slices, and because of the metal slice, it can be sensed as a key when calling out. Furthermore, based on the metal slice, the present invention adds functions as navigation, mouse operation, multimedia browser and so on. Based on the principle that the metal slices is in the different layer with the touching pad, the above basic operations are implemented with the characters of the said touching pad, while the affirming function is implemented with the metal slice, thus the user can finish the above operation with one single hand. Thus, the present invention can add the sensibility of touching, and enhance the capability of single hand operation.",INVENTEC APPLIANCES SHANGHAI C;;HO DAVID;;CHANG JACKSON;;LI KAIWU,HO DAVID;;CHANG JACKSON;;LI KAIWU,,https://lens.org/009-778-875-717-798,Patent Application,yes,3,0,2,2,0,H04M1/23;;H01H13/702;;H04M2250/22,G06F3/02;;H04M1/23,,0,0,,,,PENDING
994,BR,A,BR 9101614 A,019-460-646-910-845,1991-12-10,1991,BR 9101614 A,1991-04-22,US 51314690 A,1990-04-23,"PROCESSO PARA RESFRIAMENTO DE UM ESPACO SENDO AQUECIDO PELA LUZ SOLAR INCIDENTE,REVESTIMENTO DE REDUCAO DA CARGA DE AQUECIMENTO SOLAR PARA VIDROS DE AUTOMOVEL,E,REVESTIMENTO PARA REDUCAO DA TEMPERATURA INTERIOR DE UM ESPACO FECHADO POR ELEMENTOS ESTRURURAIS",,HUGHES AIRCRAFT CO,CHANG DAVID B;;JICHA ALBERT J,,https://lens.org/019-460-646-910-845,Patent Application,no,0,0,11,11,0,B05D1/00;;C03C17/3435;;C03C17/3435;;C03C17/22;;C03C17/22;;C03C17/347;;C03C17/347;;C03C17/3476;;C03C17/3476;;C03C17/3488;;C03C17/3488;;C03C2217/283;;C03C2217/283;;C03C2217/288;;C03C2217/288;;C03C2217/289;;C03C2217/289;;C03C2217/29;;C03C2217/29;;C09D5/00;;C09D5/00;;Y10S428/913;;Y10S428/913;;Y10T428/24942;;Y10T428/24942;;Y10T428/2993;;Y10T428/2993,B05D5/00;;B05D7/00;;B05D7/14;;B05D7/24;;C03C17/22;;C03C17/34;;C09D5/00;;G02B5/28,,0,0,,,,PENDING
995,US,A1,US 2016/0086439 A1,018-642-569-989-318,2016-03-24,2016,US 201514954931 A,2015-11-30,US 201514954931 A;;US 2014/0040094 W;;US 201361828327 P,2013-05-29,DYNAMIC WAGER UPDATING GAMBLING HYBRID GAME,"A gambling hybrid game with dynamic wager updating is disclosed. The gambling hybrid game includes an entertainment system engine that provides an entertainment game to a user, a real world engine that provides gambling games to one or more users, and a game world engine that monitors the entertainment game and provides gambling games when appropriate. The gambling hybrid game during the course of game play may dynamically update a wager amount to be placed on a gambling event in the gambling game",GAMBLIT GAMING LLC,ARNONE MILES;;MEYERHOFER ERIC;;CHANG DAVID,,https://lens.org/018-642-569-989-318,Patent Application,yes,2,5,8,8,0,G07F17/3227;;G07F17/3227;;G07F17/32;;G07F17/32;;G07F17/3204;;G07F17/3204;;G07F17/3286;;G07F17/3286;;G07F17/34;;G07F17/34,G07F17/32;;G07F17/34,,0,0,,,,INACTIVE
996,US,A1,US 2009/0025240 A1,038-277-512-477-971,2009-01-29,2009,US 82867107 A,2007-07-26,US 82867107 A,2007-07-26,CYCLING PEDAL LEG ANGLE OPTIMIZER,Optimizing pedal angle for a cyclist is accomplished with a template having a central body with an aperture for positioning over the lateral condyle in a cyclist's knee. A fist alignment arm extends from the central body and incorporates an alignment indicia for positioning between the knee and hip of the cyclist. A second alignment arm extends from the central body at a predetermined angle with respect to the first alignment arm and employs an angular alignment indicia for relative placement over a malleolus bone of an ankle of the cyclist.,TAYLOR JOSHUA DAVID;;HERNANDEZ CHANG LOUISE,TAYLOR JOSHUA DAVID;;HERNANDEZ CHANG LOUISE,,https://lens.org/038-277-512-477-971,Patent Application,yes,18,3,3,3,0,A61B5/1071;;A61B5/1071;;A61B5/4528;;A61B5/4528;;A61B5/6828;;A61B5/6828,A61B5/107,33/512,0,0,,,,INACTIVE
997,US,A1,US 2018/0322733 A1,025-454-061-292-961,2018-11-08,2018,US 201816036388 A,2018-07-16,US 201816036388 A;;US 201514954931 A;;US 2014/0040094 W;;US 201361828327 P,2013-05-29,DYNAMIC WAGER UPDATING GAMBLING HYBRID GAME,"A gambling hybrid game with dynamic wager updating is disclosed. The gambling hybrid game includes an entertainment system engine that provides an entertainment game to a user, a real world engine that provides gambling games to one or more users, and a game world engine that monitors the entertainment game and provides gambling games when appropriate. The gambling hybrid game during the course of game play may dynamically update a wager amount to be placed on a gambling event in the gambling game",GAMBLIT GAMING LLC,ARNONE MILES;;MEYERHOFER ERIC;;CHANG DAVID,,https://lens.org/025-454-061-292-961,Patent Application,yes,0,0,8,8,0,G07F17/3227;;G07F17/3227;;G07F17/32;;G07F17/32;;G07F17/3204;;G07F17/3204;;G07F17/3286;;G07F17/3286;;G07F17/34;;G07F17/34,G07F17/32;;G07F17/34,,0,0,,,,INACTIVE
998,CA,A1,CA 2947087 A1,026-422-240-717-021,2018-04-30,2018,CA 2947087 A,2016-10-31,CA 2947087 A,2016-10-31,SKATE,"A skate (e.g., an ice skate) for a user (e.g., a hockey player). The skate comprises a skate boot for receiving a foot of the user and a skating device (e.g., a blade and a blade holder) disposed beneath the skate boot to engage a skating surface. The skate boot may be constructed by molding (e.g., injection molding) so as to have useful performance and/or characteristics (e.g., reduced weight; enhanced fit, comfort and range of motion; enhanced appearance; etc.) while being cost-effectively manufactured.",BAUER HOCKEY CORP,CHAMPAGNE GAETAN;;DAUB DAVID;;CHANG KENT,,https://lens.org/026-422-240-717-021,Patent Application,no,0,5,3,3,0,A63C1/02;;A63C1/303;;A63C1/32;;A63C1/42;;A43B5/1666;;A43B23/26;;B29D35/126,A43B5/16;;A63C1/00;;A63C1/02,,0,0,,,,PENDING
999,TW,B,TW I353746 B,041-301-623-452-721,2011-12-01,2011,TW 95119004 A,2006-05-29,US 14147805 A,2005-05-31,Wireless terminal baseband processor high speed tu,,BROADCOM CORP,MARK DAVID HAHM;;LI FUNG CHANG,,https://lens.org/041-301-623-452-721,Granted Patent,no,0,0,11,11,0,H03M13/09;;H03M13/1102;;H03M13/23;;H03M13/2975;;H03M13/3922;;H03M13/6306;;H03M13/6362;;H03M13/658;;H04L1/0051;;H04L1/0054;;H04L1/0066;;H04L1/1819;;H04L1/1845;;H03M13/658;;H03M13/6362;;H03M13/2975;;H04L1/0066;;H03M13/23;;H03M13/6306;;H04L1/1819;;H03M13/09;;H03M13/3922;;H04L1/0054;;H04L1/0051;;H04L1/1845;;H03M13/1102,,,0,0,,,,INACTIVE
1000,US,A1,US 2019/0010604 A1,039-177-200-355-105,2019-01-10,2019,US 201816015672 A,2018-06-22,US 201816015672 A;;US 201414152751 A;;US 201361752209 P;;US 201361752549 P;;US 201361897082 P;;US 201361907628 P,2013-01-14,METHOD AND SYSTEM FOR GRAPHENE FORMATION,A method of forming graphene includes placing a substrate in a processing chamber and introducing a cleaning gas including hydrogen and nitrogen into the processing chamber. The method also includes introducing a carbon source into the processing chamber and initiating a microwave plasma in the processing chamber. The method further includes subjecting the substrate to a flow of the cleaning gas and the carbon source for a predetermined period of time to form the graphene.,CALIFORNIA INST OF TECHN,BOYD DAVID A;;YEH NAI-CHANG,CALIFORNIA INSTITUTE OF TECHNOLOGY (2014-01-09),https://lens.org/039-177-200-355-105,Patent Application,yes,22,8,14,14,0,C23C16/26;;C23C16/4405;;C23C16/511;;H01L29/92;;C01B32/184;;C01B32/186;;Y10T428/24355;;C01B32/186;;C23C16/26;;C23C16/4405;;C23C16/511;;Y10T428/24355;;C01B32/184;;C01B32/186;;C23C16/26;;C23C16/4405;;C23C16/511,C23C16/26;;C01B32/184;;C01B32/186;;C23C16/44;;C23C16/511,,0,0,,,,ACTIVE
